American Thoracic Society International Conference

May 13 - May 18, 2016
San Francisco, California
conference.thoracic.org

Final Program

Where today’s science meets tomorrow’s care™
The following members of the Education Committee have disclosed no financial relationships with commercial interests:

Carey C. Thomson, MPH, MD, Chair
Jason T. Poston, MD, Vice Chair
Gaetane C. Michaud, MD, Vice Chair
Jay S. Balachandran, MD
Debra M. Boyer, MD

Courtney Broadus
Samuel Brown, MD, MS
William G. Carlos, MD
Colleen L. Channick, MD
Charles Dela Cruz, MD, PhD
Rebecca Disler, MSc, BSc, BN, RN
Thomas W. Ferkol, MD
Henry E. Fessler, MD
David Gozal, MD
Mary Harbaugh, PhD
Shazia M. Jamil, MD
Carl A. Kaplan, MD
Patrick Lyons, MD
Atul Malhotra, MD
Jakob I. McSparron, MD
Paul E. Moore, MD
Jeremy E. Orr, MD
Susan Pasnick, MD
Grace W. Pien, MD, MS
Jessica E. Pittman, MD, MPH
Renee D. Stapleton, PhD, MD
Tisha S. Wang, MD
Carolyn H. Welsh, MD

The following members of the Education Committee have disclosed the following financial relationships with commercial interests:

Ira M. Cheifetz, MD: Hill-Rom (research support) and Philips Respironics (advisory committee)
Alison S. Clay, MD: Oakstone Publishing (reviewer)
Margaret M. Hayes, MD: Oakstone Publishing (reviewer)
Kevin L. Kovitz, MD, MBA: Olympus (research support) and PneumRx (research support)
Suzanne C. Lareau, RN, MS, FAAN: Boehringer Ingelheim (advisory committee)
Andrew Luks, MD: Springer (author royalties)
Daiana Stolz: Brahms (speaker)
Mary E. Strek, MD: BMS and Gilead (research support)

The following members of the International Conference Committee have disclosed no financial relationships with commercial interests:

Zea Borok, MD, Chair
Jess Mandel, MD, Chair Appointee
Juan C. Celedon, MD, DrPH
JiYeon Choi, PhD, RN
Colin R. Cooke, MD

Angela Haczku, MD, PhD
Steven M. Kawut, MD, MS
Anastassios C. Koumbourlis, MD, MPH
Marilyn Moy, MD, MSc
Robert L. Owens, MD
Karen M. Ridge, PhD
Margaret Rosenfeld, MD, MPH
Jussi J. Saukkonen, MD
Sally J. Singh, PhD
Gwen S. Skloot, MD
Anne I. Sperling, PhD
Renee D. Stapleton, PhD, MD
Lynn T. Tanoue, MD
Mihaela Teodorescu, MD, MS
Renda S. Wiener, MD, MPH
Janelle Yorke, RN, PhD

The following members of the International Conference Committee have disclosed the following financial relationships with commercial interests:

Sonye K. Danoff, MD, PhD: Boehringer Ingelheim (speaker, Advisory Committee)
Ivor S. Douglas, MD: Accelerate Diagnostics (Advisory Committee)
Charles Feldman, MD, PhD: Aspen GlaxoSmithKline (speaker, Advisory Committee); Pfizer (speaker, Advisory Committee)
Ravi Kalhan, MD, MS: GlaxoSmithKline (research support); PneumRx (research support)
Augusto A. Litonjua, MD: Springer Humana Press (author); UpToDate, Inc. (author)
Geoffrey N. Maksym, PhD: Thorasys Thoracic Medical Systems Inc. (Advisory Committee, stock/options owned)
Patricia J. Sime, MD: Boehringer Ingelheim (consultant); Galecto Pharmaceuticals (Advisory Committee); Interune Pharmaceuticals (Data and Safety Monitoring Board); Maresins Pharma (Advisory Committee); Pulmonary Fibrosis Foundation (Advisory Committee)
This year the session portion of the Final Program for the ATS International Conference is available in printed and digital format. This publication contains the programs and speakers for the postgraduate courses, scientific and educational sessions presented at the conference.

You can download this PDF, the Conference APP or access the program via the online program itinerary.

1    Friday Postgraduate Courses
13   Saturday Postgraduate Courses
26   Sunday Conference Sessions
133  Monday Conference Sessions
234  Tuesday Conference Sessions
334  Wednesday Conference Sessions

The information contained in this program is up to date as of March 9, 2016. For the most current session information, please visit the online program itinerary.
PG1 STATE OF THE ART COURSE ON PLEURAL DISEASES: A CASE-BASED APPROACH

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $475 In-Training Member: $300
Non-Member: $550 In-Training Non-Member: $400

Registrants must bring a laptop to the course to view the course material.

Assemblies on Clinical Problems; Allergy, Immunology and Inflammation; Critical Care; Thoracic Oncology

8:00 a.m. - 4:00 p.m. MOSCONE CENTER

Target Audience
Pulmonologist, thoracic surgeons, critical care specialists, nurses and healthcare professionals involved with the management of patients with pleural diseases.

Objectives
At the conclusion of this session, the participant will be able to:
• manage pleural space infections using the best evidence;
• learn and apply evidence-based approaches to management of patients with malignant pleural effusions;
• learn minimally invasive techniques for the diagnosis and treatment of pleural diseases and refer patients appropriately when needed.

Pleural diseases represent a considerable burden for patients, providers, and the healthcare system as a whole. Traditionally, management of pleural diseases has been based on empiric approaches largely relying on expert opinion and anecdotal evidence. The last decade has witnessed unprecedented research efforts from the pleural community, which have resulted in the development of evidence-based recommendations. In this session, we will review this evidence in a practical case-based format and provide hands-on experience highlighting the techniques now considered standard of care.
PG2A CRITICAL CARE ULTRASOUND AND ECHOCARDIOGRAPHY: PART I

This is part 1 of a two-part course which includes PG2B on Saturday, May 14. Those registering for PG2A will be registered for PG2A and PG2B.

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $900 In-Training Member: $675
Non-Member: $1,200 In-Training Non-Member: $775

Registrants must bring a laptop to the course to view the course material.

Assembly on Critical Care
8:00 a.m. - 4:00 p.m. MOSCONE CENTER
Room 2008 (West Building, Level 2)

Target Audience
Providers of adult and pediatric critical care or emergency medicine.

Objectives
At the conclusion of this session, the participant will be able to:

• apply hands-on ultrasound techniques at bedside to assess critically ill patients and recognize alternative etiologies of shock;
• understand and administer hands-on ultrasound techniques to guide fluid administration in the critically ill patient;
• apply hands-on ultrasound techniques to guide common ICU procedures.

This is a 2-day postgraduate course that consists of didactic lectures and hands-on stations. The focus is primarily bedside transthoracic echocardiography, with some diagnostic ultrasound. The topics include basic and intermediate critical care echocardiography (including hemodynamic measures), assessment of fluid status, procedural guidance for vascular access and thoracentesis, venography. The hands-on stations will include both healthy models and simulators that can demonstrate abnormal pathology. A track will be offered for pediatric intensivists as well, with pediatric intensivists teaching hands-on skills.

Chairing: M.J. Lanspa, MD, MS, Salt Lake City, UT
X. Monnet, MD, PhD, Paris, France

8:00 Welcome and Introduction to Critical Care Ultrasound: Training and Competency
M.J. Lanspa, MD, MS, Salt Lake City, UT

8:20 Basic Physics, Artifacts, Knobology
Z. Shaman, MD, Cleveland, OH

8:45 Transthoracic Windows and Views, FATE Exam
S. Nikravan-Weber, MD, Stanford, CA

9:15 Basic Evaluation of LV, Systolic Function, Cardiac Output
S. Price, MBBS, PhD, EDICM, London, United Kingdom

9:45 Basic Evaluation of RV Size and Function
A. Leibowitz, MD, Boston, MA

10:15 Break

10:30 Practical Skills Sessions: Hands-On Stations I

Apical Window
X. Monnet, MD, PhD, Paris, France
T. Brakke, MD, Omaha, NE
Z. Shaman, MD, Cleveland, OH
A. Leibowitz, MD, Boston, MA
L. Grecu, MD, Stony Brook, NY

Parasternal Window
P. Mohabir, MD, Stanford, CA
M. Hamlin, MD, Burlington, VT
J. Kasal, MD, St. Louis, MO
S. Price, MBBS, PhD, EDICM, London, United Kingdom
S. Nikravan-Weber, MD, Stanford, CA

Subcostal Window
C.K. Grissom, MD, Murray, UT
L. Rapoport, MD, Santa Clara, CA
V.A. Dinh, MD, Loma Linda, CA
E. Teo, MD, Atlanta, GA
J.E. Pittman, MD, Salt Lake City, UT

Chairing:
M.J. Lanspa, MD, MS, Salt Lake City, UT
X. Monnet, MD, PhD, Paris, France

8:00 Welcome and Introduction to Critical Care Ultrasound: Training and Competency
M.J. Lanspa, MD, MS, Salt Lake City, UT

8:20 Basic Physics, Artifacts, Knobology
Z. Shaman, MD, Cleveland, OH

8:45 Transthoracic Windows and Views, FATE Exam
S. Nikravan-Weber, MD, Stanford, CA

9:15 Basic Evaluation of LV, Systolic Function, Cardiac Output
S. Price, MBBS, PhD, EDICM, London, United Kingdom

9:45 Basic Evaluation of RV Size and Function
A. Leibowitz, MD, Boston, MA

10:15 Break

10:30 Practical Skills Sessions: Hands-On Stations I

This session and the International Conference are supported by an in-kind grant from FUJIFILM SonoSite, Inc.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
PG3  GENETIC PULMONARY MEDICINE

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350  In-Training Member: $200
Non-Member: $425  In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Allergy, Immunology and Inflammation; Clinical Problems; Respiratory Cell and Molecular Biology

8:00 a.m. - 4:00 p.m.  MOSCONE CENTER
Room 2003 (West Building, Level 2)

Target Audience
All pulmonary physicians, pulmonary physician assistants, pulmonary fellows who care for patients with respiratory disease.

Objectives
At the conclusion of this session, the participant will be able to:

• recognize and diagnose genetic lung diseases including short telomere syndrome, primary ciliary dyskinesia, surfactant deficiency, LAM and BHD;

• better integrate new treatment options in discussing HHT, CF, or LAM with patients;

• apply basic principles of genetics and genotype-phenotype correlation, together with current classification of genetic variants to better interpret genetic test results.

This course will provide attendees with a comprehensive overview of the ever increasing role of genetics in the practice of pulmonary medicine. Regardless of background, attendees will come away from this course with a solid understanding of the basic principles of clinical genetics. Attendees will understand when to suspect genetic disease in patients with lung disease and will be able to determine if testing in these patients is warranted. Attendees will learn how to interpret genetic test results, and determine when further investigations are required. The course will conclude with an interactive case-based session of four clinical scenarios.

Chairing:  B.A. Raby, MD, MPH, Boston, MA
            M. Leigh, MD, Chapel Hill, NC

8:00  Introductions and Outline
       B.A. Raby, MD, MPH, Boston, MA

8:15  Molecular Genetics 101: Mutations vs SNPs and How They Cause Disease
       L. Yonker, MD, Boston, MA

8:40  Interpreting Genetic Reports: Is My Mutation Pathogenic?
       S. Amr, PhD, Cambridge, MA

9:20  Genetic Counseling: Why It Matters
       N. Carmichael, CGC, Boston, MA

9:45  Break

10:00  Neonatal Respiratory Distress: How Rapid Genetic Screening is Changing Clinical Practice
        N. Hamvas, MD, Chicago, IL

10:25  Interstitial Lung Disease: Telomeres, Surfactant, and All that MUC
       C.K. Garcia, MD, PhD, Dallas, TX

10:50  Bronchiectasis 1: The Dawn of a New Age in the Treatment of CF
       J.M. Collaco, MD, Baltimore, MD

11:20  Bronchiectasis 2: Primary Ciliary Dyskinesia - Time for a New Diagnostic Algorithm
       M. Knowles, MD, Chapel Hill, NC

11:45  LUNCH

12:45  Emphysema: Alpha-1-Antitrypsin Deficiency and Beyond
       M. Brantly, MD, Gainesville, FL

1:10  Cystic Lung Disease: From LAM to Birt-Hogg-Dube
       E. Henske, MD, Boston, MA

1:35  Pulmonary Vasculopathies: From PPH to HHT
       C.G. Elliott, MD, Murray, UT

2:00  Break

2:15  The Increasingly Blurring of the Lines Between Clinical Practice and Genetic Research
       L.M. Nogee, MD, Baltimore, MD

2:40  Case-Based Workshop
       B.A. Raby, MD, MPH, Boston, MA
       L. Yonker, MD, Boston, MA
       N. Carmichael, CGC, Boston, MA
       M. Leigh, MD, Chapel Hill, NC

3:50  Concluding Remarks
       M. Leigh, MD, Chapel Hill, NC

This session and the International Conference are supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

PG4  PALLIATIVE CARE IN THE ICU: CLINICAL, ETHICAL,
     AND RESEARCH CHALLENGES

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $400  In-Training Member: $250
Non-Member: $475  In-Training Non-Member: $350

Registrants must bring a laptop to the course to view the course material.

Assemblies on Behavioral Science and Health Services Research; Critical Care; Nursing

8:00 a.m. - 4:15 p.m.  MOSCONE CENTER

3022 (West Building, Level 3)
Target Audience
Providers in the ICU (physicians, nurses, social workers and therapists) who wish to learn more about the importance of providing effective palliative care (PC) and end of life (EOL) care in the ICU. Additionally, anyone conducting research on dying patients in the ICU will benefit from this course.

Objectives
At the conclusion of this session, the participant will be able to:
• have new strategies to manage the care of the dying patient in the ICU;
• understand the ethical issues related to palliative and end of life care in the ICU and apply the recent ATS guidelines;
• improve communication with dying patients and their families in the ICU.

This novel postgraduate course will focus on providing the learner with the current evidence and best practices for palliative care in the ICU. This course is unique in that it will cover this topic from clinical, ethical and research perspectives, and will be appealing to multiple learners.

Chairing:
M.M. Hayes, MD, Boston, MA
J.R. Curtis, MD, MPH, Seattle, WA

8:00 Welcome and Conference Goals
J.R. Curtis, MD, MPH, Seattle, WA
M.M. Hayes, MD, Boston, MA

Clinical Challenges
8:10 Palliative Care (PC) in the ICU
J.R. Curtis, MD, MPH, Seattle, WA

Case Studies in Specific Difficult EOL Issues
8:55 Treating Dyspnea in the Dying
M.L. Campbell, PhD, RN, Detroit, MI

10:25 What Do We Do with the LVAD? EOL in the Cardiac ICU
S.P. Keller, MD, PhD, Pittsburgh, PA

10:55 Questions and Answers: Panel Discussion
M.L. Campbell, PhD, RN, Detroit, MI
R.S. Stephens, MD, Baltimore, MD
D. Brodie, MD, New York, NY
S.P. Keller, MD, PhD, Pittsburgh, PA

11:15 Break

11:30 Effective Communications in the ICU
M.M. Hayes, MD, Boston, MA

11:45 Simulated Family Meetings
M.M. Hayes, MD, Boston, MA
D. Lamas, MD, Boston, MA
E.K. Kross, MD, Seattle, WA
J.R. Curtis, MD, MPH, Seattle, WA
G.L. Anesi, MD, MBE, Philadelphia, PA
R.S. Stephens, MD, Baltimore, MD
A.C. Long, MD, MS, Seattle, WA
S.P. Keller, MD, PhD, Pittsburgh, PA
A.E. Turnbull, DVM, MPH, PhD, Baltimore, MD

12:45 LUNCH

Ethical Challenges
1:30 The Ethics of End of Life
Speaker To Be Announced

2:15 Ask the Experts: A Multidisciplinary Discussion of the Policy Statement
J.R. Curtis, MD, MPH, Seattle, WA
G.L. Anesi, MD, MBE, Philadelphia, PA
A.E. Turnbull, DVM, MPH, PhD, Baltimore, MD

2:50 Break

Research Challenges
3:00 Conducting Research on the Dying
A.E. Turnbull, DVM, MPH, PhD, Baltimore, MD

3:30 Top 10 PC/EOL in the ICU Studies
E.K. Kross, MD, Seattle, WA

4:00 Wrap up, Questions and Answers
M.M. Hayes, MD, Boston, MA
J.R. Curtis, MD, MPH, Seattle, WA

CLINICAL POSTGRADUATE COURSE
CME Credits Available: 6.5
PG5 THORACIC IMAGING FOR THE PULMONOLOGIST AND CRITICAL CARE PHYSICIAN

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.
Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Clinical Problems; Microbiology, Tuberculosis and Pulmonary Infections; Pulmonary Circulation; Thoracic Oncology
8:00 a.m. - 4:00 p.m. MOSCONE CENTER
Room 3007 (West Building, Level 3)

Target Audience
Pulmonologists, critical care physicians, thoracic surgeons, mid level providers, residents, fellows, and students.

Objectives
At the conclusion of this session, the participant will be able to:
• formulate a differential diagnosis of respiratory diseases based on diagnostic imaging findings;
• improve strategies for the evaluation of solitary pulmonary nodules and for staging lung cancer;
• state the value of a multidisciplinary approach to diagnosis and management of patients with diffuse lung disease.

This course will review major aspects of thoracic imaging with presentations targeted toward the pulmonologist and critical care physician. Subspecialized thoracic radiologists will give lectures focusing on the practical aspects of chest
imaging. Lectures will be image rich and focus on key imaging findings, differential diagnoses, and potential pitfalls. Topics will cover a broad range of chest disease and will be relevant to trainees, generalists, and specialists, alike. At the conclusion of the course, learners will have increased knowledge about thoracic imaging and be able to apply this knowledge to their respective practices.

Chairing: J.P. Kanne, MD, Madison, WI
C.C. Wu, MD, Houston, TX

8:00 Imaging of Small Airways Diseases
T.S. Henry, MD, San Francisco, CA

8:30 Imaging of Large Airways Diseases
S. Rossi, MD, Buenos Aires, Argentina

9:00 Imaging of Pulmonary Vascular Diseases
J.P. Kanne, MD, Madison, WI

9:30 Pulmonary Thromboembolism
C. Schaefer-Prokop, MD, Nijmegen, Netherlands

10:00 Break

10:15 Imaging of Pleural Diseases
C.C. Wu, MD, Houston, TX

10:45 Solitary Pulmonary Nodule
J.H. Chung, MD, Chicago, IL

11:15 Lung Cancer Imaging
A. Leung, MD, Stanford, CA

11:45 LUNCH

12:45 HRCT of Diffuse Lung Disease
L. Ketai, MD, Albuquerque, NM

1:15 Pulmonary Infection
D.A. Lynch, MD, Denver, CO

2:00 Multidisciplinary Approach to Diffuse Lung Diseases
K.K. Brown, MD, Denver, CO
D.A. Lynch, MD, Denver, CO
S. Groshong, MD, Denver, CO

8:00 a.m. - 3:55 p.m. MOSCONET CENTER
Room 3016/3018 (West Building, Level 3)

Target Audience
Clinicians, nurses, other allied health staff, researchers, investigators in basic and clinical science pertinent to interstitial lung disease, sponsors for research.

Objectives
At the conclusion of this session, the participant will be able to:

• accurately diagnosis patients with specific forms of ILD;
• understand the current concepts in the pathogenesis and genetic aspects of pulmonary fibrosis and new therapeutic strategies to treat patients with ILD/pulmonary fibrosis;
• provide better care to the patients with ILD through comprehensive management strategies.

This course provides an introduction and update on the diagnosis and management of interstitial lung disease (ILD), with particular attention to the chronic fibrotic ILDs and sarcoidosis. Discussion of the clinical, radiological, and pathological approaches to the diagnosis of ILD will be supplemented by case presentations that illustrate the multidisciplinary nature of diagnosis in action. Additional talks will focus on the comprehensive management of ILD including novel therapies, symptoms management, and lung transplantation.

Chairing: G. Raghu, MD, Seattle, WA
L. Richeldi, MD, PhD, Southampton, United Kingdom

8:00 Introduction and Conference Goals
G. Raghu, MD, Seattle, WA

8:05 Interstitial Lung Disease : An Overview and Approach to Diagnosis
G. Raghu, MD, Seattle, WA

8:30 Imaging in ILD: Clues to Diagnosis
D.A. Lynch, MD, Denver, CO

9:00 Histopathology Features of ILD
J.L. Myers, MD, Ann Arbor, MI

9:25 Connective Tissue Disease for the Pulmonologist in Evaluating Interstitial Lung Disease: A Rheumatologists View
V. Steen, MD, Washington, DC

9:50 Genetic Predisposition Factors of Pulmonary Fibrosis: Time for Genetic Screening and Intervention?
I. Noth, MD, Chicago, IL

10:15 Break

10:25 Hypersensitivity Pneumonitis
M. Vasakova, MD, PhD, Prague, Czech Republic

10:50 Pulmonary Fibrosis: Concepts in Pathogenesis and Targets for Treatment
A.M. Tager, MD, Charlestown, MA

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

This session and the International Conference are supported by an educational grant from AstraZeneca LP.

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350  In-Training Member: $200  Non-Member: $425  In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350  In-Training Member: $200  Non-Member: $425  In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.
11:15 Case Discussion with Panel of Experts (Multidisciplinary Discussion)
B. Collins, MD, Seattle, WA
L. Ho, MD, Seattle, WA

12:15 LUNCH

12:45 Interstitial Lung Disease, Other than IPF Associated with Cigarette Smoking
K.R. Flaherty, MD, MS, Ann Arbor, MI

1:10 Lymphangioleiomyomatosis (LAM)
M. Glassberg, MD, Miami, FL

1:35 Sarcoidosis: New Treatment Beyond Prednisone and Methotrexate
D.A. Culver, DO, Cleveland, OH

1:55 Co-Morbidities in Patients with IPF
J. Behr, MD, Munich, Germany

2:20 Break

2:30 Idiopathic Pulmonary Fibrosis: Current Treatment, Assessment of Treatment Response and Monitoring Clinical Course
F.J. Martinez, MD, New York, NY

2:55 Reducing Symptoms and Cough and Improving Quality of Life for Patients with IPF: Therapeutic Needs Versus Palliative Care
M. Wijsenbeek, MD, PhD, Rotterdam, Netherlands

3:15 Lung Transplantation for Patients with ILD
E.D. Lease, MD, Seattle, WA

3:35 New Treatment Directions for IPF: Current Status of Ongoing and Upcoming Clinical Trials
L. Richeldi, MD, PhD, Southampton, United Kingdom

Target Audience
Pediatric intensivists; pediatric pulmonologists; adult intensivists who manage children; respiratory therapists; perfusionists; critical care nurse practitioners.

Objectives
At the conclusion of this session, the participant will be able to:

- discuss the optimal conventional ventilatory approach to the child with ARDS;
- explore the recent advances based on published data in the management of the pediatric ARDS patient;
- consider the possibilities for future strategies to further improve clinical outcomes for pediatric ARDS.

The management approach for pediatric acute respiratory distress syndrome has traditionally been based on extrapolated data from adult patients and anecdotal experience in pediatrics. The recent Pediatric Acute Lung Injury Consensus Conference has provided the first pediatric based approach to the management of the child with ARDS. This course will review the available data, explore possible therapeutic options, and discuss recommended approaches to the pulmonary management of the pediatric ARDS patient. Time will be allocated to audience participation via two panel discussions and an interactive case discussion.

Chairing:
I.M. Cheifetz, MD, Durham, NC
J. Arnold, MD, Boston, MA

8:00 Welcome and Introduction
I.M. Cheifetz, MD, Durham, NC
J. Arnold, MD, Boston, MA

8:10 Optimizing Conventional Mechanical Ventilation
I.M. Cheifetz, MD, Durham, NC

8:45 PEEP Titration/Lung Recruitment
G. Wolf, MD, Boston, MA

9:20 High Frequency Oscillatory Ventilation
J. Arnold, MD, Boston, MA

9:55 Break

10:15 Modes to Augment Patient-Ventilator Synchrony
G. Emeriaud, MD, PhD, Montreal, Canada

10:50 Prone Positioning
M.A.Q. Curley, PhD, RN, Philadelphia, PA

11:25 Neuromuscular Blockade
M.C.J. Kneyber, MD, PhD, Groningen, Netherlands

12:00 Panel Discussion

12:30 LUNCH

1:30 Inhaled Nitric Oxide
A. Rotta, MD, Cleveland, OH

2:00 Venovenous ECMO
H.J. Dalton, MD, Anchorage, AK

2:30 Break

2:50 Case Discussion
I.M. Cheifetz, MD, Durham, NC
M.A.Q. Curley, PhD, RN, Philadelphia, PA

3:25 Panel Discussion

3:50 Course Summary
I.M. Cheifetz, MD, Durham, NC
J. Arnold, MD, Boston, MA

PG7 PEDIATRIC ACUTE RESPIRATORY DISTRESS SYNDROME: AN EVIDENCE-BASED APPROACH TO MANAGEMENT

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350	In-Training Member: $200
Non-Member: $425	In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Critical Care; Pediatrics
8:00 a.m. - 4:00 p.m.
MOSCON CENTER
Room 2005 (West Building, Level 2)

This session and the International Conference are supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
PG8 CRITICAL CARE MEDICINE FOR ADVANCED PRACTICE PROVIDERS (NP/PA)

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $200  In-Training Member: $125
Non-Member: $238  In-Training Non-Member: $175

Registrants must bring a laptop to the course to view the course material.

Objectives
At the conclusion of this session, the participant will be able to:

• evaluate and manage patients with critical illness, including acute respiratory failure, acute respiratory distress syndrome, shock, sepsis, and nosocomial infections;
• develop a systematic approach to chest radiograph interpretation, arterial blood gas interpretation, and mechanical ventilation troubleshooting;
• describe a basic approach to the use of sedation and analgesia in the intensive care unit, including methods of assessment for sedation and delirium.

This postgraduate course is designed for advanced practice providers and is comprised of nine 45-minute sessions on core critical care topics. The talks will have a focus on evidence-based management of commonly encountered conditions such as acute respiratory failure, shock, sepsis, and nosocomial infections. Skill based sessions on chest radiograph interpretation, arterial blood gas interpretation, and mechanical ventilation troubleshooting will be included. Sessions will be designed to be interactive and case-based, with opportunities for breakout sessions and team-based problem solving.

Chairing: B. Coruh, MD, Seattle, WA
L.D. Rosenthal, ACNP, DNP, Aurora, CO

8:00 Acute Respiratory Failure
G.A. Schmidt, MD, Iowa City, IA

8:45 Mechanical Ventilation
B. Coruh, MD, Seattle, WA

9:30 Break

9:45 Acute Respiratory Distress Syndrome
P. Senecal, ACNP, CCNS, Aurora, CO

10:30 Sedation, Analgesia, and Delirium
L.D. Rosenthal, ACNP, DNP, Aurora, CO

11:15 Shock and Vasopressors
D. Holloway, ACNP, MSN, Cleveland, OH

8:00 a.m. - 4:00 p.m.  MOSCONEx CENTER
Room 2024 (West Building, Level 2)

PG9 THE PHYSIOLOGY OF PEDIATRIC RESPIRATORY FAILURE

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350  In-Training Member: $200
Non-Member: $425  In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Objectives
At the conclusion of this session, the participant will be able to:

• apply several basic respiratory principles to the diagnosis and management of children with respiratory failure;
• learn how physiologic measurements can be used to change interventions and enhance outcomes;
• identify the rationale for several measurement techniques and determine when these should be used.

This postgraduate course is designed for advanced practice providers and is comprised of nine 45-minute sessions on core critical care topics. The talks will have a focus on evidence-based management of commonly encountered conditions such as acute respiratory failure, shock, sepsis, and nosocomial infections. Skill based sessions on chest radiograph interpretation, arterial blood gas interpretation, and mechanical ventilation troubleshooting will be included. Sessions will be designed to be interactive and case-based, with opportunities for breakout sessions and team-based problem solving.

Chairing: B. Coruh, MD, Seattle, WA
L.D. Rosenthal, ACNP, DNP, Aurora, CO

8:00 Acute Respiratory Failure
G.A. Schmidt, MD, Iowa City, IA

8:45 Mechanical Ventilation
B. Coruh, MD, Seattle, WA

9:30 Break

9:45 Acute Respiratory Distress Syndrome
P. Senecal, ACNP, CCNS, Aurora, CO

10:30 Sedation, Analgesia, and Delirium
L.D. Rosenthal, ACNP, DNP, Aurora, CO

11:15 Shock and Vasopressors
D. Holloway, ACNP, MSN, Cleveland, OH

8:00 a.m. - 4:00 p.m.  MOSCONEx CENTER
Room 3014 (West Building, Level 3)
8:00 a.m. - 4:00 p.m.  
MOSCONET CENTER

Room 2022 (West Building, Level 2)

**Target Audience**
Lung health care providers, clinical and research fellow, investigators interested or involved in basic, translational and clinical research related to airway biology and pathogenesis of chronic lung diseases, research and care providers engaged in pulmonary and critical care medicine.

**Objectives**
At the conclusion of this session, the participant will be able to:

- understand fundamental principles, heterogeneous phenotypes and specific mechanisms of airway remodeling in chronic human lung diseases; and how different cell types in the human airways interact with each other during the development of disease-associated remodeling phenotypes.
- learn about advanced state of art methods and technologies to model and study human airway remodeling using patient derived samples.
- implement current knowledge about airway remodeling in everyday research and understand how to translate the novel knowledge about complex mechanisms and phenotypes of airway remodeling into clinically relevant precision medicine approaches to better prevent, diagnose and treat human lung disease in a personalized manner.

This course will have an innovative, “lab meeting” format, first successfully introduced at the ATS International Conference in 2015 by Dr. Shaykhiev and colleagues. As compared to the prior “big lab meeting” postgraduate course (PG25), which was focused on airway epithelium, the specific theme of the current session - airway remodeling - is broader and more multidisciplinary and translational in nature. The course will provide discussion of recent advancements in understanding of the contributions of and interactions among various tissue components (epithelium, fibroblasts, extracellular matrix, smooth muscle cells, vasculature, and innate immune cells) to airway remodeling in human chronic lung diseases. Special emphasis will be made on personalized approaches to study human airway remodeling and novel precision medicine approaches to prevent and treat lung diseases characterized by airway remodeling.

**Chairing:**
R. Shaykhiev, MD, PhD, New York, NY
M. Konigshoff, MD, PhD, Munich, Germany
R. Freishat, MD, MPH, Washington, DC

**8:00** Airway Remodeling: Introduction to a Big Lab Meeting 2016

**8:10** Keynote Lecture: The Many Faces of Airway Remodeling in Lung Disease
J.C. Hogg, MD, PhD, Vancouver, Canada

**8:40** Basal Stem Cells and Airway Remodeling in COPD
R. Shaykhiev, MD, PhD, New York, NY

**9:00** Cellular Origins of Airway Remodeling in Asthma
T. Hackett, PhD, Vancouver, Canada

**9:20** Airway Regeneration and Remodeling in Cystic Fibrosis
C. Coraux, PhD, Reims, France

**9:40** Patient-Derived Models of Airway Remodeling
S.H. Randell, PhD, Chapel Hill, NC

**10:00** Break

---

**AIRWAY REMODELING IN HUMAN LUNG DISEASE: A BIG LAB MEETING 2016**

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

- **Member:** $350
- **In-Training Membership:** $200
- **Non-Member:** $425
- **In-Training Non-Member:** $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Clinical Problems; Critical Care; Environmental, Occupational and Population Health; Microbiology, Tuberculosis and Pulmonary Infections; Pediatrics; Pulmonary Circulation; Pulmonary Rehabilitation; Respiratory Structure and Function; Sleep and Respiratory Neurobiology; Thoracic Oncology
10:10  Extracellular Matrix, Mechanotransduction and Airway Remodeling  
D. Tschumperlin, PhD, Rochester, MN

10:30  Epithelial-Matrix Interactions in Preclinical Models of Asthma  
R. Freishtat, MD, MPH, Washington, DC

10:50  Airway Fibroblasts and Subepithelial Fibrosis in Asthma  
M. Kraft, MD, Tucson, AZ

11:10  Angiogenesis and Vascular Remodeling in Chronic Lung Diseases  
E.H. Walters, DM, DSc, Hobart Tasmania, Australia

11:30  Break

11:45  Luncheon Sessions: Airway Inflammation, Remodeling, and Disease  
Keynote Lecture: Inflammatory Mechanisms and Structural Changes in Airway Disease  
P.J. Barnes, MD, DSc, London, United Kingdom

11:50  How Innate Immunity Contributes to Airway Remodeling in Lung Disease  
M.J. Holtzman, MD, St. Louis, MO

12:00  Mechanisms Linking Inflammation and Airway Fibrosis in COPD  
S. Nishimura, MD, San Francisco, CA

12:10  Mast Cells and Airway Smooth Muscle Remodeling in Asthma and COPD  
C.E. Brightling, BSc, MBBS, PhD, Leicester, United Kingdom

12:20  Molecular Signatures of Airway Remodeling: Towards Precision Medicine  
M. van den Berge, MD, Groningen, Netherlands

1:45  Break

2:00  “A Big Lab Meeting”  
R. Shaykhiev, MD, PhD, New York, NY  
M. Konigshoff, MD, PhD, Munich, Germany  
R. Freishtat, MD, MPH, Washington, DC  
J.C. Hogg, MD, PhD, Vancouver, Canada  
T. Hackett, PhD, Vancouver, Canada  
C. Coraux, PhD, Reims, France  
S.H. Randell, PhD, Chapel Hill, NC  
D. Tschumperlin, PhD, Rochester, MN  
M. Kraft, MD, Tucson, AZ  
E.H. Walters, DM, DSc, Hobart Tasmania, Australia  
P.J. Barnes, MD, DSc, London, United Kingdom  
M.J. Holtzman, MD, St. Louis, MO  
S. Nishimura, MD, San Francisco, CA  
C.E. Brightling, BSc, MBBS, PhD, Leicester, United Kingdom  
M. van den Berge, MD, Groningen, Netherlands

PG11  TESTING IN THE PULMONARY FUNCTION LAB: FROM PHYSIOLOGY TO CLINICAL PRACTICE

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.
Member: $350  In-Training Member: $200  
Non-Member: $425  In-Training Non-Member: $300
Registrants must bring a laptop to the course to view the course material.

Assemblies on Respiratory Structure and Function; Clinical Problems  
8:00 a.m. - 4:00 p.m.  
Room 2014 (West Building, Level 2)

8:00  Introduction to Pulmonary Function Testing from Simple to Complex  
M.C. McCormack, MD, MHS, Baltimore, MD  
D.A. Kaminsky, MD, Burlington, VT  
C.E. Berry, MD, Tucson, AZ

8:10  Lung Function Across the Ages  
M. Rosenfield, MD, MPH, Seattle, WA

8:40  As You Predicted...Interpretation of Spirometry and Updates In Reference Equations  
B.H. Culver, MD, Olga, WA

9:10  When Size Matters- Measurement of Lung Volumes  
B. Borg, BAppSc, CRFS, Prahran, Australia

9:40  Break

9:55  Clearing Up the Confusion Between DLCO and KCO (DLCO/VA)  
C.E. Berry, MD, Tucson, AZ
Advanced Troubleshooting for Pulmonary Function Equipment
G.L. Ruppel, MEd, RRT, RPFT, St. Louis, MO

Make Your Case
G. Hall, PhD, Subiaco, Australia

The Forced Oscillation Technique: What’s Forced? What’s Oscillating? And How Can We Use It?
D.A. Kaminsky, MD, Burlington, VT

Measuring Airways Inflammation in the PFT Lab (Use of Fractional Exhaled Nitric Oxide)
M.C. McCormack, MD, MHS, Baltimore, MD

Going the Distance with High Altitude Simulation Testing
C.D. Mottram, RRT, RPFT, Rochester, MN

Do We Have Clearance? The Use of Multiple Breath Nitrogen Washout
P. Latzin, MD, PhD, Basel, Switzerland

Bronchoprovocation Testing
T.S. Hallstrand, MD, MPH, Seattle, WA

Approaching the Patient with Suspected Neuromuscular Weakness
N. Lechtzin, MD, Baltimore, MD

Complex Cases
D. Weiner, MD, Pittsburgh, PA

Sleep and Critical Illness: Bridging The Two Pillars!

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350  In-Training Member: $200
Non-Member: $425  In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Sleep and Respiratory Neurobiology; Clinical Problems; Critical Care; Nursing; Pediatrics

8:00 a.m. - 4:00 p.m.  MOSCONE CENTER
Room 3020 (West Building, Level 3)

Target Audience
Critical care and sleep physicians, nurses, researchers, trainees, and pharmacists.

Objectives
At the conclusion of this session, the participant will be able to:
• learn new findings about the mechanistic underpinnings of the interactions between sleep, circadian rhythms and critical illness;
• gain new strategies to manage the care of critically ill patients with sleep disturbances;
• improve the quality of life/health status of their critically ill patients by improving their sleep and circadian rhythms.

Sleep and critical illness are individually complex processes with significant implications to health and well being. The interaction between these two complex spheres can cause morbidity and mortality during critical illness and furthermore leave sequelae upon recovery. Sleep and circadian derangements and disorders are common in patients suffering from critical illness. Identifying the pathophysiology of sleep and circadian derangements in critically ill patients and instituting appropriate management improves sleep disturbances and may provide long term benefit. This postgraduate course will discuss the mechanistic underpinnings of the interactions between sleep, circadian rhythms and critical illness; the clinical implications of such complex interactions; and raise awareness and insights of clinicians and scientists.

Chairs: B.K. Gehlbach, MD, Iowa City, IA
R.L. Owens, MD, La Jolla, CA
M. Knauert, MD, PhD, New Haven, CT

8:00 Introduction: Sleep and Critical Illness: The Two Pillars Shall Meet!
S. Parthasarathy, MD, Tucson, AZ

8:10 Neurobiology of Sleep and Sedation: Sleep = Sedation?
M. Maze, MBChB, San Francisco, CA

8:40 Circadian “Dys-Rhythms” of Critical Illness
B.K. Gehlbach, MD, Iowa City, IA

9:10 Measuring Sleep During Critical Illness: A Challenge?
R.L. Owens, MD, La Jolla, CA

9:40 Sleep and Mechanical Ventilation: Modes and Mechanics
K. Bosma, MD, Ontario, Canada

10:00 Break

10:25 Surviving Critical Illness but Suffering Sleep Problems and Sleep Deprivation
S. McKinley, RN, PhD, Sydney, Australia

10:55 Perceived Sleep Quality and Cognition
B. Kamdar, MD, MBA, MHS, Los Angeles, CA

11:25 Sedation Interventions During Critical Illness: More or Less?
M. Pisani, MD, New Haven, CT

11:55 Sleep, Critical Illness and the Developing Brain: The Pediatric ICU
S.R. Kudchadkar, MD, Baltimore, MD

12:25 Lunch

1:20 Sleep and Death: Poor Sleep Leads to Eternal Sleep?
P. Watson, MD, Nashville, TN

1:50 Environmental Interventions to Promote Sleep: More than Just Noise?
M. Knauert, MD, PhD, New Haven, CT

2:20 Break

2:30 Sleep-Disordered Breathing During Critical Illness: Don’t Stop Breathing!
V. Malik, MD, Denver, CO
3:00 Non-Invasive Ventilation During Critical Illness: Sleep Mask?  
X. Drouot, MD, PhD, Poitiers, France

3:30 Sleep Promotion as a Patient-Centered Outcome: Sleep, Nourish, and Heal  
S. Parthasarathy, MD, Tucson, AZ

**BEHAVIORAL • CLINICAL**

**POSTGRADUATE COURSE**

**CME Credits Available: 7.0**

**PG13 IMPLEMENTATION OF CORE COMPONENTS OF A LUNG CANCER SCREENING PROGRAM**

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

<table>
<thead>
<tr>
<th>Membership</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member</td>
<td>$350</td>
</tr>
<tr>
<td>In-Training Member</td>
<td>$200</td>
</tr>
<tr>
<td>Non-Member</td>
<td>$425</td>
</tr>
<tr>
<td>In-Training Non-Member</td>
<td>$300</td>
</tr>
</tbody>
</table>

Registrants must bring a laptop to the course to view the course material.

Assemblies on Thoracic Oncology; Behavioral Science and Health Services Research; Nursing

8:00 a.m. - 4:00 p.m. MOSCONE CENTER  
Room 3011 (West Building, Level 3)

**Target Audience**
Physicians, nurses, and advanced practice nurses who are actively engaged in lung cancer screening or considering starting lung cancer screening programs.

**Objectives**
At the conclusion of this session, the participant will be able to:

- demonstrate an in depth understanding of the critical components of a lung cancer screening program;
- summarize the national screening recommendations and requirements in the provision of lung cancer screening;
- describe how to implement a safe and responsible lung cancer screening program.

This postgraduate course is organized to give participants the critical components of a responsible lung cancer screening program. Each critical component will be discussed in a panel format with 2 discussants followed by question and answer period. Evidence-based presentations will provide both knowledge and tangible tools for direct application to their respective programs. As an example the importance of shared decision making will be discussed and supported by the ATS tool for achieving effective shared decision making, this approach will be replicated for each component giving participants both the knowledge and the tools for effective lung cancer screening.

**Chairing:**  
J.A. Gorden, MD, Seattle, WA  
C.G. Slatore, MD, Portland, OR  
J.T. Fathi, ARNP, ARNP, Seattle, WA

8:00 Introduction  
J.A. Gorden, MD, Seattle, WA

8:10 Patient and Provider Education. Shared Decision Making. What Do Patients Hear?  
C.G. Slatore, MD, Portland, OR

8:50 CT Scan Performance, Nodule Identification and Structured Reporting (Standardization of Imaging and Reporting, LungRads and ACR/CMS Registry Data Base)  
E. Kazerooni, MD, Ann Arbor, MI

9:30 Break

9:40 Screening Eligibility and the Referral. Who Is Offered Screening and for How Long (Avoiding Emotional Screening)  
N.T. Tanner, MD, MSCR, Charleston, SC

10:20 Smoking Cessation (Effective Approaches to Counseling and Treatment in the Setting of Lung Cancer Screening)  
J.T. Fathi, ARNP, DNP, Seattle, WA

11:00 Practical Implementation of a Lung Cancer Screening Program: Example 1 - Yale University  
P. Sather, APRN, New Haven, CT

11:30 Panel Discussion

12:00 LUNCH

12:45 Nodule Management 1-7 mm. The Case for Watchful Waiting (Surveillance Intervals Understanding Nodule Change)  
M.K. Gould, MD, MS, Pasadena, CA

1:15 Lung Nodule Management>8mm (Utilization of National Guidelines Counseling in the Face of the Anxious Patient)  
G.A. Silvestri, MD, Charleston, SC

1:45 Break

1:55 Thoracic Surgery and the Multidisciplinary Lung Cancer Screening Program  
F.C. Detterbeck, MD, New Haven, CT

2:35 Multidisciplinary Approaches to Nodule Sampling  
J.A. Gorden, MD, Seattle, WA

2:55 Practical Implementation and Financial Model of an Innovative Lung Cancer Screening Program: Example 2 - Swedish Cancer Institute  
J.T. Fathi, ARNP, DNP, Seattle, WA

3:20 Panel Discussion

3:30 Break

3:40 Screening Eligibility and the Referral. Who Is Offered Screening and for How Long (Avoiding Emotional Screening)  
N.T. Tanner, MD, MSCR, Charleston, SC

4:20 Smoking Cessation (Effective Approaches to Counseling and Treatment in the Setting of Lung Cancer Screening)  
J.T. Fathi, ARNP, DNP, Seattle, WA

5:00 Practical Implementation of a Lung Cancer Screening Program: Example 1 - Yale University  
P. Sather, APRN, New Haven, CT

5:30 Panel Discussion

6:00 LUNCH

6:45 Nodule Management 1-7 mm. The Case for Watchful Waiting (Surveillance Intervals Understanding Nodule Change)  
M.K. Gould, MD, MS, Pasadena, CA

7:15 Lung Nodule Management>8mm (Utilization of National Guidelines Counseling in the Face of the Anxious Patient)  
G.A. Silvestri, MD, Charleston, SC

7:45 Break

8:05 Thoracic Surgery and the Multidisciplinary Lung Cancer Screening Program  
F.C. Detterbeck, MD, New Haven, CT

8:35 Multidisciplinary Approaches to Nodule Sampling  
J.A. Gorden, MD, Seattle, WA

9:05 Practical Implementation and Financial Model of an Innovative Lung Cancer Screening Program: Example 2 - Swedish Cancer Institute  
J.T. Fathi, ARNP, DNP, Seattle, WA

9:35 Panel Discussion

**This session and the International Conference are supported by an educational grant from AstraZeneca LP.**

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

---

**CLINICAL**

**POSTGRADUATE COURSE**

**CME Credits Available: 6.75**

**PG14 PULMONARY AND CRITICAL CARE REVIEWS: BUILT AROUND THE 2015 ABIM-SEP MODULES**

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

<table>
<thead>
<tr>
<th>Membership</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member</td>
<td>$350</td>
</tr>
<tr>
<td>In-Training Member</td>
<td>$200</td>
</tr>
<tr>
<td>Non-Member</td>
<td>$425</td>
</tr>
<tr>
<td>In-Training Non-Member</td>
<td>$300</td>
</tr>
</tbody>
</table>

Education Committee

8:00 a.m. - 4:00 p.m. MOSCONE CENTER  
Room 1606 (West Building, Level 2)

**Target Audience**
Clinicians practicing pulmonary and/or critical care medicine; clinicians seeking ABIM MOC credit.

8:00 Introduction  
J.A. Gorden, MD, Seattle, WA

8:10 Patient and Provider Education. Shared Decision Making. What Do Patients Hear?  
C.G. Slatore, MD, Portland, OR

8:50 CT Scan Performance, Nodule Identification and Structured Reporting (Standardization of Imaging and Reporting, LungRads and ACR/CMS Registry Data Base)  
E. Kazerooni, MD, Ann Arbor, MI

9:30 Break

9:40 Screening Eligibility and the Referral. Who Is Offered Screening and for How Long (Avoiding Emotional Screening)  
N.T. Tanner, MD, MSCR, Charleston, SC

10:20 Smoking Cessation (Effective Approaches to Counseling and Treatment in the Setting of Lung Cancer Screening)  
J.T. Fathi, ARNP, DNP, Seattle, WA

11:00 Practical Implementation of a Lung Cancer Screening Program: Example 1 - Yale University  
P. Sather, APRN, New Haven, CT

11:30 Panel Discussion

12:00 LUNCH

12:45 Nodule Management 1-7 mm. The Case for Watchful Waiting (Surveillance Intervals Understanding Nodule Change)  
M.K. Gould, MD, MS, Pasadena, CA

1:15 Lung Nodule Management>8mm (Utilization of National Guidelines Counseling in the Face of the Anxious Patient)  
G.A. Silvestri, MD, Charleston, SC

1:45 Break

1:55 Thoracic Surgery and the Multidisciplinary Lung Cancer Screening Program  
F.C. Detterbeck, MD, New Haven, CT

2:35 Multidisciplinary Approaches to Nodule Sampling  
J.A. Gorden, MD, Seattle, WA

2:55 Practical Implementation and Financial Model of an Innovative Lung Cancer Screening Program: Example 2 - Swedish Cancer Institute  
J.T. Fathi, ARNP, DNP, Seattle, WA

3:20 Panel Discussion
Objectives
At the conclusion of this session, the participant will be able to:

• critically review and interpret recent literature in pulmonary and critical care medicine;
• apply recent literature in pulmonary and critical care medicine to clinical practice;
• complete the 2015 ABIM Pulmonary and Critical Care SEP module.

Led by expert faculty, this active learning course is a clinical practice and literature review designed around the most recent ABIM Self Evaluation Process modules in pulmonary and critical care medicine. In addition to a valuable review of high impact medical knowledge and critical thinking, this session will provide a convenient opportunity to fulfill ABIM maintenance of certification requirements while at the ATS international conference.

Chairing: J.T. Poston, MD, Chicago, IL

8:00  Introduction
      J.T. Poston, MD, Chicago, IL

8:10  Critical Care Review
      J.B. Hall, MD, Chicago, IL

9:50  Break

10:00 Critical Care Review
      J.T. Poston, MD, Chicago, IL

11:40 LUNCH

12:30 Pulmonary Review
      J. Mandel, MD, La Jolla, CA

2:10  Break

2:20  Pulmonary Review
      K.A. Smith, MD, Philadelphia, PA
**PG2B  CRITICAL CARE ULTRASOUND AND ECHOCARDIOGRAPHY: PART II**

This is part 2 of a two-part course which includes PG2A on Friday, May 13.

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

See PG2A for course fees.

Registrants must bring a laptop to the course to view the course material.

Assembly on Critical Care

<table>
<thead>
<tr>
<th>Assembly on Critical Care</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 a.m. - 4:00 p.m.</td>
<td>MOSCON CENTER Room 2008 (West Building, Level 2)</td>
</tr>
</tbody>
</table>

**Target Audience**
Providers of adult and pediatric critical care or emergency medicine.

**Objectives**
At the conclusion of this session, the participant will be able to:

- apply hands-on ultrasound techniques at bedside to assess critically ill patients and recognize alternative etiologies of shock;
- understand and administer hands-on ultrasound techniques to guide fluid administration in the critically ill patient;
- apply hands-on ultrasound techniques to guide common ICU procedures.

This is a 2-day post-graduate course that consists of didactic lectures and hands-on stations. The focus is primarily bedside transthoracic echocardiography, with some diagnostic ultrasound. The topics include basic and intermediate critical care echocardiography (including hemodynamic measures), assessment of fluid status, procedural guidance for vascular access and thoracentesis, venography. The hands-on stations will include both healthy models and simulators that can demonstrate abnormal pathology. A track will be offered for pediatric intensivists as well, with pediatric intensivists teaching hands-on skills.

**Chairing:**
M.J. Lanspa, MD, MS, Salt Lake City, UT
X. Monnet, MD, PhD, Paris, France

**8:00** Vascular Ultrasound: DVT Evaluation
L. Rapoport, MD, Santa Clara, CA

**8:20** Vascular Access
M.J. Lanspa, MD, MS, Salt Lake City, UT

**8:45** Tamponade: Diagnosis and Physiology
C.K. Grissom, MD, Murray, UT

**9:15** Using Ultrasound to Assess Intravascular Volume and Fluid Responsiveness
X. Monnet, MD, PhD, Paris, France

**9:45** Ultrasound for Diuresis and Dialysis
E. Hirschberg, MD, MS, Salt Lake City, UT

**10:15** Break

**10:30** Practical Skills Sessions: Hands-On Station III

**Volume Status**
X. Monnet, MD, PhD, Paris, France
P. Mohabir, MD, Stanford, CA
J. Kasal, MD, St. Louis, MO
E. Teo, MD, Atlanta, GA
A. Leibowitz, MD, Boston, MA

**Tamponade Evaluation**
M. Hamlin, MD, Burlington, VT
C.K. Grissom, MD, Murray, UT
S. Price, MBBS, PhD, EDICM, London, United Kingdom
S. Nikravan-Weber, MD, Stanford, CA
T. Brakke, MD, Omaha, NE

**Vascular Ultrasound**
L. Rapoport, MD, Santa Clara, CA
V.A. Dinh, MD, Loma Linda, CA
Z. Shaman, MD, Cleveland, OH
L. Grecu, MD, Stony Brook, NY
J.E. Pittman, MD, Salt Lake City, UT

**12:00** Lunch and Clinical Cases
E. Teo, MD, Atlanta, GA

**12:45** Abdominal Ultrasonography: Hydronephrosis, Ascites, Paracentesis, FAST Exam
V.A. Dinh, MD, Loma Linda, CA

**1:15** Goal Directed Management of Shock Using Echocardiography
J. Kasal, MD, St. Louis, MO

**1:45** Incorporating Echocardiography into Shock and CPR
M. Hamlin, MD, Burlington, VT

**2:15** Break

**2:30** Practical Skills Sessions: Hands-On Session IV

**Echo in Shock and CPR**
P. Mohabir, MD, Stanford, CA
S. Nikravan-Weber, MD, Stanford, CA
T. Brakke, MD, Omaha, NE
S. Price, MBBS, PhD, EDICM, London, United Kingdom
L. Grecu, MD, Stony Brook, NY
Abdominal Ultrasound
L. Rapoport, MD, Santa Clara, CA
V.A. Dinh, MD, Loma Linda, CA
Z. Shaman, MD, Cleveland, OH
A. Leibowitz, MD, Boston, MA
J.E. Pittman, MD, Salt Lake City, UT

Ask the Expert
E. Hirshberg, MD, MS, Salt Lake City, UT
J. Kasal, MD, St. Louis, MO
X. Monnet, MD, PhD, Paris, France
M. Hamlin, MD, Burlington, VT
E. Teo, MD, Atlanta, GA

This session and the International Conference are supported by an in-kind grant from FUJIFILM SonoSite, Inc.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

---

PG15 BRONCHOSCOPY COURSE AND WORKSHOP

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $475
Non-Member: $550

Registrants must bring a laptop to the course to view the course material.

Assemblies on Clinical Problems; Behavioral Science and Health Services Research; Thoracic Oncology

8:00 a.m. - 4:00 p.m. MOSCONE CENTER Room 2005 (West Building, Level 2)

Target Audience
Pulmonary and thoracic surgery fellows in training, allied health professionals, anesthesiologists and those interested in quality improvement and implementation of clinical programs. Clinicians interested in skills in basic bronchoscopy.

Objectives
At the conclusion of this session, the participant will be able to:

- understand how to apply the techniques and principles of bronchoscopy, using both didactic teaching methods as well as hands-on training;
- support the standardization and the practice of bronchoscopy.

The bronchoscopy course and workshop addresses evidence-based bronchoscopy topics pertinent to core skills in an accredited pulmonary fellowship program. Techniques covered include various diagnostic skills with airway examination, biopsy of lung parenchyma and lymph nodes, as well as incorporating new technologies to apply to management of patients with chest and/or airway diseases.

Chairing: J.A. Gorden, MD, Seattle, WA
A.W. Sung, MD, Stanford, CA
K.L. Kovitz, MD, MBA, Elk Grove Village, IL
Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.
Member: $350
Non-Member: $425
In-Training Member: $200
In-Training Non-Member: $300
Registrants must bring a laptop to the course to view the course material.

Assemblies on Allergy, Immunology and Inflammation; Clinical Problems; Critical Care; Environmental, Occupational and Population Health; Microbiology, Tuberculosis and Pulmonary Infections; Pediatrics; Pulmonary Circulation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function; Thoracic Oncology

Objectives
At the conclusion of this session, the participant will be able to:

- understand fundamental principles of macrophage origins, nomenclature, markers/phenotypes, functions in lung immunity and tissue homeostasis;
- learn about novel state of art technologies that can be utilized to study human lung macrophages at the molecular (genome, transcriptome, epigenetics, bioinformatics, single cell analysis), and cellular (advanced imaging and molecular phenotyping methods, single cell analysis) levels and how information obtained using these methods can be used to better understand the role of macrophages in the pathogenesis of human lung diseases;
- understand how to translate the novel knowledge about lung macrophage heterogeneity, plasticity, and polarization into clinically relevant precision medicine approaches to better prevent, diagnose and treat human lung diseases in a personalized manner.

This postgraduate course is focused on:(1)recent advances in understanding of the origin, phenotypic and functional diversity, plasticity, polarization programs and local homeostasis of lung macrophages;(2)pathologic programming of macrophages in human lung disease;(3)the role of macrophages in lung host defense, inflammation and regeneration;(4)state of art personalized analysis of human lung macrophage biology; and(5)macrophage-based precision medicines for human lung disease.

Chairing: R. Shaykhiev, MD, PhD, New York, NY

A. Haczku, MD, PhD, Davis, CA
D. Singh, MD, Manchester, United Kingdom
M. Kopf, PhD, Zurich, Switzerland
C. Jakubzick, PhD, Denver, CO
J. Bhattacharya, MD, DPhil, New York, NY
J. Schultze, MD, Bonn, Germany
R. Shaykhiev, MD, PhD, New York, NY

B.C. Trapnell, MD, Cincinnati, OH
J.R. Rock, PhD, San Francisco, CA
T. Wynn, PhD, Bethesda, MD
M.J. Holtzman, MD, St. Louis, MO
D. Singh, MD, Manchester, United Kingdom
L. Donnelly, PhD, London, United Kingdom
J.R. Rock, PhD, San Francisco, CA
M.H. Sieweke, PhD, Marseille, France
A. Haczku, MD, PhD, Davis, CA
R. Shaykhiev, MD, PhD, New York, NY

8:00 Introduction
A. Haczku, MD, PhD, Davis, CA

8:10 Keynote Lecture: Identity and Self-Renewal of Tissue Macrophages
M.H. Sieweke, PhD, Marseille, France

8:40 Unique Origins and Differentiation Pathways of Lung Macrophages
M. Kopf, PhD, Zurich, Switzerland

9:10 Macrophage Heterogeneity in the Human Lung
C. Jakubzick, PhD, Denver, CO

9:35 Live Imaging of Macrophage - Epithelium Interactions in the Lung
J. Bhattacharya, MD, DPhil, New York, NY

10:00 Break

10:15 Transcriptional Programming of Human Macrophages
J. Schultze, MD, Bonn, Germany

10:40 Human Alveolar Macrophage Polarization: M1, M2 and Beyond
R. Shaykhiev, MD, PhD, New York, NY

11:00 Personalized Macrophage Responses to Disease-Modifying Therapies in Asthma and COPD
D. Singh, MD, Manchester, United Kingdom

11:20 Defective Macrophage Phagocytosis of Bacteria in Chronic Lung Disease
L. Donnelly, PhD, London, United Kingdom

11:45 Luncheon Sessions: Alveolar Macrophages in Host-Microbe Interactions and Lung Homeostasis
Alveolar Macrophage as a Niche for Mycobacteria and HIV
D. Russell, PhD, Ithaca, NY

How Respiratory Viruses Drive Alternative Macrophage Polarization in Lung Disease
M.J. Holtzman, MD, St. Louis, MO

Lung Macrophages, Th2 Inflammation and Pulmonary Fibrosis
T. Wynn, PhD, Bethesda, MD

The Role of Polarized Macrophages in Lung Regeneration
J.R. Rock, PhD, San Francisco, CA

Alveolar Macrophage-Based Precision Therapy for Human Lung Disease
B.C. Trapnell, MD, Cincinnati, OH

2:00 Break

2:15 “Lab Meeting”
R. Shaykhiev, MD, PhD, New York, NY
A. Haczku, MD, PhD, Davis, CA
D. Singh, MD, Manchester, United Kingdom
M. Kopf, PhD, Zurich, Switzerland
C. Jakubzick, PhD, Denver, CO
J. Bhattacharya, MD, DPhil, New York, NY
J. Schultze, MD, Bonn Germany
L. Donnelly, PhD, London, United Kingdom
D. Russell, PhD, Ithaca, NY
M.J. Holtzman, St. Louis, MO
T. Wynn, PhD, Bethesda, MD
J.R. Rock, PhD, San Francisco, CA
B.C. Trapnell, MD, Cincinnati, OH

This session and the International Conference are supported by an educational grant from AstraZeneca LP.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
PG17  SCIENTIFIC WRITING: PUBLISHING FOR ACADEMIC SUCCESS

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $400  In-Training Member: $250
Non-Member: $475  In-Training Non-Member: $350

Registrants must bring a laptop to the course to view the course material.

Assemblies on Behavioral Science and Health Services Research; Allergy, Immunology and Inflammation; Clinical Problems; Critical Care; Environmental, Occupational and Population Health; Microbiology, Tuberculosis and Pulmonary Infections; Nursing; Pediatrics; Sleep and Respiratory Neurobiology

8:00 a.m. - 3:55 p.m.  MOSCONE CENTER
Room 2014 (West Building, Level 2)

Target Audience
Postdoctoral fellows, junior faculty, pulmonary and critical care physicians, allergists, nurses, clinical, translational, and basic science researchers, behavioral scientists, and research scientists.

Objectives
At the conclusion of this session, the participant will be able to:

- identify strategies for becoming a successful scientific writer and describe the essential elements of a scientific manuscript;
- define authorship and identify the ethical responsibilities of authors;
- describe the peer review process, avoid common mistakes authors make during preparation and submission of manuscripts; and select appropriate journals based on the content of the article and the target audience.

Fellows, junior faculty, researchers, and clinicians need practical information about scientific writing and publishing. This course is designed to provide investigators from various disciplines the tools necessary to prepare scientific manuscripts that are likely to be published. Course faculty will give an overview of strategies for becoming a successful writer as well as teach participants about the elements of a manuscript, the responsibilities of authorship, the importance of journal selection, and the peer review process. The afternoon will include interactive discussions with the faculty in small group breakout sessions.

Chairing: B.J. Sheares, MD, MS, New York, NY
J. Bruzzese, PhD, New York, NY
G. Diette, MD, MHS, Baltimore, MD

8:00 Introduction and Announcements
B.J. Sheares, MD, MS, New York, NY

8:05 Strategies for Becoming a Successful Writer
H.J. Zar, MD, PhD, Cape Town, South Africa

8:35 Start with the Easy Part: Describing Methods and Reporting Results
C.R. Cooke, MD, MSc, Ann Arbor, MI

9:05 Promises, Promises: Writing Informative and Succinct Introductions
J.D. Thornton, MD, MPH, Cleveland, OH

9:35 So What? Placing Your Results in Context: The Discussion
G. Diette, MD, MHS, Baltimore, MD

10:05 Break

10:15 The Responsibilities of Authorship
J. Bruzzese, PhD, New York, NY

10:45 Publishing for Promotion: The Tenure Review Committee’s Perspective
N.W. Schluger, MD, New York, NY

11:15 Panel Discussion
A.J. Apter, MD, MSc, MA, Philadelphia, PA
R.S. Irwin, MD, Worcester, MA
J.M. Drazen, MD, Boston, MA
K. Adler, PhD, Raleigh, NC

12:05 General Discussion

12:30 LUNCH

1:30 Breakout Session I: Revise and Resubmit: Responding to Reviewers’ Comments
B.J. Sheares, MD, MS, New York, NY

2:15 Break

2:20 Breakout Session II: Writing an Abstract and Choosing a Title
R. Grad, MD, Tucson, AZ

3:05 Break

3:10 Breakout Session III: Reporting Results: Univariate, Bivariate, and Multivariate Analysis
W.M. Vollmer, PhD, Portland, OR

There will be a 5-minute discussion after each talk.

PG18  NTM LUNG DISEASE: IMPROVE YOUR PRACTICE/DEBUNK THE MYTHS

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350  In-Training Member: $200
Non-Member: $425  In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Clinical Problems; Microbiology, Tuberculosis and Pulmonary Infections

8:00 a.m. - 4:00 p.m.  MOSCONE CENTER
Room 3007 (West Building, Level 3)

Target Audience
Providers of lung health including pulmonologists, infectious disease clinicians and trainees.

Objectives
At the conclusion of this session, the participant will be able to:
to diagnose active NTM infection;
understand the pathophysiology and impact of exposure to the water supply with regards to NTM infection;
appropriately refer more complex NTM patients to centers worldwide with special competence in NTM infections.

This postgraduate course includes a state of the art update on non tuberculous mycobacterial lung disease with an emphasis on case based learning to understand the prevalence, pathophysiology, treatment strategies and controversies about the disease.

Chairing: A. O'Donnell, MD, Washington, DC
R. Thomson, MBBS, PhD, Brisbane, Australia

8:00 Why Are We Seeing an Increase in NTM Lung Disease?
K.N. Olivier, MD, MPH, Bethesda, MD

8:50 Does Exposure to Potable Water Cause NTM Infection?
R. Thomson, MBBS, PhD, Brisbane, Australia

9:30 NTM Identification: What Your Clinical Lab Needs to Tell You
A. O'Donnell, MD, Washington, DC

10:00 Break

10:15 NTM Has Been Isolated: Does the Patient Need Antibiotics?
T.R. Aksamit, MD, Rochester, MN

10:55 Antibiotic Treatment for MAC Lung Infection
K. Winthrop, MD, MPH, Portland, OR

11:45 LUNCH

12:45 M. Abscessus Lung Infection Antibiotic Treatment
T.K. Marras, MD, Toronto, Canada

1:35 Old Drugs for Old Bugs
J. Philley, MD, Tyler, TX

2:15 Break

2:30 Case Reviews
A. O'Donnell, MD, Washington, DC
A. Basavaraj, MD, New York, NY

3:30 ATS/ERS Updated NTM Guidelines/Panel Wrap Up
D.E. Griffith, MD, Tyler, TX

This session and the International Conference are supported by an educational grant from Insmed Incorporated.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

CLINICAL • TRANSLATIONAL

PG19 COPD: A DYNAMIC AND EVOLVING DISEASE

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Clinical Problems; Behavioral Science and Health Services Research; Critical Care; Pulmonary Rehabilitation; Sleep and Respiratory Neurobiology

8:00 a.m. - 4:00 p.m. MOSCONCE CENTER
Room 2001 (West Building, Level 2)

Target Audience
Clinicians, nurses and respiratory therapist; clinical and basic science researchers; physicians in training and anybody who designs or implements clinical trials in COPD.

Objectives
At the conclusion of this session, the participant will be able to:

• understand the many systemic comorbidities associated with COPD and how to treat them;
• describe interventions to use for the management of COPD and COPD exacerbations;
• describe how to use different medications in the treatment of COPD patients.

This course will provide an update on key advances in the pathophysiology, genetics and management of COPD patients. There have been extensive publications on topics related to phenotype classification, use of imaging, biomarker and early interventions in COPD. Furthermore, over the last year, there have been numerous publications of novel bronchodilators that were approved by different regulatory organizations including the FDA. COPD exacerbations continue to impact the morbidity and mortality of this disease. There is a need to address how this condition can be prevented and to discuss its treatment.

Chairing: G.J. Criner, MD, Philadelphia, PA
R. Casaburi, MD, PhD, Torrance, CA

8:00 What is the Status of COPD Today?
K.F. Rabe, MD, PhD, Grosshansdorf, Germany

8:15 How Can We Predict Disease Progression?
J. Soriano, MD, PhD, Madrid, Spain

8:45 What Are the COPD Phenotypes Relevant for Clinical Practice?
M. Miravitlles, MD, PhD, Barcelona, Spain

9:15 Accelerated Aging in COPD and Its Comorbidities: Pathways to New Therapies
P.J. Barnes, MD, DSc, London, United Kingdom

9:45 Break

9:55 Integrating Disease Severity and Co-Morbid Conditions
C. Vogelmeier, MD, Marburg, Germany

10:25 How Can Radiological Imaging Change Our Concepts and COPD Phenotypes?
G.R. Washko, MD, Boston, MA

10:55 The Association Between COPD and Cardiovascular Disease: Mechanistic Links and Clinical Implications
D. Chandra, MD, MSc, Pittsburgh, PA

11:25 How is the COPD Biomarker Qualification Consortium Helping Develop Treatments Targeted for COPD Subsets?
R. Tal-Singer, PhD, King of Prussia, PA

11:55 LUNCH

12:35 In What Patients Should I Use Fixed LABA-LAMA Combination?
A. Anzueto, MD, San Antonio, TX
In What Patients Should I Use Inhaled Corticosteroids?
P. Calverley, MD, Liverpool, United Kingdom

Emerging Anti-Inflammatory Therapies
W. MacNee, MD, MBChB, Edinburgh, United Kingdom

Update on Endobronchial Interventions
C.B. Strange, MD, Charleston, SC

How Should I Treat a Patient Who Has an Acute Worsening in Symptoms?
S. Sethi, MD, Buffalo, NY

Putting It All Together
B.R. Celli, MD, Boston, MA

Questions and Answers
G.J. Criner, MD, Philadelphia, PA
R. Casaburi, MD, PhD, Torrance, CA

This session and the International Conference are supported by an educational grant from AstraZeneca LP.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

PG20 PHYSIOLOGY OF MECHANICAL VENTILATION IN ARDS

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.
Member: $400
Non-Member: $475
In-Training Member: $250
In-Training Non-Member: $350

Registrants must bring a laptop to the course to view the course material.

Assemblies on Critical Care; Pulmonary Circulation; Respiratory Structure and Function
8:00 a.m. - 4:00 p.m.  MOSCONGE CENTER
Room 3011 (West Building, Level 3)

Target Audience
Intensivists, fellows and respiratory therapists who wish to improve their ability to manage complex cases of respiratory failure.

Objectives
At the conclusion of this session, the participant will be able to:
• titrate PEEP in severe ARDS;
• assess patients for possible prone ventilation;
• interpret PV curves in severe ARDS.

This course is focused on the bedside management of mechanical ventilation in severe respiratory failure. Participants will learn a physiologic approach to managing the ventilator and interpreting the effects of interventions. We will cover the uses and physiologic effects of PEEP, heart and lung interaction as it relates to mechanical ventilation, and the physiology behind improved oxygenation in prone ventilation and improved V/Q matching with the use of pulmonary vasodilators. We will explore controversies in the physiologic literature concerning these techniques and critically examine common clinical rationales for their use.

Chairing: C. Hardin, MD, PhD, Boston, MA
K.A. Hibbert, MD, Boston, MA
S. Loring, MD, Boston, MA

8:00 Introduction - Overview of Physiologic Principles
K.A. Hibbert, MD, Boston, MA

8:40 The Pressure-Volume Curve in ARDS
C. Hardin, MD, PhD, Boston, MA
J. Butler, PhD, Boston, MA

9:20 Chest Wall and Mechanical Ventilation
S. Loring, MD, Boston, MA

10:00 Break

10:20 Heart-Lung Interaction
S. Magder, MD, Montreal, Canada

11:00 The Distribution of Perfusion and Ventilation-Perfusion Matching in Health and in Lung Injury
S.R. Hopkins, MD, PhD, La Jolla, CA

11:40 LUNCH

12:40 Physiologic Effects of PEEP
A. Malhotra, MD, La Jolla, CA

2:00 Prone Ventilation
I.S. Douglas, MD, Denver, CO

2:40 Break

2:55 Vent Management and PEEP Titration
K.A. Hibbert, MD, Boston, MA
C. Hardin, MD, PhD, Boston, MA
**Target Audience**
Researchers and public health practitioners in respiratory and environmental health.

**Objectives**
At the conclusion of this session, the participant will be able to:

- understand and apply key concepts in the design and analysis of studies of DNA methylation and lung disease;
- comprehend the impact of epigenetic studies on prevention (e.g., biomarker development), diagnosis, and treatment of lung disease;
- learn new and alternative approaches to epigenetic studies.

Lung diseases are multi-factorial, resulting from interactions between genetic and environmental factors. Heritable and/or de novo changes in gene expression that occur without alterations in DNA sequence (epigenetic) mediate some environmental effects on lung disease. We will review state of the art approaches to designing and implementing studies of epigenetics in general and in pulmonary/critical care/sleep medicine in particular.

**Chairing:**
J.C. Celedon, MD, DrPH, Pittsburgh, PA
C. Breton, ScD, Los Angeles, CA

**8:00** Designing Studies of DNA Methylation
J.C. Celedon, MD, DrPH, Pittsburgh, PA

**8:40** Laboratory Assays for Epigenetic Studies
S. Belinsky, PhD, Albuquerque, NM

**9:25** Data Analysis for Studies of DNA Methylation
C. Breton, ScD, Los Angeles, CA

**10:10** Break

**10:20** Murine Studies of Epigenetics
L. Kobzik, MD, Boston, MA

**11:05** Birth Cohort Studies of Epigenetics
J. Herbstman, PhD, New York, NY

**11:50** MicroRNA Studies
P.G. Woodruff, MD, MPH, San Francisco, CA

**12:35** LUNCH

**1:35** Twin Studies of Epigenetics
J.C. Celedon, MD, DrPH, Pittsburgh, PA

**2:20** Break

**2:30** Histone Modification
K.H. Albertine, PhD, Salt Lake City, UT

**3:15** Where Do We Go from Here?
B.A. Raby, MD, MPH, Boston, MA
10:30 Practical Guide for the Management of Bronchiectasis  
J.D. Chalmers, MBChB, PhD, Dundee, United Kingdom

11:00 What Is New in CAP: Outcomes and Emerging Pathogens  
G.W. Waterer, MBBS, PhD, MBA, Perth, Australia

11:30 Panel Discussion  
J.D. Chalmers, MBChB, PhD, Dundee, United Kingdom  
G.W. Waterer, MBBS, PhD, MBA, Perth, Australia  
Y.C.G. Lee, MBChB, PhD, Perth, Australia

11:45 LUNCH

12:45 Pulmonary Infections and Respiratory Microbiome Alterations in HIV/AIDS  
K.A. Crothers, MD, Seattle, WA

1:15 IGRA Versus TST for the Management of LTBI Including While on Anti-TNF Therapy  
C. Daley, MD, Denver, CO

1:45 Panel Discussion  
K.A. Crothers, MD, Seattle, WA  
C. Daley, MD, Denver, CO

2:00 Break

2:15 Pneumonia in Patients with Hematologic Malignancies and HSCT Recipients  
S.E. Evans, MD, Houston, TX

2:45 Pneumonia in the Solid Organ Transplant Recipient: Aspergillosis and Beyond  
C.A. Hage, MD, Indianapolis, IN

3:15 Pneumonia in Patients Treated with Anti-TNF Therapy and Other Novel Biologics  
K. Winthrop, MD, MPH, Portland, OR

3:45 Panel Discussion  
K. Winthrop, MD, MPH, Portland, OR  
S.E. Evans, MD, Houston, TX  
C.A. Hage, MD, Indianapolis, IN

Target Audience  
Pediatric pulmonologists and allergists, adult pulmonologists and allergists who take care of children; pediatric intensivists, nurses and respiratory therapists.

Objectives  
At the conclusion of this session, the participant will be able to:
- choose the appropriate tests for a variety of conditions encountered in clinical practice;
- recognize and avoid pitfalls in the interpretation of various diagnostic tests;
- learn how new diagnostic modalities may help in reaching a more accurate diagnosis in various clinical problems.

This course will provide a comprehensive overview of diagnostic tests that are available in clinical practice for the evaluation of pediatric patients with airway and lung parenchymal disorders. The presenters will discuss the advantages and limitations of each test in making a diagnosis, as well as the pitfalls in the performance of the tests that may result into erroneous results. Finally, when applicable, there will be a discussion on safety issues (e.g. when sedation may be necessary for the performance of the test) as well as on the cost of the various tests.

Chairing:  
A.C. Koumbourlis, MD, MPH, Washington, DC  
S. Davis, MD, Indianapolis, IN  
E. Eber, MD, Graz, Austria

8:00 Genetic Testing for Pulmonary Disorders  
L.M. Nogee, MD, Baltimore, MD

8:40 Evaluation of the Patient with Lung Disease Suspected to Be Secondary to Immune Dysfunction or Auto-Immunity  
A.M.H. Casey, MD, Boston, MA

9:20 Testing for Disorders of Mucociliary Clearance  
A.J. Shapiro, MD, Montreal, Canada

9:55 Break

10:10 When to Order and What to Do with the Results of a Sleep Study  
G. Nino, MD, Washington, DC

10:45 Choosing and Interpreting an Exercise Test  
P. Pianosi, MD, Rochester, MN

11:20 Chest Imaging  
B. Newman, MD, Palo Alto, CA

12:00 LUNCH

12:40 Interpreting the Results of a Bronchoscopy  
E. Eber, MD, Graz, Austria

1:15 Pulmonary Function Testing in Children  
S. Ranganathan, MBChB, MRCP, PhD, Parkville, Australia

1:50 How to Define “Normal” in PFTs  
S. Stanojevic, PhD, Toronto, Canada

2:25 Break

2:40 The Newer Tests: IOS  
N. Eid, MD, Louisville, KY

3:15 Infant and Preschool Pulmonary Function Testing  
S. Davis, MD, Indianapolis, IN

PG23 DIAGNOSTIC TESTS IN PEDIATRIC PULMONOLOGY: INDICATIONS AND INTERPRETATIONS  
CLS POSTGRADUATE COURSE  
CME Credits Available: 6.75

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350  
In-Training Member: $200  
Non-Member: $425  
In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Clinical Problems; Critical Care; Nursing; Pulmonary Rehabilitation; Sleep and Respiratory Neurobiology

8:00 a.m. - 3:50 p.m.  
MOSCON CENTER  
Room 3016 (West Building, Level 3)
### PG24  CRITICAL CARE OF THE PATIENT WITH PULMONARY VASCULAR DISEASE

**Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.**

- **Member:** $350  
  - In-Training Member: $200  
- **Non-Member:** $425  
  - In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

**Assemblies on Pulmonary Circulation; Clinical Problems; Critical Care**

8:00 a.m. - 4:00 p.m.  
MOSCONTE CENTER  
Room 3018 (West Building, Level 3)

**Target Audience**

Pulmonary and cardiology faculty, intensivists of all backgrounds, trainees, and allied health professionals.

**Objectives**

At the conclusion of this session, the participant will be able to:

- understand etiology and pathophysiology of RV failure in critically ill patients;
- integrate strategies for the diagnosis and treatment of pulmonary vascular disease in critically ill patients;
- interpret common pulmonary artery catheter waveform patterns and learn about the basics of RV echocardiography in critically ill patients with pulmonary vascular disease.

This comprehensive course will provide the learner with a strategy to care for critically ill patients with pulmonary hypertension of various etiologies. Presenters will provide a framework for understanding pathophysiology, etiology, hemodynamics, and specific high-risk scenarios using state of the art evidence and clinical expertise. Common pitfalls and knowledge gaps in caring for patients with pulmonary vascular and right heart failure will be addressed. By the conclusion, learners should have a refined approach for the management of these challenging patients.

**Chairing:**

- **C.E. Ventetuolo, MD, MS, Providence, RI**
- **T.M. Bull, MD, Aurora, CO**
- **T. Lahm, MD, Indianapolis, IN**

**8:00**  
Mechanisms of RV Failure in Critical Illness  
R. Naeije, MD, PhD, Brussels, Belgium

**8:30**  
Epidemiology of Pulmonary Vascular Disease and RV Failure in the ICU  
R.T. Zamanian, MD, Stanford, CA

**9:00**  
The PA Catheter in Critically Ill Patients with Pulmonary Vascular Disease: The Nuts and Bolts of PAC Waveform Analysis  
J.B. Hall, MD, Chicago, IL

**10:00**  
Break

**10:15**  
Management of PAH in ICU: Supportive Care: Volume, Arrhythmias, Mechanical Ventilation  
T. Lahm, MD, Indianapolis, IN

**10:45**  
Management of PAH in ICU: Pulmonary Vasodilators and Management of Hemodynamics (Pressors and Inotropes)  
J.R. Klinger, MD, Providence, RI

**11:15**  
Pregnancy in PAH  
A.R. Hemnes, MD, Nashville, TN

**11:45**  
Perioperative Management of PAH  
J.L. Diaz-Gomez, MD, Jacksonville, FL

**12:15**  
LUNCH

**1:15**  
Pro/Con on the Treatment of High and Intermediate-Risk PE: To Lyse or Not to Lyse and How  
J.A. Kline, MD, Indianapolis, IN

**1:30**  
Rebuttal  
T.M. Bull, MD, Aurora, CO

**1:45**  
Pro/Con on IVC Filters  
T.M. Bull, MD, Aurora, CO

**2:00**  
Rebuttal  
J.A. Kline, MD, Indianapolis, IN

**2:15**  
RV Ischemia in PAH and RV Infarct  
S. Archer, MD, Kingston, Canada

**2:45**  
Break

**3:00**  
Echo in the ICU: What Can It Help Us with in the Critically Ill Pulmonary Vascular Disease Patient?  
A. Vieillard-Baron, MD, Boulogne-Billancourt, France

**3:30**  
ECMO as a Bridge or Salvage Therapy in PH  
C.E. Ventetuolo, MD, MS, Providence, RI

### PG25  MASTER PHYSIOLOGY CLASS: CORE PRINCIPLES OF RESPIRATORY PHYSIOLOGY

**Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.**

- **Member:** $400  
  - In-Training Member: $250  
- **Non-Member:** $475  
  - In-Training Non-Member: $350

Registrants must bring a laptop to the course to view the course material.

**Assemblies on Respiratory Structure and Function; Clinical Problems; Critical Care**

8:00 a.m. - 4:00 p.m.  
MOSCONTE CENTER  
Room 3022 (West Building, Level 3)

**Target Audience**

Practicing clinicians including physicians and advanced practice practitioners; resident and fellow level trainees whose clinical focus is pulmonary and/or critical care medicine.

**8:00**  
Mechanisms of RV Failure in Critical Illness  
R. Naeije, MD, PhD, Brussels, Belgium

**8:30**  
Epidemiology of Pulmonary Vascular Disease and RV Failure in the ICU  
R.T. Zamanian, MD, Stanford, CA

**9:00**  
The PA Catheter in Critically Ill Patients with Pulmonary Vascular Disease: The Nuts and Bolts of PAC Waveform Analysis  
J.B. Hall, MD, Chicago, IL

**10:00**  
Break

**10:15**  
Management of PAH in ICU: Supportive Care: Volume, Arrhythmias, Mechanical Ventilation  
T. Lahm, MD, Indianapolis, IN

**10:45**  
Management of PAH in ICU: Pulmonary Vasodilators and Management of Hemodynamics (Pressors and Inotropes)  
J.R. Klinger, MD, Providence, RI

**11:15**  
Pregnancy in PAH  
A.R. Hemnes, MD, Nashville, TN

**11:45**  
Perioperative Management of PAH  
J.L. Diaz-Gomez, MD, Jacksonville, FL

**12:15**  
LUNCH

**1:15**  
Pro/Con on the Treatment of High and Intermediate-Risk PE: To Lyse or Not to Lyse and How  
J.A. Kline, MD, Indianapolis, IN

**1:30**  
Rebuttal  
T.M. Bull, MD, Aurora, CO

**1:45**  
Pro/Con on IVC Filters  
T.M. Bull, MD, Aurora, CO

**2:00**  
Rebuttal  
J.A. Kline, MD, Indianapolis, IN

**2:15**  
RV Ischemia in PAH and RV Infarct  
S. Archer, MD, Kingston, Canada

**2:45**  
Break

**3:00**  
Echo in the ICU: What Can It Help Us with in the Critically Ill Pulmonary Vascular Disease Patient?  
A. Vieillard-Baron, MD, Boulogne-Billancourt, France

**3:30**  
ECMO as a Bridge or Salvage Therapy in PH  
C.E. Ventetuolo, MD, MS, Providence, RI
Objectives

At the conclusion of this session, the participant will be able to:

- describe the basic principles of respiratory physiology that affect the transport of oxygen and carbon dioxide to and from the environment and tissues;
- explain how the core principles of respiratory physiology are altered in special patient populations including pregnant women, the obese and children;
- understand and explain how the respiratory system responds to stresses such as sustained high level exercise, hypobaric hypoxia and hyperbaria.

This postgraduate course will use a combination of didactic lectures and small group breakout sessions to review the core principles of respiratory physiology including advanced instruction in respiratory system mechanics, gas exchange, blood gas transport, control of breathing and the pulmonary circulation and how these principles apply in both special patient populations (pregnancy, obesity, pediatrics) and special circumstances (diving, exercise, high altitude). Emphasis will be placed throughout the course on the bedside application of the principles covered in each course component.

Chairing: A.M. Luks, MD, Seattle, WA
R.W. Glenny, MD, Seattle, WA

8:00 Introduction
A.M. Luks, MD, Seattle, WA

8:10 Core Principles: Mechanics
R. Schwartzstein, MD, Boston, MA

8:50 Core Principles: The Pulmonary Circulation
R.W. Glenny, MD, Seattle, WA

9:30 Core Principles: Gas Exchange
J. Petersson, MD, Stockholm, Sweden

10:10 Break

10:25 Small Group Case Review
A.M. Luks, MD, Seattle, WA
B. Coruh, MD, Seattle, WA
H.L. Manning, MD, Lebanon, NH
R. Schwartzstein, MD, Boston, MA
P.G. Carvalho, MD, Boise, ID
A.S. Clay, MD, Durham, NC
F. Laghi, MD, Hines, IL

11:40 Lunch

12:30 Core Principles: Blood Gas Transport
H.L. Manning, MD, Lebanon, NH

1:10 Core Principles: Respiratory Muscle and Chest Wall Physiology
F. Laghi, MD, Hines, IL

1:50 Break

2:05 Core Principles: Control of Breathing
J. Leiter, MD, Lebanon, NH

2:45 Small Group Case Review
A.M. Luks, MD, Seattle, WA
B. Coruh, MD, Seattle, WA
R. Schwartzstein, MD, Boston, MA
H.L. Manning, MD, Lebanon, NH
R.W. Glenny, MD, Seattle, WA
B.A. Cockrill, MD, Boston, MA
J.T. Poston, MD, Chicago, IL
M.M. Hayes, MD, Boston, MA
P.G. Carvalho, MD, Boise, ID
A.S. Clay, MD, Durham, NC
F. Laghi, MD, Hines, IL

PG26 CENTRAL APNEAS, CHEYNE-STOKES AND PERIODIC BREATHING: NEW INSIGHTS AND THEIR IMPACT ON DAILY PRACTICE

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350 In-Training Member: $200
Non-Member: $425 In-Training Non-Member: $300
Registrants must bring a laptop to the course to view the course material.

Assemblies on Sleep and Respiratory Neurobiology; Clinical Problems; Critical Care; Pediatrics

8:00 a.m. - 4:00 p.m. MOSCON CENTER

Target Audience
Pulmonologists, sleep physicians, fellows, nurses, fellows in training, clinical researchers, everybody involved in critical care and ventilation, pediatricians, geriatric physicians and nurses, cardiologists.

Objectives
At the conclusion of this session, the participant will be able to:

- put the new results from basic and clinical research regarding the causality of central apneas and periodic breathing into clinical perspective and to understand treatment alternatives to improve patient outcome;
- understand the differences in the results between the two recent, Serve HF and ADVENT-HF trials, and their impact on treatment for patients with central apneas in heart failure;
- develop skills for the daily work with geriatric patients, who show signs of complex and difficult to treat forms of sleep apnea.

This postgraduate course is designed to give the learner the most updated information on knowledge about all forms of central apneas, and to build confidence in individualizing decisions concerning the importance of central apneas and periodic breathing for each patient. The course is also an opportunity to put the disturbing results of the Serve HF studies from previous year into the right perspective for each clinical practice. The opportunity to discuss controversial results of clinical studies with experts in the field after each talk and at the round table will reduce uncertainties in younger clinicians and nurses, when it comes to central apneas in younger and older patients.
**BASIC • BEHAVIORAL • CLINICAL • TRANSLATIONAL**

**POSTGRADUATE COURSE**

CME Credits Available: 6.5

**PG27 LUNG CANCER: STATE OF THE ART IN 2016**

- Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.
  - Member: $350
  - In-Training Member: $200
  - Non-Member: $425
  - In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

**Assemblies on Thoracic Oncology; Behavioral Science and Health Services Research; Clinical Problems; Respiratory Cell and Molecular Biology**

**8:00 a.m. - 3:35 p.m.**

**MOSCONEx CENTER**

Room 2011 (West Building, Level 2)

**Target Audience**

All providers caring for patients with lung nodules, lung cancer. This includes pulmonologists, thoracic surgeons, radiation oncologists, nurse practitioners and physician assistants.

**Objectives**

At the conclusion of this session, the participant will be able to:

- describe the benefits and risks of lung cancer screening;
- explain the roles that surgery and stereotactic body radiation therapy have for patients with early NSCLC;
- describe the recent advances in molecular medicine as it relates to lung cancer.

This course will provide a comprehensive review of topics in the evaluation and management of patients with lung cancer including risk assessment and screening, the approach to pulmonary nodules, and the importance of molecular characterization of lung cancer. In addition, we will discuss treatment options for early stage and locally advanced NSCLC, the role in interventional pulmonology and palliative care in the management of patients with lung cancer and disparities in lung cancer burden, evaluation and treatment. Novel diagnostic tools and treatment modalities including biomarkers/genomic classifiers and immunomodulating therapies. The importance of tobacco cessation programs and tobacco control will also be discussed. Interactive tumor boards will be held to highlight main teaching points.

**Chairing:**

D.J. Feller-Kopman, MD, Baltimore, MD

M.P. Rivera, MD, Chapel Hill, NC

**8:00**

**Introduction**

D.J. Feller-Kopman, MD, Baltimore, MD

**8:05**

**Tobacco and E-Cigarettes: Control or Out of Control?**

A. Vachani, MD, MS, Philadelphia, PA

**8:30**

**Lung Cancer Screening: Who, Why and How**

N.T. Tanner, MD, MSCR, Charleston, SC

**8:55**

**The Role of Advanced Diagnostic Bronchoscopy in the Diagnosis and Staging of Lung Cancer**

J.A. Akulian, MD, MPH, Chapel Hill, NC

**9:20**

**Tumor Board**

D.J. Feller-Kopman, MD, Baltimore, MD

**9:55**

**Break**
10:10  Is My Patient Fit for Surgery?
K.I. Berger, MD, New York, NY

10:35  Surgery Is Better for Stage 1 NSCLC
J. Shragar, MD, Stanford, CA

11:00  SBRT Is Better for Stage 1 NSCLC
B. Loo, MD, PhD, Palo Alto, CA

11:25  Rebuttal

11:35  Tumor Board
M.P. Rivera, MD, Chapel Hill, NC

12:10  LUNCH

12:50  Disparities in Lung Cancer
M.P. Rivera, MD, Chapel Hill, NC

1:15  “Systems Genetics” in Lung Cancer
D. Jablons, MD, San Francisco, CA

1:40  Treating YOU: Targeted Therapy and Immunotherapy in the Treatment of Lung Cancer
C. Pecot, MD, Chapel Hill, NC

2:05  Tumor Board
D.J. Feller-Kopman, MD, Baltimore, MD

2:30  Break

2:45  How Not to Die Short of Breath: Treatment of Malignant Pleural Effusions
D.J. Feller-Kopman, MD, Baltimore, MD

3:10  Journal Club: Last Year’s Top 5 Papers in Lung Cancer
G.A. Silvestri, MD, MS, Charleston, SC

This session and the International Conference are supported by educational grants from AstraZeneca LP, Boston Scientific Corporation, Inc.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

PG28  CONFLICT RESOLUTION IN CRITICAL CARE: A SKILLS COURSE

Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited.

Member: $350  In-Training Member: $200
Non-Member: $425  In-Training Non-Member: $300

Registrants must bring a laptop to the course to view the course material.

Assemblies on Ethics and Conflict of Interest Committee; Behavioral Science and Health Services Research; Critical Care; Nursing

8:00 a.m. - 4:00 p.m.  MOSCONE CENTER
Room 2024 (West Building, Level 2)

Target Audience
Any clinician directly involved in providing healthcare, whether or not specifically in critical care, can benefit from enhancing his/her skills in resolving conflict.

Objectives
At the conclusion of this session, the participant will be able to:
• describe and explain at least ten specific skills and strategies for communicating in a setting of significant conflict;
• explain how and when each such skill or strategy is best used;
• gain practice in conflict resolution skills, so that they come readily into use when needed.

ATS’s ground-breaking 2015 Policy Statement on potentially inappropriate treatments in critical care observes that “conflicts typically develop and worsen over time as communication breaks down and parties become entrenched in their positions,” hence emphasizes the need for “increased efforts to teach clinicians end of life communication skills, including conflict resolution skills.” This course, a compact version of a successful intensive 3-day training, provides ATS’s first direct opportunity to meet that goal. Faculty will introduce a number of skills, beyond ordinary clinical communication skills, specifically attuned to address conflict. Participants will practice those skills in realistic scenarios followed by extensive debriefing.

Chearing:  H. Morreim, JD, PhD, Memphis, TN
D.B. White, MD, MAS, Pittsburgh, PA

8:00  ATS’s Official Policy Statement Regarding Requests for Potentially Inappropriate Treatments in ICUs
J.R. Curtis, MD, MPH, Seattle, WA

8:30  ATS’s Official Policy Statement Regarding Requests for Potentially Inappropriate Treatments in ICUs: Addressing Intractable Conflict
D.B. White, MD, MAS, Pittsburgh, PA

9:00  A Broad Look at Conflict in Health Care
H. Morreim, JD, PhD, Memphis, TN

9:15  First Set of Skills
H. Morreim, JD, PhD, Memphis, TN
J.R. Curtis, MD, MPH, Seattle, WA
D.B. White, MD, MAS, Pittsburgh, PA
R.D. Stapleton, MD, PhD, Burlington, VT
L.F. Reinke, ARNP, PhD, Edmonds, WA
M. Bugnitz, MD, Memphis, TN

9:45  Break

10:00  Practice Scenario #1 and Debrief
H. Morreim, JD, PhD, Memphis, TN
D.B. White, MD, MAS, Pittsburgh, PA
J.R. Curtis, MD, MPH, Seattle, WA
R.D. Stapleton, MD, PhD, Burlington, VT
L.F. Reinke, ARNP, PhD, Edmonds, WA
M. Bugnitz, MD, Memphis, TN

10:30  Second Set of Skills and Brief Exercise
H. Morreim, JD, PhD, Memphis, TN
D.B. White, MD, MAS, Pittsburgh, PA
J.R. Curtis, MD, MPH, Seattle, WA
R.D. Stapleton, MD, PhD, Burlington, VT
L.F. Reinke, ARNP, PhD, Edmonds, WA
M. Bugnitz, MD, Memphis, TN
11:00  Practice Scenario #2 and Debrief  
H. Morreim, JD, PhD, Memphis, TN  
D.B. White, MD, MAS, Pittsburgh, PA  
J.R. Curtis, MD, MPH, Seattle, WA  
R.D. Stapleton, MD, PhD, Burlington, VT  
L.F. Reinke, ARNP, PhD, Edmonds, WA  
M. Bugnitz, MD, Memphis, TN  

11:30  LUNCH

12:30  Conflict Resolution Strategies  
H. Morreim, JD, PhD, Memphis, TN  
D.B. White, MD, MAS, Pittsburgh, PA  
J.R. Curtis, MD, MPH, Seattle, WA  
R.D. Stapleton, MD, PhD, Burlington, VT  
L.F. Reinke, ARNP, PhD, Edmonds, WA  
M. Bugnitz, MD, Memphis, TN  

1:15  Practice Scenario #3 and Debrief  
H. Morreim, JD, PhD, Memphis, TN  
D.B. White, MD, MAS, Pittsburgh, PA  
J.R. Curtis, MD, MPH, Seattle, WA  
R.D. Stapleton, MD, PhD, Burlington, VT  
L.F. Reinke, ARNP, PhD, Edmonds, WA  
M. Bugnitz, MD, Memphis, TN  

2:00  Break

2:15  Practice Scenario #4 and Debrief  
H. Morreim, JD, PhD, Memphis, TN  
D.B. White, MD, MAS, Pittsburgh, PA  
J.R. Curtis, MD, MPH, Seattle, WA  
R.D. Stapleton, MD, PhD, Burlington, VT  
L.F. Reinke, ARNP, PhD, Edmonds, WA  
M. Bugnitz, MD, Memphis, TN  

3:15  Final Exercise  
H. Morreim, JD, PhD, Memphis, TN  
D.B. White, MD, MAS, Pittsburgh, PA  
J.R. Curtis, MD, MPH, Seattle, WA  
R.D. Stapleton, MD, PhD, Burlington, VT  
L.F. Reinke, ARNP, PhD, Edmonds, WA  
M. Bugnitz, MD, Memphis, TN  

4:30 p.m. - 5:30 p.m.  
OPENING CEREMONY  
MOSCONE CENTER  
Gateway Ballroom 102-104 (South Building, Lower Level)  
The American Thoracic Society invites you to attend the Opening Ceremony for the 2016 International Conference. The keynote speaker is pioneering scientific researcher, J. Craig Venter, PhD. Contributions in sequencing a draft human genome, the first complete diploid human genome and construction of the first synthetic bacterial cell are among his many accomplishments. He is the founder, chairman and CEO of the J. Craig Venter Institute (JCVI), founder and CEO of the company, Synthetic Genomics Inc. (SGI) and a co-founder and CEO of Human Longevity Inc. (HLI).  
Sonia Buist, MD, ATS past president and founder of the ATS Methods in Epidemiologic, Clinical, and Operations Research (MECOR) program, will be the first recipient of the ATS Foundation Vision Award. This award honors innovative individuals who have had a transformative impact on the delivery of health care.  
The Ceremony will be followed by a networking gathering with light refreshments, where attendees can meet up with friends and colleagues.

5:30 p.m. - 6:30 p.m.  
S1 THE NETWORKING EXCHANGE FOR EARLY CAREER PROFESSIONALS  
MOSCONE CENTER  
Lobby (West Building, Level 2)  
The Networking Exchange for Early Career Professionals is an annual networking event for medical students, residents, fellows, post docs, junior faculty and new conference attendees. This one hour event is intended to provide a relaxed atmosphere where attendees can network with peers, ATS leaders, program directors, associate program directors and division directors, as well as other prominent leaders. The Training Committee, Membership Committee, Education Committee, and Members in Transition and Training Committee (MITT) jointly host the Networking Exchange for Early Career Professionals. Cocktails and appetizers will be provided.  
Conference badges are required for admission.  
Space is limited. There is no additional fee.
**Target Audience**

Pediatric pulmonary and critical care physicians who work in a clinical setting and are currently engaged in maintenance of certification.

**Objectives**

At the conclusion of this session, the participant will be able to:

- remain current with medical knowledge relevant to their practice in pediatric pulmonology;
- evaluate their understanding of key skills and content areas in pediatric pulmonology as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The Pediatric Core Curriculum symposia promotes lifelong learning and the enhancement of the clinical judgment and skills essential for practicing pediatricians. The symposia will address topics that have been identified by an ATS pediatric working group, which is comprised of members of the ATS Education Committee and the International Conference Committee, who have identified important areas within pediatric medicine (including vasculitic pulmonary diseases, lung defense mechanism, congenital abnormalities of the airways, and respiratory failure). Attendees will increase their medical knowledge as a result of attending this symposium, and this will be measured by a comparison of pre-test vs. post-test results on the corresponding maintenance of certification module. The ATS Pediatric Core Curriculum will focus on a 3-year content cycle of key medical content in the area of pediatric medicine.
A1    CLINICAL YEAR IN REVIEW 1

9:00 a.m. - 11:00 a.m.  MOSCONE CENTER
Gateway Ballroom 102-104 (South Building, Lower Level)

Target Audience
Providers including physicians, nurses, respiratory therapists, nurse practitioners, and physician assistants. Trainees including residents fellows, and clinical researchers will also benefit.

Objectives
At the conclusion of this session, the participant will be able to:

• apply new clinical research knowledge to clinical practice;
• learn new findings about key conditions in pulmonary, critical care and sleep;
• gain new strategies to manage the care of common conditions in pulmonary, critical care, and sleep.

The annual Clinical Year in Review symposia topic reviews of the key clinical research publications over the last year. Each speaker is asked to review the 5-7 most important and influential publications on their topic from the prior year.

Chairing: J.L. Taylor-Cousar, MD, Denver, CO
            D.J. Lederer, MD, MS, New York, NY
            D.W. Ford, MD, MSCR, Charleston, SC

9:00    COPD
C.P. Hersh, MD, MPH, Boston, MA

9:30    Pulmonary Rehabilitation
S.J. Singh, PhD, Leicester, United Kingdom

10:00   Lung Transplantation
J.A. Belperio, MD, Los Angeles, CA

10:30   Cystic Fibrosis
J.L. Taylor-Cousar, MD, Denver, CO

This session and the International Conference are supported by an educational grant from AstraZeneca LP.
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

A3    FELLOWS CASE CONFERENCE

Training Committee; Assemblies on Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Clinical Problems

9:00 a.m. - 11:00 a.m.  MOSCONE CENTER
Room 134 (North Building, Lower Level)

Target Audience
Clinicians, nurses, fellows, residents, and researchers looking to broaden their clinical acumen to facilitate clinical and translational research.

Objectives
At the conclusion of this session, the participant will be able to:

• recognize clinical, radiographic, and pathologic findings of rare diseases;
• gain insight into clinical decision making skills demonstrated by master clinicians, radiologists and pathologists which will improve the quality of learners’ practice and potentially improve quality of care for the learner’s patients;
• develop strategies to evaluate patients with common symptoms that include uncommon/rare diseases in the differential diagnosis when appropriate.

This session will consist of unique cases presented and discussed by fellows with a panel of clinical experts to moderate the discussion and provide commentary. The cases will provide new insights into disease pathogenesis, diagnosis, and/or treatment. Selected cases will include clear clinical teaching points with review of associated pathology and radiology as appropriate. Finally, the discussion will highlight medical decision making important for both physicians-in-training and seasoned clinicians.

Chairing: J.W. McCallister, MD, Columbus, OH

9:00    Introduction
J.W. McCallister, MD, Columbus, OH

9:10    Case Presentations
Progressive Dyspnea and Abnormal CT of the Chest
A. Singla, MD, Cincinnati, OH
Spontaneous Pneumothorax: an Unusual Presentation of Systemic Disease
K. Ma, MD, New York, NY
A4 NEW ERA OF EVIDENCE GENERATION: MEASURING EFFECTIVENESS IN CRITICAL CARE

Assemblies on Critical Care; Clinical Problems; Nursing

9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 3000/3002/3004 (West Building, Level 3)

Target Audience
Critical care providers; intensivists; nurse practitioners; quality improvement researchers; hospital administrators; ICU administrators.

Objectives
At the conclusion of this session, the participant will be able to:

• understand novel trial design aspects of comparative effectiveness research in critically ill patients and how the ICU can be a learning health care system;
• interpret and apply the results of large effectiveness trials done in critically ill patients;
• understand the ethics of comparative effectiveness research and issues of consent.

Clinical trials using pragmatic design principles aimed at truly testing effectiveness of process of care aspects or currently used treatments are becoming increasingly popular. Federal funding, including both the NIH and PCORI, have emphasized the need for these types of trials. Comparative effectiveness and pragmatic trials conducted in the ICU are an emerging field in both clinical and quality improvement research. This session will discuss the increasing use of novel trial designs to generate estimates of treatment effectiveness in the critically ill and how to interpret and apply the results of these types of ICU studies.

Chairing:
T.W. Rice, MD, MSc, Nashville, TN
D. Janz, MD, MSc, New Orleans, LA

9:00 What's Pragmatic about Pragmatic Trials?
T.W. Rice, MD, MSc, Nashville, TN

9:10 Patient Centered Outcomes and Other Endpoints in Practical ICU Studies
D. Janz, MD, MSc, New Orleans, LA

9:25 Unique Trial Designs: Recent Novel Pragmatic Trials in Critical Illness
M.W. Semler, MD, Nashville, TN

9:40 Interpreting ICU Effectiveness Trials: Are the Results Applicable to My ICU or Patients?
B.T. Thompson, MD, Boston, MA

10:00 To Ask or Not To Ask? Ethics, Informed Consent, and Stopping Rules in Comparative Effectiveness Trials in Critical Illness
B. Cuthbertson, MD, Toronto, Canada

10:20 Fusing RCTs with Big Data in Critical Illness
D.C. Angus, MD, MPH, Pittsburgh, PA

10:40 The ICU as a Learning Healthcare Environment
J.V. Selby, MD, MPH, Washington, DC

A5 UNDERSTANDING LUNG DISEASE PHENOTYPES: NETWORKS AND SYSTEMS BIOLOGY

Assemblies on Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 2009/2011 (West Building, Level 2)

Target Audience
Basic and clinical scientists, research and clinical trainees, drug discovery and development sector workers, providers of lung health care.

Objectives
At the conclusion of this session, the participant will be able to:

• understand fundamental approaches for systems biology and their application in research of pathophysiology;
• become aware of approaches to study epigenetic, transcriptional, post translational mechanism that contribute to lung diseases;
• learn new findings about post-transcriptional gene regulation.

The session highlights the state of the art in high throughput technologies and bioinformatics relevant to a broad range of lung disorders. How advanced bioinformatics can be used to understand integration of complex responses will be discussed, focusing on how to understand complexities of cell signaling disease pathogenesis.

Chairing:
A.J. Ammit, PhD, Sydney, Australia
A. Fedulov, MD, PhD, Boston, MA

9:00 Asthma Is a Systemic Epigenetic Disease
R.L. Miller, MD, New York, NY
A6
JOINT ATS/ERS/JRS SYMPOSIUM ON SEVERE ASThma: A GLObAL PERSPECTIVE
Assemblies on Allergy, Immunology and Inflammation; Clinical Problems; Environmental, Occupational and Population Health; Nursing; Pediatrics; Respiratory Cell and Molecular Biology; Respiratory Structure and Function
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 2001/2003 (West Building, Level 2)

Target Audience
Providers of lung health and those taking care of patients with asthma.

Objectives
At the conclusion of this session, the participant will be able to:
• review recent advances in the epidemiology and molecular basis of severe asthma;
• understand the clinical and molecular heterogeneity of severe asthma;
• highlight areas of needed research to reduce the impact of this disease on human health.

This symposium proposal represents an international collaborative effort between members of the Japanese Respiratory Society, The European Respiratory Society, and the American Thoracic Society to foster interactions towards a precision medicine approach to severe asthma. Globally, severe asthma represents a subset of asthma accounting for approximately 5-10% of patients with asthma. However health care utilization for this subset has been estimated to be up to 40% of the economic burden of asthma. Recently there has been significant efforts to determine the underlying basis for this disease in terms of epidemiology, physiology, immunology, and genetics that influence this phenotype. Data are emerging that serve asthma consists of several endotypes. This phenotypic and now molecular classification may greatly aid in patient management with improved disease control, improved clinical outcomes and reduced medical costs. This symposium will highlight recent advances as well as highlight needed areas of research to advance treatment and prevention of this disease.

Chairing:
G.P. Downey, MD, Denver, CO
K. Asano, MD, Kanagawa, Japan
S. Hashimoto, MD, Tokyo, Japan
B.D. Levy, MD, Boston, MA
N.N. Jarjour, MD, Madison, WI

10:14
Current Therapies for Severe Asthma in 2016
M. Kraft, MD, Tucson, AZ
Parker B. Francis Speaker

10:32
Severe Asthma Phenotype/Endotype Guided Therapy
P.J. Sterk, MD, PhD, Amsterdam, Netherlands

10:50
Summary of Symposium and Panel Discussion
N.N. Jarjour, MD, Madison, WI

This session and the International Conference are supported by an educational grant from AstraZeneca LP.

A7
ATS MYTHBUSTER: REVERSING FIBROSIS IN THE LUNGS IS BIOLOGICAL MISSION (IM)POSSIBLE
Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Clinical Problems; Respiratory Structure and Function
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 2016/2018 (West Building, Level 2)

Target Audience
Basic, translational, clinical researchers, and clinicians interested in fibrotic lung diseases, including IPF, connective tissue disease-ILD, chronic hypersensitivity pneumonitis and sarcoidosis.

Objectives
At the conclusion of this session, the participant will be able to:
• understand both the overall potential, and the current barriers, to reverse established fibrosis in patients with fibrotic lung diseases;
• understand how effector fibroblasts and extracellular matrix could be targeted to induce the regression of established fibrosis;
• understand recent advances in experimental models of type 2-predominant asthma;
• understand the lung’s capacity for compensatory re-growth of functional alveolar units after they are injured or lost.

In this provocative session we will explore the hypothesis that pulmonary fibrosis biology dictates that fibrosis cannot be reversed once it is established. We will use the very successful “mythbusters” format: leading researchers will give talks relevant to this hypothesis, after which expert “mythbusters” will discuss its validity. The session will end with an audience vote on the validity of the hypothesis. We hope to pair this session with another mythbusters session exploring the clinical implications of this hypothesis: that the best that we can hope to achieve with new therapies for fibrotic lungs diseases is the prevention of progression.

Chairing: M.R.J. Kolb, MD, PhD, Hamilton, Canada
M. Konigshoff, MD, PhD, Munich, Germany
A.M. Tager, MD, Charlestown, MA

9:00 A Patient’s Perspective
S. Rock, Rancho Murieta, CA

9:05 Once a Myofibroblast, Always a Myofibroblast? Can Lung Myofibroblasts Revert Like They Do in the Liver?
T. Kisseleva, MD, PhD, La Jolla, CA

9:25 Targeting Matrix Cross-Linking: The Achilles Heel of Fibrosis?
P.J. Sime, MD, Rochester, NY

9:45 Turning Fibrosis Down a Notch while Turning Up Regeneration: Progenitor Cell Notch Signaling Determines Outcome of Lung Injury
H. Chapman, MD, San Francisco, CA

10:00 Busting the Myth that the Lung Cannot Regenerate
B. Ding, PhD, New York, NY

10:25 Panel Discussion
G. Laurent, PhD, Nedlands, Australia
J. Gauldie, PhD, Hamilton, Canada
Z. Borok, MD, Los Angeles, CA

There will be a 5-minute discussion after each talk.

This session and the International Conference are supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

## A9
### CONTROVERSIES IN SLEEP MEDICINE: DAVIDS, GOLIATHS, AND SOME BLOOD ON THE FLOOR!

Assemblies on Sleep and Respiratory Neurobiology; Clinical Problems

9:00 a.m. - 11:00 a.m.  
Room 3003/3005 (West Building, Level 3)

Target Audience
Sleep physicians, researchers, nurses, and trainees.

Objectives
At the conclusion of this session, the participant will be able to:
- learn new findings about the effects of sex steroid signaling on lung structure and function;
- apply knowledge about sex steroids to management of patients with non-neoplastic lung diseases;
- apply knowledge about sex steroids to management of patients with lung cancer.

Sex steroids (i.e., reproductive hormones) have biologic and pathophysiologic actions in the lung mediated by both genomic and non-genomic mechanisms. This session will review the biology of sex steroids and their receptors in the lung, discuss the impact of sex steroids on lung structure and function, and explore the role of sex steroid signaling in lung diseases with known gender differences in incidence and in morbidity and mortality. The learner will better understand the impact of sex steroids on disease manifestation and severity and will appreciate the potential for these hormones as biomarkers and therapeutic targets in lung disease.

Chairing: G.S. Skloot, MD, New York, NY
Y.S. Prakash, MD, PhD, Rochester, MN
M. MacLean, PhD, Glasgow, United Kingdom

9:00 Introduction to Sex Steroid Signaling and Effects on Lung Structure and Function
Y.S. Prakash, MD, PhD, Rochester, MN

9:25 The Role of Sex Steroid Signaling in Pulmonary Hypertension
M. MacLean, PhD, Glasgow, United Kingdom

9:50 The Role of Sex Steroid Signaling in Airway Disease
B.N. Melgert, PhD, Groningen, Netherlands

10:15 The Role of Sex Steroid Signaling in Lung Cancer
C.A. Powell, MD, New York, NY

10:40 Future Directions: Sex Steroids as Potential Biomarkers and Therapeutic Targets
S.E. Wenzel, MD, Pittsburgh, PA

There will be a 5-minute discussion after each talk.

This session and the International Conference are supported by an educational grant from AstraZeneca LP.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
• learn about the mechanistic underpinnings of the interactions between sleep-disordered breathing and heart failure and consequent effects of patient outcomes;
• apply appropriate patient selection practices to identify candidates for novel emerging therapies for obstructive sleep apnea other than CPAP therapy;
• understand the relationship between sleep-disordered breathing and cancer and whether this can be translated into practice.

Sleep medicine is at the cusp of major advancements and impact on population health and well-being. However, there are thorny issues that have emerged as areas of controversies that need to be debated. While cardiovascular disease and cancer remain top killers, the role of treatment of sleep disordered breathing in patients with heart failure, and the relationship between sleep-disordered breathing and cancer are hotly debated. Moreover, emerging treatments for sleep-disordered breathing are rapidly changing the landscape as they disrupt and find their rightful place in the treatment hierarchy. This symposium features “world heavy-weights in the respective areas of sleep medicine who will “reconcile” their differences while keeping bloodshed to a minimum. Attendees will learn about the mechanistic underpinnings of the interactions between sleep, heart failure and cancer; the clinical implications of such complex interactions; and emerging treatment approaches to sleep disordered breathing. This symposium is not for the weak hearted.

Chairing: N.A. Antic, MBBS, PhD, Adelaide, Australia
S. Parthasarathy, MD, Tucson, AZ
J.P. Bakker, PhD, Boston

9:00 PRO: Should We Treat Sleep Disordered Breathing in Heart Failure?
D. Bradley, MD, Toronto, Canada

9:20 CON: Should We Treat Sleep Disordered Breathing in Heart Failure?
M. Naughton, MBBS, MD, East Melbourne, Australia

9:40 PRO: Sleep Disordered Breathing Causes Cancer?
R. Farre, PhD, Barcelona, Spain

10:00 CON: Sleep Disordered Breathing Causes Cancer?
C.P. O'Donnell, PhD, Pittsburgh, PA

10:20 PRO: There Will Never Be a Superior Treatment for OSA than CPAP
C. Sullivan, MBBS, PhD, Sydney, Australia

10:40 CON: There Will Never Be a Superior Treatment for OSA than CPAP
D.P. White, MD, Denver, CO

There will be a 5-minute discussion after each talk.

Target Audience
Neonatologists, pediatric pulmonologists, basic scientists interested in lung development, inflammation, genetic basis of disease and stem cell biology.

Objectives
At the conclusion of this session, the participant will be able to:
• learn new findings about molecular targets important in the pathogenesis of BPD identified through animal and human studies;
• apply stem cell based approaches to their patients in order to improve outcomes in BPD;
• describe new advances in the molecular understanding of the timing of normal birth and the importance of fetal lung maturity and inflammation in the process of initiation of labor.

Bronchopulmonary dysplasia (BPD) continues to be a major cause of morbidity and mortality for prematurely born infants. This session will highlight recent advances in our understanding of the causes of BPD from newer mouse models and large-scale human genetic studies, contributions of the lung microbiome to neonatal disease, and newer approaches to therapy using cell based therapies, as well as new links to understanding the causes of timing of parturition, as prevention of preterm birth is the ultimate therapy for the prevention of BPD.

Chairing: L.M. Nogee, MD, Baltimore, MD
B. Thebaud, MD, PhD, Ottawa, Canada

9:00 Chronic Lung Injury Induced by Ventilation: Insights from Neonatal Mouse Models
R. Bland, MD, Stanford, CA

9:20 The Lung Microbiome and Chronic Lung Disease in the Premature Infant
A. Hamvas, MD, Chicago, IL

9:40 Genomic Approach to Understanding BPD
N. Ambalavanan, MD, Birmingham, AL

9:55 Honing in on Rare Variants Contributing to BPD
H.M. O’Brodovich, MD, Stanford, CA

10:10 Cell Based Therapies for BPD
B. Thebaud, MD, PhD, Ottawa, Canada

10:30 Lung Maturation, Inflammation and the Timing of Parturition
C. Mendelson, PhD, Dallas, TX

10:50 Discussion
B. Thebaud, MD, PhD, Ottawa, Canada
L.M. Nogee, MD, Baltimore, MD

There will be a 5-minute discussion after each talk.
Target Audience
Clinicians, researchers and educators with an interest in lung cancer and in global lung health.

Objectives
At the conclusion of this session, the participant will be able to:

• learn new findings about best practices for early detection of lung cancer;
• apply recent guidelines and policy statements to be able to better diagnose and stage lung cancer;
• integrate new treatment and prevention options in discussing lung cancer with patients.

Lung cancer is the leading cause of cancer death in the world. The challenge to decrease lung cancer mortality through prevention, early detection, rapid diagnosis, staging, and precision therapy is global; yet approaches to these efforts vary. Speakers for this session are drawn from the International Relations Working Group of the ATS Thoracic Oncology Assembly with leaders from ATS, JRS, ERS, the Chinese Respiratory Association, and the Latin American Thoracic Association. Topics will include prevention, lung cancer screening, precision therapy, updates in lung cancer classification and staging, and quality benchmarks for diagnosis and treatment.

Chairing:
C.A. Powell, MD, New York, NY
M. Gaga, MD, PhD, Athens, Greece
S. Quadrelli, MD, PhD, Buenos Aires, Argentina
C. Bai, MD, PhD, Shanghai, China

9:00 The Role of Smoking Cessation in the Prevention of Lung Cancer
J.M. Samet, MD, MS, Los Angeles, CA

9:20 WHO-IARC, IASLC-ATS Updates of Lung Cancer Classification, C.A. Powell, MD, New York, NY

9:40 Integration of Imaging and Molecular Biomarkers for Lung Cancer Detection
C. Bai, MD, PhD, Shanghai, China

10:00 Screening for Lung Cancer: Maximizing Benefits and Minimizing Harms
M.K. Gould, MD, MS, Pasadena, CA

10:20 Precision Therapy of Lung Cancer: Targets, Resistance, and Opportunities
K. Kiura, MD, PhD, Okayama, Japan

10:40 European Initiative for Quality Management in Lung Cancer Care
M. Gaga, MD, PhD, Athens, Greece

This session and the International Conference are supported by an educational grant from AstraZeneca LP.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
A13  NOVEL INNATE IMMUNE PATHWAYS IN SEVERE ASTHMA
9:00 a.m. - 11:00 a.m.  MOSCONE CENTER

Chairing:  K.F. Chung, MD, PhD, London, United Kingdom
M. Idzko, MD, Freiburg, Germany
R.W. Harper, MD, Sacramento, CA

Oral Presentations


10:00  Role of Interferon Regulatory Factor-1 (IRF-1) in Modulating Steroid Insensitive Pathways in Severe Asthma/A. Gavrila, L. Chachi, O. Tilba, C.E. Brightling, Y. Amrani, Leicester, United Kingdom, p.A1005

10:15  P2Y6R Signaling: A Double-Edged Sword in Allergen-Induced Airway Inflammation/A. Zech, A. Meyer, M. Idzko, Freiburg, Germany, p.A1006


10:45  TSLP in Patients with Asthma, COPD and ACOS/P. Korosec, S. Korn, S. Skrgat, R. Marcun, R. Buhl, M. Flezar, Golnik, Slovenia, p.A1008

A14  ADVANCE CARE PLANNING AND PALLIATIVE CARE: PATIENTS TO POLICY
9:00 a.m. - 11:00 a.m.  MOSCONE CENTER

Chairing:  R.D. Stapleton, MD, PhD, Burlington, VT
E.K. Kross, MD, Seattle, WA

Oral Presentations
9:00  Validation of a Prognostic Model to Predict 6-Month Mortality in Medical Intensive Care Unit (MICU) Patients/R.G. Sangani, K. Chapman, S. Hadique, S. Culp, S. Khan, J.E. Parker, A. Moss, Morgantown, WV, p.A1009


9:45  Using the Early Warning System (EWS) to Identify and Establish Goals of Care/Advanced Directives in a High Risk Patient Population: A Randomized, Prospective Trial/D. Picker, M. Dans, T. Bailey, K. Heard, M.H. Kollef, St. Louis, MO, p.A1012

10:00  Attitudes of Critical Care Clinicians Toward the Use of Triggers for Intensive Care Unit-Based Palliative Care Consultation/N.G. Wysham, D.M. Jones, W. Reagan, H. Goucher, S. Gundel, C.T.L. Hough, J. Mcfarlin, M. Hua, C.E. Cox, Durham, NC, p.A1013


10:30  The Association Between Hospice Utilization and Performance on Publicly Reported Outcome Measures/S. Lah, E. Wilson, S.M. Brown, Murray, UT, p.A1015


A15  EMERGING DATA ON COPD EXACERBATIONS
9:00 a.m. - 11:00 a.m.  MOSCONE CENTER

Chairing:  J.A. Wedzicha, MD, PhD, London, United Kingdom
E.C. Oelsner, MD, MPH, New York, NY
S. Sethi, MD, Buffalo, NY
Oral Presentations


Oral Presentations


9:30 Surgical but not Natural Menopause Is Associated with an Increased Asthma Incidence: Results from the E3N Prospective Cohort/B. Matulonga, D. Courbon, A. Fournier, A. Bedard, S. Mesrine, M. Sanchez, G. Thabut, R. Varraso, B. Leynaert, Paris, France, p.A1027


MINI SYMPOSIUM

A17 GENETICS AND GENOMICS OF CHILDHOOD LUNG DISEASE

9:00 a.m. - 11:00 a.m. MOSCONE CENTER

Room 3006/3008 (West Building, Level 3)

Chairs: A. Hamvas, MD, Chicago, IL
D. Pillai, MD, Washington, DC
E. Forno, MD, MPH, Pittsburgh, PA

Oral Presentations

9:00 Exome Sequencing Identifies Common Coding Variants Associated with Severe Respiratory Outcomes Following Preterm Birth/T.J. Mariani, R. Feng, F. Wang, M. Bhattacharjee, S. Bhattacharya, J. Mereness, Y. Bi, A. Ahmad, P.L. Ballard, A. Hamvas, Rochester, NY, p.A1033

9:30 Early ‘OMIC’ Biomarkers Predict Bronchopulmonary Dysplasia (BPD)/C.V. Lal, V. Bhandari, N. Ambalavanan, Birmingham, AL, p.A1035


### MINI SYMPOSIUM

**A18 BLINDED BY THE LIGHT: INSIGHT FROM GENETICS IN PAH**

9:00 a.m. - 11:00 a.m. MOSCONE CENTER Room 3016/3018 (West Building, Level 3)

Chairing: M. Aldred, PhD, Cleveland, OH
N.W. Morrell, MD, Cambridge, United Kingdom

Oral Presentations


9:30 PPARy Controls the DNA Damage Response by Modulating UBR5 Interaction with the MRE11-RAD50-NBS1 Complex, an Impaired Signalling Pathway in Pulmonary Arterial Hypertension/C.G. Li, C.S. Mahon, E. Verschueren, V. Kantamani, N. Sweeney, I. Diebold, S. Sa, L. Wang, A. Cao, J.K. Hennigs, K. Cimprich, M. Rabinovitch, Stanford, CA, p.A1043


**Featured Speaker**

10:45 Genetics in PAH: 2016 and Beyond/N.W. Morrell, MD, Cambridge, United Kingdom

### MINI SYMPOSIUM

**A19 GETTING POLARIZED: MR IMAGING IN OBSTRUCTIVE LUNG DISEASE**

9:00 a.m. - 11:00 a.m. MOSCONE CENTER Room 2020/2022 (West Building, Level 2)

Chairing: J.C. Woods, PhD, Cincinnati, OH
S.B. Fain, PhD, Madison, WI

Oral Presentations

9:00 Characterizing the Ventilation Distribution in Healthy Normal Subjects to Establish Robust Quantitative Analysis of 129Xe MRI/M. He, S.H. Robertson, J.M. Wang, L.G. Que, K. Mahmood, B. Driehuys, Y.-C. Huang, Durham, NC, p.A1048


---

A21  CHRONIC AIRWAY INFLAMMATION: MICROBIAL INFLUENCE

9:00 a.m. - 11:00 a.m.  MOSCONC CENTER

Room 2024 (West Building, Level 2)

Poster Viewing 9:00-9:45

Discussion 9:45-11:00

Chairing:  J.S. Deshane, PhD, Birmingham, AL
M.R. Stampfl, PhD, Hamilton, Canada
P.S. Foster, PhD, Callaghan, Australia
S. Bozinovski, PhD, Bundoora, Australia

601  The Effects of Smoking on The Lower Airway DNA Virome/B.C. Keller, G. Zhao, B.G. Wu, J.C. Clemente, L.N. Segal, St. Louis, MO, p.A1056

611  Effects of Recombinant Myristoylated Rhinovirus VP4 Protein on Primary Alveolar Macrophages/J.K. Bentley, S. Jaipalli, M. Han, J. Lei, M.B. Hershenson, Ann Arbor, MI, p.A1066

---


603  A Study to Define the Microbiome of the Asthmatic Airway/E. Hunt, S. Lapthorne, C. Ward, J. Eustace, B. Plant, D. Murphy, J. MacSharry, Cork, Ireland, p.A1058

604  Nasal Microbiome Composition Varies over Time in Pediatric Asthma/M. Perez-Losada, L. Alamri, A. Goldstein, K.A. Crandall, R.J. Freishtat, Ashburn, VA, p.A1059


609  Group A Streptococcus (GAS) Induces Bronchial Asthma (BA)/T. Matsuda, Misato-shi, Saitama, Japan, p.A1064


611  Effects of Recombinant Myristoylated Rhinovirus VP4 Protein on Primary Alveolar Macrophages/J.K. Bentley, S. Jaipalli, M. Han, J. Lei, M.B. Hershenson, Ann Arbor, MI, p.A1066


614  Infants with Early Wheeze Have Decreased Lung Function and Microbial Changes of Their Upper Airway at 3 Months of Age/K. Kleopfer, S. Srivatsa, J.E. Hatch, D. Nelson, S. Janga, S.D. Davis, Indianapolis, IN, p.A1069
665 Respiratory Syncytial Virus Exacerbates OVA-Mediated Asthma Through C3a/C3aR and C5a/C5aR Signaling Regulating CD4+T Cells Immune Responses/X. Hu, X. Li, C. Hu, J. Feng, Changsha, China, p.A1070


667 Changes in the Lung Microbiome Induced by Exposure to Tobacco Smoke in Healthy Mice and Mice with Chronically Inflamed Airways/M. Engle, B. Zorn, C. Jania, J.R. Martin, M.C. Wolfgang, C.M. Doerschuk, Chapel Hill, NC, p.A1072


A1092 Electronic Medical Record Smoking History Does Not Initial Clinician Impressions of a Novel Interactive Medical Electronic Health Record Recognition of Safety Issues by the Development of EHR-Based Detection of Major Adverse Using the Electronic Medical Record to Define Pre-Hospital Predicting 30-Day Pneumonia Readmissions Using Electronic Automated Detection of Undertreated Outpatient Pneumonia/ Pre-Hospital Iterative Development, Usability, and Acceptability Testing of Predicting 30-Day Pneumonia Readmissions Using Electronic Predicting 30-Day Pneumonia Readmissions Using Electronic Automated Detection of Undertreated Outpatient Pneumonia/ • San Francisco

ATS 2016 • San Francisco


1009 Understanding Failures in Delivery of Care for COPD Patients with 30-Day Readmission; Exploring Process Improvement Opportunities/M.A. Zafar, E. Alessandri, M.H. Eckman, E.J. Warm, R.J. Panos, Cincinnati, Ohio, p.A1114


1012 Predictors of Re-Admission After Hospitalization for Acute Exacerbation of COPD: Role of Glucocorticoid Dose and Duration/N. Csikesz, L. Nici, Providence, RI, p.A1117


1014 Role of Long-Acting Bronchodilators and Inhaled Corticosteroids in 30 Days Readmission After Index Hospitalization for COPD/R. Bishwakarma, W. Zhang, Y.F. Kuo, G. Sharma, Galveston, TX, p.A1119


1016 Comparative Effectiveness of Tiotropium Compared to No Long-Acting Bronchodilator After Hospitalization for COPD/M.H. Roberts, D.W. Mapel, H. Petersen, Albuquerque, NM, p.A1121

1017 Chronic Obstructive Pulmonary Disease (COPD)-Related Hospitalizations by Health Status Response Among Patients Receiving Arformoterol Tartrate or Placebo: Post Hoc Analyses from a 52-Week Randomized, Controlled Study/J. Donohue, V. Ganapathy, X. Zhou, L. Nelson, Chapel Hill, NC, p.A1122


1022 COPD Is Associated with Significantly Higher Long-Term Readmission and Mortality but Has No Association with 30-Day All-Cause or Heart Failure Readmission or All-Cause Mortality in Older Medicare Beneficiaries Hospitalized for Heart Failure/A.W. McLean, R. Khosia, P. Deedwania, A. Iyer, C. Inampudi, C. Morgan, S. Zhang, H. Sheriff, C. Faselis, R.D. Fletcher, G.C. Fonarow, W.S. Aronow, W.-C. Wu, C.J. Brown, S.D. Anker, R.M. Allman, A. Ahmed, Washington, DC, p.A1127

1023 Characteristics and Comorbidities of Patients Readmitted to Yale-New Haven Hospital Following Index Admission for COPD Exacerbation/S. Farasat, C.L. Rochester, J.D. Possick, Derby, CT, p.A1128


1025 Chronic Obstructive Pulmonary Disease Risk Factors for Readmission in a Southern California Teaching Hospital/K.C. Fan, D. Dworsky, P. Averell, J. Waalen, D. Elias, La Jolla, CA, p.A1130

1026 Autoimmune Interstitial Lung Disease

A24 AUTOIMMUNE INTERSTITIAL LUNG DISEASE
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 133 (North Building, Lower Level)
Poster Viewing 9:00-9:45
Discussion 9:45-11:00

Chairing: J. Dematte, MD, MBA, Chicago, IL
R. Hallowell, MD, Boston, MA
T. Moua, MD, Rochester, MN


**703** What Are Normal Nerve Conduction Study Amplitudes for Intensive Care Unit Patients?/D.A. Kelmenson, D. Quan, M. Moss, Aurora, CO, p.A1158

**704** Physical Function Differs Among Intensive Care Unit Patients with Critical Illness Polynuromyopathy, Deconditioning and Normal Strength/D.A. Kelmenson, D. Quan, M. Moss, Aurora, CO, p.A1159


**707** Impact of Age and ICU Mobility Scores on Healthcare Outcomes/A.M. Pastva, S. Silva, V. Sabol, Durham, NC, p.A1162

**708** Development of a Medical Record-Derived Frailty Index for ICU Patients/E.J. Luxenberg, A.A. Hope, M.N. Gong, S.J. Hsieh, Bronx, NY, p.A1163


**710** A Prognostic Model to Predict Disability Free Survival One Year and Five Years After Mechanical Ventilation: A Population Based Cohort Study/M. Wilson, K. Heise, T. Loftsgard, M.A. Dziadzko, K. sarvottam, P. Novotny, O. Gajic, M. Biehl, Rochester, MN, p.A1165

**711** Burden of Comorbid Illness Is Associated with 1-Year Survival but Not Early Disability After Critical Illness: Results from the RECOVER Program/E. Merman, T. ICU Recovery Study Investigators, Melbourne, Australia, p.A1167

**POSTER DISCUSSION SESSION**

**A26  SMOKE, POLLUTANTS, AND TOXINS: INSIGHTS FROM BENCH STUDIES**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 a.m. - 11:00 a.m.</td>
<td>MOSCONE CENTER Room 2010/2012 (West Building, Level 2)</td>
</tr>
<tr>
<td>Poster Viewing</td>
<td>9:00-9:45</td>
</tr>
<tr>
<td>Discussion</td>
<td>9:45-11:00</td>
</tr>
</tbody>
</table>

**Chairing:** C. Carlsten, MD, MPH, Vancouver, Canada  
N.E. Alexis, PhD, Chapel Hill, NC  
M.J. Campen, PhD, Albuquerque, NM

**Presentations:**

401 Interleukin-11 Receptor, Alpha Chain 1 Contributes to the Development of Ozone-Induced Airway Hyperresponsiveness in Mice/R.A. Johnston, J.B. Richards, N.C. Mitchell, C.L. Atkins, I.U. Haque, Houston, TX, p.A1181


404 Inhalation of Fine Particles from Mexico City Produce Fatal Asthma in a Guinea Pig Model of Allergic Airways Inflammation/C.I. Falcon-Rodriguez, A. Osornio-Vargas, A. De Vizcaya-Ruiz, I. Rosas-Perez, P. Segura-Medina, Mexico City, Mexico, p.A1184


407 Effects of Ambient Air Pollution on Local Antibody Responses to Pneumocystis in HIV+ Patients/R.J. Blount, K.R. Daly, E. Chang, S. Fong, R.F. Miller, P.D. Walzer, L. Huang, San Francisco, CA, p.A1187


411 Age-Related Modulation of Pulmonary and Systemic Innate Immunity Against Influenza A/PR/8/34 by Environmental Tobacco Smoke in Mice/J.K. Dhillon, L. Wang, M. Kaur, K.E. Pinkerton, Davis, CA, p.A1191


A27  ADVANCES IN PEDIATRIC SLEEP

9:00 a.m. - 11:00 a.m.  MOSCONE CENTER
Room 3011 (West Building, Level 3)

Poster Viewing  9:00-9:45
Discussion  9:45-11:00

Chairs:  M.L. Chen, MD, Seattle, WA
I. Narang, MD, Toronto, Canada
R. Bhattacharjee, MD, San Diego, CA


A. The Usefulness of OSA-18 Quality of Life Questionnaire in Identifying Moderate-to-Severe Obstructive Sleep Apnea in Children Who Have Normal/Inconclusive McGill Oximetry Score/S. Sritippayawan, K. Sunkonkit, S. Hantrakul, J. Deerojanawong, N. Prapphal, Bangkok, Thailand, p.A1219


823 Anthropometric Measures in Obese Children to Predict the Risk of Obstructive Sleep Apnea / S. Bin-Hasan, S. Al-Saleh, R. Amin, R. Narang, I. Narang, Toronto, Canada, p.A1227

A28 FROM PE TO CTEPH: FADE AWAY OR NOT?

9:00 a.m. - 11:00 a.m. MOSCONE CENTER

Poster Viewing 9:00-9:45
Discussion 9:45-11:00

Room 3014 (West Building, Level 3)

Chairing: G.A. Heresi, MD, Cleveland, OH
T.M. Bull, MD, Aurora, CO
J. Pepke-Zaba, MD, PhD, Cambridge, United Kingdom


904 Do Baseline or Follow-Up Imaging Variables Correlate with Exercise Capacity on Cardiopulmonary Exercise Testing (CPET) 1 Year Post Pulmonary Embolism (PE)? Results from the ELOPE Study / A. Hirsch, S. Kahn, A. Akaber, D. Anderson, P.S. Wells, M. Rodger, S. Solymoss, M.J. Kovacs, L. Rudski, A. Shimonys, C. Dennie, C. Rush, P. Hernandez, S. Aaron, J.T. Granton, Montreal, Canada, p.A1231


908 Preoperative Serum CD40 Ligand Level as a Promising Predictor of Surgical Outcome in Patients with Chronic Thromboembolic Pulmonary Hypertension / A. Shigeta, N. Tanabe, A. Naito, T. Jujo, A. Sekine, R. Nishimura, T. Sugirua, S. Sakao, K. Ishida, M. Masuda, K. Tatsumi, Los Angeles, CA, p.A1235


914 Hospital Length of Stay and Hospitalization Costs for Pulmonary Embolism Comparing Patients Receiving Rivaroxaban or Warfarin / J.A. Kline, S. Deitelzweig, J.M. Margolis, M. Raut, O. Tran, D.M. Smith, C. Crivera, B. Bookhart, J. Schein, W. Olson, Indianapolis, IN, p.A1241

915 Patient-Centered Outcomes from a Protocol to Treat Low Risk Patients with Venous Thromboembolism at Home with Monotherapy Oral Anticoagulation / J.A. Kline, Z.P. Kahler, D.M. Beam, Indianapolis, IN, p.A1242
A29 INFLAMMATION AND MECHANISMS OF AIRWAY SMOOTH MUSCLE CONTRACTION

9:00 a.m. - 11:00 a.m. MOSCON Center
Room 2014 (West Building, Level 2)

Poster Viewing
9:00-9:45
Discussion
9:45-11:00

Chairing:
S.J. Gunst, PhD, Indianapolis, IN
Y.S. Prakash, MD, PhD, Rochester, MN
J.E. Bourke, PhD, Clayton, Australia


Modulation of Mitochondrial Dynamics and Functions in Human Airway Smooth Muscle Cells by Bitter Taste Receptor Agonists/S. Pan, B. Tiesg, D.A. Deshpande, Philadelphia, PA, p.A1257

Analysis of the Splicing Regulation of the Smooth Muscle Myosin Heavy Chain Fast Contracting Isoform/M. Issouf, A. Vargas, St-Hyacinthe, Canada, p.A1258

Serine Phosphorylation of Non-Muscle Myosin II Heavy Chain Regulates the Contraction of Airway Smooth Muscle (ASM) by Regulating the Assembly of Adhesion Junction Signaling Complexes/W. Zhang, S.J. Gunst, Indianapolis, IN, p.A1259


Blood Transcriptome in Patients with Chronic Thromboembolic Pulmonary Hypertension Differs from Patients with Pulmonary Arterial Hypertension and Healthy Controls/D.T. Matthews, J. West, E.D. Austin, A.R. Hemnes, Nashville, TN, p.A1245


Naringin as Natural Fruit Product and Bitter Taste Agonist Induces Relaxation of Airway Smooth Muscle Cells Via Intracellular Calcium Signaling/L. Deng, Y. Lu, Y. Wang, M. Luo, X. Shi, Y. Pan, Changzhou, China, p.A1254

Serelaxin is a Novel Potent Bronchodilator in Rat Precision Cut Lung Slices (PCLS) and Trachea/J.E. Bourke, S.G. Royce, C. Donovan, M. Jelinic, L. Parry, C. Samuel, M. Lam, Clayton, Australia, p.A1255


Modulation of Mitochondrial Dynamics and Functions in Human Airway Smooth Muscle Cells by Bitter Taste Receptor Agonists/S. Pan, B. Tiesg, D.A. Deshpande, Philadelphia, PA, p.A1257

Analysis of the Splicing Regulation of the Smooth Muscle Myosin Heavy Chain Fast Contracting Isoform/M. Issouf, A. Vargas, St-Hyacinthe, Canada, p.A1258

Serine Phosphorylation of Non-Muscle Myosin II Heavy Chain Regulates the Contraction of Airway Smooth Muscle (ASM) by Regulating the Assembly of Adhesion Junction Signaling Complexes/W. Zhang, S.J. Gunst, Indianapolis, IN, p.A1259


520 TNFα and IFNγ Alter Effects of Corticosteroids on NFκB in Developing Human Airway Smooth Muscle/R. Britt, I. Kuipers, S. Sasse, M.A. Thompson, C. Pabelick, A. Gerber, Y.S. Prakash, Rochester, MN, p.A1265


524 Desmethylbenzodiazepines Induce OGR1 Signaling in Airway Smooth Muscle Cells/T. Pera, D.A. Deshpande, B. Tieg, M. Ippolito, H. Schorsch, T. Murphy, R. Penn, Philadelphia, PA, p.A1269


---

A30 ADVANCES IN LUNG CANCER SCREENING AND PULMONARY NODULE ASSESSMENT

9:00 a.m. - 11:00 a.m.  MOSCONE CENTER

Room 304 (South Building, Esplanade Level)

Poster Viewing                9:00-9:45
Discussion                  9:45-11:00

Chairing: D.A. Arenberg, MD, Ann Arbor, MI
P. Mazzzone, MD, MPH, Cleveland, OH
J.A. Gorden, MD, Seattle, WA

201 Maximum Intensity Projection (MIP) Versus Computer-Aided-Detection (CAD) in CT Lung Cancer Screening/A. Christie, L. Ebner, Bern, Switzerland, p.A1271


203 Primary Care Providers’ Views on Lung Cancer Screening/N.M. Kanodra, C. Pope, L.J. Rice, C. Hughes Halbert, N.T. Tanner, Charleston, SC, p.A1273

---


205 Cost-Effectiveness of Implementing Computed Tomography Screening for Early Diagnosis of Lung Cancer in Taiwan/S.-C. Yang, L.-J. Ku, J.-D. Wang, Tainan, Taiwan, p.A1275


208 The Impact of Structured Reading for Incidental Findings Identified on Lung Cancer Screening Low-Dose Computed Tomography (LDCT) Scans/P. Sather, D. Dicks, J. Killam, A. Curtis, F.C. Detterbeck, M. Pisani, L.T. Tanoue, New Haven, CT, p.A1278


212 Lung Cancer Screening: Early Results Exceed NLST-Based Expectations/S.E.E. Stephens, C. Chiles, C. Bellinger, Winston-Salem, NC, p.A1282


P16  Knowledge of Risks of Asthma and Its Treatments Amongst Healthcare Professionals: A Questionnaire-Based Survey/A. Rameh, J. Blakey, Liverpool, United Kingdom, p.A1311

P17  Serum Periostin Level May Predict Asthma Exacerbation After ATS 2016 • San Francisco

P18  Characteristic Features of Late-Onset Hypereosinophilic Asthma/ M. Toyoshima, Y. Kamiya, T. Suda, Hamamatsu, Japan, p.A1313

Facilitator: N. Miyahara, MD, PhD, Okayama, Japan


P20  Mechanism of Reduced Glucocorticoid Sensitivity in Human Pulmonary Epithelial Cells: Implications for Regulation by Interferon Regulatory Factor (IRF1)/S.V. Shah, R. Newton, Calgary, Canada, p.A1315


P24  Topical NSAID and NERD Phenotype Asthma Control/A.A. Hsu, Singapore, Singapore, p.A1319

P25  Clinical Endpoint Bioequivalence Study of Salmeterol Xinafoate (SX)/Fluticasone Propionate (FP) Combination Brand and Generic Candidate Products in Patients with Asthma/M. Longphre, K. Beasley, E. Burmeister Getz, R. Fuller, Berkeley, CA, p.A1320


Facilitator: J.G. Zangrilli, MD, Philadelphia, PA

P27  Step Down Strategy; Can LTRA Be Withdrawn Safely From Combination Therapy with Medium to High Dose of ICS/LABA, Tiotropium Bromide and LTRA in Severe Asthmatics?/M. Hojo, M. Ikura, M. Suzuki, H. Sugiyama, Tokyo, Japan, p.A1322


P30  Chinese Herbs for Acute Asthma: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial/G. Wang, Chengdu, China, p.A1325


P32  Efficacy of the Anti-IgE Monoclonal Antibody Omalizumab in Patients with Severe Asthma Complicated with Eosinophilic Otitis Media/E. Tagaya, R. Mizobuchi, A. Kubo, K. Harai, K. Takeyama, M. Kondo, J. Tamaoki, Tokyo, Japan, p.A1327

P33  Interleukin 17 (IL-17) Targeting Therapy in Asthma/M. Mahdavian, A. Ferrell, S. Asghari, Y. Yi, S.D. Aaron, Ottawa, Canada, p.A1328


P35  Assessment of Asthma Control in Adults Using Extraline Inhaled Beclometasone/Formoterol Combination as Maintenance Therapy or Maintenance and Reliever Therapy: A Multicentre Prospective Observational Study/R. Pawlczák, B. Rogala, T. Debowsi, Lodz, Poland, p.A7769


A32 ADAPTIVE IMMUNITY IN LUNG DISEASE

9:00 a.m. - 4:15 p.m. MOSCON CENTER

Area A, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: K.M. Gowdy, PhD, Research Triangle Park, NC


P39 Human Lung Fibroblasts Are Antigen-Presenting Cells that Activate Bacteria-Specific Autologous Memory CD4+ T Cells/A.J. Hutton, K.J. Staples, T.M.A. Wilkinson, J. Warner, Southampton, United Kingdom, p.A1331

P40 Lungs from Mice with Intestinal Inflammation Exhibit a Proinflammatory Profile/A. Metwalli, P.S. Thorne, N. Inc., D.E. Elliott, Iowa City, IA, p.A1332

P41 Comparison of IL-17A and IL-17F Cytokine-Expression in CD4+ Lymphocytes Between Asthma, COPD and Healthy Subjects/T. Morimoto, S.G. Smith, J.P. Oliveria, S. Beaudin, A. Schlatman, K. Howie, C. Obminski, G. Nusca, R. Sehmi, G.M. Gautreau, P.M. O’Byrne, Hamilton, Canada, p.A1333

THEMATIC POSTER SESSION

A33 AIRWAY SMOOTH MUSCLE

9:00 a.m. - 4:15 p.m. MOSCON CENTER

Area N, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: O. Tilba, DVM, PhD, Philadelphia, PA


P1543 CYP1 P450 Via an EETs Mechanism Controls NF-kB Signaling in Asthmatic Airway Smooth Muscle/B. Al Suliman, A. Gardner, Worcester, MA, p.A1346

P1547 IL-13 Promotes Airway Hyperresponsiveness in Asthma
Facilitator: R. Sehmi, PhD, Hamilton, Canada


Facilitator: R. Sehmi, PhD, Hamilton, Canada

P1550 Delineating the Importance of CD34 Expression in Contractile and Non-Contractile Elements of Airway Reactivity/K. Lortie, A. Langlois, Y. Bosse, M.-R. Blanchet, Sainte-Foy, Canada, p.A1353

P1551 The Molecular Basis for the Gain in Contractile Capacity Elicted by Tone in Airway Smooth Muscle/M. Gazzola, A. Lee-Gosselin, L. Auger, K. Lortie, M.-R. Blanchet, Y. Bosse, Ste Foy, Canada, p.A1356

P1552 Theophylline Represses IL-8 Secretion from ASM Cells Independently of PDE Inhibition: Novel Role as a PP2A Activator/B. S. Patel, M. M. Rahman, N. N. Rumzham, B. G. Oliver, N. M. Verrills, A. J. Ammit, Sydney, Australia, p.A1355


Facilitator: C. Mikacenic, MD, Seattle, WA

P513 Hypothermia and TRPV4 Channel Inhibition Mitigates Thrombin-Induced Endothelial Permeability/D. Corwin, N. G. Shah, A. Ramarathnam, D. Slack, M. A. Olman, R. G. Scheraga, J. D. Hasday, Baltimore, MD, p.A1358


THEMATIC POSTER SESSION

A34 ARDS AND LUNG INJURY
9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area E, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

THEMATIC POSTER SESSION

A35 CASE REPORTS IN AUTOIMMUNE LUNG DISEASE
9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators
P691 C-ANCA Vasculitis: A 12 Hour Journey to Respiratory Failure/ E. Espinoza Moscoso, D. Ouellette, N. Huda, Detroit, MI, p.A1366

P692 37 Year Old Female with 7 Year History of Intermittent Dyspnea of Few Minutes Duration/D. Cota, P. Slocum, S. Al-Farrah, Fort Worth, TX, p.A1367


P696 A Case Report of IgG4-Related Disease Masquerading as a 4.1 Centimeter Necrotic Pulmonary Mass with Bilateral Pulmonary Nodules/C.C. Radchenko, A. Gohar, Kansas City, MO, p.A1371


P701 Zebras Have Hooves Too: A Case of Granulomatosis with Polyangiitis/S.K. Avastalara, B. Small, H. Ahmad, G. Tatem, Detroit, MI, p.A1376

P702 Pulmonary AA Amyloidosis Presenting as Interstitial Infiltrates in Rheumatoid Arthritis/M. Aljasmi, C. Stone, J. Jennings, K. Thavarajah, Detroit, MI, p.A1377


P704 Mycobacterium Avium Complex Secondary to Pulmonary Alveolar Proteinosis: A Case Report/M.A. Azevedo, M.D. Kaushal, A. Rossetti, Columbus, OH, p.A1379

Facilitator: T. Dolinay, MD, PhD, Philadelphia, PA

P705 IgG4 Related Disease (IgG4-RD): A Differential Diagnosis for Fever of Unknown Origin/S. Zanoria, R. Foley, Farmington, CT, p.A1380


P707 Diffuse Alveolar Hemorrhage and Cardiac Involvement in Eosinophilic Granulomatosis with Polyangiitis: A Rare Presentation of a Rare Disease/L. Cagino, A. Somoracki, A. Ataya, Gainesville, FL, p.A1382


P710 Hydralazine Induced ANCA Vasculitis/B.S. Pannu, V.N. Iyer, M. Baqir, Rochester, MN, p.A1385


THEMATIC POSTER SESSION

A36 CLINICAL PROBLEMS IN ASTHMA AND ALLERGY
9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Facilitator: A.L. Fuhlbrigge, MD, Boston, MA


P54 Metabolic Syndrome Limits the Bariatrically-Induced Weight Loss Benefit on Asthma Control/P. Zhang, M. Nouraie, F. Holguin, Pittsburgh, PA, p.A1388


P57 Evaluation of the Inhaler Technique, Patients Knowledge and Disease Control Among Asthmatic Patients/F.P.G. Rizzatti, T.L. Silva, Sao Carlos, Brazil, p.A1391

P58 A Phase III Multi-Center, Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Desloratadine in Japanese Patients with Chronic Urticaria/S. Hisada, Y. Imai, N. Oshima, Y. Tanaka, C.I. Weinstein, M. Hide, Tokyo, Japan, p.A1392

P59 A Phase III Multi-Center, Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety

P60 Clinical Implication of Adenosine Triphosphate in Sputum in Asthma/T. Soma, T. Kobayashi, K. Nakagome, M. Nagata, Saitama, Japan, p.A1394


Facilitator: A. Yokoyama, MD, PhD, Kochi, Japan

P62 Responder Rate Analysis of Asthma Control Questionnaire Scores in Patients Treated with Once-Daily Fluticasone Furoate/ Vilanterol or Fluticasone Furoate/C. Poor, S. Faison, L. Sutton, D. Stempel, Research Triangle Park, NC, p.A1396

P63 Impact of Irreversible Airflow Obstruction in Clinical Course of Patients with Severe Atopic Asthma/K. Orimo, K. Takeyama, E. Tagaya, M. Kondo, J. Tamaoki, Tokyo, Japan, p.A1397

P64 Exploring Asthma Patients for Whom Switching to Formoterol/Fluticasone Is Recommendable Among Patients Inadequately Controlled with Salmeterol/Fluticasone/T. Kamei, K. Kato, H. Mizutani, M. Hayashi, N. Kihara, Takamatsu, Japan, p.A1398


P66 Short-Term Effectiveness of Bronchial Thermoplasty on Development of a Questionnaire to Evaluate Asthma Control in Optimal Sampling Designs for Studies of Multiple Flow Exhaled Nitric Oxide/S.P. Eckel, N. Molschatski, Los Angeles, CA, p.A1402

P67 Does Asthma Phenotype Have Impact on Disease Control - Can Detection of Inflammation and Hyperresponsiveness Ensure Stable Disease Faster (APERITIF)?/K.F. Bernholm, A.-S., Homëe, H. Meteran, C. Porsbjerg, V. Backer, Copenhagen, Denmark, p.A1401


P69 Allergic Bronchopulmonary Aspergillosis in South Asia with Special Reference to Indian Children: The Demographic and Clinical Presentation/M. Singh, N. Paul, A. Chauhan, K.S. Sodhi, A. Chakrabarti, Chandigarh, India, p.A1403


Facilitator: J.G. Zein, MD, Cleveland, OH

P71 Reduction in FeNO Is Correlated with FEV1 Improvement in Lebrikizumab Treated Asthma Patients/F. Cai, Y. Zheng, C. Holweg, D. Choy, J. Olsson, J. Matthews, H. Schereens, South San Francisco, CA, p.A1405

P72 Efficacy and Safety of Tratinterol Hydrochloride Tablets in Bronchial Asthma: A Randomized, Double-Blind and Multicenter Clinical Trial/L. Kong, J. Kang, Y. Zhao, Shenyang, China, p.A1406


P75 Airway Eosinophilic Inflammation Assessed by Induced Sputum and Blood IgE In Asthmatic Children/M. Ghezzi, A. Kantar, Ponte San Pietro, Italy, p.A1409


P79 Gender-Specific Effect of Overweight and Obesity on Total Serum IgE in Adults with Allergic Asthma/M. Imaoka, Fukuoka, Japan, p.A7776


THEMATIC POSTER SESSION

A37 CYSTIC FIBROSIS: IMMUNE REGULATORY PATHWAYS

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion

11:45-12:45: authors will be present for discussion with assigned facilitators
P715 PB01: A Recombinant Human Follistatin Protein for the Treatment of Neutrophilic Lung Diseases/ B.M. Kita, C.L. Hardy, R.E. O’Hehir, M. Hedger, D.M. De Kretser, Caulfield North, Australia, p.A1413


P717 Altered Phagosomal Degranulation in Neutrophils of Individuals with Cystic Fibrosis; an Impairment Corrected by CFTR Potential Therapy/ N. Browne, F. Gargoum, P. Hawkins, E. Reeves, N.G. McElvaney, Dublin, Ireland, p.A1415


P144 Evaluation of Th2 and Th17 Cytokine Levels in Serum from Asthmatics Using the High Sensitivity Quanterix Simoa HD-1 Platform/ M.L. Gavala, D. Smith, South San Francisco, CA, p.A1428


P149  Allergen Sensitization and Obstruction Indices of Allergic Asthmatics with High IgE (30-700 IU/ml) in an Urban Population: Super-obese (BMI 40 Kg/m²) vs Normal BMI (BMI =18.5-25 Kg/m²)/M. Ahmad, N. Tambe, T. Thakur, J. Zacharias, A. Sharma, E. Schulman, Philadelphia, PA, p.A1433

P150  Comparison of COPD Related Breath VOCs Assessed by a Compact High-Resolution Closed-Loop GC-IMS and by Standard GC-MS/O. Holz, M. Allers, A. Gaïda, S. Schuchardt, J.M. Hohlfeld, S. Zimmermann, Hannover, Germany, p.A1434

Facilitator:  L.E. Crotty Alexander, MD, San Diego, CA

P151  Study on the Grass Pollen Allergen Sensitization Mode and Their Relationships with Bronchial Hyperresponsiveness Patients with Asthma and/or Allergic Rhinitis in Southern China/M. Luo, B. Sun, Guangzhou, China, p.A1435


P155  Nasal Polyps and Airway Hyperresponsiveness Determine Outcome of Adult-Onset Asthma; a 5 Year Prospective Follow-Up Study/G. Westerhof, H. Coumou, S. De Nijs, E. Weersink, E.H. Bel, Amsterdam, Netherlands, p.A1439

P156  Bronko Test® Sputum Colour as a Marker of Neutrophilic Bronchitis in Adults with Asthma/J.L. Simpson, A. Loehrin, L.G. Wood, P.G. Gibson, New Lambton, Australia, p.A1440


P159  Lack of Allergy Diagnostics in Severe Asthmatic Patients in Germany/J. Schreiber, K. Grog, Magdeburg, Germany, p.A1443

P160  Raised Serum IgG4 as a Marker for Th2 Mediated Inflammation in Persistent Asthma/A. Rashidian, S. Sazgar, J. Mejia, T. Tyner, B. Abejje, V.V. Jain, J.J. Vempilly, Fresno, CA, p.A1444

P161  Ability of Exhaled Nitric Oxide to Discriminate for Airflow Obstruction Among Frequent Exacerbators of Clinically Diagnosed Asthma/L. Jalota, R. Allison, J. Vempilly, V.V. Jain, Fresno, CA, p.A1445


P164  Fractal Dimension as a Global Index of Air Trapping/G. Marin, S. Bommart, N. Molinari, L. Knabe, Y. Cabon, I. Vachier, C. Devautour, A. Bourdin, Montpellier, France, p.A1448


P168  Fetuin-B (FETUB): A Plasma Biomarker Candidate Related to the Severity of Lung Function in COPD/W.-.Q. Diao, B. He, N. Shen, Beijing, China, p.A7780


THEMATIC POSTER SESSION

A39  EOSINOPHILIC AIRWAYS DISEASE

9:00 a.m. - 4:15 p.m.  MOSCONTE CENTER
Area G, Hall D (North Building, Lower Level)

Viewing:  Posters will be on display for entire session.
Discussion:  11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator:  I. Ito, MD, PhD, Kyoto, Japan


P726  Type 2 Cytokines IL-5 and IL-13 Act Synergistically on Eosinophils but Only IL-13 Induces Airway Hyperreactivity and Goblet Cell Metaplasia in Murine Asthma/H. Beckert, S. Reuter, H. Meyer-Martin, S. Korn, R. Buhl, Mainz, Germany, p.A1453


P729  Patients with Difficult to Control Eosinophilic Granulomatosis with Polyangiitis of a Vasculitis Clinical Center in Sao Paulo, Brazil/E.P. Oliveira, J. Pinaffi, M.S. Tavares, L.K. Dourado, C.S.V. Barbosa, Sao Paulo, Brazil, p.A1456


P733  Effect of Reslizumab Treatment on Rescue Systemic Corticosteroid Use in Patients with Asthma and Elevated Blood Eosinophils: Results from a Pooled Analysis of Two Phase 3, Placebo-Controlled Trials/P. Bardin, K. Murphy, M. Garin, Melbourne, Australia, p.A1778

P734  The Circadian Clock Regulates Allergic Lung Inflammation: Implications for Asthma/H. Durrington, A. Loudon, D. Ray, Manchester, United Kingdom, p.A1778


P738  L-citrulline Prevents Asymmetric Di-methyl Arginine Uncoupling of Nitric Oxide Synthase in Primary Human Airway Epithelial Cells/D.E. Winnica, H. Grasemann, L.G. Que, B. Freeman, K. Wasil, S.E. Wenzel, F. Holguin, Pittsburgh, PA, p.A1462


P743  Regulation of Dipeptidyl Peptidase-4 (DPP4) Expression in Bronchial Epithelial Cells (BECs)/K. Chibana, T. Shiobara, T. Watanabe, Y. Horigane, A. Takemasa, Y. Ishii, Mibu Machi, Tochigi prefecture, Japan, p.A1467


P745  Bronchial Epithelial Cells Expression of IL-17A and IL-17F in Asthma and COPD/T. Morimoto, S.G. Smith, J.P. Oliveria, S. Beaudin, A. Schlatman, K. Howie, C. Obminsky, G. Nusca, R. Sehmi, G.M. Gauvreaux, P.M. O’Byrne, Hamilton, Canada, p.A1469

Facilitator:  A.L. Linderholm, PhD, Davis, CA

P746  Airway Progenitor Clone Formation Is Enhanced by Y-27632-Dependent Changes in the Transcriptionome/S.D. Reynolds, C. Rios, A. Wosielowska-Andersen, M. Pinter, C. Happoldt, G.M. Solomon, D.P. Nichols, M.A. Seibold, Columbus, OH, p.A1470


P748  The Physiological Glucocorticoid (GC), Hydrocortisone, Limits Selected Actions of Synthetic GC in Human Airway Epithelium/D. Radojicic, C.R. Keenan, A.G. Stewart, Parkville, Australia, p.A1472
P749 Induction of Human Airway Epithelial to Mesenchymal Transition (EMT) upon Human Rhinovirus Infection/D. Minor, S. Traves, D. Proud, Calgary, Canada, p.A1473


P753 Transcriptional Profiles of Bronchial Epithelial Cells in Asthmatics Differ From Controls/N. Assad, Y. Tesfaigzi, S.A. Ness, A. Sood, Albuquerque, NM, p.A1477

P754 Relationship Between Airway Hyperresponsiveness to Dosed Exercise Load and Hyperosmolar Stimuli in Patients with Asthma/J.M. Perelman, L.G. Nakhamchen, E. Afnas'eva, A. Prikhodko, V. Kolosov, Blagoveschensk, Russian Federation, p.A1478


Facilitator: R.W. Harper, MD, Sacramento, CA

P756 The Role of Secreted HSP90a on Asthmatic Airway Epithelial Barrier Dysfunction Induced by HDM/H. Dong, C. Huang, Y. Le, L. Luo, Z. Xie, S. Cai, Guangzhou, China, p.A1480


P761 Human β-Defensin 1, 2 and 3 Enhance TGF-β1-Mediated Epithelial-Mesenchymal Transition (EMT) in Bronchial Epithelial Cells/X.-Y. Qu, X.-M. Dang, D. Shang, W.-J. Wang, D. Xu, Y.-P. Shao, W.-Y. Lu, Y. Chang, Xi’an, China, p.A1485

P762 Spleen Tyrosine Kinase and Calcium Play Critical Roles in the Release of IL-33 from Airway Epithelial Cells Exposed to Fungus Alternaria Alternata/N. Sasaki, H. Kita, Y. Nakamura, K. Yamauchi, Rochester, MN, p.A1486


Facilitator: D.A. Knight, PhD, Callaghan, Australia


P768 Malondialdehyde-Acetaldehyde (MAA) Adducted Surfactant Protein Alters SRA/CD204 Gene and Protein Expression in Mouse Lung/M. Sapkota, J.M. DeVasure, T.A. Wyatt, Omaha, NE, p.A1492


P174 Do We Confirm the “O” in COPD?/P171 Role of Spoken Language in Education of Inhaler Technique:

P170 Peer Researchers’ Knowledge, Confidence and Self-Reported Discussion:

Viewing:

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

A41 THE SPECTRUM COPD CARE: FROM IDENTIFICATION TO POLICY

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area B, Hall D (North Building, Lower Level)

Facilitator: M.J. Joo, MD, PhD, Chicago, IL


Facilitator: R.G. Barr, MD, DrPH, New York, NY

P176 Prevalence of Low Peak Inspiratory Flow Rate (PIFR) in Chronic Obstructive Pulmonary Disease (COPD) Patients at Discharge After an Exacerbation- Interim Findings from a Prospective Study/G.G. Sharma, D.A. Mahler, V. Mayorga, K. Deering, V. Ganapathy, Galveston, TX, p.A1506


P178 Prevalence of Chronic Obstructive Pulmonary Disease (COPD) Among Patients Previously Treated for Pulmonary Tuberculosis (PTB) in Manila: A Multi-Center Study (PreCOPT Study)/C.B. Gulay, H.S. Delfin, J. Benedicto, L. Fernandez, R. Pagcatipunan Jr, Manila, Philippines, p.A1508


P180 Empirically Identifying Clinical COPD Subphenotypes and Their Stability/D. Blagev, S. Rea, D.S. Collingridge, Murray, UT, p.A1510

P181 Diagnosis Differences for Pulmonary Restrictive Defects Between NHANESIII and GLI12 Predictions on Caucasian Populations/O.J. Linares, M. Hegewald, R.L. Jensen, J. Hankinson, A. Morris, Salt Lake City, UT, p.A1511

Facilitator: A.S. Gershon, MD, MSc, Toronto, Canada


P183 Mortality Outcomes of Long-Term Domiciliary Non-Invasive Ventilation in Stable Chronic Obstructive Pulmonary Disease with Chronic Type 2 Respiratory Failure/P. Lee, E. Innes, J. Qian, C. Chen, A.T. Ng, Sydney NSW, Australia, p.A1513


P186 Disease Severity as a Determinant of Health Status in Patients with Chronic Obstructive Pulmonary Disease/N. Malik, K. Chima, Lahore, Pakistan, p.A1516

Facilitator: V.G. Press, MD, MPH, Chicago, IL


P189 Standardizing Inhaler Training Across a COPD Care Management Project/B.W. Carlin, K. Kanel, G. Thomas, S. Campus, Pittsburgh, PA, p.A1519

P190 The Use of an Spirometry Instructional Program for Healthcare Providers as a Component of a COPD Care Management Project/B.W. Carlin, G. Thomas, K. Kanel, Sewickley, PA, p.A1520

P191 Determinants and Patterns of Adherence to Inhaled Therapy by Patients with Severe Chronic Obstructive Pulmonary Disease (COPD)/R. Sulaiman, J. Seheult, E. MacHale, D. Seow, F. Rawat, B. Deering, B. Cushen, M. Mokoca, C. Moran, F. Bolland, R. Costello, Dublin, Ireland, p.A1521

P192 Examination of Quality Measure Application in Chronic Obstructive Pulmonary Disease in an Internal Medicine Residents’ Teaching Clinic/R.M. Burkes, U. Chaddha, T. Mkorombindo, N. Kubiak, K. El-Kersh, R. Cavallazzi, Louisville, KY, p.A1522


Facilitator: C.H. Martinez, MD, MS, MPH, Ann Arbor, MI

P194 Effect of an Online, Case-Based Educational Intervention in COPD Among Pulmonologists and Primary Care Physicians/E.L. Jackson, P. Chatterjee, New York, NY, p.A1524


P196 Clinical Features and Discharge Characteristics of Patients Readmitted Within 30 Days Following Index Admission for COPD Exacerbation at Yale-New Haven Hospital/J.D. Possick, C.L. Rochester, Derby, CT, p.A1526

P197 Factors Affecting the 30 Day Readmission Rate for Chronic Obstructive Pulmonary Disease (COPD) in a Tertiary Care Community Hospital/B. Diede, D. Sese, M. Nasser, R. Rosario, T. McNatt, A. Diwakar, Akron, OH, p.A1527

P198 Impact of Continuous Positive Airway Pressure Use on Hospitalization Rates in Medicare Beneficiaries with Coexisting COPD and Obstructive Sleep Apnea: The Overlap Syndrome/G.P. Singh, W. Zhang, Y.F. Kuo, R. Sultana, G. Sharma, Galveston, TX, p.A1528

P199 BiPAP Use in Type Two Respiratory Failure: A Predictor of Mortality/M. Quinn, R.J. Fahy, Dublin, Ireland, p.A1529

Facilitator: J.K. Quint, MBBS, PhD, London, United Kingdom

P200 Effects of Outside Environment on the Performance of the 6 Minute Walk Test in COPD/P. Patel, S. Paredes, M. Campos, Miami, FL, p.A1530

P201 Mindfulness Based Stress Reduction for Patients with Chronic Lung Disease/N.-C. Liang, E.C. Bernadas, R. Jen, Y. Li, A. Minassian, A. Malhotra, A. Ries, S. Hickman, San Diego, CA, p.A1531


THEMATIC POSTER SESSION

A42 AUTOIMMUNE MYOSITIS, ANTISYNTHETASE, SCLERODERMA, AND IPAF

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion

11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: A. Fischer, MD, Denver, CO

P1219 Clinical and Radiological Predictor of Polymyositis and Dermatomyositis Associated Interstitial Lung Disease/T. Kishaba, H. Nagano, Y. Nei, S. Yamashiro, Uruma, Japan, p.A1536
A44 DRUG INDUCED AND RARE LUNG DISEASE
9:00 a.m. - 4:15 p.m. MOSCONE CENTER
Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

THEMATIC POSTER SESSION

P1251 Osteoporosis and Osteopenia in COPD Alpha 1 Antitrypsin Deficiency/M. Berlacher, K. Diab, Indianapolis, IN, p.A1567
P1252 Demographics and Clinical Profile of Patients with Alpha 1 Antitrypsin Deficiency PiMS Genotype Started on Augmentation Therapy/N.S. Zaidi, D.L. Greek, S. Kearns, L. Kristofek, Joplin, MO, p.A1568
P1253 Improving Survival Among ZZ Patients in the AlphaNet Program/R. Choate, D. Mannino, R.A. Sandhaus, D. Barber, K. Holm, Lexington, KY, p.A1569
P1254 Differences Between ZZ and SZ Patients in the AlphaNet Program/R. Choate, D. Mannino, D. Barber, R.A. Sandhaus, K. Holm, Lexington, KY, p.A1570
P1255 Gender Differences in Alpha 1-Antitrypsin Deficiency/M.A. Pardinas Gutierrez, M. Miraieidi, R.A. Sandhaus, M. Campos, Miami, FL, p.A1571

P1258 Alpha 1 Antitrypsin Deficiency in Romania - First Steps (Results of First Three Years of Screening)/R. Ulmeanu, A.M. Zaharie, J. Chorostowska Wynlmko, O.C. Deleanu, F.D. Mihaltan, Bucharest, Romania, p.A1574
P1259 Alpha 1 Antitrypsin Level Increase During an Inflammatory State: A Potential Cause of Missed Diagnosis in Alpha 1 Antitrypsin Deficiency/D.A. DeLapp, P. Nystrom, Dayton, OH, p.A1575

Facilitator: D.F. Dilling, MD, Maywood, IL

P1260 Alpha 1 Antitrypsin Deficiency - Do We Really Understand It? Case Presentations/A.-M. Zaharie, F.D. Mihaltan, C. Popa, O.C. Deleanu, R. Ulmeanu, Bucharest, Romania, p.A1576
P1261 Bronchiectasis as the Sole Presentation of Alpha 1 Antitrypsin Deficiency in a Never-Smoker/E. Kawar, N. Batarseh, Sioux Falls, SD, p.A1577
P1266 Generating a Novel Model of Alpha 1 Antitrypsin Deficiency Pathogenesis by Deriving Type II Alveolar Cells from Pluripotent Stem Cells/K. Hurley, A. Jacob, D.C. Thomas, F. Hawkins, A. Wilson, D.N. Kotton, Boston, MA, p.A1582
P1268 Effects of Recombinant Alpha 1-Antitrypsin IgG1 Fc-Fusion Protein (AAT-Fc) in Experimental Emphysema/K. Takeda, S. Kim, E.W. Gelfand, Denver, CO, p.A1584
Facilitator: M.P. Keane, MD, Dublin, Ireland


Facilitator: E.M. Fireman, PhD, Tel Aviv, Israel

P1276 Baseline Characteristics and Demographics of Patients Receiving Daptomycin and Incidence of Toxicity Associated with Daptomycin Use/M.K. Ellis, A. Szabo, K. Joshi, Milwaukee, WI, p.A1591


P1278 Case-Control Study of HLA Region in Brazilian Carriers of Granulomatosis with Polyangiitis (Wegener’s)/M.S. Tavares, C.S.V. Barbas, L.K. Dourado, T. Antunes, J. Pinaffi, Sao Paulo, Brazil, p.A1593


P1280 Clinical Features of IgG4-Related Respiratory Disease/S. Matsui, H. Yamamoto, S. Minamoto, T. Handa, Y. Waseda, M. Mishima, K. Kubo, Toyama, Japan, p.A1595

Facilitator: J.A. De Andrade, MD, Birmingham, AL

P1282 Acute Fibrinous Organizing Pneumonia: Rituximab Induced Fibrin Bails Within Alveoli, an Unknown Entity/N. Victor, Dover, DE, p.A1596

P1283 Cryptogenic Organizing Pneumonia in a Patient with Crohn’s Disease on Infliximab- An Extra Intestinal Pulmonary Manifestation or Drug Induced Complication?/M. Mauro, N. Yellappa, I. Harbuz-Miller, D. Markley, Morristown, NJ, p.A1597


P1285 Drug Induced Organizing Pneumonia by Immune-Checkpoint Inhibitor, Nivolumab/M. Nagamata, M. Yomota, T. Okamura, K. Yoshino, T. Hischma, Tokyo, Japan, p.A1599


P1287 Severe Symptomatic Hypercalcemia and Diffuse Pulmonary Nodules as the Presenting Symptoms of Adalimumab Induced Sarcoid-Like Granulomatosis/C. Bielick, W. Wong, A. Sosa, Worcester, MA, p.A1601

P1288 Golimumab Induced Sarcoid-Like Interstitial Lung Disease and Pulmonary Hypertension/W. He, B. Mann, M.B. Beasley, H. Poor, New York City, NY, p.A1602


P1290 Rituximab-Induced Hypersensitivity Pneumonitis Masked by Concomitant Corticosteroid Therapy/M. Nagamata, M. Yomota, T. Okamura, K. Yoshino, T. Hischma, Tokyo, Japan, p.A1599


P1292 Did Rituximab Do the Trick?/A. Gupta, R. Gripaldo, Columbia, SC, p.A1606

THEMATIC POSTER SESSION

A46 LUNG DISEASE DUE TO OTC AND ILLICITS: CASE REPORTS
9:00 a.m. - 4:15 p.m.
Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: N. Patel, MD, Philadelphia, PA

P1325 Microscopic Polyangiitis with an Unusual Pulmonary Manifestation and no Renal Involvement/H. Simo, A. Kubbara, C. Kakish, Y. Yoon, Toledo, OH, p.A1637

P1326 A Curious Case of Acute Respiratory Failure - Anti-Synthetase Syndrome/G. Malhotra, N. Ramreddy, M. Iliescu, Chicago, IL, p.A1638

P1327 PM-DM Associated Interstitial Disease/Z.S. Shakir, Kansas City, KS, p.A1639

P1328 Flare of Anti-Synthetase Interstitial Lung Disease with Cessation of Immunosuppression/L.J. Witt, J.M. Oldham, J.J. Curran, M.E. Strek, Chicago, IL, p.A1640

P1329 Infliximab for Treatment of Anti PL-12 Antisynthetase Syndrome: Misdiagnosis Led to New Potential Treatment for Rare Disease/T. Thanityavarn, Atlanta, GA, p.A1641

P1330 Improved Pulmonary Function and Lung Shadow with Pirfenidone Administration for a Chinese Case with Systemic Sclerosis Associated Interstitial Lung Disease/H. Huang, S. Li, K. Xu, Y. Bi, R. Feng, Z. Xu, Beijing, China, p.A1642


P1332 Acute Cardiopulmonary Complications of Systemic Lupus Erythematosus/A.L. Smith, A. Mora, Dallas, TX, p.A1644

P1333 Shrinking Lung Syndrome - An Unusual Cause of Dyspnea in Patients with Systemic Lupus Erythematosus/A. Vyas, La Jolla, CA, p.A1645


THEMATIC POSTER SESSION

A48 CONVENTIONAL DRUG ASSOCIATED LUNG DISEASE

9:00 a.m. - 4:15 p.m. MOSCONCE CENTER

Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion 11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: M.J. Hamblin, MD, Kansas, City, KS


P1336 Alveolar Hemorrhage Induced by Chemotherapy/R. Bansal, A. Surana, K. Thakur, Upland, PA, p.A1648


P1338 Successful Treatment of Amiodarone Induced Lung Toxicity with Steroids and Veno-Venous Extra-Corporeal Membrane Oxygenation/A. Avula, A. Saqib, A. Khalil, New York, NY, p.A1650


P1340 Pulmonary Eosinophilia from Inhaled Colistin/P.-.A. Lepine, A. Dumas, L.-P. Boulet, Quebec, Canada, p.A1652

P1341 Capcitabine-Induced Lung Injury/C.J. Benthin, G. Allada, Portland, OR, p.A1653

P1342 Concomitant Daptomycin and Ceftriaxone-Induced Eosinophilic Pneumonia: A Case Report/D.J. Pepper, E. Delbecq, A.P. Burke, C. White, E.J. Britt, Bethesda, MD, p.A1654

P1343 Daptomycin Induced Myopathy, Eosinophilic Interstitial Nephritis, and Acute Eosinophilic Pneumonia/A. Bosak, C. Jivcu, Phoenix, AZ, p.A1655


P1348 Barium Bronchogram/A. Shawkat, G. Trikha, Syracuse, NY, p.A1660

P1349 Acute Eosinophilic Pneumonia Secondary to Sertraline Use/A.B. Nassri, P. Harford, Austin, TX, p.A1661


P1351 Sarcoidosis as Paradoxical Effect of Tumor Necrosis Factor-α Blockers/B.K. Patibandla, B.C. Moutlou, Portland, OR, p.A1663

P1352 Pulmonary Infiltrates Following Peripheral Stem Cell Transplantation, Not Always Infectious Pneumonia. A Case of Busulfan-Induced Pulmonary Injury/M.R. Mourad, M.S. Crosser, Kansas City, KS, p.A1665


P1354 Giant Cell Interstitial Pneumonitis (GIP) as a Rare Manifestation of Chronic Nitrofurantoin Lung Toxicity/E. Alkhankan, M. Alzoby, M. Al-Ourani, Huntington, WV, p.A1665

A49 COPD: CARE DELIVERY

9:00 a.m. - 4:15 p.m.
Moscone Center

A-900

Area B, Hall D (North Building, Lower Level)

Facilitator: F.C. Sciurba, MD, Pittsburgh, PA

P1358 Paclitaxel Induced Pneumonitis as an Uncommon Cause of Severe Acute Respiratory Distress Syndrome/J. MacLeod, E. Chen, G.R. Bourjeily, R. El-Bizri, Providence, RI, p.A1669

P1359 Metastatic Pulmonary Calcification Following Orthotopic Liver Transplant: A Bronchoscopic Diagnosis/V. Kundel, T.J. Harkin, New York, NY, p.A1670


P1361 Eosinophilic Pneumonia Induced by IM Progesterone After In Vitro Fertilization/A. Baig, S.L. Schmidt, Grand Rapids, MI, p.A1672

P1362 Delayed Paclitaxel-Induced Interstitial Pneumonitis in Breast Cancer/N. Durairajan, A. Ali, Detroit, MI, p.A1673


P1365 “Into the Blue”: A Case of Symptomatic Rasburicase-Induced Methemoglobinemia/D. Rudym, N. Jindal, R. Greene, New York, NY, p.A1676


P1369 Biloptysis as a Late Complication of Hepatic TheraSpherer Radiation for Metastatic Breast Cancer/S. Hayat, Grand Rapids, MI, p.A1680


THEMATIC POSTER SESSION

A49 COPD: CARE DELIVERY

9:00 a.m. - 4:15 p.m.
Moscone Center

Area B, Hall D (North Building, Lower Level)

Facilitator: N.E. Bracken, ACNPC, MSN, Chicago, IL


P212 Results of a Canadian Parallel Survey for Family Physicians and COPD Patients: The Exacerbation Prevention in Canada Program/A.G. Kaplan, M. Balter, C. Poirier, R. Leigh, Richmond Hill, Canada, p.A1686

P213 Developing a Spirometry Program in the Primary Care Setting to Enhance COPD Diagnosis/C. Rodriguez Flores, M.V. Lopez Varela, E. Pacheco, M. Mamchur, J. Nunez, K. Rabunal, F. Gimenez, A. Tempone, K. Fagundez, C. Silva, Montevideo, Uruguay, p.A1687


P218 Impact of Education in Chronic Obstructive Pulmonary Disease (COPD) Patients: A Single Center Experience/C. Boyle-Daoust, S. Preville-Ratelle, Y. Dubois, C. Poirier, C. Bergeron, Montreal, Canada, p.A1692


Facilitator: J. Trevor, MD, Birmingham, AL


P97 Asthma Treatment Transition and Its Asthma-Related Clinical Events in Patients with Severe Asthma/P. Dilothorn sakul, A.M. Thompson, J.D. Campbell, Muang, Phitsanulok, Thailand, p.A1723

P98 Association of Asthma Treatment Transitions and Clinical Events in Patients with Mild Asthma/P. Dilothorn sakul, A.M. Thompson, J.D. Campbell, Muang, Phitsanulok, Thailand, p.A1724


P101 Peripheral Airway Dysfunction in the Dunedin Cohort at Age 38 Years/P.D. Robinson, G.G. King, M.R. Sears, C. Yen Hong, R. Hancox, Sydney, Australia, p.A1727

Facilitator: F. Holguin, MD, MPH, Pittsburgh, PA


P107 The Effect of Prolonged Duration of Clinic Visits on Asthma Control and Patient-Doctor Relationships/S. Cai, Z.Y. Qin, C. Ping, J. Fen, Hunan Province, China, p.A1733


P109 A One-Day-Visit Program in a Specialized Severe Asthma Center Improves Asthma Control, Quality of Life and Healthcare Utilization After One Year/A. Van Der Meer, H. Pasma, W. Kempenaar, J. Pelinck, M. Schutten, H. Storm, A. Ten Brinke, Leeuwarden, Netherlands, p.A1735


Facilitator: W. Stevens, MD, Chicago, IL

P112 Inhaler Errors After Reading the Patient Information Leaflet in Patients with Asthma: Elliptor Compared with Three Inhaler Devices/M. Thomas, J. Van Der Palen, H. Chrystyn, R. Sharma, V. Imber, H. Svedsater, N. Barnes, Southampton, United Kingdom, p.A1738


P118  The Impact of Psychological Factors on Asthma Patients/S. Beyhan Sagmen, S. Olgun, H. Baykan, M. Ozdemir, B. Ceyhan, Malatya, Turkey, p.A1744

P119  Causes of Uncontrolled Clinical Course of Bronchial Asthma in Belarus/D. Ruzanau, E. Davydouskaya, T. Baranovskaya, I. Manichev, Gomel, Belarus, p.A1745


Facilitator:  K. Sumino, MD, MPH, St. Louis, MO

P122  Effect of Khat (catha edulis) on Bronchial Asthma in Jimma University Specialized Hospital, Adult Chest Clinic, Jimma, Ethiopia/E.Y. Teferedegn, A. Ayana, Izmir, Turkey, p.A1748


P125  Comparison of Change in Oxygen Consumption and Heart Rate Following Albuterol and Levalbuterol in Healthy Adults/M.K. Virk, J. Hotz, R.G. Khemani, C.J. Newth, P.A. Ross, Los Angeles, CA, p.A1751

P126  Nasal Disease, a Common Comorbidity in Patients with Chronic Severe Asthma (CSA) and Eosinophilic Granulomatosis with Poliangitis (EGPA)/M. Latorre, V. Seccia, C. Baldini, F.L. Dente, E. Bacci, S. Cianchetti, P. Paggiaro, Pisa, Italy, p.A1752


P131  The Use of Fractional Exhaled Nitric Oxide-Based Management for Non-Eosinophilic Asthma During Pregnancy/V.E. Murphy, P.G. Gibson, Callaghan, Australia, p.A1757

THEMATIC POSTER SESSION

A51  BRONCHIECTASIS: CLINICAL AND EPIDEMIOLOGIC STUDIES

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area F, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator:  G. Tino, MD, Philadelphia, PA


P610  The Bronchiectasis Severity Index as a Surrogate Marker of Morbidity, Quality of Life and Future Risk/S.M. Finch, M. Crichton, T. Fardon, J.D. Chalmers, Dundee, United Kingdom, p.A1759


P612  The Effect of Inhaled Hypertonic Saline on Quality of Life in Primary Ciliary Dyskinesia Patients: A Double-Blind Randomized Controlled Cross-Over Trial/T. Paff, J. Daniels, A. Vonk-Noordegraaf, E. Weersink, R. Lutter, E. Haarman, Amsterdam, Netherlands, p.A1761


P622 Acute Exacerbations of Non-Cystic Bronchiectasis: What Can Promise Non-Invasive Ventilation for Patients with Type 2 Respiratory Failure?/A. Sadigov, S. Akhundov, F. Abdullayev, Baku, Azerbaijan, p.A1771


P624 The Relationship Between Vitamin D Levels and Lung Function, Clinical Indices, Depression and Anxiety Symptoms in Adult Patients with Non-Cystic Fibrosis Bronchiectasis/M. Bekir, D. Kocakaya, S. Olgun Yildizeli, H. Arkan, E. Eryuksel, B. Bagci Ceyhan, Istanbul, Turkey, p.A1773

P625 Non-Cystic Fibrosis Bronchiectasis in Patients with Hematologic Malignancy/L.W. Chen, W.B. Karkowsky, S. Montner, P.J. McShane, S.R. White, M.E. Strek, Chicago, IL, p.A1774


P627 Profile of Exacerbations Among Patients with Non-Cystic Fibrosis Bronchiectasis at the State University of Rio de Janeiro/R.K.R. Leal, R.E.B. Salles, W. Costa, A.B.A. Silva, T.F. Cruz, B.R.A. Silva, Rio de Janeiro, Brazil, p.A1776


P629 Procalcitonin Levels in Cystic Fibrosis Exacerbations/G. Loh, A. Skabelund, A. French, J. Morgan, San Antonio, TX, p.A1778


P633 The Impact of Aspergillus Fumigatus and Its Treatment on Outcomes in Cystic Fibrosis/T. Basnayake, F. Finlayson, A. Peleg, J. Wilson, T. Kotsimbos, Prahran, Australia, p.A1782

Facilitator: E.T. Naurecks, MD, Chicago, IL

P634 The Genetic Profile of Chinese Patients with Cystic Fibrosis/X. Tian, Y. Liu, X. Li, X. Zhang, K.-F. Xu, Beijing, China, p.A1783

P635 Fenretinide Normalizes Aberrant Lipid Metabolism and Prevents Excessive Inflammation During Pulmonary Exacerbation in Adult Cystic Fibrosis Patients/D. Radzioch, G. Wojewodka, S. Cupri, P. Colin, R. Pislinu, D. Garic, I. Kianicka, E. Matouk, Montreal, Canada, p.A1784

P636 How does CPET Compared to Yearly Lung Function Follow-Up in Adult Cystic Fibrosis Patients/T.S. Hynes, P. Harnett, B. Casserly, Limerick, Ireland, p.A1785


P640 Epidemiology And Natural History of Pseudomonas aeruginosa Infection in Patients with Non-Cystic Fibrosis Related Bronchiectasis/R. Lim, T. Woo, J. Duong, B. Waddell, C. Mody, H. Rabin, D.G. Storey, M.D. Parins, Calgary, Canada, p.A1789
P641 Prevalence of Mycobacterial Infection in Adult Brazilian Patients with Cystic Fibrosis/E.P. Oliveira, A.N. Costa, Sao Paulo, Brazil, p.A1790


P643 DNA Extraction from Cystic Fibrosis Sputum Samples is Not Method Dependent/M.C. Tracy, A. Yacoe, C. Chen, C.E. Milla, D.N. Cornfield, Palo Alto, CA, p.A1792

P644 Airway Microbiome Prior To M. Abscessus Complex Or M. Avium Complex Infections In Cystic Fibrosis/L. Caverly, A. Forde, J. LiPuma, Ann Arbor, MI, p.A1793

P645 The Impact of Persistent Growth of Non-tuberculous Mycobacteria on Rate of Lung Function Decline in Adults with Cystic Fibrosis/G. Kirkpatrick, B. Quon, Vancouver, Canada, p.A1794


THEMATIC POSTER SESSION

A52 CRITICAL CARE: ICU PROCEDURES, PROCESSES OF CARE, AND NOVEL TECHNIQUES

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: D. Park, MD, Seattle, WA
E.J. Schenck, MD, New York, NY


P913 Standard and Deferred Consent in the Age of Transfused Blood (ABLE) Trial in Critically Ill Adults/K. E.A. Burns, P. Hebert, D. Fergusson, J. Lacroix, Toronto, Canada, p.A1811
### A53 RESPIRATORY FAILURE: RISK FACTORS AND OUTCOMES IN ARDS

**9:00 a.m. - 4:15 p.m.**

**MOSCONET CENTER**

**Area E, Hall D (North Building, Lower Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:00-11:45: authors will be present for individual discussion 11:45-12:45: authors will be present for discussion with assigned facilitators

**Facilitators: A.M. Esper, MD, MSc, Atlanta, GA**
- R. Kashyap, MBBS, Rochester, MN

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P525</td>
<td>Modified Early Warning Score Is Associated with the Later Development and Timing of Acute Respiratory Failure in Acutely Ill Patients Admitted from an Emergency/Department/C. Risaliti, M. Exline, J. Kynyk, E. Adkins, N. Ali, Columbus, OH, p.A1827</td>
<td></td>
</tr>
<tr>
<td>P528</td>
<td>Association of Tobacco Exposure with Development of Acute Respiratory Distress Syndrome in Burn-Injured Adults/M. Afshar, W. Adams, G. Netzer, M.J. Mosier, E.J. Kovacs, R.S. Cooper, R. Durazo-Avizu, S. Kliethermes, Maywood, IL, p.A1830</td>
<td></td>
</tr>
</tbody>
</table>
P533  High Altitude Pulmonary Edema in Mountain Children with No Recent Travel/C.A. Ebert-Santos, Frisco, CO, p.A1835


Facilitators: M.N. Gong, MD, MS, Bronx, NY
J.P. Reilly, MD, MS, Philadelphia, PA


P538  Pulmonary Physiologic Variables Predicting Mortality in Moderate to Severe Acute Respiratory Distress Syndrome/J.C. Diaz Soto, M.N. Vogt, J.K. Bohman, Rochester, MN, p.A1840


P540  Trajectory of Red Cell Distribution Width (RDW) and In-Hospital Mortality in Acute Respiratory Distress Syndrome (ARDS) Patients/A. Alkhathib, R. Esteitte, L.L. Price, H. Chang, P. LaCamera, Brighton, MA, p.A1842

P541  Clinical Characteristics and Predictors of Hospital Mortality Differ Between Direct and Indirect Acute Respiratory Distress Syndrome (ARDS)/L. Luo, C.M. Shaver, Z. Zhao, T. Koyama, C.S. Calfee, J.A. Bastarache, L.B. Ware, Wuxi, China, p.A1843


P543  Patient Characteristics, Etiologies and Outcomes of Acute Respiratory Failure by Assessment of APACHE-II Score/A. Gaud, K. Trivedi, N. Sinha, P. Ajankar, M.S. Pandharipande, P.P. Joshi, Nagpur, India, p.A1845

P544  Low Vitamin D Status Occurs in 90% of Patients with ARDS and Is Associated with Longer Duration of Mechanical Ventilation/E.K. Bajwa, I. Bhan, S. Quraishi, M. Matthay, B.T. Thompson, Boston, MA, p.A1846


Facilitators: A.B. Mehta, MD, Boston, MA
F. Moazed, MD, San Francisco, CA

P548  Clinical Practice Regarding Acute Respiratory Distress Syndrome in Japan: A Nationwide Web-Based Survey by the Japanese Respiratory Society/S. Tasaka, K. Tatsutili, Tokyo, Japan, p.A1850


**P557** Comparison of rhCC10 Effects in Ovine Model of Traumatic Smoke Inhalation with and Without Dermal Burn/A.L. Pilon, E. Lopez, M.E. Winn, R.S. Clayton, P. Enkhbaatar, Rockville, MD, p.A1859


**P559** Long Term Pulmonary Outcomes from Thoracic Trauma During OIF/OEF Deployment/C. Borders, M.J. Morris, Fort Sam Houston, TX, p.A1861


**P562** Identification of Patients with Acute Respiratory Distress Syndrome Using an Algorithm that Mines the Data from the Electronic Medical Record/C.-P. Wu, L. Lee, M.N. Gong, New York, NY, p.A7793


**Facilitators:** D.L. Hotchkine, MD, MSc, Portland, OR
A. Basit, MBBS, PhD, New Haven, CT

**P565** Diffuse Alveolar Hemorrhage Due to Electronic Cigarette Use/J.L. Long, S. Devabhaktuni, S. Hadique, P. Jain, Morgantown, WV, p.A1862

**P566** Primary Cardiac Angiosarcoma: A Rare Cause of Diffuse Alveolar Hemorrhage/Y. Greenstein, A. Palkar, E. Gottesman, N. Hajizadeh, New Hyde Park, NY, p.A1863


**P568** An Unusual Presentation of Diffuse Alveolar Hemorrhage in a Transplant Recipient/O. Anozie, D. Manta, Syracuse, NY, p.A1865


**P570** Metastatic Gastric Adenocarcinoma Masquerading as Pulmonary Edema/A. Agarwal, P. Gorukanti, M.A. Sheny, P.K. Irukulla, W. Pascal, Y. Kuper, New York, NY, p.A1867

**P571** Use of Venovenous ECMO for Post-Pneumonectomy ARDS in a Community Hospital/J. Berrocal, G. Crooke, J. Shaw, Brooklyn, NY, p.A1868


**P573** Long Term Extracorporeal Membrane Oxygenation Therapy and an Importance of Prone Position for H1N1 Influenza Related Acute Respiratory Distress Syndrome and Several Complications During the Treatment/B.D. Kosovalli, F.I. Yesiler, T.T. Peker, M. Ozcelik, M.K. Bayar, Ankara, Turkey, p.A1870

**P574** Successful Use of Extracorporeal Membrane Oxygenation (ECMO) Therapy Without Intravenous Heparin in a Patient with Acute Intracranial Hemorrhage and Severe ARDS/T. Plush, E. Casanova-Ghosh, E. Gnall, L. Samuels, S. Gregory, Wynnewood, PA, p.A1871

**Facilitators:** J.A. Gold, MD, Portland, OR
M. Jabaudon, MD, MSc, Clermont-Ferrand, France


**P578** Candida Tracheobronchitis: A Case Report of a Rare Disease/A. H. Khan, R. Tandon, Chicago, IL, p.A1875
SUNDAY • MAY 15

A55  CRITICAL CARE CASE REPORTS: NEURO CRITICAL CARE AND TOXICOLOGY

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

THEMATIC POSTER SESSION

P579 Spontaneous Tracheal Rupture After Severe Coughing as First Presentation of Adolescent Asthma/C.J. Grime, C. Barker, P. James, A. Nyman, A. Durward, London, United Kingdom, p.A1876


P582 One Hamburger, Two Causes of Edema/M. Bergman, S. Thomas, Y.I. Lee, New York, NY, p.A1879


Facilitators: M. Hua, MD, MSc, New York, NY
D. Baheti, MBBS, Baltimore, MD


P586 Reactivation of Indolent Pulmonary Coccidiomycosis Presenting as Acute Respiratory Distress Syndrome/A. Arunachalam, H. Grewal, G. Khirafan, S. Krishnan, Cleveland, OH, p.A1883

P587 Severe ARDS and Necrotizing Myopathy- Not Your Usual Case of Influenza Bi/L. Littlefield, I. Subramanian, C. Feeney, Oakland, CA, p.A1884

P588 Surviving Herpes Simplex Virus Type 1 Interstitial Pneumonitis with Viremia Presenting as Acute Respiratory Distress Syndrome in an Immunocompromised Host/N. Bajaj, S.K. Tan, A.H. Tan, Singapore, Singapore, p.A1885


P590 Acute Respiratory Distress Syndrome: An Indolent Presentation of Histoplasmosis/C. Patel, C. Henry, S. Ghamande, Temple, TX, p.A1887

P591 Acute Respiratory Distress Syndrome as a Result of Longstanding Cutaneous Blastomycosis/A.A. Al-Fares, Montreal, Canada, p.A1888


Facilitator: E.C. Goligher, MD, Toronto, Canada


P596 Subpleural Cystic Lung Disease in Severe H1N1 Influenza-Induced Acute Respiratory Distress Syndrome (ARDS)/Y. Matusov, A. Aggarwal, J.S. Sager, Santa Barbara, CA, p.A1893


P598 Successful Treatment of Legionella-Induced Severe ARDS with Antibiotics and IVIG/A. Attaway, J. Fernandez, C. Teba, Cleveland, OH, p.A1895

P599 Antithymocyte Globulin-Induced Acute Respiratory Distress Syndrome After Liver Transplantation/M.J. Kioka, G. Tatem, K. Takahashi, Detroit, MI, p.A1896

P600 Autonomic Instability of Hemodynamic Vital Signs in a Patient with Legionella Pneumonia on ARDS Protocol/A. Flora, Toledo, OH, p.A1897


P603 The Corticosteroid Conundrum: A Case of Systemic Glucocorticoids Resulting in Dramatic Improvement Influenza A (H1N1) Associated ARDS/A. Egan, P.R. Bauer, V.N. Iyer, Rochester, MN, p.A1900

P604 Early Tracheostomy in a Patient on ECMO with Severe ARDS Due to Legionella Pneumonia/M. Shahidi, S. Leung, Bronx, NY, p.A1901

P605 Severe Rhabdomyolysis in a Patient with Legionella Pneumonia Complicated by ARDS/S. Korzan, S. Zanoria, S. Prunk, Farmington, CT, p.A1902
Facilitators: A. Goffi, MD, Toronto, Canada
D.A. Kelmenson, MD, Aurora, CO


P932 Sinusitis and Seizures, Nothing to Snooze or Sneeze At/ A. Tirmizi, Jackson, MS, p.A1904

P933 Creutzfeldt-Jakob Disease, Incurable and Fatal/ A. Tirmizi, S. Butt, Jackson, MS, p.A1905

P934 Propofol Infusion Syndrome - A Rare Complication of Propofol Use/ I.G. Malhotra, N. Verma, M. Iliescu, Chicago, IL, p.A1906

P935 Methadone - A Replacement for Deadly Heroin, Can Kill You Too/ I.G. Malhotra, S. Sivaraman, Chicago, IL, p.A1907

P936 Surviving Sedation/ N.M. Vasquez, M. Fadilla, D. Chairman, Columbia, MO, p.A1908


P938 Two Cases of Moya Moya in Middle-Aged Females in a Suburban Hospital in Missouri/ E. Leung, O. Al-Abboud, M. Salih, M. Benzaquen, St. Louis, MO, p.A1910

P939 Anti-NMDA Receptor Encephalitis: A Potentially Reversible Form of Psychosis/ N. Dodia, C. Kapp, Chicago, IL, p.A1911


P941 A Rare Presentation of Delayed Onset Central Pontine Myelinolysis/ R. Supakul, A. Sodhi, D. Kadaria, Memphis, TN, p.A1913

Facilitators: S.R. Kudchadkar, MD, Baltimore, MD
R.D. Mantilla, MD., Roanoke, VA


P944 Not Your Typical Encephalitis/ G.K. Lin, C.M. Kirsch, San Jose, CA, p.A1916

P945 Cerebral Air Emboli After Transthoracic CT Guided Needle Biopsy/ G.S. Sahota, J.J. Vempilly, Fresno, CA, p.A1917

P946 Spontaneous Intracranial Hypotension as a Rare Cause of Chronic Bilateral Subdural Hematomas/ B. Li, W. Khan, New Brunswick, NJ, p.A1918

P947 Severe Acute Pancreatitis in a Patient Recently Started on Tamoxifen/ B. Li, W. Khan, New Brunswick, NJ, p.A1919


P949 Spongebrain: The Evolution of Brain Imaging in a Patient with DIC/ D. Pearson, L. Lee, A. Skabelund, M.J. Morris, Fort Sam Houston, TX, p.A1921


P952 Super Refractory Status Epilepticus (SRSE) in ICU, a Therapeutic Challenge/ B. Sharma, E. Hennessey, Palo Alto, CA, p.A1924

Facilitators: H. Bhardwaj, MD, Oklahoma City, OK
J. Heavner, MD, New Haven, CT

P953 A Case of Central Diabetes Insipidus in a Non HIV Patient with Cryptococcal Meningitis/ M.K. Loya, Sayre, PA, p.A1925


P955 Cerebral Edema Induced Altered Mental Status as a Presenting Symptom of Acute Hypercapnic Respiratory Failure/ Abu Homoud, A. Khan, E. Costanzo, Neptune City, NJ, p.A1927


P957 Heroin Induced Sudden Sensorinueral Hearing Loss Treated with Steroids/ J. Leap, S. Yadram, R. Adurty, Pittsburgh, PA, p.A1929

P958 A Not So SILENT Manifestation of Lithium Toxicity/ A. Gour, M.A. Shenoy, A.P. Kamath, S. Khanijao, A. Saxena, K. Kitchloo, Brooklyn, NY, p.A1930


P964 High Dose Insulin Infusion for Life Threatening Calcium Channel Blocker Overdose/ P. Jagtap, S.S. Hoskote, F. Hashmi, R.A. Oeckler, Rochester, MN, p.A1936
Facilitators: N.E. Brummel, MD, Nashville, TN
M.C. Antkowiak, MD, Burlington, VT

P965 Severe Autoimmune Hemolytic Anemia and Pancytopenia Induced by PegInterferon Alfa-2a and Ribavirin Refractory to Glucocorticosteroids and Erythropoietin/ J. Pinto, F. Hafeez, M. Olibrice, New York, NY, p.A1937

P966 Propylene Glycol Toxicity Resulting in Severe Lactic Acidosis After Standard Dose Trimethoprim/Sulfamethoxazole Infusion/ M. Bulathsinghala, K. Keefer, A. Van De Louw, Hershey, PA, p.A1938


P968 Ibogaine Toxicity in a Case of Good Intentions/ A. Audi, T. Kamangar, Sylmar, CA, p.A1940


P971 Profound Lactic Acidosis Associated with Metformin Use in a Patient Without Chronic Kidney Disease/ A. Vengerovsky, V. Trivedi, D. Sanghavi, O. Gajić, K.B. Kashani, Rochester, MN, p.A1943

P972 A Case of Viekira Pak-Induced Lactic Acidosis and Shock/ M. Acho, H. Poor, New York, NY, p.A1944

P973 Tamoxifen Induced Hypertriglyceridemia: An Underrecognized and Rare Cause of Pancreatitis/ R. Sedhom, D. Schaer, W. Khan, New Brunswick, NJ, p.A1945


P975 Lower Extremity Numbness and Aortic Dissection/ A. Audi, T. Ashour, Rochester, NY, p.A1947

THEMATIC POSTER SESSION

A56 CRITICAL CARE CASE REPORTS: HEMATOLOGY/ONCOLOGY

9:00 a.m. - 4:15 p.m. MOSCONE CENTER Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: M.P. Kerlin, MD, Philadelphia, PA
R. Kohn, MD, Philadelphia, PA


Facilitators: A.B. Lipke, MD, Seattle, WA
T.R. Leclair, MD, Burlington, VT


P992 Persistent Type B Lactic Acidosis and Hypoglycemia as a Complication of Burkitt’s Lymphoma Without Hepatic Involvement: A Rare Presentation/ R.M. Hoffman, Y.A. Khan, I. El-Abbassi, New Orleans, LA, p.A1963


P1030 Sometimes the Best Thing to Do Is Nothing at All/E. Feuerborn, H. Avella, Boise, ID, p.A1996


A58 EPIDEMIOLOGY OF COPD AND LUNG CANCER
9:00 a.m. - 4:15 p.m.
MOSCONETR CENTER
Area C, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion 11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: D.M. Mannino, MD, Lexington, KY


Facilitator: D.L. DeMeo, MD, MPH, Boston, MA


P246 The Role and Diagnostic Value of Gene Variants in Chronic Obstructive Pulmonary Disease Risk/Z. Yan, X. Tong, H. Fan, Chengdu, China, p.A2007


P248 Social Media (Twitter) for Assessing Concerns About Obstructive Airway Disease/P.I. Harber, G. Leroy, Tucson, AZ, p.A2009

Facilitator: W.G. Kuschnier, MD, Palo Alto, CA


Facilitator: A.M. Ahasic, MD, MPH, New Haven, CT

P255 Health-Related Quality of Life in New Mexican Hispanic Smokers with Asthma and Chronic Bronchitis/A.A. Diaz, H. Petersen, P.M. Meek, A. Sood, B. Celli, Y. Testaigz, Boston, MA, p.A2016
P652 Synthetic Cannabinoid Poisoning in New York City - a Growing
P651 Short Term Effects of a School-Based Computer Assisted
P650 Smoking and Asthma: Examining Factors Associated with
Discussion:
V.D. Upson, MA, MD, Albuquerque, NM
Facilitator:

P259 Lung Cancer, Has It Changed in the Last Ten Years?/D. Bravo
Blanco, O. Liguingo Ochandianio, I. Murga Arizabaleta, E. Marijuan
Gomez, L. Tomas Lopez, J.L. Lobo Beristain, P. Sobradillo
Ecenarro, Vitoria-Gasteiz, Spain, p.A2020

P653 How Much Increases the Risk of Cardiovascular Disease at
Smoker Workers?/N. Bozkurt, E. Dikbas, A.I. Bozkurt, Denizli, Turkey, p.A2025

P654 Smoking Prevalence Among Employees of a University
Hospital/M. M. Knorst, M.B. Sarmento, G. Buffon, T. Muller, L.

P655 Smoking Related Interstitial (SRIF) Is Less Prevalent with
Smoking Cessation and In Those Aged 60+ Years: Regression or Marker of Increased Mortality?/K. Sharma, T. McEnery, A.
Fabre, M.P. Keane, D. Healy, J.D. Dodd, M. Butler, Dublin, Ireland, p.A2027

Facilitator: S.E. Jordt, PhD, Durham, NC

P656 Outpatient Prescription Narcotic Use in Patients Admitted to a
Community Hospital General Medicine Service with a Primary
Respiratory Diagnosis/C.J. vanHooke, B. Warner, A. Taylor, M.
Beer, J. Gould, A. Laursen, R. Loredo, U. Mba, C. O’Neil, E. Wei,
B. Delgado, D. Tangel, Longmont, CO, p.A2028

P657 Effect of Altitude and Cigarette Smoke Exposure on
Bronchoalveolar Lavage Fluid Cellularity/M.K. Ishaq, C. Cross,
City, OK, p.A2029

P658 Mass Media Interventions for Preventing Smoking in Young
People: A Cochrane Systematic Analysis/H. Jayasinghe, K.V.
Carson, J. Van Ageren, F. Ameer, K. Hnin, B. Smith, Adelaide,
Australia, p.A2030

P659 The Impact of Acute Smoking on Airway Gene-Expression/E.
Billatos, Y.B. Gesthalter, N.H.T. Ten Hacken, D.S. Postma, I.H.
Heijink, W. Timens, C.A. Brandsma, A. Faiz, M. van den Berge, M.
Lenburg, A. Spira, Boston, MA, p.A2031

P660 Effects of Nicotine-Containing E-Cigarette Vapor on
Mucociliary Clearance in NHBE Cells/A. Grosche, N.
Baumlin-Schmid, S. Krick, J.S. Dennis, M. Salathe, Miami, FL,
p.A2032

P661 The Effect of Electronic Cigarette Exposure on Bronchial
Epithelial Cells/A. Higham, G. Booth, D. Singh, Manchester,
United Kingdom, p.A2033

Facilitator: E.R. Neptune, MD, Baltimore, MD

P662 In Vitro Cytotoxicity and Molecular Effects of Electronic
Cigarette Vapor Extract on Primary Isolated Mouse Lung
Seeger, F. Grimminger, N. Weissmann, Giessen, Germany, p.A2034

P663 Inspiratory Performance of Smokers and Nonsmokers Using
the Test of Incremental Respiratory Endurance (TIRE)/
M.F. Formiga, N.D. DeLuca, C. Garcia, T.S. Denis, B. Eisenhardt,
S. Colas-Salgado, M. Cohen, L.P. Cahalin, Coral Gables, FL,
p.A2035

P664 Environmental Influence on Tobacco Use in Pulmonary
Patients/M. Weir, H. Cuesta, D. Kolman, F. Patterson, A. Satti,
Philadelphia, PA, p.A2036

P653 How Much Increases the Risk of Cardiovascular Disease at
Smoker Workers?/N. Bozkurt, E. Dikbas, A.I. Bozkurt, Denizli, Turkey, p.A2025

P654 Smoking Prevalence Among Employees of a University
Hospital/M. M. Knorst, M.B. Sarmento, G. Buffon, T. Muller, L.

P655 Smoking Related Interstitial (SRIF) Is Less Prevalent with
Smoking Cessation and In Those Aged 60+ Years: Regression or Marker of Increased Mortality?/K. Sharma, T. McEnery, A.
Fabre, M.P. Keane, D. Healy, J.D. Dodd, M. Butler, Dublin, Ireland, p.A2027

Facilitator: S.E. Jordt, PhD, Durham, NC

P656 Outpatient Prescription Narcotic Use in Patients Admitted to a
Community Hospital General Medicine Service with a Primary
Respiratory Diagnosis/C.J. vanHooke, B. Warner, A. Taylor, M.
Beer, J. Gould, A. Laursen, R. Loredo, U. Mba, C. O’Neil, E. Wei,
B. Delgado, D. Tangel, Longmont, CO, p.A2028

P657 Effect of Altitude and Cigarette Smoke Exposure on
Bronchoalveolar Lavage Fluid Cellularity/M.K. Ishaq, C. Cross,
City, OK, p.A2029

P658 Mass Media Interventions for Preventing Smoking in Young
People: A Cochrane Systematic Analysis/H. Jayasinghe, K.V.
Carson, J. Van Ageren, F. Ameer, K. Hnin, B. Smith, Adelaide,
Australia, p.A2030

P659 The Impact of Acute Smoking on Airway Gene-Expression/E.
Billatos, Y.B. Gesthalter, N.H.T. Ten Hacken, D.S. Postma, I.H.
Heijink, W. Timens, C.A. Brandsma, A. Faiz, M. van den Berge, M.
Lenburg, A. Spira, Boston, MA, p.A2031

P660 Effects of Nicotine-Containing E-Cigarette Vapor on
Mucociliary Clearance in NHBE Cells/A. Grosche, N.
Baumlin-Schmid, S. Krick, J.S. Dennis, M. Salathe, Miami, FL,
p.A2032

P661 The Effect of Electronic Cigarette Exposure on Bronchial
Epithelial Cells/A. Higham, G. Booth, D. Singh, Manchester,
United Kingdom, p.A2033

Facilitator: E.R. Neptune, MD, Baltimore, MD

P662 In Vitro Cytotoxicity and Molecular Effects of Electronic
Cigarette Vapor Extract on Primary Isolated Mouse Lung
Seeger, F. Grimminger, N. Weissmann, Giessen, Germany, p.A2034

P663 Inspiratory Performance of Smokers and Nonsmokers Using
the Test of Incremental Respiratory Endurance (TIRE)/
M.F. Formiga, N.D. DeLuca, C. Garcia, T.S. Denis, B. Eisenhardt,
S. Colas-Salgado, M. Cohen, L.P. Cahalin, Coral Gables, FL,
p.A2035

P664 Environmental Influence on Tobacco Use in Pulmonary
Patients/M. Weir, H. Cuesta, D. Kolman, F. Patterson, A. Satti,
Philadelphia, PA, p.A2036


P669  Proteomics Analysis of BALF in Sarcoidosis Associated Pulmonary Fibrosis/Y. Nukui, Y. Miyazaki, N. Inase, Tokyo, Japan, p.A2041

P670  Sarcoidosis Undergoing Clinical Resolution Demonstrates Reduced Numbers of Apoptotic Bronchoalveolar Lavage (BAL)-Derived CD4+ T Cells/S. Ladhani, C. Hawkins, D.A. Shelton, W. Drake, Nashville, TN, p.A2042


P672  Sarcoidosis in Active Duty Military Personnel Deployed to Southwest Asia/D. Mabe, M. Sobieszczuk, A. Holley, K. Sheikh, Bethesda, MD, p.A2044


P675  The Challenge of Estimating the Burden of Idiopathic Pulmonary Fibrosis (IPF) Using Medical and Public Records Databases/J.E. Gibson, V. Navaratnam, D. Strachan, R. Hubbard, Nottingham, United Kingdom, p.A2047


Facilitator:  K.A. Johansson, MD, Calgary, Canada


P685  Effect of Focal Tracheal Deviation (Tracheal Kink) on Ozone Tracheal Flux in Fibrotic Lung Disease Patients: A Simulation Study/S. Borhan, S.P. Motevalian, J. Ultman, T. Kuhlengel, A.E.F. Dimmock, R. Bascom, A. Borhan, University Park, PA, p.A7798
THEMATIC POSTER SESSION

A61  CLINICAL ASPECTS OF NON-BACTERIAL LUNG INFECTIONS

9:00 a.m. - 4:15 p.m.  MOSCONE CENTER
Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: D.J. Marchant, PhD, Edmonton, Canada


P780  Physician’s Attitude to a Positive Respiratory Viral Panel (RVP) on Bronchoalveolar Lavage (BAL) in Adult In-Patients with Acute Lower Respiratory Tract Infection/P. Agarwal, A.S. Nyquist, J. Timpone, D. Lazarous, Washington, DC, p.A2057


P784  Association of rt-PCR Respiratory Viral Assay Results with Antibiotic Usage and Length of Stay in Hospitalized Patients/S. Ashraf, N. Hakimi, D. Wakefield, J. Fine, Norwalk, CT, p.A2061


P786  Diagnostic Accuracy of Serum Procalcitonin to Identify Viral Pneumonia in Patients Admitted to the Intensive Care Unit/J. Krings, J.E. Reynolds, N.W. Lin, B. Trinh, R.D. Shah, R.G. Wunderink, Chicago, IL, p.A2063

Facilitator: Y. Imai, MD, Akita, Japan


P789  Concordance Between Rhinovirus Found in Exhaled Breath and Bronchoalveolar Lavage Fluid/A. Mitchell, H. Lam, M. Peters, L. Morgan, B.G. Oliver, Glebe, Australia, p.A2066


Facilitator: S.T. Qureshi, MD, Montreal, Canada


P798  Monitoring Respiratory Syncytial Virus (RSV) Infections in Alberta, Canada During the 2014 - 2016 Seasons Using Whole Genome Sequencing, Descriptive Epidemiology and Virological Analysis Revealed the Transmission Dynamics and the Age Group Tropism of RSV /D.J. Marchant, D. Zhu, L. Forss, B. Hazes, L. Bilawchuk, C. Griffiths, L. Jensen, S.J. Drews, Edmonton, Canada, p.A2075


P800  Invasive Pulmonary Aspergillosis in Non-Immunocompromised Patients: Clinical Features and Treatment/Y.-L. Liu, Z. Wang, Beijing, China, p.A2077


P808  Frequency of Isolation of Candida from the Respiratory Tract in Immunocompromised Patients at the University of Michigan/K. Pendleton, R.P. Dickson, D. Newton, G.B. Huffnagle, Ann Arbor, MI, p.A2083


P806  False Positivity of Coccidioides Enzyme Immunoassay (EIA) for the Serologic Diagnosis of Coccidioidomycosis in Children/S. Maw, F. Naeem, M.A. Tablizo, Fresno, CA, p.A2085

P805  Clinical Outcomes of Blastomycosis at a Tertiary Care Center - a Retrospective Study/S. Pruksaritanond, P. Jagtap, B.S. Pannu, R. Tedja, C. Thongprayoon, V.N. Iyer, Rochester, MN, p.A2086


P818  Cardiac Complications in Adult Patients with Community-Acquired Pneumonia and Diabetes Mellitus/M.S. Bader, Y. Yi, K. Abouchehade, L. Bishop, B. Haroon, J. Hawboldt, Hamilton, Canada, p.A2094


Facilitator: M. Prickett, MD, MPH, Chicago, IL


P827 Legionnaire’s Disease in Eight Potentially Epidemiologically-Linked Patients During Two Recent New York City Outbreaks: Case Reports and Literature Review/S. Fahme, M. O’Donnell, New York City, NY, p.A2103


P830 Neutrophil Extracellular Traps Are Associated with Disease Severity in Chronic Obstructive Pulmonary Disease/C. Fong, A.J. Dicker, M. Crichton, G. Suarez-Cuartin, O. Sibila, S. Schembri, S. Marshall, C.N.A. Palmer, J.D. Chalmers, Dundee, United Kingdom, p.A2106

P831 Relation Between Biomarkers on Admission, Radiologic Abnormalities and Risk Score in Patients with Community Acquired Pneumonia (CAP)/R. Duijkers, W.G. Boersma, Alkmaar, Netherlands, p.A2107

Facilitator: M.I. Restrepo, MD, MSc, San Antonio, TX


P833 A Retrospective Study Comparing Procalcitonin with Physiological Severity Score in Community Acquired Pneumonia in a Middle Eastern Tertiary Centre/J.A. Palaki, A.M. Maliyakkal, L. Ahmed, M. Ganeshdas, N.M. Shaath, Al Wakra, Qatar, p.A2109


P835 Is Neutrophil to Lymphocyte Ratio Useful Prognostic Marker for Patients with Community Acquired Pneumonia/C. Son, Busan, Korea, Republic of, p.A2111


Facilitator: J.A. Ramirez, MD, Louisville, KY

P839 Respiratory Fluoroquinolones Versus /Lactams for Non-Intensive Care Unit Hospitalized Community-Acquired Pneumonia Patients: A Pooled Analysis/S. Liu, X. Tong, H. Fan, Chengdu, China, p.A2115


P841 Ceftaroline Activity Against MDR Streptococcus Pneumoniae Subsets from United States Medical Centers (2014)/D.D. Farrell, R.E. Mendes, R.K. Flam, H.S. Sader, R.N. Jones, North Liberty, IA, p.A2117


P843 An Exploration of De-Escalation Strategies in Hospitalized Patients with Community Acquired Pneumonia/F. Papik, G. Nair, P.R. Yeturu, M.J. Fazzari, D. Kurbaban, M.S. Niederman, Mineola, NY, p.A2119

P844 Current Management and Associated Risks of Pediatric Patients Diagnosed with Community-Acquired Pneumonia (CAP) in Mongolia/G. Dorj, Ulaanbaatar, Mongolia, p.A2120

P845 Social Factors on Hospitalization Period of Elderly Patients with Pneumonia Reveals the Association of Age and Smoking with Extent of Recovery/G. Dorj, S. Palomar, Argentina, p.A2122


P854 An Analysis of 58 Cases of Community-Acquired Lung Bronchoalveolar Lavage Among Hematopoietic Stem Cell Facilitator: E. Polverino, MD, PhD, Barcelona, Spain

P60 A Prospective, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of Nebulized Amikacin as Adjunctive Therapy in Hospital Acquired and Ventilator Associated Pneumonia in Surgical ICUs/N.A.E.K. Hassan, F.F. Awadallah, N.A. Sabry, Giza, Egypt, p.A2136

P851 Auditing the Effectiveness of a Novel Virtual Pneumonia Follow-Up Clinic/J.V. Krishnan, C. Duffus, B.G. Marshall, Southampton, United Kingdom, p.A2127

P856 Factors Associated with Positive Ratio of Pleural Effusion at Our Hospital/C. Morris, E. Forno, Y.Y. Han, E. Forno, A.M. Turner, D. Osanji, Birmingham, United Kingdom, p.A2137


P857 Factors for the Long-Term Survival of Patients with Pneumonia in Surgical ICUs/M. Kolditz, MD, Dresden, Germany


P853 Early Readmission and Related Costs for Pneumonia: The Trade-Off Between the Rehospitalization and the Quality of Assistance Marginal Costs. Evidence from an Italian Regional Hospital Discharge Registry/A. Rossi Zadra, C. Di Novi, Torino, Italy, p.A2125

P858 Empiric Antibiotic Treatment for Ventilator-Associated Abscess Whose Pathogen was Microbiologically Confirmed by New York, NY, p.A2128

P856 Clinical Features and Outcomes of Patients with Hospital Acquired Pneumonia in a 12-Month Service Evaluation Project of a UK Cohort/C. Morris, E. McCance, S. Sushanth Vayalapra, T. Cutburt, A.M. Turner, D. Osanji, Birmingham, United Kingdom, p.A2137

P863 Azithromycin is Associated with Improved Survival in Patients with Healthcare-Associated Pneumonia/E.M. Mortensen, M.L. Metersky, C.R. Frei, R.T. Attridge, A. Anzueto, Dallas, TX, p.A2139


P856 Clinical Characteristics of Community-Acquired Pneumonia in the Patients with Pulmonary Fibrosis/T. Tateishi, T. Fujie, Y. Miyazaki, N. Inase, Tokyo, Japan, p.A2132

P854 An Analysis of 58 Cases of Community-Acquired Lung Abscess Whose Pathogen was Microbiologically Confirmed by Transthoracic Needle Aspiration/R. Kagami, T. Kawamura, Y. Onishi, Y. Mochizuki, Y. Nakahara, S. Sasaki, Himeji, Japan, p.A2130

P857 An Analysis of Hospital Acquired Infection Focused on Hospital Acquired Pneumonia Based on a One Year Surveillance for All Hospitalized Patients in a Japanese Community Hospital/H. Nakamura, T. Inoue, K. Tanimoto, K. Yokota, Kagawa, Japan, p.A2133


P851 Auditing the Effectiveness of a Novel Virtual Pneumonia Follow-Up Clinic/J.V. Krishnan, C. Duffus, B.G. Marshall, Southampton, United Kingdom, p.A2127


Facilitator: E. Polverino, MD, PhD, Barcelona, Spain

Facilitator: M. Kattan, MD, New York, NY

Facilitator: M. Kolditz, MD, Dresden, Germany

Facilitator: E. Forno, MD, MPH, Pittsburgh, PA

Facilitator: M. Kattan, MD, New York, NY

Facilitator: M. Kolditz, MD, Dresden, Germany

Facilitator: E. Polverino, MD, PhD, Barcelona, Spain

Facilitator: E. Forno, MD, MPH, Pittsburgh, PA
P1055  Relationship Between Health Literacy and Numeracy of Parents and Asthma Control in Their Children/S. Krishnan, A.J. Dozor, Valhalla, NY, p.A2149


P1057  Identifying Barriers to Care and Health/Treatment Beliefs Facilitates a Better Understanding of Uncontrolled, Severe Asthma in the Pediatric Patient/L. Kertz, K. Rivera-Spoljaric, St. Louis, MO, p.A2167

Facilitator:  S. Lovinsky-Desir, MD, New York, NY


P1060  Meta-Analysis of Obesity and Lung Function/E. Forno, Y.Y. Han, J. Mullen, J.C. Celedon, Pittsburgh, PA, p.A2153


Facilitator:  M.N. Eakin, PhD, Baltimore, MD


P1067  Assessment of Pediatric Asthma Knowledge After the First Year of Residency Training/S.Q. Ahmad, S. Agrawal, M. George, D. Weaver, Brooklyn, NY, p.A2143


Facilitator:  S.K. Ramratnam, MD, MPH, Madison, WI

P1069  Improving Asthma Care in a Pediatric Teaching Clinic/J.S. Lee, A. Gogo, D. Tancred, U. Shaikh, Sacramento, CA, p.A2145

P1070  Asthma and Allergy Screening in a Sports Medicine Clinic/ R.C. Cohn, C. Driscoll, E. Koenig, L. Scott, Dayton, OH, p.A2146

P1071  Effects of Lung Function Tests on Doctor’s Decision in Modifying the Diagnosis and Outcome of Asthma/J.H. Baek, M.Y. Han, Hwaseong, Korea, Republic of, p.A2148

P1072  A Multidisciplinary Clinic for Difficult to Treat (DTT) Asthma Improves Asthma Control/K.M. McDowell, T.W. Guilbert, L. Gu, C.M. Kercsmar, Cincinnati, OH, p.A2150


P1074  Continuous Quality Network (CQN) Pediatric Asthma/C. Landen, T. Torices, Ventura, CA, p.A2171

Facilitator:  S.O. Okelo, MD, PhD, Los Angeles, CA


P1079  Controller Therapy in Children with Asthma Presenting to the Pediatric Emergency Department/M. Kumar, T. Liang, D. Patel, A.J. Dozor, S. Krishnan, Valhalla, NY, p.A2159

P1080  Characteristics of Children Attending Emergency Care for Acute Asthma in the City of Esmeraldas, Ecuador/ C. Aroda-Garcia, P. Hurtado, E. Arias, C. Sandoval, J. Blakey, P.J. Cooper, Liverpool, United Kingdom, p.A2168

A64 TRANSLATIONAL RESEARCH IN PEDIATRIC ASTHMA

9:00 a.m. - 4:15 p.m.  MOSCONET CENTER

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: J.S. Debley, MD, MPH, Seattle, WA


P1084 The Increased Cholinergic Innervation Following Early Life Allergen Exposure Induces Persistent Airway Hyper-Reactivity and Remodeling/K. Patel, Y. Bai, K. Trieu, X. Ai, Boston, MA, p.A2177

P1085 The Role of Hyluronan on Chronic Asthma: Expanding Target for Mesenchymal Stem Cells?/B.D. Goldstein, M.E. Lauer, T.L. Bonfield, Cleveland, OH, p.A2182


Facilitator: G.R. Nino, MD, Washington, DC


P1089 A Clinically Relevant Laboratory Investigation Into Facemask-to-Face Seal, Simulating the Administering of Inhaled Medication Via a Valved Holding Chamber (VHC) with Facemask (FM) to an Infant Face Model/J. Suggett, M. Nagel, C. Doyle, V. Wang, D. Coppolo, J.P. Mitchell, London, Canada, p.A2181


Facilitator: D.J. Lee, MD, Hacksensack, NJ

P1094 Leukocytes in Expressed Breastmilk of Asthmatic Mothers Differ in Both Proportion and Activation State/D.-L. Dixon, K. Forsyth, Bedford Park, Australia, p.A2174


P1096 Sphingolipid Synthesis and Composition are Altered in Children with Asthma/J.G. Ono, T. Worgall, S. Worgall, New York, NY, p.A2179


**THEMATIC POSTER SESSION**

A65 NICU, PICU AND CHRONICVENTILATION

9:00 a.m. - 4:15 p.m.  MOSCONET CENTER

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: C.L. Carroll, MD, Hartford, CT


P1108 Factors Associated with Hypoxaemia in High Risk Neonates at the Special Care Baby Unit of a Resource-Constrained Centre/B. P. Kuti, D. K. Kuti, T. Ogundele, Il-Ife, Nigeria, p.A2193


P1110 Outcomes of Children Post Congenital Heart Surgery Who Were Discharged on Home Mechanical Ventilation Via Tracheostomy/A. Cristea, B. Benneyworth, S. Davis, V. Ackerman, Indianapolis, IN, p.A2202

P1111 Patterns of Home Ventilator Assistance In The Province Of Alberta, Canada: A Retrospective Population-Based Cohort Study/E. J. MacIntyre, K. Rimmer, C. Cyr, D. A. McKim, J. MacLean, D. Littmann, M. Heule, A. Massia, L. Rose, S. M. Bagshaw, Edmonton, Canada, p.A2206


P1117 Nebulized Corticosteroid for Preventing Post-Extubation Stridor in Children: A Randomized, Double Blind Controlled Trial (Preliminary Study)/P. Prasertsan, N. Anantasit, Bangkok, Thailand, p.A2205


Facilitator: R.L. Damico, MD, PhD, Baltimore, MD


P1405 Genome-Wide Association Study with Interactome-Based Scoring Identifies Dok4 and Ppp2ca as Novel Candidate Genes in High-Fat Diet-Induced Pulmonary Hypertension/N. Kelly, J. Radder, J. Baust, C. Burton, B. Agostini, J. Wood, A. Gregory, A. Leme, S.D. Shapiro, Pittsburgh, PA, p.A2219


Facilitator: M.R. Nicolls, MD, Palo Alto, CA


P1416 Oral CAR Peptide Adjuvant Enhances Sildenafil Therapy for Pulmonary Arterial Hypertension/D. Mann, X. Yue, J. Sawada, M. Komatsu, Goleta, CA, p.A2230

P1417 CAR Peptide Adjuvant Enables Effective Pulmonary Hypertension Treatment with Imatinib at Reduced Doses/D. Mann, X. Yue, J. Sawada, N. Ambalavanan, M. Komatsu, Goleta, CA, p.A2231

P1418 Composition and Structure of the Vascular Basement Membrane in Pulmonary Hypertension/I. Hoffmann, B. Ghanim, W. Klepetko, G. Kovacs, H. Olschewski, A. Olschewski, G. Kwapiszewska, Graz, Austria, p.A2232

P1419 Inhibition of L-Type Amino Acid Transporter 1 (LAT-1) Export or Resistant to Chronic Hypoxia-Induced Pulmonary Artery Fibroblasts/K. Brodsky, H. Eltzschig, K.R. Stenmark, Aurora, CO, p.A2235


P1422 Comparative Analysis of Global Gene Expression Profile in Mouse Strains After Hypoxic Challenge Either Susceptible to or Resistant to Chronic Hypoxia-Induced Pulmonary Hypertension/W. Nichols, N. Dasgupta, P. Hale, T. Le Cras, P. Pastura, M. Pauciulo, Cincinnati, OH, p.A2236


Influence of IP Receptor Density on Agonist Activity of ACT-333679, the Active Metabolite of Sel lexipag/ J. Gatfield, K. Menyhart, O. Nayler, Allschwil, Switzerland, p.A2239


Transportation of Translationally Controlled Tumor Protein (TCTP) Via Exosomes Contributes to The Pathology of Pulmonary Arterial Hypertension/ F. Ferrer-Andres, B.J. Dunmore, M.L. Ormiston, S. Moore, J.R. Lavoie, D.J. Stewart, Cambridge, United Kingdom, p.A2243

Facilitator: D.E. Green, MD, Atlanta, GA

Modifier Mutations Associated with Hyper-Responsiveness to VEGFR2 Inhibition Resulting in Severe Pulmonary Arterial Hypertension in a Sub-Strain of Sprague-Dawley Rats/ K.R. Chaudhry, Y. Deng, A. Yang, X. Wen, E. Cuppen, D.J. Stewart, Ottawa, Canada, p.A2244

O-GlcNAc Transferase Regulates Glucose Metabolism in Idiopathic Pulmonary Arterial Hypertension/ J.W. Barnes, L. Tian, S.A.A. Comhair, R. Dweik, Cleveland, OH, p.A2245

NKX2-5 Is Associated with Pulmonary Arterial Hypertension/ A. Dritsoul a, C. Fonseca, J. Martin, C. Denton, M. Ponticos, London, United Kingdom, p.A2246

Activation of Anoctamin-1 Causes Apoptosis of Pulmonary Endothelial Cells Mediated Via p38/ A. Allawzi, A. Vang, N. Kue, G. Choudhary, Providence, RI, p.A2247

Multiple Metabolic Pathways Are Involved in Hypoxia-Induced Proliferation of Pulmonary Artery Endothelial Cell/ M. Husain, N. Mariappan, I. Zafar, S. Ahmad, A. Ahmad, Birmingham, AL, p.A2248


PPAR Gamma Modulates PINK1 in Hypoxia-Exposed Human Pulmonary Artery Smooth Muscle Cells/ A. Chaudhry, T. Murphy, M. Hart, D.E. Green, Atlanta, GA, p.A2251

Smooth Muscle-Specific Insulin-Like Growth Factor-1 Mediates Chronic Hypoxia-Induced Pulmonary Hypertension in Neonatal Mice/ M. Sun, R. Ramchandran, J. Chen, Q. Yang, J.U. Raj, Chicago, IL, p.A2252

THEMATIC POSTER SESSION

A67 CASE REPORTS IN PULMONARY VASCULAR DISEASE

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: W.H. Fares, MD, MSc, New Haven, CT

P1440 A Case of Inflammatory Pseudotumor Presenting as Chronic Thromboembolic Disease: A Rare and Controversial Entity/ C.M. Bojanowski, E.S. Yi, H.-Y. Wang, G.V. Pretorius, W.R. Auger, G.Y. Lin, La Jolla, CA, p.A2253

P1441 Prominent Bronchial Artery Contributing to Pulmonary Hypertension in a Patient with Hereditary Hemorrhagic Telangiectasia/ N. Li, H. Poor, New York, NY, p.A2254

P1442 A Case Report of Pulmonary Tumor Emboli Leading to the Diagnosis of Underlying Squamous Cell Cancer: The Role of Thromboendarterectomy/ J.N. McNeill, R. Channick, Boston, MA, p.A2255


P1444 A Ballooning Problem/ A. Law, B. Murphy, B.L. LeVarge, Boston, MA, p.A2257

P1445 Severe Pulmonary Hypertension with Unexpected Autopsy Finding in a 70 Years Old Man/ A. Ali, Y.A. Al Ahwel, A. Milad, S.U. Rehman, M. Taleb, R. Assaly, Toledo, OH, p.A2258


**P1448** Pulmonary Arterial Hypertension (PAH) Associated with Interferon β1B: A Case Report/R. Papani, A. Duarte, Galveston, TX, p.A2261

**P1449** Embolic Temblor: A Case of Rapidly Progressive RV Failure in a Patient with Severe Pulmonary Hypertension and Metastatic Cancer/E. Mou, D. Lazzareschi, D. Blayney, A. Connolly, A. Rogers, Palo Alto, CA, p.A2262

**P1450** Diffuse Alveolar Hemorrhage Due to Intravascular Large B Cell Lymphoma: The Great Imitator/A. Somoracki, L. Cagino, R. Helton, A. Ataya, H. Alnuaimat, Gainesville, FL, p.A2263


**P1452** Successful Management of Massive Pulmonary Tumor Embolism/S. Ayub, M.T. Shakoor, T. Barter, Little Rock, AR, p.A2265

**P1453** Airway and Pulmonary Effects of A Giant Left Atrium/K.C. Poh, A.A. Hsu, Singapore, Singapore, p.A2266

**P1454** A 45-Year-Old Woman with Neurofibromatosis Type-1-Associated Pulmonary Arterial Hypertension Responsive to Epoprostenol/M.L. Gibbs, J.L. Garland, Jacksonville, FL, p.A2267

**P1455** Management of Pulmonary Hypertension in In-Vitro Fertilization Twin Pregnancy/T.T.T. Aldan, B. Matsuda, G.P. Devendra, Honolulu, HI, p.A2268

**P1456** Pulmonary Hypertension Diagnosed 20 Years After Onset of Castleman’s Disease in a 58 Year Old Female/B.A. Kelly, M. Mendez, R. Awdish, Detroit, MI, p.A2269

**P1457** An Unusual Case of Severe Pulmonary Hypertension Due to Pulmonary Amyloidosis Along with Cardiac Amyloidosis Presenting with Atypical Features in the Same Patient/S. Afreenn, F.T. Ogundipe, F. Khan, S. Sawhney, J. Arhinful, Y. Habiegebriel, A. Thomas, P. Mehotra, V. Poddar, Washington, DC, p.A2270

**P1458** Intimal Sarcoma of the Pulmonary Artery Presented as Pulmonary Embolism/C. Villaquiran-Torres, D.L. Rey, Bogota, Colombia, p.A2271

**P1459** Pulmonary Artery Obstruction Secondary to a Primary Mediastinal Ewing’s Sarcoma/Primitive Neuroectodermal Tumor (ES/PNET)/C. Villaquiran-Torres, J.E. Cita, A. Canas-Arboleda, Bogota, Colombia, p.A2272

**P1460** Two Rare Conditions Linked by an Activin Receptor-Like Kinase 1 (ALK-1) Mutation/A. McCambridge, R. Cartin-Ceba, Rochester, MN, p.A2273

**P1461** Pulmonary Arterial Hypertension (PAH) Masked by Coexisting Respiratory Bronchiolitis Interstitial Lung Disease (RB-ILD), Diagnosed Histologically/M. Mahmoud, S. Hegab, M. Mendez, C. Stone, R. Awdish, Detroit, MI, p.A2274

**P1462** An Unusual Cause of Pulmonary Hypertension and Cor Pulmonale/C. Liu, T. Brown, R. Tangel, R. Sharma, New Brunswick, NJ, p.A2275

**P1463** Scimitar Syndrome Presenting with Pulmonary Emboli and Right Heart Failure Requiring ECMO/P.J. Simpson, G. Are, R.A. Lopez, Jamaica, NY, p.A2276

**P1464** A Case of Behcet’s Disease Presenting with Right Atrial Thrombus and Pulmonary Embolism/Y. Yang, K. Xu, Beijing, China, p.A2277

**P1465** Pulmonary Hypertension Due to Pulmonary Tumor Embolism Syndrome Successfully Treated with Pulmonary Vasodilator Therapy as a Bridge to Chemotherapy/M. Bender, S.S. Kim, O. Friedman, New York, NY, p.A2278

**P1466** A Case of a Runaway Wire/L. Sargsyan, S. Sahay, B. Patel, Houston, TX, p.A2279

**P1467** Radiation Induced Pulmonary Artery Stenosis. Use of SPECT CT Perfusion Scan for Accurate Diagnosis/M. Rudrappa, K. Trivedi, S.R.K. Marri, L. Kokatnur, Shreveport, LA, p.A2280

**P1468** Pulmonary Embolism; Idiopathic or from Very Rare Etiology?Y. Im, J. Kopita, Dallas, TX, p.A2281

**P1469** Resolution of Severe Pulmonary Hypertension and Right Ventricular Failure in a Patient with Antiphospholipid Antibody Syndrome and Suspected Chronic Thromboembolic Pulmonary Hypertension/B.T. Bevill, R.G. Argula, C.B. Strange, G. Gilkeson, N.H. Kim, Charleston, SC, p.A2282

**P1470** An Unusual Cause of Pulmonary Arterial Hypertension in a Young Mother of Two/M. Plataki, A. Jacobi, S. Dua, New York, NY, p.A2283

**P1471** Spontaneous Pneumothorax Resulting from an Aseptic Ruptured Pulmonary Infarct/A. Vasudevan, S. Khanna, S. Dhesi, M. Lippmann, Philadelphia, PA, p.A2284

---

**THEMATIC POSTER SESSION**

**A68 THE RISING: UNDERSTANDING THE RIGHT VENTRICLE**

**9:00 a.m. - 4:15 p.m.**

**MOSCONETE**

**Area M, Hall D (North Building, Lower Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:00-11:45: authors will be present for individual discussion 11:45-12:45: authors will be present for discussion with assigned facilitators

**Facilitator:** B. Fenster, MD, Denver, CO


The L-Carnitine Ameliorates Pulmonary Arterial Hypertension/Resting, Non-Invasive Cardiac Output Monitoring (NICOMr) in Exercise Cardiac Magnetic Resonance Imaging: A Novel Technique for Assessing Right Ventricular Contractile Reserve/D.A. Beard, N. Chesler, Madison, WI, p.A2290


The L-Carnitine Ameliorates Pulmonary Arterial Hypertension/Resting, Non-Invasive Cardiac Output Monitoring (NICOMr) in Exercise Cardiac Magnetic Resonance Imaging: A Novel Technique for Assessing Right Ventricular Contractile Reserve/D.A. Beard, N. Chesler, Madison, WI, p.A2290


Facilitator: R.S. Novitch, MD, White Plains, NY


High-Intensity Interval Training Improves Maximal Oxygen Consumption in Untrained Adult Asthmatics/L. Toennesen, N. Meier, M. Hostrup, C. Porsbjerg, V. Backer, Copenhagen, Denmark, p.A2304

P1495 Determinants of Peak Aerobic Capacity and Six-Minute Walk Distance in Patients Treated for Lung Cancer/C. Burtin, F. Franssen, L. Vanfleteren, M.T. Groenen, E. Wouters, M. Spruit, Diepenbeek, Belgium, p.A2306


Facilitator: A.E. Holland, PhD, Melbourne, Australia

P1497 High-Intensity Exercise to Treat a Patient with Tuberous Sclerosis Complex-Lymphangiomyomatosis (TSC-LAM)/T.W. Lowder, T.J. Whitney, Houston, TX, p.A2308

P1498 Exercise Training Improves Pulmonary Function and Bone Mineral Density in Women with Lymphangiomyomatosis (LAM)/T.W. Lowder, T.J. Whitney, Houston, TX, p.A2309


P1501 Pulmonary Rehabilitation for Interstitial Lung Diseases: An Italian Experience/G. Brunetti, E. Paracchini, C. Beretta, A. Malovini, G. Piaggio, V. Rossi, Pavia, Italy, p.A2312


Facilitator: D. Langer, PhD, PT, Leuven, Belgium


P1508 Outpatient-Based Rehabilitation Program Improves Right Ventricular Function in Patients with Pulmonary Hypertension: Results from a Pilot Study/N.R. Morris, W. Strugnell, H. Seale, A. Lin, J. Harris, C. Hamilton-Craig, F. Kermeen, Southport, Australia, p.A2319

P1509 Veterans Entering Pulmonary Rehabilitation with Posttraumatic Stress Disorder and Anxiety May Be Greater than Expected and Be at a Substantial Disadvantage/N.D. DeLuca, M.F. Formiga, M. Campos, M.A. Pardinas Gutierrez, L.P. Cahalin, Coral Gables, FL, p.A2320

P1510 Pulmonary Rehabilitation on Aerobic Capacity and Health-Related Quality of Life in Patients with Sequelae of Pulmonary TB/J.A. Rivera Motta, E.C. Vilchez, R.P. Mosquera, Cali, Colombia, p.A2321

THEMATIC POSTER SESSION

A70 THE GOOD, THE BAD, AND THE UGLY OF AGING

9:00 a.m. - 4:15 p.m. MOSCON CENTER

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: D.M. Guidot, MD, Atlanta, GA


P373 Pulmonary Vascular Stiffening in Human PAH and with Aging/D. Sicard, L. Fredenburgh, D.J. Tschumperlin, Rochester, MN, p.A2324

P374 Genetic Inactivation of the Phospholipase A2 Receptor (PLA2R1) Protects Against Lung Cell Senescence in Chronic Obstructive Pulmonary Disease (COPD)/J. Huang, A. Attwe, E. Marcos, V. Amsellem, M. Breaux, K. Kebe, A. Houssaini, P. Validire, B. Maître, D. Vindrieux, D. Bernard, S. Adnot, Creteil, France, p.A2325

P375 Endothelial TLR4 Regulates DNA Damage, Genome Stability and Senescence During Oxidant Stress/Y. Zhang, J.-N. Min, P. Shan, X. Zhang, P.J. Lee, New Haven, CT, p.A2326

P377 **Attenuation of EC-SOD Gene Expression in Aging Lung Fibroblasts: Role of Histone Acetylation**/N. Zeiko, J.D. Ritzenthaler, S. Barve, S. Ghare, J. Roman, Louisville, KY, p.A2328

P378 **AMPK Activators Reduces Cigarette Smoke-Induced Inflammatory Responses and Elastase-Induced Mouse Emphysema**Y.-Y. Li, C. Huang, J. Li, H.-W. Yao, Hefei, China, p.A2329

P379 **Targeting the mTOR Signaling Pathway to Inhibit Lung Cell Senescence in Chronic Obstructive Pulmonary Disease (COPD)**/A. Houssaini, K. Kebe, M. Breau, E. Marcos, J. Huang, A. Attwe, E. Bizard, S. Abid, P. Validire, B. Maitre, S. Meiners, V. Amselfeim, S. Adnot, Creteil, France, p.A2330


**Facilitator:** R.J. Freishtat, MD, MPH, Washington, DC

**P381 Regenerative Asynchrony Is a Driver in Chronic Inflammation in Aging**/C.E. Hoptay, S. Alcala, E.P. Hoffman, R.J. Freishtat, Washington, DC, p.A2332


**P383 Cigarette Smoke Exposure- and Aging- Impair Autophagy that Mediates COPD-Emphysema Pathogenesis**/N. Vij, P. Chandramani, C.V. Westphal, R. Hole, T. Min, M. Bodas, Mt. Pleasant, MI, p.A2334


**Facilitator:** L.M. Schnapp, MD, Charleston, SC

**P386 Aging Is Not Enough! Bleomycin-Induced Fibrosis in an Accelerated Aging Mouse Model**/J. Calyeca, R. Olmos, R. Jasso, M. Gaxiola, C. Lopez-Otin, M. Selman, A. Pardo, Mexico City, Mexico, p.A2337


**P389 Telomere Shortening and Progression in Patients with Chronic Obstructive Pulmonary Disease (COPD)**/E. Cordoba-Lanus, A. Espinoza-Jimenez, R. Baz-Davila, S. Cazorla, A. Montejo-de-Garcini, A. Aguierre-Jaime, B. Celli, C. Casanova, Santa Cruz de Tenerife, Spain, p.A2340


---

**THEMATIC POSTER SESSION**

**A71 EPIGENETICS**

9:00 a.m. - 4:15 p.m. MOSCONIC CENTER

**Area D, Hall D (North Building, Lower Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:**

11:00-11:45: authors will be present for individual discussion

11:45-12:45: authors will be present for discussion with assigned facilitators


THEMATIC POSTER SESSION

A72 MECHANISMS OF LUNG CANCER BIOLOGY

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion

11:45-12:45: authors will be present for discussion with assigned facilitators.

Facilitator: Y.M. Janssen-Heininger, PhD, Burlington, VT


P263 Expression and Clinical Significance of S100 Calcium Binding Protein A2 in Lung Cancer/H. Ren, T. Wang, M. Chen, Xi’an, China, p.A2355


P265 Study of Erythromycin on Histone Deacetylase 2 in A549 Cells Exposed to Cigarette Smoke Extract/H.S. Ming, L.L. Hua, Y.L. Kai, X.M. Peng, G.N. Liu, Nanning, China, p.A2357

P266 Grape Seed Proanthocyanidin Extract Modulates RNA Exosome Expression in A549 Lung Cancer Cells/J.T. Mao, J. Smoake, H. Park, B. Xue, Albuquerque, NM, p.A2358

P267 Fibronectin and Hepatocyte Growth Factor Produced from Lung Fibroblasts Can Increase in Migration and Invasion of Malignant Pleural Mesothelioma Cells/N. Kanaji, A. Tadokoro, N. Kita, T. Takagi, T. Ishii, N. Watanabe, S. Bandoh, Kagawa, Japan, p.A2359

Facilitator: V. Keshamouni, PhD, Ann Arbor, MI

P268 Leptin Gene Polymorphism Increases Risk of Lung Cancer?/S. Peng, X. Tong, H. Fan, Chengdu, China, p.A2360

P269 Vimentin Regulates the Invasivity of Lung Cancer Cells and Is a Poor Prognostic Marker in Non-Small Cell Lung Cancer/A. Tadokoro, N. Kanaji, T. Ishii, T. Takagi, N. Watanabe, N. Kita, S. Bandoh, Kagawa, Japan, p.A2361


P272 Induction of L1 Retroelement in Human Bronchial Epithelial Cells by Tobacco Carcinogens/P. Bojang, K. Ramos, Tucson, AZ, p.A2364

P273 Inflammatory Microenvironment in Chronic Obstructive Pulmonary Disease Induces Epithelial-Mesenchymal Transition in Lung Cancer Cells Via TGF-β1/Smad3 Signaling Pathway/N. Wang, Q. Hong, C. Bai, Shanghai, China, p.A2365


P275 Neutral Sphingomyelinase 2 Promotes Cell Proliferation of Human Airway Epithelial Cells During Chronic Cigarette Smoke Exposure Via Sphingosine-1-Phosphate/S. Chung, S.L. Vu, S. Filosito, T. Goldkorn, Davis, CA, p.A2367

P276 Osteopontin as an Airway Epithelial Tumor Promoter/I. Psallidas, N.M. Rahman, G. Stathopoulos, Oxford, United Kingdom, p.A2368

P277 Molecular Discrimination of Intrapulmonary Metastasis and Multiple Primary Lung Cancer/C. Shen, X. Wang, L. Liu, G. Che, Chengdu, China, p.A2369


P279 Leptin Gene Polymorphism Increases Risk of Lung Cancer?/S. Peng, X. Tong, H. Fan, Chengdu, China, p.A2360

A73  LUNG FIBROSIS: NEW DIRECTIONS TO INFORM THE FUTURE

9:00 a.m. - 4:15 p.m.  MOSCONCE CENTER
Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators


P282 Targeting the HDAC6/HSP90 Axis to Destabilize the Notch1 Receptor in Non-Small Cell Lung Cancer/B. Deskin, B. Shan, J. Lasky, New Orleans, LA, p.A2374

P283 Erlotinib-Cycloexetrin Complex Loaded Biodegradable Nanoparticles for Enhanced Anti-Proliferative Efficacy Against Non-Small Cell Lung Cancer/V. Gupta, B. Vaidya, Claremont, CA, p.A2375


P287 Targeting the HDAC6/HSP90 Axis to Destabilize the Notch1 Receptor in Non-Small Cell Lung Cancer/B. Deskin, B. Shan, J. Lasky, New Orleans, LA, p.A2374


P405 Using Pulmonary Surfactant as Pirfenidone Vehicle to Target Fibrosis/L. Wollin, J. Schuett, A. Ostermann, F. Herrmann, Biberach, Germany, p.A2384

P406 Cigarette Smoke Enhances the Expression of Profibrotic Molecules in Alveolar Epithelial Cells/M. Checa, A. Pardo, V. Ruiz, J. Hagood, S. Garcia-Trejo, C. Becerril, C. Garcia-de-Alba, J. Cisneros-Lira, M. Montano, M. Selman, Mexico City, Mexico, p.A2386


P413 The Effect of Nintedanib on Platelet Derived Growth Factor-Stimulated Contraction of Human Primary Lung Fibroblasts/L. Wollin, J. Schuett, A. Ostermann, F. Herrmann, Biberach, Germany, p.A2384


The Anti-Fibrotic Effect of Endostatin-Derived Peptide Is Mediated by the Urokinase Pathway Via Binding to Enolase-1 and Urokinase Plasminogen Activator Receptor/ T. Nishimoto, T. Takhara, L. Mlakar, Y. Su, R. Chambers, C. Feghali-Bostwick, Charleston, SC, p.A2395


Epithelial Mesenchymal Transition: Is It Still Relevant to Pulmonary Fibrosis?/ E.S. Baker, D. Kass, Pittsburgh, PA, p.A2397


WISP1 Mediates IL6-Dependent Proliferation in Healthy and IPF-Derived Primary Human Lung Fibroblasts/ S. Klee, M. Lehmans, D.E. Wagner, H.A. Baarsma, M. Konigshoff, Munich, Germany, p.A2399


PM2.5 May Play an Important Role in the Pathogenesis of Pulmonary Fibrosis by Initiating Oxidative Stress, Inflammation and TGF-β Signaling/ Y. Hu, D. Weng, Shanghai, China, p.A2401


FGF2 Overexpression Decreases Bleomycin-Induced Pulmonary Fibrosis/ R. Guzy, L. Li, S. Cilvik, S. House, D. Ornitz, Chicago, IL, p.A2409


The GPCR Repertoire Changes in Lung Fibroblasts Treated with TGFβ and in Fibroblasts of Patients with Idiopathic Pulmonary Fibrosis/ A.V. Michkov, K. Sriram, N. Aronsaakol, P.A. Insol, La Jolla, CA, p.A2411


Glucose Uptake in TGFβ-Induced Fibroblast Differentiation/ L. Azuelos, B. Selvarajah, E. Forty, M. Plate, D. Anastasiou, P. Mercer, R. Chambers, London, United Kingdom, p.A2413


Differential Role of Phospholipase D in Regulating EMT and Fibroblast Differentiation in Bleomycin-Induced Pulmonary Fibrosis/ S. Suryadevara, L.S. Huang, E.V. Beryshev, A.M. Tager, T. Royston, V. Natarajan, Chicago, IL, p.A2415


New Promising Therapy for Idiopathic Pulmonary Fibrosis and Its Application Using Wound Healing Facilitator Stanniocalcin-1 (STC1)/ S. Ohkouchi, M. Ono, M. Ichinose, H. Kurosawa, Sendai, Japan, p.A2420


A74  MATRIX: DRIVERS AND TARGETS

9:00 a.m. - 4:15 p.m.  MOSCONEN CENTER

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators


P460  Type I Collagen Signaling Regulates Fibroblast Activation, Proliferation, and Apoptosis/S. Jia, J.C. Horowitz, T. Loo, M. Agarwal, K.K. Kim, Ann Arbor, MI, p.A2432

P461  Expression of Heparan Sulfate and Heparan Sulfate Proteoglycans in Idiopathic Pulmonary Fibrosis/X. Yue, M.A. Jesseu, New Orleans, LA, p.A2433


P463  Inhibition of Lysyl Oxidase Enzyme Activity In Vitro Inhibits TGF-β Induced Collagen Remodeling in 3D Collagen Models/ G. Tjin, E.S. White, E.P.W. Kable, J.K. Burgess, Sydney, Australia, p.A2435

P464  Tissue Turnover of Collagen Type I, III and Elastin Are Elevated in the Rat Precision-Cut Lung Slice Model of IPF and Can Be Restored Back to Vehicle Levels Using a PDE Inhibitor/N.U.B. Hansen, M.A. Karsdal, S. Brockbank, S. Cruwys, A. Young, P. Nath, D.J. Leeming, Herlev, Denmark, p.A2436


P468  Extracellular Matrix Changes After Repetitive Instillations of Whole Gastric Contents in the Rat Lung/P. Ayala, M. Meneses, J. Torres, J. Aracis, G.R. Borzone, Santiago, Chile, p.A2440

P469  Lysyl Oxidase Induces Fibrosis Via Uregulation of IL-6 and Serves as a Biomarker to Monitor Response to Therapy/T. Nishimoto, T. Takihara, L. Mlakar, J. Heywood, A. Bradshaw, C. Feghali-Bostwick, Charleston, SC, p.A2441


P471  Clinically Validated Serum Extracellular Matrix Turnover Markers of IPF in Combination with a Bleomycin In-Vivo and an Ex-Vivo Model May Be Used as an Intelligent Drug Screening Tool/D.J. Leeming, S. Brockbank, N.U.B. Hansen, M.A. Karsdal, P. Nath, D. Rider, V.P. Russel, E. Sadler, A. Young, S. Cruwys, Herlev, Denmark, p.A2443


THEMATIC POSTER SESSION

A75 STEM CELLS
9:00 a.m. - 4:15 p.m. MOSCONE CENTER
Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion:
11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: F.F. Cruz, MD, PhD, Rio de Janeiro, Brazil
A.E. Tzouvelekis, MD, PhD, New Haven, CT


THEMATIC POSTER SESSION

A76 LAM: NEW BIOLOGY AND NEW INSIGHTS
9:00 a.m. - 4:15 p.m. MOSCONE CENTER
Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion:
11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: A.S. Kristof, MD, Montreal, Canada

P481 Expression and Activity of Cathepsin K in Lymphangioleiomyomatosis (LAM)/A. Dongre, D. Clements, S.R. Johnson, Nottingham, United Kingdom, p.A2451


Facilitator: S. Y. El-Chemaly, MD, MPH, Boston, MA


P486 Integrin β5 Implication in the Tumorigenic Potential of TSC-Deficient LAM Cells/A. Tyryshkin, N.T. Eissa, Houston, TX, p.A2456

THEMATIC POSTER SESSION

A77 AIRWAY SMOOTH MUSCLE: TUNING, TINKERING, AND TREATING
9:00 a.m. - 4:15 p.m. MOSCONE CENTER
Area A, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion:
11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: C.A. Singer, PhD, Reno, NV


A78 AIRWAY SMOOTH MUSCLE: WHAT'S UNDER THE HOOD?
9:00 a.m. - 4:15 p.m.
MOSCONCE CENTER
Area N, Hall D (North Building, Lower Level)

Facilitator:

Facilitator:
T. Tran, PhD, Singapore, Singapore

Facilitator:
H. Parameswaran, PhD, Boston, MA

Facilitator:
C.Y. Seow, PhD, Vancouver, Canada

Facilitator:
Y.-S. Han, M. Dogan, P. Delmotte, G.C. Sieck, Rochester, MN, p.A2475

Organizers:

Organizers:

Organizers:
N. Sorensen, S. Ahmadi-Noorbakhsh, J.J. Pillow, P.B. Noble, Nedlands, Australia, p.A2483

Organizers:
H. Gerthoffer, Indianapolis, IN, p.A2464

Organizers:
H. Parameswaran, PhD, Boston, MA

Organizers:

Organizers:

Organizers:

Organizers:

Organizers:

Organizers:

Organizers:

Organizers:

Organizers:
A79  LUNG IMAGING: CT AND BEYOND

9:00 a.m. - 4:15 p.m.  MOSCONE CENTER

Area N, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:15: authors will be present for discussion with assigned facilitators

Facilitator: G.K. Prisk, DSc, PhD, La Jolla, CA


P1595 Tracheomalacia: Getting the Diagnosis Right/M. Nygaard, E. Bendstrup, O. Hilberg, F. Rasmussen, Aarhus, Denmark, p.A2492

Facilitator: T. Winkler, PhD, Boston, MA


P1602 Reassess the Value of 18F-FDG PET/CT for Relapsing Polychondritis Diagnose and Therapeutic Response Monitoring/J. Wang, S. Li, Y. Zeng, Guangzhou, China, p.A2499


Facilitator: M.J. Suter, PhD, Boston, MA


A80-A  ARE HSTS OBSCOLE? NOVEL DIAGNOSTICS IN SDB
9:00 a.m. - 4:15 p.m.  MOSCONE CENTER
Area K, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators
Facilitator: I.A. Ayappa, PhD, New York, NY

P1127  Obstructive Sleep Apnea - Correlations Between Clinical Exam, Epworth Sleepiness Scale and Sleep Study Tools (Poligraphy and Polysomnography)/G. Jimboerean, I. Dombi, P. Postolache, E.S. Ianosi, Targu Mures, Romania, p.A2507


P1129  The Role of Berlin Questionnaire in Predicting Obstructive Sleep Apnea Syndrome Confirmed by Hospital-Based Polysomnography or Home Embletta Sleep Tests/D.S.-C. Hui, S. Ng, K.-W. To, F. Ko, J. Ngai, K.K. Chan, W.-H. Yip, T.-O. Chan, W.W.-S. Tam, Shatin, Hong Kong Prc, p.A2509


Facilitator: A. Yadollahi, PhD, Toronto, Canada

P1132  DO I Snore 50: A Preoperative Sleep Questionnaire Derived from Hospital Complications/A.M. Namen, D. Forest, A. Chatterjee, Z. Ahmad, S. Kumar, K. Huang, A.W. Pickens, E.F. Haponik, Winston-Salem, NC, p.A2512


Facilitator: T. Penzel, PhD, Berlin, Germany

P1137  Comparison of Outcomes Using Two Different Scoring Criteria for Obstructive Sleep Apnea (OSA) - Unlocking Pandora's Box?/A. Fazleen, P. Sankaran, R. Phillips, P.F. Grunstein, Norwich, United Kingdom, p.A2517


P1140  Importance of Red Cell Distribution Width for Evaluation of Response to Positive Airway Pressure Therapy in Patients with Obstructive Sleep Apnea Syndrome/H. Lakadamyali, T. Rivanc, B.D. Yagbasan, Antalya, Turkey, p.A2520


Facilitator: D.P. White, MD, Denver, CO


P1143  A New Marker of Cardiovascular Disease in Patients with Sleep-Disordered Breathing: Results from the Wisconsin Sleep Cohort Study/A. Sankari, L.A. Finn, S. Maresh, M.S. Hamdon, G. Al-kubaisi, M. Sadr, P.E. Peppard, Detroit, MI, p.A2523

P1144  Investigating New Pre-Sleep Biomarkers to Predict the Risk of Sleep Apnea Due to Fluid Overloading/D. Vena, B. Gavrillovic, O. Lyons, D. Bradley, M.R. Popovic, A. Yadollahi, Toronto, Canada, p.A2524

P1145  Sex Specific Variations in Tracheal Sound Features Due to Fluid Retention in the Neck/M. Shokrollahi, F. Rudzicz, A. Yadollahi, Toronto, Canada, p.A2525


Facilitator: S.A. Sands, PhD, Boston, MA

P1147  Assessment of Acute Mountain Sickness: All Psychology or What? Do the Lake Louise Scale, a Visual Analogue Scale and Psychological Well-Being Scales Measure the Same?/A. Fabi, N. Netzer, M. Bartscher, M. Faulhaber, S. Wimmer, M. Koop, Innsbruck, Austria, p.A2527

P1149 Risks of False Negative Obstructive Sleep Apnea Diagnosis: The Single Tertiary Hospital Base Study/L. W. Hang, Taichung, Taiwan, p.A2529


P1151 The Effect of Body Mass Index on the Upper Airway of Severe Obstructive Sleep Apnea Patients/L. Oliveira, N.T. Fonseca, J.J. Urbano, S. Romano, G. Insalaco, Sao Paulo, Brazil, p.A2538


Facilitator: K. Kairaitis, MD, Sydney, Australia


P1156 Effect of PCI on the Stability of Respiratory Center Function in Patients with Heart Failure and Sleep Apnea/X. Zhao, F. Zhao, L. Zhang, G. Li, Y. Li, Tianjin, China, p.A2544

Facilitator: B. A. Edwards, PhD, Melbourne, Australia

P1157 Risks of False Positive Obstructive Sleep Apnea Diagnosis: The Single Tertiary Hospital Base Study/L. W. Hang, Taichung, Taiwan, p.A2529

P1158 Gender Differences in Prevalence of Obstructive Sleep Apnea (OSA) and Arousal Threshold in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)/R. Jen, R. L. Owens, A. Malhotra, A. L. Ries, X. Soler, La Jolla, CA, p.A2535

Facilitator: N. L. Deacon, PhD, La Jolla, CA

P1159 The Effect of Body Mass Index on the Upper Airway of Severe Obstructive Sleep Apnea Patients/L. Oliveira, N.T. Fonseca, J.J. Urbano, S. Romano, G. Insalaco, Sao Paulo, Brazil, p.A2538


Facilitator: K. Kairaitis, MD, Sydney, Australia


P1165 Effect of PCI on the Stability of Respiratory Center Function in Coronary Heart Disease Patients Complicated with OSAHS/X. Zhao, F. Zhao, L. Zhang, G. Li, Y. Li, Tianjin, China, p.A2544

P1166 Effects of Overnight Rostral Fluid Shift on the PCO2 in Patients with Heart Failure and Sleep Apnea/A. Yadollahi, T. Inami, T. D. Bradley, Toronto, Canada, p.A2545

Facilitator: B. A. Edwards, PhD, Melbourne, Australia


P1169 The Developmental Change of Central Sleep Apnea in Infants with Congenital Laryngomalacia/W. Ratanakorn, J. Zhou, N. Simakajornboon, Cincinnati, OH, p.A2548


P1179 Membrane Progesterone Receptors

P1178 Prevalence of Sleep-Disordered Breathing in a Multiethnic Obstructive Sleep Apnea Risk and Excessive Daytime Prevalence of Sleep Disordered Breathing in a Saudi Facilitator: D.M. Rapoport, MD, New York, NY

P1176 Prevalence of Sleep Disordered Breathing in a Saudi Population Facilitator: R. Mehra, MD, Cleveland, OH

P1175 Prevalence of Acromegaly Among Patients Referred for Sleep Apnea Syndrome: ACROSAS Study Facilitator: D.M. Rapoport, MD, New York, NY

P1174 The Effect of Different Altitude on Sleep Apnea of Han Nationality and Uyghur Nationality Facilitator: R. Savai, PhD, Bad Nauheim, Germany

P1173 Evaluation of Upper Airway Characteristics and Upper Airway Stimulation Response Facilitator: D.M. Rapoport, MD, New York, NY

P1172 Acoustic Pharyngometry Assessments with Unilateral Hypoglossal Stimulation for OSA Facilitator: D.M. Rapoport, MD, New York, NY

P290 Dynamic Monitoring of EGFR Mutation in Plasma Cell-Free ATS 2016 • San Francisco

P289 ADAM9 Enhances CDCP1 Protein Expression by Suppressing miR-218 for Lung Tumor Metastasis Facilitator: R. Savai, PhD, Bad Nauheim, Germany

P291 Self-Assembled Triangular DNA Nanoparticles-Conjugated Atg101 siRNA Induces the Apoptosis of Lung Cancer A549 Cells by Activating p53-p21 Pathways Facilitator: R. Savai, PhD, Bad Nauheim, Germany

P292 Histology-Specific Effects of Parathyroid Hormone-Related Protein on Integrin Traffic in Human Lung Cancer Facilitator: R. Savai, PhD, Bad Nauheim, Germany

P293 PAI-1 Plays an Important Role in Lung Cancer Progression Through Differentiation of Cancer-Associated Fibroblasts to Myofibroblasts Facilitator: R. Savai, PhD, Bad Nauheim, Germany

P294 Laricitrin, a Polyphenolic Compound of Red Grape, Inhibits Lung Cancer-Mediated Dendritic Cell Suppression by Decreasing Signal Transducer and Activator of Transcription 3 Pathway Facilitator: R. Savai, PhD, Bad Nauheim, Germany

P295 Modulation of FAK Activity by MARCKS Is Involved in Migration of Lung Cancer Cells Facilitator: R. Savai, PhD, Bad Nauheim, Germany

P296 FASN Promote Non-Small-Cell Lung Cancer Growth and Chemo Resistance by Upregulation PKM2 and Enhancing Warburg Effect Facilitator: R. Savai, PhD, Bad Nauheim, Germany

P297 The Role of Acyl-CoA Thioesterase Gene Family in Lung Adenocarcinoma Facilitator: R. Savai, PhD, Bad Nauheim, Germany

P298 Microsomal Prostaglandin E Synthase-1 (mPGES-1) Facilitates Mobilization of MDSC from Bone Marrow and Induces Lung Metastasis Formation Facilitator: R. Savai, PhD, Bad Nauheim, Germany

P299 Cosuppression of Stat3 and Src/p190RhoGAP Leads Synergistic Growth Inhibition in KRAS Mutant Lung Adenocarcinoma Facilitator: R. Savai, PhD, Bad Nauheim, Germany

P300 Lung Cancer Associated Fibroblast-Mediated Cancer Progression and Immune Inhibition Through TDO2/Kynurenine Loop Facilitator: R. Savai, PhD, Bad Nauheim, Germany

P301 Angiotensin Antagonist Drugs Inhibit the Growth and Lymphatic Metastasis of Lung Adenocarcinoma in Nude Mice Facilitator: R. Savai, PhD, Bad Nauheim, Germany

P302 Genome-Wide DNA Methylation Study Identified Lung Cancer Specific Differentially Methylated Regions Facilitator: R. Savai, PhD, Bad Nauheim, Germany

P303 Elevated Plasma Ciz1b Variant Expressions in Non-Small Cell Lung Cancer Are Reduced After Surgical Resection of Stage I Lung Cancer Facilitator: R. Savai, PhD, Bad Nauheim, Germany

THEMATIC POSTER SESSION

A80-C MOLECULAR AND IMMUNOBIOLOGY OF LUNG CANCER

9:00 a.m. - 4:15 p.m. MOSCONC CENTER

Area C, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion

11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: R. Savai, PhD, Bad Nauheim, Germany


P307 Implication of YY1 in Non-Small Cell Lung Cancer/O. Boucherat, S. Chabot, A. Bourgeois, S. Provencher, R. Paulin, F. Maltais, S. Bonnet, Quebec, Canada, p.A2577

P308 High Levels of Beclin-1 in Induced Sputum of Lung Cancer Patients as a Marker of Increased Autophagy/A. Bar-Shai, A. Ahimor, N. Ofir, Y. Schwarz, E.M. Fireman, Tel-Aviv, Israel, p.A2578


P310 IARS2 Silencing Induced Non-Small Cell Lung Cancer Cells Proliferation Inhibition, Cell Cycle Arrest and Promoted Cell Apoptosis/K. Wang, J. Yin, R. Li, Changchun, China, p.A2580

P311 Inhibiting Autophagy Promotes Cisplatin-Induced Apoptotic Cell Death in A549 Human Lung Cancer Cells/L. Jie, Changsha, China, p.A2581


Facilitator: S.J. Moghaddam, MD, Houston, TX


P315 Adenylate Cyclase-Associated Protein 1 Is Associated with Metastasis of Non-Small Cell Lung Cancer Especially in Brain Metastasis Patients and Promotes the Lung Cancer Cell Proliferation and Migration In Vitro As Well as Its Growth and Metastasis In Vivo/C. Wang, S. Xie, Shanghai, China, p.A2585

P316 PTX-3 Overexpression in BLAF Is Associated with High Value for the Diagnosis of Lung Cancer/Z. Sun, Q. Shadike, T. Wang, Xi’an, China, p.A2586

P317 Expression of Protein Kinase EML4-ALK Gene in Non-Small Cell Lung Cancer in Fundacion Valle del Lili, a University Hospital of Reference in Latin America/L. Fernandez, L.F. Sua, C.A. Munoz, J.G. Restrepo, Cali, Colombia, p.A2587


P323 MiR-1 Expression in the Vicinity of Non-Small Cell Cancer Correlates with Patient Survival/A. Ramaswamy, L. Jin, B. Hu, D. Boffa, M. Pisani, J.T. Puchalski, S. Takyar, New Haven, CT, p.A2593
WS1 GUIDELINES FOR THE EVALUATION OF THE WHEEZING INFANT

Registration Fee: $75.00 (includes box lunch)
Attendance is limited. Pre-registration is required.

Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Clinical Problems; Respiratory Structure and Function
11:45 a.m. - 1:15 p.m. MOSCONE CENTER
Room 301 (South Building, Esplanade Level)

Target Audience
Clinicians caring for infants and young children with respiratory disease.

Objectives
At the conclusion of this session, the participant will be able to:
• use bronchoscopy to identify causes of infantile wheezing;
• know the role of food allergy testing in the evaluation of infantile wheezing;
• diagnose GERD in wheezing infants.

Infantile wheezing is a common clinical problem encountered by pediatric respiratory specialists. In 2011, an ATS project to develop evidence based guidelines for diagnostic evaluation of infantile wheezing was initiated. The recommendations have been completed and will be submitted for peer review this summer. This workshop will review the key recommendations that the working group developed.

Chairing: C.L. Ren, MD, Indianapolis, IN

11:45 Introduction
C.L. Ren, MD, Indianapolis, IN

12:05 Role of Bronchoscopy in the Evaluation of the Wheezing Infant
C.R. Esther, MD, PhD, Chapel Hill, NC

12:25 Evaluation of Food Allergy in Infantile Wheezing
O. Yilmaz, MD, Manisa, Turkey

12:40 Role of Infant PFTs in the Evaluation of Infantile Wheezing
J.S. Debley, MD, MPH, Seattle, WA

12:55 GERD and Infantile Wheezing
M.M. Sockrider, MD, DrPH, Houston, TX

1:10 Wrap Up
C.L. Ren, MD, Indianapolis, IN
**WS2  OBSTRUCTIVE SLEEP APNEA IN THE ELDERLY: A DISCUSSION OF KEY CLINICAL QUESTIONS**

**Registration Fee:** $75.00 (includes box lunch)

Attendance is limited. Pre-registration is required.

**Assembly on Sleep and Respiratory Neurobiology**

11:45 a.m. - 1:15 p.m.  
MOSCONE CENTER  
Room 302 (South Building, Esplanade Level)

**Target Audience**
Pulmonologists, sleep physicians, fellows, nurses, fellows in training, clinical researchers, everybody involved in sleep units, pediatricians, geriatric physicians and nurses.

**Objectives**
At the conclusion of this session, the participant will be able to:

- understand the preconditioning hypoxia phenomenon and its relationship with intermittent hypoxia;
- distinguish between physiology and pathology related to the number and severity of sleep disorder-breathing in elderly;
- know the effect of CPAP treatment on cardiovascular, quality of life and neurocognitive domains in elderly with OSA compared with the effect in younger people and decide what to do in very old patients (more than 80 years) with clinical suspicion of obstructive sleep apnea, regarding treatment with CPAP.

This workshop has been designed to discuss some important clinical questions that all clinicians who follow elderly patients with obstructive sleep apnoea have. The course is also an opportunity to discuss with some of the most important researchers in the area of sleep apnoea in the elderly, what is the impact of OSA and treatment of CPAP in older patients compared with younger ones, to understand the pathophysiological pathways which govern this impact and decide, from a clinical point of view, the limits of OSA studies and treatment in very old patients.

**Chairing:**  
M. Martinez-Garcia, MD, Valencia, Spain  
N.C. Netzer, MD, PhD, Bad Aibling, Germany

11:45 Introduction  
M. Martinez-Garcia, MD, Valencia, Spain

11:50 Sleep-Disordered Breathing in the Elderly: Where Is the Limit Between the Physiology and Pathology?  
N.C. Netzer, MD, PhD, Bad Aibling, Germany

12:10 Preconditioning by Intermittent Hypoxia in the Elderly: Clinical Implications  
M. Morrell, MD, PhD, London, United Kingdom

12:30 From Cardiovascular to Neurocognitive Effects of CPAP in the Elderly  
M. Martinez-Garcia, MD, Valencia, Spain

12:50 Is CPAP Forever? How Should We Manage Patients Over 80 Years?  
S. Ancoli-Israel, PhD, La Jolla, CA

---

**CC1  PULMONARY CLINICAL CORE CURRICULUM I**

**Adult Core Curriculum Working Group**

11:45 a.m. - 1:15 p.m.  
MOSCONE CENTER  
Gateway Ballroom 102-104 (South Building, Lower Level)

**Target Audience**
Internists and subspecialists in pulmonary, critical care, and sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification.

**Objectives**
At the conclusion of this session, the participant will be able to:

- remain current with medical knowledge relevant to their practice in pulmonary, critical care, and sleep medicine;
- evaluate their understanding of key skills and content areas in pulmonary, critical care and sleep medicine, as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of pulmonary, critical care, and sleep medicine. The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice, as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

**Chairing:**  
G.C. Michaud, MD, New York, NY  
C.L. Channick, MD, Boston, MA

11:45 COPD: Pathophysiology/Diagnosis/PFT  
J.B. McCannon, MD, Boston, MA

12:05 COPD Management: Pharmacological and Non-Pharmacological  
G. Garrison, MD, Burlington, VT

12:45 Rare Lung Diseases: Rare Vascular Abnormalities and Rare Complications of Asthma  
P. Akuthota, MD, San Diego, CA

This session and the International Conference are supported by an educational grant from **AstraZeneca LP.**

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
### U.S. FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

#### L1 GENERIC DRUG DEVELOPMENT FOR RESPIRATORY PRODUCTS: U.S. FOOD AND DRUG ADMINISTRATION UPDATE

12:15 p.m. - 1:15 p.m.  
MOSCONE CENTER

**Room 3016/3018 (West Building, Level 3)**

**Target Audience**  
Clinicians in practice, researchers, pharmaceutical industry representatives, international drug regulators.

**Objectives**  
At the conclusion of this session, the participant will be able to:

- recognize key aspects of the generic drug regulatory approval process, and their impact on inhaled generic drug products;
- describe how the Office of Generic Drugs (OGD) evaluates bioequivalence for complex inhaled generic drug products, using a weight-of-evidence approach, and how pharmacodynamic (PD) studies are used to establish equivalent local delivery;
- articulate how device and formulation similarity, in vitro performance studies, and pharmacokinetic (PK) studies are utilized within the weight-of-evidence approach to establish bioequivalence for generic inhaled drug products.

This session will describe respiratory product development of generic drugs within the U.S., focusing on paths forward to bring safe and effective generic respiratory products to the American public. History of the generic drug approval process will be explored, distinguishing generic approval from new drug approvals, and identifying key regulations by which approvals are governed. Generic drug program requirements including bioequivalence, pharmaceutical equivalence, and product performance will be discussed, including the role of clinical endpoint studies, recommendations for combination drug products, and drug-device issues specific for metered dose inhaler (MDI) and dry powder inhaler (DPI) products.

**Chairing:** K.A. Witzmann, MD, Silver Spring, MD

12:15 Introduction  
K.A. Witzmann, MD, Silver Spring, MD

12:18 Overview of FDA Generic Inhaled Drug Approval Process  
L. Lapteva, MD, MHS, Silver Spring, MD

12:35 Discussion of the Generic Approval Process, Specific to Inhaled Drug Products  
K.A. Witzmann, MD, Silver Spring, MD

12:52 Bioequivalence for Complex Inhaled Generic Drug Products: Formulation Similarity, In Citro Studies and Pharmacokinetics (PK)  
B. Saluja, PhD, Silver Spring, MD

1:09 Questions and Answers  
K.A. Witzmann, MD, Silver Spring, MD

---

### NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, NIH

#### L2 INSIGHTS INTO ASTHMA SEVERITY FROM THE INNER-CITY ASTHMA CONSORTIUM

12:15 p.m. - 1:15 p.m.  
MOSCONE CENTER

**Room 3006/3008 (West Building, Level 3)**

**Target Audience**  
Clinicians, researchers, health care administrators, public health specialists, asthma educators.

**Objectives**  
At the conclusion of this session, the participant will be able to:

- understand how host and environmental factors work in concert to determine asthma severity;
- learn how IgE levels influence viral infection and illness;
- learn how lowering IgE levels restores anti-viral immunity focusing on the dendritic cell.

The Inner City Asthma Consortium (ICAC) has over 20 years experience studying asthma morbidity among inner city children and adolescents. This session will present data from two recently completed ICAC studies demonstrating the complex interaction of host and environmental factors on asthma severity and the impact of IgE level on viral respiratory infections and subsequent exacerbations.

**Chairing:** P.J. Gergen, MD, MPH, Rockville, MD

12:15 Risk Pathways Determining Asthma Severity  
A. Liu, MD, Denver, CO

12:35 How Does Omalizumab Affect Viral Respiratory Infections and Illnesses in Asthma?  
J.E. Gern, MD, Madison, WI

12:55 Understanding the Role of Dendritic Cells in Anti-Viral Immunity  
M. Gill, MD, Dallas, TX

---

### NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES

#### 50TH ANNIVERSARY SESSION

#### L3 INDOOR EXPOSURE TO BIOMASS/WOODSMOKE EXPOSURE AND PULMONARY HEALTH

12:15 p.m. - 1:15 p.m.  
MOSCONE CENTER

**Room 3010/3012 (West Building, Level 3)**

**Target Audience**  
Basic and clinical researchers, physicians, pulmonologists and community and public health specialists.

**Objectives**  
At the conclusion of this session, the participant will be able to:

- understand the levels and potential effects of indoor air pollution on pulmonary health;
• gain knowledge on biochemical and molecular pathways involved in exposure to particulates from biomass combustion;

• understand current efforts on developing potential interventions strategies.

Globally half of the population relies on solid fuels for their everyday energy requirements. The rural households in developing and underdeveloped countries mainly use biomass fuels (wood, dung, crop wastes) that are typically burned in inefficient, poorly ventilated homes (often open fires). Women and infants in these homes have very high exposures to smoke, typically levels that are considered harmful to health by the U.S. Environmental Protection Agency (EPA) and the World Health Organization (WHO). The presentations at this session will highlight our current efforts in addressing these issues from monitoring exposure to developing preventive and intervention measures.

Chairing: S.S. Nadadur, PhD, Durham, NC
J.R. Balmes, MD, San Francisco, CA

12:15 Introduction
S.S. Nadadur, PhD, Durham, NC

12:20 Use of the MicroPEM to Support Biomass Cookstove Exposure and Health Outcome Studies
J. Thornburg, PhD, Durham, NC

12:37 Household Air Pollution: A Major Preventable Cause of COPD
J.R. Balmes, MD, San Francisco, CA

12:54 Development of Interventions for PM Induced Airway and Systemic Diseases
D. Peden, MD, Chapel Hill, NC
L6  MOLECULAR ATLAS OF LUNG DEVELOPMENT

12:15 p.m. - 1:15 p.m.  MOSCONEN CENTER

Room 2001/2003 (West Building, Level 2)

Target Audience
Providers of lung health, medical fellows in training, and basic researchers on lung biology, developmental biology, pediatrics, and informatics.

Objectives
At the conclusion of this session, the participant will be able to:

• learn the newest datasets of LungMAP;
• understand and learn the innovative technologies for molecular profiling and imaging of the developing lung;
• learn how to access the LungMAP resources.

Molecular Atlas of Lung Development (LungMAP) is an NHLBI-sponsored program. The overall goal of this program is to build an open-access reference resource by creating a comprehensive molecular atlas of the late-stage developing lung with data and reagents available to the research community. The atlas will integrate gene and protein expression profiles, transcriptome, epigenome, and other molecular characterizations with high-resolution anatomical information to provide molecular profiles of functionally or anatomically defined cell types in the developing lung. Participants in this session will learn about the newest data generated by the LungMAP, data analysis tools, and how to access the website, database and other publicly available resources of LungMAP.

Chairing:  R.F. Clark, PhD, Research Triangle Park, NC
S. Lin, PhD, Bethesda, MD

12:15  BREATHE: A Web Accessible Database of Normal Human and Mouse Lung Development
R.F. Clark, PhD, Research Triangle Park, NC

12:27  Mass Spectrometry-Based Omics and High Throughput Imaging Characterization of Lung Development
C. Ansong, PhD, Richland, WA

12:39  Reconstructed Regulatory Networks Provide Novel Insights into Mechanisms of Postnatal Mouse Lung Development
N. Ambalavanan, MD, Birmingham, AL

12:51  LungMAP Postnatal Human Lung Tissue and Dissociated Cell Repository
G.S. Pryhuber, MD, Rochester, NY
fellows and established scientists in basic research on lung biology, tuberculosis pathogenesis, infectious disease, informaticians and systems biology researchers.

Objectives
At the conclusion of this session, the participant will be able to:

• understand the potential impact of the implementation of systems biology;
• learn new findings about the pathobiology of tuberculosis in the human lung;
• apply new learned knowledge to their own ongoing research.

Approximately one-third of the world’s population is latently infected with Mtb with a 10% risk of developing pulmonary tuberculosis. It is the second highest cause of death from infectious diseases after HIV/AIDS, and is the biggest killer of people infected with HIV. The primary route of infection with Mtb is through the lung and interactions with the host lung defenses determine the course of the disease. This session will present the overall results from the NHLBI sponsored TB Systems Biology Program that was conceived with the objective of applying systems biology approaches to better understand the pathobiology of TB. Results from the integration of computational modeling strategies, “omics” technologies, and advances in bioengineering will be presented and how the implementation of such methodologies can help overcome obstacles in understanding complex host-mycobacterial interactions and host immune response networks, and helped to understand the latency and reactivation cycle of TB in the human lung.

Chairing:
P.C. Karakousis, MD, Baltimore, MD
E. Caler, PhD, Bethesda, MD

12:15 Novel Approaches to Understanding and Combating Latent TB Infection
P.C. Karakousis, MD, Baltimore, MD

12:30 Systems Biology of Immune Evasion by M. Tuberculosis
W.H. Boom, MD, MD, Cleveland, OH

12:45 Tuberculosis: Learning from In Vivo and In Silico Models
J. Flynn, PhD, Pittsburgh, PA

1:00 Vitamin D Receptor Signaling in Tuberculosis: Multiple Systems
H. Salamon, PhD, Berkeley, CA

With the passage of the 2009 Family Smoking Prevention and Tobacco Control Act, the FDA acquired the authority to regulate the manufacture, marketing, and distribution of tobacco products in order to protect human health. Within the framework of this Act, the NIH and FDA formed an interagency partnership to foster tobacco regulatory research administered through the Tobacco Regulatory Science Program (TRSP). Projects supported through TRSP include behavioral, clinical, animal, and in vitro research. This session will focus on TRSP-supported research that touches on tobacco products — including cigarettes, cigars, waterpipe, and e-cigarettes — and their effects on pulmonary health.

Chairing:
P. Callahan-Lyon, MD, Silver Spring, MD
L. Postow, PhD, Bethesda, MD

12:15 The Relationship Between Use of Electronic Cigarettes and Smoking Cigarettes in California Youth
J.M. Samet, MD, MS, Los Angeles, CA

12:27 Improved Models to Inform Tobacco Product Regulation
S. Glantz, PhD, San Francisco, CA

12:39 Disordered Lung Biology Associated with Alternative Tobacco Use
R.G. Crystal, MD, New York, NY

12:51 PGP: A Possible Biomarker for COPD Exacerbations and/or Progression
J.M. Wells, MD, Birmingham, AL

1:03 Impact of Tobacco Exposure on the Lung’s Innate Defense System
R. Tarran, PhD, Chapel Hill, NC

MEET THE PROFESSOR SEMINARS
CME Credits Available: 1.0

Registration Fee: $70.00 (includes box lunch.)
Attendance is limited. Pre-registration is required.

12:15 p.m. - 1:15 p.m. INTERCONTINENTAL HOTEL

MP401 PROSTAGLANDIN REGULATION OF ASTHMA
R.S. Peebles, MD, Nashville, TN
Union Square (Third Floor)

MP402 THE ASTHMA-COPD OVERLAP SYNDROME (ACOS): INSIGHTS INTO A NEW DISEASE PHENOTYPE
A.A. Zeki, MD, MAS, Sacramento, CA
SoMa (Third Floor)

MP403 THE FUTURE OF IPF: WHAT WILL IT LOOK LIKE?
H.R. Collard, MD, San Francisco, CA
L. Richeldi, MD, PhD, Southampton, United Kingdom
Mission (Third Floor)

MP404 ALPHA-1 ANTITRYPSIN DEFICIENCY
C.B. Strange, MD, Charleston, SC
Marina (Third Floor)

MP405 LUNG AND PLEURAL INFECTIONS: CONTROVERSIES AND ADVANCES
G.W. Waterer, MBBS, PhD, MBA, Perth, Australia
Y.C.G. Lee, MBChB, PhD, Perth, Australia
Grand Ballroom C (Third Floor)
ME1 HOW TO IMPROVE YOUR BEDSIDE TEACHING

Registration Fee: $70.00 (includes lunch)

Attendance is limited. Pre-registration is required.

12:15 p.m. - 1:15 p.m. INTERCONTINENTAL HOTEL

Target Audience
This session is aimed at faculty members and trainees who perform clinical teaching at the patient’s bedside.

Objectives
At the conclusion of this session, the participant will be able to:

• describe the advantages and disadvantages of bedside teaching in various formats;
• identify and address barriers to successful bedside teaching;
• implement specific strategies and techniques to round effectively at the bedside.

Bedside rounding has decreased from 75% of medicine attending rounds in the 1960’s to less than 15% currently. The data show patients, learners, and attendings prefer it to conference room attending but concerns for lost efficiency and patient discomfort create barriers to doing so. The MiPLAN approach to effective bedside teaching is based on adult learning theory and structured interviews with master clinicians. Participants will review the primary literature on bedside rounding from the patient, learner, and attending perspectives. Videos will help attendees deconstruct the MiPLAN approach and adopt it to their own attending practice going forward.

Speakers:
J.M. Beck, MD, Denver, CO
M. Anderson, MD, Denver, CO

TSS1 CONTEMPORARY CONTROVERSIES IN THE DIAGNOSIS AND MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS: A PRO/CON DEBATE

Registration Fee: $140.00 for full series (includes lunch)

Attendance is limited. Pre-registration is required.

This is a 3-part series. Those registering for this seminar series will be registered for all 3 parts. The topics and schedule for each part are listed below.

Assembly on Clinical Problems
Sunday 12:15 p.m. - 1:15 p.m. INTERCONTINENTAL HOTEL

PRO: Transbronchial Cryobiopsies Should Replace Surgical Lung Biopsy in the Diagnosis of IPF
V. Poletti, MD, Forli, Italy

CON: Transbronchial Cryobiopsies Should Replace Surgical Lung Biopsy in the Diagnosis of IPF
F.J. Martinez, MD, New York, NY
**Monday 12:15 p.m. - 1:15 p.m.**

**PRO:** Bronchoalveolar Lavage Should Routinely be Performed in the Diagnostic Work-Up of IPF
A.U. Wells, MD, London, United Kingdom

**CON:** Bronchoalveolar Lavage Should Routinely be Performed in the Diagnostic Work-Up of IPF
H.R. Collard, MD, San Francisco, CA

**Tuesday 12:15 p.m. - 1:15 p.m.**

**PRO:** Decline of 10% or Greater in FVC Should be Regarded as Treatment Failure in IPF
V. Cottin, MD, PhD, Lyon, France

**CON:** Decline of 10% or Greater in FVC Should be Regarded as Treatment Failure in IPF
P.W. Noble, MD, Los Angeles, CA

---

**THEMATIC SEMINAR SERIES**

**CME Credits Available: 1.0**

**TSS2 REDUCING HOSPITAL READMISSIONS**

**Registration Fee:** $140.00 for full series (includes box lunch)
Attendance is limited. Pre-registration is required.
This is a 3-part series. Those registering for this seminar series will be registered for all 3 parts. The topics and schedule for each part are listed below.

**Assembly on Clinical Problems**
Sunday 12:15 p.m. - 1:15 p.m. INTERCONTINENTAL HOTEL
InterContinental Ballroom B (Fifth Floor)

*Patients at High Risk of Hospital Readmissions*
Impact of Hospital Readmissions
B.J. Make, MD, Denver, CO

Targeting Populations at High Risk for Readmission
D.H. Au, MD, MS, Seattle, WA

*Why Are Patients with Pneumonia Readmitted?*
S. Sethi, MD, Buffalo, NY

*Why Are Patients with COPD Readmitted?*
D.M. Mannino, MD, Lexington, Kentucky

**Monday 12:15 p.m. - 1:15 p.m.**

*Approaches to Reduce Hospital Readmissions*

**Effective Components of a Readmission Reduction Program**
S.S. Braman, MD, New York, NY

**Novel Interventions to Reduce Readmissions**
V.G. Press, MD, MPH, Chicago, IL

**Partnering with Patient Navigators and Peer Advocates**
J.A. Krishnan, MD, PhD, Chicago, IL

**Tuesday 12:15 p.m. - 1:15 p.m.**

**PRO:** Medications Are the Key to Reducing Readmissions in COPD
G.T. Ferguson, MD, Livonia, MI

**CON:** Medications Are the Key to Reducing Readmissions in COPD
R.A. Wise, MD, Baltimore, MD

---

**CLINICAL • TRANSLATIONAL**

**YEAR IN REVIEW**

**CME Credits Available: 2.0**

**Nursing Contact Hours Available: 2.4**

**A81 PEDIATRIC YEAR IN REVIEW**

Assemblies on Pediatrics; Clinical Problems; Microbiology, Tuberculosis and Pulmonary Infections; Nursing; Sleep and Respiratory Neurobiology
2:15 p.m. - 4:15 p.m. MOSCONCE CENTER
Room 3006/3008 (West Building, Level 3)

**Target Audience**
Pediatric pulmonologists, pediatric intensivists, neonatologists, registered nurses, advanced practice nurses, respiratory therapists, clinical and translational researchers and other providers of health care to children with lung diseases.

**Objectives**
At the conclusion of this session, the participant will be able to:
- discuss new findings from current literature related to pediatric cardiopulmonary conditions;
- apply recent advances and evidence-based care practices to pediatric cardiopulmonary care;
- describe strategies to manage the care of patients with pediatric cardiopulmonary conditions.

Important advances in the diagnosis and treatment of respiratory disorders in children occur every year. The range of new discoveries makes it difficult for the
clinician and researcher to stay current. However, health care providers who deal with children must be informed of the most recent advances and evidence-based care practices. Pediatric Year in Review will present a scholarly discussion of several of the most important and influential papers in key clinical topic areas published within the past two years. Experts in their respective fields will discuss the selected papers and allow time for discussion.

Chairing: M. Rosenfeld, MD, MPH, Seattle, WA
A.C. Koumbourlis, MD, MPH, Washington, DC

2:15 Sleep Medicine
E.S. Katz, MD, Boston, MA

2:45 Bronchiectasis in Children
A. Chang, MBBS, PhD, Brisbane, Australia

3:15 Pediatric Pulmonary Genetics and Genomics
L.M. Nogee, MD, Baltimore, MD

3:45 Sickle Cell Disease
A. Greenough, MBBS, MD, London, United Kingdom

There will be a 5-minute discussion after each talk.

---

**CLINICAL**

**SCIENTIFIC SYMPOSIUM**

CME Credits Available: 2.0

**A82 TREATMENT OF EARLY STAGE AND SCREEN-DETECTED LUNG CANCER: A PRO/CON DEBATE**

Assemblies on Thoracic Oncology; Behavioral Science and Health Services Research; Clinical Problems

2:15 p.m. - 4:15 p.m. MOSCONE CENTER

Room 303/305 (South Building, Esplanade Level)

**Target Audience**

Clinicians who care for patients with lung cancer; researchers and policy makers interested in thoracic oncology; patients and family members of patients with lung cancer.

**Objectives**

At the conclusion of this session, the participant will be able to:

- determine when to refer patients for limited resection versus lobectomy for stage I NSCLCa;
- learn new findings about the role of SBRT for treatment of early stage NSCLCa;
- improve discussions around appropriateness of therapy for non-solid lung cancers.

Early stage lung cancer accounts for ~15% of cases. However, a considerable increase in the number of cases is expected based on the new USPSTF guidelines for CT screening. The optimal treatment of patients with stage I non-small cell lung cancer, and screen-detected malignancies in particular, is unclear. Using a pro-con debate approach, this session will address key questions such as: what are the indications for limited resection for lung cancer \( \leq 2 \) cm in size, cancer \( \leq 2 \) cm in size., what is the role of SBRT for clinically and screen detected cancers, and what is the best management of subsolid cancers identified via screening.

---

**CLINICAL**

**CLINICAL TOPICS IN PULMONARY MEDICINE**

CME Credits Available: 2.0

**A83 GREAT CASES: CLINICAL, RADIOLOGIC, AND PATHOLOGIC CORRELATIONS BY MASTER PHYSICIANS**

Council of Chapter Representatives

2:15 p.m. - 4:15 p.m. MOSCONE CENTER

Room 134 (North Building, Lower Level)

**Target Audience**

Clinicians in the fields of pulmonary and critical care medicine, pediatric pulmonology, sleep medicine, thoracic surgery, and infectious disease.

**Objectives**

At the conclusion of this session, the participant will be able to:

- integrate the clinical presentation, radiologic and pathologic findings for 7 challenging cases;
- understand the clinical reasoning used to determine differential diagnosis by master clinicians using a multidisciplinary approach;
- describe the associated pathology and radiology of the cases.

Learners will have the opportunity to observe master clinicians approach challenging clinical problems by working through 7 unknown cases selected from the abstract pool. Collaboration with a master radiologist reviewing the films and a master pathologist reviewing pathology slides will demonstrate the multidisciplinary approach to difficult cases. The audience will participate though
interactive questions that are tallied electronically. Additional discussion by presenters and master panelists will enhance the educational experience.

Chairing:
S. Kirtland, MD, Seattle, WA
R. Gross, MD, Washington, DC

2:15 Case Presentations
Mysterious Antibodies
B. Tashtoush, MD, Weston, FL
The Heart of the Matter
R. Beg, MD, Miami, FL
Simply Breathtaking
H. Wu, MD, Washington, DC
It's Not Easy Being Green
S. Pandey, MD, Pittsburgh, PA
Noisy Baby
C. Leon Astudillo, MD, Boston, MA
Pop Goes the Lung
J. Lee, MD, Newark, NJ
Full of Fluid
A. Ataya, MD, Gainesville, FL

3:15 Experts
Master Clinicians
S.I.S. Rounds, MD, Providence, RI
M.I. Schwarz, MD, Aurora, CO
P.C. Stillwell, MD, Aurora, CO
Master Radiologist
J.D. Newell, MD, Iowa City, IA
Master Pathologist
H. Tazelaar, MD, Scottsdale, AZ

A84 THE NEW ENGLAND JOURNAL OF MEDICINE AND JAMA. DISCUSSION ON THE EDGE: REPORTS OF RECENT CRITICAL CARE RESEARCH

2:15 p.m. - 4:15 p.m. MOSCON CENTER

This session will provide a forum for attendees to interact with the authors and editors about papers published in the New England Journal of Medicine and JAMA. Papers presented will be recent publications, selected by the editors, to be of significant importance to the field of critical care medicine. Attendees will have the opportunity to hear presentations directly from the author and address questions to both the authors and editors. The discussion is intended to provide a unique insight into these papers, the selection process, and how the research applies directly to the field of critical care medicine.

Chairing:
D.C. Angus, MD, MPH, Associate Editor, JAMA
J.M. Drazen, MD, Editor-in-Chief, New England Journal of Medicine

A85 MOVING TOWARD PRECISION MEDICINE FOR LUNG DISEASE

Assemblies on Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

2:15 p.m. - 4:15 p.m. MOSCON CENTER

This session will address how composite knowledge and capacity in biology and medicine is now seated for the delivery of “precision medicine”, and provides some current examples in pulmonary medicine of emerging and ongoing effort in this area. Talks that cover broad lung disease areas are presented, emphasizing how networks, bioinformatics, high throughput and stem cell technologies are being harnessed. The session also features discussion about emerging policies for the delivery of precision medicine care.

Chairing:
M. McDonald, PhD, Boston, MA
D.J. Weiss, MD, PhD, Burlington, VT

2:15 Cystic Fibrosis Genetics: From Molecular Understanding to Clinical Application
G.R. Cutting, MD, Baltimore, MD

2:39 Induced Pluripotent Stem Cells: The Ultimate in Personalized Stem Cells for Lung Diseases
A. Firth, PhD, Los Angeles, CA

3:03 Translating the Airway Transcriptome into Biomarkers for Lung Cancer and COPD
A. Spira, MD, Boston, MA

3:27 Pharmacogenetic Discoveries and the Future of Personalized Medicine in Asthma
E. Bleecker, MD, Winston-Salem, NC

3:51 The Path to Personalized Medicine in COPD
D.D. Sin, MD, Vancouver, Canada

There will be a 5-minute discussion after each talk.
A86 BRINGING ORDER TO THE CHAOS OF ACOS (ASTHMA-COPD OVERLAP SYNDROME)

Assemblies on Allergy, Immunology and Inflammation; Clinical Problems; Nursing; Respiratory Cell and Molecular Biology; Respiratory Structure and Function
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 2005/2007 (West Building, Level 2)

Target Audience
Physicians, basic scientists, physiologists, physician-scientists, clinical fellows and residents, graduate and postdoctoral research trainees, and nurses interested in asthma, COPD, and ACOS. This topic also has broader appeal for epidemiologists, nurses, and respiratory therapists, given the significant clinical and public health impact of this new syndrome/disease phenotype.

Objectives
At the conclusion of this session, the participant will be able to:

• understand the molecular, pathophysiological, and clinical features of ACOS and use these criteria to distinguish ACOS from asthma or COPD;
• offer timely and appropriate diagnosis and treatment by recognizing ACOS patients, their higher disease severity, and risk profile, while closely monitoring patient outcomes;
• discuss and appreciate the significant heterogeneity and overlap between asthma and COPD where ACOS serves as an emerging and important clinical phenotype linking both diseases.

Some patients manifest an intermediate or overlapping phenotype of asthma and COPD, i.e. the “asthma-COPD overlap syndrome” (ACOS). Yet, ACOS has largely been ignored in clinical trials. ACOS comprises 15 to 55% of patients with obstructive lung diseases, and manifests more symptoms, greater lung function decline, increased risk of severe exacerbations, and possibly a reduced life span. Such observations have spawned a recent and broad international interest in ACOS. This session presents a comprehensive overview of ACOS in relation to the controversial British and Dutch Hypotheses, and offers novel insights regarding the genetic origins, pathogenesis, diagnosis, and treatment of ACOS.

Chairing: A.A. Zeki, MD, MAS, Sacramento, CA
K. Chung, MD, PhD, London, United Kingdom
M.J. Holtzman, MD, St. Louis, MO

2:15 How to Clinically Distinguish ACOS from Asthma and COPD
P.G. Gibbson, MBBS, Newcastle, Australia

2:35 Shared Immunity in Asthma and COPD
M.J. Holtzman, MD, St. Louis, MO

2:55 Genetic Origins of ACOS
M.E. Hardin, MD, Boston, MA

3:15 Genomic and Molecular Phenotyping to Distinguish ACOS from Asthma and COPD
P.G. Woodruff, MD, MPH, San Francisco, CA

3:35 Smoking in Asthma: An ACOS Phenotype?
K. Chung, MD, PhD, London, United Kingdom

3:55 Treatment of ACOS: Lessons From Clinical Studies in Asthma and COPD
S.I. Rennard, MD, Melbourne, United Kingdom

This session and the International Conference are supported by an educational grant from AstraZeneca LP.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

A87 E-CIGARETTE VAPING: PRECLINICAL AND CLINICAL PULMONARY HEALTH EFFECTS

Assemblies on Environmental, Occupational and Population Health; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Respiratory Cell and Molecular Biology; Respiratory Structure and Function
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 130-132 (North Building, Lower Level)

Target Audience
Basic and translational/clinician scientists working on lung diseases. Lung health researchers, nurses, pharmacists, users of e-cigarettes, smoking cessation professionals, manufacturers and retailers of e-cigarettes and e-liquids/e-juices, students, fellows, residents with clinical, research, tobacco control lobbyists, or people with health care and administrative responsibilities.

Objectives
At the conclusion of this session, the participant will be able to:

• learn about e-cigarettes vaping and flavorings pulmonary health consequences;
• learn and understand the current clinical trials based on harm reduction, perceptions, addictions, and environmental effects of vaping in susceptible populations and patients with respiratory diseases;
• learn scientific debates and regulatory aspects on public and environmental health and understanding the pulmonary and extrapulmonary effects of vaping will provide insights on behavior, addiction, cessation and/or aggravating pulmonary diseases and their exacerbations.

Electronic cigarettes (e-cigs) use flavored/non-flavored e-liquids/e-juices, which contain propylene glycol/glycerol (humectants), nicotine, and flavors (e.g. candy flavors including sweeteners). These device generate aerosol containing reactive oxygen species, aldehydes, ultrafine/nanoparticles, and heavy metal particles. E-cig products are launched without the FDA approval, and an increasing number of products are being launched every day without knowing the harmful consequences. This symposium is aimed towards understanding the pulmonary studies on e-cig exposure including biomarkers, inhalation and basic preclinical/translational science, and host-innate response, as well as clinical epidemiological studies for prediction of pulmonary health effects of e-cigarette vaping and flavoring agents.

Chairing: I. Rahman, PhD, Rochester, NY
I. Jaspers, PhD, Chapel Hill, NC
S. Biswal, PhD, Baltimore, MD
B. Tomoko, MD, Tokyo, Japan
A88 COMMUNITY ACQUIRED PNEUMONIA IN THE ELDERLY PATIENT

Assemblies on Microbiology, Tuberculosis and Pulmonary Infections; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Clinical Problems; Critical Care; Nursing; Respiratory Cell and Molecular Biology

Target Audience
Health care providers, at all levels of training, who are caring for patients with pneumonia; clinical researchers, translational and bench investigators.

Objectives
At the conclusion of this session, the participant will be able to:
- learn new findings regarding alterations associated with aging that affect host response to lung infections and effectiveness of vaccines;
- identify risk factors for and implement strategies to prevent pneumonia in elderly patients;
- implement appropriate management of pneumonia.

Pneumonia is a leading cause of mortality globally. As the population is aging, the incidence of pneumonia is increasing, related to alterations in host defense as a consequence of aging and cellular senescence, and also the concomitant greater burden of comorbidities and polypharmacy in older patients. This translational session will discuss bench investigations elucidating mechanisms impacting host defense to lung infection and host immune responses to vaccines in older adults. Clinically oriented presentations will consider the syndrome of aspiration pneumonia and the impact of comorbidities and medications on risk for community acquired pneumonia. Talks will also address management and prevention of pneumonia in elderly patients.

Chairing: K.A. Crothers, MD, Seattle, WA
C.M. Luna, MD, PhD, Buenos Aires, Argentina
E.R. Neptune, MD, Baltimore, MD

A89 FROM BEAUTY TO BREAKING BAD: UNCOVERING THE WORLD OF DRUG INDUCED PULMONARY HYPERTENSION

Assembly on Pulmonary Circulation

Target Audience
Pulmonary and critical care physicians, nurse practitioners, social workers, researchers in pulmonary vascular biology, addiction specialists and trainees who care for patients with pulmonary hypertension.

Objectives
At the conclusion of this session, the participant will be able to:
- diagnose drug related pulmonary vascular toxicity;
- learn new findings about the mechanism and pathobiology of drug induced pulmonary hypertension;
- relate recent clinical and basic findings to future scientific environment and patient exposures.

Timed to the 50th anniversary of the European Aminorex epidemic, the goal of this symposium is to highlight the impact of therapeutics and illicit drugs in causing pulmonary vascular disease and bring awareness to a disease sub-phenotype which is often less focused on. This session will start with a broad historical perspective on known and recently discovered drug induced PH entities, move quickly to pathobiology and mechanisms underlying the clinical disorder, and identify novel phenotypes associated with prescribed and illicit drugs. The session will then advance onto the discussion of aberrancies in drug metabolism and the unique role of the pulmonary vasculature in this process. The session will conclude with a perspective from regulatory agencies (US-FDA) on post-approval drug safety monitoring and the concept of pharmacovigilance.
A90 ABNORMAL METABOLISM: EMERGING CONCEPTS IN UNDERSTANDING LUNG DISEASE

Target Audience
Basic and clinician scientists, clinicians, public health officials, student and postdoctoral trainees with an interest in the biology of metabolism and its role in respiratory disease.

Objectives
At the conclusion of this session, the participant will be able to:
• improve the health of patients by identifying new biomarkers for disease using metabolomics approaches;
• identify metabolic modifiers in lung disease;
• understand how metabolic processes can contribute to lung disease.

This session will provide information about the impact of metabolic processes in the development and progression of lung diseases. Topics will include many pulmonary diseases, including fibrosis, hypertension, cancer, and COPD, but will also include the underlying theme of the role of altered metabolism. The goal of this session is to fill a knowledge gap in our understanding of the role that metabolic pathways and metabolites play in lung disease.
Finally, a clinical case study of obstructive sleep apnea will be used to review and highlight key points discussed in the other lectures.

**Chairing:** J.C. Celedon, MD, DrPH, Pittsburgh, PA
M.S. Badr, MD, Detroit, MI
E.R. Neptune, MD, Baltimore, MD

**2:15** Introduction and Overview
J.C. Celedon, MD, DrPH, Pittsburgh, PA

**2:20** A Patient’s Perspective
T. Massey Davis, Decatur, GA

**2:25** Improving Illness Self-Management in Minority Patients
K. Riekert, PhD, Baltimore, MD

**2:46** Personalized Medicine: What About Minorities and the Poor?
E.G. Burchard, MD, MPH, San Francisco, CA

**3:07** Migrant Health
M.B. Schenker, MD, MPH, Davis, CA

**3:28** Systems Approaches to Addressing Disparities in Critical Care
C.R. Cooke, MD, MSc, Ann Arbor, MI

**3:49** Obstructive Sleep Apnea: A Clinical Case Study in Health Disparities
S.S. Redline, MD, MPH, Boston, MA

### MINI SYMPOSIUM

#### A93 EXPLORING THE HUMAN RESPIRATORY ADAPTIVE IMMUNE RESPONSE

**2:15 p.m. - 4:15 p.m. MOSCON CENTER**

**Chairing:** A.P. Fontenot, MD, Aurora, CO
B.D. Medoff, MD, Boston, MA

**Oral Presentations**

**2:15** Lung-Specific Clonality and Plasticity of T Cell Receptor-Restricted CD4+ T Cells in Sarcoidosis - Implications for Pulmonary Antigen Recognition

**2:30** Regulatory T Cells in Pulmonary Sarcoidosis
K.C. Patterson, T. Akimova, W. Hancock, Philadelphia, PA, p.A2595

**2:45** Anti-Inflammatory Effects of Bromodomain and Extra-Terminal Domain Inhibition in Cystic Fibrosis Lung Inflammation

**3:00** CCR4-Expressing CD4+ T Cells Are Increased in Lungs of Patients with Idiopathic Pulmonary Fibrosis and Correlate with Lung Function
A. Adegunsoye, C.L. Hrusch, C. Bonham, M. Jaffery, K. Blaine, I. Noth, M.E. Strek, A.I. Sperling, Chicago, IL, p.A2597

**3:15** Th17 Cells Are Associated with Protection Against Ventilator Associated Pneumonia
M. Orlov, M.M. Wurfel, C. Mikacenic, Seattle, WA, p.A2598

**3:30** T Regulatory Cell Levels in Asthmatic Children Correlate With Yearly Ambient Air Pollution Levels Using Single-Cell Mass Spectrometry

**3:45** Innate Type 2 Receptor Expression on Airway Allergen-Specific CD4+ T Cells Distinguishes Allergic Asthmatics from Allergic Non-Asthmatics

**4:00** Exosomes and T Helper Cell Polarization in Asthma
K. Blaine, S. Kullberg, M.E. Strek, A.I. Sperling, Chicago, IL, p.A2597

#### A94 NEW INSIGHTS IN IPF

**2:15 p.m. - 4:15 p.m. MOSCON CENTER**

**Chairing:** R.J. Kaner, MD, New York, NY
K.A. Johansson, MD, Calgary, Canada

**Oral Presentations**

**2:15** Case-Validated Epidemiology of Idiopathic Pulmonary Fibrosis in the Kaiser Permanente Northern California Member Population

**2:30** Quantitative Computed Tomography Analysis Predicts Outcomes in Idiopathic Pulmonary Fibrosis

**2:45** Pirfenidone and Nintedanib for Pulmonary Fibrosis in Real-World Clinical Practice: Tolerability and Adverse Drug Reactions

**3:00** Contribution of Mutations in Genes Encoding Proteins of the Surfactant Metabolism to Idiopathic Interstitial Pneumonia and Idiopathic Pulmonary Fibrosis in a Cohort of 265 Families

**3:15** Anxiety and Depression in Idiopathic Pulmonary Fibrosis
S. Moodley, T.J. Corte, A.E. Holland, Melbourne, Australia, p.A2606
3:00 Inspiratory Muscle Training to Enhance Recovery from Critical Illness

2:30 Sarcoptenia on Admission to the ICU Is Associated with Critical Illness Neuroumopathy

2:45 Ultrasonographic Assessment of Skeletal Muscle in Severe Sepsis: Rectus Femoris Cross-Sectional Area May Be Superior to Quadriceps Thickness

3:00 Inspiratory Muscle Training to Enhance Recovery from Prolonged Mechanical Ventilation: A Randomized Trial

3:15 Frailty Is Associated with New Or Worsening Disability After Critical Illness

3:30 Muscle Atrophy and Clinical Outcomes in Patients with ARDS

3:45 Early Mobilization Attenuates the Risk of ICU-Acquired Weakness in Patients Receiving Vasoactive Medications

4:00 Pre-Hospital Alcohol Use is Associated with Long-Term Physical Functional Impairment in Acute Respiratory Distress Syndrome Survivors

A95 CRITICAL CARE: RECOVERY OF PHYSICAL FUNCTION AFTER CRITICAL ILLNESS

2:15 The Association Between Biomarkers of Inflammation and Long-Term Cognitive Impairment and Disability in Survivors of Critical Illness

2:30 Sarcoptenia on Admission to the ICU Is Associated with Critical Illness Neuroumopathy

2:45 Ultrasonographic Assessment of Skeletal Muscle in Severe Sepsis: Rectus Femoris Cross-Sectional Area May Be Superior to Quadriceps Thickness

3:00 Inspiratory Muscle Training to Enhance Recovery from Prolonged Mechanical Ventilation: A Randomized Trial

3:15 Frailty Is Associated with New Or Worsening Disability After Critical Illness

3:30 Muscle Atrophy and Clinical Outcomes in Patients with ARDS

3:45 Early Mobilization Attenuates the Risk of ICU-Acquired Weakness in Patients Receiving Vasoactive Medications

4:00 Pre-Hospital Alcohol Use is Associated with Long-Term Physical Functional Impairment in Acute Respiratory Distress Syndrome Survivors
MINI SYMPOSIUM

A97 ROLE OF AGING ON THE DEVELOPMENT OF LUNG DISEASE(S)

2:15 p.m. - 4:15 p.m. MOSCON CENTER

Room 2020/2022 (West Building, Level 2)

Chairing: V.J. Thannickal, MD, Birmingham, AL
A.L. Mora, MD, Pittsburgh, PA
C.J. Le Saux, PhD, San Antonio, TX

Featured Speaker

2:15 Macrophage Heterogeneity in the Aging Lung/G.R.S. Budinger, MD, Chicago, IL,

Oral Presentations

2:30 Transcriptional Profiling Reveals an Aging Signature that Persists During Influenza Infection/P.A. Reyfman, S. Berdnikovs, A.C. Mc Quattie-Pimentel, F.J. Gonzalez-Gonzalez, J.I. Sznejder, G.S. Budinger, A.V. Misharin, Chicago, IL, p.A2626


3:00 Role of p16(Ink4a) in Cigarette Smoke-Induced Lung Senescence/I. Sundar, C.A. Lerner, H. Yao, I. Rahman, Rochester, NY, p.A2628


3:45 Histone Modification H4K16 Acetylation Regulates Pro-Fibrotic Gene Expression in IPF Lung Fibroblasts and in an Aging Model of Persistent Lung Fibrosis/Y. Sanders, H. Liu, V.J. Thannickal, Birmingham, AL, p.A2631

4:00 Aging and ER Stress Regulates Mitochondrial Homeostasis in Lung Epithelial Cells: ATF3 Regulates PINK1 Transcription/M. Bueno, J. Brans, R. Mallampalli, A.L. Mora, Pittsburgh, PA, p.A2632

Featured Speaker

4:00 Disentangling the Traits: Role of Phenotyping in Developing New Treatment for Sleep Apnea/D.A. Wellman, MD, PhD, Boston, MA

A98 DOES THIS MEAN I HAVE TO WEAR THAT MASK? NON PAP THERAPIES FOR SDB

2:15 p.m. - 4:15 p.m. MOSCON CENTER

Room 2006/2008 (West Building, Level 2)

Chairing: R.J. Schwab, MD, Philadelphia, PA
D.J. Eckert, PhD, Sydney, Australia
F.R. Almeida, DDS, MSc, PhD, Vancouver, Canada

Oral Presentations


3:00 Predicting Pharyngeal Collapsibility (Pcrit) Using Polysomnographic and Anthropometric Indices/P. Genta, F. Schorr, B.A. Edwards, A. Wellman, G. Lorenzi-Filho, Sao Paulo, Brazil, p.A2636


Featured Speaker

4:00 Disentangling the Traits: Role of Phenotyping in Developing New Treatment for Sleep Apnea/D.A. Wellman, MD, PhD, Boston, MA

POSTER DISCUSSION SESSION

A101 HOST DEFENSE, LUNG INJURY, AND FIBROSIS: INNATE MECHANISMS

2:15 p.m. - 4:15 p.m. MOSCON CENTER

Room 133 (North Building, Lower Level)

Poster Viewing 2:15-3:00
Discussion 3:00-4:15

Chairing: A. Rogers, MD, MPH, Palo Alto, CA
M.T. Borchers, PhD, Cincinnati, OH
C.S. Dela Cruz, MD, PhD, New Haven, CT

A103  IPF: MORE ABOUT THERAPY AND OUTCOMES
2:15 p.m. - 4:15 p.m.  MOSCONE CENTER
Poster Viewing 2:15-3:00
Discussion 3:00-4:15

Chairing: P.J. Sime, MD, Rochester, NY


202 Efficacy of Nintedanib on Acute Exacerbations Reported as Serious Adverse Events in the INPULSiSr Trials in Idiopathic Pulmonary Fibrosis (IPF)/M. Kreuter, H. Koegler, M. Trampisch, S. Geier, L. Richeldi, Heidelberg, Germany, p.A2689

203 Effect of Baseline GAP Index Stage on Decline in Lung Function with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis (IPF)/C.J. Ryerson, M. Kolb, L. Richeldi, J. Lee, T. Kimura, S. Stowasser, V. Poletti, Vancouver, Canada, p.A2691


205 Effect of Nintedanib on Disease Progression in the INPULSiSr Trials in Patients with Idiopathic Pulmonary Fibrosis (IPF)/G. Raghu, Y. Inoue, J. Behr, V. Cottin, S. Stowasser, W. Stansen, T.M. Maher, Seattle, WA, p.A2693


210 PROOF: A Prospective Observational Registry to Describe the Disease Course and Outcomes of Idiopathic Pulmonary Fibrosis Patients in a Real-World Clinical Setting.


212 Two Agents for Idiopathic Pulmonary Fibrosis: Which One to Choose/S. Daouk, A. Aljaafareh, I. Faruqi, Gainesville, FL, p.A2700


216 Comparison of the GAP Index and Staging System with the Japanese Severity Classification System in Patients with Idiopathic Pulmonary Fibrosis/M. Bando, Y. Sugiyama, A. Azuma, M. Ebina, H. Taniguchi, Y. Taguchi, H. Takahashi, S. Homma, Shimotsuke, Japan, p.A2704


A104 CRITICAL CARE: SEPSIS TRANSLATIONAL INSIGHTS

2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 3001 (West Building, Level 3)

Poster Viewing 2:15-3:00
Discussion 3:00-4:15

Chairs: M.M. Wurfel, MD, PhD, Seattle, WA
W. Fang, MD, Kaohsiung, Taiwan
E.P. Schmidt, MD, Aurora, CO


702 Regulation of Creb-Binding Protein


710 Plasma Asymmetric Dimethylarginine (ADMA) Association with Risk of Death in Septic Shock - Subgroup Analysis of Patients from the VANISH Trial/S. Lambden, J. Leiper, A. Gordon, London, United Kingdom, p.A2723


715 Hydrocortisone Treatment Decreases Nitric Oxide Levels and Increases Blood Pressure and Survival Following B. anthracis Cell Wall Peptidoglycan Challenge in Rats/D.A. Suffredini, X. Cui, Y. Li, Y. Fitz, P. Eichacker, Bethesda, MD, p.A2728


723 Protection Effect of Shenfuhuang Prescription on Organs of Septic Rats and its Molecular Mechanism/L. Wang, X. Zhu, G. Li, Q. Liu, Beijing, China, p.A2736

724 Type 2 Inflammatory Responses Protect Against Staphylococcus aureus-Induced Sepsis/P.A. Verhoef, P.A. Krishack, J. Bubeck Wardenburg, A.I. Sperling, Chicago, IL, p.A2737

725 The rs805305 SNP of Dimethylarginine Dimethylaminohydrolase 2 (DDAH2) is Associated with Reduced Duration of Shock, Improved Mortality and an Elevated Plasma ADMA:SDMA Ratio in Septic Shock - Subgroup Analysis of Patients from the VANISH Trial/S. Lambden, J. Leiper, A. Gordon, London, United Kingdom, p.A7800

A105 CRITICAL CARE : VARIABILITY IN CARE, OPPORTUNITIES FOR ADOPTION OR DEADOPTION

2:15 p.m. - 4:15 p.m. MOSCON CENTER

Room 3011 (West Building, Level 3)

Poster Viewing 2:15-3:00

Discussion 3:00-4:15

Chairs: C.R. Cooke, MD, MSc, Ann Arbor, MI
J.M. Kahn, MD, MSc, Pittsburgh, PA
K.S. Mathews, MD, MPH, New York, NY


805 Factors Associated in De-Escalation of Antibiotics in Critically Ill Patients with Nosocomial Pneumonia/N. Ariyoshi, J. Davis, J. Dworkin, G.P. Devendra, Honolulu, HI, p.A2742

806 Antibiotic Stewardship in Medical ICU: Importance of a Multidisciplinary Approach for Antibiotic De-Escalation/G.E. Holguin, M.F. Petrin, D. Haynes, Jackson, MS, p.A2743

807 How Procalcitonin Changed Antimicrobials Use in ICU Patients with Lower Respiratory Infections/S. AlSamman, K. Shahwa, J. Hong, M.A. AlSamman, C. Hayner, S. Friedstrom, J. Steinbrunner, Detroit, MI, p.A2744


811 Early Hyperoxia, Neurologic Outcome, and Mortality in Post-Cardiac Arrest Syndrome/L. Hsu, R.J. Anderson, T.B. Ghafoori, S. Tyagi, J. Joshua, J.R. Beitler, La Jolla, CA, p.A2748

812 Sedative Infusions in Already-Comatose Patients After Out-of-Hospital Cardiac Arrest/J. Joshua, R.J. Anderson, L. Hsu, T.B. Ghafoori, S. Tyagi, J.R. Beitler, La Jolla, CA, p.A2749


815 The Effect of Clinical Trial Results on the Use of Neuromuscular Blockade for Severe ARDS/M.P. Siedsma, T.Q. Le, J.M. Kahn, C.W. Seymour, Pittsburgh, PA, p.A2752


819 Patients with Multiple Rapid Response Activations Have Worse Outcomes and Increased Health Care Costs/J. Yang, E. Hemmen, E. Botts, D. Paulson, R. Sell, San Diego, CA, p.A2756


822 Reducing Inappropriate Blood Transfusions with the Use of an Electronic Medical Record (EMR)/R. Sengupta, B. Small, I. Lopez-Plaza, B. DiGiovine, Detroit, MI, p.A2759


825 Pharmacological Management of Delirium (PMD) Trial/B. Khan, A. Perkins, S. Gao, M. Boustanli, Indianapolis, IN, p.A7801

---

**A106 EPIDEMIOLOGY AND RISK FACTORS OF ASTHMA: FROM THE CRIB TO ADULTHOOD**

2:15 p.m. - 4:15 p.m.  
MOSCONCE CENTER
Room 3024 (West Building, Level 3)
Poster Viewing  
2:15-3:00
Discussion  
3:00-4:15

Chairing:  
F. Holguin, MD, MPH, Pittsburgh, PA  
S. Sharma, MD, MPH, Aurora, CO  
C. Lemiere, MD, Montreal, Canada


---


1005 Associations of Residence Near Primary Traffic Arterials with Asthma and Wheezing in a Sample of Mexican American Children/K. Eldeirawi, V. Persky, C. Kunzweiler, B. Riley, Y. Gao, N. Rosenberg, Chicago, IL, p.A2766


1008 Environmental Exposure to Polycyclic Aromatic Hydrocarbons and the Relationship with Lung Function and Oxidative Damage/M.L. Perez Humara, L. Hernandez Cadena, A. Barraza-Villarreal, I. Alvarardo Cruz, B. Quintanilla Vega, M.C. Escamilla-Nunez, Cuernavaca, Morelos, Mexico, p.A2769


1010 Environmental Exposure to NOx and NO2 and Respiratory Function in Schoolchildren from Mothers who Participated in a Randomized Clinical Trial During Pregnancy/A. Barraza-Villarreal, M.C. Escamilla-Nunez, L. Hernandez-Cadena, P.D. S. Li, U. Ramakrishnan, I. Romieu, Cuernavaca, Morelos, Mexico, p.A2771

1011 Airway Inflammation and Oxidative Stress as a Response to Exposure to PM2.5 in Adolescents with and Without Asthma in Mexico City/L. Hernandez Cadena, P. Ibinarriaga Montiel, B.E. Del Rio Navarro, I. Romieu, E. Navarro, M.C. Escamilla-Nunez, A. Barraza-Villarreal, Cuernavaca, Morelos, Mexico, p.A2772


Cycling During Diesel Exhaust Exposure May Decrease the Bronchodilatory Response to Exercise in Asthmatics/R. Tran, S. Koch, A. Lee, C. Carlsten, J. Guenette, M. Koehle, Vancouver, Canada, p.A2783


1018 2:15 p.m. - 4:15 p.m. MOSCONE CENTER

A107  ETIOLOGY OF PAH: GO YOUR OWN WAY

Chairing:

J.P. Fessel, MD, PhD, Nashville, TN
R.F. Machado, MD, Chicago, IL
S.Y. Farha, MD, Cleveland, OH


Bone Marrow Transplantation Reduces Susceptibility to Pulmonary Hypertension in Bone Morphogenetic Receptor Type 2 (BMPR2) Deficient Mice/A. Crosby, E. Soon, E. Groves, M. Southwood, B.J. Dunmore, M. Toshner, N.W. Morrell, Cambridge, United Kingdom, p.A2790


Loss of Endothelial Nitric Oxide (NO) Synthase Drives Mortality in Bone Morphogenetic Protein Receptor Type II (BMPR2) Mutant Mice and Is Associated with Increased Inducible NO Synthase and Increased Glycolysis/E.G. Kocurek, C. Moore, T. Luong, S. Shay, J. French, S. Gladson, J. West, J.P. Fessel, Nashville, TN, p.A2794
A109 REMODELING AND THE MATRIX

2:15 p.m. - 4:15 p.m.

MOSCON CENTER

Room 2014 (West Building, Level 2)

Poster Viewing

2:15-3:00

Discussion

3:00-4:15

A109 REMODELING AND THE MATRIX

2:15 p.m. - 4:15 p.m.

MOSCON CENTER

Room 2014 (West Building, Level 2)

Poster Viewing

2:15-3:00

Discussion

3:00-4:15
514 Validation of the 3DBioRing™ Airway: a 3D-Bioprinted Contractile Airway Tissue/S.J. Wadsworth, S. Pan, T. Mohamed, S. Beyer, Vancouver, Canada, p.A2837


516 Secretion of Brain Derived Neurotrophic Factor Is Regulated by Inflammation-Induced Signals in Asthmatic Airway Smooth Muscle Cells/B. Aravamudan, M.A. Thompson, C. Pabelick, Y.S. Prakash, Rochester, MN, p.A2839


518 Estrogen and Testosterone Influence Brain-Derived Neurotropic Factor Release from Human Airway Smooth Muscle Cells/S.-Y. Wang, M.R. Freeman, V. Sathish, M.A. Thompson, C.M. Pabelick, Y.S. Prakash, Xi’an, China, p.A2841


521 Extracellular Matrix Within the Airway Smooth Muscle Layer Correlates with Age but Not in Cases of Asthma/J. Elliot, N. Sandosham, R. Jones, S.-A. Drew, K. McKay, P. Noble, A. James, Nedlands, Australia, p.A2844


A110 THE SLEEPY AND AGING BRAIN: OSA AND COGNITION IN THE ELDERLY

2:15 p.m. - 4:15 p.m. MOSCONCE CENTER

Author Summaries 2:15-2:45

Poster Viewing/Discussion 2:45-4:15

Chairs: M.J. Morrell, MD, PhD, London, United Kingdom
A. Vakulin, PhD, Daw Park, Australia
T.E. Weaver, PhD, RN, Chicago, IL

601 Six Months of Continuous Positive Airway Pressure (CPAP) Treatment Improves Neurobiological Function and Quantitative Sleep Electroencephalographic (EEG) Parameters in Obstructive Sleep Apnea/C.M. Hoyos, A. D’Rozario, K. Wong, J.W. Kim, D. Kim, C. Field, A. Vakulin, R. Grunstein, D. Bartlett, Glebe, Australia, p.A2845


Evaluation of CPAP Treatment on Memory Processes in Obstructive Sleep Apnea Patients Through a Randomized Controlled Trial/J.L. Pepin, M. Joyceux-Faure, B. Naegele, R. Tamisier, P. Levy, S. Launois, Grenoble, France, p.A2847


404 Decision Time Is AHI Dependent Significantly Reduced After Sleep at Simulated 5500m in a Normobaric Chamber/N. Netzer, S. Wimmer, M. Koop, H. Gatterer, M. Faulhaber, M. Burtscher, N.C. Netzer, Bad Aibling, Germany, p.A2849


408 7 Years Follow-Up: The Correlation Among Sleep Apnea Syndrome and Hypertension, Diabetes Disease/H. Zhongming, H. Fang, L. Jiangping, D. Xiaosong, S. Juan, Keramay, China, p.A2853

409 Gender, Nocturnal Hypoxia and Arousal Influence Brainstem Auditory Evoked Potentials in Patients with Obstructive Sleep Apnea/W. Wang, J. Su, D. Kong, J. Pang, J. Kang, Shenyang City, China, p.A2854


Initiation and Adherence to Positive Airway Pressure in Post-Stroke Patients/K. Wilton, C.M. Ryan, Toronto, Canada, p.A2858

Estradiol Prevents Brain Oxidative Stress Induced by Chronic Intermittent Hypoxia in Female Rats/S. Laouafa, V. Pialoux, A. Ribon, D. Roussel, A. Bairam, V. Joseph, Quebec, Canada, p.A2859

4:30 p.m. - 6:30 p.m.

2016 RESPIRATORY HEALTH AWARDS
GIVEN BY THE AMERICAN THORACIC SOCIETY
MOSCONNE CENTER
Gateway Ballroom 102-104 (South Building, Lower Level)

Amberson Lecture
The Amberson Lecturer is an individual with a career of major lifetime contributions to clinical or basic pulmonary research and/or clinical practice. The Lecture is given in honor of James Burns Amberson, an international authority on chest disease and tuberculosis.

Lecturer: Marlene Rabinovitch, MD, Stanford, CA
Lecture Title: From EVE to ADAM to Finding a Cure for Pulmonary Hypertension
Introducer: Michael A. Matthay, MD, San Francisco CA

Trudeau Medal
The Trudeau Medalist is an individual with lifelong major contributions to prevention, diagnosis and treatment of lung disease through leadership in research, education, or clinical care. This award was established in 1926 and is given in honor of Edward Livingston Trudeau, a founder and the first president of the American Lung Association.

Awardee: Joe G.N. Garcia, MD, Tucson, AZ
Introducer: Juan C. Celedon, MD, DrPH, Pittsburgh, PA

Distinguished Achievement Award
The Distinguished Achievement Award is given to individuals who have made outstanding contributions to fighting respiratory disease through research, education, patient care, or advocacy.

Awardees: Claire M. Doerschuk, MD, Chapel Hill, NC
J. Usha Raj, MD, Chicago, IL

World Lung Health Award
The World Lung Health Award is given to an individual with recognized contributions to improving world lung health in the area of translational or implementation research, delivery of healthcare, continuing education or care of patients with lung disease, or related political advocacy with a special emphasis on efforts that have the potential to eliminate gender, racial, ethnic, or economic health disparities worldwide.

Awardee: Charles L. Daley, MD, Denver, CO

Outstanding Educator Award
The Outstanding Educator Award recognizes lifetime contributions in education and mentoring in the fields of pulmonary, critical care or sleep medicine. This award honors excellence in clinical or research education as it relates to pulmonary disease.

Awardee: Robert Kotloff, MD, Cleveland, OH
This award will be presented at the ATS Plenary Session, Tuesday, May 17, 11:45 a.m.

Jo Rae Wright Award for Outstanding Science
The Jo Rae Wright Award for Outstanding Science is based on demonstrated potential for significant scientific achievement and contributions. This award is aimed at the rising generation of individuals who will be tomorrow's leaders in science.

Awardee: Megan N. Ballinger, PhD, Columbus, OH

Public Service Award
The Public Service Award is presented to an individual with recognized contributions in public health related to improvement of indoor and outdoor air quality, eradication of tobacco usage, prevention of lung disease, improved management of communicable respiratory diseases, or improvement in the ethical delivery, and access to healthcare in areas related to lung diseases, sleep disorders, or critical care. There is a special emphasis on efforts that have the potential to eliminate gender, racial, ethnic or economic disparities.

Awardee: John R. Balmes, MD, San Francisco, CA

Outstanding Clinician Award
The Outstanding Clinician Award is presented to an individual who embodies excellence in the clinical practice of lung health medicine. The awardee has spent a substantial part of his/her career in the clinical care of patients with lung disease, and has made substantial contributions in the clinical care of patients with lung disease on a local or national level.

Awardee: Jay M. Shames, MD, New Orleans, LA

The Recognition Awards for Scientific Accomplishments will be presented on Monday, May 16th at 2:15 p.m.
6:30 p.m. - 8:30 p.m.

ASSEMBLY MEMBERSHIP MEETINGS
The fourteen Assemblies are the primary groups of the American Thoracic Society. Each Assembly holds an annual Membership Meeting at the International Conference. All Assembly members and other interested individuals are invited to attend.

The Assembly Membership Meetings provide an update on the Assembly’s activities via the Assembly’s Leadership and provide Assembly members the chance to have input on future directions, information on how to get involved and networking opportunities. Voting results for the Assembly’s future leaders will also be announced.

The Assembly Membership Meetings will be held on Monday, May 16, 5:00 p.m. - 7:00 p.m., with the exception of the Assemblies on Behavioral Science and Health Services Research and Pediatrics (see below.)

BEHAVIORAL SCIENCE
AND HEALTH SERVICES RESEARCH
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 10-12 (Lower B2 Level)

Chairing: K.A. Riekert, PhD, Baltimore, MD

PEDIATRICS
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 8 (Lower B2 Level)

Chairing: J.F. Chmiel, MD, MPH, Cleveland, OH

7:00 p.m. - 9:00 p.m.

STRATEGIES FOR TB CONTROL: POSTER SESSION
INTERCONTINENTAL HOTEL
InterContinental Ballroom B-C (Fifth Floor)

Sponsored by:
U.S. CENTERS FOR DISEASE CONTROL
AND PREVENTION STOP TB USA

This public health poster forum will focus on innovative techniques, which are helping to meet the challenges of TB control, prevention, and elimination in the United States. Specific topics include: targeted TB testing and treatment of latent TB infection; conducting/expanding contact investigations; performing outbreak investigations; improving treatment adherence; addressing multi-drug-resistant TB; dealing with TB related to HIV/AIDS; providing TB education; and building TB-related coalitions.

Target Audience:
National, state and local TB program staff, public health professionals (nurses, physicians, epidemiologists), pulmonary specialists, infectious disease specialists, TB and HIV clinicians, epidemiologists, TB consultants, laboratory scientists, and microbiologists.

Chairing: S. Mase, MD, Atlanta, GA
K. Schmit, MD, Atlanta, GA
M. Sage, MPH, Washington, DC
Target Audience
Pediatric pulmonary and critical care physicians who work in a clinical setting and are currently engaged in maintenance of certification.

Objectives
At the conclusion of this session, the participant will be able to:

• remain current with medical knowledge relevant to their practice in pediatric pulmonology;
• evaluate their understanding of key skills and content areas in pediatric pulmonology as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison
• support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements

The Pediatric Core Curriculum symposia promotes lifelong learning and the enhancement of the clinical judgment and skills essential for practicing pediatricians. The symposia will address topics that have been identified by an ATS pediatric working group, which is comprised of members of the ATS Education Committee and the International Conference Committee, who have identified important areas within pediatric medicine (including vasculitic pulmonary diseases, lung defense mechanism, congenital abnormalities of the airways, and respiratory failure). Attendees will increase their medical knowledge as a result of attending this symposium, and this will be measured by a comparison of pre-test vs. post-test results on the corresponding maintenance of certification module. The ATS Pediatric Core Curriculum will focus on a 3-year content cycle of key medical content in the area of pediatric medicine.

Chairing: D.M. Boyer, MD, Boston, MA  
P.E. Moore, MD, Nashville, TN

6:45 Lung Defense Mechanisms  
R. Wang, MD, Boston, MA

7:15 Lung Growth and Development  
J. Wambach, MD, St. Louis, MO

SUNRISE SEMINARS
CME Credits Available: 1.0

Registration Fee: $65.00 (includes continental breakfast.)  
Attendance is limited. Pre-registration is required.

6:45 a.m. - 7:45 a.m.  
INTERCONTINENTAL HOTEL

SS101 LUNG TRANSPLANTATION IMMUNOLOGY MADE EASY: SIMPLE RATIONALES FOR SOPHISTICATED DRUGS  
J.R. Greenland, MD, PhD, San Francisco, CA  
Union Square (Third Floor)

SS102 EFFECTIVE UTILIZATION AND INTEGRATION OF PALLIATIVE CARE IN PULMONARY AND CRITICAL CARE MEDICINE  
D.R. Sullivan, MD, MA, Portland, OR  
SoMa (Third Floor)

SS103 AN UPDATE IN SCLERODERMA LUNG DISEASE  
F. Castelino, MD, Boston, MA  
Mission (Third Floor)

SS104 ASTHMA/COPD OVERLAP SYNDROME  
M.E. Hardin, MD, Boston, MA  
D.J. Maselli, MD, San Antonio, TX  
Marina (Third Floor)

SS105 IDENTIFICATION, DIAGNOSIS AND MANAGEMENT OF IMMUNODEFICIENCY IN LUNG DISEASE  
K.A. Provost, DO, PhD, Buffalo, NY  
Grand Ballroom C (Third Floor)

SS106 PRACTICAL APPLICATION OF LUNG CANCER SCREENING USING LOW INTENSITY CT SCANS  
A. Malave, MD, San Antonio, TX  
Grand Ballroom B (Third Floor)

SS107 MANAGEMENT OF MALIGNANT PLEURAL EFFUSION  
A.H. Sardi, MD, Columbus, OH  
Grand Ballroom A (Third Floor)

SS108 RHEUMATOID ARTHRITIS-ASSOCIATED ILD: CURRENT KNOWLEDGE AND FUTURE DIRECTIONS  
T.J. Doyle, MD, MPH, Boston, MA  
Twin Peaks (Fourth Floor)

SS109 BRONCHIOLITIS OBLITERANS SYNDROME AFTER HEMATOPOIETIC CELL TRANSPLANTATION: DIAGNOSIS AND MANAGEMENT  
G. Cheng, MD, Seattle, WA  
Telegraph Hill (Fourth Floor)

SS110 THORACOSCOPY: AN EVIDENCE BASED REVIEW OF RIGID AND FLEXIBLE TECHNIQUES  
N.M. Rahman, MSc, PhD, Oxford, United Kingdom

The information contained in this program is up to date as of March 9, 2016.  
For the most current session information, please visit the online program itinerary.
FACULTY DEVELOPMENT SEMINAR

FD1 HOW TO SUCCESSFULLY COMPETE FOR AN ACADEMIC JOB: WHAT DIVISION DIRECTORS WANT AND DO NOT WANT IN CANDIDATES

Pre-registration is required. There is no additional fee. Attendance is limited.

6:45 a.m. - 7:45 a.m. INTERCONTINENTAL HOTEL
InterContinental Ballroom A (Fifth Floor)

Target Audience
Early career clinical and/or research faculty, clinical and post doctoral fellows, graduate students, residents, nurses, and allied health professionals already involved in or seeking a career in academic pulmonary, allergy, critical care, and/or sleep medicine.

FACULTY DEVELOPMENT SEMINAR

FD1 HOW TO SUCCESSFULLY COMPETE FOR AN ACADEMIC JOB: WHAT DIVISION DIRECTORS WANT AND DO NOT WANT IN CANDIDATES

Pre-registration is required. There is no additional fee. Attendance is limited.

6:45 a.m. - 7:45 a.m. INTERCONTINENTAL HOTEL
InterContinental Ballroom A (Fifth Floor)

Target Audience
Early career clinical and/or research faculty, clinical and post doctoral fellows, graduate students, residents, nurses, and allied health professionals already involved in or seeking a career in academic pulmonary, allergy, critical care, and/or sleep medicine.

Objectives
At the conclusion of this session, the participant will be able to:
• identify components necessary for success in their career path;
• understand key steps needed to build a competitive portfolio;
• strategies to improve their chances in obtaining a faculty appointment.

This seminar will identify and review critical steps in finding a successful placement in an academic career with topics broadly applicable to fellows, post-docs and junior faculty regardless of specialty or career track. This seminar will provide guidance for fellows and post-docs who are looking for their first jobs as well as for junior faculty who are looking to relocate to new positions.

Chairs: D.W. Ford, MD, MSCR, Charleston, SC

Speakers: I. Petrache, MD, Denver, CO
L.M. Schnapp, MD, Charleston, SC
J. Roman, MD, Louisville, KY
G. Loughlin, MD, New York, NY
B1 CLINICAL YEAR IN REVIEW 2

9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Gateway Ballroom 102-104 (South Building, Lower Level)

Target Audience
Providers including physicians, nurses, respiratory therapists, nurse practitioners, physician assistants. Trainees including residents and fellows; clinical researchers.

Objectives
At the conclusion of this session, the participant will be able to:
• apply new clinical research knowledge to clinical practice;
• learn new findings about key conditions in pulmonary, critical care and sleep;
• gain new strategies to manage the care of common conditions in pulmonary, critical care, and sleep.

The annual Clinical Year in Review symposia topic reviews of the key clinical research publications over the last year. Each speaker is asked to review the 5-7 most important and influential publications on their topic in the prior year.

Chairing: J.L. Taylor-Cousar, MD, Denver, CO
D.J. Lederer, MD, MS, New York, NY
D.W. Ford, MD, MSCR, Charleston, SC

9:00 ARDS
C.S. Calfee, MD, San Francisco, CA

9:30 Non-Invasive and Mechanical Ventilation
B. Fauroux, MD, PhD, Paris, France

10:00 Update in Critical Care
E.L. Burnham, MD, Aurora, CO

10:30 Sepsis
D. Scales, MD, PhD, Toronto, Canada

B2 HOT TOPICS IN COPD: A PRO/CON DEBATE

Assemblies on Clinical Problems; Behavioral Science and Health Services Research; Environmental, Occupational and Population Health; Nursing

9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 135 (North Building, Lower Level)

Target Audience
Providers of lung health including registered nurses, advanced practice nurses, and those with clinical and research responsibilities.

Objectives
At the conclusion of this session, the participant will be able to:
• appropriately use dual bronchodilator therapy in practice;
• implement case finding approaches to COPD;
• appropriately use new imaging methodologies in COPD.

COPD is a rapidly evolving field with new research and treatments that are leading us to rethink our approach to the COPD patient. This session highlights important current controversies in COPD diagnosis and management in a pro con debate format.

Chairing: R.A. Wise, MD, Baltimore, MD
C. Jenkins, MD, MBBS, Concord, Australia
R.A. Stockley, MD, DSc, Birmingham, United Kingdom

9:00 PRO: GOLD 0 Should Be Brought Back
P.G. Woodruff, MD, MPH, San Francisco, CA

9:12 CON: GOLD 0 Should Not Be Brought Back
R. Rodriguez-Roisin, MD, PhD, Barcelona, Spain

9:24 PRO: Screening for COPD Improves Outcomes
F.J. Martinez, MD, New York, NY

9:36 CON: Screening for COPD Does Not Improve Outcomes
D.M. Mannino, MD, Lexington, KY

9:48 PRO: The GOLD Strategy Results in Improved COPD Patient Care
C. Vogelmeier, MD, Marburg, Germany

10:00 CON: The GOLD Strategy Does Not Result in Improved COPD Patient Care
K.F. Rabe, MD, PhD, Grosshansdorf, Germany

10:12 PRO: CT Should Be Part of Routine Clinical Care for COPD
G. Washko, MD, Boston, MA

10:24 CON: CT Should Not Be Part of Routine Clinical Care for COPD
M.K. Han, MD, MS, Ann Arbor, MI

10:36 PRO: LAMA/LABA Combination Therapy Should Be Used as Initial Maintenance Treatment for COPD
C. Vogelmeier, MD, Marburg, Germany

10:48 CON: LAMA/LABA Combination Therapy Should Not Be Used as Initial Maintenance Treatment for COPD
B.R. Celli, MD, Boston, MA

This session and the International Conference are supported by an educational grant from AstraZeneca LP. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
Target Audience
Pulmonologists, post graduate fellows and trainees, advanced practice nurses.

Objectives
At the conclusion of this session, the participant will be able to:

• identify clinical features from a patient’s history that can help distinguish among the non-IPF ILDs in patients with newly recognized ILD;

• identify radiographic features from a patient’s HCRT that can help distinguish among the non-IPF ILDs in patients with newly recognized ILD;

• identify pathologic features from a patient’s biopsy that can help distinguish among the non-IPF ILDs in patients with newly recognized ILD.

Distinguishing among the non-IPF interstitial lung diseases can be very challenging for the clinician. This symposium will seek to review the evidence for the best discriminating clinical, pathologic and radiologic features that can be used to differentiate among the non IPF ILDs. Following a review of these characteristics, 3 ILD clinicians will discuss real life cases that they will have been given ahead of time (without the diagnosis) to demonstrate how best to work thorough these challenging cases.

Chairing: M. Kreider, MD, Philadelphia, PA
G. Tino, MD, Philadelphia, PA
A. Olson, MD, MSPH, Denver, CO

9:00 Introduction
G. Tino, MD, Philadelphia, PA

9:10 Top 5 Clinical Features to Differentiate Among Non-IPF ILD
K.K. Brown, MD, Denver, CO

9:30 Top 5 Radiographic Features to Differentiate Among Non-IPF ILD
D. Hansell, MD, London, United Kingdom

9:45 Top 5 Pathologic Features to Differentiate Among Non-IPF ILD
W.D. Travis, MD, New York, NY

10:00 Case I
T.M. Maher, MD, MSc, PhD, London, United Kingdom
A. Olson, MD, MSPH, Denver, CO

10:15 Case II
C.D. Fell, MD, MSc, Calgary, Canada
M. Kreider, MD, Philadelphia, PA

10:30 Case III
G. Tino, MD, Philadelphia, PA
J.S. Lee, MD, Aurora, CO

10:45 Questions and Answers
M. Kreider, MD, Philadelphia, PA

This session and the International Conference are supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
B5 HARNESSING BREAKTHROUGHS IN CRISPR GENE EDITING TECHNOLOGY FOR RESEARCH AND THERAPY

Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Microbiology, Tuberculosis and Pulmonary Infections; Respiratory Structure and Function; Thoracic Oncology

9:00 a.m. - 11:00 a.m. MOSCONCE CENTER
Room 2009/2011 (West Building, Level 2)

Target Audience
Basic and translational researchers seeking to understand the most important advance in biotechnology in the last decade and clinical investigators and clinicians interested in learning more about this technology that is poised to move into clinical application in the coming decade.

Objectives
At the conclusion of this session, the participant will be able to:

• learn new findings about the CRISPR system functions and how it can be adapted to edit human and other animal genomes;
• improve lung research by learning new strategies for selectively turning genes on and off, creating lung cancer models, performing genome-wide screens, and imaging the genome;
• contribute to conversations that will shape scientific and ethical approaches to the use of CRISPR technology to treat human disease.

The development of the CRISPR system for efficient and selective editing of the human genome represents the most important scientific breakthrough of the past decade. CRISPR-based systems are already being widely used for inactivating or repairing individual genes in human cells and animal models and for genome-wide studies of the functions of coding and non-coding RNAs. This session will introduce the basic CRISPR/Cas9 system, explain how this technology is being modified to allow selective inactivation, activation, and live imaging of the genome, and illustrate how the technology can be applied to study and treat lung diseases, including cancer.

Chairing:
- D. Erle, MD, San Francisco, CA
- S. Albelda, MD, Philadelphia, PA
- N. Chandel, PhD, Chicago, IL

9:00 CRISPR: From Biology to Transformative Technology
J. Corn, PhD, Berkeley, CA

9:30 Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation
J. Weissman, PhD, San Francisco, CA

10:00 Dissecting the Role of Oxidative Homeostasis in Lung Cancer Using CRISPR/Cas9 Genome Engineering
T. Papagiannakopoulos, PhD, New York, NY

10:30 CRISPR Tools for Complex Transcription Control and Functional Study
S. Qi, PhD, Stanford, CA

This session and the International Conference are supported by an educational grant from AstraZeneca LP.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

B6 BUILDING E-BRIDGES: TOOLS AT OUR FINGERTIPS FOR ENHANCING COLLABORATIVE CARE

Assemblies on Behavioral Science and Health Services Research; Clinical Problems; Critical Care; Nursing; Thoracic Oncology

9:00 a.m. - 11:00 a.m. MOSCONCE CENTER
Room 303/305 (South Building, Esplanade Level)

Target Audience
Clinicians and scientists seeking to understand developments in shared decision-making and to explore cutting edge tools aimed at advancing interdisciplinary, patient centered collaboration across pulmonary and critical care.

Objectives
At the conclusion of this session, the participant will be able to:

• present new findings about the complexity of shared decision-making to enhance patient-centered care;
• apply novel, innovative tools to enrich risk communication and improve the quality of life and health of patients;
• evaluate future directions and barriers to collaborative, personalized care.

For most medical decisions, multiple options are available with each choice having its own list of benefits and harms. Decisions inconsistent with patient preferences may have unintended consequences to both patients and the health system. Shared decision-making provides a model for personalized medicine to enhance patient-centered care. This session will allow leading experts to discuss: (1) how traditional communication has failed and why shared decision-making has evolved; (2) the complexity of the decision-making process; (3) what tools are available, across pulmonary and critical care, to enhance communication; (4) what future directions and barriers may lie ahead in patient-centered risk communication.

Chairing:
- T.S. Valley, MD, Ann Arbor, MI
- R.S. Wiener, MD, MPH, Boston, MA
- C.E. Cox, MD, MPH, Durham, NC

9:00 A Patient’s Perspective
K. Erickson, Coral Gables, FL

9:05 Helping Me Help You: Making the Right Decision for Different Patients
T.S. Valley, MD, Ann Arbor, MI

9:23 So You’re Telling Me There’s a Chance? Theories to Improve Risk Communication
J.L. Hart, MD, Philadelphia, PA
9:40 Empowering Patients with Asthma: Customizing Care to Patient Beliefs
M.R. George, AE-C, PhD, RN, New York, NY

9:00 Physical Activity: Should it Be an Outcome for Large Clinical Trials?
A. Hamilton, PhD, Burlington, Canada

10:00 Why Wouldn’t I Want to Know? Moving Lung Cancer Screening from Standardized to Personalized
R.S. Wiener, MD, MPH, Boston, MA

10:20 Enhancing Physical Activity with Rehabilitation
R.S. Goldstein, MD, Toronto, Canada

10:40 How Can We Use Technology to Improve Physical Activity for Individuals with COPD?
H. Demeyer, PhD, Leuven, Belgium

There will be a 5-minute discussion after each talk.

### CLINICAL

#### SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0

#### B7 ONE STEP AT A TIME: HAS PHYSICAL ACTIVITY DELIVERED AS AN OUTCOME IN CLINICAL TRIALS?

Assemblies on Pulmonary Rehabilitation; Clinical Problems; Nursing

9:00 a.m. - 11:00 a.m. MOSCONE CENTER

Room 2020/2022 (West Building, Level 2)

Target Audience
Health care professionals who are interested in the measurement and enhancement of clinical activity. Researchers who use physical activity as outcomes in clinical trials.

Objectives
At the conclusion of this session, the participant will be able to:

- understand the importance of physical activity in patients with COPD and the wider health implications of inactivity;
- learn about new developments with respect to measuring physical activity;
- understand new strategies to improve physical activity.

This session will provide an overview of the importance of physical activity to the population at large and of course for those with respiratory disease, specifically COPD. We will explore the development of the measurement, and the physical and psychological benefits of physical activity. The complexities of measurement for clinical trials will be addressed and finally how we might improve physical activity through rehabilitation or novel technologies.

Chairing: S.J. Singh, PhD, Leicester, United Kingdom
M.L. Moy, MD, MSc, Boston, MA

9:00 The (Short) History of Physical Activity Measurement in COPD
R. Casaburi, MD, PhD, Torrance, CA

9:10 Physical Activity: Does it Keep Us Alive?
J. Myers, PhD, Palo Alto, CA

9:35 Physical Activity: Does it Keep Those with COPD Happy? The Patient Centered Perspective
T. Troosters, PhD, Leuven, Belgium

### B8 SLEEP, SLEEP DISORDERS AND PERFORMANCE IN ATHLETES

Assemblies on Sleep and Respiratory Neurobiology, Behavioral Science and Health Services Research

9:00 a.m. - 11:00 a.m. MOSCONE CENTER

Room 2001/2003 (West Building, Level 2)

Target Audience
Sleep physicians, those interested in public health, those interested in human performance, those interested in real-world applications of sleep medicine

Objectives
At the conclusion of this session, the participant will be able to:

- learn new findings about the role of sleep and health in athletic performance;
- better understand how sleep impacts health and performance from the perspective of an elite athlete;
- better assess, diagnose, and treat sleep disorders among athletes.

Insufficient and/or misaligned sleep, sleep apnea and other sleep disorders have been shown to impact health, neurocognitive and physical performance. In addition, training at altitudes, hypoxic training, and other respiratory effects have also been studied. These are all domains that are relevant to athletes. For this reason, there has been increased attention from both the scientific community and from athletic organizations regarding the importance of sleep and respiratory health. Some of this effort has focused on the high prevalence of sleep apnea in football players. Further, the National Collegiate Athletic Association recently adopted best practices for addressing mental health in student athletes, and screening for sleep disorders (including sleep apnea) is prominently featured in those guidelines. This session will be the first of its kind at the ATS meeting and will focus on the (1) state of the science of sleep and respiratory health in athletes and then delve into the specific areas of (2) the new NCAA guidelines for student athletes related to sleep and (3) sleep apnea in athletes, football players specifically. Finally, the session will feature the perspectives of a professional athlete and a coach who can discuss their experiences when it comes to sleep and related aspects in maintaining performance.

Chairing: M. Grandner, PhD, Tucson, AZ
P.J. Strollo, MD, Pittsburgh, PA
S. Halson, PhD, Belconnen, Australia
### CLINICAL SCIENTIFIC SYMPOSIUM

**B9 SICKLE CELL DISEASE AND THE LUNG ACROSS THE LIFESPAN**

Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Clinical Problems; Pulmonary Circulation; Sleep and Respiratory Neurobiology  
9:00 a.m. - 11:00 a.m.  
MOSCONET CENTER  
Room 3007/3009 (West Building, Level 3)

#### Target Audience
Pediatric and adult pulmonary fellows, clinicians and researchers interested in the pulmonary complications of sickle cell disease (SCD) across the lifespan.

#### Objectives
At the conclusion of this session, the participant will be able to:
- gain an understanding of the burden of SCD around the globe and the importance of newborn screening and early intervention in the context of early SCD mortality in resource-poor settings;  
- review the state of evidence-based management of pulmonary complications of SCD with emphasis on current guidelines as well as areas where evidence is lacking;  
- understand the impact of abnormalities throughout the respiratory system (airway, gas exchange, and vascular) as disease modulators in the long term pathogenesis of SCD throughout the lifespan.

Despite a high and growing global burden of SCD with an estimated 400,000 births per year by 2050, evidence-based interventions against its pulmonary complications are limited. Pulmonary complications are among the most common causes of the observed accelerated mortality in the SCD population. The goal of this session is to present the spectrum of acute and chronic pulmonary complications of SCD that impact patients across the lifespan to actively engage pediatric and adult clinicians and researchers with the goals of improved coordination of scientific efforts and implementation of state of the art clinical care for patients.

#### Chairing
- E.S. Klings, MD, Boston, MA  
- S.C. Sadreameli, MD, MHS, Baltimore, MD  
- M.T. Gladwin, MD, Pittsburgh, PA

### BASIC • TRANSLATIONAL SCIENTIFIC SYMPOSIUM

**B10 NEW CONCEPTS IN ASTHMA BIOLOGY**

Assemblies on Respiratory Structure and Function; Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology  
9:00 a.m. - 11:00 a.m.  
MOSCONET CENTER  
Room 2005/2007 (West Building, Level 2)

#### Target Audience
Basic scientists and clinicians interested in emerging concepts in asthma pathobiology.

#### Objectives
At the conclusion of this session, the participant will be able to:
- appreciate newly discovered facets of the asthma phenotype;  
- learn about asthma mechanisms that may be independent of type 2 inflammation;  
- identify new experimental methods to assess function and dysfunction of structural cells of the airway.

Type 2 inflammation occurs in many asthma patients, but not all, and has shaped much of current thinking. Nevertheless, origins of the disease remain unclear. This symposium is designed to consider new thinking in asthma pathobiology, key structural cells of the airway, and unrecognized mechanisms of disease that may be independent of type 2 inflammation.

#### Chairing
- J.J. Fredberg, PhD, Boston, MA  
- R. Krishnan, PhD, Boston, MA

### Other Sessions

- **B9 SICKLE CELL DISEASE AND THE LUNG ACROSS THE LIFESPAN**
  - **Improving Sleep in Athletes: An Overlooked and Underutilized Training Method**  
    - B. Marcello, PhD, Carlsbad, CA
  - **Sleep and Circadian Misalignment in Athletes**  
    - S. Halson, PhD, Belconnen, Australia
  - **Athletes Sleeping/Training in Hypoxia: Good Idea or Bad?**  
    - J. Dempsey, PhD, Madison, WI
  - **Sleep, Health, and Performance in Student Athletes**  
    - M. Grandner, PhD, Tucson, AZ
  - **Sleep Apnea Risk, Diagnosis and Treatment in Professional Football**  
    - I. Gurubhagavatula, MD, MPH, Philadelphia, PA
  - **Sleep Disorders in Athletes: A Player’s Perspective**  
    - A. Taylor, San Diego, CA

- **B10 NEW CONCEPTS IN ASTHMA BIOLOGY**
  - **A Patient’s Perspective**  
    - T. Pruitt, Oakland, CA
  - **Unanswered Questions in the Pathophysiology of Sickle Cell Lung Disease in Pediatric and Adult Care**  
    - E.S. Klings, MD, Boston, MA
  - **Global Health Care Equality in Sickle Cell Disease**  
    - A.P. Ruhl, MD, MHS, Bethesda, MD
  - **Night and Day: Intermittent Hypoxia in SCD**  
    - J.L. Allen, MD, Philadelphia, PA
  - **How Should We Characterize Airway Disease in Sickle Cell Patients?**  
    - R.T. Cohen, MD, MPH, Boston, MA
  - **State of the Art Management of the Acute Chest Syndrome**  
    - J. Howard, MD, London, United Kingdom
  - **Thrombosis, Hypoxia, and Hemolysis as Modulators of Pulmonary Vascular Dysfunction in Sickle Cell Disease**  
    - R.F. Machado, MD, Chicago, IL

There will be a 5-minute discussion after each talk.
B11  SCIENTIFIC BREAKTHROUGHS IN SARCOIDOSIS RESEARCH AND PHENOTYPING: THE NHLBI GRADS CONSORTIUM

Assemblies on Allergy, Immunology and Inflammation; Clinical Problems; Environmental, Occupational and Population Health; Respiratory Cell and Molecular Biology

9:00 a.m. - 11:00 a.m.  MOSCONE CENTER
Room 2002/2004 (West Building, Level 2)

Target Audience
Those with clinical and research responsibilities, clinical providers of lung health, those needing instruction in areas of medicine outside their specialty, those serving patients with sarcoidosis.

Objectives
At the conclusion of this session, the participant will be able to:

• apply our current understanding of common sarcoidosis phenotypes and the clinical data that defines them to better care for sarcoidosis patients;

• learn new findings regarding immunophenotypes, immune dysregulation and microbiome;

• understand the role of clinical, immune and microbiome phenotyping on sarcoidosis pathogenesis, prognosis and treatment paradigms.

This session will provide exciting new integrative study results that have arisen from the latest NHLBI consortium on sarcoidosis, the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS). The GRADS study is an observational translational study evaluating the relationship between sarcoidosis phenotypes, immune networks, and gene expression and the microbiome patterns. The data generated by the multi-center and site specific studies expands our understanding of the clinical manifestations, and cellular and molecular mechanisms of disease to help define the biological basis of the clinical heterogeneity in sarcoidosis.

Chairing:
L.A. Maier, MD, Denver, CO
E. Chen, MD, Baltimore, MD
N. Kaminski, MD, New Haven, CT

9:00  A Patient’s Perspective
B. Clark, Emeryville, CA

9:05  A New Phenotypic Paradigm and the Clinical Data Supporting the GRADS Approach
N. Hamzeh, MD, Denver, CO

9:25  Is Sarcoidosis a Th17 Disease? Revisiting T Cell Phenotyping
L. Koth, MD, San Francisco, CA

9:45  Programmed Death-1 Inhibition of Sarcoidosis T Cell Proliferation: Potential Therapeutic Option?
W. Drake, MD, Nashville, TN

10:05  Neuroimmune Molecules and Innate Immunity in Pulmonary Sarcoidosis
E. Herzog, MD, PhD, New Haven, CT

10:25  Sarcoidosis BAL and Lung Tissue Microbiome: Closely Related or Distant Relatives
R.G. Collman, MD, Philadelphia, PA

10:45  Panel Discussion
E. Chen, MD, Baltimore, MD

B12  GLOBAL HEALTH: THE WHAT, WHERE AND WHY IN THE 21ST CENTURY

Membership Committee and International Health Committee; Assemblies on Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Clinical Problems; Environmental, Occupational and Population Health; Microbiology, Tuberculosis and Pulmonary Infections; Nursing; Pediatrics

9:00 a.m. - 11:00 a.m.  MOSCONE CENTER
Room 130-132 (North Building, Lower Level)

Target Audience
Clinicians, nurses, behavioral and translational scientists seeking to practice in a global community, addressing health inequalities; those seeking to develop or participate in research in global health communities.

Objectives
At the conclusion of this session, the participant will be able to:

• define the current pathways in international respiratory health and outlining approaches to developing expertise and continuing scholarship in those areas;

• identify career goals and plan accordingly for success in international respiratory health;

• identify major obstacles broadly defined in 3 categories: financial challenges, personal mentoring and academic skills acquisition.

This symposium will present practical approaches in developing a career in global health in the 21st century as it pertains to Pulmonary, Allergy and Critical Care.
Medicine. The symposium will provide the perspective of leaders and future leaders within the field of international respiratory health, identify common obstacles, and provide strategies for career development for early and mid-level career scientists, physicians and other professionals within and outside the United States.

Chairing: Y.N. Mageto, MD, MPH, Burlington, VT
G. Matute-Bello, MD, Seattle, WA

9:00 Collaborative Team Field Science: Skills and Methodology Required for Success
A.S. Buist, MD, Portland, OR

9:20 Translational Research in Low Resource Settings: Skills and Methodology Required for Success
T.E. West, MD, MPH, Seattle, WA

9:40 Education and Training Development in Low and Middle Income Countries: The Nuts and Bolts
E.J. Carter, MD, Providence, RI

10:00 Capacity Building in Developing Countries: Challenges and Opportunities on the Ground
D. Obaseki, MD, MPH, Ile-Ife, Nigeria

10:20 Epidemiology and Implementation Science: Targeting Chronic Respiratory Diseases in Developing Countries
C.M. Patino, MD, PhD, Los Angeles, CA

10:40 Challenges and Opportunities on the Ground: Ethics, Language, and Giving Back
S. Gordon, MA, MD, DTM&H, Blantyre, Malawi

There will be a 5-minute discussion after each talk.

B13 APPLIED PHYSIOLOGY IS ALIVE AND WELL
9:00 a.m. - 11:00 a.m. MOSCONET CENTER
Room 2016/2018 (West Building, Level 2)

Target Audience
Students, clinicians, scientists and educators.

Objectives
At the conclusion of this session, the participant will be able to:
• define the inflammatory reflex;
• apply the concept of driving pressure at the bedside;
• define loop gain and understand its therapeutic importance.

Although some people have suggested that physiology is dead, this session will present the case that physiology is still alive and well. Many of the advances in patient care which have occurred in recent years have been a result of physiology. Even though molecular and cellular biology have made major advances, the importance of function remains critical. Similarly with advances in genetics and genomics in recent years, the importance of these genes is assessed by functional assessments. Terms such as deep phenotyping reflect acknowledgement that physiological function remains crucial.

Chairing: A. Malhotra, MD, La Jolla, CA
T.S. Simonson, PhD, La Jolla, CA

9:00 Respiration Mechanics: Saving Lives for Nearly a Century
J.M. Drazen, MD, Boston, MA

9:10 Applied Physiology in Sleep Apnea and Control of Breathing
M.K. Younes, MD, PhD, Winnipeg, Canada

9:35 Unjamming and Cell Shape in the Asthmatic Airway Epithelium
J.J. Fredberg, PhD, Boston, MA

10:00 From Sepsis Mechanisms to the Origin of Bioelectronic Medicines
K.J. Tracey, MD, Manhasset, NY

10:25 Assessing Regional Lung Strain and Perfusion at the Bedside: The Future Is Now
M.B.P. Amato, MD, PhD, Sao Paulo, Brazil

10:50 Young Investigators Presentations

LATE BREAKING MINI SYMPOSIUM

B14 HIGH IMPACT LATE-BREAKING CLINICAL TRIALS
9:00 a.m. - 11:00 a.m. MOSCONET CENTER
Room 3010/3012 (West Building, Level 3)

Chairing: R. Kalhan, MD, MS, Chicago, IL
R.K. Albert, MD, Aurora, CO
M.T. Naughton, MBBS, MD, Prahran, Australia

Oral Presentations


9:15 Surgical and Large Bore Procedures in Malignant Pleural Mesothelioma and Radiotherapy Trial (SMART Trial) - An RCT Evaluating Whether Prophylactic Radiotherapy Reduces the Incidence of Procedure Tract Metastases/N.A. Maskell, A.O. Clive, Bristol, United Kingdom, p.A2863


9:45 Results of a Randomized Controlled Trial Testing if a Bedside Consult that Coordinates Outpatient Services and Adds Automated Follow-Up Helps Hospitalized Smokers Quit/R.A. Mularski, L.A. Waiwaiolo, M.C. Leo, M.C. Francisco, K. Funkhouser, J.L. Fellows, Portland, OR, p.A2865

10:00 Profound Antitussive Response to P2X3 Blockade with AF-219 Permits Correlation of Objective Measure of Cough with Improvement in Patient Reported Outcomes/J.A. Smith, M. Kitt, M. Sher, P. Butera, A.P. Ford, Manchester, United Kingdom, p.A2866


10:00 Inhaled Diesel Exhaust Alters Allergen-Induced Bronchial Secretome in Humans/N. Moorkherjee, P. Ezzati, V. Spicer, J.A. Hirota, C. Carlsten, Winnipeg, Canada, p.A2876


**MINI SYMPOSIUM**

**B16 CYSTIC FIBROSIS (CF) AND NON-CF BRONCHIECTASIS**

9:00 - 11:00 a.m. MOSCON CENTER Room 3016/3018 (West Building, Level 3)

**Chairing:** M.L. Metesky, MD, Farmington, CT

A. O’Donnell, MD, Washington, DC

**Oral Presentations**


9:45 SPLUNC1 Dysregulation in the Sputum of Stable Adult Cystic Fibrosis Subjects/C.J. Britto, N. Niu, E. Bruscia, C. Barone, M. Egan, L.E. Cohn, New Haven, CT, p.A2881

10:00 Anti-Pseudomonas Aeruginosa IgG Antibodies and Chronic Airway Infection in Non-Cystic Fibrosis Bronchiectasis/G. Suarez-Cuartin, O. Sibila, A. Smith, H. Abo-Leyah, A. Rodrigo-Troyano, S. Vidal, V. Plaza, T.C. Fardon, J.D. Chalmers, Barcelona, Spain, p.A2882


10:30 Gentamicin Induces the Formation and Alters the Composition of Gram Negative Rod Biofilms. This Process is Blocked by Erythromycin Co-Treatment/Y.E. Wang, N. Gonella, R. Devries, D. Witt, S. Prasad, Stanford, CA, p.A2884

MINI SYMPOSIUM

B17  TUBERCULOSIS: SUSCEPTIBILITY AND IMMUNE RESPONSE
9:00 a.m. - 11:00 a.m.  MOSCONE CENTER
Room 3020/3022 (West Building, Level 3)

Chairs: S. Schwander, MD, PhD, Piscataway, NJ
P.C. Karakousis, MD, Baltimore, MD
H. Koziel, MD, Boston, MA
R.N. van Zyl-Smit, MBChB, PhD, Cape Town, South Africa

Featured Speaker
9:00 Impact of Smoke on TB Pathogenesis/R.N. van Zyl-Smit, MBChB, PhD, Cape Town, South Africa

Oral Presentations
9:30 Histone H3K14 Hypoacetylation and H3K27 Hypermethylation Along with HDAC1 Up-Regulation and KDM6B Down-Regulation Are Associated with Active Pulmonary Tuberculosis Disease/Y.-C. Chen, M.-C. Lin, T.-Y. Chao, S.-Y. Leung, C.-C. Wu, W.-F. Fang, Kaohsiung, Taiwan, p.A2887

MINI SYMPOSIUM

B18  SYMPTOM ASSESSMENT: THE PRACTICAL REALITY
9:00 a.m. - 11:00 a.m.  MOSCONE CENTER
Room 307 (South Building, Esplanade Level)

Chairs: V.M. McDonald, PhD, RN, New Lambton Heights, Australia
M. Hodson, MSC, RN, London, United Kingdom

Oral Presentations
9:15 Use of Validated Dyspnea Scales Increases Nurses’ Confidence in Their Assessment and Treatment of Dyspnea in Palliative Care Patients/M. Yannacone, V. Carrieri-Kohlman, S. Barbour, San Francisco, CA, p.A2894
9:45 Patients with COPD Prioritise Symptoms Experience Differently to Respiratory Nurse Specialists/S. Prigmore, A. Caress, J. Yorke, Manchester, United Kingdom, p.A2896
10:00 Dyspnoea-12 Scores Reported “These Days” Are Greater than Those Reported “Today”: Differences in People with COPD, Asthma and ILD/A.-M. Russell, J.P. Stevens, K.N. Johnston, J. Yorke, M.T. Williams, London, United Kingdom, p.A2897

MINI SYMPOSIUM

B19  BEST OF PEDIATRICS
9:00 a.m. - 11:00 a.m.  MOSCONE CENTER
Room 3006/3008 (West Building, Level 3)

Chairs: M. Rosenfeld, MD, MPH, Seattle, WA
A.C. Koumbourlis, MD, MPH, Washington, DC
Oral Presentations

9:00 | Does Cardiopulmonary Fitness and Pulmonary Function Differ Between Age Matched Groups of Children with Primary Ciliary Dyskinesia (PCD) and Cystic Fibrosis (CF) During One Year?/A.M. Ring, K. Green, F.F. Buchvald, K.G. Nielsen, Copenhagen, Denmark, p.A2901


10:00 | Sex Associated Differences in Gene Expression in Neonates with BPD/D. Chhabra, C. Espinoza, J. Hagood, San Diego, CA, p.A2905


10:30 | Long-Term Respiratory Morbidity in Recipients of Pediatric Solid Organ Transplants: A Retrospective Review/M.F.A. Wright, M. Chilvers, T. Blydt-Hansen, Vancouver, Canada, p.A2907

Featured Speaker

10:45 | Accidental Career/A.C. Koumbourlis, MD, MPH, Washington, DC

B20 HOOKED ON PH'OMICS

9:00 a.m. - 11:00 a.m.

Room 3003/3005 (West Building, Level 3)

Chairing: C.E. Ventetuolo, MD, MS, Providence, RI
A.A. Desai, MD, Tucson, AZ
A.R. Hennes, MD, Nashville, TN

Oral Presentations


10:00 | Whole Exome Sequencing Reveals CES1 as a Novel Gene in Methamphetamine Induced Pulmonary Arterial Hypertension/V. De Jesus Perez, M. Orcholski, A. Krushudyan, K. Yuan, R.T. Zamanian, Palo Alto, CA, p.A2912


Featured Speaker

10:45 | More Data, More Problems/M.W. Geraci, MD, Indianapolis, IN

POSTER DISCUSSION SESSION

B21 GENETICS, GENOMICS, AND GENE EXPRESSION IN ASTHMA AND COPD

9:00 a.m. - 11:00 a.m.

Room 2024 (West Building, Level 2)

Chairing: D. Vercelli, MD, Tucson, AZ
C.P. Hersh, MD, MPH, Boston, MA
S. Sharma, MD, MPH, Aurora, CO

Poster Viewing 9:00-9:45
Discussion 9:45-11:00


Reduced Pulmonary Function Growth in Childhood Asthmatics

Polymorphisms of IL4RA and ADAM33, Risk Variants in Patients with Asthma Exacerbations with Type 2-Predominant Condition

Greater Urban Tree Canopy Exposure May Be Linked to Asthma and DNA Methylation of the IL4 Gene Promoter

The Effect of Smoke Exposure on Gene Expression: From Fetal Development to COPD

Genome Wide Association Study of Lung Function and Allergy Related Traits in Subjects with Asthma

Flow Cytometry to Generate Transcriptional Profiles from Individual Myeloid Populations Isolated from Human Lung Tissues

Where Next in Asthma Research? A Review of Current Understanding and Future to Prevent and Cure Asthma

Exome Array Analysis Identifies IL27 as a Susceptibility Locus for Chronic Obstructive Pulmonary Disease

Children with an Acute Respiratory Illness Infected with Human Rhinovirus (RV) Species C, that Have a CDHR3 rs6967330 A Allele, Are More Likely to Have a Recurrent Wheezing Hospital Presentation

DNA Co-Methylation Modules Associate with COPD in African Americans

The Role of Genes Identified in Genome-Wide Association Studies of Asthma Susceptibility in the Developmental Origin of Asthma

Genetic and Epigenetic Regulation of Myosin Light Chain Kinase by Inflammatory Lung Disease Associated Polymorphisms

Risk Factors Associated with Irreversible Airway Obstruction in Asthma: A Meta-Analysis and Systematic Review

Flow Cytometry to Generate Transcriptional Profiles from Individual Myeloid Populations Isolated from Human Lung Tissues

Where Next in Asthma Research? A Review of Current Understanding and Future to Prevent and Cure Asthma

Exome Array Analysis Identifies IL27 as a Susceptibility Locus for Chronic Obstructive Pulmonary Disease

Children with an Acute Respiratory Illness Infected with Human Rhinovirus (RV) Species C, that Have a CDHR3 rs6967330 A Allele, Are More Likely to Have a Recurrent Wheezing Hospital Presentation

Smoking-Associated Changes in DNA Methylation Are Widely Abolished by Vitamin C Supplementation to Pregnant Smokers


**POSTER DISCUSSION SESSION**

**B22 BURDEN OF PULMONARY AND CRITICAL CARE MEDICINE: COST AND UTILIZATION**

9:00 a.m. - 11:00 a.m. MOSCONE CENTER

Room 304 (South Building, Esplanade Level)

Poster Viewing

9:00-9:45

Discussion

9:45-11:00

Chairing: S.S. Carson, MD, Chapel Hill, NC

J.K. Gerald, MD, PhD, Tucson, AZ

M.P. Kerlin, MD, Philadelphia, PA

201 Healthcare Use and Costs Among Patients with Non-Cystic Fibrosis Bronchiectasis in the US/C.M. Blanchette, J.M. Noone, G. Stone, E. Zacherle, M.C. Runken, R. Howden, Charlotte, NC, p.A2939


208 Medical Service Utilization Among Australian Older Women with Asthma/P. Efftekhari, P.M. Forder, J.E. Byles, Callaghan, Australia, p.A2946


224 Intermediate Care Resource Utilization Among Patients Hospitalized with Pneumonia/A. Admon, H. Wunsch, T.J. Iwashyna, C.R. Cooke, Ann Arbor, MI, p.A2962

225 Patterns of Non-Invasive Home Ventilation Usage in the Province of Alberta, Canada: A Retrospective Population-Based Cohort Study/E.J. MacIntyre, K. Rimmer, C. Cyr, D.A. McKim, M. Heule, A. Massia, L. Rose, S.M. Bagshaw, Edmonton, Canada, p.A2963

POSTER DISCUSSION SESSION

B23 CARDIOVASCULAR AND RESPIRATORY INTERACTIONS IN COPD

9:00 a.m. - 11:00 a.m. MOSCONCE CENTER

Room 133 (North Building, Lower Level)

Poster Viewing

9:00-9:45

Discussion

9:45-11:00

Chairing:

R.G. Barr, MD, DrPH, New York, NY

M.J. Cuttica, MD, Chicago, IL

J.M. Wells, MD, Birmingham, AL


102 Tricuspid Annular Plane Systolic Excursion (TAPSE) as a Predictor of Long Term Survival in Hospitalized Patients with Chronic Obstructive Pulmonary Disease/M. Diamond, J. Barry, V. Lakhter, K. Shenoy, M. Keane, G.J. Criner, Philadelphia, PA, p.A2965


109 Effect of Nasal High Flow on Digital Vascular Tone During Sleep in COPD Patients/K. Friche, H. Schneider, L. Grote, Baltimore, MD, p.A2973


111 Pulmonary Hypertension in COPD from Exposure to Biomass Fuel/M. Gholamnejad, Y. Roosta, Urmia, Iran, p.A2975

112 Eligibility for the STATCOPE Trial: A Review of Statin Use in a Hospital-Based Cohort of COPD Patients/R. Young, C. Chen, R.J. Hopkins, G.D. Gamble, Auckland, New Zealand, p.A2975

113 Pulmonary Hypertension in COPD from Exposure to Biomass Fuel/M. Gholamnejad, Y. Roosta, Urmia, Iran, p.A2976

114 Evaluation of T Peak-T End Interval in Patients with Chronic Obstructive Pulmonary Disease (COPD)/G. Karadeniz, F. Ucsular, M. Demir, S. Bulac Kir, S. Doruk, Izmir, Turkey, p.A2977

115 Plasma von Willebrand Factor and Longitudinal Change in Pulmonary Hypertension in COPD from Exposure to Biomass Fuel/M. Gholamnejad, Y. Roosta, Urmia, Iran, p.A2976


117 Association of Chronic Obstructive Pulmonary Disease (COPD) and Diabetes Mellitus with Cardiovascular Diseases; and Review of Health-Care Associated Costs’ for COPD Patients from the Medical Expenditure Panel Survey (MEPS) Dataset/I.A. Lalani, L. Liu, Long Branch, NJ, p.A2980
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>118</td>
<td>Comparison of the Prognostic Impact of Chronic Versus Paroxysmal Atrial Fibrillation in Patients with Chronic Obstructive Pulmonary Disease</td>
<td>T. Tomioka, S. Miyata, K. Inoue, H. Shimokawa, Miyagi, Japan</td>
<td>p.A2981</td>
<td></td>
</tr>
<tr>
<td>119</td>
<td>Occult Cardiac Disease Can Be Identified by Dynamic 256-Slice CT During Chronic Obstructive Pulmonary Disease Exacerbation</td>
<td>M.I. MacDonald, A.-M. Wong, P. King, S. Lockwood, J. Troupis, P.G. Bardin, Melbourne, Australia</td>
<td>p.A2982</td>
<td></td>
</tr>
<tr>
<td>120</td>
<td>Higher Plasma Myostatin Levels in Cor Pulmonale Secondary to Chronic Obstructive Pulmonary Disease</td>
<td>C. Ju, J. Zhang, M. Chen, R. Chen, Guangzhou, China</td>
<td>p.A2983</td>
<td></td>
</tr>
<tr>
<td>123</td>
<td>The Early Effectiveness of Noninvasive Positive Pressure Ventilation on Right Ventricular Function in Chronic Obstructive Pulmonary Disease Patients with Acute Hypercapnic Respiratory Failure</td>
<td>H. Feiz Disfani, S. M.Lari, D. Attaran, V. Vakilian, M. Kamandi, Mashhad, Iran</td>
<td>p.A2986</td>
<td></td>
</tr>
<tr>
<td>124</td>
<td>Lung Function Impairment Linked to Coronary Atherosclerotic Lesions in Patients with Chronic Obstructive Pulmonary Disease - Data from COPDGene Study</td>
<td>D. Li, C. Tan, R.H. Casaburi, J.D. Crapo, E.K. Silverman, G. Washko, B.J. Make, D.A. Lynch, J. Hokanson, M.J. Budoff, Torrance, CA</td>
<td>p.A2987</td>
<td></td>
</tr>
</tbody>
</table>

**POSTER DISCUSSION SESSION**

**B24 OCCUPATIONAL MEDICINE**

9:00 a.m. - 11:00 a.m. MOSCONC CENTER

Room 2010/2012 (West Building, Level 2)

**Poster Viewing** 9:00-9:45

**Discussion** 9:45-11:00

Chairs: P.K. Henneberger, MPH, ScD, Morgantown, WV

N. Suganuma, MD, PhD, Kochi, Japan

K. Cummings, MD, MPH, Morgantown, WV

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
<th>Page</th>
</tr>
</thead>
</table>

415 Is the Cardiopulmonary Exercise Testing Better than Spirometry to Detect Early Ventilatory Changes Related to Occupational Exposure to Particulate Matter?IV.Z. Dourado, E.F. Sperandio, C.T. Ping, M. Romiti, A. Gagliardi, R. Arantes, Santos, Brazil, p.A3003


417 Exposure to High Endotoxin Concentration Increases Wheezing Prevalence Among Laboratory Animal Workers/E.O. Vianna, A.S. Freitas, C.S. Simoneti, E. Ferraz, M.C. Borges, Ribeirao Preto, Brazil, p.A3005


420 Comparing Plasma, Serum, and Whole Blood Indium Concentrations from Workers at an Indium-Tin Oxide (ITO) Production Facility/R.R. Harvey, M.A. Virji, N.T. Edwards, K. Cummings, Morgantown, WV, p.A3008

421 5-ASA Treatment in Chronic Beryllium Disease/L. Maier, B. Barkes, M. Gillespie, J. Elliott, G. Mondello, J. Huang, B. Day, Denver, CO, p.A3009

422 The Role of JAK2 in Chronic Beryllium Disease/L. Li, N. Hamzeh, M. Gillespie, G. Mondello, P.M. Mroz, L. Maier, Denver, CO, p.A3010


424 Development of Pulmonary Fibrosis Following Bromine Inhalation Injury/A. Lam, S. Aggarwal, M.A. Carlisle, N. Vetal, A. Agarwal, S. Matalon, Birmingham, AL, p.A3012


---

**POSTER DISCUSSION SESSION**

**B25 NON-TUBERCULOUS MYCOBACTERIA: EPIDEMIOLOGY, DIAGNOSIS, AND TREATMENT**

9:00 a.m. - 11:00 a.m. MOSCON Center

Room 3014 (West Building, Level 3)

Poster Viewing 9:00-9:45
Discussion 9:45-11:00

**Chairing:**

K.L. Winthrop, MD, MPH, Portland, OR
T.R. Aksamit, MD, Rochester, MN
C. Swenson, MD, Atlanta, GA

Epidemiology of Nontuberculous Mycobacterial Lung Disease in Hawai'i/J. Adjemian, T.B. Frankland, Y.G. Daida, J.R. Honda, K.N. Ollivier, A. Zelazny, S. Honda, D.R. Prevots, Bethesda, MD, p.A3013


Clinical Significance of Nontuberculous Mycobacteria Isolated from Respiratory Specimens in a Chinese Tuberculosis Tertiary Care Center/H. Duan, N. Chu, Beijing, China, p.A3016


The Usefulness of Radiological Severity Score in Patients with Mycobacterium Avium Complex Lung Disease/K. Fujuchi, A. Ito, T. Hashimoto, S. Kumagai, T. Ishida, Kurashiki, Okayama, Japan, p.A3023
912 Should Patients Aged 85 Years and Older Be Treated for Nontuberculous Mycobacterial Lung Disease?/B.A. Buchcic, T.T. Yamanaka, D.R. Fraidenburg, I. Rubinstein, Chicago, IL, p.A3024

913 Mycobacterium Avium Complex Disease Treated with Standard Treatment Combined with Amikacin and Clofazimine: A Retrospective Cohort Study/S. Kops, S. Zweijpfenning, J. Van Ingen, M. Boeree, S. Kuipers, W. Hoefsloot, C. Magis-Escurra, Nijmegen, Netherlands, p.A3025


POSTER DISCUSSION SESSION

B26 UPDATES IN PEDIATRIC LUNG INFECTIONS

9:00 a.m. - 11:00 a.m. MOSCONET CENTER

Room 3011 (West Building, Level 3)

Poster Viewing
9:00-9:45

Discussion
9:45-11:00

Chairing:
A. Colin, MD, Miami, FL
T. Moraes, MD, Toronto, Canada
O. Herrera, MD, Santiago, Chile


802 Cyclic AMP Activation Regulates Respiratory Syncytial Virus-Induced Airway Barrier Dysfunction and Viral Replication by Modulating Occludin/F. Rezaee, T.J. Harford, P.M. Brown, A. Belkadi, G. Piedimonte, Cleveland, OH, p.A3028


804 Real World Effectiveness of Palivizumab in Reducing Risk for Respiratory Illness for Otherwise Healthy Infants 29 to 36 Weeks Gestation/H.J. Farber, B. Lachman, F. Buckwold, E. Buck, M. Arun, J.S. Simpson, A.M. Valadez, Houston, TX, p.A3030


807 Metabolic Changes in Airway Epithelial Cells Following Human Metapneumovirus Infection/A. Casola, Y. Zhao, M. Sinha, R.P. Garofalo, Galveston, TX, p.A3033

808 Is Capnometry Helpful in Children with Bronchiolitis?/F. Hakim, R. Jacob, R. Brik, I. Shavit, L. Bentur, Haifa, Israel, p.A3034


813 Trp Channel Activation in Response to Hypertonic Saline Differs Between Human Pediatric Primary Bronchial Epithelial Cells and Airway Smooth Muscle Cells/T.J. Harford, P.M. Brown, F. Rezaee, G. Piedimonte, Cleveland, OH, p.A3039


818 Microbial Diversity and Abundance in Respiratory Disease and HIV in Children from Mozambique/A. Annamalay, P. James, M. Lanaspa, J. Bizzintino, S. Acacio, L. Madrid, M. Cox, Q. Bassat, M. Moffatt, P. Le Souef, W.O. Cookson, Subiaco, Australia, p.A3044

820 Experiences with the Finger Prick Method for Dried Blot Spot Analysis of Anti-Tuberculosis Drugs in Paraguayan Children/N.F. Martinez, C. Magis-Escurra, Asuncion, Paraguay, p.A3046


822 Factors that Negatively Affect the Prognosis of Community-Acquired Pneumonia in a Country with Limited Resources (Itigi - Tanzania)/N. Ullmann, S. Caggiano, M. Mkwambe, E. Verrillo, R. Cutrer, Rome, Italy, p.A3048


POSTER DISCUSSION SESSION

B27 HYPOXIA AND THE PULMONARY VASCULATURE: BREATHLESS IN SAN FRANCISCO

9:00 a.m. - 11:00 a.m. MOSCONE CENTER Room 3024 (West Building, Level 3)

Poster Viewing 9:00-9:45
Discussion 9:45-11:00

Chairing: L. Shimoda, PhD, Baltimore, MD
C. Guignabert, PhD, Le Plessis Robinson, France
C.M. Hart, MD, Atlanta, GA


1002 T Helper 17 Cells Contribute to Chronic Hypoxia-Induced Pulmonary Hypertension/L.D. Maston, D.T. Jones, J.L. Cannon, W. Wang, Y. Wei, W. Xuan, T.C. Resta, L. Gonzalez Bosc, Albuquerque, NM, p.A3053

1003 MicroRNA-1 Is Decreased by Hypoxia and Contributes to the Development of Sphingosine Kinase 1 (SphK1)/J.R. Sysol, J. Chen, S. Singla, V. Natarajan, R.F. Machado, Chicago, IL, p.A3054

1004 Deficiency of Toll-Like Receptor 3 (TLR3) Exacerbates Pulmonary Hypertension in Mice/A.A.R. Thompson, N.D. Arnold, A.T. Braithwaite, H.L. Casbolt, J.A. Pickworth, J.E. Cole, C. Monaco, D. Kiely, I. Sabroe, A. Lawrie, Sheffield, United Kingdom, p.A3055

1005 Transcriptomic Profiling of Lung Macrophage Subsets in Hypoxic Pulmonary Hypertension Reveals a Time and Compartment Specific Activation/S. Pugliese, W. Janssen, K. El Kasi, K.R. Stenmark, Aurora, CO, p.A3056


1008 The Effects of Chronic Cigarette Smoke Exposure on Cardiovascular Function in Mice/G. Vanderstocken, M.A. Allwood, M.R. Stampfl, J.A. Simpson, Hamilton, Canada, p.A3059


1011 Altered Interleukin-15 Signalling Complex and Lymphocyte Homeostasis in Hypoxic Pulmonary Hypertension/S. Jafri, S. Moore, N.W. Morrell, M.L. Ormiston, Cambridge, United Kingdom, p.A3062

1012 Maturation, Hypoxia, and α-Adrenergic Dependent Pulmonary Contractility in Sheep/D. Moretta, Loma Linda, CA, p.A3063

1013 The Role of the Mitochondrial Proteins p66shc and Cypophillin D in Hypoxic Pulmonary Vasconstriction and Chronic Hypoxia Induced Pulmonary Hypertension/M. Gierhardt, N. Sommer, O. Pak, A. Sydykov, K. Quanz, A. Esfandiary, H.A. Ghofrani, R.T. Schermuly, W. Seeger, R. Schulz, N. Weissmann, Giessen, Germany, p.A3064

1015 Resveratrol Can Improve Chronic Hypoxia Induced Pulmonary Hypertension Only in Absence of Sirtuin 1 Catalytic Activity/M. Taha, Y. Deng, M. McBurney, D.J. Stewart, Ottawa, Canada, p.A3066

1016 Endosomal Proteins p18 and Rab4 Are Differentially Regulated in Pulmonary Hypertension and COPD/Emphysema/H. Chichger, A. Vang, Q. Lu, G. Choudhary, E.O. Harrington, Cambridge, United Kingdom, p.A3067


1018 Plasma Levels of Angiopoietin-2 in COPD: Effects of Smoking and Pulmonary Hypertension/V.I. Peinado, J. Garcia-Lucio, T. Paul, O. Tura, I. Blanco, J.A. Barbera, Barcelona, Spain, p.A3069

1019 RASSF1A Regulates ROS-HIF Axis in Hypoxia Driven Pulmonary Hypertension/S. Dabral, C. Muecke, M. Schmoranzer, C. Valsarajan, A. Weitelmann, R. Savai, W. Seeger, R. Dammann, S.S. Pullamsetti, Bad Nauheim, Germany, p.A7808

1051 Human Bone Marrow Derived Mesenchymal Stem Cells and Their Released Microvesicles May Promote the Resolution of Acute Lung Injury in Mice Through Inhibition of Multidrug Resistance-Associated Protein 1/Q. Hao, V. Gudapati, A. Monsel, H. Lim, J.-W. Lee, San Francisco, CA, p.A3070

1052 Generation of Purified Human Type II Alveolar Cells from Gene-Edited Pluripotent Stem Cells/A. Jacob, F. Hawkins, K. Benson, M. Serra, D.N. Kotton, Boston, MA, p.A3071

1053 Mesenchymal Stem Cells Drive Cell Repopulation In an In Vivo Model of Lung Regeneration/J. Sembrat, C. Caufield, N. Cardenes, R.R. Vanderpool, M. Bennewitz, S. Snovida, P. Sundd, M. Rojas, Pittsburgh, PA, p.A3072

1054 The Role of BMP Signaling in Deriving Endothelial Cells from Human Pluripotent Stem Cells/M. Jamal, N. Ruopp, N. Prasain, J.C. Jean, E.D. Austin, S. Majka, M. Yoder, D.N. Kotton, Boston, MA, p.A3073


506 Bone Marrow Derived Human Mesenchymal Stem Cells Exposed to Pro-Inflammatory Cytokines Lose their Mesenchymal Marker Expression and Transform into Cells with Antigen Presenting Cell Gene Expression Patterns/M. Schwede, E.M. Wilfong, C.S. Calfee, M. Matthy, San Francisco, CA, p.A3075

507 Characterizing Embryonic Stem Cell Derived Multipotent Lung Stem Cells/A. Kidyoor, S. Murphy, A. Atala, Winston Salem, NC, p.A3076


510 Mesenchymal Stem Cells Attenuate Hypoxia-Induced Pulmonary Epithelial Injury Via an NF-κB Dependent Paracrine Mechanism/N. Shologu, D. O'Toole, M. Scully, J. Laffey, Galway, Ireland, p.A3079

511 Forkhead BOX F1 Is a Novel Regulator of Autotaxin and Modulates Migration of Human Lung-Resident Mesenchymal Stem Cells/P. Cao, N. Walker, S. Mazzoni, Y. Aoki, V. Lama, Ann Arbor, MI, p.A3080


517 Dependence of Lung Epithelial Stem Cell Proliferation and Differentiation on Fibroblast-Specific FGFR2 Signaling/M. Ozaki, A. Hegab, R. Guzy, D. Ornitz, T. Betsuyaku, Tokyo, Japan, p.A3086

518 Alveolar Epithelial Type II Cell-Specific Deletion of Foxo1 Results in Increased Stem/Progenitor Cell Proliferation In Vitro/Y. Yeragunta, D.R. Castillo, M. Rieger, J.M. Liebler, P. Flodby, B. Zhou, E.D. Crandall, Z. Borok, Los Angeles, CA, p.A3087
B30 MOLECULAR AND IMMUNOLOGICAL ASPECTS OF LUNG CANCER

9:00 a.m. - 11:00 a.m.  MOSCONET CENTER  Room 309 (South Building, Esplanade Level)

Author Summaries  9:00-9:30

Poster Viewing/Discussion  9:30-11:00

Chairing: C.A. Powell, MD, New York, NY


303 Highly Exhausted T Cell Subsets in Human NSCLC Are Co-Defined by the Predominant Expression of Distinct Inhibitory Receptors/W.A. Moersig, D.S. Thommen, F. Uhlenbrock, P. Herzig, S. Savic Prince, A. Zippelius, D. Lardinois, Basel, Switzerland, p.A3115


305 Characterizing the Role of Immune Cells in the FGF9-Induced Lung Adenocarcinoma Mouse Model/A.E.M. Hegab, T. Kinoshita, T. Yaguchi, Y. Kawakami, D. Ornitz, T. Betsuyaku, Tokyo, Japan, p.A3117

306 Cytotoxic T Lymphocyte Antigen 4 (CTLA4) in Non-Small Cell Lung Cancer/J. Li, H. Zhang, P. Dutta, N. Sabri, W.X. Li, La Jolla, CA, p.A3118

307 Impact Of Interleukin-22 On K-ras Mutant Lung Cancer Promotion And Stemness Properties/N. Khosravi, A.M. Cumpian, S. Daliri, M.S. Caetano, S.J. Moghaddam, Houston, TX, p.A3119

308 IL-17-Mediated Inflammation Promotes Cigarette Smoke-Induced Genomic Instability/C. Cao, H. Zhou, B. Tian, Z. Chen, W. Li, S. Ying, H. Shen, Hangzhou, China, p.A3120


315 Overexpression of Slug Drives Malignant Phenotypes in Models of Lung Premalignancy and Cancer/B.S. Grimes, T.C. Walser, R. Li, Z. Jing, L. Tran, S.M. Dubinett, Los Angeles, CA, p.A3127


317 Ciz1b Variant as a Surrogate Marker in Surveillance of Lung Cancer Recurrence/N. Iiachco, M. Risco, A. Ryazantsev, O. James, G. Rubiaco, K. Almodovar, D. Upadhyay, Fresno, CA, p.A3129

318 Long Non-Coding RNA FAM83H-AS1 Promotes Tumor Progression and Related to Disease Free Survival in Lung Adenocarcinomas/J. Zhang, Xi'an, China, p.A3130

319 MARCKS-Inhibitory Peptides Synergize with Cisplatin to Inhibit Metastasis and Primary Tumor Growth in Mouse Orthotopic Lung Cancer Models/Q. Yin, S. Fang, J. Park, A. Crews, I. Parkih, B. Dickson, K. Adler, Raleigh, NC, p.A3131


Arsenic Trioxide Inhibits Cancer Stem Cells Via Down-Regulation of Hedgehog Pathway in Lung Cancer/B. Li, M.-H. Yang, K.-J. Chang, Shanghai, China, p.A3134

Synergy Between Anti-MARCKS Peptides and Chemotherapeutic Agents in Attenuation of NSCLC Metastasis and Tumor Growth Could Be Based on MARCKS Cell Cycle Regulation/S. Fang, Q. Yin, J. Park, A. Crews, B. Dickson, K. Adler, Raleigh, NC, p.A3135


THEMATIC POSTER SESSION

B31 ALPHA-1 ANTITRYSIN DEFICIENCY

9:00 a.m. - 4:15 p.m. MOSCONCE CENTER

Area B, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion 11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: C.E. Cross, MD, Sacramento, CA

P135 The Clinical Associations of Aβ-Val360 in Alpha-1-Antitrypsin Deficiency/E.V. Low, P.R. Newby, R.G. Edgar, R.A. Stockley, A.M. Turner, Birmingham, United Kingdom, p.A3138


P137 PRMT6 Mediates Inflammation, Apoptosis and Oxidative Stress in a Cigarette Smoke Extract-Induced Mouse Emphysema Model/X. He, Y. Chen, N. Kang, T. Li, H. Zeng, Z. Chen, Changsha, Hunan, China, p.A3140


P139 Cela1 Promotes Postnatal Alveolar Enlargement and Its Expression and Binding to Elastin Is Regulated by Stretch/B. Varisco, S. Liu, R. Joshi, Cincinnati, OH, p.A3142


THEMATIC POSTER SESSION

B32 ALVEOLAR MACROPHAGE BIOLOGY

9:00 a.m. - 4:15 p.m. MOSCONCE CENTER

Area B, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion 11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: R. Vlahos, PhD, Bundoora, Australia


P148 Recruitment and Proliferation of Macrophage Polarization States During Allergic Lung Inflammation/C. Draijer, C.E. Boorsma, E. Post, F. Van Dijk, B.N. Melgert, Groningen, Netherlands, p.A3148

P149 Rac2 Promotes Alternative Macrophage Activation in Bleomycin Induced Pulmonary Fibrosis/S. Joshi, A. Singh, S. Wong, M. Zulicic, V. Craig, J. Hagoood, D. Durden, San Diego, CA, p.A3149


P151 Effect of Nintedanib on Pro-Fibrotic and Anti-Fibrotic Cytokine Release from Alveolar Macrophages in Interstitial Lung Diseases/F. Bonella, X. Long, X. He, D. Theegarten, T.E. Wessendorf, J. Guzman, U. Costabel, Essen, Germany, p.A3151

**Facilitator:** A.M. Manicone, MD, Seattle, WA

**P153** BRD9 Is a Novel Epigenetic Regulator for Human Alveolar Macrophages Polarization/Y. Morias, A. Schinwald, T. Naessens, H. Boyd, D. Cunoosamy, Molndal, Sweden, p.A3153

**P154** Induction of IL-17Rb and IL-25 in Human Monocytes and Macrophages Through the Action of Th2 Cytokine IL-4/N. Weathington, S.M. Kanth, J.S. Bednash, Q. Gong, R. Mallampalli, Pittsburgh, PA, p.A3154


**P156** Decellularized Wild Type and α-Galactosyltransferase Knockout Pig Lungs Stimulate M2 Macrophage in Human Monocyte/Macrophages/S. Wrenn, A. Coffey, F.E. Uhl, J. Bianchi, B. Dacken, T. Petersen, D.E. Wagner, J.E. Boyson, D.J. Weiss, Burlington, VT, p.A3156


**P159** Critical Role of the Class A Scavenger Receptor on Alveolar Macrophages in Chronic Obstructive Pulmonary Disease Airway Inflammation/R. Dong, L. Xie, M. Zhou, Shanghai, China, p.A3159

**Facilitator:** S. Sengupta, MD, MPH, Philadelphia, PA

**P160** Ethanol-Induced Oxidative Stress and Altered AMPK Signaling in Human Alveolar Macrophages/L. Kaphalia, B.S. Kaphalia, W.J. Calhoun, Galveston, TX, p.A3160

**P161** S-nitrosoglutathione Reductase (GSNR) Deficiency Impairs Macrophage Phenotypic Differentiation/C. Guo, J. Gow, M. Govendraj, A.J. Gow, Piscataway, NJ, p.A3161

**P162** Ursolic Acid Inhibits Cigarette Smoke-Induced Alveolar Macrophages Activity Injury Via ERK Signaling Pathway/Y. Yin, G. Hou, Q. Wang, E. Li, J. Kang, Shen Yang City, China, p.A3162

**P163** Increased Number of Macrophages in the Induced Sputum for Patients with Acute Myocardial Infarction/N. Kononova, G. Einvik, A. Hoiseth, A. Neukamm, T. Omland, V. Søyseth, Oslo, Norway, p.A3163

**THREATMENT POSTER SESSION**

**B33** ANTIOXIDANTS, VITAMINS AND RELATED PATHWAYS IN AIRWAYS DISEASE

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:00-11:45: authors will be present for individual discussion 11:45-12:45: authors will be present for discussion with assigned facilitators

**Facilitator:** J.S. Deshane, PhD, Birmingham, AL

**P164** Alveolar Macrophage-Mediated Efferocytosis in Alpha-1 Antitrypsin Deficiency/U. Parthasarathy, K. Krotova, M. Brantly, Gainesville, FL, p.A3164

THEMATIC POSTER SESSION

B34 CASE REPORTS IN IMMUNODEFICIENCIES AND ALLERGY
9:00 a.m. - 4:15 p.m.  MOSCONÉ CENTER
Area B, Hall D (North Building, Lower Level)

Facilitator:  N.A. Parada, MD, New Orleans, LA


P188 Intravenous Immunoglobulin as a Steroid-Sparing Agent to Treat Refractory Bronchiolitis Obliterans in a Patient Without Sinopulmonary Infections/C. Halpin, E. McGovern, J. Hoag, Philadelphia, PA, p.A3182

P189 To Steroid, or Not to Steroid: A Case Study Reviewing Controversial Corticosteroid Treatment in Levamisole-Induced Leukocytoclastic Vasculitis/K. Gupta, P. Aleksiejuk, A. Kalakonda, P. Kohlitz, Syracuse, NY, p.A3183

P190 Anaphylaxis to Vancomycin in Setting of IL-2 Induced Eosinophilia/D. Mann, M. Wong, B. Schneider, B. Modena, R. Sell, La Jolla, CA, p.A3184


P193 Rare Presentation of Selective Immunoglobulin M Deficiency in Patient with Recurrent Pneumonia/R. Hsiao, M. McCarra, T. Sharma, San Diego, CA, p.A3187


P195 Allergic Bronchopulmonary Aspergillosis Treated with Omalizumab/A. Reyes Esteves, L.A. Soto, H. Bhatti, Orlando, FL, p.A3189

P196 A Unique Presentation of DRESS/M. Yaqoob, A. Alkhateib, C. Nader, Brighton, MA, p.A3190

P197 A Case of Life Threatening Acute Isolated Uvular Edema/S. Eikermann, G. Shanmuganathan, R.R. Holmes, C. Bulathsinghala, Corpus Christi, TX, p.A3191


P199 A Rare Case of Angioedema/R. Chugh, L. Gross, K. Keshava, A. Majhoub, A.Y. Huang, Brooklyn, NY, p.A3193
P1049 Development and Implementation of a Program to Train Discussion:
9:00 a.m. - 4:15 p.m. MOSCONE CENTER
B35 INNOVATIONS IN MEDICAL EDUCATION
T.S. Wang, MD, Los Angeles, CA
Facilitator:

P1049 Development and Implementation of a Program to Train Critical Care Fellows in the Use of Point of Care Ultrasound in the Care of Critically Ill Patients/S.P. Keller, D.J. Wallace, C.K. Schott, Pittsburgh, PA, p.A3194


P1051 Feasibility and Effectiveness of a Hands on Critical Care Ultrasound Training Course for Pulmonary Critical Fellows/M. Nusrat, N. Pastis, T. Huggins, Charleston, SC, p.A3196


P1054 Using a Teaching Electronic Medical Record for Assessing Medicine Residents in the Care of Critically Ill Patients: A Pilot Study/J. Smith, W.G. Carlos, D. Litzelman, Madison, WI, p.A3199
Facilitator: G.R. Connors, MD, New Haven, CT


P1057 Knowledge in Mechanical Ventilation Among Internal Medicine Residents Before and After a Respiratory ICU Rotation/P.P.M.R. Ayres, A. Miethke-Morais, E.L.V. Costa, P. Caruso, C.S.V. Barbosa, C.R.R. Carvalho, J.C. Ferreira, Sao Paulo, Brazil, p.A3202


P1059 Nutrition in Critical Care: Addressing the Need for Training and Improving Quality in Education/L. Yuhico, M. Rath, R. Wehner, E. Mireles, Cleveland, OH, p.A3204
Facilitator: C.J. Schroedl, MD, Chicago, IL

P1060 Overcoming Time and Room Limitations During In-Situ Simulations in the Intensive Care Unit/J. Charnin, C. Arsenault, L. Mark, S. Muse, E. Eromo, Boston, MA, p.A3205

P1061 Using High Fidelity Simulation to Integrate Fellow and Nursing Education to Improve Team Based Learning and Performance in the ICU/J.A. Gold, R. Dottin, N. McCully, S.N. Nons, Portland, OR, p.A3206

P1062 The Effects of Structural Crew Resource Management (CRM)/Medical Team Work (MTW) Training in the ICU, the MTW Impact and Evaluation Study/P.A. Katinakis, P.E. Spronk, Apeldoorn, Netherlands, p.A3207


P1064 The Perceptions and Effects of Intern Duty Hour Changes in an Intensive Care Unit Rotation at a Community Teaching Hospital/S. Thapa, R.D. Chow, Baltimore, MD, p.A3209
Facilitator: J.W. McAllister, MD, Columbus, OH

P1065 Mobility in the ICU: A Fellowship Quality Improvement Educational Initiative/N. Esteghlali, A. Fea-Mulhearn, E. Jackson, Y. Negatu, A. Mahoney, D. Khabbaza, M. Exline, J. Kynyk, Columbus, OH, p.A3210


P1068 A Longitudinal Interprofessional Curriculum for Pediatric Critical Care Fellows Using Situated Cognition as a Theoretical Framework/D. Castro, K. Roy, E.A. Williams, J. Lawrence, T. Thomas, K. Abela, S. Thammasilboon, M.H. Tcharmtchi, Houston, TX, p.A3213


P1070 Building a Pediatric Pulmonary Nursing Curriculum for Thailand/S.S. Kun, Los Angeles, CA, p.A3215
Facilitator: P.H. Lenz, MD, MEd, Cincinnati, OH


P1074 Physiology “Flipped Classroom”/L.M. Sarzynski, E.D. Allen, Columbus, OH, p.A3219


P1079 The Study of Learning Curve of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration/Z.W. Chao, Shanghai, China, p.A3224


P239 Utilizing Once Daily Use of Tissue Plasminogen Activator (Tpa) and Deoxyribonuclease (Dnase) for Management of Intrapleural Sepsis/H.J. Mehta, A. Biswas, A.M. Penley, M. Jantz, Gainesville, FL, p.A3228


P244 Preliminary Cost-Effectiveness Analysis of Intrapleural Therapies for Pleural Infection from the MIST2 Randomised Controlled Trial/J.M. Wrightson, J.P. Corcoran, N.A. Maskell, I. Psallidas, N.M. Rahman, Oxford, United Kingdom, p.A3233

P245 Factors Affecting Success of Intrapleural Treatment Using Combination tPA and DNase for Pleural Infection/J.M. Wrightson, J.P. Corcoran, R. Hallifax, N.A. Maskell, I. Psallidas, N.M. Rahman, Oxford, United Kingdom, p.A3234


P247 Prevalence and Types of Radiographic Thoracic Manifestations in Patients with Primary Klebsiella Liver Abscess/A. Gupta, E. Yoo, O. Epelbaum, Queens, NY, p.A3236


P249 Intrapleural tPA 5mg (with DNase) Is an Effective Alternative to the Recommended tPA 10mg (with DNase) Dose for Treatment of Pleural Infection/N. Popowicz, O. Bintcliffe, F. Piccolo, D. Wong, A. Edey, N.A. Maskell, Y.C.G. Lee, Perth, Australia, p.A3238


Comparision of Cell Block and Cytology Techniques in Pleural Biopsy for Diagnosis of Unilateral Pleural Effusions: An Effective Approach

Flexible Thoracoscopy: Shining a Light on Pleural Effusions

Combination US-Guided Cutting-Needle Biopsy and Standard Pleural Biopsy for Diagnosis of Unilateral Pleural Effusions: An Effective Approach

Why Fibrinolysis Is Recommended in our Local Standards of Practice for Empyema Management

Retrospective Review of Patients Undergoing Talc Pleurodesis for Management of Symptomatic Pleural Effusions

Organizing and Promoting a Dedicated Pleural Service at an Academic Medical Center

Is a Dedicated Pleural Procedures List Justified Within a District General Hospital?

Flexible Thoracoscopy: Shining a Light on Pleural Effusions

A Prospective Assessment of the Clinical Utility of Intercostal Artery Identification in Pleural Intervention

Comparison of Cell Block and Cytology Techniques in Diagnosis of Malignant Pleural Effusion

Time to Reconsider Light’s Criteria for Pleural Effusion

Does Chest Tube Size Matter?: A Comparison with British Thoracic Society Pleural Disease Guidelines

A Speciality of Specialist Pleural Service: Eight Years' Experience in a Tertiary Hospital

The Epidemiology of Pneumothorax in England (1968-2011)

Prevalence of Sjogren’s Syndrome in Patients with Non-specific Pleuritis on Thoracoscopic Pleural Biopsies: A Retrospective Study

Intrapleural Target Therapies (Anti-VEGF and Anti-EGFR) Reduce Malignant Pleural Effusion and Morbidity in an Experimental Model

Feasibility of Early Postoperative Pleurodesis in the Treatment of Air Leak After Lobectomy

Thrombin Correlates with Inflammation and Fibrosis in Infectious Pleural Effusions

Comparison of Pleural Investigation on a Specialist Vs. Non-Specialist Ward

Reducing Tube Thoracostomy Associated Complications in a Tertiary Hospital

Post-Pneumonectomy Empyemas: Microbiology, Management and Prognosis

Intrapleural Target Therapies (Anti-VEGF and Anti-EGFR) Reduce Malignant Pleural Effusion and Morbidity in an Experimental Model

Intraoperative and Postoperative Management of Empyema

Expanding the Indications for Pleural Catheter Use

The SEAL-MPE Trial: A Phase I Safety Evaluation of a Novel Drug Coated Indwelling Pleural Catheter


P378  A Not so Fine Needle Aspiration/J.D. Johnson, J. Lubawski, R. Hargrove, A. Goyal, Maywood, IL, p.A3267

P379  Mediastinitis Complicating Endobronchial Ultrasound Guided Biopsy of Subcarinal Melanoma/J.L.-Y. Wong, L. Bashoura, C. Jimenez, R. Miller, Houston, TX, p.A3268


Facilitator:  C.T. Phan, DO, Chicago, IL


P382  Severe Bilateral Airway Ischemic Necrosis in a Lung Transplant Patient Treated with Sequential Balloon Dilation/H. Inaty, A.H. Alraiyes, A. Kumar, M. Machuzak, Cleveland, OH, p.A3271


P390  A Rare Case of Massive Hemoptysis Due to Pulmonary Artery Aneurysm/K.L. Niehaus, R. Balestra, T. Srirprasad, A. Aragaki-Nakahodo, S. Benzaquen, Cincinnati, OH, p.A3279

Facilitator:  N.A. Ninan, MD, New Orleans, LA


P393  Tracheal Stenosis as a Complication from Transtracheal Oxygen Therapy/G. Pierson, C. Shapiro, Pueblo, CO, p.A3282


P395  All that Glitters Is Not Gold/A.D. Schenone, B.A. Reichardt, V. Kanchustambham, D. Stoeckel, N. Poddar, St. Louis, MO, p.A3284


P397  Thumbtack Aspiration: A Unique Bronchoscopic Challenge/S.W. Copeland, M. Sigler, R. Alalawi, Lubbock, TX, p.A3286

P398  Subconjunctival Hemorrhage, an Unusual Complication of Flexible Bronchoscopy/T. Abdo, A.C. Porter, Oklahoma City, OK, p.A3287

P399  Pneumothorax and Subcutaneous Emphysema in the Setting of Malignant Effusion and Tunneled Pleural Catheter/M. Senitko, J.T. Puchalski, K.T. Bramley, New Haven, CT, p.A3288


Facilitator:  K. Mahmood, MD, Durham, NC

P401  A Piece of Broken Metal from Intubation Stylet Retained in Tracheobronchial Tree: A Case Report and a Brief Review of the Literature/M. Fathi, B. Farzanegan, Tehran, Iran, p.A3290


P403  A Lost Lobe: A Case of Large Endobronchial Hamartoma/ C. Ghattas, A. Andoh-Duku, M. Hundal, S. Rafeq, Boston, MA, p.A3292

P404  Blame It on the Dog: A Rare Case of Disseminated Blastomycosis Diagnosed Via Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (EBUS-TBNA)/C.X. Giovacchini, K. Mahmood, Durham, NC, p.A3293

B38  PLEURAL DISEASE: CASE REPORTS

9:00 a.m. - 4:15 p.m.  MOSCONET CENTE

Area C, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion 11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator:  F. Maldonado, MD, Nashville, TN

P273  Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Chylothorax Due to Portal Hypertension/R.E. Cagnina, K.B. Enfield, Charlottesville, VA, p.A3310


P275  Malignancy Unmasked - A Rare Primary Pleural Angiosarcoma Presenting as a Complex Empyema/D. Terrington, R. Tabbara, A. Craig-McQuaide, A. Aya, King’s Lynn, United Kingdom, p.A3312


P278  Pleural Extramedullary Hematopoiesis: A Rare Cause of Bloody Pleural Effusion/D.J. Pepper, E. Delbecq, O. Ioffe, C. Enfield, Charlottesville, VA, p.A3310


Facilitator:  J.A. Akulian, MD, MPH, Chapel Hill, NC


P284  Acquired Hydrothorax After a Laparoscopic Surgery in a Patient on Peritoneal Dialysis/M. Buni, Houston, TX, p.A3321
P285  A Rare Case of Pleural Effusion in a 92-Year-Old Man/ S.M. Kanth, E.S. Baker, A.L. Van Dyke, M. Donahoe, Pittsburgh, PA, p.A3322

P286  Unusual Cause of Left Neck Swelling and Right Pleural Effusion/M. Senitko, J.T. Puchalski, New Haven, CT, p.A3323

P287  Sirotimus for Management of Spontaneous Chylothorax/K. Walker, C. Fanta, Boston, MA, p.A3324


P290  Bilateral Chylothorax as Initial Presentation of Chronic Lymphocytic Leukemia (CLL)/A. Abu Homoud, G. Al-Saoudi, M. El Sawaf, E. Costanzo, Neptune City, NJ, p.A3327


P292  Spontaneous Pneumohemothorax: An Unusual Presentation of Acute Lymphoblastic Leukemia (ALL)/A. Esguerra, P. Diaz, Columbus, OH, p.A3330


P294  Pleural Nodularity in a Vietnam Veteran/J.C. Mallen, L. Morrow, N. Dewan, Omaha, NE, p.A3331


P298  Unilateral Obstructive Urinothorax Secondary to Invasive Vaginal Squamous Cell Carcinoma/A. Abou Yassine, W. Mansour, B. Kfouri, M. Chalhoub, Staten Island, NY, p.A3335

P299  Pleural Hemorrhage Secondary to Intrapleural Alelfastase for Treatment of Loculated Empyema in a Patient on Therapeutic Anticoagulation/A.A. Ahmed, G. Huss, I.G. Berim, Omaha, NE, p.A3336


P306  Chylothorax: The Milky Truth of Cirrhosis/J. Lau, A. Usmani, Chicago, IL, p.A3343


P309  Kaposiform Lymphangiomatosis: An Unforeseen Case of Spontaneous Hemothorax and Episodic Hemoptysis/A.J. Sweatt, K. Regalia, Stanford, CA, p.A3346


P311  Pneumothorax, a Rare but Serious Complication of Acupuncture Therapy/T. Abdo, V.H. Kha, H. Bhardwaj, H. Youness, Oklahoma City, OK, p.A3348

P312  Foreign Body with Secondary Empyema/J.A. Williams, F. Lhote, Swansea, United Kingdom, p.A3349

P313  Pleural Based Masses in a Man with Occupational Exposure: A Case of Pseudomesotheliomatous Carcinoma/V.B. Nannaka, M. Adrish, Bronx, NY, p.A3350

P314  Iatrogenic Blithorax and Gall Bladder Perforation Secondary to Abdominal Liposuction/A. Husari, N. El Kara, Beirut, Lebanon, p.A3351


P317  Successful Factor XII Treatment of Pneumothorax in Tuberous Sclerosis/K.B. Sreter, B. Barisic, Zagreb, Croatia, p.A3354

P318  Warfarin, Hemothorax and Thrombolytics/S.J.A. Naqvi, K.S. Allen, Oklahoma City, OK, p.A3355

B39 INTERVENTIONAL PULMONARY MEDICINE: RECENT ADVANCES

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: F.J. Herth, MD, Heidelberg, Germany


P424 Error Introduced into a Virtual Airway Map Created from an Inspiratory Planning CT Scan for Electromagnetic Navigational Bronchoscopy Performed During Tidal Breathing/B.S. Furukawa, G.A. Silvestri, N. Pastis, Charleston, SC, p.A3361


P427 Indications, Results and Complications of Flexible Bronchoscopy in the Intensive Care Unit of Fundacion Valle del Lili, a University Hospital of Reference in Latin America/L. Fernandez, C.A. Munoz, L.F. Sua, M. Granados, Cali, Colombia, p.A3364

P428 Therapeutic Bronchoscopy in the Management of Central Airway Obstruction: Experience in Fundacion Valle del Lili, a University Hospital of Reference in Latin America/L. Fernandez, M. Velasquez, L.F. Sua, Cali, Colombia, p.A3365


P430 The Efficacy of Bronchial Artery Embolization for Repeated Hemoptysis: A Retrospective Cohort Study/T. Niwa, C. Komaki, T. Mori, Hashima-gun, Japan, p.A3368

Facilitator: K.L. Kovitz, MD, MBA, Chicago, IL


P433 Bronchial Thermoplasty in Asthmatic Patients with Severe Fixed Airflow Obstruction: Safety and Following for One Year/ T. Aguirre Perez, J.L. Miguel Reyes, E. Lopez Estrada, S. Cid Juarez, C. Ortega, M.A. Iniguez, E. Dante, Distrito Federal, Mexico, p.A3371


P435 The Use of Brachytherapy for the Treatment of Airway Obstruction/C. Parks, R. Bechera, S. Cavenaugh, Newman, GA, p.A3373


P438 Initial Experience with Use of High Flow Nasal Cannula (HFNC) During Diagnostic and Therapeutic Bronchoscopy/W. He, T.J. Harkin, New York City, NY, p.A3376


Facilitator: C.L. Channick, MD, Boston, MA


P443 Outcomes of Tracheobronchial Stenting in Benign Airway Disease/L. Frye, F. Almeida, T. Gildea, Cleveland, OH, p.A3381


P446 Investigating the Complication Rates of Rapid Bronchoscopy and Large Airways Intervention/L.E. Loewenthal, E.J. Shaw, B.P. Madden, London, United Kingdom, p.A3384


Facilitator: D.W. Hsia, MD, Torrance, CA


P454 Six Month Experience of Endobronchial Ultrasound Sampling (EBUS) in a Large Tertiary Centre in the United Kingdom (UK)/C. Dong, R.A. Mustafa, Middlesbrough, United Kingdom, p.A3392

P455 Semi-Automated Assessment of Fissure Integrity and Shape and Volume Reduction After One-Way Valve Treatment/H.G. De Oliveira, R. Rambo, S.M. De Oliveira, A.V. De Macedo Neto, Porto Alegre, Brazil, p.A3393

P456 New EBUS Bronchoscopy Programs: Predicting Procedure Volume/B.P. Young, F. Almeida, Cleveland, OH, p.A3394


Facilitator: K. Van Nostrand, MD, Atlanta, GA


P463 Evaluation of Appropriate Staging Among EBUS Bronchoscopists/R. Miller, L. Mudambi, M. Hernandez, G. Eapen, Houston, TX, p.A3401

P464 Recurrent Respiratory Papillomatosis Involving the Lower Airways Treated with Argon Plasma Coagulation and Cidofovir Intralesional Injection/S. Umekawa, R. Horie, S.J. Evans, Honolulu, HI, p.A3402


**THEMATIC POSTER SESSION**

**B40  DYSPNEA: CASE REPORTS**

9:00 a.m. - 4:15 p.m.  MOSCONE CENTER

**Area C, Hall D (North Building, Lower Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:00-11:45: authors will be present for individual discussion 11:45-12:45: authors will be present for discussion with assigned facilitators

**Facilitator:** A.F. Dimmock, BA, Hersey, PA

**P323**  An Isolated Extramedullary Plasmacytoma of the Trachea Presenting as Progressive Dyspnea on Exertion/D. Kruse, K. Trujillo, C. Huebert, Omaha, NE, p.A3405


**P328**  Diaphragm Paralysis After Atrial Fibrillation Ablation/D. Chandra, M. Quast, A.B. Thompson, Omaha, NE, p.A3410


**P331**  Do Not Count Out the Importance of a Tracheal Bronchus/M. Chang, G.W. Soo Hoo, Los Angeles, CA, p.A3429

**P332**  An Elderly Man with Shortness of Breath: A Case of Primary Pulmonary Amyloidosis/M. Forte, J.A. Stienecker, J. Gordon, Pueblo, CO, p.A3423

**P333**  Post Radiofrequency Ablation Dyspnea: An Unusual Cause of Dyspnea/M.R. Chang, G.W. Soo Hoo, Los Angeles, CA, p.A3426


**P335**  Do Not Count Out the Importance of a Tracheal Bronchus/D. Chandra, M. Quast, A.B. Thompson, Omaha, NE, p.A3429

**P336**  A Rare Case of Pulmonary Sequestration Presenting with Post Prandial Epigastric Pain/R. Gupta, A. Kim, P. Bellund, Brooklyn, NY, p.A3430

**P337**  Improvement of the Pulmonary Function After Weight Gain in a Patient with Anorexia Nervosa/R. Gupta, A. Kim, P. Bellund, Brooklyn, NY, p.A3430

**P338**  Mounier-Kuhn Syndrome: An Unusual Cause of Dyspnea/N. Tipirneni, N. Safaie, A. Chandra, M. Quast, A.B. Thompson, Omaha, NE, p.A3430

**P339**  Diffuse Scarring Pulmonary Sequestration Presenting as Progressive Dyspnea on Exertion/D. Kruse, K. Trujillo, C. Huebert, Omaha, NE, p.A3405


**P341**  Spirometry as the First Clue of Achalasia Causing Upper Airway Obstruction in a World Trade Center Disaster Responder/G.S. Schneider, G.S. Skloot, New York, NY, p.A3413

**P342**  For a Fork in the Road: Assessment of Multiple Competing Etiologies for Hypercapnia/J.S. Mendelson, R.M. Goldring, K.I. Berger, New York, NY, p.A3414

**P343**  Dangers of Flying High and Diving Low! An Unusual Case of Dyspnea/P. Ramadas, P. Krishnan, R. Chakravarty, A. Nadkarni, Syracuse, NY, p.A3415

**P344**  Segmental Airway Collapse Associated with Dyspnea and Localized Wheezing/C. McLaughlin, D. Forbes, A. Skabelund, M.J. Morris, Fort Sam Houston, TX, p.A3416

**P345**  Rare Case of ANCA Vasculitis with Alveolar Hemorrhage in Non-Hodgkin Lymphoma/A. Surana, R. Bansal, Upland, PA, p.A3417

**P346**  Treatment of Acute Dyspnea with Morphine to Avert Respiratory Failure/A. Rose, R.M. Schwartzstein, Boston, MA, p.A3418

**P347**  Unexplained Dyspnea in a Non-Smoker: Think Outside the Box/N. Tipirneni, N. Safaie, A. Chandra, M. Quast, A.B. Thompson, Omaha, NE, p.A3419

**Facilitator:** K.F. Gibson, MD, Pittsburgh, PA

**ATS 2016 • San Francisco**
**P515** Impact of Posaconazol Liquid vs. Tablet Formulation on Lung Transplantation in Scleroderma-Related Lung Disease: A Discussion:

**P356** Delayed Negative Pressure Edema in a Young Athletic Man/Y. Habtegebriel, J. Nfonoyim, A. Mehari, Staten Island, NY, p.A3438

**P357** A Case of Cryptogenic Hypoxia/C. Colaco, B. Colaco, K. Ayoub, N. Meena, T. Barter, R. Jagana, Little Rock, AR, p.A3439

**P358** A Curious Case of the Misbehaving Pancreatic-Pleural Fistula/M. Ignaszewski, R. Asterita, P. Kohlitz, Syracuse, NY, p.A3440

**P359** “Making the ‘Connection’: A Case of Abnormal Connective Tissue”/K. Mahan, M. Prekker, Minneapolis, MN, p.A3441

**P360** Are All Left Sided Pleural Effusions Caused by Congestive Heart Failure?/R. Arancibia, K. Chokshi, S. Kumanovsky, P. Krishnan, Brooklyn, NY, p.A3442

**P361** Giant Thoracic Meningoceles Causing Respiratory Failure in a Patient with Neurofibromatosis I/ L.M. Sanso, A. Sanders, K. Gudi, K. Rajwani, New York, NY, p.A3443

**P362** An “Ancient” Cause of an Anterior Mediastinal Mass/M. Stefanski, N. Rassaei, Hershey, PA, p.A3444


**P365** Cosmetic Gluteal Silicone Injection as a Cause of Unexplained Diffuse Alveolar Hemorrhage and Respiratory Failure/M. Holub, A. Berman, Newark, NJ, p.A3447

**P516** Donor Lung-Derived T Cells Differentiate into IL-17A-Producing T Cells After Lung Transplant into Lymphodeplete Recipients/Q. Wu, P. Gupta, S. Wagner, R.A. Shilling, Chicago, IL, p.A3451


**Facilitator:** A. Bharat, MD, Chicago, IL


**P526** A Clinico-Pathologic and Radiologic Correlation Study of Extracorporeal Membrane Oxygenation Associated Acute Lung Injury Among Patients with Advanced Lung Disease/E. Batchelor, M. Mohanka, S. Bollineni, V. Kaza, F. Torres, J. Mullins, M. Wait, J. Bland, D. Douglass, A. Banga, Dallas, TX, p.A3461


P529 Mechanism of Death and Relationship to Systemic and Airway Inflammation in Brain Dead Organ Donors/E.M. Lowery, M. Yong, S. Killethermes, E.J. Kovacs, Maywood, IL, p.A3464

Facilitator: P.M. Shah, MD, Baltimore, MD

P530 Inhibition of Connective Tissue Growth Factor Promotes Healthy Revascularization and Ameliorates Fibrosis in Orthotopic Tracheal Transplantation/Y.-C. Lin, X. Jiang, M. Nicolls, Palo Alto, CA, p.A3465


Facilitator: R.J. Shah, MD, MSCE, San Francisco, CA


P539 Recurrent Shock in Fresh Lung Transplant Patient: History Solves the Mystery/T. Thaniyavarn, Atlanta, GA, p.A3474


P544 A Case of Tacrolimus Associated Posterior Reversible Encephalopathy Syndrome (PRES) with Hemorrhage - A Rare but Major Complication in Post Lung Transplant Patients/K. Bagavathy, S. Ganesh, Los Angeles, CA, p.A3479


THEMATIC POSTER SESSION

B42 COPD: BIOMARKERS

9:00 a.m. - 4:15 p.m. MOSCONIC CENTER

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: V.M. Pinto-Plata, MD, Boston, MA


P900 Increased MMP-12 and Decreased Surfactant Protein A in the Airways of Individuals with COPD - Report from a Bronchoscopy Investigation Based on the Obstructive Lung Disease in Northern Sweden (OLIN) Studies/A.F. Behndig, R. Linder, J. Pourazar, A. Lindberg, A. Blomberg, Umea, Sweden, p.A3485
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>P901</td>
<td>Lactate Is a Routinely Available Biomarker in COPD</td>
<td>MacDonald, K., Polkinghorne, I., Laska, M., Qiu, A., Barberi, C., MacDonald, P., King, P.G., Baird, Melbourne, Australia, p.A3486</td>
</tr>
<tr>
<td>P905</td>
<td>Blood Inflammatory Patterns in Chronic Obstructive Pulmonary Disease: Relationship with Clinical Phenotypes/S. Nayci, E.S. Ozgur, C. Ozge, Mersin, Turkey, p.A3490</td>
<td></td>
</tr>
<tr>
<td>P907</td>
<td>Urinary Desmosines Are Associated with Emphysema Severity in Patients with Chronic Obstructive Pulmonary Disease/C. Kim, Y. Ko, Y.B. Park, Jeju-si, Korea, Republic of, p.A3492</td>
<td></td>
</tr>
<tr>
<td>P908</td>
<td>Elevated Circulating PAI-1 Levels Are Related to Disease Severity, Systematic Inflammation and Small Airway Obstruction in Chronic Obstructive Pulmonary Disease/H. Wang, T., Yang, T., Wang, F., Wen, Chengdu, China, p.A3493</td>
<td></td>
</tr>
<tr>
<td>P911</td>
<td>The Association Between Vitamin D and COPD Risk, Severity and Exacerbation: A Systematic Review and Meta-Analysis Update/M. Zhu, Y. Ji, Chengdu, China, p.A3496</td>
<td></td>
</tr>
<tr>
<td>P914</td>
<td>The Relationship Between Pulmonary Function, HRCT Image, Pulmonary Arterial Pressure and Urine Desmosine of COPD Patients/M. Kato, Kishiwada, Osaka, Japan, p.A3499</td>
<td></td>
</tr>
<tr>
<td>P916</td>
<td>Vitamin D Levels in Patients of COPD and Its Relation with FEV1/FVC/V. Chopra, P., Kaur, H., Jain, V., Bamrah, K. N., Patilaia, India, p.A3501</td>
<td></td>
</tr>
<tr>
<td>P921</td>
<td>Systemic Inflammation and Decline in Lung Function in Older People: A Prospective Nationally-Representative from the English Longitudinal Study of Ageing from 2004-2013/A.M. Yohannes, G., Tampubolon, Manchester, United Kingdom, p.A3506</td>
<td></td>
</tr>
<tr>
<td>P922</td>
<td>The Comparison of Proteases and Antiproteases in Neutrophilic Asthma and Chronic Obstructive Pulmonary Disease (COPD)/L. Jing, Z., Shi, C., Hua-ping, Y., Xu, D., Li-ping, W., Chang-zechong, Chongqing, China, p.A3507</td>
<td></td>
</tr>
<tr>
<td>P923</td>
<td>The Ideal Biomarker to Predict COPD Exacerbations/Z. Zafari, D.D. Sin, S., Bryan, M., Sadatsafavi, Vancouver, Canada, p.A3508</td>
<td></td>
</tr>
</tbody>
</table>
P925 Cluster Analysis of Chronic Obstructive Pulmonary Disease (COPD) Related Phenotypes in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS/)


P929 Macrophage Phenotype Changes Within the Small Airway Wall in Smokers and Chronic Obstructive Pulmonary Disease (COPD)/S.S. Sohal, K.D. McLindden, S. Weston, M.Q. Mahmood, M.S. Eapen, E.H. Walters, Launceston, Australia, p.A3513


P933 Angiotensin Converting Enzyme (ACE) Gene Polymorphism Is Associated with Chronic Obstructive Pulmonary Disease (COPD), and Pulmonary Hypertension in Patients with COPD/Y. Ma, H. Fan, X. Tong, Chengdu, China, p.A3517

Facilitator: C.E. Come, MD, Boston, MA


P937 Gender Phenotyping of COPD Patients Using Complex Network Analysis/S. Mihaicuta, M. Uderescu, Timisoara, Romania, p.A3521

P938 Exploratory Study of Clinical Phenotype of Airways Disease by Two-Step Cluster Analysis/Y. Guo, P. Ning, T. Sun, Beijing, China, p.A3522

P939 The Frequent Exacerbator Phenotype of Chronic Obstructive Pulmonary Disease and Lipid Metabolism/J. Liuqun, L. Qi, C. Zhe, Zhengzhou, China, p.A3523

P940 Analysis of Severity Staging of Chronic Bronchitis Reveals Frequent Instability of Diagnosis/A. Sood, H. Petersen, C. Qualls, P.M. Meek, R. Vaszquez-Guillemet, B.R. Celli, Y. Tesfaigzi, Albuquerque, NM, p.A3524


P942 Factors Associated with COPD Mortality, 2 Year Follow-Up Data from the ARCADE Study/N. Gale, A. Albarrati, M. Munnery, R. Tal-Singer, J. Cockcroft, D. Shale, Cardiff, United Kingdom, p.A3526

Facilitator: A. Lambert, MD, MHS, Baltimore, MD


P944 Association Between the Presence of Objective Evidence of COPD on the Presentation and Outcome of Patients Hospitalized with COPD Exacerbation/C.Y. Pu, R. Nunez, K. Aryal, A. Tulaimat, N. Quesada, Chicago, IL, p.A3528

P945 Airway Microbiome Dynamics in Chronic Obstructive Pulmonary Disease Patients with Acute Exacerbation and Respiratory Failure and Its Association with Weaning Outcomes- A Preliminary Report/W.-C. Huang, H.-C. Chen, S.-Y. Liu, C.-C. Huang, Taichung, Taiwan, p.A3529

MONDAY • MAY 16

P947 The Relationship Among Pulmonary Function, Exacerbation and ICU Admission Rate and Pulmonary Artery Enlargement in Patients with Advanced Chronic Obstructive Pulmonary Disease/A. Sadigov, I. Isayev, A. Bagirzadeh, Baku, Azerbaijan, p.A3531

P948 Longitudinal Changes in FEV1, Hyperinflation, and 6-Minute Walk Distance in Patients with COPD Associated with Non-Cystic Fibrosis Bronchiectasis/A. Sadigov, K. Bakhshaliyeva, S. Guliyeva, Baku, Azerbaijan, p.A3532


Facilitator: A.P. Cornellas, MD, Iowa City, IA


P953 Health Related Quality of Life in Indian Patients of Chronic Obstructive Pulmonary Disease/D.P. Bhadoria, V.P. Ghilley, L. Kumar, T. Raghuvanshi, P. Bhadoria, New Delhi, India, p.A3537


P956 The Development and Application of a Number-Axis System for Diagnosis, Treatment and Prediction of Outcome on Bronchial Asthma, Chronic Obstructive Pulmonary Disease (COPD) and Overlap Syndrome/J.-Z. Cao, H.-W. Lin, Tianjin, China, p.A3540


P959 Mild COPD Patients with a High Symptom Load: A Subgroup Analysis from the DACCORD Registry/P. Kardos, R. Buhl, C.-P. Criece, C. Vogelmeier, N. Lossi, C. Mailaender, H. Worth, Frankfurt, Germany, p.A3543

P960 Ten Years’ Mortality Data of Patients with Chronic Obstructive Pulmonary Disease from the Hokkaido COPD Cohort Study/H. Makita, M. Suzuki, S. Konno, K. Shimizu, Y.M. Ito, M. Nishimura, Sapporo, Japan, p.A3544

Facilitator: A.A. Diaz, MD, Boston, MA

P961 Adverse Events Among COPD Patients Treated with Long-Acting Anticholinergics and p2-Agonists in an Outpatient Respiratory Clinic/C. Rodrigue, M.-F. Beauchesne, F. Savaria, A. Forget, C. Lemiere, P. Larivee, L. Blais, Montreal, Canada, p.A3545

P962 Chronic Obstructive Pulmonary Disease (COPD) and Pneumonia (PN) Related Risk Variables and Ultimate Mortality Outcome/J.B. Glaser, D. Pau, N.K. Mobarakai, M. Castellano, Staten Island, NY, p.A3546

P963 BODEx Index and Multidimensional Evaluation of COPD Patients at the Altitude of Bogota [2640 m]/C.A. Celsi Preciado, A. Canas-Arboleda, J. Lasso, C. Villaquiran-Torres, J.R. Lutz, Bogota, Colombia, p.A3547

P964 Sedation and Physiological Response to Intranasal Dexmedetomidine (IN-DEX) in Patients with Severe Chronic Obstructive Pulmonary Disease (COPD)/J.C. Rojas-Gomez, P. Nystrom, Dayton, OH, p.A3548


P968 Association of Respiratory Muscle Weakness with Cardiac Autonomic Modulation in Patients with Chronic Obstructive Pulmonary Disease/R. Trimer, C.L. Goulart, J.C. Simon, N.A. Da Fonseca Miranda, P.D.B. Schneider, E.A. San Martin, A. Borghi-Silva, A.L.G. Da Silva, Sao Carlos, Brazil, p.A3552


P970 Efficiency of Neural Respiratory Drive for the Assessment of Bronchodilator Responsiveness in Patients with Chronic Obstructive Pulmonary Disease: An Exploratory Study/Y. Chen, Y. Li, Y.-H. Li, Y.-W. Luo, K. Wang, Y.-T. Chen, Guangzhou, China, p.A7817
COPD: COMORBIDITIES

9:00 a.m. - 4:15 p.m. MOSCONET CENTER

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: J.M. Bon, MD, MS, Pittsburgh, PA


P979 Relationship of HMG CoA Reductase Inhibitors and Pulmonary Function in Individuals with HIV/M. McCaughlin, M. Nouraei, N. Leo, C. Kessinger, M.E. Fitzpatrick, A. Morris, Pittsburgh, PA, p.A3560

P980 Chronotropic Incompetence and Its Relation to Exercise Intolerance in Chronic Obstructive Pulmonary Disease/J.-M. Liu, H. Liu, J. Guo, Q. Zhao, W. Yang, L. Wang, S. Gong, Shanghai, China, p.A3561

Facilitator: M.J. Divo, MD, Boston, MA


P984 Prevalence and Predictors of Pulmonary Embolism in Severe Acute Exacerbation of COPD: A Systematic Review/A. Shujaat, S. Sethi, Buffalo, NY, p.A3565


P986 The Prevalence of Poor Sleep Quality in Patients with Chronic Obstructive Pulmonary Disease Referred for Pulmonary Rehabilitation/M.M. Roberts, J.-G. Cho, J.R. Wheatley, Westmead, Australia, p.A3567

P987 Impact of Diabetes in Patients with Chronic Obstructive Pulmonary Disease (COPD) in Developing Countries; Exploring Bidirectional Relationship and Complexities Beyond Co-Morbidity/N. Bhatta, R. Maskey, P. Koirala, N. Baral, N.R. Karki, R.H. Ghimire, S. Sethi, Buffalo, NY, p.A3568


Facilitator: P.M. Calverley, MBCHB, Liverpool, United Kingdom

P989 External Validation of the COTE Index/Y. Abdou, V.G. Rodrico, Albuquerque, NM, p.A3570

P990 Validation of CODEX Index on Patients with Chronic Obstructive Pulmonary Disease in Hong Kong/K.P. Chan, W.H. Yip, S.S. Ng, J. Ngai, K.W. To, F.W. Ko, D.S. Hui, Hong Kong, Hong Kong Prc, p.A3571

P997 The Frequency of Comorbidities in Patients with COPD/Facilitator: S.P. Bhatt, MD, Birmingham, AL

P998 Comorbidities and One-Year Survival in Chronic Obstructive Pulmonary Disease/Z. Alacam, N. Dursunoglu, N. Kokturk, H. Senol, Denizli, Turkey, p.A3576

P999 Exertional Hypoxemia in Stable COPD Is Common and Predicted by Co-Existing Non-Sysyptic FibrosisBronchiectasis/A. Sadigov, S. Akhundov, Baku, Azerbaijan, p.A3577


P1003 Co-Morbidities Among COPD GOLD-U Are Higher Compared to Those with or Without Obstruction in NHANES/S.D. Kumbhare, T. Belko, C.B. Strange, Charleston, SC, p.A3584

P1004 Evaluation of Fat Infiltration in the Quadriceps of Patients with Chronic Obstructive Pulmonary Disease/S. Martinau, D. Patoine, A. Dube, V. Coats, S. Bonnet, F. Maltais, Quebec, Canada, p.A3585
Facilitator: C.L. Kuntz, MD, MS, Wynnewood, PA

P486  Anomalous Brachiocephalic Artery as a Cause of Stridor in an Adult During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)/E. Jabbour, S. Morais, J. MacLeod, A. Goizuetia, J. Meharg, Providence, RI, p.A3602

P487  Swyer-James-MacLeod Syndrome Misdiagnosed as COPD/Y.S. Intepe, B. Metin, F. Gundogdu, A. Okur, Yozgat, Turkey, p.A3603

Facilitator: G.E. Westney, MD, Atlanta, GA

P488  Yellow Nail Syndrome/M.S. Switzer, W.A. Lewis, J. Nations, Bethesda, MD, p.A3604

P489  Late Diagnosis of Primary Ciliary Dyskinesia in a Kuwaiti 38-Year-Old Male/R. Peterson, R. Boente, S. Peterson-Carmichael, S.D. Davis, K.D. Brown, Indianapolis, IN, p.A3605


P492  Pneumatocele in an Adult: Case Report and a Review of the Literature/M. splittedterber, P. Pancholy, Tampa, FL, p.A3608


Facilitator: C.L. Kuntz, MD, MS, Wynnewood, PA


P497  Mounier-Kuhn Syndrome and Cystic Fibrosis Coexist in the Same Patient with Chronic Respiratory Failure/Y. Beddawi, M. Khosravi, Lexington, KY, p.A3613


P499  3-D Reconstruction of Low-Dose Dynamic CT Imaging as a Decision Aid in Tracheobronchomalacia/M. Shafiq, H. Guo, A. Sung, Stanford, CA, p.A3615


P502  Lung Age with Ex-Smokers and Non-Smokers at Annual Medical Checkup/M. Fukakusa, Y. Ichikawa, Y. Ishida, K. Masuda, Tokyo, Japan, p.A3618

P1135  Heparin-Induced Thrombocytopenia: Low Yield and Diagnostic Complexity in Critically Ill Patients/I. Kourouni, S.F. Noronha, M. Varma, J. Shapiro, New York, NY, p.A3628


Facilitators: W. Checkley, MD, PhD, Baltimore, MD

A.C. Long, MD, MS, Seattle, WA


P1138  Sorry, You're Too Big for Our Scanners: Frequency of Diagnostic Imaging Deferment Due to Weight or Body Habitus in Obese ICU Patients/S. Shek, M. Duttuluri, D. Teplitsky Nes, R. Jean, New York, NY, p.A3631


P1140  A Retrospective Review of Admissions to an Obstetric ICU/D.K. Narendra, V. Bandi, N. Hall, S.L. Clark, M.A. Belfort, K.K. Guntupalli, Houston, TX, p.A3633

P1141  A Case-Control Study on Risk Factors of Acquired Swallowing Disorders Among Patients After Cardiac Surgery in China/M. Zhou, T. Liang, Beijing, China, p.A3634


P1143  Factors Associated with Poor Functional Outcome in Patients with Aneurysmal SAH in a Community Hospital/L. Gupta, A. Vivek, K. Hassan, San Jose, CA, p.A3636

P1144  Developing Guidelines for Post Traumatic Stress Disorder Symptoms Associated with Critical Illness/J.J.B.J. Williams, L. Ting, Newark, NJ, p.A3637


P1146  High Fluoride Levels with Isoflurane Critical Care Sedation Does Not Cause Nephrotoxicity/A. Jerath, A. Steel, N. Ferguson, M. Wasowicz, Toronto, Canada, p.A3639

Facilitators: M.A. Tidswell, MD, Springfield, MA

L.E. Ferrante, MD, New Haven, CT

P1147  Predictors and Outcomes of Prolonged Weaning Among Intubated Patients on Mechanical Ventilation Admitted to the Intensive Care Unit/A.S. Awalee, C. Uy, Davao City, Philippines, p.A3640


P1151  Low T3 Syndrome as a Predictor of Mortality in Critically Ill Patients, a Meta-Analysis and Review/T. Salim, S. Fakhri, V. Ravi, Chicago, IL, p.A3644


P1154  Neurological and Survival Outcome After Therapeutic Hypothermia at a Large Community Hospital/L. Premachandra, K. Abed, G. Singh, E. Hamaty, Atlantic City, NJ, p.A3647

P1155  The Effect of Low Phosphate Levels on Respiratory Failure and Mortality in Critically Ill Patients/C.K. Federspiel, T.S. Itenov, K.M. Thormar, M. Bestle, Hillerod, Denmark, p.A3648

P1156  Association Between Vitamin D Deficiency and In-Hospital Mortality in Intensive Care Unit: A Systematic Review and Meta-Analysis/S. Upala, A. Sanguankeo, Cooperstown, NY, p.A3649

Facilitators: T.W. Rice, MD, MSc, Nashville, TN

P.D. Sottile, MD, Aurora, CO

P1157  Hypomagnesemia and Mortality in Patients Admitted to Intensive Care Unit: A Systematic Review and Meta-Analysis/S. Upala, A. Sanguankeo, Cooperstown, NY, p.A3650


P1159  Increased Time of Blood Glucose in Range 70-139 mg/dL Is Strongly Associated with Decreased Mortality in Critically Ill Adults/M.J. Lanspa, E. Hirshberg, A.M. Hersh, J. Holmen, J. Orme, A. Morris, J.S. Kinsley, Murray, UT, p.A3652


P1164 Predictors of Mortality in Patients with Hematologic Malignancies Admitted to the ICU - A Prospective Observational Study/N. Al-Zubaidi, A. Soubani, Detroit, MI, p.A3657


Facilitators: G.S. Martin, MD, MSc, Atlanta, GA
C.M. Shaver, MD, PhD, Nashville, TN


P1174 Factors Associated with Appropriateness of Initial Antibiotic Therapy in Culture Positive Patients with Septic Shock/S. Arora, R. Nanchal, Milwaukee, WI, p.A3662


P1176 Clinical Significance of Serum Developmental Endothelial Locus-1 (Del-1) in Patients with Severe Sepsis/G.R. Chon, Y. Koh, C.-M. Lim, J.W. Huh, E.Y. Choi, Y.Y. Park, S.-B. Hong, Chungju, Korea, Republic of, p.A3664


P1178 Human Chitinases and Chitinase-Like Protein (C/CLP) as Predictors of Sepsis Due to Pneumonia/C.R. Marion, N. Andrews, J. Herazo-Maya, A. Losier, L. Sharma, T. Tolbert, W. Liu, C. Dela Cruz, New Haven, CT, p.A3666


Facilitators: K.A. Hibbert, MD, Boston, MA
S. Beesley, MD, Salt Lake City, UT


P1181 Performance of Diastolic Based Shock Indices in Adults with Sepsis/A. Otekeiwebia, Lexington, KY, p.A3669


P1184 Effectiveness of Computerized Check Points in Reducing Inappropriate Use of Stress Ulcer Prophylaxis: Benefits and Unintended Consequences/J. Danley, M. Calder, S. Penna, C.P. Farrell, K.C. Blenner, C.L. Kuntz, Media, PA, p.A3672

P1185 Time Is It! Before and After Standardizing the Controversial Sepsis Resuscitation Bundle in a Large Hybrid Academic Center/T. Ferreira, W. Sneij, R. Beg, Y. Brito, Y. Buryk, A. Wawrzyniak, L. Abbo, J. Falise, L. Lupe, S. Soorus, D. Ashley, D. Lang, Y. Diaz, Miami, FL, p.A3673


P1187 Comparison of a Novel Coding Algorithm Versus the American Burn Association Sepsis Definition to Examine the Epidemiology of Sepsis in Burn-Injured Adults/M.A. Rech, M.J. Mosier, S. Zelisko, R.S. Cooper, G. Netzer, E.J. Kovacs, M. Afshar, Maywood, IL, p.A3675


Facilitators: A. Amaral, MD, Toronto, Canada
H.C. Prescott, MD, MA, Ann Arbor, MI


P1190 Assessing the Accuracy of UHC Calculated Predicted Sepsis Mortality at Parkland Hospital/S.E. Prieto, M. Leveno, R.M. Ruggiero, T. Chung, M. Bartlett, Dallas, TX, p.A3678

P1191 To Determine the Risk Factors Associated with Mortality in Patients with Vancomycin Resistant Enterococci Bacteremia/N.E. Mathew, J. Benavidez, W. Aslam, Y. MunozMaldonado, Y. Liu, R. Fader, V. Brito, S. Ghamande, Temple, TX, p.A3679


P1193 The CURB-65 Score Used as a Predictor of Mortality in Critically Ill Patients with Non Respiratory Sepsis/S.D. Leiva, G. Vaca Ruiz, C.M. Luna, Buenos Aires, Argentina, p.A3681


P1195 Association Between the Abdominal Adiposity and Mortality in Septic Shock/Y.-J. Jeong, Y.-S. Kang, Y.-S. Yoon, J.Y. Oh, Koyang-city, Korea, Republic of, p.A3683


P1197 The Effectiveness of Early Goal-Directed Therapy in Patients with Septic Shock: A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies/Y.-W. Kuo, S.-Y. Ruan, J.-S. Jerng, K.A. Chan, Doulou City, Taiwan, p.A3685

Facilitators: D.C. Scales, MD, PhD, Toronto, Canada
D.W. Ford, MD, MSCR, Charleston, SC

P1198 Prognostic Value of Serum Vitamin D Binding Protein, 25-Hydroxyvitamin D3 and 1,25-Dihydroxyvitamin D3 in Sepsis Patients/D. Zhang, P. Yan, X. Liu, H. Gu, L. Xie, Beijing, China, p.A3686


P1200 Epidemiology and Predictors of Outcome in Patients with Sepsis and Related Syndromes Admitted to a Medical Intensive Care Unit: A Prospective Study/A. Mohan, J. Harikrishna, S.N. Challa, K.V.S. Sarma, B.S. Kumar, Tirupati, India, p.A3688


P1203 Epidemiology and Outcomes of Sepsis in Two Intensive Care Units in Rwanda/J. Nzarora, M.L. Beach, E.D. Riviello, T. Twagirumugabe, Kigali, Rwanda, p.A3691


P1207 Impact of Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) on Ward Patients/X. Han, A.M. Snyder, C. Barc, S. Sokol, N. Pettit, M.D. Howell, D.P. Edelson, M.M. Churpek, Chicago, IL, p.A7823

B48 ASTHMA: INSIGHTS FROM THE BENCH, GENETICS, AND EPIDEMIOLOGY

9:00 a.m. - 4:15 p.m.  MOSCONE CENTER

Area B, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion

Facilitator: S.M. Tarlo, MBBS, Toronto, Canada


P211 Work-Related Respiratory Symptoms and Self-Reported Asthma in British Woodworkers/R.E. Wiggins, J. Sumner, E. Robinson, C.M. Barber, Buxton, United Kingdom, p.A3702

P212 The Usefulness of a Questionnaire in a Preliminary Diagnosis of Work-Related Asthma/A.A. Lipinska-Ojrzanowska, M. Wiszniowska, J.M. Walusiak-Skorupa, Lodz, Poland, p.A3703


P215 Characteristics of Work Aggravated Asthma in the United Kingdom (UK)/L. Bradshaw, J. Sumner, P.K. Henneberger, D. Fishwick, Buxton, United Kingdom, p.A3706

Facilitator: L. Avila, MD, San Jose, Costa Rica

P216 An Epidemiological Study of Bronchial Asthma in Greenhouse Farmers in Liaoning Province from 2006 to 2009/S. Liu, G.X. Wang, Shenyang, China, p.A3707


P221 Seasonal Alterations of Respiratory Symptoms and the Health Status Among Mongolian Patients with Chronic Obstructive Pulmonary Disease and Bronchial Asthma: The Pilot Study/M. Nakao, K. Yamauchi, Y. Ishihara, B. Solongo, D. Ichinnorov, Kurume, Japan, p.A3712

Facilitator: E. Brigham, MD, Baltimore, MD


THEMATIC POSTER SESSION

B49 NON-TUBERCULOUS MYCOBACTERIAL DISEASE AND CASE REPORTS

9:00 a.m. - 4:15 p.m. MOSCONENCE CENTER

Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: T.K. Marras, MD, Toronto, Canada


P1223 Progression of Mycobacterium Avium Complex Infection to Extensive Structural Disease and Hydropneumothorax in an Otherwise Healthy Adult Male/J.C. VanHook, B. Warner, E.J. McManus, Longmont, CO, p.A3723

P1224 An Unusual Case of Mycobacterium Avium Complex/B.-C. Tran, Baltimore, MD, p.A3724

P1225 Unusual Presentation of Mycobacterium Avium Complex Lung Infection/V. Trivedi, T.R. Aksamit, L. Karnatovskaia, Rochester, MN, p.A3725

P1226 In Sickness and In Health: Distinct Presentations of Mycobacterium Avium Complex in a Married Couple/T.L. Griffiths, S.L. Schmidt, Grand Rapids, MI, p.A3726


P1230 Eosinophilic Pneumonia and Mycobacterial Infection/I.E. Hines, A. Mohamed Hosni, Ypsilanti, MI, p.A3730


Facilitator: J. Philley, MD, Tyler, TX


P1236 Nontuberculous Mycobacterial Infection in a Case Diagnosed with Ankylosing Spondylitis/N. Dirican, M. Pinar, S. Erturk, A. Aynali, S. Alayal, M. Caikr, Isparta, Turkey, p.A3736


P1239 A Case of Complicated Mycobacterium Abscessus Infection in a Lung Transplant Recipient/N. Hsu, D. Ross, Los Angeles, CA, p.A3739

P1240 A Rare Case of Severe Recurrent Hemoptysis, Gastroplmonary Fistula Associated with Mycobacterium Abscessus Infection: A Case Report/L. Fernandez, L.F. Sua, N.A. Romero, F. Rosso, C.A. Munoz, Calli, Colombia, p.A3740

P1241 Successful Use of Inhaled Antibiotics for Primary Treatment of Mycobacterial Abscessus Infection/B. Hayward, D. Addirizzo-Harris, New York, NY, p.A3741


Facilitator: S.J. Ruoss, MD, Palo Alto, CA

P1244 Attenuation of Pulmonary Mycobacterium Avium-Intracellulare Complex Disease by Active Hexose Correlated Compound (AHCC) in Mice/M. Fujita, T. Matsumoto, R. Hirano, J. Uchino, K. Watanabe, Fukuoka, Japan, p.A3744

P1245 Anti-IFN-γ Autoantibodies Reflect Disease Activities of Disseminated NTM Infection; as a Possible Serum Biomarker/ A. Aoki, T. Sakagami, K. Shima, N. Aoki, H. Moro, Y. Tanabe, T. Koya, T. Hasegawa, T. Kikuchi, Nigata, Japan, p.A3745

P1246 Relationship Between Interferon-γ/Interleukin-17 Production and Clinical Features of Non-Tuberculous Mycobacterium/ H. Kobayashi, Suzuka, Japan, p.A3746

P1247 AAT Reduces Burden Of Mycobacterium Intracellular In Human Macrophages By Inducing Phagosome-Lysosome Fusion/E. Chan, A. Bai, X. Bai, Denver, CO, p.A3747

P1248 A Rare Case of Mycobacteria Kanssii Pulmonary Infection Presented with Large Pleural Effusion in an Immunocompetent Patient/V. Patel, A. Shah, J. Raynor, M. Babury, Jamacia, NY, p.A3748


P1253 Rare Case of Pulmonary Infection by Rapidly Growing Mycobacteria in an Immunocompromised Host/J.P. Sugunaraj, C.S. Greco, Y.B. Mehta, Danville, PA, p.A3753


P1255 Mycobacterium Cavitary Pneumonia - Not Your TB Type - A Case of Rare Mycobacterium Szulgai/D.Y. Pandya, H.P. Shah, N. Dalessandro, Allentown, PA, p.A3755

P1256 Non Tuberculous Mycobacteria in Cystic Fibrosis: Does Treatment Change Outcome in High Prevalence Areas?/R. Beg, E. Mendes, C. Aguiar, A. Wawrzyniak, M. Salathe, A. Schmid, Miami, FL, p.A7826


B50 TUBERCULOSIS: CASE REPORTS

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion 11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: J. Bernardo, MD, Boston, MA


P1260 The Delayed Diagnosis of Acid-Fast Bacilli Biopsy-Negative Pulmonary Mycobacterium Tuberculosis/L. Kahlon, A. Kahlon, Syracuse, NY, p.A3757

P1261 Increasing Pulmonary Nodules, Which Gave Us a Delayed Surprise/C. Meenakshisundaram, H. Friedman, Evanston, IL, p.A3758


P1263 Pulmonary Tuberculosis in Immunocompetent Host Presenting with Complete Right Lower Lobe Consolidation/P. Pirompanich, P. Damronglerd, C. SriAroon, Pathumthani, Thailand, p.A3760

P1264 “Right Upper Lobe Syndrome” a Rare Presentation of Endobronchial Tuberculosis/J.M. Chowdry, M. Kosa, A. Mohammed, J.S. Chowdry, V. Sheht, M. Korman, Darby, PA, p.A3761
**MONDAY • MAY 16**

**P1281** Miliary Tuberculosis in an IGRA Negative Patient After Cardiomyopathy Secondary to Tuberculosis: A Case Series

**P1279** Extrapulmonary Tuberculosis as a Mimicker of Metastatic D.M. Nilsen, MD, Long Island City, NY

**P1278** Gone, but Not Forgotten: Oleothorax/VATS - Decortication in a Patient with Primary Tuberculous Pleurectomy and Nerve Block: A Treatment Option for An Unusual Cause of Pleural Effusion Following Mycobacterium Africanum Lymphadenitis in an Asian Patient Broncho-Esophageal Fistula from Broncholithiasis/Pulmonary Tuberculosis-Induced Central Vein Thrombosis of Benign Superior Vena Cava Syndrome Due to Mediastinal Tubercular Mass: A Unique and Rare Presentation/E.H. Alrajhe, H. Al-Hayaan, A. Takale, N. Bhargava, V. Pandharkar, Pune, India, p.A3768

**P1277** Persistent Dysphonia: A Rare Extrapulmonary Complication of Pleural Peel/A.M. Spivak, B. Kendall, Salt Lake City, UT, p.A3772

**P1276** Benign Superior Vena Cava Syndrome Due to Mediastinal Pulmonary Tuberculosis-Induced Central Vein Thrombosis of the Upper Extremity: A Case Report/K. Najma, T.M. Hassan, F.A. Hamid, Cheras, Malaysia, p.A3769

**P1275** Broncho-Esophageal Fistula from Broncholithiasis/A. Rajabalan, B.E. Bat, M. Aladin, A. Cutrona, Youngstown, OH, p.A3770


**P1273** An Unusual Case of Pleural Effusion Following Immunotherapy for Bladder Cancer/T. Rachakonda, J. Boltax, A.M. Spivak, B. Kendall, Salt Lake City, UT, p.A3772

**P1272** Pleurectomy and Nerve Block: A Treatment Option for Refractory Pain Secondary to Tuberculous Pleurisy/V.H. Kha, K.S. Allen, S.J. Deb, Oklahoma City, OK, p.A3773

**P1271** VATS - Decortication in a Patient with Primary Tuberculous Pleural Peel/T. Schneider, T. Jahn, G. Faller, H. Geddert, Karlsruhe, Germany, p.A3774

**P1270** Gone, but Not Forgotten: Oleothorax/M.A. Shenoy, V. Ponnusamy, P.K. Gorukanti, P. Chandar, K. Chawla, W. Pascal, Brooklyn, NY, p.A3775

**P1269** Invasive Endotracheal Tuberculosis/R.V. Dy, K. Harris, S. Dhillon, A.H. Alrajhe, Buffalo, NY, p.A3766

**P1268** Chronic Weakness in the Elderly: It’s Not All Cancer/C.J. Carter, MD, Providence, RI


**P1284** Mycobacterium Bovis Mycotic Aneurysm/S. Nandavaram, R. Lenox, Syracuse, NY, p.A3781

**P1285** Defying Diagnosis: A Case of Disseminated Tuberculosis, an Expanding Chest Wall Mass, and a Rapid Molecular Test/M.B. Lesko, C.C. Shaw, New York, NY, p.A3782


**P1287** Tuberculomas in the Spinal Cord/P.S. Pandya, London, United Kingdom, p.A3784

**P1288** Pott’s Disease, a Diagnosis that Should Not Be Missed/K. Jessamy, V. Kaul, F. Ojewee, O. Anozie, Z. Shepherd, Syracuse, NY, p.A3785

**Facilitator:** E.J. Carter, MD, Providence, RI

**Facilitator:** M.R. O’Donnell, MD, MPH, New York, NY

**Facilitator:** D.M. Nilsen, MD, Long Island City, NY

**Facilitator:** E.J. Carter, MD, Providence, RI

**Facilitator:** E.J. Carter, MD, Providence, RI

**Facilitator:** E.J. Carter, MD, Providence, RI

**Facilitator:** E.J. Carter, MD, Providence, RI

**Facilitator:** E.J. Carter, MD, Providence, RI

**Facilitator:** E.J. Carter, MD, Providence, RI

**Facilitator:** E.J. Carter, MD, Providence, RI

**Facilitator:** E.J. Carter, MD, Providence, RI
B51 PEDIATRIC ASTHMA: EVALUATION AND TREATMENT

9:00 a.m. - 4:15 p.m.    MOSCONCE CENTER

Area F, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: A.G. Vicencio, MD, New York, NY

P609 Spirometry-Induced Bronchoconstriction: A Sign of Severe Asthma in Children?/H. AlSaleh, D. Wilson, S.D.M. Dell, Toronto, Canada, p.A3801

P610 Clinical Assessment and Respiratory Impedance Plethysmography in Predicting Admission in Patients with Status Asthmaticus Presenting to the Pediatric Emergency Department/A.R. Strang, R. Heinle, L. Xie, K. Giordano, M. Attia, T.H. Shaffer, Wilmington, DE, p.A3806

P611 Bronchodilator Response Measured by Interrupter Resistance (Rint) Predicts which Wheezy Preschool Children will Respond to Inhaled Corticosteroid/P. Seddon, R. Willson, C. Olden, L. Symes, N. Beydon, E. Lombardi, D. Wertheim, Brighton, United Kingdom, p.A3808


Facilitator: A.Y. Joshi, MD, Rochester, MN


P618 Establishing the Reliability and Validity of the Pediatric Acute Asthma Score/T. Wolfe, D. Angst, C.A. Lefaiver, Oak Lawn, IL, p.A3816


Facilitator: D.K. Radhakrishnan, MD, Ottawa, Canada


P625 Evaluation of Asthma Control Test (ACT) in Association with Peak Expiratory Flow Rate (PEFR) in Indian Children/A. Chauhan, M. Singh, K. Thumburu, Chandigarh, India, p.A3812


Facilitator: I.R. Sami, MD, Washington, DC


P633 Phenotype and Medication Use of Preschool Children Seen in a Tertiary Care Asthma Program/C.E. Canesssa, X.J. Wu, K.J. Hildebrand, C.L. Yang, Vancouver, Canada, p.A3822

P634 Structural Lung Abnormalities on CT Correlate to Asthma Inflammation in BAL/D.J. Roach, K. Ruanangnana, R.J. Fleck, M. Rattan, T.W. Guilbert, J.C. Woods, Cincinnati, OH, p.A3825


P636 Pediatric Asthma Patients and Providers Prefer Color-Coded Labeling of Metered Dose Inhalers (MDIs)/P.-Y. Tsou, J. Ronayne, H. Kumar, Chicago, p.A3799

Facilitator: O. Herrera, MD, Santiago, Chile


P639 What Represents a Meaningful Improvement in Asthma Control as Measured Using the Childhood Asthma Control Test (cACT)? Perspectives from Qualitative Interviews with Children and Caregivers/L.M. Nelsen, H. Staunton, K. Sully, S.K. Khindri, H. Svedsater, R. Arbuckle, Collegeville, PA, p.A3813

P640 Metered-Dose Inhaler Compared to Nebulizer for Bronchodilator Treatment of Inpatients with Asthma Exacerbation/N.M. Pajor, M.A. Nevin, Chicago, IL, p.A3821

P641 Effect of Childhood Asthma on Lung Function at 21 Years/S. Suresh, M. O’Callaghan, A.A. Mamun, P.D. Sly, South Brisbane, Australia, p.A3827


THEMATIC POSTER SESSION

B52 NEONATAL LUNG DISEASE: FROM BENCH TO BABIES

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area F, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: R.M. Ryan, MD, Charleston, SC


P646 NADPH Oxidase 2 Regulates Sepsis-Induced Lung Inflammation and Alveolar Remodeling in Neonatal Mice/V. Sampath, H. Menden, Kansas City, MO, p.A3862


P649 Postnatal Growth Restriction Augments Oxygene-Induced Pulmonary Hypertension in a Neonatal Rat Model of Bronchopulmonary Dysplasia/S. Wedwood, C. Warford, S. Agvateesiri, S. Berkelhamer, M. Perez, M. Underwood, R. Steinhorn, Sacramento, CA, p.A3865

### Feasibility of Continuous Oximetry Recording in Home Oxygen Management of Premature Infants with Bronchopulmonary Dysplasia

**Facilitator:** T.E. Tipple, MD, Birmingham, AL

**Presentation Title:**
Feasibility of Continuous Oximetry Recording in Home Oxygen Management of Premature Infants with Bronchopulmonary Dysplasia

**Authors:** L. Frain, H. Suchy, K. Gaukler, E. Moran, L.M. Rhein, Boston, MA, p.A3832

### Breath-by-Breath Analysis of Respiratory Sinus Arrhythmia in Preterm Infants

**Facilitator:** T.E. Tipple, MD, Birmingham, AL

**Presentation Title:**
Breath-by-Breath Analysis of Respiratory Sinus Arrhythmia in Preterm Infants

**Authors:** W. Shalish, S. Rao, G. Sant’Anna, J. Mortola, Montreal, Canada, p.A3835

### Improving Indoor Air: The Feasibility of Deploying Indoor HEPA Air Filters in Homes of Inner City Non-Smoking Pregnant Women and Infants Who Live with a Smoker

**Facilitator:** L.C. Eldredge, MD, PhD, Seattle, WA

**Presentation Title:**
Improving Indoor Air: The Feasibility of Deploying Indoor HEPA Air Filters in Homes of Inner City Non-Smoking Pregnant Women and Infants Who Live with a Smoker

**Authors:** T. Cui, M. Linn, A.M. Goldsmith, Ann Arbor, MI, p.A3842

### Maternal Pre-Pregnancy Weight as a Risk Factor for Bronchopulmonary Dysplasia in Preterm Infants

**Facilitator:** H.J. Rozycki, MD, Richmond, VA

**Presentation Title:**
Maternal Pre-Pregnancy Weight as a Risk Factor for Bronchopulmonary Dysplasia in Preterm Infants


### Chest CT Volume Acquisition and Comparison of Quantitative CT Airway Measurements in Young Children with Chronic Lung Disease

**Facilitator:** L.C. Eldredge, MD, PhD, Seattle, WA

**Presentation Title:**
Chest CT Volume Acquisition and Comparison of Quantitative CT Airway Measurements in Young Children with Chronic Lung Disease

**Authors:** E. Cohen, D. Savage, T.E. Robinson, Palo Alto, CA, p.A3870

### Deficiency of Lysophosphatidic Acid Receptor 1 Protects Against LPS-Induced Lung Injury in Adult Rats with Hyperoxia-Induced Neonatal Lung Injury

**Facilitator:** M.K. Lee, S.M. Smith, R. Bajpai, P. Minoo, Los Angeles, CA, p.A3857

**Presentation Title:**
Deficiency of Lysophosphatidic Acid Receptor 1 Protects Against LPS-Induced Lung Injury in Adult Rats with Hyperoxia-Induced Neonatal Lung Injury


### Neonatal Hyperoxia Exposure Enhances Alveolar Infection of Influenza A Virus in Adult Mice


**Presentation Title:**
Neonatal Hyperoxia Exposure Enhances Alveolar Infection of Influenza A Virus in Adult Mice

**Authors:** A.P. Popova, A. J. Rozycki, X. Tang, C.-L. Na, J. Bridges, X. Lin, J.A. Whitsett, Cincinnati, OH, p.A3869

### Male Gender Associates with Distinctive Gene Expression Pattern in Neonatal Lung Mesenchymal Stromal Cells from Infants Developing Bronchopulmonary Dysplasia

**Facilitator:** H.J. Rozycki, MD, Richmond, VA

**Presentation Title:**
Male Gender Associates with Distinctive Gene Expression Pattern in Neonatal Lung Mesenchymal Stromal Cells from Infants Developing Bronchopulmonary Dysplasia

**Authors:** A.P. Popova, T. Cui, M. Linn, A.M. Goldsmith, Ann Arbor, MI, p.A3842

### sRAGE in the Lungs of Ventilated Very Low Birthweight Infants with Bronchopulmonary Dysplasia

**Facilitator:** V. Bhandari, MD, DrMed, Philadelphia, PA

**Presentation Title:**
sRAGE in the Lungs of Ventilated Very Low Birthweight Infants with Bronchopulmonary Dysplasia

**Authors:** T. Cui, M. Linn, A.M. Goldsmith, Ann Arbor, MI, p.A3842

### Surfactant Protein-D Serum Levels as an Indicator of Lung Disease in Preterm Infants Developing Bronchopulmonary Dysplasia

**Facilitator:** H.J. Rozycki, MD, Richmond, VA

**Presentation Title:**
Surfactant Protein-D Serum Levels as an Indicator of Lung Disease in Preterm Infants Developing Bronchopulmonary Dysplasia

**Authors:** R. Siddaiah, E. Ndifreke, S. Diangelo, P. Silveyra, Hershey, PA, p.A3854

### Sulforaphane Protects Against Hyperoxic Toxicity Via NF-E2 Related Factor (Nrf2) Pathway: Implications for Bronchopulmonary Dysplasia

**Facilitator:** H.J. Rozycki, J.L. Bradley, S. Karam, Richmond, VA, p.A3863

**Presentation Title:**
Sulforaphane Protects Against Hyperoxic Toxicity Via NF-E2 Related Factor (Nrf2) Pathway: Implications for Bronchopulmonary Dysplasia

**Authors:** R. Siddaiah, E. Ndifreke, S. Diangelo, P. Silveyra, Hershey, PA, p.A3854

### Protein Expression in the Pathogenesis of Bronchopulmonary Dysplasia and Pulmonary Hypertension in Preterm Infants

**Facilitator:** R. Keller, MD, San Francisco, CA

**Presentation Title:**
Protein Expression in the Pathogenesis of Bronchopulmonary Dysplasia and Pulmonary Hypertension in Preterm Infants

**Authors:** R. Siddaiah, E. Ndifreke, S. Diangelo, P. Silveyra, Hershey, PA, p.A3854

### Surfactant Protein-D Serum Levels as an Indicator of Lung Injury in Infants with Congenital Diaphragmatic Hernia

**Facilitator:** H.J. Rozycki, J.L. Bradley, S. Karam, Richmond, VA, p.A3863

**Presentation Title:**
Surfactant Protein-D Serum Levels as an Indicator of Lung Injury in Infants with Congenital Diaphragmatic Hernia

**Authors:** R. Siddaiah, E. Ndifreke, S. Diangelo, P. Silveyra, Hershey, PA, p.A3854

P16 HDAC6-Hsp90: A Shock Duo Implicated in Pulmonary Arterial Hypertension/S. Chabot, O. Boucherat, G. Ruffenach, S. Breuils-Bonnet, E. Tremblay, S. Provencher, S. Bonnet, Quebec, Canada, p.A3886

P17 Isolated Heart Model Demonstrates Evidence of Contractile and Diastolic Dysfunction in Right Ventricles from Rats with Sugen/Hypoxia-Induced Pulmonary Hypertension (SUHx-PH)/E. Nevo-Netes, A. Vayl, A. Frump, J.A. Kline, T. Lahm, Indianapolis, IN, p.A3887

P18 Evaluation of the Therapeutic Effects of Nitrite and Metformin in a Mouse Model of Pulmonary Hypertension Associated with Heart Failure and Preserved Ejection Fraction/I. McNamara, I. Saravia, I. McNamara, R.D. Sullivan, D. You, S.A. Cormier, Memphis, TN, p.A3888


P20 New Mouse Model of Pulmonary Hypertension Induced by Respiratory Syncytial Virus Bronchiolitis/D. Kimura, J. Saravia, I. McNamara, R.D. Sullivan, D. You, S.A. Cormier, Memphis, TN, p.A3890


P23 Gap Junction Connexin-43 Mislocalization and a-Actinin Expression Changes in the Right Ventricle: Potential Contributors to Right Heart Failure in Pulmonary Hypertension/O. Lohani, Aurora, CO, p.A3893


P27 Angiotensin-II (AngII) Induced AngII Type 1 Receptor Activation Upregulates Alpha-2-Antiplasmin Expression in Experimental Pulmonary Hypertension Model/S. M. Malik, A.K. Baidya, V. Chhabra, S.B. Singh, P. Reddy, New Delhi, India, p.A3897

P28 The Lung Origin of Coronary Artery Diseases in Pulmonary Hypertension Patients: Role for the DNA damage/BRD4 Axis/J. Meloche, V. Nadeau, E. Tremblay, F. Potus, S. Chabot, E. Charbonneau, S. Provencher, S. Bonnet, Quebec, Canada, p.A3898


P30 Distinct Effects of Phosphodiesterase-5 and Fibroblast Growth Factor Receptor-1 Inhibitors in Monocrotaline-Induced Pulmonary Arterial Hypertension/N.S. Felix, L. Mendonca, J.S. Da Silva, C.L. Braga, C.S. Samary, F.F. Cruz, N.N. Rocha, G. Zapata-Sudo, P.R.M. Rocco, P.L. Silva, Rio de Janeiro, Brazil, p.A3900


P33 CARSKNKDC (CAR) Selective Enhancement of Fasudil-Induced Pulmonary Vasodilation in a Porcine Model of Chronic Pulmonary Hypertension/A. Rothman, H. Restrepo, W.N. Evans, V. Sarukhanov, D. Mann, Las Vegas, NV, p.A3903

P34 The Orally Available p110δ Selective PI3K Inhibitor BYL719 Reduces Hypoxia-Induced PH in Mice/E.M. Berghausen, A. Baidya, V. Chhabra, S.B. Singh, P. Reddy, New Delhi, India, p.A3904


Examination of the CXCL11/CXCR3 Biological Axis in the Hypoxic Lung/C. Hughes, M. Paterson, P. McLoughlin, C. Costello, Dublin, Ireland, p.A3908

HIV-Nef-Induced Apoptosis in Lung Microvascular Endothelial Cells Correlates with the Upregulation of EMAPII/S. Chelvanambi, M. Clauss, R.B. Day, H. Twigg, Indianapolis, IN, p.A3909


Kinetic Analysis of 3'-Deoxy-3'-[18F]-Fluorothymidine (FLT) Positron Emission Tomography (PET) in Monocrotaline-Induced Pulmonary Hypertension Rat/A. Ashek, O. Dubois, M. Wilkins, L. Zhao, London, United Kingdom, p.A3911


Effects of Inhaled Nitric Oxide on Pulmonary Artery Smooth Muscle Cells (PASMC) Exposed to Positive Pressure Ventilation and Hypoxia/D. Alapati, S.L. Balasubramaniam, J. Hossain, S. Soundar, P. Fawcett, T.H. Shaffer, Wilmington, DE, p.A3913

Hydrogen Sulfide (H2S) Prevents the Monocrotaline Induced Pulmonary Hypertension by Regulating Inflammomodulatory Signaling/A.K. Baidya, A. Chhabra, V. Chhabra, S.M. Malik, S.B. Singh, M. Sharma, P. Reddy, New Delhi, India, p.A3914

Abrogation of Endothelial Mef2c Results in Exacerbation of Pulmonary Hypertension: Implicating the Histone Deacetylase (HDAC) II-MEF2 Signaling Axis/A. Sofer, C. Hwangbo, I. Papangeli, X. Hu, S. Park, J. Schwarz, H. Chun, New Haven, CT, p.A3915

Investigation of Neutrophil Function in IPAH Patients/M.-H. Ruchaud-Sparagano, J. Grant, L. Thirugnanasothy, S. Sasithamparanathan, J. Simpson, P. Corris, Newcastle upon Tyne, United Kingdom, p.A3916

When Ventilation-Perfusion Scan Falters: A Rare Cause of Pulmonary Hypertension Due to Unilateral Pulmonary Artery Agenesis/T.K. Vossler, S. Ganesh, Los Angeles, CA, p.A3931

An Unusual Cause of Dyspnea/L. Al ghothani, D. Chui, N. Sood, Columbus, OH, p.A3930

Pulmonary Hypertension Due to Unilateral Pulmonary Agenesis/T.K. Vossler, S. Ganesh, Los Angeles, CA, p.A3931


An Unusual Cause of Hypoxia/L. Ochieng, T. Flick, D. Johnson, Willimssport, PA, p.A3933

Atypical Hemolytic Uremic Syndrome (HUS) and Pulmonary Hypertension/C. Liu, R. Hilton, R. Sharma, S. Hussain, New Brunswick, NJ, p.A3929

Pulmonary Hypertension: A Rare Incidental Finding/Y. Eslamiazaad, H. Kalatoudis, I. Kaiser, G. Apergis, Brooklyn, NY, p.A3928

An Unusual Cause of Pulmonary Vein Varix: A Rare Incidental Finding/ Z. Safdar, MD, Houston, TX

Regional Differences in Pulmonary Hemodynamics Due to a Left Atrial Mass/A. Bhardwaj, G. Chang, R.R. Zimmer, H. Palevsky, Philadelphia, PA, p.A3935

Is It Efficacious to Switch from Infusion to Oral Therapy for Pulmonary Arterial Hypertension?/D. Khabbaza, N. Sood, Columbus, OH, p.A3936

Chronic Thromboembolism Pulmonary Hypertension in a Patient with Klipsfelter and Antiphospholipid Syndrome/S. Sanchez, A.S. Herrera, G. Delgado, M. Hinojosa, J.F. Moreno, R. Mercado, Monterrey, Mexico, p.A3937


B55 REASON TO BELIEVE: CLINICAL PH STUDIES

9:00 a.m. - 4:15 p.m. MOSCONE CENTER Area A, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: H. Olschewski, MD, Graz, Austria


A Positive Vasodilator Response to Inhaled Nitric Oxide Does Not Predict Survival in Pulmonary Arterial Hypertension: A National Single Centre Experience/G. Jayasekera, C. Church, A. Mackenzie, M. Johnson, A. Peacock, West Dunbartonshire, United Kingdom, p.A3953
P100 Pulmonary Function Test Parameters in Patients with Scleroderma-Associated Pulmonary Arterial Hypertension and Correlation with Mean Pulmonary Artery Pressure and Pulmonary Vascular Resistance/V. Yap, A. Selvachandran, M. Zantah, R. Foley, D. Datta, Farmington, CT, p.A3967


P102 Characteristics and Diagnoses of Elderly Patients Referred to a Pulmonary Vascular Clinic for Evaluation of Possible Pulmonary Arterial Hypertension/H. Edris, K. Selvan, T. Denega, T. Rodrigues, K. Nugent, Lubbock, TX, p.A3969

P103 Safety and Tolerability of Outpatient Transition of Parenteral and Inhaled Treprostinil to Oral Treprostinil in Patients with Pulmonary Arterial Hypertension/A.A. Khan, K. Ackerbauer, R. Tandon, Chicago, IL, p.A3970


P105 Connective Tissue Disease Associated Pulmonary Arterial Hypertension (CTD-PAH) - Prognosis, Predictors and Outcomes (PROPOS) Study/R. Ronaghi, B. Doremus, A.I. Khan, V. Balasubramanian, Fresno, CA, p.A3972


P107 Pulmonary Capillary Wedge Pressure (PCWP) and Its Role in Determining Outcomes in Pulmonary Arterial Hypertension (PAH)/S. Venepally, R. Ronaghi, A.I. Khan, V. Balasubramanian, Fresno, CA, p.A3974

P108 Evaluating the Role of a Pulmonary Hypertension Specialist Nurse in Early Referral/E. Loewenthal, E.J. Shaw, B.P. Brendan, London, United Kingdom, p.A3975

Facilitator: H.J. Ford, MD, Chapel Hill, NC


P112 Patients with Pulmonary Arterial Hypertension Less Represented in Clinical Trials - Who Are They and How Are They?/G. Kovacs, A. Avian, P. Douschan, V. Foris, A. Olschewski, H. Olschewski, Graz, Austria, p.A3979

The Effects of High and Low Frequency Transcutaneous Electrical Muscle Stimulation (TCEMS) on Exercise in Patients with COPD: A Pilot Study

Facilitator: M.A. Spruit, PhD, Horn, Netherlands

Facilitator: H.B. Rossiter, PhD, Torrance, CA

Facilitator: R.S. Goldstein, PhD, Leicester, United Kingdom

Facilitator: S.L. Harrison, A.L. Lee, R.S. Goldstein, D. Brooks, Middlesbrough, United Kingdom

Facilitator: R.S. Novitch, J. Kelly, B. Dehbandi, C. Semper, T.E. Dolmage, D. Brooks, Middlesbrough, United Kingdom


P1393 Proteasome Activator 200 (PA200) Is Dysregulated in Fibrotic Remodeling of the Lung/V. Welk, N. Semren, M. Korfei, A. Gunther, O. Eickelberg, Munich, Germany, p.A4011


P1398 Autophagy Deficiency Increases Endoplasmic Reticulum Stress and Pulmonary Fibrosis Susceptibility in Atg4b Knockout Mice/M. Maciel, M. Gaxiola, C. Lopez-Otin, M. Selman, A. Pardo, S. Cabrera, Mexico City, Mexico, p.A4016

P1399 Idiopathic Pulmonary Fibrosis Fibroblasts Utilize Decoy Receptor 3 to Evade the Fas Ligand-Dependent Apoptosis/J. Im, P. Hergert, R.S. Nho, Minneapolis, MN, p.A4017


P1401 SIRT3 Regulates Senescence and Secretory Phenotype of Lung Fibroblasts/D. Kurundkar, A. Kurundkar, V.J. Thannickal, Birmingham, AL, p.A4019


P1404 Regulation of IL-33 by Oncostatin M in Mouse Lung Epithelial Cells/C. Richards, L. Izakalian, A. Dubey, A. Quershi, G. Zhang, K. Kwofie, S. Wong, F. Botelho, Hamilton, Canada, p.A4022

P1405 TNS1 Is Upregulated During Pulmonary Fibrosis and Is Essential for Myofibroblast Differentiation and Extracellular Matrix Formation/N. Sandbo, E.E. Torr, K. Bernau, Madison, WI, p.A4023


P1409  Increased Expression of Plasminogen Activator Inhibitor 1 Contributes to Alveolar Type II Cell Senescence in IPF Lung/C. Jiang, G. Liu, Q. Ding, V.B. Antony, V.J. Thannickal, R.-M. Liu, Birmingham, AL, p.A4027


P1415  Adenylate Cyclase Pathway and Progression of Fibrosis/S. Mukherjee, L. Janssen, Hamilton, Canada, p.A4033

P1416  A Synthetic Cannabinoid that Exerts a Potent Anti-Fibrotic Effect During the Fibrogenic Phase of Bleomycin Lung/ M. Lucattelli, S. Fineschi, E. Selvi, E. Garcia Gonzalez, B. Bartalesi, G. De Cunto, S. Lorenzini, M. Galeazzi, G. Lungarella, Siena, Italy, p.A4034

P1417  Epitopes of Anti-Fibrotic mAbs Against Integrin α5β1 Reveal Complete Aminoacid Conservation Within Mammalian Species/Y. Yokosaki, N. Kawashima, N. Nishimichi, Hiroshima, Japan, p.A4035


P1423  OPG May Protect Bleomycin-Induced Pulmonary Fibrosis by Inhibiting SMAD2/3 Dependent TGF-β1 Activation/D. Weng, H. Li, Shanghai, China, p.A4041


P1426  Metformin Attenuates Pulmonary Fibrosis on the Established Mouse Model Induced by Bleomycin/S.H. Jeong, Y.J. Kim, J.W. Park, E.S. Son, S.Y. Kyung, S.M. Kang, Incheon, Korea, Republic of, p.A4044


P1434  The Role of Endocannabinoid System in Regulation of Radiation-Induced Pulmonary Fibrogenesis/E. Berdyhev, A. Bronova, K. Erdely, A. Maknyannis, P. Pacher, Denver, CO, p.A7839
B58 BIG AND BIGGER (DATA): OMICS AND BIOMARKERS OF COPD AND OTHER CHRONIC LUNG DISEASES

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area M, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion

11:45-12:45: authors will be present for discussion with assigned facilitators

P1434 Senescence-Associated MicroRNA Expression in Serum Exosomes and Vastus Lateralis Muscle Samples from COPD Patients with Low and Normal Fat Free Mass Index/R. Lakhdar, D. McGuinness, L. Monaghan, E. Drost, P. Shells, B. MacNee, R. Rabinovich, Edinburgh, United Kingdom, p.A4046


P1440 Altered Gene Expression Profiles in Human Bronchial Epithelial Cells Exposed to E-Cigarette Liquid: Results from a Genome-Wide Monitoring/S. Altraja, M. Mitt, A. Altraja, Tartu, Estonia, p.A4053


P1446 TAILS Proteomics in Two Species Identifies New Complement Components and Protease Inhibitors as MMP-12 Substrates During Exacerbations of COPD/B. Mallia-Millanes, A. Dufour, C.J. Philip, C.E. Bolton, S.D. Shapiro, C.M. Overall, S.R. Johnson, Nottingham, United Kingdom, p.A4059


P1448 Valosin Containing Protein Is a Novel Plasma Marker to Indicate Cigarette Smoking Response and Chronic Obstructive Pulmonary Disease (COPD)/C. Song, W. Chatila, T.J. Rogers, Philadelphia, PA, p.A4061

P1449 Integration of Molecular Interactome and Targeted Interaction Analysis to Identify a COPD Disease Network Module/A. Sharma, M. Kitsak, M. Cho, E.K. Silverman, Boston, MA, p.A4062

P1450 Genome-Wide Association Study Identifies Novel Loci Associated with FEV1 Decline Over 11 Years in Individuals with Chronic Obstructive Pulmonary Disease from the Lung Health Study/N. Fishbane, M. Obeidat, N.N. Hansel, N. Rafael, R.A. Mathias, I. Ruczinski, T.H. Beaty, K. Barnes, P.D. Pare, D.D. Sin, Vancouver, Canada, p.A4063


P1459 Airway Inflammatory Mediator Determinants of COPD Exacerbation Severity and Resolution/R.V. Dy, C. Wrcona, T. Murphy, S. Sethi, Buffalo, NY, p.A4072


P1461 Age, Sex and Genetic Factors Are Associated with Response to Ipratropium Among Individuals with Mild COPD in the Lung Health Study/M. Obeidat, N. Fishbane, N.N. Hansel, N. Rafaels, R.A. Mathias, I. Ruczinski, T.H. Beaty, K. Barnes, P.D. Pare, D.D. Sin, Vancouver, Canada, p.A4074


B60 SMOKING AND PARTICULATES IMPACT ON LUNG HEALTH

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area M, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

P1013 Excessive Rac2 Activity in ZZ-Alpha-1 Antitrypsin Deficient Individuals and the Beneficial Effect of Alpha-1 Augmentation Therapy on Aberrant Neutrophil Degranulation/S.A. Landers, F. Gargoum, N. Lacey, M. White, E. Reeves, N.G. McElvaney, Dublin, Ireland, p.A4088


P1017 miR-199a-5p, miR-598 and miR-320a Are Regulated by N Transforming Growth Factor Beta Affects MiRNA Expression in Control and COPD Fibroblasts/ and Decreased in Monocytes of ZZ Individuals Receiving Alpha-1 Antitrypsin Augmentation Therapy/T.M. Hassan, T. Carroll, S. O’Neill, N.G. McElvaney, C.M. Greene, Dublin, Ireland, p.A4092

P1018 Muc5b Deficiency Worsens Airway Hyperreactivity in Allergen Challenged Mice/C.M. Evans, D. Quatrone, A. Stefanski, B.S. Bohmmer, W. Jansen, Aurora, CO, p.A7842

P1474 Effects of Repeated Carbon Black Nanoparticle Exposures on Healthy and Nitrogen Dioxide Pre-Damaged Mice Lungs/N. Schreiber, E. Kotte, B. Muller, Marburg, Germany, p.A4096


P1477 The Presence of Serotonin in Cigarette Smoke - A Possible Mechanism in Cigarette Smoke-Induced Airway Inflammation/Y. Cui, W.K.W. Lau, K.W.K. Liu, M.S.M. Ip, J.C.W. Mak, Hong Kong, Hong Kong Prc, p.A4099


P1479 Cigarette Smoke-Induced Downregulation of the Epithelial Cell Enriched WNT Receptor Fzd4 Contributes to Reduced Wnt/β-Catenin Signaling and Alveolar Epithelial Cell Proliferation in COPD/S. Skrnska-Wasek, K. Mutze, H.A. Baarsma, D.E. Wagner, M. Stornaiuolo, M. Konigshof, Munich, Germany, p.A4101


P1482 Hexadimethrine Bromide Prevents Acute Mortality in Rats After Inhalation of Sulfur Mustard Analog, 2-Chloroethyl Ethyl Sulfide (CEES)/N. Mariappan, M. Husain, I. Zafar, S. Ahmad, A. Ahmad, Birmingham, AL, p.A4104

P1483 Secondhand Smoke Diminishes Airway Epithelial Ion Transport In Vitro and In Vivo and Is Partially Blocked by Antioxidant Therapy/L.W. Rasmussen, H. Forbinberry, S. Byzek, L. Tang, S. Rowe, S.V. Raju, Birmingham, AL, p.A4105


P1494 Determination of Asbestos Body-Associated Proteins by Laser Toxicants, Salicylic Acid and Toluene Diisocyanate, Enhance Mechanisms of Uptake/Egress and Intracellular Fate of Cigarette Smoke Decreases NALP3 Protein Levels/

ATS 2016 • San Francisco

Discussion:

Viewing:

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

B61 FIBROBLASTS AND MATRIX IN COPD

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

P1489 Quercetin Protects Cigarette Smoke Extract (CSE)-Induced Mitophagic Cell Death in Pulmonary Epithelial Cells

P1490 Cigarette Smoke-Induced Accumulation of Oxidized Phosphatidylcholine in COPD Primary Human Lung Fibroblasts: Inhibition by Simvastatin

P1491 Cigarette Smoke Decreases NALP3 Protein Levels/

P1492 Mechanisms of Uptake/Egress and Intracellular Fate of Nanoparticles in Primary Rat Alveolar Epithelial Cell Monolayers (RAECM)
### P1033 Connective Tissue Growth Factor that Promotes Pulmonary Epithelial Cell Senescence is a Severity-Dependent Biomarker for COPD


### P1034 Little Evidence for Epithelial-Mesenchymal Transition in a Murine Model of Airway Fibrosis Induced by Repeated Naphthalene Exposure


### P1035 Low Vitamin K Status Is Associated with COPD and Accelerated Degradation of Mature Elastin


### P1036 Relationship Between Pulmonary Matrix Metalloproteinases and Emphysema Sub-Types


### P1037 Matrix Metalloproteinase 10 (MMP10) Is Highly Up-Regulated in Low Input Ion Torrent RNA-Sequencing of Formalin-Fixed, Paraffin-Embedded (FFPE) Tissue from Patients with Idiopathic Pulmonary Fibrosis


### P1052 An Antagonistically Pleiotropic Role of miR-34a in the Pathogenesis of Lung Fibrosis in Young and Aged Mice

H. Cui, S. Banerjee, J. Ge, N. Xie, R.-M. Liu, V.B. Antony, V.J. Thannickal, G. Liu, Birmingham, AL, p.A4140

### P1053 Elderly-Onset Hereditary Pulmonary Alveolar Proteinosis and CSF2RA Mutation


### P1054 FENDRR Is an Epigenetic Regulator of Cellular Senescence in Pulmonary Fibroblasts


### P1055 Analysis of Long Non-Coding RNA Expression Profiles in the Mouse Model of Pulmonary Fibrosis


### P1056 Identification of Paraquat Aerosolization-Induced Lung Injury and Related Fibrosis in Mice


### P1057 NEU1 Sialidase Is Elevated in the Lungs of Patients with IPF


### P1058 Interstitial Smooth Muscle Bundles Rather than Activated Myofibroblasts Are Associated with Poor Clinical Outcomes in Patients with Histologic Areas of Organization

E. Miyazaki, K. Mutze, H.B. Schiller, D.E. Wagner, M. Konigshoff, Munich, Germany, p.A4147

### P1510 Gene Expression Profiling in End-Stage IPF Lung Fibroblasts


### P1511 Role of MAP Kinase Phosphatase 5 (MKP5) in Pulmonary Fibrosis


### P1512 Disruption of Proximal-Peripheral Epithelial Differentiation and Activation of Hippo/YAP Signaling in Idiopathic Pulmonary Fibrosis

A. Sridharan, A.W. Lange, K.A. Wikenheiser-Brokamp, B. Stripp, J.A. Whitsett, Cincinnati, OH, p.A4150

### P1513 STAT3 Is a Critical Regulator of Myofibroblast Function and Pulmonary Fibrosis


P1517 Evidence of Mesenchymal to Epithelial Transition in Human Fibroblasts Obtained from Normal Lungs and from Idiopathic Interstitial Pneumonias/C. Becerril, M. Montano, C. Ramos, J. Cisneros, C. Mendoza-Milla, M. Checa, A. Pardo, M. Selman, Mexico City, Mexico, p.A4155


P1519 The Role of p22phox-Dependent NADPH Oxidases in Bleomycin-Induced Interstitial Lung Disease/B.M. Nagy, C. Nagaraj, H. Olschewski, A. Olschewski, Graz, Austria, p.A4157

P1520 The Role of Bronchiolar Epithelial Cell Migration in Idiopathic Pulmonary Fibrosis (IPF)/J. Fukumoto, R. Soundararajan, R.F. Lockey, N. Kolliputi, Tampa, FL, p.A4158

P1521 Alveolar Epithelial Cells Release Pro-Fibrotic Mediators in Response to Endoplasmic Reticulum Stress/K.E. Black, V.A. Pace, A.M. Tager, Boston, MA, p.A4159

P1522 Whole Genome Sequencing Identifies Susceptibility Loci for DPB/Y. Jin, D. Weng, Shanghai, China, p.A4160


P1526 Lung Fibroblasts Derived from Patients with Idiopathic Pulmonary Fibrosis Are Resistant to Alternaria Alternata-Mediated Cell Death/J. Im, R.S. Nho, Minneapolis, MN, p.A4164


P1528 Electrophysiological and Pharmacological Characterization of Primary K++-, Cl—, and Ca2+-Conductances in Human Pulmonary Fibroblasts/M. Rahman, S. Mukherjee, V. Sheng, L. Janssen, Hamilton, Canada, p.A4166

P1529 Establishment of Non-Infectious Exacerbation Pulmonary Fibrosis Model in Rat/S. Chen, D. Weng, Shanghai, China, p.A4167

P1530 Identification of Novel Mediators in Lung Fibrosis/J. Verneau, London, United Kingdom, p.A4168

P1531 Melatonin Attenuates TGFß1-Induced Epithelial-Mesenchymal Transition in Lung Alveolar Epithelial Cells/Y. Na, J. Kang, Shenyang City, China, p.A4169


P1535 Urokinase Plasminogen Activator (uPA) IIs Increased in Interstitial Lung Disease (ILD): A Potential Fibrogenic Mediator and Biomarker in ILD/M. Schuliga, J. Jaffar, A. Berhan, S. Langenbach, T. Harris, G. Westall, A.G. Stewart, Parkville, Australia, p.A4173


**THEMATIC POSTER SESSION**

**B63**

**MY WAY: OSA OUTPATIENT MODELS OF CARE**

**9:00 a.m. - 4:15 p.m.**

**MOSCONÉ CENTER**

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion

11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: C. Chai-Coetzer, MBBS, PhD, Adelaide, Australia

J.P. Bakker, PhD, Boston, MA


**P1541** Should the Epworth Sleepiness Score Be Used to Prioritize Services for Suspected Obstructive Sleep Apnea?/A. Neill, A. Campbell, D. Scott, Wellington, New Zealand, p.A4178


**P1543** Role of Nocturnal Oxygen Desaturation for the Diagnosis of Coexistent Obstructive Sleep Apnea in Patients with COPD/D. Dhingani, A.S. Copur, V. Khatri, A. Fulambarker, North Chicago, IL, p.A4180

**P1544** Romanian Lesson from a Screening of Sleep Apnea and Patients with Obesity-Hypventilation Syndrome/F.D. Mihaltan, E.C. Jeler, Bucharest, Romania, p.A4181

**P1545** Sleep Apnea and Prescription Opioid Use in U.S. Veterans: Results from a National Database/S. Chowdhuri, W. Wiitala, D. Ratz, J. Davis, Detroit, MI, p.A4182

**P1546** Sleep Disorders in Breast Cancer Patients Based on Polysomnographic Data/A. Knox, D. Balachandran, V.C. Murphy, L. Bashoura, S.A. Faiz, Houston, TX, p.A4183

Facilitators: S. Mukherjee, MBBS, PhD, Toronto, Canada

A. Neill, MBChB, MD, Wellington, New Zealand


**P1551** Impact of the Purchase of Continuous Positive Airway Pressure Therapy on Acceptance and Long Term Adherence: A Belgian Model/G.B. Mwenge, J. Leemans, J. Bousata, D. Rodenstein, Bruxelles, Belgium, p.A4188

**P1552** Evaluation of a “Fast Track” Alternative Care Provider Clinic for Patients with Severe Sleep Disordered Breathing/S.R. Patel, MD, Pittsburgh, PA


**THEMATIC POSTER SESSION**

**B64**

**BOP GOES THE HEART: CARDIOVASCULAR CONSEQUENCES OF SDB**

**9:00 a.m. - 4:15 p.m.**

**MOSCONÉ CENTER**

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion

11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: S.R. Patel, MD, Pittsburgh, PA

**P1555** Effects of JAG1 Gene Polymorphism on Systemic Blood Pressure in Patients with Obstructive Sleep Apnea/R. Tkacova, I. Paranicova, V. Habalova, I. Trojova, P. Joppa, I. Tkac, Kosice, Slovak Republic, p.A4191


**P1557** The Interaction of Obesity and Nocturnal Hypoxemia on Cardio-Vascular Consequences in Adults with Obstructive Sleep Apnea: A Historical Observational Study/T. Kendzerska, N. Ayas, A.S. Gershon, G. Tomlinson, R.S. Leung, Toronto, Canada, p.A4193

**P1558** Sleep-Disordered Breathing Is Associated with Macrovascular Complications in Patients with Diabetes Mellitus Type II/S. Stadler, S. Jallil, C. Boger, M. Arzt, Regensburg, Germany, p.A4194


P1561 Characteristics of Arterial Stiffness in Young Male Patients with Arterial Hypertension, Obesity and Severe Sleep Apnea Syndrome/E. Elfimova, A. Zairova, M. Andreevskaya, A. Litvin, A. Rogoza, I. Chazova, Moscow, Russian Federation, p.A4197

P1562 Slow Wave Sleep and Incident Hypertension/S. Javaheri, Y.Y. Zhao, N. Punjabi, S. Quan, D.J. Gottlieb, S. Redline, Boston, MA, p.A4198

P1563 Purinergic P2X3 Receptor Signalling in the Carotid Body (CB) Accounts for Its Aberrant Discharge in Pathology Revealing New Therapeutic Target for Hypertension/J.F. Paton, D.J. Moraes, M.P. Da Silva, B.H. Machado, A.P. Ford, Bristol, United Kingdom, p.A7846


P1565 Association Between Nocturnal Blood Pressure Dipping and Arterial Stiffness in Patients with Mild Obstructive Sleep Apnea/L.R.A. Bittencourt, Sao Paulo, Brazil, p.A4200

P1566 The Prevalence of Obstructive Sleep Apnea in Patients with Type B Aortic Dissection/W. Ling, J.J. Fang, G. Li, C.P. Yan, W. Rui, C.J. Yan, Guangzhou, China, p.A4201

P1567 Impact of Pulmonary Hypertension on Reduction of Right Ventricular Longitudinal Strain in Patients with Obstructive Sleep Apnea Syndrome/A. Canora, S. Castaldo, C. Santoro, A. Buonaurio, R. Esposito, B. Trimarco, A. Sanduzzi Zamparelli, M. Caleri, M. Bocchino, Naples, Italy, p.A4202


P1569 Prevalence and Outcomes of Sleep Disordered Breathing in Heart Failure/S. Kotecha, K. Kee, T. Roebuck, E. Dabscheck, B. Miller, P. Bergin, M.T. Naughton, Melbourne, Australia, p.A4204

P1570 Exercise in Normobaric Hypoxia Compared to Sham Hypoxia Improves Cardiovascular Rehabilitation in Geriatric Patients/S. Pramsohler, S. Wimmer, M. Burtscher, M. Faulhaber, H. Gatterer, N. Netzner, Bad Aibling, Germany, p.A4205


P1572 6-Month Follow Up of Sleep Disordered Breathing in Congestive Heart Failure in Maputo, Mozambique/J.E. Orr, I. Mbanze, P.N. DeYoung, G. Valerio, G. Muchanga, R. Banze, E. Nunes, A. Malhotra, A. Damasceno, La Jolla, CA, p.A4207


P1574 Sleep Overnight Monitoring for Apnea in Heart Failure (SOMA-HF Study)/A. Chowdhury, A. Adams, S. Gupta, K. Flemming, L. Willis, P.J. Mather, S. Sharma, Philadelphia, PA, p.A4209


P1577 Successful Management of Breathing-Related Sleep Disorder Associated with an Orphan Syndrome, Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD)/M.I. Saadi, M.A. Tablizo, Fresno, CA, p.A4212

P1579 Parkinson’s Disease as a Contributing Cause of Obstructive Sleep Apnea, Treatable with Controlled Release Levodopa/M. Kaminaska, A.-L. Lafontaine, V. Mery, A. Robinson, R.J. Kimoff, Montreal, Canada, p.A4214

P1580 A Case of Idiopathic Bilateral Diaphragmatic Paralysis Presenting in a Young Man with Orthopnea and Sleep Disruption/T. Sahai, A. Goizueta, N. Hauser, M. Stanchina, D. Rosen, M. Kuroghlian, Providence, RI, p.A4215

THEMATIC POSTER SESSION

B65 THINGS THAT GO BUMP IN THE NIGHT: SLEEP CASE STUDIES AND NON-OSA SLEEP

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area N, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: B. Mokhlesi, MD, MS, Chicago, IL


P1577 Successful Management of Breathing-Related Sleep Disorder Associated with an Orphan Syndrome, Rapid-Onset Obesity with Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD)/M.I. Saadi, M.A. Tablizo, Fresno, CA, p.A4212

P1578 A Rare Case of Persistent Hypersomnia of Central Origin After Pneumococcal Meningitis/M.I. Saadi, L. Keenan, Fresno, CA, p.A4213

P1579 Parkinson’s Disease as a Contributing Cause of Obstructive Sleep Apnea, Treatable with Controlled Release Levodopa/M. Kaminaska, A.-L. Lafontaine, V. Mery, A. Robinson, R.J. Kimoff, Montreal, Canada, p.A4214

P1580 A Case of Idiopathic Bilateral Diaphragmatic Paralysis Presenting in a Young Man with Orthopnea and Sleep Disruption/T. Sahai, A. Goizueta, N. Hauser, M. Stanchina, D. Rosen, M. Kuroghlian, Providence, RI, p.A4215
B66  LUNG CANCER SCREENING AND NODULE EVALUATION

9:00 a.m. - 4:15 p.m.  MOSCONTE CENTER

Area E, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator:  M.P. Rivera, MD, Chapel Hill, NC


P549  Identifying Lung Cancer in Patients with Current or Previous Pulmonary Tuberculosis/C. Parker, C. Siracuse, E. Pinjic, A. Rebello, F.C. Hiran, V. Little, Boston, MA, p.A4233

P550  The Diagnostic Value of 18F-FDG PET-CT for Early Lung Occupying Lesion/Y. Li, W. Luo, W. Li, Sichuan, China, p.A4234


P553  Lung Cancer Screening Program in Public Primary Care Health System in the Southern of Brazil/M.M.R. Leite, R.S. Gutierrez, F.M. Svartman, A.P.G. Sartori, Porto Alegre, Brazil, p.A4237


Facilitator:  C.M. Kinsey, MD, MPH, Burlington, VT/

P556  FEV1 and DLCO as an Additional Risk Stratifying Parameter in Lung Screening Programs/V. Le, Y. Lei, A. Jimenez, A. Campagna, S. Regis, B. McKee, C. Lamb, Burlington, MA, p.A4240


P559 Unusual Cause of Peripheral Lung Nodules in a Patient with Idiopathic Pulmonary Fibrosis (IPF)/J. Deepak, A.E. Wyman, A. Striegel, E. Pickering, Baltimore, MD, p.A4243

P560 A Rare and Interesting Cause of Pulmonary Nodules: A Case of Epithelioid Hemangioendothelioma/A. Harper, G. Dominell, J. English, J. Johnston, Vancouver, Canada, p.A4244


P563 Multiple Calcified Pulmonary Nodules: Not Always Granulomatous/I.S.G. Arif, T. Barnes, Grand Rapids, MI, p.A4247


P566 A PET Artifact Masquerading as a PET Positive Lung Mass/P. Tunsupon, M.J. Mador, Buffalo, NY, p.A4250

P567 Cannonballs in Disguise/G. Thompson, K. Sharain, R. Carlin-Ceba, Rochester, MN, p.A4251

P568 Transthoracic Needle Biopsy- A Cautionary Tale/S. Dhungana, K. Buch, Lexington, KY, p.A4252


P575 Lung Cancer Fast Track Referrals: Evaluation of a New Referral Form in East Dorset/R. Punwani, M. Brown, W. Denehan, S. Crowther, Poole, United Kingdom, p.A4256


P577 A Noninvasive, Simple-to-Perform and Transcutaneous Measurement for Lung Cancer/J. Li, J. Zhou, Y. Song, C. Bai, Shanghai, China, p.A4258


P581 Clinical Characteristics of Lung Cancer Diagnosed During Follow-Up of Interstitial Pneumonia/M. Sema, H. Sakashita, Y. Miyazaki, N. Inase, Tokyo, Japan, p.A4262

P582 Clínico-Radio-Pathological Profile of 174 Patients of Bronchogenic Carcinoma in Udaipur Region/R.K. Sharma, G. Chhabra, Udaipur, India, p.A4263

P583 Effect of PET-CT on Staging of the Patients with Small Cell Lung Cancer Who Had Been Determined as Limited Stage with Conventional Methods/U. Yilmaz, B. Yalcin, F. Coskun, H. Arik, F. Cansun, Izmir, Turkey, p.A4264


P585 Outcomes of Stage I Non Small Cell Lung Cancer at the Princess Alexandra Hospital, Australia, 2008-2012/R. Sheehy, C. Hukins, M. Murphy, Brisbane, Australia, p.A4266


P588 High Neutrophil-Lymphocyte Ratio Confers Poor Prognosis in Patients with Small Cell Lung Cancer/D. Liu, W. Li, Chengdu, China, p.A4269


Facilitator: T. Peikert, MD, Rochester, MN

P590 Evaluation of the Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients with Actionable Mutations Treated with Molecular Targeted Therapy in the Intensive Care Unit/K.C. Kerrigan, G. Otterton, Columbus, OH, p.A4271


P594 The Efficacy of Bevacizumab for Patients with Malignant Pleural Effusion or Ascites: A Meta-Analysis from 6 Randomized Controlled Clinical Trials/J. Zhang, Shanghai, China, p.A4275


The annual ATS Women’s Forum recognizes the achievements and supports the advancement of women in pulmonary, critical care, and sleep medicine and research. At the forum Catherine R. Lucey, MD, Professor of Medicine, Vice Dean for Education, University of California San Francisco School of Medicine will discuss issues that are relevant to female medical professionals followed by a question and answer period.

In addition, the 2016 Elizabeth A. Rich, MD Award, which has honored the work and memory of Elizabeth Rich, MD since 2000, will be presented. The award is given to a woman who has made significant achievements in the practice or science of pulmonary, critical care, or sleep medicine; demonstrated leadership in her field; and has shown dedicated mentorship of junior colleagues. The 2016 award recipient is Irina Petrache, MD, Professor, Department of Medicine, Chief, Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO. Dr. Petrache will also address the audience.

The forum provides a valuable opportunity for women to meet new colleagues and ATS leaders. Men are also welcome to attend the forum. Attendees will find value in the inspirational messages and career insights that the speakers share as well as vibrant networking opportunities.

The forum is organized and presented by the ATS Membership Committee, and will be hosted by Yolanda Mageto, MD, MPH, chair of the committee.

Conference badges are required for admission. Space is limited and admittance is on a first-come, first-served basis. There is no additional fee. A plated lunch will be served.
WS3  PULMONARY REHABILITATION FOR INTERSTITIAL LUNG DISEASE: OPTIMIZING THE MODEL

Registration Fee: $75.00 (includes box lunch)
Attendance is limited. Pre-registration is required.

Assemblies on Pulmonary Rehabilitation; Clinical Problems; Nursing
11:45 a.m. - 1:15 p.m.  MOSCONE CENTER
Room 301 (South Building, Esplanade Level)

Target Audience
Providers of care to people with interstitial lung disease; providers of pulmonary rehabilitation.

Objectives
At the conclusion of this session, the participant will be able to:
• learn about the state of the science underpinning ILD rehabilitation;
• prescribe effective exercise training for people with ILD;
• gain new strategies for comprehensive rehabilitation in ILD.
This workshop will define the state of the evidence for pulmonary rehabilitation in interstitial lung disease (ILD) and explore strategies to optimize rehabilitation outcomes for patients with these diverse and disabling respiratory conditions.

Chairing:
A.E. Holland, PhD, Melbourne, Australia
L.P. Cahalin, PhD, Miami, FL

11:45  Rehabilitation for ILD: State of the Evidence
A.E. Holland, PhD, Melbourne, Australia

12:00  Peripheral Muscle in ILD: Does it Matter?
S. Mathur, PhD, PT, Toronto, Canada

12:15  Exercise Training Strategies for ILD: Meeting the Physiological Challenge
B. Vainshelboim, PhD, Petach Tikva, Israel

12:35  Beyond Exercise Training: What is Comprehensive Rehabilitation for ILD?
J.J. Swigris, DO, MS, Denver, CO

12:55  Capturing Important Changes: Measurement of Outcomes in Rehabilitation for ILD
L. Dowman, MAappSc, Heidelberg, Australia

WS4  PATIENT-DERIVED MODELS OF HUMAN LUNG DISEASE: A LAB MEETING

Registration Fee: $75.00 (includes box lunch)
Attendance is limited. Pre-registration is required.

Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Clinical Problems; Critical Care; Environmental, Occupational and Population Health; Microbiology, Tuberculosis and Pulmonary Infections; Pediatrics; Pulmonary Circulation; Pulmonary Rehabilitation; Respiratory Structure and Function; Sleep and Respiratory Neurobiology; Thoracic Oncology
11:45 a.m. - 1:15 p.m.  MOSCONE CENTER
Room 302 (South Building, Esplanade Level)

Target Audience
Lung health care providers, scientists and investigators interested or involved in basic, translational and clinical research related to the pathogenesis, pathology and clinical aspects of COPD and related human lung diseases, research and care providers engaged in pulmonary and critical care medicine.

Objectives
At the conclusion of this session, the participant will be able to:
• learn about state of the art in vivo, ex vivo and in vitro patient-derived models of human lung biology and disease;
• implement patient-derived models to study the pathogenesis, phenotype and candidate therapies for human lung diseases;
• understand how to translate information derived from patient-derived models into innovative clinically relevant approaches to study, diagnose, prevent and treat human lung diseases in a personalized manner ("precision medicine").
This workshop will discuss state of the art methods to study chronic human lung diseases (asthma, cystic fibrosis, COPD, and pulmonary fibrosis) in a personalized manner by modeling complex interaction between different cell types and tissue components (epithelial cells, extracellular matrix, fibroblasts, blood vessels, immune cells etc) using patient-derived human samples. In addition to talks by leading experts in the field, during this session, participants will have an opportunity to discuss their own research problems, ideas and questions with the faculty in a “lab meeting format” and learn how to translate discoveries derived from studies using patient-derived models into novel personalized approaches to prevent and treat human lung diseases (targeted “precision medicine” strategies).

Chairing:
R. Shaykhiev, MD, PhD, New York, NY
S.D. Reynolds, PhD, Columbus, OH
D.J. Weiss, MD, PhD, Burlington, VT

11:45  “Personalized” In Vitro and Ex Vivo Models of Human Airway Disease
S.H. Randell, PhD, Chapel Hill, NC

12:00  Patient-Derived 3D-Models of COPD and Emphysema
M. Konigshoff, MD, PhD, Munich, Germany

12:15  Preclinical Humanized Models of Airway Remodeling in Asthma
R. Freishtat, MD, MPH, Washington, DC

12:30  Modeling Lung Disease Using iPS Cells: Towards Precision Medicine
D.N. Kotton, MD, Boston, MA

12:45  “Lab Meeting” Discussion
Z. Borok, MD, Los Angeles, CA
C. Coraux, PhD, Reims, France
At the conclusion of this session, the participant will be able to:

- understand the FDA’s Center for Tobacco Products’ (CTP) strategic priorities and CTP’s vision for the regulation of tobacco products to help reduce the death and disease toll caused by tobacco use;
- discuss the Deeming Proposed Rule and how it will affect the way CTP evaluates the newly regulated products;
- understand CTP’s research portfolio and how the Office of Science uses this information to inform tobacco product regulation.

The 2009 Tobacco Control Act gave FDA regulatory authority over cigarettes, cigarette tobacco, roll-your-own tobacco, and smokeless tobacco. Newly “deemed” products in a proposed rule include electronic cigarettes, cigars, pipe tobacco, certain dissolvables that are not “smokeless tobacco,” gels, and waterpipe tobacco. Once the proposed rule becomes final, FDA will be able to use regulatory tools, such as age restrictions and rigorous scientific review of new tobacco products and claims to reduce tobacco-related disease and death. Youth use of certain unregulated tobacco products, such as e-cigarettes and cigars, is on the rise. FDA oversight of tobacco products can provide important information about proposed deemed tobacco products and help limit youth exposure to these products. Once final, the rule will also enable FDA to explore whether different products pose different levels of risk, and will help the Agency develop policies to improve public health. This session will help the medical, research, and public health communities understand the authority granted to the FDA to regulate tobacco and tobacco products and how science is used to make the most effective regulatory decisions.

**Chairing:** P. Callahan-Lyon, MD, Silver Spring, MD

12:15 FDA Regulation of Tobacco Products in the U.S.
P. Callahan-Lyon, MD, Silver Spring, MD

12:55 CTP Research Portfolio
C. Dresler, MD, Silver Spring, MD

**Target Audience**
Internists and subspecialists in pulmonary, critical care, and sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification.

**Objectives**
At the conclusion of this session, the participant will be able to:

- remain current with medical knowledge relevant to their practice in pulmonary, critical care, and sleep medicine;
- evaluate their understanding of key skills and content areas in pulmonary, critical care and sleep medicine, as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of pulmonary, critical care, and sleep medicine. The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice, as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

**Chairing:** J.S. Balachandran, MD, Chicago, IL
T.S. Wang, MD, Los Angeles, CA

11:45 Sleep Testing/Staging/Scoring: Staging and Scoring
C. Lal, MD, Charleston, SC

12:05 Sleep Testing/Staging/Scoring: In-Lab Diagnostics
N.A. Shah, MD, MPH, New York, NY

12:45 Sleep Testing/Staging/Scoring: Ambulatory Diagnostics
K.F. Sarmiento, MD, MPH, La Jolla, CA

**Target Audience**
Any attendees interested in reducing tobacco related deaths.

**Objectives**
At the conclusion of this session, the participant will be able to:

- provide an overview of the NASA Health and Air Quality Program relating to public health applications that are of interest to pulmonary clinicians and researchers.
Satellite earth observations present a unique vantage point of the earth's environment from space which offers a wealth of health applications for researchers. The session will show results of the remote sensing observations of earth and health applications. This session will detail ongoing projects within NASA and specifically related to incorporating satellite remote sensing for studying dust, forest fires and their relationship to diseases such as asthma, and other environmentally-induced lung and cardiac diseases.

Chairing: S.M. Estes, MS, Huntsville, AL  
J.A. Haynes, MS, Washington, DC

12:15  Using NASA’s Remote Sensing Data to Improve Research in Respiratory Health  
J.A. Haynes, MS, Washington, DC

12:25  Downwind of the Flames: Assessing and Predicting Wildfire Smoke Related Morbidity Using Satellites, In-Situ Measurements and Models  
R. Gan, PhD, Ft. Collins, CO

12:40  Utilization of Satellite Observation for Improved Air Quality Simulations  
A.P. Biazar, PhD, Huntsville, AL

A. Omar, PhD, Hampton, VA

VETERANS ADMINISTRATION

L13  SLEEP RESEARCH IN THE VA: GENES, COMORBIDITIES, AND GENDER  
12:15 p.m. - 1:15 p.m.  
MOSCON CENTER  
Room 3020/3022 (West Building, Level 3)

Target Audience
Providers serving patients with sleep disorders; those treating central sleep apnea in heart failure; those engaged in research related to sleep disorders; pulmonary providers or investigators in the VA.

Objectives
At the conclusion of this session, the participant will be able to:
• understand potential roles of genetic factors in sleep disorders;
• treat central sleep apnea in heart failure patients;
• recognize and treat sleep disorders among women.

Complexity in the manifestations of sleep disorders may relate to heterogeneity in genetic and gender related factors and variables impacts of co-morbid conditions including heart failure and mental illnesses. Because sleep disorders are exceedingly common among veterans, the VA Research and Development Program supports broad-based investigation into these disorders. This session will include presentations from investigators in the VA on their research related to (1) genetic causes of sleep disorders using mouse models; (2) optimal treatments for central sleep apnea in patients with heart failure; and (3) prevalence and nature of sleep disorders, including insomnia, among women and their preferences for treatment.

Chairing: J.K. Brown, MD, San Francisco, CA  
M.S. Badr, MD, Detroit, MI  
L. Nici, MD, Providence, RI

12:15  Respiratory Rhythmogenesis in Mouse Models  
K.P. Strohl, MD, Cleveland, OH

12:35  Heart Failure and Central Sleep Apnea: Beyond ASV  
D.J. Gottlieb, MD, MPH, Boston, MA

12:55  Sleep Disorders Among Women Veterans  
J.L. Martin, PhD, North Hills, CA

NATIONAL CENTER FOR ENVIRONMENTAL HEALTH, CDC

L14  UPDATE FROM CDC’S NATIONAL ASTHMA CONTROL PROGRAM  
12:15 p.m. - 1:15 p.m.  
MOSCON CENTER  
Room 3006/3008 (West Building, Level 3)

Target Audience
Clinicians, physicians, nurses, respiratory therapists, asthma educators.

Objectives
At the conclusion of this session, the participant will be able to:
• recognize the role of state health departments in asthma control;
• improve quality of asthma care provided to patients;
• understand the importance of public health/clinical care partnerships for asthma control.

Asthma is an ideal model to demonstrate public health/health care collaboration. Moreover, asthma is highly associated with disparities across racial, ethnic and socioeconomic groups. Multi-component interventions are available to address asthma, including guidelines-based medical management, self-management education, indoor and outdoor trigger reduction interventions, and linkages to social services. A strong evidence base has documented the feasibility and effectiveness of asthma interventions and the ability of asthma efforts to generate a short-term return on investment. CDC works with state and federal partners to advance public health/healthcare collaboration to maximize the reach, impact, efficiency and sustainability of comprehensive asthma control services.

Chairing: P.L. Garbe, DVM, MPH, Atlanta, GA

12:15  State Asthma Control Programs  
P.L. Garbe, DVM, MPH, Atlanta, GA

12:35  Quality Measures for Asthma Care  
S.F. Beavers, MD, Atlanta, GA

12:55  Insurance Reimbursement for Comprehensive Asthma Care  
J. Hsu, MD, Atlanta, GA
L15 ENDOTYPES AND PHENOTYPES: A BASIS FOR PRECISION-BASED MEDICINE IN COPD, THE SUBPOPULATIONS AND INTERMEDIATE OUTCOME MEASURES IN COPD STUDY (SPIROMICS)

Target Audience
Those with clinical or research responsibilities.

Objectives
At the conclusion of this session, the participant will be able to:
• understand and learn about imaging phenotyping of COPD;
• learn about molecular phenotyping of COPD;
• learn about clinical phenotyping of COPD.

SPIROMICS is an NHLBI sponsored study that supports the prospective collection and analysis of phenotypic, biomarker, genetic, genomic, and clinical data from subjects with COPD for the purpose of identifying subpopulations and intermediate outcome measures. Participants in this session will learn about new results from the SPIROMICS study that define new clinical subpopulations related to COPD, clinically relevant endotypes that affect risk, and potential intermediate markers that predict disease progression. The session will also provide information for early stage investigators and the investigative community on how to get involved with the study and access data.

Chairing:
R.G. Barr, MD, DrPH, New York, NY
L. Postow, PhD, Bethesda, MD

12:15 Overview of SPIROMICS Design
R.G. Barr, MD, DrPH, New York, NY

12:25 Significance of Large and Small Airway Phenotypes
M.K. Han, MD, MS, Ann Arbor, MI

12:40 Identifying COPD Subpopulations Based on Symptoms and Molecular Signatures
P.G. Woodruff, MD, MPH, San Francisco, CA

12:55 SPIROMICS Imaging Phenotyping
E.A. Hoffman, PhD, Iowa City, IA

1:05 Identified Subpopulations Based on Unbiased Clustering
E. Bleecker, MD, Winston-Salem, NC

L16 VIRUSES AND BACTERIA IN ASTHMA ACROSS THE AGES

Target Audience
Providers of lung health, medical fellows in training, graduate, post-doctoral fellows and established scientists in basic research on lung biology, and infectious disease.

Objectives
At the conclusion of this session, the participant will be able to:
• understand and learn new findings about the impact of nasal bacteria and viruses on respiratory illness severity and response to azithromycin therapy in preschool children with recurrent severe episodes of lower respiratory tract symptoms;
• gain knowledge about differences in the bronchial bacterial microbiome in patients with allergies and asthma and characterize modifications in the microbiome associated with the use of inhaled corticosteroids in adults with asthma;
• describe how treatment with inhaled corticosteroids alters the bronchial virome in adults with asthma.

This session highlights findings from two AsthmaNet studies that investigated effects of inhaled corticosteroids (ICS) on bacterial microbiome and virome in adults and effects of the virome on respiratory illness severity and response to azithromycin therapy in children. Findings elucidate how two components of the microbiome - bacterial and viral - are impacted by treatment and how viruses influence severity of respiratory illness and treatment response. Management insights might emerge during the panel-audience discussion, e.g., composition of the baseline airway bacterial microbiome may shape the response to viral respiratory infection, as frequently one of the treatments prescribed is an ICS.

Chairing:
W.W. Busse, MD, Madison, WI
J.P. Kiley, PhD, Bethesda, MD

12:15 Viral and Bacterial Determinants of Illness Severity and Response to Azithromycin Therapy in Preschool Children
D.J. Jackson, MD, Madison, WI

12:30 Bronchial Bacterial Microbiome: Relationships to Allergy, Asthma, and Inhaled Corticosteroid Treatment
Y.J. Huang, MD, Ann Arbor, MI

12:45 Bronchial Virome: Effects of Inhaled Corticosteroid Treatment in Adults with Asthma
A. Shifren, MD, St. Louis, MO

1:00 General Discussion
W.W. Busse, MD, Madison, WI

L17 EDUCATION RESEARCH IN SLEEP HEALTH AND SLEEP-CIRCADIAN BIOLOGY

Target Audience
Health care providers, researchers, educators, and public stakeholders interested in innovative education tools, programs and platforms that will transfer health information and scientific advances in sleep and circadian biology to medical education, health care, and community-based settings.
Objectives
At the conclusion of this session, the participant will be able to:

- describe findings from innovative educational research programs;
- understand and describe strategies for effective transfer of sleep and circadian scientific knowledge;
- describe communication goals and methods of implementation in health care and communities settings.

This session will present data-based findings and progress from an NHLBI initiative that aims to develop educational strategies for the dissemination of sleep and circadian biology based health information to health care providers and minority communities. The presentations will focus on improving sleep apnea health literacy through community-based engagement, improving sleep/circadian rhythms and the detection of sleep disorders in the inpatient setting, and enhanced sleep/circadian medical education via telemedicine for residents and primary care physicians.

Chairing
M. Twery, PhD, Bethesda, MD
J. Girardin, PhD, New York, NY

12:15 Tailored Sleep Health Education: A Community-Engaged Approach
J. Girardin, PhD, New York, NY

12:35 Tackling the Elephant in the Room: Educating Hospital Staff About Sleep Medicine
A. Vineet, MD, Chicago, IL

12:55 Use of Telemedicine to Promote Sleep Medicine Education in Health Care
I. Rosen, MD, MS, Philadelphia, PA
MEET THE PROFESSOR SEMINARS

CME Credits Available: 1.0

Registration Fee: $70.00 (includes box lunch.)
Attendance is limited. Pre-registration is required.

12:15 p.m. - 1:15 p.m. INTERCONTINENTAL HOTEL

MP501 PRIMARY IMMUNE DEFICIENCY AND PULMONARY DISEASE
A. Dosanjh, MD, San Diego, CA
Union Square (Third Floor)

MP502 ELECTRONIC CIGARETTES: POTENTIAL HARMs AND BENEFITS, PERSONAL AND PUBLIC
D.J. Upson, MA, MD, Albuquerque, NM
SoMa (Third Floor)

MP503 LUNG TRANSPLANTATION FOR CONNECTIVE TISSUE DISEASE-RELATED INTERSTITIAL LUNG DISEASE
J.A. Golden, MD, San Francisco, CA
Mission (Third Floor)

MP504 CURRENT STRATEGIES FOR MANAGING THE PATIENT WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
K.M. Wille, MD, MSPH, Birmingham, AL
Marina (Third Floor)

MP505 NEW DRUGS AND BEYOND: PRACTICAL STRATEGIES FOR TOTAL CARE OF THE IPF PATIENT
D.E. Antin-Ozerkis, MD, New Haven, CT
Grand Ballroom C (Third Floor)

MP506 TREATMENT OF BRONCHIECTASIS: WHAT SHOULD I DO?
G. Tino, MD, Philadelphia, PA
Grand Ballroom B (Third Floor)

MP507 TREATMENT OF VENOUS THROMBOEMBOLISM WITH TARGET-SPECIFIC NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS
R.D. Yusen, MD, MPH, St. Louis, MO
Grand Ballroom A (Third Floor)

MP508 TIMING OF REFERRAL FOR LUNG TRANSPLANT IN CYSTIC FIBROSIS
D. Hadjiliadis, MD, MHS, Philadelphia, PA
Twin Peaks (Fourth Floor)

MP509 HOW I DO IT: STRATEGIES OF SUCCESSFUL WOMEN IN CRITICAL CARE
E.L. Burnham, MD, Aurora, CO
P.A. Kritek, MD, Seattle, WA
L. Ware, MD, Nashville, TN
M.S. Herridge, MD, MPH, Toronto, Canada
Telegaph Hill (Fourth Floor)

MP510 AIR POLLUTION AND LUNG CANCER: ROLE OF AIRWAY EPITHELIAL CELLS
H. Bayram, MD, PhD, Gaziantep, Turkey
Potrero Hill (Fourth Floor)

MP511 THE USE OF ANTIBIOTICS AND ADJUNCTIVE THERAPIES IN CRITICALLY ILL PATIENTS WITH CAP
C. Feldman, MBCh, DSc, PhD, Johannesburg, South Africa
Nob Hill (Fourth Floor)

MP512 IMPAIRED SLEEP AND SYMPTOMS MANAGEMENT IN ACUTE AND CHRONIC ILLNESS
E.R. Chasens, PhD, RN, Pittsburgh, PA
Laurel Hill (Fourth Floor)

MP513 BRONCHIECTASIS OBILITERANS IN CHILDREN: CONSENSUS AND CONTROVERSY
G. Kurland, MD, Pittsburgh, PA
A.M.H. Casey, MD, Boston, MA
Cathedral Hill (Fourth Floor)

MP514 IMAGING IN CHRONIC THROMBOEMBOLIC DISEASE: V/Q AND CT SCAN INTERPRETATION FOR THE PULMONOLOGIST
R.N. Channick, MD, Boston, MA
Sutter (Fifth Floor)

MP515 NEW ROLES FOR APOLIPOPROTEINS IN THE PATHOGENESIS AND TREATMENT OF ASTHMA
S.J. Levine, MD, Bethesda, MD
Stockton (Fifth Floor)

MP516 ASTHMA AND WOMEN'S HEALTH. REPRODUCTIVE HORMONES: FRIEND OR FOE?
Y.S. Prakash, MD, PhD, Rochester, MN
Howard (Fifth Floor)

MP517 THE ROLE OF POLYSOMNOGRAPHY IN TECHNOLOGY DEPENDENT CHILDREN
N. Simakajornboon, MD, Cincinnati, OH
J. Brockbank, MD, Richmond, VA
Fremont (Fifth Floor)

MEDICAL EDUCATION SEMINAR

CME Credits Available: 1.0

ME2 DELIVERING TIMELY RELEVANT FEEDBACK IN CLINICAL SETTINGS

Registration Fee: $70.00 (includes box lunch)
Attendance is limited. Pre-registration is required.

12:15 p.m. - 1:15 p.m. INTERCONTINENTAL HOTEL

Target Audience
This session is aimed at faculty and trainees involved in clinical training.

Objectives
At the conclusion of this session, the participant will be able to:
• reiterate the importance of feedback in daily clinical teaching;
• provide clinicians with the tools to create an environment for delivery of effective and timely feedback;
• equip training clinicians with the means to plan and implement feedback sessions in a clinical setting.

Feedback is a cornerstone of medical training. In our daily role as clinician educators, feedback is a key component, facilitating opportunities to improve and...
Encourage trainees to reach their maximum potential. Acknowledging that the provision of meaningful feedback is a skill that can be taught, we approach this session with a literature review of relevance to working clinicians, and follow with an interactive approach to a set of scenarios, illustrated by video case studies.

Speakers: E. Kelly, MD, Dublin, Ireland
J.B. Richards, MD, MA, Charleston, SC

THEMATIC SEMINAR SERIES
CME Credits Available: 1.0

TSS1 CONTEMPORARY CONTROVERSIES IN THE DIAGNOSIS AND MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS: A PRO/CON DEBATE

Registration Fee: $140.00 for full series (includes box lunch)
Attendance is limited. Pre-registration is required.
This is part 2 of a 3-part series. Those registering for this seminar series will be registered for all 3 parts. The program for the full series is included with the Sunday, May 15, 12:15 p.m. program.

Monday 12:15 p.m. - 1:15 p.m. INTERCONTINENTAL HOTEL
InterContinental Ballroom C (Fifth Floor)

PRO: Bronchoalveolar Lavage Should Routinely be Performed in the Diagnostic Work-Up of IPF
A.U. Wells, MD, London, United Kingdom

CON: Bronchoalveolar Lavage Should Routinely be Performed in the Diagnostic Work-Up of IPF
H.R. Collard, MD, San Francisco, CA

THEMATIC SEMINAR SERIES
CME Credits Available: 1.0

TSS2 REDUCING HOSPITAL READMISSIONS

Registration Fee: $140.00 for full series (includes box lunch)
Attendance is limited. Pre-registration is required.
This is part 2 of a 3-part series. Those registering for this seminar series will be registered for all 3 parts. The program for the full series is included with the Sunday, May 15, 12:15 p.m. program.

Monday 12:15 p.m. - 1:15 p.m. INTERCONTINENTAL HOTEL
InterContinental Ballroom B (Fifth Floor)

Approaches to Reduce Hospital Readmissions
S.S. Braman, MD, New York, NY

Effective Components of a Readmission Reduction Program
V.G. Press, MD, MPH, Chicago, IL

Novel Interventions to Reduce Readmissions
J.A. Krishnan, MD, PhD, Chicago, IL

Partnering with Patient Navigators and Peer Advocates
S.R. Halayko, PhD, Winnipeg, Canada
T.W. Ferkol, MD, St. Louis, MO

The Recognition Award for Scientific Accomplishments is given to individuals for outstanding scientific contributions in basic or clinical research to the understanding, prevention and treatment of lung disease. Those considered for the award are recognized for either scientific contributions throughout their careers or for major contributions at a particular point in their careers.

Chairing: A.J. Halayko, PhD, Winnipeg, Canada
T.W. Ferkol, MD, St. Louis, MO

Awardees:
2:15 Cellular and Molecular Mechanisms in Pulmonary Hypertension
Serpil Erzurum, MD, Cleveland, OH

2:45 Asthma and Its Regulation Through the Lens of the Immune System
Anuradha Ray, PhD, Pittsburgh, PA

3:15 COPD: From Genetics to Networks
Edwin K. Silverman, MD, PhD, Boston, MA

3:45 Reactive Oxygen, Aging and Fibrotic Lung Disease
Victor J. Thannickal, MD, Birmingham, AL

ATS 2016 • San Francisco
The information contained in this program is up to date as of March 9, 2016.
For the most current session information, please visit the online program itinerary.
CC3  PULMONARY CLINICAL CORE CURRICULUM II
Adult Core Curriculum Working Group
2:15 p.m. - 4:15 p.m.
MOSCONEx CENTER
Gateway Ballroom 102-104 (South Building, Lower Level)

Target Audience
Internists and subspecialists in pulmonary, critical care, and sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification.

Objectives
At the conclusion of this session, the participant will be able to:
• remain current with medical knowledge relevant to their practice in pulmonary, critical care, and sleep medicine;
• evaluate their understanding of key skills and content areas in pulmonary, critical care and sleep medicine, as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
• support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of pulmonary, critical care, and sleep medicine. The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice, as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

Chairing:
G.C. Michaud, MD, New Haven, CT
C.L. Channick, MD, Boston, MA

2:15 Interstitial Lung Disease: Therapeutic Options
D. Sayah, MD, PhD, Los Angeles, CA

2:45 Sarcoid/HP
R. Adamson, MBBS, Seattle, WA

3:15 Opportunistic Pulmonary Infections in HIV and Non-HIV Patients
B. Coruh, MD, Seattle, WA

3:45 Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia
C.S. Dela Cruz, MD, PhD, New Haven, CT

This session and the International Conference are supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

B81  NURSING YEAR IN REVIEW
Assembly on Nursing
2:15 p.m. - 4:15 p.m.
MOSCONEx CENTER
Room 307 (South Building, Esplanade Level)

Target Audience
Registered nurses, advanced practice nurses, and any other ATS members involved in lung health, clinical research and practice and with a particular interest in global perspectives.

Objectives
At the conclusion of this session, the participant will be able to:
• compare the similarities and differences in international pulmonary clinical care and research;
• identify gaps in the international evidence base;
• discuss future international research considerations.

The session will cover key research advances in patient centered care from different international perspectives. Each presenter will present country specific advances and challenges in nursing practice and research whilst offering comparisons with international work.

Chairing:
J. Yorke, PhD, RN, Manchester, United Kingdom
J. Choi, PhD, RN, Pittsburgh, PA

2:15 Control of TB in High Burden Countries: The China Experience
Y. Jin, PhD, Changsha, China

2:35 Control of TB in Low Burden Settings: The UK Experience
A. Story, PhD, RN, London, United Kingdom

2:55 Novel Approaches to Self-Management in Australian Adults with Severe Asthma
V. McDonald, PhD, RN, New Lambton Heights, Australia

3:15 Delivery System Research: Highlights in Pulmonary Nursing Care in the USA and Beyond
H.Q. Nguyen, PhD, RN, Pasadena, CA

3:35 Integrated Care Services for Chronic Pulmonary Patients
C. Hernandez, PhD, MSc, RN, Barcelona, Spain

3:55 General Discussion
**B82 SEEING BEYOND THE VAPORS: CURRENT TOPICS ON ELECTRONIC CIGARETTE USE**

Assemblies on Clinical Problems; Behavioral Science and Health Services Research; Environmental, Occupational and Population Health; Nursing

2:15 p.m. - 4:15 p.m. MOSCONE CENTER Room 135 (North Building, Lower Level)

**Target Audience**
Pulmonologists, internists/hospitalists, trainees and researchers, clinical supervisors, nurses, respiratory therapists, pharmacists, attendees interested in electronic cigarettes, tobacco use and addiction, smoking cessation and tobacco regulation.

**Objectives**
At the conclusion of this session, the participant will be able to:
- describe the use patterns and health perceptions by e-cigarette users nationally and internationally;
- learn the current status of regulation of e-cigarettes;
- counsel patients regarding the role of e-cigarettes in smoking cessation.

Electronic cigarette (e-cigarette) use is increasing at an exponential rate in the U.S. and internationally. This symposium will provide a contemporaneous update on key topics surrounding e-cigarettes. The speakers will review prevalence and use patterns within the U.S. as well as internationally. To ensure relevance to conference attendees, additional topics will cover the diverse issues surrounding e-cigarettes including lung harms and second-hand exposure, FDA and governmental regulatory update and the role of e-cigarettes in smoking cessation. The symposium will conclude with a panel discussion on e-cigarettes.

**Chairing:** M.B. Drummond, MD, MHS, Baltimore, MD
M.N. Eakin, PhD, Baltimore, MD

K.F. Harrington, PhD, MPH, Birmingham, AL

2:35 Effect of E-Cigarettes on Pulmonary Host Defense Responses  
I. Jaspers, PhD, Chapel Hill, NC

2:55 Update on State and Federal E-Cigarette Regulations  
D.J. Upson, MA, MD, Albuquerque, NM

3:15 E-Cigarette Use: An International Perspective  
K. Carlse, MD, PhD, Oslo, Norway

3:35 E-Cigarettes as a Smoking Cessation Tool  
F.T. Leone, MD, MS, Philadelphia, PA

3:55 Panel Discussion  
There will be a 5-minute discussion after each talk.

---

**B83 PEDIATRIC CLINICAL CHEST ROUNDS**

Assemblies on Pediatrics; Allergy, Immunology and Inflammation; Clinical Problems; Critical Care; Nursing; Sleep and Respiratory Neurobiology

2:15 p.m. - 4:15 p.m. MOSCONE CENTER Room 134 (North Building, Lower Level)

**Target Audience**
Pediatric pulmonologists, intensivists, neonatologists, nurse practitioners, nurses, respiratory therapists, others who provide care to children with lung diseases.

**Objectives**
At the conclusion of this session, the participant will be able to:
- diagnose a variety of complex respiratory disorders;
- develop new strategies to manage the care of infants and children with complex or confusing respiratory disorders;
- apply appropriate diagnostic tests in complex cases.

This session discusses interesting clinical cases related to Pediatric Pulmonology. The focus is to choose cases from submitted abstracts that are unique, but also have a clear story to tell that will be of educational benefit to the audience. Duplication of cases presented in previous years are avoided by reviewing previous years’ topics. Cases are presented by fellows or junior faculty and then subsequently discussed by an expert in the field. While the case presentation will be of interest to all Pediatric Pulmonologists; special focus is given to make this session of interests for trainees. Interactive questions are included in all case presentation to engage and involve the audience actively in the process of solving the clinical dilemma to encourage interactive learning.

**Chairing:** J.S. Debley, MD, MPH, Seattle, WA
S. Goldfarb, MD, Philadelphia, PA
J. Harrison, MBChB, MRCP, MRCPCH, Melbourne, Australia

2:15 14 Year Old Boy with a Chronic Productive Cough  
A. Taylor, BA, Denver, CO

2:30 Expert Discussant  
A. Chang , MD, Brisbane, Australia

2:45 Persistent Tachypnea in a Term Infant  
M. Mathew, MD, Mineola, NY

3:00 Expert Discussant  
V. Balasubramaniam , MD, Madison, WI

3:15 14 Year Old Girl with Progressive Dry Cough and Dyspnea  
P. Phinizy, MD, New York, NY

3:30 Expert Discussant  
L. Young, MD, Nashville, TN

3:45 Two Month Old Boy with Noisy Breathing and Hypoxemia  
G. Rulong, MD, Cincinnati, OH

4:00 Expert Discussant  
M.L. Chen, MD, Seattle, WA
**B84**  AT THE EDGE OF THE EVIDENCE: MAKING DECISIONS IN THE REAL WORLD

Assemblies on Critical Care; Nursing
2:15 p.m. - 4:15 p.m. MOSCONE CENTER Room 3000/3002/3004 (West Building, Level 3)

Target Audience
Practitioners in critical care including staff physicians, fellows, medical students, nursing professionals and respiratory therapists.

Objectives
At the conclusion of this session, the participant will be able to:

* more appropriately transfuse blood products in hemorrhagic shock;
* understand and apply available evidence to determine family presence for CPR;
* apply available evidence in deciding whether to place invasive monitoring catheters in critically ill patients.

This session will present expert review of evidence in many topics within critical care and will provide strategies for making decisions “at the edge of the evidence,” where the data do not provide a clear answer. Subjects will range from when to allow family to witness resuscitation attempts to assessing neurologic prognosis after arrest to transfusion guidelines in hemorrhagic shock.

**Chairing:** K.A. Hibbert, MD, Boston, MA
H.B. Gershengorn, MD, Bronx, NY
M. Hua, MD, MSc, New York, NY

**2:15** Introduction
K.A. Hibbert, MD, Boston, MA

**2:20** The Cold Truth: Can You Accurately Determine Neurologic Prognosis After Cooling?
D. Greer, MD, New Haven, CT

**2:35** Witness to the End: Family Presence During Resuscitation Attempts
K. O’Connell, MD, New Haven, CT

**2:50** 1:1:What? Which Blood Products Should We Transfuse in Hemorrhagic Shock?
D. Yeh, MD, Boston, MA

**3:05** The Drier the Better? When Should you Diurese a Critically Ill Patient?
M.J. Lanspa, MD, MS, Salt Lake City, UT

**3:20** Poking Holes in Practice: Can Intensive Care be Less Invasive?
A. Garland, MD, MA, Winnipeg, Canada

**3:35** Wake Up and Breathe
N.E. Brummel, MS, MSCI, MD, Nashville, TN

**3:50** A Lingering Question: When is ECMO the Answer in Adult ARDS?
A. Combes, MD, PhD, Paris, France

**4:05** Question and Answer
H.B. Gershengorn, MD, Bronx, NY

---

**B85**  LUNGS CAN TELL TIME: CLOCK GENES, INFLAMMATION, IMMUNOLOGY AND SLEEP

Assemblies on Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function; Sleep and Respiratory Neurobiology
2:15 p.m. - 4:15 p.m. MOSCONE CENTER Room 2009/2011 (West Building, Level 2)

Target Audience
Basic and translational Investigators studying Inflammatory conditions of the lung, sepsis, sleep medicine, and metabolism. Systems biologists interested in genome-wide analyses of complex airway diseases. Clinicians interested in the genetic basis for time sensitive symptoms in airway disease such as nocturnal asthma and COPD.

Objectives
At the conclusion of this session, the participant will be able to:

* describe the organization of the circadian clock at the whole organism level and specifically within the lung;
* learn new findings about how clock genes regulate the lung antimicrobial responses and inflammation;
* learn new findings about the relationships between sleep, clock genes and the ill health effects competence of shift work.

Discussions will cover complex airway diseases. This session will also cover inflammatory conditions of the lung, sepsis, sleep medicine, and metabolism.

**Chairing:** J. Haspel, MD, PhD, St. Louis, MO
I. Rahman, PhD, Rochester, NY
S.P. Shea, PhD, Portland, OR

**2:15** If You Give The Lung a Watch: Introduction to Circadian Rhythms in the Lung
J. Haspel, MD, PhD, St. Louis, MO

**2:25** Circadian Rhythms in Lung Physiology and Sleep
S.P. Shea, PhD, Portland, OR

**2:40** The Lung Epithelial Clock and Its Role in Inflammation
A. Loudon, PhD, Manchester, United Kingdom

**3:10** How Much Sleep or When? Teasing Apart the Health Effects of Sleep Deprivation and Circadian Disruption
K. Gamble, PhD, Birmingham, AL

**3:40** Role of Clock Genes in COPD Pathogenesis
I. Rahman, PhD, Rochester, NY

**3:55** Clock Genes, Viral Bronchiolitis and Childhood Asthma
J. Haspel, MD, PhD, St. Louis, MO

*There will be a 5-minute discussion after each talk.*
B86 IMMUNOTHERAPY FOR LUNG CANCER: POWER TO THE HOST

Assemblies on Thoracic Oncology; Allergy, Immunology and Inflammation
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 303/305 (South Building, Esplanade Level)

Target Audience
Providers of lung health, pulmonary oncologists and/or practitioners of all health specialties participating in tumor boards, researchers in cancer and immunology, nursing (all subspecialties), pulmonary trainees.

Objectives
At the conclusion of this session, the participant will be able to:
• learn and apply new FDA approved agents for immunotherapy in lung cancer to correct subsets with the disease;
• understand new strategies to manage the care of advanced-stage lung cancer patients;
• improve current treatments through translational development and improve basic biological understanding of the immune system in lung cancer.

This scientific symposium will focus on both existing and promising translational approaches to immunotherapy in the treatment of lung cancer. It will cover both biological mechanisms that mediate baseline immunosuppression in lung cancer along with rational and state of the art use of existing (FDA approved) and highly promising approaches to achieve immune-mediated regression and/or cures in advanced-stage lung cancer. Developments in adjuvant immune-checkpoint and whole cell-based as well as vaccine approaches together with basic science concepts in immunologic signaling and host microenvironment will also be included. The science will cover novel genetic and epigenetic concepts as well.

Chairing: M.M. Fuster, MD, San Diego, CA
Z.G. Fridlender, MD, Jerusalem, Israel

2:15 State of PD1/PDL1 Targeting in Lung Cancer
R.M. Huber, MD, PhD, Munich, Germany

2:35 Immunity Biomarkers and the Mutational Landscape in Lung Cancer
E.B. Garon, MD, Los Angeles, CA

2:55 Novel Immune Checkpoint Blockade Approaches
S. Patel, MD, La Jolla, CA

3:15 Immunosuppression and the Tumor Microenvironment
A.M. Houghton, MD, Seattle, WA

3:35 Treating Thoracic Malignancies with Adoptive T Cell Transfer: Successes and Challenges
S. Albelda, MD, Philadelphia, PA

3:55 Immune Considerations and Therapy for Mesothelioma
D.H. Sterman, MD, New York, NY

B87 BEYOND BMPR2: EMERGING ROLES OF DNA DAMAGE AND SOMATIC MUTATION IN PULMONARY ARTERIAL HYPERTENSION

Assemblies on Pulmonary Circulation; Respiratory Cell and Molecular Biology
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 3007/3009 (West Building, Level 3)

Target Audience
Basic research scientists and clinician scientists.

Objectives
At the conclusion of this session, the participant will be able to:
• learn new findings about how BMPR2 mutations impact the redox state and signaling environment of pulmonary arterial cells and impose a mutagenic risk on the mitochondrial genome;
• learn new concepts about mitochondria retrograde signaling to the nucleus and how this process is impacted by mtDNA mutations;
• learn new concepts about DNA damage and somatic mutation in pulmonary arterial hypertension.

Like cancer, pulmonary artery hypertension (PAH) has a prominent genetic component. For example, in familial as well as a proportion of sporadic PAH, germline mutations in the BMPR2 gene are a documented risk factor for the disease. In addition, hypertensive pulmonary cells also display an array of somatic mutations, but little is known about mechanisms of their formation, their functional consequences, and the potential that such somatic mutations could serve as diagnostic or prognostic biomarkers or therapeutic targets.

Accordingly, the goal of this Scientific Symposium is to highlight emerging roles of DNA damage and somatic mutation in pulmonary arterial hypertension.

Chairing: M. Aldred, PhD, Cleveland, OH
M.N. Gillespie, PhD, Mobile, AL

2:15 The Link Between BMPR2, Mitochondrial Dysfunction and Vulnerability to DNA Damage in Pulmonary Hypertension
M. Rabinovitch, MD, Stanford, CA

2:35 Mitochondrial DNA Mutations and Their Impact on Nuclear Gene Expression
D. Wallace, PhD, Philadelphia, PA

2:55 Transcriptional Regulation in Hypoxic Cells by Controlled DNA “Damage” and Repair
M.N. Gillespie, PhD, Mobile, AL

3:15 The DNA Damage Response in PAH
S. Bonnet, PhD, Quebec, Canada

3:35 DNA Damage and Repair and Somatic Mutation in PAH
M. Aldred, PhD, Cleveland, OH

3:55 The Cancer Paradigm for Pulmonary Arterial Hypertension: An Update
M.J.C. Humbert, MD, PhD, Le Kremlin Bicetre, France
B88 IMPROVING REAL WORLD CARE THROUGH INNOVATIVE TRIAL DESIGNS

Assemblies on Behavioral Science and Health Services Research; Critical Care; Thoracic Oncology
2:15 p.m. - 4:15 p.m. MOSCON CENTER
Room 306/308 (South Building, Esplanade Level)

Target Audience
Pulmonary and critical care clinicians, trainees, clinical researchers.

Objectives
At the conclusion of this session, the participant will be able to:
• understand and learn about novel techniques in clinical trial design;
• learn new findings about management of respiratory infection, lung cancer, and pulmonary nodules;
• better apply clinical trial findings to making decisions for individual patients.

Pulmonary, sleep, and critical care medicine are plagued with expensive negative clinical trials that do not change clinical practice. To advance patient care in an increasingly resource constrained research environment, innovative, creative study designs have evolved. These designs move beyond traditional approaches that largely explore one intervention in one disease in a single population to monitoring multiple treatments and combinations of treatments in real world populations. In this symposium, we will use exemplars from recent and ongoing high profile trials across the fields of pulmonary and critical care medicine to show how novel designs can greatly improve efficiency, value, and translatability of findings to individual patients.

Chairing: H.C. Prescott, MD, MA, Ann Arbor, MI
S.J. Bartlett, PhD, Montreal, Canada
V. Liu, MD, MS, Oakland, CA

2:15 Novel Trial Designs to Optimize Efficiency and Real World Impact
S.J. Bartlett, PhD, Montreal, Canada

2:20 PREPAREing for Future Epidemics: Platform Trial with Adaptive Randomization
A. Nichol, MD, Dublin, Ireland

2:40 Personalizing Care for Lung Cancer: Testing 10 Treatments All at Once
J. Kern, MD, Denver, CO

3:00 Real World Management of Lung Nodules: Large Pragmatic Trials
M.K. Gould, MD, MS, Pasadena, CA

3:20 Making Trials More Useful by Analyzing RCTs for Heterogeneity of Treatment Effects
T.J. Iwashyna, MD, PhD, Ann Arbor, MI

3:35 Evaluative Frameworks to Confirm Research Paradigms Work as Intended
D. Hickam, MD, MPH, Washington, DC

3:50 Panel Discussion
W.M. Vollmer, PhD, Portland, OR
S.D. Halpern, MD, PhD, Philadelphia, PA
L. Reineck, MD, Bethesda, MD

This session and the International Conference are supported by an educational grant from AstraZeneca LP.
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

B89 HEALTH EFFECTS OF INHALED TOXINS: FROM THE BENCH TO THE TRENCHES: A GLOBAL PERSPECTIVE

Assemblies on Environmental, Occupational and Population Health; Clinical Problems
2:15 p.m. - 4:15 p.m. MOSCON CENTER
Room 2006/2008 (West Building, Level 2)

Target Audience
Basic scientists and translational researchers interested in mechanisms of inhalation injury and emerging therapies; clinicians treating patients acutely exposed to inhalational toxins; clinicians, public health physicians, and epidemiologists involved in long term care of these patients.

Objectives
At the conclusion of this session, the participant will be able to:
• learn new findings regarding lung injury due to inhalational toxins;
• apply this knowledge to the care of individuals presenting with inhalational lung injury;
• discuss emerging new potential strategies for the treatment of the acute and chronic effects of lung injury due to inhalational toxins.

The symposium will provide a venue for basic, scientific, clinical, and epidemiologic researchers to present an overview of our current understanding of the underlying biology of inhalational lung injury as well as recent advances in the medical management of specific inhalational toxins. Within this broad field, we plan to focus on recent global events, which either have affected or are putting at risk local populations for injury secondary to tear and chlorine gas. Following mass-inhalational events, those with underlying lung disease are at increased risk for short and long-term pulmonary and systemic effects, including increased susceptibility to infections, increased airway hyperreactivity, development of restrictive lung diseases as well as cardiac abnormalities. With this session, we aim to improve knowledge of pulmonary and critical care specialists caring for victims of acute lung injury secondary to inhalational toxins, as well as providing care for those with chronic respiratory disease following inhalational injury. Further, we will provide updates and pave the way for future collaborative endeavors and studies to assess the effectiveness of countermeasures. We are very fortunate to have a number of outstanding speakers including the Scientific Committee Chair for the Turkish Thoracic Society, with direct involvement of patients exposed to massive amounts of tear gas in Turkey; the Deputy Medical Director of Medecins Sans Frontieres (MSF); and a disaster epidemiologist, who performed ground-breaking epidemiological studies on persons exposed to chlorine during the Graniteville train derailment.
and a number of basic and translational scientists who contributed greatly in our understanding of basic mechanisms by which tear gas and chlorine damage the cardiopulmonary systems.

Chairing: S. Matalon, PhD, Birmingham, AL

2:15 Introduction
E. Summerhill, MD, Pawtucket, RI

2:20 Pulmonary and Systemic Consequences of Tear Gas Exposure in an Urban Turkish Population
E. Dagli, MD, Istanbul, Turkey

2:40 Chemosensation and Reflex Control in Inhalational Exposures
S.E. Jordt, PhD, Durham, NC

3:00 Mechanisms and Modification of Chlorine and Other Halogen Gas Induced Injury
S. Matalon, PhD, Birmingham, AL

3:15 Graniteville, SC Railway Derailment: Acute and Chronic Effects of Chlorine Gas Exposure
E.R. Svendsen, PhD, Charleston, SC

3:35 Managing Chemical Disasters Across the Globe: A Doctor Without Borders Perspective
F. Baud, MD, Paris, France

3:55 Novel Countermeasures for Inhalational Exposures: Is There Hope on the Horizon?
C.W. White, MD, Denver, CO

This session will provide attendees with a state of the art review of emerging scientific principles and clinically relevant advances that are pertinent to the understanding of invasive fungal infection of the respiratory system. Individual speakers will describe novel primary immune deficiencies that predispose certain individuals to fungal pneumonia as well as the systems biology approach to comprehensively understand fungal-host cell interactions. Recent insights molecular and cellular pathogenesis of endemic and opportunistic fungal pneumonias will then be considered. Finally, the latest advances in clinical diagnostic strategies and therapeutic approaches for respiratory fungal diseases will be reviewed.

Chairing: S. Qureshi, MD, Montreal, Canada
S.E. Evans, MD, Houston, TX
C.S. Dela Cruz, MD, PhD, New Haven, CT

2:15 Primary Immunodeficiencies Underlying Respiratory Fungal Infection
A. Puel, PhD, Paris, France

2:35 Systems Biology Analysis of the Fungal-Host Cell Interaction
L. Romani, MD, PhD, Perugia, Italy

2:55 Pathogenesis of Opportunistic Fungal Pneumonia
A.H. Limper, MD, Rochester, MN

3:15 Subversion of Host Immunity by Endemic Fungal Pathogens
S. Qureshi, MD, Montreal, Canada

3:35 Novel Diagnostic Tools and Approaches to Fungal Pneumonia
C.A. Hage, MD, Indianapolis, IN

3:55 Current Therapeutic Approaches for Fungal Pneumonia
S.E. Evans, MD, Houston, TX

There will be a 5-minute discussion after each talk.
**B93 THINKING ABOUT LUNG HEALTH AND DEFINING EARLY COPD**

**2:15 p.m. - 4:15 p.m.**

**Room 130-132 (North Building, Lower Level)**

**Chairing:** R. Kalhan, MD, MS, Chicago, IL  
M.T. Dransfield, MD, Birmingham, AL  
C.E. Berry, MD, Tucson, AZ

**Featured Speaker**

**2:15** Shifting Focus: The Study of Lung Health Versus Lung Disease/R. A. Wise, MD, Baltimore, MD

**Oral Presentations**


---

**B94 PREDICTORS OF OUTCOME IN ILD**

**2:15 p.m. - 4:00 p.m.**

**Room 3020/3022 (West Building, Level 3)**

**Chairing:** S. K. Danoff, MD, PhD, Baltimore, MD  
B. J. Ley, MD, San Francisco, CA  
A. W. Brown, MD, Falls Church, VA

**Oral Presentations**


3:00 Mortality, Costs, and Length of Stay in Patients with Idiopathic Pulmonary Fibrosis/ J. Mooney, K. Raimundo, E. Chang, M.S. Broder, Stanford, CA, p.A4286


Oral Presentations


2:30 A Randomized Controlled Trial of a Fresh Frozen Plasma Transfusion Dosing Algorithm for Cirrhotic Patients/ S.C. Berngard, S. Higgins, A. Benson, J. Gralla, M. Moss, La Jolla, CA, p.A4291


3:45 A Multicenter Randomized Controlled Trial of Palliative Care-Led Informational/Emotional Support Meetings for Family Decision Makers of Patients with Chronic Critical Illness/ S.S. Carson, C.E. Cox, S. Wallenstein, L. Hanson, M. Danis, J.A. Tulsky, E. Chai, J. Nelson, Chapel Hill, NC, p.A4296


MINI SYMPOSIUM

B96 HUNGRY HEART: RV FUNCTION IN PH

2:15 p.m. - 4:15 p.m. MOSCONE CENTER Room 3003/3005 (West Building, Level 3)

Chairing: F. De Man, PhD, Amsterdam, Netherlands D.G. Kiely, MD, Sheffield, United Kingdom D. Dewachter, MD, Brussels, Belgium

Oral Presentations

2:15 Role of Lymphatics in Right Ventricular Edema and Pericardial Effusion in Pulmonary Hypertension/ M.E. Yeager, O. Lohani, K.L. Colvin, Aurora, CO, p.A4297
### Mini Symposium B97: Mitochondria Dysfunction in the Development of Lung Disease

**Time:** 2:15 p.m. - 4:15 p.m.

**Location:** MOSCONICENTER

**Chairing:** N. Chandel, PhD, Chicago, IL
R. Guzy, MD, PhD, Chicago, IL

**Oral Presentations**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15</td>
<td>Staphylococcus Aureus Causes Mitochondrial Injury in Lung Alveoli</td>
<td>N. Chandel, J. Hook, B. Battacharya</td>
<td>New Brunswick, NJ</td>
</tr>
<tr>
<td>2:45</td>
<td>Premature Infants Have an Intrinsic Airway Secretory Signature Characterized by Enhanced Production of Airway Remodeling Growth Factors</td>
<td>C. J. Koziol-White, New Brunswick, NJ</td>
<td>Groningen, Netherlands</td>
</tr>
</tbody>
</table>

### Mini Symposium B98: Signaling, Remodeling and Contraction in the Airway

**Time:** 2:15 p.m. - 4:15 p.m.

**Location:** Room 2020/2022

**Chairing:** C. J. Koziol-White, PhD, New Brunswick, NJ
J. K. Burgess, PhD, Groningen, Netherlands

**Oral Presentations**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15</td>
<td>Premature Infants Have an Intrinsic Airway Secretory Signature Characterized by Enhanced Production of Airway Remodeling Growth Factors</td>
<td>C. J. Koziol-White, New Brunswick, NJ</td>
<td>Groningen, Netherlands</td>
</tr>
</tbody>
</table>


3:45 Neutrophil Elastase Promotes the Activation of Signaling Pathways that Mediate the Inflammatory Phenotype in Airway Smooth Muscle/A.D. Lockett, S.J. Gunst, Indianapolis, IN, p.A4319

4:00 Deep Inspiration, Fluidization and the Actin Binding Protein Cofilin/B. Lan, C.Y. Park, K. Jae Hun, R. Krishnan, J.J. Fredberg, Boston, MA, p.A4320

**MINI SYMPOSIUM**

**B99 THE BEST OF EVERYTHING: HOT TOPICS IN SLEEP**

2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 2001/2003 (West Building, Level 2)

**Chairing:** M. Teodorescu, MD, MS, Madison, WI
N.A. Antic, MBBS, PhD, Adelaide, Australia
S.P. Patil, MD, PhD, Baltimore, MD

**Oral Presentations**

2:15 Identifying Obstructive Sleep Apnea Patients Vulnerable to Opioid-Induced Respiratory Depression - A Randomized Double-Blind Placebo-Controlled Crossover Trial/D. Wang, L. Rowsell, K. Wong, B. Yee, D.J. Eckert, A. Somogyi, J. Duffin, R. Grunstein, Camperdown, Australia, p.A4321


**POSTER DISCUSSION SESSION**

**B101 PHENOTYPING OF ASTHMA IN THE ERA OF BIOMARKERS AND OMICS**

2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 2014 (West Building, Level 2)

**Chairing:** A.N. Gerber, MD, PhD, Denver, CO
C. Taube, MD, Leiden, Netherlands
G.M. Gauvreau, PhD, Hamilton, Canada

**Poster Viewing**
2:15-3:00

**Discussion**
3:00-4:15

**501 Longitudinal Replication of Severe Asthma Exhaled Breath Phenotypes by the U-BIOPRED Electronic Nose Platform/**


510 A Blood Eosinophil Count of Greater Than 150 Cells/µL Predicts Sputum Eosinophilia â¥ 3% in Patients with Severe Asthma with Other Markers of Inflammatory Lung Disease/D. Austin, I. Pouliquen, S. Yancey, E. Bleeker, Stockley Park, United Kingdom, p.A4338


523 High Blood Eosinophil Concentrations and Serum Biomarkers of Low IL-13 Pathway Activation at Baseline Predict Exacerbation Rate Reduction by Benralizumab for Patients with Moderate to Severe Asthma/P. Newbold, Y. Wu, V. Shih, M. Liang, I. Vainshtein, K. Ranade, Gaithersburg, MD, p.A4351

524 Cigarette Smoke Modifies the IL-13-Induced Th2 Gene Signature in Primary Human Bronchial Epithelial Cells/T.C.J. Mertens, A.M. Van Der Does, D.K. Ninaber, P.S. Hiemstra, C. Taube, Leiden, Netherlands, p.A4352
525 Clinical Cluster Phenotypes from the Severe Asthma Research Program (SARP1/2): Reproducibility in SARP 3 and the Importance of Baseline Lung Function in Disease Stability and Progression


209 Application of Interventions that Maximize Compliance with Patient Care Checklists in the Academic Intensive Care Unit Setting

J. Caraballo, A. Pezzulo, Iowa City, IA, p.A4361

210 Bi-Level Non-Invasive Ventilation for Acute Respiratory Failure: A Quality Improvement Review of Local Health Region Practice and Management

J.C.D. Hasmatali, K. Whittermore, D. Marciniuk, Saskatoon, Canada, p.A4362

211 Improving Patient and Physician Comfort with Code Status

S.L. Rhoads, A. Charles, Providence, RI, p.A4363

212 Are We Calling Palliative Care On Time? A Retrospective Study of Advanced Stage Non Small Cell Lung Cancer, Pancreatic and Colon Cancer at an Academic Hospital


213 Identification of Targets to Improve 30-Day Returns to Emergency Department and Inpatient Care Among Thoracotomy Procedure Patients


214 Implementation of Ontario’s Emergency Department Asthma Care Pathway: Determinants of Uptake


215 Pilot Data from a Comprehensive Respiratory Therapist Driven COPD Care Management Program


216 Evaluation and Documentation of Oxygen Requirements in Patients Hospitalized with COPD: Time for Oxygen Reconciliation?


217 Cystic Fibrosis Patients Benefit from CF Legal Hotline

B. Sufian, J. Passamano, A. Sopchak, Houston, TX, p.A4369

218 No Pain! Great Gain!! Improving Pain Management at Howard University Hospital


219 Pneumococcal Vaccination in a Cancer Center


220 Quality Improvement in a Fellows Clinic: Implementation of a Patient Centered Inhaler Education Program

A.G. Cole, P. Lenz, Cincinnati, OH, p.A4372

221 Pre-Discharge Airway Evaluation in Tracheostomy-Dependent Children: A Quality Improvement Safety Initiative

J.J. Soares, A. Strieg, K. Johnson, S. Panik, L. Elder, T. Ong, Seattle, WA, p.A4373

222 Influence of ‘Out of Network’ Pulmonary Hypertension Care and VA Pharmacy Consultation on Potentially Inappropriate Prescribing of Phosphodiesterase-5-Inhibitors in the VA

M.R. Freiman, A.J. Rose, D. Miller, R.S. Wiener, Boston, MA, p.A4374

223 Could Current Methods of Sputum Analysis Be Improved in Non-CF Bronchiectasis? A Health Service Review


POSTER DISCUSSION SESSION

B103 ADVANCES IN DIAGNOSTIC BRONCHOSCOPY

2:15 p.m. - 4:15 p.m. MOSCONE CENTER

Room 309 (South Building, Esplanade Level)

Poster Viewing
2:15:00-3:00

Discussion
3:00:00-4:15

Chairing:
A.C. Mehta, MBBS, Cleveland, OH
M.M. Wahidi, MD, Durham, NC
S. Shojaei, MD, Richmond, VA


Transbronchial Cryobiopsy in Diffuse Parenchymal Lung Disease: Retrospective Analysis of 75 Cases/K. Ussavarungsi, J.H. Ryu, E.S. Edell, Rochester, MN, p.A4379


Granulomatous Inflammation Found by Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA) in Patients with Malignancy - A Quaternary Referral Centre Experience/A. Fon, A. Baumann, H. Jersmann, P. Robinson, P. Nguyen, Adelaide, Australia, p.A4387

Utility of Probe Based Confocal Laser Endomicroscopy to Aid in Transbronchial Cryobiopsy for Diagnosis of Diffuse Interstitial Lung Diseases/K. Trivedi, A. Wellikoff, R.C. Holladay, Shreveport, LA, p.A4388

Transbronchial Cryobiopsy for Diagnosis of Diffuse Interstitial Lung Diseases: Experience at the Louisiana State University (Shreveport) Hospital/K. Trivedi, A. Wellikoff, R.C. Holladay, Shreveport, LA, p.A4389

Transbronchial Cryobiopsies: Are They the Future of Bronchoscopic Lung Biopsies?/N. Al Nasrallah, K. Diab, Indianapolis, IN, p.A4390


Interobserver Variability of Sonographic Features of Mediastinal Lymph Nodes by EBUS: Need for Qualitative or Quantitative Measurements/?N. Ozcelik, Y. Abul, Y. Bulbul, I. Eyuboglu, S. Ozsu, F. Oztuna, T. Ozlu, Trabzon, Turkey, p.A4392

Sensitivity of Different Sampling Modalities with Electromagnetic Navigational Bronchoscopy and Effect of Radial EBUS on Yield/D. Sharma, C. Bellinger, Winston Salem, NC, p.A4393


B104 RESPIRATORY FAILURE: LUNG REGIONAL AND TRANSLATIONAL MECHANISMS IN ARDS

2:15 p.m. - 4:15 p.m. MOSCONE CENTER Room 3001 (West Building, Level 3)

Poster Viewing: 2:15-3:00
Discussion: 3:00-4:15

Chairing: J.H.T. Bates, DSc, PhD, Burlington, VT
J.A. Bastarache, MD, Nashville, TN


706 High-Resolution Metabolomics Reveals Distinct Pathways in Septic Patients that Developed Acute Respiratory Distress Syndrome/K. Uppal, V. Tran, D. Jones, S. Li, A.M. Esper, Atlanta, GA, p.A4407


714 Time Course of Increased Secretory Phospholipase Group II A in Human ARDS from Pneumonia or Aspiration/M.V. Novotny, A. Chakrabarti, M.C. Seeds, C. Ruppert, J. Wagner, A. Guenther, R.D. Hite, Cleveland, OH, p.A4415


B105  COPD: EPIDEMIOLOGY AND GENETICS

2:15 p.m. - 4:15 p.m.  MOSCONE CENTER

Room 133 (North Building, Lower Level)

Poster Viewing 2:15-3:00 Discussion 3:00-4:15

Chairing: C.P. Hersh, MD, MPH, Boston, MA
I. Pavord, MD, Oxford, United Kingdom
M.C. McCormack, MD, MHS, Baltimore, MD

POSTER DISCUSSION SESSION
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>119</td>
<td>Inflammatory Bowel Disease and Risk of Mortality in Chronic Obstructive Pulmonary Disease (COPD) and Asthma-COPD Overlap Syndrome (ACOS)/P. Brassard, M. Vutucovic, P. Ernst, A. Kezouh, S. Suissa, A. Bitton, Montreal, Canada, p.A4445</td>
</tr>
<tr>
<td>122</td>
<td>Reproductive and Hormone-Related Factors Are Associated with Lower Lung Function in COPDGene/D.L. DeMeo, M.G. Foreman, E.A. Regan, S.P. Bhatt, M.K. Han, J. Hokanson, J.D. Crapo, E.K. Silverman, B.J. Make, Boston, MA, p.A4449</td>
</tr>
</tbody>
</table>
**907** The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Exhibits Bilateral Entry and Exclusively Apical Egress in Well-Differentiated Human Airway Epithelial Cells/K. Li, C.L. Wohlford-Lenane, P.B. McCray, Iowa City, IA, p.A4457

**908** Mouse Models to Study Middle East Respiratory Syndrome Disease Pathogenesis and Treatment/C.L. Wohlford-Lenane, K. Li, D.K. Meyerholz, S. Perlman, P.B. McCray, Iowa City, IA, p.A4458

**909** RIPK3 Regulates Type I IFN Mediated Immunity to Pulmonary Influenza A Virus Infection/J. Downey, E. Pernet, F. Coulombe, B. Allard, J. Jaworska, S. Qureshi, J.G. Martin, P. Joubert, M. Divangahi, Montreal, Canada, p.A4459


**911** Severity of Type II Cell Depletion Influences the Recruitment of Krt5+ Epithelial Cells Following Influenza A Virus Infection/M. Yee, W. Domm, R.M. Kottmann, P.J. Sime, M. O’Reilly, Rochester, NY, p.A4461


**913** Characterisation of the Neutrophil in Respiratory Syncytial Virus Bronchiolitis/G.L. Saint, R. Smyth, B.F. Planagan, P.S. McNamara, Liverpool, United Kingdom, p.A4463


**915** Respiratory Syncytial Virus Recruits Its Receptor, Nucleolin, to the Cell Surface Prior to Viral Fusion and Mediates Viral Entry by Toll-Like Receptor-4 Signaling/C. Griffiths, L. Bilawchuk, L. Jensen, D.J. Marchant, Edmonton, Canada, p.A4465

**916** RSV Pulmonary Infection Induces Human Anti-RSV Immune Responses and Pathology in Humanized Mice/A. Sharma, B. Sung, W. Wu, J. Huang, T. Tsao, X. Li, R. Gomi, M. Tsuji, S. Worgall, New York, NY, p.A4466


**918** Enterovirus D68 Lower Respiratory Tract Infection Causes Elevated Airway Hyperreactivity in Fischer-344 Rats/P.M. Brown, T.J. Harford, A. Belkadi, V. Agrawal, F. Rezaee, G. Piedimonte, Cleveland, OH, p.A4468


**920** Inter-Relationships Between Regulatory T Cells, Effector T Cells, the PD-1 Signaling Pathway, and Immunomodulatory Lung Dendritic Cells in Mice with Persistent Cryptococcal Lung Infection/J.A. Roussey, S. Teitz-Tennenbaum, M.A. Olszewski, J.J. Osterholzer, Ann Arbor, MI, p.A4470

**921** Inhaled Corticosteroids Alter Pathogenicity Profile of Airway Pathogens Pseudomonas Aeruginosa and Staphylococcus Aureus/J. Joshua, A. Vyas, L.E. Crotty Alexander, San Diego, CA, p.A4471


**923** First Successful Expression of a Trimeric Human Fragment of SP-A and Demonstration of Its Increased Efficacy in Neutralisation of RSV Compared with Native Human SP-A/A. Watson, C.M. Spalluto, K. Kronqvist, K. Staples, J. Johansson, T.M.A. Wilkinson, J. Madsen, H. Clark, Southampton, United Kingdom, p.A7856

**924** Targeting Bruton’s Tyrosine Kinase Protects Mice from Adverse Effects of Streptococcus Pneumoniae Induced Pneumonia/A. Kudowska, J.M. Florence, A. Jeffers, A. Krupa, T.A. Tucker, Tyler, TX, p.A7857


---

**POSTER DISCUSSION SESSION**

**B107 TUBERCULOSIS: ISSUES DURING TREATMENT**

2:15 p.m. - 4:15 p.m.   MOSCONE CENTER

**Room 3024 (West Building, Level 3)**

**Poster Viewing** 2:15-3:00

**Discussion** 3:00-4:15

**Chairing:** M.C. Lipman, MD, London, United Kingdom
N.D. Walter, MD, Denver, CO
W.O. Worodria, MBChB, MMEd, PhD, Kampala, Uganda


1008 Negative Interaction of Diabetes Mellitus with Clinical Characteristics and Treatment Success of Tuberculosis in Indonesia/D. Arlinda, A. Yulianto, A.K. Syarif, A.D. Harso, R.I. Sugiyono, M. Karyana, Jakarta Pusat, Indonesia, p.A4479


1011 Association of Previously Treated Tuberculosis Using Second Line TB Drugs with Conversion Rate of Multi Drugs Resistance (MDR-TB) Patients in Indonesia/D. Handayani, N. Librianty, P.Z. Soepandi, Dki Jakarta, Indonesia, p.A4482

1012 Role of Nutrition Status in Multidrug Resistant Tuberculosis (MDR-TB) Conversion/N. Librianty, P. Subbarao, M. Karyana, Jakarta Pusat, Indonesia, p.A4483

1013 Association of NFE2L2 Polymorphisms and Anti-Tuberculosis Drug-Induced Hepatotoxicity/G. Ji, A.J. Sandford, J. He, Chengdu, China, p.A4484

1014 An Updated Meta-Analysis on CYP2E1 Rsal/PstI and Dral Polymorphisms and Risk of Anti-Tuberculosis Induced Hepatotoxicity: Evidence from 26 Studies/J. He, F.-J. Wang, Y. Wang, T. Niu, Chengdu, China, p.A4485


High Intensity Interval Versus Moderate Intensity Continuous Training in a Pulmonary Rehabilitation Programme for Patients with Interstitial Lung Disease/D. Nikoleto, C. Lech, I. McNaughton, R. Aul, I. Chis-Ster, P.W. Jones, London, United Kingdom, p.A4520


Short-Term and Long-Term Changes in Chronic Respiratory Questionnaire Domains and Total Scores From Different Exercise-Training Protocols in Chronic Obstructive Pulmonary Disease/A. Milot, G. Moullec, K.A. Duckworth, V. Pepin, Montreal, Canada, p.A4522


An Exploration of the Relationship Between Physical Activity, Mortality and Time to First Admission in Subjects Admitted into Hospital with an Acute Exacerbation of Chronic Respiratory Disease (CRD)/T.C. Harvey-Dunstan, N. Greening, S.F. Hussain, E. Chaplin, R. Chimera, M.D.L. Morgan, M. Steiner, S.J. Singh, Leicester, United Kingdom, p.A4525

Physical Activity Performed in Intervals of More than 10 Minutes Is Associated with Better Lung Function Over 3-Years in Adults with Cystic Fibrosis/N.S. Cox, J.A. Alison, B.M. Button, J.W. Wilson, J.M. Morton, A.E. Holland, Melbourne, Australia, p.A4526


How Smart Are These Socks? Using Smart Socks to Detect Slow Walking Speeds During Overground Walking in Healthy Adults/N.R. Morris, K. Cheng, J. Houlihan, J. Wootherspoon, N. Tuttle, Southport, Australia, p.A4528


A Randomized Controlled Pilot Study Using a Virtual Game System (VGS) as a Home-Based Exercise Modality Following Pulmonary Rehabilitation (PR) in Patients with COPD/H. Kotrach, E. Dajczman, M.A. Baltzan, R. Wardini, S. Levitz, M. Rotaple, F. Abcarius, M. Statathos, D. Lynch, N. Wolkove, C. Sounan, Montreal, Canada, p.A4530

Pedometer-Directed Step Count Targets as an Adjunct to Pulmonary Rehabilitation in COPD: A Randomized Controlled Trial/C.M. Nolan, M. Maddocks, J.L. Canavan, S.E. Jones, S.S.-C. Kon, D. Kalaraju, M. Polkey, W.D.-C. Man, Harfield, United Kingdom, p.A7862


Physical Frailty and Pulmonary Rehabilitation in COPD/ W.D.-C. Man, M. Maddocks, S.S.-C. Kon, J.L. Canavan, S.E. Jones, C.M. Nolan, A. Labey, M.I. Polkey, Harfield, United Kingdom, p.A7864

405 The Proteome Signature of Disease Progression in Idiopathic Pulmonary Fibrosis/D.N. O’Dwyer, S. Ashley, M. Xia, S. Murray, E. Grant, E.S. White, K.R. Flaherty, F.J. Martinez, B.B. Moore, Ann Arbor, MI, p.A4535

406 Alveolar Type II Cell Transplantation Improves Alveolar Dynamics and Structure in Bleomycin Induced Lung Fibrosis/G. Gay-Jordi, E. Lopez-Rodriguez, M. Ochs, A. Serrano-Mollar, Barcelona, Spain, p.A4536


419 Amelioration of Pulmonary Fibrosis by Targeting the Unfolded Protein Response/M. Thamsen, B.J. Backes, F.R. Papa, San Francisco, CA, p.A4549


422 Administration of Sphingosine Kinase 1 Inhibitor Post-Bleomycin Challenge Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice: Role of YAP1/L.S. Huang, V. Natarajan, Chicago, IL, p.A4552


424 XBP1 Deficiency in Type II Alveolar Epithelial Cells Protects Against Lung Fibrosis/J. Brands, M. Bueno, M. Rojas, A.L. Mora, Pittsburgh, PA, p.A4554

5:00 p.m. - 7:00 p.m.

ASSEMBLY MEMBERSHIP MEETINGS
The fourteen Assemblies are the primary groups of the American Thoracic Society. Each Assembly holds an annual Membership Meeting at the International Conference. All Assembly members and other interested individuals are invited to attend.

The Assembly Membership Meetings provide an update on the Assembly’s activities via the Assembly’s Leadership and provide Assembly members the chance to have input on future directions, information on how to get involved and networking opportunities. Voting results for the Assembly’s future leaders will also be announced.

The Assembly Membership Meetings will be held on Monday, May 16, 2016, 5:00 p.m. - 7:00 p.m., with the exception of the Assemblies on Behavioral Science and Health Services Research and Pediatrics (see below.)

ALLERGY, IMMUNOLOGY AND INFLAMMATION
SAN FRANCISCO MARRIOTT MARQUIS
Golden Gate A (B2 Level)
Chairing: M.A. Olman, MA, MD, Cleveland, OH

BEHAVIORAL SCIENCE AND HEALTH SERVICES RESEARCH
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 10-12 (Lower B2 Level)
Chairing: K.A. Riekert, PhD, Baltimore, MD
This Assembly will meet on Sunday, May 15, 2016
6:30 p.m. - 8:30 p.m.

CLINICAL PROBLEMS
HILTON SAN FRANCISCO UNION SQUARE
Continental Ballroom 6 (Ballroom Level)
Chairing: G. Tino, MD, Philadelphia, PA

CRITICAL CARE
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 8 (Lower B2 Level)
Chairing: C.S. Calfee, MD, San Francisco, CA

ENVIRONMENTAL OCCUPATIONAL AND POPULATION HEALTH
HILTON SAN FRANCISCO UNION SQUARE
Continental Ballroom 4 (Ballroom Level)
Chairing: J.R. Harkema, DVM, PhD, East Lansing, MI

MICROBIOLOGY, TUBERCULOSIS AND PULMONARY INFECTIONS
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 4-6 (Lower B2 Level)
Chairing: R.G. Wunderink, MD, Chicago, IL

NURSING
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 10-12 (Lower B2 Level)
Chairing: D.M. Donesky, PhD, San Francisco, CA

PEDIATRICS
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 8 (Lower B2 Level)
Chairing: J.F. Chmiel, MD, MPH, Cleveland, OH
This Assembly will meet on Sunday, May 15, 2016
6:30 p.m. - 8:30 p.m.

PULMONARY CIRCULATION
HILTON SAN FRANCISCO UNION SQUARE
Continental Ballroom 5 (Ballroom Level)
Chairing: T. Stevens, PhD, Mobile, AL

PULMONARY REHABILITATION
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 13-15 (Lower B2 Level)
Chairing: C.L. Rochester, MD, New Haven, CT

RESPIRATORY CELL AND MOLECULAR BIOLOGY
SAN FRANCISCO MARRIOTT MARQUIS
Golden Gate B (B2 Level)
Chairing: N. Kaminski, MD, New Haven, CT

RESPIRATORY STRUCTURE AND FUNCTION
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 9 (Lower B2 Level)
Chairing: R.A. Panettieri, MD, New Brunswick, NJ

SLEEP AND RESPIRATORY NEUROBIOLOGY
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 7 (Lower B2 Level)
Chairing: S.P. Patil, MD, PhD, Baltimore, MD

THORACIC ONCOLOGY
SAN FRANCISCO MARRIOTT MARQUIS
Club Room (Second Level)
Chairing: M.K. Gould, MD, MS, Pasadena, CA
ASSEMBLY DINNERS AND RECEPTIONS

Assembly members and non-members, students and fellows are invited to join us for an evening of good food, great company, camaraderie and a very entertaining program. This is a wonderful opportunity to introduce young members and trainees to Assembly leaders, to connect with old friends and to set up new interactions and collaborations.

Pre-registration and an additional fee are required. Seating is limited.

The following Assemblies will hold a dinner or reception on Monday May 16, 2016 from 7:00 p.m. - 10:00 p.m. immediately following the Assembly Membership Meetings.

Assembly on Allergy, Immunology and Inflammation &
Assembly on Respiratory Cell and Molecular Biology
Joint Reception
SAN FRANCISCO MARRIOTT MARQUIS
Golden Gate C (B2 Level)
$27.00 - For all

Assembly on Pediatrics Dinner
SAN FRANCISCO MARRIOTT MARQUIS
Atrium (Second Level)
$80.00 - Fellow
$100.00 - Member
$110.00 - Non Member

Assembly on Clinical Problems Reception
HILTON SAN FRANCISCO UNION SQUARE
Continental Ballroom 7 (Ballroom Level)
$17.00 - Fellow
$37.00 - Member
$47.00 - Non Member

Assembly on Respiratory Structure and Function Reception
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 9 (Lower B2 Level)
$80.00 - Fellow
$100.00 - Member
$110.00 - Non Member

Assembly on Critical Care Reception
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 8 (Lower B2 Level)
$17.00 - Fellow
$37.00 - Member
$47.00 - Non Member

Assembly on Sleep, Respiratory and Neurobiology Reception
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 7 (Lower B2 Level)
$50.00 - Fellow
$90.00 - Member
$110.00 - Non Member

Assembly on Microbiology, Tuberculosis and Pulmonary Infections Reception
SAN FRANCISCO MARRIOTT MARQUIS
Yerba Buena Salon 1-3 (Lower B2 Level)
$17.00 - Fellow
$37.00 - Member
$47.00 - Non Member

Assembly on Thoracic Oncology Reception
SAN FRANCISCO MARRIOTT MARQUIS
Foothill G (Second Level)
$17.00 - Fellow
$37.00 - Member
$47.00 - Non Member

Dinner/Reception Disclaimer – Event prices reflect menu selections.
For more information on the Assembly Dinners and Receptions please visit the ATS Assembly home page at: http://www.thoracic.org/members/assemblies/about/
The Pediatric Core Curriculum symposia promotes lifelong learning and the enhancement of the clinical judgment and skills essential for practicing pediatricians. The symposia will address topics that have been identified by an ATS pediatric working group, which is comprised of members of the ATS Education Committee and the International Conference Committee, who have identified important areas within pediatric medicine (including vasculitic pulmonary diseases, lung defense mechanism, congenital abnormalities of the airways, and respiratory failure). Attendees will increase their medical knowledge as a result of attending this symposium, and this will be measured by a comparison of pre-test vs. post-test results on the corresponding maintenance of certification module. The ATS Pediatric Core Curriculum will focus on a 3-year content cycle of key medical content in the area of pediatric medicine.
SS211 PHYSIOLOGIC EVALUATION OF PATIENTS WITH OCCUPATIONAL LUNG DISEASE FOR DIAGNOSIS, IMPAIRMENT, AND DISABILITY
C.J. Schroedl, MD, Chicago, IL
Nob Hill (Fourth Floor)

SS212 TREATMENT OF NTM: ALTERNATIVES TO CURRENT ANTIMICROBIALS
J. Cook, MD, Maywood, IL
M. Prickett, MD, MPH, Chicago, IL
Laurel Hill (Fourth Floor)

SS213 MANAGEMENT OF PARAPNEUMONIC EFFUSION IN CHILDREN: AN UPDATE
R.E. Myers, MD, Cleveland, OH
K.R. Ross, MD, Cleveland, OH
Cathedral Hill (Fourth Floor)

SS214 DIAGNOSING PULMONARY HYPERTENSION: TRICKS OF THE TRADE
A. Vaidya, MD, Philadelphia, PA
Sutter (Fifth Floor)

SS215 INSPIRATORY MUSCLE TRAINING IN COPD
D. Langer, PhD, PT, Leuven, Belgium
Stockton (Fifth Floor)

SS216 OPTIMIZATION OF THE 3D IN VITRO ASSAY TO STUDY LUNG STEM/PROGENITOR CELLS
A.E.M. Hegab, MD, PhD, Tokyo, Japan
Howard (Fifth Floor)

SS217 UPDATE IN HYPERBARIC MEDICINE
J. Evangelista, MD, Detroit, MI
Fremont (Fifth Floor)

SS218 SLEEP DISORDERED BREATHING IN ADULTS WITH NEUROMUSCULAR DISEASE
J.E. Orr, MD, La Jolla, CA
InterContinental Ballroom C (Fifth Floor)

SS219 LUNG CANCER IN ASIANS: A DIFFERENT BEAST ALTOGETHER?
C. Chang, MD, Los Angeles, CA
InterContinental Ballroom B (Fifth Floor)

FD2 NUTS AND BOLTS IN NEGOTIATING A JOB
Pre-registration is required. There is no additional fee.
Attendance is limited.
6:45 a.m. - 7:45 a.m. INTERCONTINENTAL HOTEL
InterContinental Ballroom A (Fifth Floor)

Target Audience
Early career clinical and/or research faculty, clinical and post doctoral fellows, graduate students, residents, nurses, and allied health professionals already involved in or seeking a career in academic pulmonary, allergy, critical care, and/or sleep medicine.

Objectives
At the conclusion of this session, the participant will be able to:
- identify how their success is gauged.
- understand basic elements needed for advancement in their ideal job.
- learn strategies to negotiate for key items to support their career development.

As a junior faculty member, are you unsure of how to prepare a CV, how to prepare for an interview and how to negotiate what you want when applying for a job? This seminar will provide helpful tips on how to best prepare for and negotiate your ideal job.

Chairing: C.C. Thomson, MD, MPH, Cambridge, MA
 Speakers: M. Moss, MD, Aurora, CO
S.S. Carson, MD, Chapel Hill, NC
J.M. Beck, MD, Denver, CO
C.S. Rand, PhD, Baltimore, MD

K5 THE CHANGING NATURAL COURSE OF COPD
8:00 a.m. - 8:45 a.m. MOSCONE CENTER
Room 134 (North Building, Lower Level)
Speaker: Bartolome R. Celli, MD, Boston, MA
This session and the International Conference are supported by an educational grant from AstraZeneca LP.
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

K6 STRUCTURAL INSIGHTS INTO GPCR SIGNALING: IMPLICATIONS FOR DRUG DISCOVERY
8:00 a.m. - 8:45 a.m. MOSCONE CENTER
Room 135 (North Building, Lower Level)
Speaker: Brian Kobilka, MD, Stanford, CA
This session and the International Conference are supported by an educational grant from AstraZeneca LP.
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
C1  CLINICAL YEAR IN REVIEW 3
9:00 a.m. - 11:00 a.m.  MOSCON CENTER
Gateway Ballroom 102-104 (South Building, Lower Level)

Target Audience
Providers including physicians, nurses, respiratory therapists, nurse practitioners, physician assistants. Trainees including residents and fellows; clinical researchers.

Objectives
At the conclusion of this session, the participant will be able to:
• apply new clinical research knowledge to clinical practice;
• learn new findings about key conditions in pulmonary, critical care and sleep;
• have new strategies to manage the care of common conditions in pulmonary, critical care, and sleep.

The annual Clinical Year in Review symposia topic reviews of the key clinical research publications over the last year. Each speaker is asked to review the 5-7 most important and influential publications on their topic in the prior year.

Chairing: J.L. Taylor-Cousar, MD, Denver, CO
D.J. Lederer, MD, MS, New York, NY
D.W. Ford, MD, MSCR, Charleston, SC

9:00  Palliative Care
C.E. Cox, MD, MPH, Durham, NC

9:30  Lung Cancer
N.T. Tanner, MD, MSCR, Charleston, SC

10:00  Sleep in Critical Illness
R.L. Owens, MD, La Jolla, CA

10:30  Sleep Disordered Breathing
J.L. Pepin, MD, PhD, Grenoble, France

This session and the International Conference are supported by an educational grant from AstraZeneca LP.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

C2  TOBACCO SMOKING AND CESSATION IN VULNERABLE POPULATIONS
Assemblies on Clinical Problems; Behavioral Science and Health Services Research
9:00 a.m. - 11:00 a.m.  MOSCON CENTER
Room 135 (North Building, Lower Level)

Target Audience
Physicians, nurses, public health officials, physicians in training.

Objectives
At the conclusion of this session, the participant will be able to:
• enhance the knowledge of smoking behaviors and smoking cessation therapies in different subpopulations;
• become aware of targeted or customized treatment options for smoking cessation;
• understand and become aware of the risks of light or moderate smoking.

Tobacco smoking is a major risk factor for a variety of diseases. Tobacco smoking substantially impacts respiratory, cardiac, and vascular health resulting in excess health care costs and premature loss of life. Some ethnic groups and communities are disproportionately impacted, manifesting greater risk of smoking-related lung cancer and death. This session explores the state of the knowledge on the genetics of tobacco smoking and smoking cessation; tobacco use in several ethnic groups; and targeted smoking cessation programs.

Chairing: M.G. Foreman, MD, Atlanta, GA
D.J. Upson, MA, MD, Albuquerque, NM

9:00  Tobacco Use in African Americans
E.R. Neptune, MD, Baltimore, MD

9:25  Tobacco Use in Latinos
F. Holguin, MD, MPH, Pittsburgh, PA

9:50  Ethnic Variation in Lung Cancer Among Smokers
M.P. Rivera, MD, Chapel Hill, NC

10:15  Best Approaches to Smoking Cessation in Targeted Groups
M. Castro, MD, MPH, St. Louis, MO

10:40  Genetics of Tobacco Addiction and Smoking Cessation
M.G. Foreman, MD, Atlanta, GA

C3  KEY MANAGEMENT CONSIDERATIONS IN SARCOIDOSIS
Assemblies on Clinical Problems; Allergy, Immunology and Inflammation
9:00 a.m. - 11:00 a.m.  MOSCON CENTER
Room 134 (North Building, Lower Level)

Target Audience
Practitioners who actively care for patients with sarcoidosis, as well as investigators involved in clinical or translational sarcoidosis studies.

Objectives
At the conclusion of this session, the participant will be able to:
• screen for and diagnose cardiac sarcoidosis;
• understand when to start immunosuppression for pulmonary sarcoidosis and for other “dangerous” sarcoidosis phenotypes;
• devise a steroid sparing treatment regimen, and know better how to counsel patients on the rationale for the various options.

We begin this session by a review of the pathophysiology of sarcoidosis from the perspective of providing rationale for treatment strategies. We then highlight
management of cardiac sarcoidosis, fibrotic pulmonary sarcoidosis, and pulmonary hypertension - the phenotypes of sarcoidosis most associated with poor outcomes and increased mortality. Following this, we review indications and use of currently available immunosuppressive agents, and introduce potential new therapies for sarcoidosis by summarizing the status of current clinical trials.

**Chairing:**
K.C. Patterson, MD, Philadelphia, PA
A.S. Morgenthau, MD, New York, NY

9:00 **A Patient’s Perspective**
J. Ploudre, St. Louis, MO

9:05 **Etiology and Immunopathogenesis of Sarcoidosis**
D.R. Moller, MD, Baltimore, MD

9:20 **When Is a Sarcoidosis Patient in Danger from Their Disease and in Need of Treatment?**
A.U. Wells, MD, London, United Kingdom

9:35 **When Should We Move on from Prednisone and What Should We Give?**
J.C. Grutters, MD, PhD, Nieuwegein, Netherlands

9:50 **What Is the Role of Immunosuppression in Preventing Pulmonary Fibrosis in Sarcoidosis?**
K.C. Patterson, MD, Philadelphia, PA

10:05 **Should Sarcoidosis-Associated Pulmonary Hypertension be Treated?**
R.P. Baughman, MD, Cincinnati, OH

10:20 **How Should We Diagnose and Treat Cardiac Sarcoidosis?**
D.A. Culver, DO, Cleveland, OH

10:35 **What Are the Potential New Treatments for Sarcoidosis? An Update on Clinical Trials**
A.S. Morgenthau, MD, New York, NY

Sepsis is the single most expensive cause of hospitalization and the largest contributor to hospital death. Despite its staggering impact, almost nothing is known about how to treat sepsis patients outside of the six “golden hours” immediately after presentation. In this session, leading experts will review the emerging evidence to inform clinicians about improving sepsis treatment across different time windows and discuss critical knowledge gaps that require future research. In the process, attendees will gain new insight into the intersection of sepsis with pre-hospital care, sepsis care on the wards, sepsis related hospital readmission, and systems-level sepsis quality improvement.

**Chairing:**
V. Liu, MD, MS, Oakland, CA
H.C. Prescott, MD, MA, Ann Arbor, MI

9:00 **Sepsis Screening in the Community: How Do We Inform the Public?**
S. Simpson, MD, Kansas City, KS

9:18 **Pre-Hospital Care of Sepsis: Leveraging Emergency Medical Service Providers**
C.W. Seymour, MD, MSc, Pittsburgh, PA

9:35 **Life After Rivers: Neither EGDT Nor Neglect**
S. Peake, PhD, Victoria, Australia

9:52 **Identifying Sepsis Outside the ICU: SIRS or qSOFA?**
D.C. Angus, MD, MPH, Pittsburgh, PA

10:09 **Enabling Best Sepsis Care Through Tele-Medicine**
D.W. Ford, MD, MSCR, Charleston, SC

10:26 **The Long Tail of Sepsis: Readmissions and Beyond**
H.C. Prescott, MD, MA, Ann Arbor, MI

10:43 **Optimizing Learning Health Care Systems to Address Sepsis**
V. Liu, MD, MS, Oakland, CA

---

**Target Audience**
Clinicians and researchers who seek to improve the care of sepsis patients.

**Objectives**
At the conclusion of this session, the participant will be able to:

- understand methods of improving the early identification of sepsis, including public awareness campaigns, EMS identification, and SOFA score in ER/hospital ward;
- deliver evidence-based care, including fluid-resuscitation, use of e-ICU;
- improve health system approaches to quality improvement and addressing long-term sequelae of sepsis.
This session will describe the emerging understanding of chronic cognitive and affective disorders complicating critical illness survivorship from a multiscale perspective, from population level data to animal models.

Chairing: B.H. Singer, MD, PhD, Ann Arbor, MI
W.J. Ehlenbach, MD, Madison, WI
R.O. Hopkins, PhD, Murray, UT

9:00 A Patient’s Perspective
P. Popp, Evergreen, CO

9:05 Cognitive and Affective Disorders in Survivors of ICU Hospitalization
R.O. Hopkins, PhD, Murray, UT

9:30 Survivorship After Sepsis: A Population Perspective
T.J. Iwashyna, MD, PhD, Ann Arbor, MI

9:55 Neuropathology in Long Term Survivors of Sepsis
W.J. Ehlenbach, MD, Madison, WI

10:15 Mechanisms of Long Term Brain Dysfunction After Critical Illness
B.H. Singer, MD, PhD, Ann Arbor, MI

10:35 Neuroinflammation and Cognitive Decline After Stroke
M. Buckwalter, MD, PhD, Stanford, CA

There will be a 5-minute discussion after each talk.

CLINICAL

SCIENTIFIC SYMPOSIUM

CME Credits Available: 2.0
Nursing Contact Hours Available: 2.4

C6 A REPORT CARD ON EDUCATION DURING PULMONARY REHABILITATION: HOW ARE WE DOING?

Assemblies on Pulmonary Rehabilitation; Behavioral Science and Health Services Research; Nursing

9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 130-132 (North Building, Lower Level)

Target Audience
Individuals engaged in the education of pulmonary patients; physicians, nurses, physical/physiotherapists and respiratory therapists.

Objectives
At the conclusion of this session, the participant will be able to:

• outline the current approach to patient education in pulmonary rehabilitation and present the evidence illustrating the effects of patient education on outcomes such as knowledge, quality of life, self-efficacy, healthcare utilization;

• describe the challenges with eliciting health behavior change and how education and learning new information is only one component of changing, while detailing other factors that impact behavioral change;

• formulate ideas for future directions in education in pulmonary rehabilitation.

The objectives of this symposium are to explore our current approaches to engaging people with COPD in educational activities, using pulmonary rehabilitation education programs as a model. We will explore current educational approaches (didactic and interactive self-management education), their successes and failures in our current communities of practice, and how we might adapt these approaches to modernize educational activities and meet the learning needs of people with COPD in 2015. Participants will be involved in a discussion on the complexity of facilitating health behavior change in people with COPD, how education may be a component of this and what future directions may be in the digital learning world.

Chairing: S. Lareau, MS, RN, Aurora, CO
R. ZuWallack, MD, Hartford, CT
L. Nici, MD, Providence, RI
F.C. Blackstock, PhD, BPhysio(Hons), Melbourne, Australia

9:00 Historical Approach to Education in Pulmonary Rehabilitation for People with COPD
S. Lareau, MS, RN, Aurora, CO

9:15 A Patient Perspective on Education in Pulmonary Rehabilitation
E. Egbert, San Francisco, CA

9:20 Current Educational Models in Pulmonary Rehabilitation: Do They Pass or Fail?
F.C. Blackstock, PhD, BPhysio(Hons), Melbourne, Australia

9:50 Health Literacy: “I Don’t Understand, So How Can I Learn?”
Moving Towards Patient Tailored Education
M.R. George, AE-C, PhD, RN, New York, NY

10:15 Challenges of Changing Behavior: Education Is Only One Component
J. Bourbeau, MD, Montreal, Canada

10:40 Education in Pulmonary Rehabilitation: Where Do We Need to Go Next?
L. Nici, MD, Providence, RI

There will be a 5-minute discussion after each talk.

This session and the International Conference are supported by an educational grant from AstraZeneca LP.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
• understand how PAH trials are designed and the basics of statistical interpretation (e.g.-what is a hazard ratio?);
• understand the data emerging in PAH and how it applies to patients;
• outline the importance of various endpoints in PAH trials and why they are important to patient care.

This session will focus on the wealth of clinical trials data in pulmonary hypertension. Starting with a discussion of how such trials are designed and then covering specific trials and endpoints will give the audience an overview that they can apply to the care of patients with pulmonary arterial hypertension.

Chairing:
R.N. Channick, MD, Boston, MA
V. McLaughlin, MD, Ann Arbor, MI

9:00 How Are Clinical Trials in PAH Designed: The Basics
Speaker to be Announced

9:30 Comparing Endpoints in PAH Trials: Surrogate, Correlate, or Something Else?
S.M. Kawut, MD, MS, Philadelphia, PA

9:50 PRO: Long-Term Morbidity Mortality Trials Are the Way to Go in PAH
V. McLaughlin, MD, Ann Arbor, MI

10:05 CON: Event Driven Trials Are of Limited Value. Trials Need to Be Designed to Determine if a Drug Actually Improves Patients’ Lives
V. Tapson, MD, West Hollywood, CA

10:20 PRO: Upfront Combination Therapy Should Now Be the Standard of Care in PAH
M.J.C. Humbert, MD, PhD, Le Kremlin Bicetre, France

10:35 CON: Upfront Combination Therapy Has Not Been Proven to Be Superior to Sequential Combination Therapy
R.N. Channick, MD, Boston, MA

10:50 Panel Discussion
R.N. Channick, MD, Boston, MA
bronchiectasis that may cause end-stage lung disease by adulthood. This session will highlight new insights into pathomechanisms of disease that have come from both model systems and human gene discovery studies, as well as clinical insights that have arisen from multi-center efforts in North America and Europe to study PCD cohorts over the past decade. Clinical insights will include genotype-phenotype associations, new diagnostic tests and an update on clinical trials that are currently being conducted around the world.

Chairing: S.D.M. Dell, MD, Toronto, Canada
T.W. Ferkol, MD, St. Louis, MO

9:00 A Patient’s Perspective
M. Kitlowski, Baltimore, MD
R. Giannokos, Silver Spring, MD

9:05 Mechanisms of Ciliary Assembly Defects in PCD
S. Brody, MD, St. Louis, MO

9:30 Phenotype-Genotype Relationships in Children and Adults
S. Davis, MD, Indianapolis, IN

9:50 Incorporating Emerging Genetic Testing into Diagnostic Strategies
M. Leigh, MD, Chapel Hill, NC

10:10 Airway Microbiology and Inflammation in PCD
K.N. Olivier, MD, MPH, Bethesda, MD

10:30 The Impact of Disease Management Strategies on Long-Term Prognosis
J. Lucas, PhD, Southampton, United Kingdom

There will be a 5-minute discussion after each talk.

C10 ACHIEVING “ENVIRONMENTAL JUSTICE”: A MAJOR STEP TOWARD RESPIRATORY HEALTH EQUALITY

Assemblies on Environmental, Occupational and Population Health; Allergy, Immunology and Inflammation; Behavioral Science and Health Services Research; Clinical Problems; Critical Care; Microbiology, Tuberculosis and Pulmonary Infections; Nursing; Pediatrics; Sleep and Respiratory Neurobiology; Health Equality Sub-Committee

9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 2002/2004 (West Building, Level 2)

Target Audience
Clinicians, researchers and public health practitioners focusing on the prevention and treatment of respiratory diseases.

Objectives
At the conclusion of this session, the participant will be able to:

• learn new findings about the impact of major environmental risk factors on respiratory health disparities;
• apply new strategies to advocate for environmental justice as means to achieve respiratory health equality;
• discuss feasible and necessary policies to achieve environmental justice and thus move toward respiratory health equality.

Because the frequency of major environmental risk factors for respiratory diseases differs across demographic groups (defined by socioeconomic status, race/ethnicity, sexual orientation, health care access, occupation, or other characteristics), respiratory health disparities are commonly encountered in pediatric and adult pulmonary medicine. Attainment of respiratory health equality requires the ending of respiratory health disparities, which can be achieved only through multidisciplinary efforts to eliminate detrimental environmental exposures. This symposium will review and discuss the current challenges posed by key environmental risk factors for health disparities (smoking, air pollution and occupation), focusing on knowledge gaps and health policy needs.

Chairing: J.C. Celedon, MD, DrPH, Pittsburgh, PA
J.M. Samet, MD, MS, Los Angeles, CA
E.G. Burchard, MD, MPH, San Francisco, CA

9:00 Environmental Justice and Health Equality: Conceptual Framework
J.C. Celedon, MD, DrPH, Pittsburgh, PA

9:20 Tobacco Use and Respiratory Health Disparities
P. Ling, MD, San Francisco, CA

9:40 Traffic-Related Air Pollution: Who Lives Closer to Major Highways?
J.R. Balmes, MD, San Francisco, CA

10:00 Countering Targeted Campaigns Against Vulnerable Populations: Menthol Cigarettes as a Case Study
E.R. Neptune, MD, Baltimore, MD

10:20 Not All Occupations Are Equal: Migrant Workers as a Case Study
M.B. Schenker, MD, MPH, Davis, CA

10:40 Short and Long Term Policies to Achieve Environmental Justice
M.B. Rice, MD, MPH, Boston, MA

C11 PATHOGENESIS AND TREATMENT OF OBSTRUCTIVE LUNG DISEASES: NEW INSIGHTS

Assemblies on Respiratory Structure and Function; Allergy, Immunology and Inflammation; Microbiology, Tuberculosis and Pulmonary Infections; Respiratory Cell and Molecular Biology

9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 2006/2008 (West Building, Level 2)

Target Audience
Allergists, pulmonologists, basic scientists, physiologists, translational researchers, fellows and residents, and graduate trainees interested in the pathophysiology and emerging treatment options for obstructive lung diseases.

Objectives
At the conclusion of this session, the participant will be able to:

• describe factors contributing to the onset and progression of obstructive lung diseases;
• understand the role of genetics, epigenetics and the microbiome on lung function in obstructive lung diseases;
• learn about new findings on potential therapeutic strategies and research endeavors in obstructive lung diseases.

The factors responsible for the initiation, maintenance, progression, and exacerbations of obstructive lung diseases are incompletely understood. Airway remodeling, acute and chronic inflammation and airway hyperresponsiveness are well known established hallmarks of these syndromes. However, the contributions of microbial and environmental exposures as well as the influence of genetic and epigenetic changes to disease risk and treatment are being actively investigated, elucidated and appreciated. This integrated symposium will present insights into the impact of these diverse factors to the development and progression of asthma and COPD, and how this knowledge is being applied to identify novel targets for therapy.

Chairing: B. Camoretti-Mercado, PhD, Tampa, FL
T. Pera, PhD, Philadelphia, PA
J.E. Bourke, PhD, Clayton, Australia

9:00 Obstructive Pulmonary Disease: What Went Wrong and How to Fix It
M. Kraft, MD, Tucson, AZ
Parker B. Francis Speaker

9:20 Detection of Early Stages of Pulmonary Obstructive Disease: An Ambitious Goal
S.I. Rennard, MD, Melbourn, United Kingdom

9:40 Genomics of Obstructive Lung Diseases: New and Old Players
P.G. Woodruff, MD, MPH, San Francisco, CA

10:00 Epigenetic Control of Smooth Muscle Phenotype
W. Gerthoffer, PhD, Mobile, AL

10:20 Significance and Interactions of the Lung Microbiome in Obstructive Lung Diseases
S.V. Lynch, PhD, San Francisco, CA

10:40 Searching New Interventions for Obstructive Lung Diseases: Promises and Challenges
S.R. White, MD, Chicago, IL

There will be a 5-minute discussion after each talk.

This session and the International Conference are supported by an educational grant from AstraZeneca LP.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
Target Audience
All clinicians, basic researchers, and other lung health care professionals looking to learn about state of the art developments in stem cell biology and their applications to lung diseases

Objectives
At the conclusion of this session, the participant will be able to:

• appreciate the current state of the art with respect to stem cell biology;
• appreciate the current state of the art with respect to cancer stem cells;
• appreciate applications of stem cell and cancer stem cell biology to respiratory diseases and critical illnesses.

The potential for use of stem cells to prevent or treat human disease has led to unprecedented growth of the field of regenerative medicine. Moreover, increasing evidence demonstrates the feasibility of utilizing an individual's own cells in developing potential stem cell-based therapeutic approaches: the ultimate in personalized medicine. This symposium will provide a strong basic scientific and clinical rationale and current state of the art in this rapidly developing area. The speakers are all accomplished stem cell investigators from outside the respiratory field who will bring new knowledge and perspective that will help guide future developments in lung regenerative medicine.

Chairing:
D.J. Weiss, MD, PhD, Burlington, VT
D.N. Kotton, MD, Boston, MA

9:00 Normal and Neoplastic Stem Cells
I. Weissman, MD, Stanford, CA

9:30 Imaging Cancer Heterogeneity and Therapy Resistance in Real Time
T. Reya, PhD, La Jolla, CA

10:00 Interspecific Blastocyst Complementation: A Novel Approach to Generate Functional Organs
T. Rashid, MD, London United Kingdom

10:30 Defining the Lung Cell By Cell
M. Krasnow, PhD, Palo Alto, CA

MINI SYMPOSIUM

C14 FINDING THE SWEET SPOT BETWEEN TOO MUCH AND TOO LITTLE CARE
9:00 a.m. - 11:00 a.m. MOSCON CENTER
Room 307 (South Building, Esplanade Level)
Chairing: R.S. Wiener, MD, MPH, Boston, MA
A. Garland, MD, MA, Winnipeg, Canada

Oral Presentations

C15 TB GAME CHANGERS: DIAGNOSTICS, HIV, DRUG-RESISTANCE, AND TREATMENT
9:00 a.m. - 11:00 a.m. MOSCON CENTER
Room 3016/3018 (West Building, Level 3)
Chairing: R. Reves, MD, MSc, Denver, CO
P. Nahid, MD, MPH, San Francisco, CA
C. Daley, MD, Denver, CO

Oral Presentations


MINI SYMPOSIUM

C17 FASCINATING MECHANISMS IN LUNG FIBROSIS
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 3003/3005 (West Building, Level 3)

Oral Presentations


10:30 Hippo Signaling is Deranged in Idiopathic Pulmonary Fibrosis and Correlates with Disease Severity/D.E. Wagner, K. Mutz, H.B. Schiller, R. Costa, N. Kaminski, M. Königshoff, Munich, Germany, p.A4586

MINI SYMPOSIUM

C18  ADVANCES IN MEASURING LUNG FUNCTION: SMALL AIRWAYS AND UP

9:00 a.m. - 11:00 a.m.  MOSCONE CENTER

Room 2009/2011 (West Building, Level 2)

Chairing: D.A. Kaminsky, MD, Burlington, VT
M.J. Hegewald, MD, Murray, UT
C. Thamrin, PhD, Glebe, Australia

Oral Presentations


9:15 Age and Sex Influences on Dynamic Air-Trapping in Asthma/R. Sorkness, C. Kienert, M. O’Brien, S. Fain, N.N. Jarjour, Madison, WI, p.A4589


10:00 Breath-To-Breath and Day-To-Day Variability of Respiratory Impedance in Asthma Patients/C.D. Nguyen, A. Gobbi, R.L. Dellaca, G.G. King, C. Thamrin, Sydney, Australia, p.A4592


MINI SYMPOSIUM

C19  FROM GENES TO MOTOR NEURONS: ADVANCES IN CONTROL OF BREATHING

9:00 a.m. - 11:00 a.m.  MOSCONE CENTER

Room 2001/2003 (West Building, Level 2)

Chairing: E.B. Gauda, MD, Baltimore, MD
N. Nichols, PhD, Columbia, MO
F.J. Jacono, MD, Cleveland, OH

Oral Presentations


9:45 Effect of Acute Intermittent Hypoxia on Ventilation in Patients with Chronic Spinal Cord Injury During Sleep/A. Sankari, A.T. Bascom, M.S. Badr, Detroit, MI, p.A4599

10:00 Determination of Optimal Supplemental Oxygen Flow Rate for Treatment of Infants with Obstructive Sleep Apnea (OSA)/J. Brockbank, M. Dixon, N. Simakajornboon, Richmond, VA, p.A4600


Featured Speaker

10:45 The Latest and Greatest in Neural Control of Breathing/J.M. Ramirez, PhD, Seattle, WA

MINI SYMPOSIUM

C20  ADVANCES IN THE CELLULAR AND MOLECULAR UNDERSTANDING OF LUNG CANCER

9:00 a.m. - 11:00 a.m.  MOSCONE CENTER

Room 306/308 (South Building, Esplanade Level)

Chairing: S. Albelda, MD, Philadelphia, PA
V.C. Broaddus, MD, San Francisco, CA

Featured Speaker

9:00 Learning from Within: The Role of the Microenvironment in Lung Cancer/S. Dubinett, MD, Los Angeles, CA

9:15 Non-Small Cell Lung Cancer (NSCLC) Tumor Progression is Inhibited in an Inducible Vascular-Specific MicroRNA-1 (miR-1) Transgenic Model/A. Korde, L. Jin, M. Haslip, S. Takyar, New Haven, CT, p.A4603


10:30 The Examination of CD47 and Its Potential Therapy Target Study on the Migration and Invasion in Non-Small Cell Lung Cancer/Q. Wang, H. Zhao, J. Wang, X. Du, E. Li, Dalian, China, p.A4608


BASIC SCIENCE CORE POSTER DISCUSSION SESSION

C21 APPLYING ‘OMICs TECHNOLOGIES TO REVEAL GENE REGULATORS AND BIOMARKERS IN LUNG DEVELOPMENT AND DISEASE

9:00 a.m. - 11:00 a.m. MOSCONE CENTER Room 2010/2012 (West Building, Level 2)

Poster Viewing 9:00-9:45
Discussion 9:45-11:00

Chairing: N. Kaminski, MD, New Haven, CT
M.W. Geraci, MD, Indianapolis, IN
C.E. Wheelock, PhD, Stockholm Sweden

401 Transcriptomic Changes Common to Diverse Chronic Lung Diseases Indicate a Core Response to Chronic Injury/B.M. Cherry, B. Juan-Guardela, K. Sakamoto, N. Kaminski, J. Herazo-Maya, New Haven, CT, p.A4610


408 Genome-Wide Assessment Reveals Marked Differences in the Transcriptomes of Mononuclear Phagocytes in the Developing Lung/E. Saji, V. Link, C. Romanoski, G. Fonseca, T. Troutman, L. Prince, C. Glass, La Jolla, CA, p.A4617


SDF-1/CXCR4 Signaling Regulates Bone Marrow Mesenchymal Stem Cell Trafficking to Promote Airway Remodeling in Asthmatic Rats/B. Mo, Z. Wang, C. Wang, J. Wei, L. Ma, D. Yao, J. Wang, G. Huang, J. Huang, Q. Xu, Guilin, China, p.A4651

Maintenance of IRF1 by IL1B and Dexamethasone in Human Pulmonary Epithelial Cells: Role of the Mitogen-Activated Protein Kinase Phosphatase, DUSP1/S.V. Shah, M.M. Mostafa, R. Newton, Calgary, Canada, p.A4652


213 Impact of Body Fat Composition on Hospital Length of Stay and One Year Readmission Rate in Patients Post Bilateral Lung Transplantation/O. Ahmad, M. Browning, M. Baz, C. Hage, J. Wu, M. Duncan, D. Roe, Indianapolis, IN, p.A4671


221 Associations Between Pre-Transplant Body Mass Index, Pectoralis Muscle Area, and Underlying Disease in Patients Undergoing Lung Transplantation/G.W. Li, V. Hoang, N.L. Capuano, C.C. Kao, G. Dronavalli, A.D. Parulekar, Houston, TX, p.A4679


225 Change in the Lung Allocation Score and Survival of Candidates Awaiting Lung Transplantation/D.R. Nunley, L.A. Szalacha, G.S. Bauldoff, Louisville, KY, p.A4683

305 Predictors of Patient and Family Ratings of Overall Satisfaction with Care in the Intensive Care Unit/S. Lah, E. Wilson, R. Rozenblum, E. Hirshberg, J. Orme, R. Hopkins, S.M. Brown, Murray, UT, p.A4734


308 Incidence and Predictors of Anxiety and Depression in Caregivers of Critically Ill Patients and Comparison of These Symptoms at the Time of Admission and Discharge from the Intensive Care Unit (ICU): A Prospective Study/D. Chaudhry, N. Jain, A. Singh, S. Sethi, S. Virdi, Rohatik, India, p.A4737


311 Barriers and Facilitators to the Conduct of Interdisciplinary Family Meetings in the ICU: Preliminary Findings from a Qualitative Exploration/J.B. Seaman, R. Arnold, M. Nilsen, A. Argenas, A.-M. Shields, D. White, Pittsburgh, PA, p.A4748


---

**POSTER DISCUSSION SESSION**

**C27 NEWS FROM THE NICU AND PICU**

9:00 a.m. - 11:00 a.m. MOSCON CENTER Room 3011 (West Building, Level 3)

**Poster Viewing**  9:00-9:45

**Discussion**  9:45-11:00

**Chairing:** J.K. McGuire, MD, Seattle, WA
V. Ackerman, MD, Indianapolis, IN


806 Heart Rate Variability in Extremely Preterm Infants While Receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) and Continuous Positive Airway Pressure (CPAP) Immediately After Exubtation/S. Lairemouille, L. Kanbar, P. Lamer, A. Al-Jabri, W. Shalish, R. Kearney, G. Sant’Anna, Montreal, Canada, p.A4755


BAL Culture Results Are Not Specific to VAP Signs and Symptoms in Mechanically Ventilated Children/A.L. Beardsley, M.E. Nitu, Indianapolis, IN, p.A4760


Usefulness of Polysomnography for Evaluation and Management of Chronic Mechanical Ventilation in Children/N. Gurbani, D. Benscoter, N. Simakajornboon, Cincinnati, OH, p.A4764


The Feasability of Probe-Based Confocal Endomicroscopy (pCLE) in Children/C. McHendry, C. Towe, S. Moore, J. Shannon, M.G. Schecter, Cincinnati, OH, p.A4766

Rates of Clinical Improvement Following Therapeutic Flexible Bronchoscopy in Critically Ill Children/D.R. Spielberg, J.J. Brewington, D. Benscoter, Cincinnati, OH, p.A4767


1010 Cell-Free Hemoglobin Causes Acute Lung Injury and Increases Mortality in a Mouse Model of Polymicrobial Sepsis/J.A. Bastarache, C.M. Shaver, N.D. Putz, J.L. Kuck, M.G. Paul, J.L. Wynn, L.B. Ware, Nashville, TN, p.A4781

1011 Role of TRPM2 in Sphingolipid-Mediated Radiation-Induced Lung Injury/Y. Epshtein, H. Wang, A.B. Malik, J. Jacobson, Chicago, IL, p.A4782


1017 Role of Syndecan-1 in Mechanical Stress-Induced Lung Endothelial Cell Inflammatory Responses Mediated by Integrin β4/W. Chen, R.O. Dull, J.R. Jacobson, Chicago, IL, p.A4788

POSTER DISCUSSION SESSION

C29 PROTECTORS OF THE LUNG: INNATE IMMUNE RESPONSES IN ACUTE LUNG INJURY

9:00 a.m. - 11:00 a.m. MOSCONE CENTER Room 2014 (West Building, Level 2)

Poster Viewing 9:00-9:45

Discussion 9:45-11:00

Chairing: C.M. Waters, PhD, Memphis, TN E. Herzog, MD, PhD, New Haven, CT J.A. Bastarache, MD, Nashville, TN H. Garn, PhD, Marburg, Germany R. Paine, MD, Salt Lake City, UT J. Liu, PhD, Chicago, IL N.V. Kolliputi, PhD, Tampa, FL

1018 IL-36R Blockade Attenuates Lung Injury and Mortality After H1N1 Influenza Virus Infection in Mice/T. Aoyagi, M.W. Newstead, X. Zeng, M. Kaku, T.J. Standiford, Ann Arbor, MI, p.A4789


1021 IL-22 / IL-22 Binding Protein (IL-22ra2) Balance Is Critical for the Resolution of Influenza Induced Lung Pathology/D. Pociask, J. Kolls, New Orleans, LA, p.A4792

1022 SPLUNC1 Regulates LPS-Induced Innate Immune Activation and Lung Neutrophilic Inflammation/C.J. Britto, N. Niu, L.E. Cohn, New Haven, CT, p.A4793


1024 HO-1 Mediates the Cytoprotective Effects of NLRP3 Deficiency Via Autophagy/Y. Zhang, P.J. Lee, New Haven, CT, p.A4795

1025 Toll-Like Receptor 4 Mediates the Protective Effects of VEGF in Lung Endothelium/Y. Zhang, S. Takyar, P. Shan, P.J. Lee, New Haven, CT, p.A4796


1028 Lipoteichoic Acid Upregulates Plasminogen Activator Inhibitor-1 Expression in Human Pleural Mesothelial Cells Via TLR2/6NLRP1/Pathway/K.L. Lee, W.H. Newstead, K.S. Lai, C.L. Chung, Taipei City, Taiwan, p.A4799

1029 Effects of Ethanol’s on Pulmonary Expression of Inflammatory Cytokines and Activation of Anti-Microbial Peptides Via Vitamin D Pathway/O. Ogunsakin, New Orleans, LA, p.A4800

1030 Innate Memory of Airway Epithelial Cells Augments LPS-Induced Mucous Secretory Response/H.S. Chand, Y. Mebratu, Y. Tesfai, Albuquerque, NM, p.A4801


517 Hypoxia Suppresses Innate Immune Function in Primary Murine Alveolar Epithelial Cells Through Effects on the Redox-Sensitive Factor, NFkB/A. Sturrock, D. Woller, R. Paine, Salt Lake City, p.A4805

518 Redox Imbalance Induced by Angiotensin II Aggravated Pulmonary Fibrosis Via Activating NALP3 Inflammasomes/Y. Meng, Y. Chen, M. Pan, Q. Yang, Z. Zheng, Guangzhou, China, p.A4806

519 RING Finger E3 Ligase PPP1R11 Regulates TLR2 Signaling and Innate Immunity/B. Chen, A. Mckelvey, S. Dunn, T. Lear, Y. Liu, Pittsburgh, PA, p.A4807

520 Asian Sand Dust Increases MUC8 and MUC5B Expressions Via TLR4-Dependent ERK2 and p38 MAPK in Human Airway Epithelial Cells/Y.-D. Kim, Y.S. Choi, H.G. Na, C.H. Bae, S.-Y. Song, Daegu, Korea, Republic of, p.A4808

521 Lung WWOX Knockdown Causes Neutrophilic Inflammation Associated with Increased Epithelial IL-8 Secretion/S. Singla, J. Chen, J.R. Sysol, R.F. Machado, Chicago, IL, p.A4809

522 Notch Signaling in the Differentiation of Alveolar Type II to Type I Cells After Pseudomonas Aeruginosa Induced Lung Injury/J. Finn, Y. Liu, Chicago, IL, p.A7865


525 Diet-Induced Obesity Induces Endoplasmic Reticulum Stress in the Lung Endothelium and Predispose to LPS Induced Acute Lung Injury/D. Shah, F. Romero, R. Summer, Philadelphia, PA, p.A7868

526 Alpha-Klotho Protects Zucker Diabetic Fatty Rat Lung Against Hypoxic Injury/A. Kaczka, MD, PhD, Iowa City, IA, p.A4810


528 Deletion of c-FLIP in CD11b+ Macrophages Protects Against Bleomycin Induced Lung Fibrosis/A.L. McCubrey, L. Barthel, W. Janssen, Denver, CO, p.A4812


532 Lipopolysaccharide-Induced Lung Injury Is More Severe in Old Compared to Young Mice/C. Brandenberger, K.M. Kline, E. Lopez-Rodriguez, C. Pfarrer, C. Muhlfeld, Hannover, Germany, p.A4816


539 Alpha-Klotho Protects Zucker Diabetic Fatty Rat Lung Against Hyperoxic Injury/P. Ravikumar, E.V. Wechsler, O.W. Moe, C.W. Hsia, Dallas, TX, p.A4823

540 Solubilized Lung-Derived Extracellular Matrix Mitigates Hyperoxic Lung Injury/P. Ravikumar, C.T. Atkins, J. Wu, Y. Hong, C.W. Hsia, Dallas, TX, p.A4824
C31 EXPERIMENTAL ASTHMA THERAPIES

9:00 a.m. - 4:15 p.m. MOSCONOE CENTER

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: J.F. Alcorn, PhD, Pittsburgh, PA


P372 Targeting the Immunological Drivers of Asthma with Inhaled Delivery of a JAK1 Inhibitor/M.C. Catley, A. Smalagic, M. Rhedin, N. Parker, M. Nilsson, A. Aurell Holmberg, R. Hendrickx, K. Johansson, Gothenburg, Sweden, p.A4836


P376 Leukotriene Receptor Blockade Decreases Mucin Production Triggered by Acute Ethanol Ingestion in Allergen-Sensitized Mice/B. Lussier, T. Hsieh, D. Remick, Boston, MA, p.A4840


P378 Effects of Chronic Treatment with CAPE, a Specific NF Kappa-B Inhibitor, Compared to Rho Quinase Inhibitor or Corticosteroid on Airway Hyperresponsiveness in Mice with Chronic Allergic Pulmonary Inflammation/I. F. Tiberio, F. C. R. Souza, T. M. Santos, L. R. Aristeoetes, R. F. Righetti, B. Saraiva-Romanhohlo, C. M. Prado, F. M. A. Costa, E. A. Leick, M. A. Martins, Brazil, p.A4842

P379 Acetaminophen Attenuates House Dust Mite Induced Allergic Airway Disease in Mice/G. J. Smith, R. S. Thrall, M. M. Cloutier, J. E. Manautou, J. B. Morris, Storrs, CT, p.A4843

Facilitator: A. Haczku, MD, PhD, Davis, CA

P380 Electronic Cigarette Inhalation Promotes Inflammatory Cytokines Within the Airways and Systemic Inflammation in Mice/D. Mathew, J.H. Wang, L.E. Crotty Alexander, San Diego, CA, p.A4844

P381 PGE2-Treated Macrophages Inhibit Development of Allergic Lung Inflammation in Mice/C. Draijer, C.E. Boorsma, C. Reker-Smit, E. Post, K. Poelstra, B.N. Melgert, Groningen, Netherlands, p.A4845


P385 Dermatophagoides Pteronyssinus 1 and Dermatophagoides Pteronyssinus 2 Specific Immunoglobulins E Curative Effect Evaluation for Specific Immunotherapy/P. Zheng, B. Sun, Guangzhou, China, p.A4849

P386 The Cardiomyocyte Protein Alpha-T-Catenin Contributes to Asthma Through Regulating Pulmonary Vein Inflammation/C.J. Gottardi, G.R.S. Budinger, P. Bryce, S.S. Folmsbee, Chicago, IL, p.A4850

P387 Preventive Administration of IL-27 Improves Airway Inflammation of Ovalbumin -Induced Asthma Mice Model Via Both STAT1 and GADD45γ/p38MAPK Pathways/Z. Chen, X. Su, K. Xu, J. Pan, X. Wang, Shanghai, China, p.A4851


P139 Nitrogen Mustard-Induced Lung Fibrosis Visualized by MRI and CT Imaging Is Accompanied by Accumulation of Foamy Macrophages/A.J. Gow, A. Venosa, D. Adler, J. Laskin, E. Yurkow, D. Laskin, Piscataway, NJ, p.A4856

P140 Hyperleukocytic Acute Myeloid Leukemia: Radiographic Findings and Clinico-Radiological Correlation in a Large Series of Patients/M. Stefanski, C. Jamis-Dow, A. Van De Louw, Hershey, PA, p.A4857

C33 IMMUNE PATHOLOGY OF VIRAL INFECTIONS

9:00 a.m. - 4:15 p.m. MOSCON CENTER Area B, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: B.Y. Besecer, MD, Columbus, OH

P144 Role of Endogenous Hydrogen Sulfide in Airway Hyperresponsiveness (AHR) and Inflammation in a Mouse Model of Cigarette Smoke Exposure and Respiratory Syncytial Virus (RSV) Infection/R.P. Garofalo, Galveston, TX, p.A4858


P146 Silver Nanoparticles Down-Regulate Retinoic Acid-Inducible Gen 1 (RIG-I) Signalling Pathway During Influenza Infection Resulting in Lower Activation of TANK-Binding Kinase 1 (TBK1) and Reduced CCL5 Production/ J. Garcia-Verdugo, A. Dieu, B. Villeret, B. Solhonne, J.-M. Sallenave, Paris, France, p.A4860


P150 Detrimental Role of IL-18 in a Mouse Model of Cigarette Smoke and H1N1 Influenza Infection/G. Vanderstocken, M.C. Morissette, P. Shen, A.B. Roos, A.J. Beaulieu, A. Tabuchi, W.M. Kuebler, M.R. Stampfli, Hamilton, Canada, p.A4864
P165 Phenotyping Immune Responses in Asthma and Respiratory Infections

Facilitator: S.A. Cormier, PhD, Memphis, TN

P164 The Nasopharyngeal Microbiome During Acute RSV Infection Resembles the Bacterial Profile Associated with Increased Risk of Childhood Asthma

Facilitator: C. Rosas-Salazar, M.H. Shilts, S. Yooseph

P163 Azithromycin Therapy During Severe RSV Bronchiolitis: Upper Airway Microbiome Alterations and Subsequent Recurrent Wheeze

Facilitator: T.J. Harford, E.A. Lendermon, J. Dodd-o, T.A. Coon, F.R.

P162 The Potential Roles of IFIT Genes and Interferon Induction for Antiviral Immune Response to Influenza Virus Infection in Nasal Mucosa

Facilitator: H.J. Kim, S.N. Hong, W.H. Lee, Seoul, Korea, Republic of

P161 Rhinovirus Infection Induces Abnormal Repair in a Model of Regenerating Airway Epithelium

Facilitator: A. Belkadi, P.M. Brown, S. Manti, F. Rezaee, G. Piedimonte, Cleveland, OH, p.A4873

P160 Rhinovirus Induces CXCL-10 Via IL-33/ST2 Signaling Axis in Human Bronchial Epithelial Cells


P159 Respiratory Syncytial Virus Infection Affects the Survival and Differentiation of Human Neuroprogenitor Cells

Facilitator: A. Belkadi, P.M. Brown, S. Manti, F. Rezaee, G. Piedimonte, Cleveland, OH, p.A4873

P158 Toll Like Receptor 7 Regulates the Electrolytes Secretion from Airway Submucosal Gland

Facilitator: S. Konno, MD, Sapporo, Japan

P157 Trp Channel Activation in Response to Respiratory Syncytial Virus Differ Between Human Pediatric Primary Bronchial Epithelial Cells and Airway Smooth Muscle Cells

Facilitator: T.J. Harford, P.M. Brown, F. Rezaee, G. Piedimonte, Cleveland, OH, p.A4871

P156 Plasmacytoid Dendritic Cells Play a Critical Role in Regulating Gene Expression Patterns Induced by Human Rhinoviruses

Facilitator: J. Upham, C. Xi, O. Pena, A. Bosco, Brisbane, Australia, p.A4870

P155 Parainfluenza 3 Virus Induces Increased Cough Sensitivity, BDNF Expression, and Vagal Sensory TRPV1 Expression in the Airways


P154 Chronic Pulmonary Inflammation in HIV Positive Subjects on Long Term Antiretroviral Therapy

Facilitator: M.A. McInerney, P.A. Smith, F.X. McCormack, Cincinnati, OH, p.A4867

P153 The Proliferative State of Alveolar Type II Cells Determines Susceptibility to Influenza Pneumonia


P152 The Effects of Depleting Peripheral Monocytes on Pulmonary Regenerating Airway Epithelium

Facilitator: S. Konno, MD, Sapporo, Japan

P151 Novel Insights into the H1N1 Pandemic: Mice Sensitized with House Dust Mite Extract Demonstrate Increased Morbidity from H1N1 Infection


P150 Bacterial Lipopolysaccharide Promotes Cytokine Expression and Cytotoxic CD8+ T Cell Function in the Human Nasal Mucosa

Facilitator: T.J. Harford, E.A. Lendermon, J. Dodd-o, T.A. Coon, F.R.

P149 The Nasopharyngeal Microbiome During Acute RSV Infection Affects the Survival and Differentiation of Human Neuroprogenitor Cells

Facilitator: A. Belkadi, P.M. Brown, S. Manti, F. Rezaee, G. Piedimonte, Cleveland, OH, p.A4873

P148 The Effects of Bone Marrow-derived Mesenchymal Stem Cells on the Expression of CD206 (MDCR) and IL-10 in Human Dendritic Cells

Facilitator: T.J. Harford, E.A. Lendermon, J. Dodd-o, T.A. Coon, F.R.

P147 Chronic Pulmonary Inflammation in HIV Positive Subjects on Long Term Antiretroviral Therapy

Facilitator: M.A. McInerney, P.A. Smith, F.X. McCormack, Cincinnati, OH, p.A4867

P146 The Potential Roles of IFIT Genes and Interferon Induction for Antiviral Immune Response to Influenza Virus Infection in Nasal Mucosa

Facilitator: H.J. Kim, S.N. Hong, W.H. Lee, Seoul, Korea, Republic of

P145 Azithromycin Therapy During Severe RSV Bronchiolitis: Upper Airway Microbiome Alterations and Subsequent Recurrent Wheeze

Facilitator: T.J. Harford, E.A. Lendermon, J. Dodd-o, T.A. Coon, F.R.

P144 The Effects of Depleting Peripheral Monocytes on Pulmonary Regenerating Airway Epithelium

Facilitator: S. Konno, MD, Sapporo, Japan

P143 The Potential Roles of IFIT Genes and Interferon Induction for Antiviral Immune Response to Influenza Virus Infection in Nasal Mucosa

Facilitator: H.J. Kim, S.N. Hong, W.H. Lee, Seoul, Korea, Republic of

P142 Rhinovirus Infection Induces Abnormal Repair in a Model of Regenerating Airway Epithelium

Facilitator: A. Belkadi, P.M. Brown, S. Manti, F. Rezaee, G. Piedimonte, Cleveland, OH, p.A4873

P141 Rhinovirus Induces CXCL-10 Via IL-33/ST2 Signaling Axis in Human Bronchial Epithelial Cells


P140 Respiratory Syncytial Virus Infection Affects the Survival and Differentiation of Human Neuroprogenitor Cells

Facilitator: A. Belkadi, P.M. Brown, S. Manti, F. Rezaee, G. Piedimonte, Cleveland, OH, p.A4873

P139 Toll Like Receptor 7 Regulates the Electrolytes Secretion from Airway Submucosal Gland

Facilitator: S. Konno, MD, Sapporo, Japan

P138 Novel Insights into the H1N1 Pandemic: Mice Sensitized with House Dust Mite Extract Demonstrate Increased Morbidity from H1N1 Infection


P137 The Effects of Depleting Peripheral Monocytes on Pulmonary Regenerating Airway Epithelium

Facilitator: S. Konno, MD, Sapporo, Japan

P136 The Potential Roles of IFIT Genes and Interferon Induction for Antiviral Immune Response to Influenza Virus Infection in Nasal Mucosa

Facilitator: H.J. Kim, S.N. Hong, W.H. Lee, Seoul, Korea, Republic of
Facilitator: P. Burkett, MD, PhD, Boston, MA

P175 Levels of Surfactant Protein D in Bronchial Aspirates Within Six Hours of Lung Transplantation Are Associated with Clinical Outcomes/J. Madsen, S. Rideout, L. Thakuria, R. Romano, A. Simon, A. Popov, F. De Roberts, S. Soresi, M. Carby, A. Reed, N. Marczin, H. Clark, M. Griffiths, L. Roberts, United Kingdom, p.A4887


THEMATIC POSTER SESSION

C35 INNATE IMMUNE MECHANISMS IN COPD

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Facilitator: S. Garantziotis, MD, Research Triangle Park, NC


P1222 Inflammation Paradox - A Detailed Analysis of Inflammatory Profile in the Large and Small Airway Wall in Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients/M.S. Eapen, K.D. McAlinden, D. Tan, H.K. Muller, S.S. Sohal, E.H. Walters, Hobart, Australia, p.A4895


P1224 Platelets of COPD Patients Are Hyper-Responsive/F. Aleva, Q. De Maet, K. Van Braet, P. De Groot, Y. Heijdra, A. Van Der Ven, Nijmegen, Netherlands, p.A4897

Facilitator: M. Divangahi, PhD, Montreal, Canada


P1226 Inhibition of p38 MAPK in Human Skeletal Muscle Cells Attenuates the SAA1 Secretion Initiated by Inflammatory Stimulation and Could Be Helpful Against Muscle Targeted Inflammation in COPD/D. Patoine, A. Dube, M.-E. ThAcriault, S. Bonnet, F. Maltais, Quebec, Canada, p.A4899


Marco Regulates the In Vivo Response to Low Molecular Weight Hyaluronan Fragments/A. Birukova, Z. Li, J.W. Hollingsworth, R.M. Tighe, Durham, NC, p.A4906

Cigarette Smoke-Induced Lung Inflammation in Chronic Obstructive Pulmonary Disease Mediated Via LTB4/BLT1/SOCS1 Pathway/R. Dong, K. Zhao, L. Xie, M. Zhou, Shanghai, China, p.A4907


Type 1 Innate Lymphoid Cells Are Increased in COPD and May Contribute to Pathogen-Induced Exacerbations of Disease/A.A. Humbles, J. Kearley, A. Copenhagen, C. Sanden, M. Mori, L. Yu, G. Harms Pritchard, A. Berlin, C. Hunter, R.P. Bowler, J.S. Erjefalt, R. Kolbeck, J.S. Silver, Gaithersburg, MD, p.A7872


C36 NOVEL MECHANISMS OF ALLERGIC AIRWAY INFLAMMATION IN ANIMAL MODELS

9:00 a.m. - 4:15 p.m.
Area B, Hall D (North Building, Lower Level)
MOSCONET CENTER

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:15: authors will be present for discussion with assigned facilitators

Facilitator: L.A. Miller, PhD, Davis, CA

Effects of Concurrent Exposure of Diesel Exhaust Particles and House Dust Mite on Development of Allergen-Induced Airways Inflammation/Y. Zhang, A. Hin, X. Wang, S. Salehi, J.A. Scott, C. Carlsten, C.-W. Chow, Toronto, Canada, p.A4909


Prior Chronic Exposure to Diesel Exhaust Particles Enhances Airways Hyperresponsiveness and Inflammation in an Acute Model of House Dust Mite-Induced Airways Inflammation/X. Wang, A. Hin, Y. Zhang, S. Salehi, J.A. Scott, C. Carlsten, C.-W. Chow, Toronto, Canada, p.A4913


Glucocorticoid Induced Leucine Zipper Protein (GILZ) Deficient Mice Show a Similar Response as Wild Type Mice in Allergic Airway Disease Whereas Mice with GILZ Deficiency in Just the Bronchial Epithelial Cells Show an Enhanced Response in a Murine Asthma/A. Doerner, J. Eddleston, M. Miller, D. Broide, B. Zuraw, La Jolla, CA, p.A4915

Facilitator: I.P. Lewkowich, PhD, Cincinnati, OH


Chronic Ovalbumin Sensitization Enhances Cough and Expiratory Reflexes Elicited by Inhaled Irritant Gases in Awake Mice/C. Zhang, R.-L. Lin, M. Khosravi, L.-Y. Lee, Guiyang, China, p.A4918


Facilitator: A.I. Sperling, PhD, Chicago, IL

Chronic Mouse Model of Chemical-Induced Asthma/L. Pollaris, F. Devos, S. Seys, B. Nemery, P.H.M. Hoet, J. Vanoirbeek, Leuven, Belgium, p.A4923

**THEMATIC POSTER SESSION**

**C37 PULMONARY FIBROSIS**

*9:00 a.m. - 4:15 p.m.*  

**MOSCONET CENTER**  
Area B, Hall D (North Building, Lower Level)

**Viewing:** Posters will be on display for entire session.

**Discussion:**  
11:00-11:45: authors will be present for individual discussion  
11:45-12:45: authors will be present for discussion with assigned facilitators

**Facilitator:** R.G. Scheraga, MD, Cleveland, OH

**P206**  
5'Ectonucleotidase (CD73) Impacts on Radiation-Induced Immune Changes/S. De Leve, F. Wirsdorfer, F. Cappuccini, M. Stuschke, V. Jendrossek, Essen, Germany, p.A4929

**P207**  
A Retrospective Cohort Analysis of Anti-Jo Associated Lung Disease/P.D. Jackson, C. Hutchinson, T. Siddharthan, Portland, OR, p.A4930

**P208**  

**P209**  

**P210**  

**P211**  

**P212**  

**Facilitator:** M.N. Ballinger, PhD, Columbus, OH

**P213**  
Insights from a Multi-Centre Real Life Experience in Germany with Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis/F. Bonella, M. Kreuter, L. Hagmeyer, C. Neurohr, C. Keller, M. Kohlhaeufj, J. Muller-Quernheim, K. Milger, A. Prasse, Essen, Germany, p.A4936

**P214**  
Combination Potential of Pirfenidone and Silymarin for Treatment of Idiopathic Pulmonary Fibrosis/S. Dasari, R. Alluri, K.V. Routhu, Hyderabad, India, p.A4937

**P215**  

**P216**  

**P217**  

**P218**  
Resident Memory T Cells Arrest and Reverse Pulmonary Fibrosis/A.H. Hughes, Y. Chan-Li, C.L. Vigeland, S.L. Collins, M.R. Horton, Baltimore, MD, p.A4941

**P219**  
Performance Characteristic of Six Minute Walk Test in Scleroderma Patients with Interstitial Lung Disease/C. Ghattas, A. Gadre, O.A. Minai, K.B. Highland, Boston, MA, p.A4942

**Facilitator:** R. Guzy, MD, PhD, Chicago, IL

**P220**  

**P221**  
Idiopathic Interstitial Pneumonia with Autoimmune Features: Clinical Characteristics and Prognosis in a French Cohort/K. Ahmad, T. Barba, J. Traclet, C. Khouatra, V. Cottin, Bron, France, p.A4944

P223 Effects of Endotoxin Injection on Diaphragm Muscle/ P2224 The Effect of N-Acetylcysteine on Idiopathic Pulmonary Fibrosis: A Meta-Analysis/W. Luo, Y.L. Li, Chongqing, China, p.A4947


Facilitator: R. Vij, MD, Chicago, IL

Discussion: 11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: K.A. Riekert, PhD, Baltimore, MD

Viewing: Posters will be on display for entire session.

P612 Medication Adherence Among Difficult-to-Treat Asthmatics/S. Gagermeier, S. Qazi, R. Tehrani, Maywood, IL, p.A4957


P617 Do Asthma or COPD Cost-Effectiveness Models Have Similar Structures and Inputs?/J.D. Campbell, C.H. Kim, P. Dilokthornsakul, Aurora, CO, p.A4964

P618 A Longitudinal Claims Analysis of 90-Day Asthma Treatment Step Patterns/J.D. Campbell, A.M. Thompson, P. Dilokthonsakul, Aurora, CO, p.A4965


Facilitator: S.B. Khatri, MD, MSc, Cleveland, OH

P621 Phone Interventions Reduce ED Visits in Moderate Persistent Asthma in a Resident Run Community Hospital/K. Gopalratnam, A. Geeti, Y.A. Adjepong, M.J. Smith, D. Lindahl, Bridgeport, CT, p.A4968

P622 Patient Characteristics and Health Outcomes Among Patients with Allergic Asthma Treated with Inhaled Corticosteroids and Long-Acting Beta Agonists Combination Therapy/L.K. Lee, S. Gabriel, E. Obi, B. Paknis, B.E. Chippis, Foster City, CA, p.A4969


P627 Asthma Care Paths in Urban Settings: Identifying Local Barriers to Care to Pilot Targeted Solutions/J. Chang, M. Latifi, M. Ferrari, R. Engineer, S. Podolfsky, S.B. Khatri, Cleveland, OH, p.A7879

P628 Allergic Status is Associated with Increased Number of Asthma Exacerbations/W.J. Calhoun, T.A. Omachi, S.R. Reddy, E. Chang, M.S. Broder, J. Antonova, Galveston, TX, p.A4970


P635 The Usefulness of Direct Hemoperfusion with Polymyxin B-Immobilized Fiber (PMX-DHP) Treatment on Acute Exacerbation of Interstitial Pneumonitis/H. Furusawa, M. Sugihara, Y. Miyazaki, N. Inase, Tokyo, Japan, p.A4984


C39 IFP: MORE ON DIAGNOSIS AND THERAPY

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion 11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: G. Raghu, MD, Seattle, WA


P393 The Changes and Clinical Significance of Serum Laminin, Type IV Collagen, Type III Procollagen N-Terminal Peptide and Hyaluronic Acid in Pulmonary Fibrosis Patients/Y. Su, D. Weng, Shanghai, China, p.A4975

P394 Care of Patients with IFP at a Community Hospital in the UK. Adherence to National Institute for Health and Care Excellence (NICE) Guidance and Implications for Network Care/S. Diver, S. Paterson, T. Gatheral, Lancaster, United Kingdom, p.A4976


P402 The Usefulness of Direct Hemoperfusion with Polymyxin B-Immobilized Fiber (PMX-DHP) Treatment on Acute Exacerbation of Interstitial Pneumonitis/H. Furusawa, M. Sugihara, Y. Miyazaki, N. Inase, Tokyo, Japan, p.A4984


P405 Relationship of Serum Sodium Level to Outcomes in Patients with Interstitial Lung Disease/P.R. Yeturu, D. Kurbano, C. Cherian, J. Pang, M.J. Fazzari, G. Nair, Mineola, NY, p.A4987


P415 CPI and DLCO Parameters Identifying Patients at Risk of Acute Exacerbation of IPF/E. Fraser, R. Hoyles, L.P. Ho, Oxford, United Kingdom, p.A4997


P420 Implications of Pulmonary Physiology and Exercise Testing Results in Idiopathic Pulmonary Fibrosis (IPF) in a Real World Cohort/C. Sharp, G. Dixon, A. Edwards, H. Adamali, A.B. Millar, Bristol, United Kingdom, p.A5002


P425 Airway Expression of Transient Receptor Potential Channels in Idiopathic Pulmonary Fibrosis/N.X. Hutchinson, S. Wozniak, A. Gibbs, A.J. Tonks, B. Hope-Gill, Cardiff, United Kingdom, p.A5007


P428 The Preliminary Evaluation of the Effectiveness and Safety of <Pulmonary Fibrosis Rehabilitation Exercise>&gt;/L. Shen, Q.H. Li, D. Weng, Shanghai, China, p.A5010


P430 A Retrospective Analysis to Assess the Clinical Significance of an Isolated Reduction in Residual Volume/A. Kumar, J.D. Lopez, T. Salim, A. Sahnai, A. Tulaimat, S.S. Fakhry, Chicago, IL, p.A5012

P431 Relationship Between Systemic and Localized Inflammatory Protein Expression in Combined Pulmonary Fibrosis and Emphysema (CPFE), Interstitial Pulmonary Fibrosis, and Emphysema/W. Cornwell, C. Kim, A.C. Lastra, C. Dass, S. Bolla, H. Wang, N. Marchetti, T.J. Rogers, G.J. Criner, Philadelphia, PA, p.A5013


P434 Different Genetic Characteristic Profiles of Combined Pulmonary Fibrosis and Emphysema/H. Qiu, D. Weng, Shanghai, China, p.A5016


THEMATIC POSTER SESSION

C41  SARCOIDOSIS: CASE REPORTS

9:00 a.m. - 4:15 p.m.  MOSCONNE CENTER

Area C, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: S.R. Russell, MD, Chicago, IL

P251  A Diagnostic Challenge: A Rare Case of Cavitary Pulmonary Sarcoidosis/L.-P. Nguyen, A. Zeki, R. Harper, Sacramento, CA, p.A5035

P252  Case Report of Non-Caseating Granulomas in Bronchial Washings of Patient with Sarcoidosis/J. Leap, T. Cheema, Pittsburgh, PA, p.A5036

P253  Vanishing Hepatic Sarcoidosis Preceding Miliary Sarcoidosis/F. Afridi, H. Bhatti, Orlando, FL, p.A5037

P254  Necrotizing Sarcoid Granulomatosis (NSG), a Rare Form of Granulomatous Lung Disease IA.-M. Edwards, Kalamazoo, MI, p.A5038

P255  Unusual Subcutaneous Swelling of the Extremities as the Presenting Manifestation of Sarcoidosis/S. Farooq, C. Chhakchhuak, N. Gupta, Cincinnati, OH, p.A5039


P257  Lofgren’s Syndrome: Acute Onset of Sarcoidosis/A. Gandhi, Abington, PA, p.A5041


P261  A Rare Presentation of Pulmonary Sarcoidosis as Right Middle Lobe Syndrome/Y. Habtegebriel, A. Thomas, A. Mehari, V. Poddar, Washington, DC, p.A5045

P262  Bullous Sarcoidosis/C. Meenakshisundaram, H. Friedman, Evanston, IL, p.A5046

Facilitator: K. Thavarajah, MD, Detroit, MI

P263  Extremity Lymphedema Can Be an Initial Presentation of Sarcoidosis/E. Alkhankan, H. Al Krad, F. Alkhankan, Huntington, WV, p.A5047


P266  Upper Airway Obstruction Requiring Emergent Trachesostomy Secondary to Laryngeal Sarcoidosis/C. Ryu, E. Herzog, H. Pan, R. Homer, M. Gulati, New Haven, CT, p.A5050

P267  Can a Leopard Change Its Spots: Metastatic Breast Cancer or Sarcoidosis?/C. Parker, K. Allen, S. Browning, Oklahoma City, OK, p.A5051

P268  Non-Caseating Granulomas Infiltrating the Bone Marrow: A Unique Presentation of Sarcoidosis/A. Fee-Mulhearn, E. Amin, Columbus, OH, p.A5052

P269  Case Series of Patients with Testicular Sarcoidosis/M.M.H.S. Khan, M.A. Judson, Albany, NY, p.A5053


P271  A Case of Human Adjuvant Disease Complicated with Sarcoidosis/T. Oishi, H. Koh, J. Kagyo, A. Iwamuro, T. Yamamoto, K. Ota, Tokyo, Japan, p.A5055


THEMATIC POSTER SESSION

C42  LAM, CYSTIC LUNG DISEASE, AND MIMICS: CASE REPORTS

9:00 a.m. - 4:15 p.m.  MOSCONE CENTER

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: C.D. Fell, MD, MSc, Calgary, Canada

P441  Diffuse Cystic Lung Disease in A Heavy Smoker: A Rare Case of Pulmonary Langerhans’ Cell Histiocytosis/Y.R. Sedhai, R. Parajuli, A. Asija, A. Mohammed, R.S.R. Edara, A.A. Hameed, M. Alauddin, Darby, PA, p.A5058
P462 Comparison of Four Scores for Ultrasound Assessment of Controlled-Delivery of Aerosol Furosemide (40 mg) Does Not Facilitator: Clinical Practice of Zhao’s Artificial Trachea: 10-Years

P460 Controlled Delivery of High Dose Aerosol Furosemide (80mg) Preliminary Validation Results of the Brazilian Version of the Specialist Pulmonologist Assessment Avoids Unnecessary Impact of Level of Lesion and Spinal Curvature on Pulmonary Discussion:

Viewing:

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

C45 DYSPNEA: TAKES YOUR BREATH AWAY

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion

11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: A.E. Holland, PhD, Melbourne, Australia


P456 Specialist Pulmonologist Assessment Avoids Unnecessary CT Pulmonary Angiography in Suspected Pulmonary Embolism/B.A. Shuker, M. Saroka, L. Satterthwaite, D. Parr, Coventry, United Kingdom, p.A5150


P458 Controlled Delivery of High Dose Aerosol Furosemide (80mg) Does Not Improve Consistency of Treatment Effect on Laboratory-Induced Dyspnea/C.R. O’Donnell, R. Banzett, R. Lansing, D. Beach, R.M. Schwartzstein, Boston, MA, p.A5152


P463 Progression from Respiratory Dysfunction to Failure in Late-Onset Pompe Disease/K.I. Berger, Y. Chan, W.N. Rom, R.M. Goldberg, New York, NY, p.A5157

P464 Differences in Respiratory Physiology in Obese Patients with Hypoventilation Syndrome and Obese Patients Without/ T.S. Hynes, S. Saleem, B. Casserly, Limerick, Ireland, p.A5158


P352 Dyspnea and Steroid Responsive Pulmonary Infiltrates in a Middle Aged Smoker/S. Zaidi, J. Taillon, S. Milan, A. Saleh, Brooklyn, NY, p.A5147

P353 A Elderly Asian Lady Presenting with Pulmonary Fibrosis and Ascites/ P.S. Pandya, London, United Kingdom, p.A5148

C46 COUGH: EVALUATION AND TREATMENT

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion

11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: M.R. Horton, MD, Baltimore, MD


P470 Expression of Transient Receptor Potential Channels in Pulmonary Epithelial Cells Exposed to Gastric Fluid Constituents/N.X. Hutchinson, B. Hope-Gill, A.J.T. Tonks, Cardiff, United Kingdom, p.A5164

P1240 Outcomes Following Virus and Non-Virus Associated Acute Exacerbations of COPD/B. M. Walsh, N. Menon, D. Francis, C. Francis, P.F. Simonelli, Danville, PA, p.A5177


P1242 Lung-Function Profile Before and After the First Moderate to Severe Exacerbation During the WISDOM Study/E. Wouters, H. Magnussen, R. Rodriguez-Roisin, K. Tetzlaff, S. Bell, P.M. Calverley, Maastricht, Netherlands, p.A5179


Facilitator: S. Stowasser, MD, Rhein, Germany


P475 Use of Non-Steroidal Inflammatory Drugs (NSAID) in Post-Infectious Cough/A. Zanasi, F. Saibene, L. Lanata, M. Mazzolini, Bologna, Italy, p.A5168

Facilitator: S. Stowasser, MD, Rhein, Germany
P1253  Nocturnal Hypercapnia and Acidosis Despite Normoxemia in Patients Hospitalized for Exacerbation of Chronic Obstructive Pulmonary Disease/C. Kim, N. Marchetti, G.J. Criner, Philadelphia, PA, p.A5190


P1255  Blood Eosinophil Count and Outcomes in Adults Admitted with an Acute Exacerbation of COPD: Data from the Pre-AWARD Study/R. Russell, R. Pullinger, T. Doggett, S. Beer, I. Pavord, M. Bafadhel, Oxford, United Kingdom, p.A5192


Facilitator: A.G. Henderson, MD, Chapel Hill, NC


P1263  Respiratory Symptom Patterns over One Year in Patients with COPD: Results from the Acute Exacerbation and Respiratory Infections (AERIS) Study/R. Russell, S. Beer, R. Pullinger, T. Doggett, I. Pavord, M. Bafadhel, Oxford, United Kingdom, p.A5200

Facilitator: M. Kirby, PhD, Vancouver, Canada


P1276 Branching Patterns and Automated Labeling of Sub-Segmental Human Airways/J. Tschirren, M.K. Han, R.G. Barr, E.A. Hoffman, Coralville, IA, p.A5212

P1277 Combined Airway Disease and Emphysema Is a Poor Prognostic Factor in Chronic Obstructive Pulmonary Disease/C.K. Rhee, H.K. Yoon, Y.-M. Oh, S.-D. Lee, Seoul, Korea, Republic of, p.A5213


P1279 Correlation Between the Parameters Quantified by Thoracic High-Resolution Computed Tomography and Pulmonary Function Tests in Patients with Chronic Obstructive Pulmonary Disease/X. Tang, S. Chen, X. Jin, Y. Song, Shanghai, China, p.A5215


C49 RESPIRATORY FAILURE: CLINICAL AND TRANSLATIONAL ASPECTS OF VILI AND LUNG PROTECTIVE MV

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:15: authors will be present for discussion with assigned facilitators

Facilitators: I.S. Douglas, MD, Denver, CO
M.B.P. Amato, MD, PhD, Sao Paulo, Brazil


P693 Variable Ventilation Improves Respiratory System Elastance and Reduces Lung Damage in Experimental Lung Ischemia-Reperfusion/A. Soluri-Martins, L. Moraes, R.S. Santos, C.L. Santos, R. Huhle, V.L. Capelozzi, P.L. Silva, P. Pelosi, M.G. De Abreu, P.R.M. Rocco, Rio de Janeiro, Brazil, p.A5221


P697 Therapeutic Hypothermia Attenuates Pulmonary Vascular Permeability and Inflammation in a Mouse Model of Ventilator-Induced Lung Injury/D. Slack, D. Corwin, N.G. Shah, M. Tulapurkar, J.D. Hasday, Baltimore, MD, p.A5225


P702 The Effects of Prone Positioning on Transpulmonary Facilitators: L.J. Brochard, MD, Toronto, Canada


P711 Respiratory System and Transpulmonary Driving Pressures in ARDS/E.N. Baedorf Kassiss, S. Loring, D.S. Talmor, Boston, MA, p.A5240

P712 Peak Pressures and PaO2/FiO2 Ratios on Day 2 Predict Outcomes in Patients on Mechanical Ventilators/H. Edriss, J. Whiting, S. Yang, K. Nugent, Lubbock, TX, p.A5240


P716 Is Low Stretch APRV Possible?/E. Hirshberg, M.J. Lanspa, C.K. Grissom, J. Peterson, Salt Lake City, UT, p.A5244


P720 Change in Mechanical Ventilation Settings After Post-Intubation Arterial Blood Gases in a University Hospital Intensive Care Unit/M.I. Pino, O. Llanos, C. Colaco, N. Meena, Phoenix, AZ, p.A5251


P722 Surfactant Protein-A Nanobody-Conjugated Liposomes Loaded with Methylprednisolone Demonstrate High Lung Targeting and Therapeutic Effect for Acute Lung Injury/H. Li, D. Weng, Shanghai, China, p.A5250


P729 Human Umbilical Cord Mesenchymal Stem/Stromal Cells Reduce Inflammation and Injury in Rodent E Coli Pneumonia and in Monocytes from Patients with Severe Sepsis/G. Hogan, M. Jerkic, S. Gagnon, C. Masterson, J.G. Laffey, G.F. Curley, Toronto, Canada, p.A7881

---

**THEMATIC POSTER SESSION**

**C50 CRITICAL CARE: DELIRIUM AND SEDATION IN THE ICU**

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

**Area G, Hall D (North Building, Lower Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

**Facilitators:** R. Clouser, DO, Burlington, VT
A.M. Ahasic, MD, MPH, New Haven, CT
M.P. Goldklang, MD, New York, NY


P733 Concordance Between Bedside Nursing and Protocolized Sedation Assessments in Medical Intensive Care Unit Patients/C.C. Anderson, S.E. Jolley, J. Johnson, B. DeBoisblanc, New Orleans, LA, p.A5258


P736 Dose Using Richmond Agitation-Sedation Scale (RASS) Verses Motor Activity Assessment Scale (MAAS) Score Reduce the Amount of Sedation in ICU/B.M. Abdulkademi, K. Alghamdi, Jeddah, Saudi Arabia, p.A5261


P738 Inappropriate Continuation of Atypical Antipsychotics Started in the Intensive Care Unit (ICU) Upon Discharge from the Hospital/K. Karamchandani, A. Prasad, A. Quintili, Hershey, PA, p.A5263

P739 Transitioning from Dexmedetomidine to Clonidine Causes Longer Stay in the Intensive Care Unit/A. Mohammed, A. Maheshwari, J.M. Chowdhury, Y.R. Sedhai, N. Pozzessere, S. Manns, Darby, PA, p.A5264

Facilitators: J.P. Kress, MD, Chicago, IL
B.H. Singer, MD, PhD, Ann Arbor, MI

P740 High Doses of Dexmedetomidine May Result in Increased Length of Stay and Mortality in the Intensive Care Unit/J.M. Chowdhury, A. Maheshwari, A. Mohammed, N. Pozzessere, Y. Sedhai, S. Manns, Darby, PA, p.A5265


P743 Initial Synchronized Intermittent Mandatory Ventilation Versus Assist/Control Ventilation in Decreasing Delirium in Patients with Moderate Acute Respiratory Distress Syndrome: A Prospective Randomized Controlled Trial/J. Luo, M.-Y. Wang, B.-M. Liang, H. Yu, Z.-A. Liang, Chengdu, China, p.A5268


P745 Dexmedetomidine: Sedative of Choice in Patients with a History of Alcohol/A. Maheshwari, A. Mohammed, J.M. Chowdhury, Y. Sedhai, N. Pozzessere, S. Manns, Darby, PA, p.A5270

C51  RESPIRATORY FAILURE: HIGH FLOW OXYGEN, LIBERATION, NON-INVASIVE, AND PROLONGED VENTILATION

9:00 a.m. - 4:15 p.m.  MOSCONE CENTER

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion

11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: J.R. Beitler, MD, MPH, La Jolla, CA
N.D. Ferguson, MD, MSc, Toronto, Canada

P752  Continuous Biobehavioral Measures to Identify Patient Ventilator Asynchrony: Methodological and Practice Challenges/K.G. Mellott, D.J. Jones, S.K. Hanneman, Houston, TX, p.A5274


P756  Intrinsic Positive End Expiratory Pressure (PEEPi) Measurement in Spontaneously Breathing Patients Using Conditioned Central Venous Pressure (CVP) Signal/P.J.C. Biselli, R.S. Nobrega, Sao Paulo, Brazil, p.A5278


P761  Impact of Anemia and Immunity on Weaning and Survival Outcomes in Patients with Ventilator-Dependent Respiratory Failure/M. Zantah, V. Yap, P. Scalise, D. Datta, Farmington, CT, p.A5283


Facilitators: R.G. Brower, MD, Baltimore, MD
K. Karamchandani, MD, Hershey, PA

P764  Outcome and Predictors in Prolonged Mechanical Ventilation Patients with Heart Failure in Taiwan/H. Hung-Yu, L. Li-Fu, K. Kuo-Chin, H. Chi-chen, C. Ning-Hung, Taoyuan City, Taiwan, p.A5286


P768  Comparison of Two Weaning Trials of Mechanical Ventilation in Medico-Surgical ICU. Assessment of Pulmonary and Cardiac Parameters. CARWEAN Study/T. Godet, S. Perbet, A. Soummer, L. Roszyk, B. Pereira, J.-J. Rouby, J.-M. Constantin, Clermont-Ferrand, France, p.A5290


P773  Identifying APACHE II and SOFA Threshold Values that Predict Successful Weaning and Exubation from Mechanical Ventilation/U. Bien, I. Peres Costa, R. Arena, L.M.M. Sampaio, Sao Paulo, Brazil, p.A5295

P775 Role of Integrated Pulmonary Index in Identifying Extubation Failure/R. Kaur, D.L. Vines, Chicago, IL, p.A5297

Facilitator: N.S. Hill, MD, Boston, MA


P777 Interdisciplinary Communication Dashboards to Reduce Ventilator Hours/S.S. Palakuru, B. Patel, A.A. Aman, Houston, TX, p.A5299

P778 The Role and Clinical Utility of Ward-Based Respiratory Failure Units: Experience from Three Australian Units/J. Hadfield, M. Murphy, C. Hukins, J. Douglas, G. Tay, D. Stead, B. Singh, Perth, Australia, p.A5300

P779 Healthcare Utilization Following Patients with Tracheostomy/ S. Leung, V. Pittignano, V. Kvetan, Bronx, NY, p.A5301

P780 Patients with Acute Type 2 Respiratory Failure Due to COPD Can Be Successfully Managed in a Ward-Based Respiratory High Dependency Unit (RHDU) Irrespective of Respiratory Failure Severity/S. Gleeson, C. Hukins, P. McLeod, M. Murphy, Brisbane, Australia, p.A5302


P785 Outcomes of Patients on Noninvasive Ventilation in Acute Respiratory Failure Due to Pneumonia/A.J. Hayek, K. Lipatov, P. Yau, A. Arroliga, E. Stock, S. Ghamande, Temple, TX, p.A5307


P787 Ventilator Settings and Outcome of Noninvasive and Invasive Ventilation for Patients with Acute Respiratory Failure on Chronic Interstitial Lung Disease/K. Wakabayashi, T. Tateishi, Y.U. Adachi, N. Inace, K. Nakazawa, Tokyo, Japan, p.A5309

Facilitator: E. Fan, MD, PhD, Toronto, Canada


P796 Short Term Physiological Effects of Nasal High Flow (NHF) on Respiratory Mechanics in Stable Patients with Chronic Obstructive Pulmonary Disease (COPD)/L. Pisani, N. Corcione, V. Comellini, F. Natali, L. Fasano, S. Nava, Bologna, Italy, p.A5318

P797 Daytime Breathing Pattern Changes by Nasal High Flow Therapy in Chronic Hypercapnic COPD Patients/G. Nilius, K.-J. Franke, U. Domanski, M.F. Schroeder, S. Tatkov, Hagen, Germany, p.A5319


P800 Nasal Highflow (NHF) - Worsening Oxygenation Without FIO2 Adjustment/J. Braunlich, H. Wirtz, Leipzig, Germany, p.A5322

C52  CRITICAL CARE CASE REPORTS: RESPIRATORY FAILURE/MECHANICAL VENTILATION
9:00 a.m. - 4:15 p.m. MOSCONЕ CENTER

Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: P. Subedi, MD, Loma Linda, CA
G. Garrison, MD, Burlington, VT

P805 An Adjunct to Intubation Criteria for Patients with Guillain-Barre Syndrome/ A. Rudkovskiaja, J.-P. Ayala, Bridgeport, CT, p.A5324


P807 Recurrent Pneumonia Caused by Diffuse Laryngotracheal Stenosis as a Consequence of Prior Prolonged Intubation in a Patient with Systemic Lupus Erythematosus/ M.G. Sperry, J. Deepak, Baltimore, MD, p.A5326

P808 Urgent Tracheostomy Post tPA Infusion for Ischemic Stroke/ A. Ali, Y.A. Al Ahwel, H. Zughaiib, A. Milad, F. Safi, Toledo, OH, p.A5327


P810 Effects of Increasing the Slope of Inspiratory Flow on Lung Viscelasticity and Alveolar Ventilation in a Patient with Status Asthmaticus/ K. Waksmundzki, M. Stefanski, P. Hauouzi, Hershey, PA, p.A5329


P814 “A Case of Complete Bilateral Lung Collapse by Saddle Mucous Plug”/ M. Kashif, D. Lvovsky, Bronx, NY, p.A5333

P815 Foreign Body Aspiration as Cause of Cardiac Arrest and Its Early Recognition with Better Outcome/ M. Kashif, H.R.T. Hashmi, M. Khaja, Bronx, NY, p.A5334

P816 Education for ACLS Includes Ultrasound Training/ P. Vishwasrao, S. Ahmad, Stony Brook, NY, p.A5335

P817 A Fatal Case of Pulmonary Kaposi’s Sarcoma - Associated Immune Reconstitution Syndrome After Initiation of ART/ M. Abidali, A. Abidali, A. Bozak, R. Garcia Orr, Phoenix, AZ, p.A5336

P818 Myeloid Sarcoma Involving the Anterior Mediastinum Causing Hypercapnic-Hypoxemic Respiratory Failure/ N.K. Ahuja, R. Balk, Chicago, IL, p.A5337

Facilitators: K.F. Sarmiento, MD, MPH, La Jolla, CA
N.M. Kanodra, MBBS, Charleston, SC

P819 Boerhaave Syndrome: A Rare Cause of Tension Hydropneumothorax/ S.E. Richter, P. Nayyar, O. Rojanapairat, D. Chatterjee, A.C. Lucero, A. El-Sherief, G.W. Soo Hoo, J. Betancourt, Los Angeles, CA, p.A5338


P821 Application of Negative Pressure Wound Vacuum Therapy for Treatment of Severe Air Leak Syndrome in a Critically Ill Pediatric Patient/ D.S. Kripilani, Loma Linda, CA, p.A5340

P822 Usefulness of a Non-Invasive Minute Ventilation Monitoring in Poly-Substance Overdose/ J. Moss, S.W. Robison, Jacksonville, FL, p.A5341


P825 Management of Respiratory Depression from Tianeptine Overdose with Naloxone/ R. Pillai, B. Zakhary, V. Mukherjee, New York, NY, p.A5344

P826 Feeding the Lung/ K. Vadmalalai, G. Ogunbayo, Rochester, NY, p.A5345


P829 Hypercapnic Respiratory Failure: A Late Presentation of Myotonic Dystrophy/ E. Levine, D. Kuggel, A. Rajkumar, G. Kefalas, Canton, OH, p.A5347


P841 Fatal Case of Pasteurella Multocida Septicemia and Multiorgan Failure

ATS 2016 • San Francisco

Facilitators: A.N. Chesnutt, MD, Portland, OR  N. Adhikari, MD, MS, Toronto, Canada


P849 An Unusual Case of Cirrhosis/R. Helton, I. Faruqi, A. Somoracki, Gainesville, FL, p.A5365

P850 A Rare Differential to a Familiar Symptom of Exophthalmos/Y.C. Yeh, J.M. Scoon, Houston, TX, p.A5366


P853 Multi-Organ Failure Following “Worb Water” Ingestion/M. Jegapragasan, K. Pennington, L. Karnatovskaya, Rochester, MN, p.A5369

P854 Severe Multiorgan Failure Hours After High Dose Carfilzomib Therapy for Refractory Multiple Myeloma/A. El-bakush, M. Al-janabi, A. Ismail, M.Z. Rizwan, R. Dietrich, Richmond, VA, p.A5370

P855 Descending Necrotizing Mediastinitis Presenting with Multisystem Organ Failure in a Bodybuilder Due to Anabolic Steroid Use/J. Nguyen, B. Garber, N. Barot, Sylmar, CA, p.A5371

P856 An Atypical Presentation of Acute Febrile Neutrophilic Dermatosis as Drug-Induced Bullous Variant Sweet’s Syndrome/S. Savajiyani, A. Higashi, R. Garcia Orr, Phoenix, AZ, p.A5372

P857 The Case of the Killer Mocha: Pheochromocytoma Crisis Induced by a Caffeinated Beverage/A. Pariyadath, G. Gipson, K. Sayball, G. Phan, S. Smith, K. Miller, Richmond, VA, p.A5373


Facilitator: V. Sharma, MD, Chicago, IL


P863 Hemophagocytic Lymphohistiocytosis Associated with Systemic Lupus Erythematosus/D. Nualles-Percy, A. Friedenberg, San Jose, CA, p.A5379


P865 Acquired Hemophagocytic Lymphohistiocytosis: A Great Mimicker of Sepsis and Ongoing Diagnostic and Therapeutic Dilemma/M. Abidali, J. Hall, R. Garcia Orr, Phoenix, AZ, p.A5381


P868 Clinical Course and Treatment of Systemic Capillary Leak/J. Barlow, E. Fagley, Seattle, WA, p.A5384


C54 CRITICAL CARE CASE REPORTS: SEPSIS

9:00 a.m. - 4:15 p.m. MOSCON CENTER

Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: D.J. Niven, MD, MSc, Calgary, Canada
I.D. Peltan, MD, MSc, Murray, UT

P873 Pasteurella Multocida Bacteremia Causing Septic Shock in a Cirrhotic Patient/M. Shahidi, P.V. Dicpinigaitis, Bronx, NY, p.A5386


P875 A Rare Cause of Morbidity in the Immunocompromised Host/T.T. Wong, L. Logue, S. Shahzad, A. Leong, Brooklyn, NY, p.A5388

P876 Klebsiella Liver Abscess/G.W. Williams, Memphis, TN, p.A5389


P878 20 Year Old Healthy Male with Descending Necrotizing Mediastinitis/A. El-bakush, M. Al-janabi, C. Anciano, R. Dietrich, M. Bowling, Greenville, NC, p.A5391


P881 Pyogenic Liver Abscess: A Rare Case of Monomicrobial Fusobacterium Nuceaturn Liver Abscess with Sepsis in a Immunocompetent Host/A. Avula, S. Toom, A. Niroula, A. Gandhi, New York, NY, p.A5394

P882 A Rare Case of Corynebacterium Striatum Endocarditis in an Immunocompromised Patient/A. Amarani, C. Difelice, C. Barrett, A. Surender, Kalamazoo, MI, p.A5395

Facilitators: P.R. Menon, MD, Burlington, VT
G.J. Soto, MD, Bronx, NY

P883 Sepsis from Too Much Air/P. Patel, W. Krimsky, S.J. Kausik, D.P. Harley, St. Louis, MO, p.A5396

P884 Bilateral Adrenal Hemorrhage-A Rare Fatal Complication of Pneumonia/M. Hundal, C. Ghattas, A. Alkhatib, S. Rafeq, Boston, MA, p.A5397


P886 A Classic Case of a Crustacean Calamity/L. Kimmig, W. Krimsky, S.J. Kausik, D.P. Harley, St. Louis, MO, p.A5399


P890 A Little Toxin Goes a Long Way/J.L. Newitt, E. Crowley, M. Williams, Indianapolis, IN, p.A5403

P891 Septic Plague Presenting as Shoulder Pain and Weakness/N. Settergren, A. Patel, Pueblo, CO, p.A5404

C55  CARDIOPULMONARY EFFECTS OF AIR POLLUTION

9:00 a.m. - 4:15 p.m.  MOSCONEN CENTER
Area J, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: D.C. Christiani, MD, MPH, MS, Boston, MA

**P1049** Comparison of the Biological Effects of Wintertime California and China PM in Healthy Young Mice/X.L. Sun, H.Y. Wei, K.J. Bein, D.E. Young, Q. Zhang, A.R. Castaneda, K.E. Pinkerton, Jinan, China, p.A5406


**P1051** Effects of Simulated Microgravity on JNK/c-Jun/c-Fos Signaling Pathway in Lung of Rhesus Monkey/H. Li, P. Wang, C. Xu, Y. Cai, Y. Chen, Beijing, China, p.A5408

**P1052** Cx43 Mediates Particulate Matter-Induced Human Lung Endothelial Barrier Disruption/X. Wu, X. Xu, J.G.N. Garcia, T. Wang, Tucson, AZ, p.A5409

**P1053** Carbonaceous Particulate Matter in the Alveolar Macrophage and Lung Surface Tissue Compartments of Residents from Sao Paulo, Brazil/M.G. Padovan, P.H.D.N. Saldiva, A.L.F. Braga, A. Whitehouse, J. Grigg, Brazil, p.A5410


Facilitator: J.A. Hirota, PhD, Vancouver, Canada

**P1055** Pre-Exposure to Particulate Matter Enhances RSV-Induced Barrier Dysfunction/F. Rezaee, T.J. Harford, P.M. Brown, A. Belkadi, G. Piedimonte, Cleveland, OH, p.A5412

**P1056** Pulmonary Function Response to Exposure to Low Concentration Ozone in Young Adults: Inter-Comparison Among Studies and Meta-Analysis/C.S. Kim, H. Kehrl, A. Rappold, M. Case, R. Devlin, D. Diaz-Sanchez, Research Triangle Park, NC, p.A5413

**P1057** Effects of Desert Dust Storms and Climatological Factors on Mortality and Morbidity Due to Respiratory Diseases in Gaziantep, South East Turkey/H. Bayram, S. Kul, M. Bogan, B. Al, Gaziantep, Turkey, p.A5414


P1059  Indoor Particulate Matter (PM) 2.5 Levels in Elementary School Classrooms in UB Are in Compliance with WHO Standards in the Fall Season/D. Ulzii, T. Altantuya, G. Khishigmaa, B. Nandin-Erdene, D. Warburton, Ulaanbaatar, Mongolia, p.A5416


Facilitator: M.B. Rice, MD, MPH, Boston, MA

**P1061** Commuting Mode and Cardiovascular Risk Factors in a Shanghai, China/A. Gaffney, J.-Q. Hang, M.-S. Lee, L. Su, F.-Y. Zhang, D.C. Christiani, Boston, MA, p.A5418

**P1062** Socioeconomic Status and Cardiovascular Health in Shanghai, China/A. Gaffney, J.-Q. Hang, M.-S. Lee, L. Su, F.-Y. Zhang, D.C. Christiani, Boston, MA, p.A5419


**P1065** The Restrictive Spirometry Pattern, Cardiac Structure, and Incident Heart Failure Risk: The Jackson Heart Study/ M. Jankowich, W.-C. Wu, C. Blackshear, W. Wang, M. Godfrey, S. Abbasi, G. Choudhary, Providence, RI, p.A5422


**P1068** Traffic-Related Air Pollution (TRAP) Intervention Study/S. Vedal, N. Zhang, R. Zhao, B. Han, J. Xu, W. Yang, Z. Bai, Seattle, WA, p.A7884

---

**THEMATIC POSTER SESSION**

C56  OCCUPATIONAL MEDICINE AND LUNG FUNCTION

9:00 a.m. - 4:15 p.m.  MOSCONEN CENTER
Area J, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators
**Facilitator:** L.A. Maier, MD, MPH, Denver, CO


**P1072** Spirometry Quality Control and Intraindividual FEV1 and FVC Variability/I. Sumner, D. Fishwick, Buxton, United Kingdom. p.A5426

**P1073** Longitudinal Assessment of Spirometry Performed for Occupational Health Surveillance/I. Sumner, D. Fishwick, Buxton, United Kingdom. p.A5427

**P1074** Impulse Oscillometry in Veterans Exposed to Depleted Uranium/S.E. Hines, A. Barnes, P. Gucer, J. Gaitens, M. Oliver, M. Condron, T. Roth, K. Squibb, M. McDiamid, Baltimore, MD. p.A5428


**P1076** Pulmonary Function in Military Firefighters Pre and Post Southwest Asia Deployment/A.D. George, A.J. Skabelund, M.J. Morris, A.N. Young, Fort Sam Houston, TX. p.A5430


**Facilitator:** P.I. Harber, MD, MPH, Tucson, AZ

**P1078** Comparison of the Pulmonary Function Test Between Teaching and Nonteaching Staff in a Public High School in Davao City, Philippines/M.C. Kasigal, C. Uy, Davao City, Philippines. p.A5432


**Facilitator:** C.A. Redlich, MD, MPH, New Haven, CT


**Facilitator:** S.E. Hines, MD, MPH, Baltimore, MD

**P1093** Heme Oxygenase Activity Increases After Exercise in Healthy Volunteers/A. Ghio, M. Case, J. Soukup, Chapel Hill, NC. p.A5447

**P1094** Heme Oxygenase Activity Correlates with Serum Indices of Iron Homeostasis in Healthy Non-Smokers/A. Ghio, D. Schreinemachers, Chapel Hill, NC. p.A5448


P1100 First-Time Monitoring of Simultaneous Effects of Hypergravity on Heart and Lung by Electrical Impedance Tomography/J.B. Borges, G. Hedenstierna, J.S. Bergman, C. Dussault, M.B.P. Amato, S. Montmerle-Borgdorff, Uppsala, Sweden, p.A7885

THEMATIC POSTER SESSION

C57 CELLULAR/MOLECULAR MECHANISMS AND TRANSLATIONAL ASPECTS OF RESPIRATORY INFECTIONS

9:00 a.m. - 4:15 p.m. MOSCONE CENTER Area K, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: J.P. Mizgerd, ScD, Boston, MA

P1127 Disruption of Murine Lower Airway Microbiome/B.G. Wu, B.D. Scaglione, J. Gilani, A. Wang, Y. Li, L. Segal, New York, NY, p.A5454


P1132 Treatment with Synergistic TLR Ligands that Protect Against Leukemia-Associated Pneumonias Does Not Worsen Tumor Burden/H.H. Ware, M.M. Leiva-Juarez, C.T. Kirkpatrick, V.V. Kulkarni, Y. Wang, S.E. Evans, Houston, TX, p.A5459


Facilitator: C.S. Dela Cruz, MD, PhD, New Haven, CT

P1134 Comparison of an Anti-Alpha Toxin (AT) and Clumping Factor A (CFA) mAb Combination and Bi-Specific Antibodies for Protection in S. Aureus Pneumonia/C. McKenzie, A. Vyas, J.H. Hwang, J. Joshua, L.E. Crotty Alexander, New York, NY, p.A5462


P1139 The Pulmonary OX40 Ligand Expression Induced by the Influenza Infection Plays a Potential Role in the Pathogenesis/T. Hirano, T. Kikuchi, N. Tode, H. Sugiiura, M. Ishikose, Sendai, Japan, p.A5466


P1142 Cyclic GMP-AMP Synthase (cGAS), Stimulator of Interferon Genes (STING) and Interferon Activated Gene 16 (IFI16) Are Essential for Intrinsic Lung Epithelial Responses Against Influenza A Infection, but Not for Therapeutically Induced Antiviral Resistance/V.V. Kulkarni, Y. Wang, C.T. Kirkpatrick, M.M. Leiva-Juarez, A.K. Plumler, H.H. Ware, S.E. Evans, Houston, TX, p.A5469
C58  TUBERCULOSIS INFECTION AND DISEASE

9:00 a.m. - 4:15 p.m.  MOSCONETR CENTER

Area K, Hall D (North Building,Lower Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator:  J. Bernardo, MD, Boston, MA


P1158  Mast Cell C57 Activation by Mycobacterium Tuberculosis Lipids and Mycobacterium Bovis Bacille Calmette-Guerin (BCG)/S. Rosero, I. Torres, A. Goodridge, City of Knowledge, Panama, p.A5484


P1162  Association Between Macrophage Migration Inhibitory Factor (MIF) Gene Polymorphisms and Serum MIF with Pulmonary Tuberculosis/X. Tong, H. Fan, Y. Ma, S. Liu, Chengdu, China, p.A5488

P1163  Polymorphisms in Mannose Binding Lectin-2 Gene Were Associated with the Risk of Tuberculosis/J. He, W.C. Li, X.Y. Li, Chengdu, Sichuan, China, p.A5489

P1164  Association of CYBA Polymorphisms with Tuberculosis Susceptibility in the Chinese Han Population/Q. Liu, Y. Wang, S. Wu, G. Ji, J.-Q. He, Chengdu, China, p.A5490

Facilitator:  P. Escalante, MD, Rochester, MN


<table>
<thead>
<tr>
<th>Paper Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1173</td>
<td>QFT®-TB Gold in Tube and T-SPOT®.TB in Patients with Suspected Lung Tuberculosis/N. Okimoto, Okayama, Japan</td>
<td>p.A5499</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1174</td>
<td>Effect of Tuberculosis Treatment on Newly Developed QuantiFERON-TB® Gold Plus/A. Kamada, M. Amishima, T. Inbe, Sapporo, Japan</td>
<td>p.A5500</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1175</td>
<td>The Relationship Between PTH and PPD in Patients Undergoing Hemodialysis Treatment/S. Deniz, J.C. Emre, Aydin, Turkey</td>
<td>p.A5501</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1179</td>
<td>Adherence of Physicians-in-Training to the 2009 International Standards of Tuberculosis Care (ISTC) at the University of the Philippines-Philippine General Hospital/A.F. Zagala, J. Benedicto, Manila, Philippines</td>
<td>p.A5505</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1184</td>
<td>Value of Laboratory Parameters Used in the Diagnosis of Tuberculous Pleurisy/A. Arisoy, M.S. Tasbakan, A. Sayiner, Izmir, Turkey</td>
<td>p.A5510</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1186</td>
<td>Expected and Induced Sputum Collection in Patients with Tuberculous Pleural Effusion in a High Prevalence Hospital in the United States: an Analysis of Incremental Yield/A. Gupta, S. Shahabuddin, O. Epelbaum, Queens, NY</td>
<td>p.A5512</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1189</td>
<td>To Study the Diagnostic Yield of Medical Thoracoscopy in Patients with Pleural Effusion of Undetermined Etiology Presented to a Tertiary Care Center Catering to Rural Population in Central India/A.R. Mishra, R. Swarnakar, B. Vaghani, Nagpur, India</td>
<td>p.A5515</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### P632 Differences in Perceptual Experiences of Breathlessness and Impairment Between People with Moderate-Severe COPD in Australia and the United Kingdom/A.-M. Russell, K.N. Johnston, J. Yorke, M.T. Williams, London, United Kingdom, p.A5540


### P634 Functional Assessment of Patients with COPD, Pulmonary Hypertension and Intestinal Lung Diseases Using the Index Oxygen Desaturation-Distance-Ratio (DDR)/F. Burgos, X. Alsina, C. Gistau, I. Blanco, J. Roca, Barcelona, Spain, p.A5542

### P635 Exercise and Pulmonary Rehabilitation Participation Among Patients with Alpha-1 Antitrypsin Deficiency/J. Nolte, T. Kurtz, M.L. Brantly, Gainesville, FL, p.A5543

**Facilitator:** R.T. Disler, PhD, RN, Sydney, Australia

### P636 Correlates of Sleep Quality in Women: Results of the National Sleep Foundation 2013 Poll/E.R. Chasens, L.M. Baniak, C.E. Kline, Pittsburgh, PA, p.A5544

### P637 Review of Nurse Supported Sodium Oxybate Service for Patients with Narcolepsy/M.F. Docherty, C. Carlin, C. Livingston, E. Livingston, Glasgow, United Kingdom, p.A5545

### P638 Sleep and Activity as Predictors of Subjective Health Status in Middle-Aged Women/L.M. Baniak, C.E. Kline, J.L. Morris, E.R. Chasens, Pittsburgh, PA, p.A5546

### P639 Assisting Tobacco Users to Quit with Text Messaging/P.A. Folan, C. Fardellone, A. Spatarella, N. Kohn, A. Talwar, Great Neck, NY, p.A5547

### P640 Nurse-Conducted Smoking Cessation Program in Patients Admitted in a Respiratory Ward Hospitalization/D. Macias, C. Florencio, J. Hilares, V. Gomez, N. Reyes, I. Allageme, Seville, Spain, p.A5548

### P641 Patients’ Views About Living and Dying with Pulmonary Arterial Hypertension/I. Armstrong, J. Yorke, J. Warden, P. Sephton, L. McGowan, Sheffield, United Kingdom, p.A5549

**Facilitator:** Z. Chen, BSN, Seattle, WA

### P642 The Lived Experience of Idiopathic Pulmonary Fibrosis: A Qualitative Study/I. Egerod, D. Overgaard, G. Kaldan, K. Marsaa, T.L. Nielsen, S.B. Shaker, Copenhagen, Denmark, p.A5550

### P643 HIV Infection and Comorbidity as Predictors of Palliative Care Consultation in Adults Hospitalized with Heart Failure/S.L. Feder, S. Jeon, J.P. Tate, J. Womack, M. Funk, N. Redeker, K. Akgun, West Haven, CT, p.A5551


### P646 The Relaxation Effects of Hand-Massage Therapy on Autonomic Nervous Function and Emotions among Patients Receiving Palliative Care/T. Sato, Y. Yamashita, R. Maruyama, Sendai, Japan, p.A5554

### P647 Pecs that will Leave You Breathless/K.J. Jackson, San Francisco, CA, p.A5555

---

**THEMATICA POSTER SESSION**

**C60 ALL ABOUT CYSTIC FIBROSIS**

**9:00 a.m. - 4:15 p.m.**

**MOSCONCE CENTER**

**Area E, Hall D (North Building, Lower Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:00-11:45: authors will be present for individual discussion

11:45-12:45: authors will be present for discussion with assigned facilitators

**Facilitator:** F.A. Ratjen, MD, PhD, Toronto, Canada

### P513 The ATP Binding Cassette C4 (ABCC4) Transporter Regulates Extracellular cAMP Transport, Intracellular PKA Activity, and CFTR Channel Activity in Human Airway Epithelial Cells/ C.F. Rider, R. Newton, C. Bear, C. Carlsten, J.A. Hirota, Vancouver, Canada, p.A5557


### P515 Nano-Based Autophagy-Induction Rescues ΔF508-CFTR and Pa Infection in CF Cells/S.M. Brockman, M. Bodas, P. Chandramani, N. Vij, Mount Pleasant, MI, p.A5570


### P518 Losartan Rescues Cystic Fibrosis (CF)-Related Mucociliary Dysfunction in CF Cells In Vitro and in a Novel CF Sheep Model In Vivo/M. Salathe, N. Baumlin, A. Kis, S. Krick, A. Schmid, J.R. Sabater, W.M. Abraham, Miami, FL, p.A5573

Altered Toll-Like Receptor 4 and Histone Deacetylase 2 Expression in CFBE410- Cells Regulates Hemeoxygenase I Via Nuclear Factor Erthyroid 2-Related Factor 2/S. G. Garapati, P. Mahavadi, M. Henke, A. Guenther, S.P. Chilappagari, Giessen, Germany, p.A5560

Increased TGF-β1 Alters Cellular Glutathione and Oxidant Stress in Neonatal Alveolar Macrophage with CFTR Mutation/T.W. Gauthier, X.D. Ping, L.A.S. Brown, Atlanta, GA, p.A5563

Qualitative and Quantitative Changes of Gel Forming Mucins and Exosomes in Response to Infection and Inflammation in the Airways/B. Batson, M. Arifuzzaman, P. Haridass, H. Dang, P. Mieczkowski, C. Ribeiro, L. Abdullah, M. Kesimer, Chapel Hill, NC, p.A5565


IL1R1 Regulates MUC5B Production and Inflammatory Induction Following Potentiator Therapy Modifies Inflammatory Induced Neutrophil Trends in Cystic Fibrosis in Ireland: A National Review/K.N. McCarthy, Co Westmeath, Ireland, p.A5567

High-Dose Ibuprofen Dampens Inflammatory Signaling Via Microtubule Structure and Dynamics in Cystic Fibrosis Epithelial Cells/S. Rymut, C.U. Cotton, J.T. Kelley, Cleveland, OH, p.A5569

How to Effectively Degrade Neutrophil Extracellular Traps (NETs) by Airway Nucleases/N. Palaniyar, D.N. Douda, C. Licht, L. Yip, Toronto, Canada, p.A5577

Sustained Effectiveness of Ivacaftor Therapy in Three Sisters with S549N CFTR/A.R. Strang, K. Peeke, A. Shenoy, A. Chidekel, Wilmington, DE, p.A5583

Trends in Cystic Fibrosis Hospital Admissions in Ireland: A National Review/K.N. McCarthy, Co Westmeath, Ireland, p.A5582


Improved Homogeneity of Particle Deposition Following Ivacaftor Treatment in Cystic Fibrosis/W.D. Bennett, K.L. Zeman, B.L. Laube, J. Wu, P.J. Mogayzel, S.H. Donaldson, Chapel Hill, NC, p.A5586
### C61 PEDIATRIC SLEEP: SCREENING AND OUTCOMES

**9:00 a.m. - 4:15 p.m.**

**MOSCONET CENTER**

**Area E, Hall D (North Building, Lower Level)**

1. **Viewing:** Posters will be on display for entire session.
2. **Discussion:**
   - 11:00-11:45: authors will be present for individual discussion
   - 11:45-12:45: authors will be present for discussion with assigned facilitators
3. **Facilitator:** L. Kheirandish-Gozal, MD, MSc, Chicago, IL

<table>
<thead>
<tr>
<th>Poster</th>
<th>Title</th>
<th>Author(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P546</td>
<td>End-Expiratory Lung Volume Is Not Associated with Gas Trapping on CT in Early Cystic Fibrosis Lung Disease/</td>
<td>T. Rosenow, C. Mok, K.A. Ramsey, C. Murray, G. Hall, S. Stick, Subiaco, Australia, p.A5591</td>
<td></td>
</tr>
<tr>
<td>P548</td>
<td>Harmful Effects of In Utero Tobacco Smoke Exposure on Development of Early Infection and Structural Lung Disease in Children with Cystic Fibrosis/</td>
<td>L. Turkovic, A. Hutchin, T. Rosenow, G. Hall, S. Stick, I.A. Laing, Subiaco, Australia, p.A5593</td>
<td></td>
</tr>
<tr>
<td>P549</td>
<td>Predicting the Development of Bronchiectasis in Preschool Children with Cystic Fibrosis/</td>
<td>D. Caudri, L. Turkovic, N. De Klerk, T. Rosenow, S. Ranganathan, S. Stick, Subiaco, Australia, p.A5580</td>
<td></td>
</tr>
</tbody>
</table>

### THEMATIC POSTER SESSION

**P546** End-Expiratory Lung Volume Is Not Associated with Gas Trapping on CT in Early Cystic Fibrosis Lung Disease/T. Rosenow, C. Mok, K.A. Ramsey, C. Murray, G. Hall, S. Stick, Subiaco, Australia, p.A5591


**P548** Harmful Effects of In Utero Tobacco Smoke Exposure on Development of Early Infection and Structural Lung Disease in Children with Cystic Fibrosis/L. Turkovic, A. Hutchin, T. Rosenow, G. Hall, S. Stick, I.A. Laing, Subiaco, Australia, p.A5593

**P549** Predicting the Development of Bronchiectasis in Preschool Children with Cystic Fibrosis/D. Caudri, L. Turkovic, N. De Klerk, T. Rosenow, S. Ranganathan, S. Stick, Subiaco, Australia, p.A5580


**Facilitator:** R. Amin, MD, Toronto, Canada

**P557** Follow-Up of Children with Obstructive Sleep Apnea After Tonsillectomy and Adenoidectomy/Z.N. Soutlan, C.E. Amedro, Syracuse, NY, p.A5599


**P559** Overnight Pulse Oximetry for the Diagnosis of Obstructive Sleep Apnea Syndrome in Children with Obesity/A. Sathyaprasad, J. Stoll, N. Al-Hammadi, M. Bird, J.S. Kemp, A. Coverstone, St. Louis, MO, p.A5600

**P560** Sleep and Quality of Life of Adolescents in Ibadan, Nigeria/A. Alohan, E. Oromadegun, J. Yaria, Ibadan, Nigeria, p.A5601

**P561** Bronchoscopic Findings in Infants with Polysomnography/A. Bandypoapadhyay, H.N. Muston, J.E. Slaven, W.A. Engle, A. Dafty, Indianapolis, IN, p.A5602


**Facilitator:** H. Tan, MD, London, United Kingdom


**P564** Screening for Sleep Disordered Breathing in the Difficult-to-Treat Asthma Population Using the Pediatric Sleep Questionnaire/A.R. Lopez, C.M. Kercsmar, N. Simakajornboon, Cincinnati, OH, p.A5605


P578 Pulmonary Interstitial Lymphoid Hyperplasia and Autoimmune Lactic Acidosis in Status Asthmaticus: A Potential Side Effect When the Nebs Aren’t Helping: Paradoxical Facilitator: F.O. Ogunlesi, MD, Washington, DC


P581 Probable Primary Ciliary Dyskinesia in the Presence of Complex Congenital Heart Disease and Juvenile Dermatomyositis/J. Cogen, T. Ong, Seattle, WA, p.A5635

P582 Worsening Hypoxemia in an 11 Year-Old with Hereditary Hemorrhagic Telangiectasia (HHT)/A.P. Vendittelli, C. Sabogal, Orlando, FL, p.A5640

P583 A Delayed Diagnosis of Post Infectious Bronchiolitis Obliterans Associated with RSV/A. Arastu, M. Corden, M. Bansal, Los Angeles, CA, p.A5617

P584 Histoplasmosis Myocarditis: A Rare Manifestation of Disseminated Disease in an Immunocompetent Host/B. Scott, J. Sherwin, C. Ozment, Durham, NC, p.A5619

P585 Longitudinal Profiles of Serum Specific Immunoglobulins E and G4 to Whole and Component Dermatophagoides Pteronyssinus Allergens during Immunotherapy in Southern Chinese Children/B. Sun, P. Zheng, Guangzhou, China, p.A5623

P586 Diagnosis and Management of Sporadic Pulmonary Arteriovenous Malformation Not Associated with Hereditary Hemorrhagic Telangiectasia/C. Okorie, S. Bhargava, Palo Alto, CA, p.A5625


P589 Drug-Induced Bronchiolitis Obliterans Organizing Pneumonia (BOOP) in a Pediatric Patient/E. Sayad, A. Dossul, S. Cardenas, Cleveland, OH, p.A5618


P592 Successful Use of Non Invasive Ventilation in a Child Affected by Congenital Myotonic Dystrophy Syndrome/ V. Caldarelli, M. Paglietti, E. Verrillo, R. Cutrera, Reggio Emilia, Italy, p.A5632

P593 Primary Ciliary Dyskinesia, Hypotrichosis and Macular Dystrophy: Coincidence or a Novel Syndrome?/E. Basora, E. Sayad, A. Dossul, S. Cardenas, Cleveland, OH, p.A5633

P594 Continuous Renal Replacement Therapy for Profound Hyperammonemia in Pediatric Metabolic Disease/J. Hong, T. Sweberg, K. Tsirilakis, New Hyde Park, NY, p.A5616


P596 Investigation of an Unusual Cause of Airway Obstruction in a Pediatric Patient with Tracheobronchomalacia/H. Shaffer, Wilmington, DE, p.A5628


P599 Primary Ciliary Dyskinesia, Hypotrichosis and Macular Dystrophy: Coincidence or a Novel Syndrome?/E. Basora, E. Sayad, A. Dossul, S. Cardenas, Cleveland, OH, p.A5633

P600 Continuous Renal Replacement Therapy for Profound Hyperammonemia in Pediatric Metabolic Disease/J. Hong, T. Sweberg, K. Tsirilakis, New Hyde Park, NY, p.A5616

P601 Probable Primary Ciliary Dyskinesia in the Presence of Complex Congenital Heart Disease and Juvenile Dermatomyositis/J. Cogen, T. Ong, Seattle, WA, p.A5635

P602 Worsening Hypoxemia in an 11 Year-Old with Hereditary Hemorrhagic Telangiectasia (HHT)/A.P. Vendittelli, C. Sabogal, Orlando, FL, p.A5640

P603 A Delayed Diagnosis of Post Infectious Bronchiolitis Obliterans Associated with RSV/A. Arastu, M. Corden, M. Bansal, Los Angeles, CA, p.A5617

P604 Histoplasmosis Myocarditis: A Rare Manifestation of Disseminated Disease in an Immunocompetent Host/B. Scott, J. Sherwin, C. Ozment, Durham, NC, p.A5619

P605 Longitudinal Profiles of Serum Specific Immunoglobulins E and G4 to Whole and Component Dermatophagoides Pteronyssinus Allergens during Immunotherapy in Southern Chinese Children/B. Sun, P. Zheng, Guangzhou, China, p.A5623

P606 Diagnosis and Management of Sporadic Pulmonary Arteriovenous Malformation Not Associated with Hereditary Hemorrhagic Telangiectasia/C. Okorie, S. Bhargava, Palo Alto, CA, p.A5625


C62 PEDIATRIC CASES I

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area E, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion 11:45-12:15: authors will be present for discussion with assigned facilitators

Facilitator: D.M. Boyer, MD, Boston, MA


P573 Severe BPD Complicated by PIG/T. Simoneau, A. McLaughlin, F. Balarezo, C. Lapin, Hartford, CT, p.A5628

P574 Children Affected by Congenital Central Hypoventilation Syndrome: Decannulation and Non Invasive Ventilation/V. Caldarelli, M.G. Paglietti, E. Verrillo, R. Cutrera, Reggio Emilia, Italy, p.A5632


Facilitator: F.O. Ogunlesi, MD, Washington, DC


P579 A Unique Case of Pulmonary Lymphangectasia in a Teenager/F. Afolabi, Dallas, TX, p.A5622

Facilitator: E. Belteton, MD, Las Victorias, Guatemala

P596  Successful Outcome of a Genetic Lethal Condition in a Term Newborn/A. Baig, C. Burg, H. Thomas, Omaha, NE, p.A5642


P598  Gorham-Stout Disease in a Young Pregnant Female-A Management Dilemma/L. Jalota, K. Bilello, Fresno, CA, p.A5626

P599  Two Unusual Cases of Cystic Fibrosis/Y. B. zheng, L. Cao, China, p.A5638


P601  A Chinese Girl with Cystic Fibrosis Confirmed by 2 Cystic Fibrosis Transmembrane Regulator (CFTR) Gene Mutations/A.Y.-F. Yip, Hong Kong, Hong Kong Prc, p.A5641

C63  BORN TO RUN: EXERCISE IN CARDIOPULMONARY DISEASE

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area M, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: I.R. Preston, MD, Boston, MA

P1393  Breathing Intolerance Index (BII) in Cardiomyopathy Patients - Understanding Respiratory Muscle Endurance in Response to Exercise with Medical Management/K. Bagavathy, A. Tran, L. Palilickal, M. Fong, A. Baydur, Los Angeles, CA, p.A5643

P1394  Slope of 6MWD as a Predictor of Clinical Outcome in PAH/M.G. Risbano, Y. Rao, J. Cleveland, Pittsburgh, PA, p.A5644

P1395  Cardiopulmonary Exercise Test in Pulmonary Embolism/J.-M. Liu, J. Guo, S. Chen, L. Wang, Q. Zhao, W. Yang, S. Gong, China, p.A5645

P1396  Oxygen Uptake Efficiency Slope, an Objective Submaximal Parameter in Evaluating Exercise Capacity in Pulmonary Thromboembolism/J.-M. Liu, J. Guo, S. Chen, Q. Zhao, W. Yang, L. Wang, S. Gong, Shanghai, China, p.A5646

P1397  Difference in Exercise Capacity and Ventilatory Efficiency Between Chronic Obstructive Pulmonary Disease Associated Pulmonary Hypertension and Idiopathic Pulmonary Hypertension/J.-M. Liu, H. Liu, J. Guo, L. Wang, W. Yang, Q. Zhao, S. Gong, Shanghai, China, p.A5647

P1398  Improvement of Exercise Capacity and Ventilatory Efficiency in Patients with Pulmonary Embolism After Anticoagulant Therapy/J.-M. Liu, D. Huang, J. Guo, L. Wang, W. Yang, Q. Zhao, S. Gong, Shanghai, China, p.A5648


P1402  End-Tidal CO2 in Patients with Pulmonary Arterial Hypertension/L. Truong, I. Lee, A. Hugh, S. Ganesh, A.A. Balezian, Los Angeles, CA, p.A5652


P1404  Significant Improvement of Oxygen Saturation of Peripheral Artery During Exercise in Patients with CTEPH Treated with Riociguat/M. Hatano, H. Maki, T. Inaba, S. Minatsuki, I. Komuro, Tokyo, Japan, p.A5654


P1406  Sex-Specific Cardiopulmonary Exercise Testing Parameters as Predictors in Patients with Idiopathic Pulmonary Arterial Hypertension/P. Yuan, T.-X. Chen, J.-M. Liu, Shanghai, China, p.A5656


P1408  Exercise Determinants of Ventilatory Efficiency in Heart Failure with Preserved Ejection Fraction/E. Van Iterson, E.M. Snyder, T.P. Olson, Rochester, MN, p.A5658

P1409  Ventilatory Response to Exercise in Heart Failure with Preserved or Reduced Ejection Fraction/E. Van Iterson, E.M. Snyder, T.P. Olson, Rochester, MN, p.A5659


P1411  Effect of Voluntary Exercise on Inflammation, Vascular and Airway Remodeling in a Mouse Model of Pulmonary Hypertension Induced by Exposure to Antigen and Urban Particulate Matter/N. Durmus, B. Bleck, J. Reibman, G. Grunig, Tuxedo, NY, p.A5661
P1412 Chronic Endurance Exercise Attenuates Impairments in VO2max in Rats with Pulmonary Arterial Hypertension/D. McCullough, A. Yang, S. Heo, G. Choudhary, Auburn, AL, p.A5662


C64 ALI AND BARRIER FUNCTION

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area M, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion

11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: B.J. McVerry, MD, Pittsburgh, PA


P1418 The S1P Transporter, Spsn2, Regulates HGF/C-Met-Mediated Lamellipodia Formation and Migration of Human Lung Endothelial Cells/P. Fu, P.V. Usatyuk, D.L. Ebenezer, V. Natarajan, Chicago, IL, p.A5667


P1420 Hsp90 Inhibitors Prevent NF-κB-Dependent Gene Activation in Human Lung Microvascular Endothelial Cells by Inducing MDM2-Dependent Sirt-2-Promoter Binding/G. S. Thangjam, B. Charalampos, B. Nektarios, B.W. Gregory, M.A. Clements, J. Newton, J.D. Catravas, Norfolk, VA, p.A5669


P1428 Many Roles of Vinculin in Regulation of Endothelial Monolayer Integrity: Location, Location, Location/Y. Ke, A.S. Shah, T. Ohmura, N. Sarich, A.A. Birukova, K.G. Birukov, Chicago, IL, p.A5677

P1429 Multifunctional Regulator of Small GTPases IQGAP1 Mediates Lung Endothelial Response to Barrier Enhancing Oxidized Phospholipids/Y. Ke, O. Oskolkova, T. Ohmura, N. Sarich, K.G. Birukov, Chicago, IL, p.A5678

Facilitator: E.N. Grayck, MD, Aurora, CO


P1432 Inhibition of Hsp90 Repairs the LPS-Induced ALI in Mice/T. Shah, C. Bardita, N. Jeganathan, R. Balk, D. Predescu, S.A. Predescu, Chicago, IL, p.A5681


C65  ONE STEP UP FROM PE TO CTEPH
9:00 a.m. - 4:15 p.m.  MOSCONE CENTER
Area M, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: V. De Jesus Perez, MD, Stanford, CA


P1438  D-Dimer in Chronic Thromboembolic Pulmonary Hypertension (CTEPH)/N. Skoro-Sajer, C. Gerges, S. Taghavi, R. Sadushti-Kolic, W. Klepetko, I. Lang, Vienna, Austria, p.A5686

P1439  Does Thrombolytic Therapy During the Clinical Course of Acute Pulmonary Embolism Improve Prognosis?/M. Koslow, A. Osadchy, F. Fanadka, Y. Neumann, D. Shitrit, Givatayim, Israel, p.A5687


P1444  Expression of Tissue Factor and Forkhead Box Transcription Factor O-1 in a Rat Model for Chronic Thromboembolic Pulmonary Hypertension/C. Deng, D. Wu, M. Yang, Y. Chen, C. Wang, Z. Zhong, N. Lian, H. Chen, S. Wu, Fuzhou, China, p.A5692


P1448  Role of Bedside Chest Ultrasound and Echocardiography in the Diagnosis of Pulmonary Embolism in Emergency Rooms/M. Khan, H. Makhloaf, A. Abd El-Azim, A.A. AlKarn, Assiut, Egypt, p.A5696

Facilitator: S. C. Mathai, MD, MHS, Baltimore, MD

P1449  Predictors of Hospital Mortality in Patients with Acute Pulmonary Embolism in Intensive Care Units/T. Salim, C.C. Portillo, J. Sethi, C. Pena Orbea, R. Lenhardt, Chicago, IL, p.A5697


P1451  An Analysis of Mechanism of Hypoxia in Chronic Thromboembolic Pulmonary Hypertension/S. Minatsuki, H. Maki, T. Inaba, M. Hatano, I. Komuro, Tokyo, Japan, p.A5699

P1452  Relationship Between Improved Pulmonary Arterial Pressure and Changes in the Wall Thickness of Right Ventricle Myocardium by 320-Slice CT in Patients Under Pulmonary Endarterectomy/T. Sugiura, N. Tanabe, A. Sasaki, H. Kasai, Y. Matsuura, N. Kawata, S. Sakao, K. Tatsumi, Chiba, Japan, p.A5700


Facilitator: J.D. West, PhD, Nashville, TN

P1461 Isolated Sub-Segmental Pulmonary Embolism Frequently Coincide with Other Significant CT Chest Findings in a High Risk Orthopedic Population: A Retrospective Study/J.S. Mendelson, V. Mukherjee, D. Steiger, S. Funk, E. Dweck, New York, NY, p.A5709


P1464 Improving Turn-Around Time from Requisition to Diagnosis for CT Pulmonary Angiography: Follow-Up at Six Years/N.A. Avila, S. Zaidi, R. Smith, S. Grimes, A.J. Dwyer, Washington, DC, p.A5712


P1466 The Predictive Value of Wells and Revised Geneva Score and D-Dimer for the Diagnosis of Acute Pulmonary Embolism in Critical Care Unit/D. Li, A. Xu, Shanghai, China, p.A5714


P1469 Cardiopulmonary Exercise Test Differences in Healthy Adults with and Without Anxiety Disorders - Does Activity Level and Non-Smoker Hypoxemia Have an Influence?/L.P. Cahalin, M.L. Wong, K. Allsup, M.D.L. Morgan, M.C. Steiner, S.J. Singh, Leicester, United Kingdom, p.A5725

P1470 Comparison of Cardiopulmonary Exercise Test in Smoker and Non-Smoker/J. Zhang, yinchuan, Ningxia, China, p.A5727


P1473 Improving Turn-Around Time from Requisition to Diagnosis for CT Pulmonary Angiography: Follow-Up at Six Years/N.A. Avila, S. Zaidi, R. Smith, S. Grimes, A.J. Dwyer, Washington, DC, p.A5712


P1476 The Predictive Value of Wells and Revised Geneva Score and D-Dimer for the Diagnosis of Acute Pulmonary Embolism in Critical Care Unit/D. Li, A. Xu, Shanghai, China, p.A5714


P1479 The Reference Equation for Six-Minute Walk Test Distance: Is It a Good Predictor of Mortality?/A. Biswas, P. Markey, B. Jacob, West Yorkshire, United Kingdom, p.A5724


P1482 Comparison of Cardiopulmonary Exercise Test in Smoker and Non-Smoker/J. Zhang, yinchuan, Ningxia, China, p.A5727


Facilitator: M.N. Bartels, MD, MPH, Bronx, NY


P1485 Serum C-Reactive Protein Levels in COPD Patients After Eight Week Comprehensive Pulmonary Rehabilitation Program/I. Candemir, P. Ergun, D. Kaymaz, N. Demir, F. Tasdemir, Ankara, Turkey, p.A5730

Facilitator: M.N. Bartels, MD, MPH, Bronx, NY


Facilitator: M.N. Bartels, MD, MPH, Bronx, NY

P1487 The Reference Equation for Six-Minute Walk Test Distance: Is It a Good Predictor of Mortality?/A. Biswas, P. Markey, B. Jacob, West Yorkshire, United Kingdom, p.A5724

Facilitator: D. Brooks, PhD, Toronto, Canada
P659 Can Information from Cardiopulmonary Exercise Testing Predict Outcome After Pulmonary Rehabilitation in Patients with COPD? R.J. Perez, R. ZuWallack, D. Datta, Farmington, CT, p.A5731

P660 Comorbidities in Patients with Chronic Obstructive Pulmonary Disease and Pulmonary Rehabilitation Outcomes P. Tunsupon, A. Lal, M.A. Khamis, M.J. Mador, Buffalo, NY, p.A5732

P661 Short Duration Dyspnea Challenge Test to Assess Severity of Dyspnea in Patients with Chronic Obstructive Pulmonary Disease P. Sharma, N.R. Morris, M. Sabaratnam, L. Adams, Southport, Australia, p.A5733


P663 Clinical, Socio-Demographic and Psychological Characteristics of Participants and Non-Participants to Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease (COPD) E. D. Rivard, V. Pepin, F. Beaucage, L. Blais, G. Mouillic, RESP Team, Montreal, Canada, p.A5735


P665 Pulmonary Rehabilitation Is Associated with Improvement in Short Physical Performance Battery Scores in COPD/C. Teneback, P. Savage, Burlington, VT, p.A5737

Facilitator: H. Demeyer, PhD, Leuven, Belgium

P666 Postural Deviations in People with Chronic Obstructive Pulmonary Disease (COPD) A.L. Lee, K. Zabjek, R.S. Goldstein, D. Brooks, Toronto, Canada, p.A5738

P667 “Who Wants to Hurt?” - A Qualitative Exploration of Pain Experiences and Their Meaning in People with Chronic Obstructive Pulmonary Disease (COPD) A.L. Lee, S.L. Harrison, R.S. Goldstein, D. Brooks, Toronto, Canada, p.A5739


P673 A Screening Tool to Predict Obstructive Sleep Apnea in Patients with Chronic Obstructive Pulmonary Disease: A Pilot Study of the UCSD COPD-OSA Questionnaire X. Soler, S.-Y. Liao, A.L. Ries, A. Malhotra, San Diego, CA, p.A5745

THEMATIC POSTER SESSION

C67 ACUTE LUNG INJURY

9:00 a.m. - 4:15 p.m. MOSCONE CENTER Area M, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: L.G. Dobbs, MD, Oakland, CA


P1476 F Box Protein FBXO10 Targets the Receptor for Advanced Glycation End Products (RAGE) for Ubiquitination and Degradation in Human Bronchial Epithelial Cells J. Evankovich, S. Dunn, A. Mckelvey, T. Lear, B.B. Chen, R. Mallampalli, Pittsburgh, PA, p.A5747


P1479 Deletion of αENaC in Alveolar Type I Cells Demonstrates the Integral Role of Type I Cells in Maintaining Lung Fluid Balance M. Johnson, S. Balan, A.M. Gillespie, L. Dobbs, San Francisco, CA, p.A5750

Facilitator: G.M. Mutlu, MD, Chicago, IL

P1480 AKB-9785, a VE-PTP Inhibitor, Decreases Inflammation and Alters the Angiopoietin/Tie2 System Dynamic Response in a S. Aureus Sepsis Model R. Bartz, T. McCord, H. Suliman, T. Orr, C.A. Piantadosi, C. Kontos, Durham, NC, p.A5751

P1481 Differential Pulmonary Gene and Protein Expression in Wild Type, Cyp1a1-Null and Cyp1a2-Null Mice in Acute Hyperoxic Lung Injury: Role of Cytochrome P450 (CYP) 1A/J. Lingappan, S. Maity, W. Jiang, L. Wang, X. Couroucli, C. Coarfa, B. Moorthy, Houston, TX, p.A5752


Facilitator: E. Roan, PhD, Memphis, TN


P1486 LPS Relocates Nuclear Resided Fbxo24 into Cytoplasmic Compartment to Augment Histone Acetyltransferase GCN5L2 Mediated Transcriptional Activity in Lung Epithelial Cells/J. Li, Q. Wu, C. Zou, Pittsburgh, PA, p.A5757


P1489 Myosin Phosphatase Protects Against LPS-Induced Pulmonary Endothelial Barrier Dysfunction/A. Kasa, B.A. Ghorsakov, K.-M. Kim, S. Kumar, S.M. Black, D. Fulton, C. Dimitopolou, J.D. Catravas, A.D. Verin, Augusta, GA, p.A5760

Facilitator: I. Vadasz, MD, Giessen, Germany

P1490 TGF-β Promotes Ubiquitination, Endocytosis and Degradation of the Protein Transporter Megalin in Alveolar Epithelial Cells/L.C. Mazzocchi, C. Vohwinkel, W. Seeger, I. Vadasz, Giessen, Germany, p.A5761


P1493 Tumor Necrosis Factor Alpha (TNF-α) Increases Strain Field Heterogeneity in Alveolar Epithelial Cells Leading to Monolayer Damage/J.D. Herwig, C.M. Waters, E. Roan, Memphis, TN, p.A5764


Facilitator: D.W. Kamp, MD, Chicago, IL

P1495 The Effect of PGC-1α on Acute Lung Injury/J. Wang, Y. Jiao, Chongqing City, China, p.A5766

P1496 AMP-Activated Protein Kinase and Extracellular Signal-Regulated Kinase 1/2 Mediate Hypercapnia-Induced Polyubiquitination and Endocytosis of ENaC in the Alveolar Epithelium/P. Gwozdzinska, B.A. Buchbinder, W. Seeger, I. Vadasz, Giessen, Germany, p.A5767


Facilitator: I. Rahman, PhD, Rochester, NY


Facilitator: H. Kubo, MD, PhD, Tokyo, Japan

P1506  Remembering the Ancestral Language: Mammalian Mitochondria
Directly Recognize and Respond to Bacterial Quorum Signals/J.L.
Kuck, O. Dougherty, C. Moore, T. Luong, L. Letterman, S. Orfield, J.P.
Fessel, E. Brittain, Q.S. Wells, Nashville, TN, p.A5777

P1507  Macrophage Akt1-Mediated Mitochondrial Biogenesis
Regulates Pulmonary Fibrosis/J. Casey, A.B. Carter, Birmingham, AL, p.A5777

P1508  Mitochondrial Catalase Enforced Expression (MCAT-EE)
Transgenic Mice Are Protected Against Asbestos- and Bleomycin-Induced Lung Fibrosis in Part Via Beneficial Effects
on AECs/J.P. Chereshe, S.-J. Kim, R.P. Jablonski, A. Yeldandi, L.
Morales Nebreda, Y. Cheng, M. Chi, R. Piseaux, K.M. Ridge, C.M.
Hart, N. Chandel, G.S. Budinger, D. Kamp, Chicago, IL, p.A5779

P1509  Mitochondrial ROS Induce Up-Regulation of SIRT1 in
LPS-Induced Acute Lung Injury/Y.C. Lee, S.R. Kim, H.J. Kim, S.H.
Kim, S.Y. Park, Jeonju, Republic of korea, p.A5780

Facilitator:  R. Lucas, PhD, Augusta, GA

P1510  Bronchial Epithelial Calcium Metabolism Impairment in Smokers:
Decreased ORAI3 Signaling Involved in Cilia Beating/A. Fort, L.
Vacheri, A. Bourdin, Montpellier, France, p.A5781

P1511  ASIC1a/Enac Hybrid Channels Contribute to Alveolar Fluid

P1512  AMP-Activated Protein Kinase Deactivation and Lung Injury in
C57BL/6 Mice Fed Chronic-Binge Ethanol/ L. Kaphalia, B.S.
Kaphalia, W.J. Calhoun, Galveston, TX, p.A5783

P1513  Resolution of Acute Lung Injury Induced by Whole Gastric
Juice in the Hamster/G.R. Borzone, J. Araos, M. Meneses, P.
Ayala, Santiago, Chile, p.A5784

P1514  FollistatinLike-1 Aggravates Radiation-Induced Lung Injury/Y.
Fang, L. Wang, Z. Chen, W. Ning, Tianjin, China, p.A5785

Facilitator:  S.P. Reddy, PhD, Chicago, IL

P1515  Overexpression of IL-38 Protein in the Lungs of Drug Induced
Lung Injury/M. Tominaga, M. Okamoto, T. Kawayama, S. Kaieda,
M. Matsuoka, Y. Sakazaki, T. Kinoshita, T. Hoshino, Kurume, Japan, p.A5786

P1516  Acid Sphingomyelinase Is a Novel Regulator of LYNUS and
Petrame, Denver, CO, p.A5787

P1517  Low Phosphate Diet Arrests and Reverses Stone
Accumulation and Acute Lung Injury in Mice with Pulmonary
Alveolar Microlithiasis/Y. Uehara, N.M. Nikolaidis, A. Saito, L.
McCormack, Cincinnati, OH, p.A5788

P1518  Characterize the Lung Extracellular Vesicles in the Presence of
Jin, Boston, MA, p.A5789

P1519  Ischemic Lung Injury Following Cardio-Pulmonary Bypass
(CPB) Is Associated with Inflammation and Differentiation/A.L.
Durham, E. Al Jaaly, F. Fiorentino, P. Brook, K. Heesom, P.
Lavender, G. Angelini, I. Adcock, London, United Kingdom, p.A5790

THEMATIC POSTER SESSION

C68  IMMUNE CELL INTERACTIONS IN COPD
9:00 a.m. - 4:15 p.m.  MOSCONE CENTER

Viewing:  Posters will be on display for entire session.
Discussion:  11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

P1284  Recombinant Human Granulocyte Colony-Stimulating Factor
Versus Bone Marrow Mononuclear Cells in Treatment of
Pulmonary Emphysema Model/M.K. El Badrawy, N. Shalabi, M.A.
Mohamed, A. Ragab, N. Anber, H.W. Abdelwahab, M.A. Sobh, Y.
Khater, A. Abdel Hamid, Mansoura, Egypt, p.A5791

P1285  GM-CSF Drives Human Lung Tissue Macrophages Towards a
More Pro-Inflammatory Phenotype/J. Ilmil, J.P. Barnes, L.
Donnelly, London, United Kingdom, p.A5792

P1286  Differential Effects of Budesonide and Fluticasone Propionate
in Human Bronchial Epithelial Cells Exposed to Strepotococcus
Pneumonia and Viral Mimetic Poly-(l:C)/I.H. Heijink, M.R. Jonker,
D.S. Postma, M. Van Den Berge, Groningen, Netherlands, p.A5793

P1287  Biology of the Circulating CD45+Col1+ Cells During the
Pathogenesis of  Pulmonary Emphysema/Y.M. Shim, M.
Burdick, K. Qing, T.A. Altes, J.P. Mugler, B. Mehrad, C.E. Rose,
Jr., Charlottesville, VA, p.A5794

P1288  The Decrease of TRPV2 Expression in Alveolar Macrophage by
Cigarette Smoke Exposure Raises Chronic Inflammation in
Lung/H. Masubuchi, M. Ueno, T. Maeno, K. Hara, K. Yamaguchi,
T. Suga, M. Kurabayashi, Maebashishi, Japan, p.A5795

P1289  Aberrant Airway Epithelial Differentiation Resulting from
Cigarette Smoke Exposure Leads to Loss of Constitutive Host
Defence Protein Expression/A.M. Van Der Does, G. Amatngalim,
F. Dishchekenian, T.C.J. Mertens, D.K. Ninaber, A. Van Der
Fernand, C. Taube, P.S. Hiemstra, Leiden, Netherlands, p.A5796

P1290  Smoking Increases Bacterial Growth and Biofilm
Formation/L.G. Vargas Buonfiglio, J.A. Borcherding, R.
Fernandez-Ruiz, M. Cano, L. Powers, A.K. Gerke, A.P. Comellas,
Iowa city, IA, p.A5797

P1291  Water Pipe Condense (WPC) regulates the Expression of
TLRs on Human Macrophages Via Reactive Oxygen Species/E.
Mortaz, G.F. Folkerts, J. Garssen, A.K. Kiani, H.R. Jamaati, M.
El-Sabbana, A.A. Velayati, I.M. Adcock, Tehran, Iran, p.A5798

P1292  Neutrophil Death in a Population of Patients with Neutrophilic
COPD/J.L. Cane, K. Hambleton, C. Borg, C. Connolly, T. Powell,
J.L. Cane, K. Hambleton, C. Borg, C. Connolly, T. Powell, L.
Xue, I. Padvor, M. Baladhel, Oxford, United Kingdom, p.A5799

P1293  Effect of Inhaled Anticholinergics on Pathogenicity of
Pseudomonas Aeruginosa and Staphylococcus Aureus/A.
Vyas, J. Joshua, L.E. Crotty Alexander, San Diego, CA, p.A5800

P1294  Effects of the Novel Pharmacological Compound Sul-121 on
LPS-Induced Acute Lung Injury/B. Han, W.J. Poppinga, H.
Zuo, P. Vogelaar, K. Van Der Graaf, A.J. Halayko, H. Meurs, M.
Schmidt, Groningen, Netherlands, p.A5801


P1297  Increased Neutrophil Gelatinase-Associated Lipocalin (NGAL) Promotes Airway Remodeling in COPD/X. Hao, Y. Wang, I. Adcock, P.J. Barnes, Nanjing, China, p.A5804

P1298  Involvement of IL-17A in Development of Airway Fibrosis in Mice/H. Yanagisawa, M. Hashimoto, S. Minagawa, J. Araya, A. Bondesson, A. Budelsky, S. Nishimura, Tokyo, Japan, p.A5805

P1299  Characterization of Pulmonary Immunophenotype in Patients with COPD/N.M. Mark, J.K. Kargl, S. Pipavath, A.M. Houghton, Seattle, WA, p.A5806

P1300  Langerhans Cells Are Highly and Widely Distributed in Respiratory Bronchioles with Smoking-Related Changes of the Lungs in Smokers/A. Masunaga, T. Takemura, E. Yamaguchi, Y. Horio, S. Saeki, T. Mori, M. Suzuki, H. Kohrogi, Kumamoto City, Japan, p.A5807


P1311  Fissure Integrity and Rate of Emphysema Progression: SubPopulations and Intermediate Outcome Measures In COPD Study (SPIROMICS)/J.M. Charbonnier, D.A. Lynch, S.M. Humphries, M. Strand, E.M. Van Rikxoort, Nijmegen, Netherlands, p.A5817


P1314  In Vivo Imaging of Polymers in α1-Antitrypsin Deficiency/II. Haq, D.A. Lomas, London, United Kingdom, p.A5820


C70  THE NEXT NEW THERAPEUTIC TARGET?  TRANSLATIONAL STUDIES OF COPD THERAPIES

9:00 a.m. - 4:15 p.m.  MOSCONET CENTER

Area L, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators


P1320  Compartment-Specific and Time-Dependent Analysis of Mice with Smoke-Induced Pulmonary Hypertension and Emphysema/M. Bednorz, J. Wilhelm, R.T. Schermuly, H.A. Ghofrani, W. Seeger, N. Weissmann, M. Seimetz, Giessen, Germany, p.A5825


P1325  Chronic Bronchitis Enhancement in Newborn Mice from Exposure to Environmental Tobacco Smoke/J. Jia, T.M. Conlon, C. Ballester Lopez, O. Eickelberg, M.A. Mall, A.O. Yildirim, Munich, Germany, p.A5830


P1330  Synergistic Effects Between Olodaterol and Tiotropium on Methacholine-Induced Contraction in Guinea Pig Airways Smooth Muscle/H. Kume, T. Isoya, Y. Tohda, Osakasayama, Japan, p.A5835


P1337  Effects of Soluble Guanylate Cyclase (sGC) Stimulation on Extrapulmonary Oxidative Stress in Guinea Pigs Chronically Exposed to Cigarette Smoke/T. Paul, A. Salazar, V.I. Peinado, M. Cortes, E. Ferrer, E. Puig, O. Tura, I. Blanco, E. Barreiro, J.A. Barbera, Barcelona, Spain, p.A5842

**P1339** Erythropoietin Receptor (EPOR)/β-Common Receptor (β-CR) Signalling: A Potential Therapeutic Role in Lung Disease/K. Rochfort, S. Whelan, E. Coleman, K. Howell, Dublin, Ireland, p.A5844


**P1343** Association of Increased Autophagy in COPD and Dysregulation of Zinc Handling Systems/E. Roscioli, H. Bac-Tran, R. Hamon, P. Zalewski, S.J. Hodge, Adelaide, Australia, p.A5848

---

**C71** YOU ARE WHAT YOU BREATHE: AIRWAY CELL BIOLOGY IN COPD

9:00 a.m. - 4:15 p.m. MOSCONET CENTER

**Area L, Hall D (North Building, Lower Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators


**P1349** Hydrogen Sulfide Attenuates Bronchial Epithelial Cell Apoptosis by Inhibiting Endoplasmic Reticulum Stress/Y. Chen, F. Lin, C. Liao, Y. Sun, Y. Bai, Y. Liao, M. Li, Y. Qi, Beijing, China, p.A5853

**P1350** Expression and Function of MTUS1 in a Cell Model of Cigarette Smoke Extract Induced Chronic Obstructive Pulmonary Disease/X. Gong, J. Zhou, Y. Song, C. Bai, Shanghai, China, p.A5854

**P1351** Role of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) in Acute Exacerbation of Chronic Obstructive Pulmonary Disease and the Potential Mechanism/Y. Zhu, C. Bai, Y. Song, X. Wang, Shanghai, China, p.A5855

**P1352** Localization and Expression of Fam13a and Ireb2 in Mouse Lung Tissue/M. Sato, S. Inoue, A. Igarashi, Y. Tokairin, T. Nemoto, K. Sato, M. Kobayashi, Y. Abe, I. Kubota, Y. Shibata, Yamagata, Japan, p.A5856

**P1353** Quantification and Characterization of Human Lung Mesenchymal Stem Cells/T. Cruz, A. Lopez-Giraldo, A. Agusti, R. Faner, Barcelona, Spain, p.A5857

**P1354** Intercellular Adhesion Molecule 1 (ICAM-1) Expression is Upregulated in Smokers and Patients with Chronic Airflow Limitation (CAL)/S.D. Shukla, H.K. Muller, R. Latham, S.S. Sohal, H. Walters, Hobart, Australia, p.A5858

**P1355** Induced-Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Attenuate Cigarette Smoke-Induced Mitochondrial Dysfunction And Apoptosis in Airway Smooth Muscle Cells/X. Li, C. Michaeloudes, Y. Zhang, Q. Lian, J.C.W. Mak, P.K. Bhavsar, K.F. Chung, Hong Kong, Hong Kong Prc, p.A5859

**P1356** In Search of Ckit+ Stem Cells in Lung Tissue/A. Lopez-Giraldo, T. Cruz, A. Agusti, R. Faner, Barcelona, Spain, p.A5860


**P1358** Flavored E-liquids Alter Cell Proliferation and Calcium Signaling/T.R. Rowell, S. Sizer, R. Tarran, Chapel Hill, NC, p.A5862

**P1359** HMGA1 Permits Human Airway Basal Stem/Progenitor Cells to Regenerate the Normal Airway Epithelium/H. Zhang, J. Yang, M.S. Walters, R.G. Crystal, New York, NY, p.A5863


**P1362** Inhibition of Nephrin/ectin Expression in Human Bronchial Epithelial Cells Using siRNA Knock-Down/G. Qian, A. Henry, B. Liu, S. Miller, C.K. Billington, I.P. Hall, Nottingham, United Kingdom, p.A5866
P1364 p53- and PAI-1-Mediated Induction of C-X-C Chemokines and CXCR2: Importance in Pulmonary Inflammation Due to Cigarette Smoke Exposure/N. Tiwari, A.S. Marudamuthu, B. Puthusseri, S. Idell, S. Shetty, Tyler, TX, p.A5868


P1366 Monitoring Local Pulmonary cAMP Levels: Combining Precision Cut Lung Slice (PCLS) and Fluorescence Resonance Energy Transfer (FRET) Technologies in Mice/H. Zuo, W.J. Poppinga, E. Zeisberg, V.O. Nikolaev, M. Schmidt, Groningen, Netherlands, p.A5870

P1367 Effects of Two Doses of Bone Marrow-Derived Mesenchymal Stromal Cells in a Model of Elastase-Induced Severe Emphysema/H.A. Poggio, N.N. Rocha, J.Z. Kitoko, M.M. Morales, P.C. Olsen, P.R.M. Rocco, M.A. Antunes, F.F. Cruz, Rio de Janeiro, Brazil, p.A5871


P1370 Differential Induction of MUC5AC Mucin Gene Expression by Haemophilus spp. Isolated from Patients with COPD/A. Tarig, C. Wrona, S. Sethi, Buffalo, NY, p.A5874


C72 EPITHELIAL BIOLOGY

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

THEMATIC POSTER SESSION

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion

11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: L.A. Dada, PhD, Chicago, IL

P897 Production of Inflammatory Mediators and Induction of Apoptosis in Pleural Mesothelial Cells, Lung and Breast Cancer Cells Exposed to Talc Particles/M.M. Acencio, L.R. Teixeira, V.A. Alvarenga, C.S.R. Silva, R.K.B. Sales, E. Marchi, Sao Paulo, Brazil, p.A5881


Facilitator: S. Idell, MD, PhD, Tyler, TX

P903 Towards Therapeutic Alveolar Regeneration - Characterization of a Novel Wnt-Responsive Subpopulation of Type II Pneumocyte which Exhibits Increased Progenitor Cell Function in the Adult Mammalian Lung/W.J. Zachariou, D. Frank, J. Zepp, M. Morley, E.E. Morrissey, Philadelphia, PA, p.A5887


P906 **TGF-β Induces Alveolar Epithelial Cell Apoptosis Through Activation of a FADD/Caspase 8 Pathway**/A.K. Wheaton, M. Agarwal, K.K. Kim, Ann Arbor, MI, p.A5890

P907 **Autophagy Is Required for Basal and ATP-Activated MUC5AC Secretion in Airway Epithelial Cells**/J.D. Dickinson, J.M. Sweeter, S.L. Brody, Omaha, NE, p.A5891

P908 **Autophagy Dependent Superoxide ROS Is Increased in Airway Epithelial Cells During Chronic IL-13 Stimulation**/J.D. Dickinson, J.M. Sweeter, M.C. Zimmerman, S.L. Brody, Omaha, NE, p.A5892

P909 **Cadherin-26 (CDH26) Is a Novel Apical Membrane Protein Facilitator**/S.L. Brody, MD, St. Louis, MO

P910 **Effect of β-Glucan on MUC4 and MUC5B Expression in Human Airway Epithelial Cells**/Y.S. Choi, Y.-D. Kim, J.H. Ahn, C.H. Bae, S.-Y. Song, Daegu, Korea, Republic of, p.A5893

P911 **Immunolocalization of β-ENaC and NKCC1 Reveals Distinct Epithelial Cells with Either Absorptive or Secretory Phenotypes in Porcine Airways**/G. Flores-Delgado, P. Quinton, La Jolla, CA, p.A5895

P912 **Maresin-1 Regulates Epithelial to Mesenchymal Transition and Wound Healing Processes in Bronchial Epithelial Cells**/T.M. Nordgren, A.J. Heires, K.L. Bailey, D.J. Romberger, Omaha, p.A5896

P913 **Role of FOXC2 Gene in Differentiation of Alveolar Type1 Epithelial Cells**/M. Tsuji, M. Morishima, K. Shimizu, M. Kondo, T. Kume, T. Tamaoki, T. Ezaki, Tokyo, Japan, p.A5897

P914 **Effects of the Apical Krebs Solution on Ion Transport of Cultured Pig Tracheal Epithelia**/W. Xu, W.N.F. Li, J.-H. Chen, Hong Kong, Hong Kong PRC, p.A5898

P915 **Investigating the Activity of a Rhinovirus Capsid-Binding Compound, AZ13694531, on Rhinovirus-C and Rhinovirus-A Replication in Differentiated Primary Airway Epithelial Cells: New Insights into Rhinovirus Species Coverage and Mechanism of Action**/C. McCrae, J. Horndahl, P. Hazon, R. Svard, P. Svanberg, D. Keeling, Molndal, Sweden, p.A5899

P916 **Effects of Mycoplasma Pneumoniae on Airway Epithelial Culture Morphology**/T. Krunosky, O. Prince, D. Krause, Athens, GA, p.A5900


P918 **Nutrition Polarization Promote the Cilia Formation of Epithelial Cell**/L. Deng, Y. Jin, Y. Duan, Changzhou, China, p.A5902


**THEMATIC POSTER SESSION**

**C73 OXIDANTS**

9:00 a.m. - 4:15 p.m. MOSCONE CENTER

Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: R.E. Morty, MD, Giessen, Germany

P921 **Deficiency of Two-Pore-Domain Potassium (K2P) Channels Promotes Hyperoxia-Induced Lung Injury**/A. Schwingshackl, B. Teng, C. Luellen, C.M. Waters, Los Angeles, CA, p.A5904


P923 **The Role of EGFR Inhibition in Hyperoxia-Induced ARDS**/B.J. Clark, Y. Sun, B. D’Amico, P.J. Lee, J. Koff, New Haven, CT, p.A5906


P927 **Gene Expression Profiling Identifies Cell Proliferation and Inflammation as the Predominant Pathways Regulated by Aryl hydrocarbon Receptor in Primary Human Fetal Lung Cells Exposed to Hyperoxia**/B. Shivanna, S. Zhang, A. Patel, S. Maity, J. Belmont, S. Welty, C. Coarfa, B. Moorthy, Houston, TX, p.A5910


P930 Hyperoxia-Compromised Phagocytic Function in Macrophages Is Improved by Salicylates Via Inhibition of HMGB1 Release/M. Wang, L.L. Martell, Queens, NY, p.A5913


P932 The Effect of the Mitochondria-Targeted Antioxidant MitoQ on Hypoxic Pulmonary Vasoconstriction and Chronic Hypoxia-Induced Pulmonary Hypertension/O. Pak, S. Scheibe, A. Esfandiarri, M. Gierhardt, A. Sydovik, A. Fysikopoulos, F. Veit, F. Kroschel, R.T. Schermuly, H.A. Ghofrani, W. Seeger, M. Murphy, N. Weissmann, N. Sommer, Siegen, Germany, p.A5915


P951 Knockout of RAGE Ameliorates Cigarette Smoke-Induced Airway Inflammation in Mice/M. Chen, T. Wang, L. Liu, D. Xu, F. Wen, L. Chen, Chengdu, China, p.A5933

P952 A Manufacturing- and Regulatory-Friendly Cell Expansion Technology Allowing for Trillion-Fold Expansion of Primary Airway Epithelial Cells/C. Zhang, A. Shrivastava, Gaithersburg, MD, p.A5934


P955 TGFβ and IL-13 Induce Pro-Fibrotic Changes in the 3DBioBarrier™ Airway Epithelial/Fibroblast Model System/ S.J. Wadsworth, C. Overed-Sayers, L. Murray, M.A. Sleeman, D. Clarke, Vancouver, Canada, p.A5937


P958 Validation of a Novel Rabbit S. Pneumoniae Model of Empyema and Responses to Intrapleural Fibrinolytic Therapy with tPA or scuPA/G. Florova, A. Komissarov, O.A. Azghani, A. Buchanan, K. Koenig, C. Schaefer, J. Boren, S. Ideil, Tyler, TX, p.A5940

P959 Establishment of a Novel Nanobody Specific for Anti-Human Pulmonary Surfactant Protein A and Its Targeting Capacity/X. He, S. Wang, Z. Yin, D. Weng, H. Li, Nantong, China, p.A5941


P966 Deletion of Rpspt1 in a Mouse Model of Primary Ciliary Dyskinesia Results in a Mild Phenotype/E.L. Ostrowski, A. Livraghi-Butrico, W. Yin, P. Sears, T. Rogers, B. Grubb, Chapel Hill, NC, p.A5948

---

**THEMATIC POSTER SESSION**

**C75 IMPROVING AND ASSESSING RESPIRATORY FUNCTION**

**9:00 a.m. - 4:15 p.m.**

**Area H, Hall D (North Building, Lower Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

**Facilitator:** K.I. Berger, MD, New York, NY


P972 Respiratory Impedance Measuring by ©MostGraph-01 Is Affected by Obesity/Z. Isobe, Fukaya city, Japan, p.A5953

P974  The Effect of Spermidine on Obesity-Associated Pathological Changes of the Lung/J. Schipke, E. Lopez-Rodriguez, C. Muhlfeld, Hannover, Germany, p.A5955

Facilitator: V.J. Kelly, PhD, BS, Boston, MA

P975  Reference Values to Spirometry in Sample of Brazilian Facilitator: V.J. Kelly, PhD, BS, Boston, MA


Facilitator: D.G. Chapman, PhD, Burlington, VT

P980  Automated Analysis of Neural Respiratory Drive from Parasternal Intercostal Muscle Electromyography Predicts Safe Discharge in Exacerbations of COPD/S. Devot, J. Van De Laar, R. Priori, R. Derkx, P.B. Murphy, E.-S. Suh, N. Hart, Cambridge, United Kingdom, p.A5961


P982  Pneumoperitoneum Inflation with Different Levels of Pressure in Rats Promotes Pulmonary Inflammation with Different Repercussion/J. Brandao, C.B.N. Andreia Dato, K. Vasconcelos, L. Falcao, I. Oliveira-Junior, Sao Paulo, Brazil, p.A5963


C76  VENTILATORY CONTROL: GETTING ON MY NERVES

9:00 a.m. - 4:15 p.m. MOSCONC CENTER Area N, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: C.A. Sinderby, PhD, Toronto, Canada


P1542  The Effect of Thoracic Nerve Blocks on Chest Wall Mechanics/G. Elshafie, P. Kumar, R. Steyn, M. Kalkat, R. Wilson, E. Bishay, P. Rajesh, B. Naidu, Birmingham, United Kingdom, p.A5969


Facilitator: M.G. Drake, MD, Portland, OR

P1544  Resistive Breathing Induced IL-6 Impairs the Respiratory Control Response to Hypercapnic and Hypoxic Stimuli Via the Carotid Body and Augmented It Via the Phrenic Nerve/E. Perikos, I. Koutsourelakis, G. Prezerakos, A. Sotiriou, M. Dettoraki, C.E. Giannakopoulou, A. Papalois, T. Vassilakopoulos, Athens, Greece, p.A5971


P1546  The Effect of Acrolein on Lung Function and Substance P Release in Mice/Z. Wu, J.E. Hanson, R.D. Mey, Morgantown, WV, p.A5973

P1547  Pulmonary Function in Parkinson’s Disease/A. Begeman, M. Luinstra, S. Vroegop, E. Frijlink, Groningen, Netherlands, p.A5974
### THEMATIC POSTER SESSION

**C77**  
**DIGGING DOWN DEEP: MEASURING SDB PHYSIOLOGICAL TRAITS**

<table>
<thead>
<tr>
<th>Topic</th>
<th>Author(s)</th>
<th>Location</th>
<th>Facilitator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obstructive Sleep Apnea and Airway Structure Characterization During Wakefulness Using Tracheal Breathing Sounds</td>
<td>A.M. Elwall, Z. Moussavi, Winnipeg, Canada</td>
<td>MOSCONE CENTER Area N, Hall D (North Building, Lower Level)</td>
<td>A.R. Schwartz, MD, Baltimore, MD</td>
</tr>
<tr>
<td>Utility of Acoustic Pharyngometry in the Diagnosis of Obstructive Sleep Apnea</td>
<td>T. Kendzerska, M. Grewal, C.M. Ryan, Toronto, Canada</td>
<td>MOSCONE CENTER Area N, Hall D (North Building, Lower Level)</td>
<td>A.R. Schwartz, MD, Baltimore, MD</td>
</tr>
<tr>
<td>Differences in Respiratory Rate Variability Among Patients with and Without Obstructive Sleep Apnea</td>
<td>A.W. McLean, R. Pirouz, G. Alrehaili, C. Bolinger, K. Rider, H. Kaya, S. Kimbro, R. Amdur, V. Jain, J. Ahari, J. Williams, A. Bawa, Washington, DC</td>
<td>MOSCONE CENTER Area N, Hall D (North Building, Lower Level)</td>
<td>A.R. Schwartz, MD, Baltimore, MD</td>
</tr>
<tr>
<td>Development and Validation of an Acoustic Model of the Upper Airway for Snore Sound Generation</td>
<td>M. Shokrollahi, S. Saha, M. Taheri, Z. Moussavi, A. Yadollahi, Toronto, Canada</td>
<td>MOSCONE CENTER Area N, Hall D (North Building, Lower Level)</td>
<td>P. Catcheside, PhD, Daw Park, Australia</td>
</tr>
</tbody>
</table>

### THEMATIC POSTER SESSION

**C78**  
**NOT STRANGERS IN THE NIGHT: SLEEP AND THORACIC DISEASES**

<table>
<thead>
<tr>
<th>Topic</th>
<th>Author(s)</th>
<th>Location</th>
<th>Facilitator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac Function of Preadolescent Young Males with Duchenne Muscular Dystrophy and Early Onset of Sleep Disordered Breathing</td>
<td>A.R. Lopez, H. Sawhani, J.E. Pascoe, N. Simakajornboon, Cincinnati, OH</td>
<td>MOSCONE CENTER Area N, Hall D (North Building, Lower Level)</td>
<td>L.F. Wolfe, MD, Chicago, IL</td>
</tr>
<tr>
<td>The Effect of Sleep Disordered Breathing on Heart Rate Variability in Boys with Duchenne Muscular Dystrophy</td>
<td>J.E. Pascoe, K. McConnell, A.R. Lopez, A. Minkara, H. Sawhani, T.J. Dye, N. Simakajornboon, Cincinnati, OH</td>
<td>MOSCONE CENTER Area N, Hall D (North Building, Lower Level)</td>
<td>L.F. Wolfe, MD, Chicago, IL</td>
</tr>
<tr>
<td>Obesity Hypoventilation Syndrome: Prevalence in Ambulatory Obese and Validity of Venous Bicarbonates for Improving Diagnosis Capabilities</td>
<td>J.C. Borel, F. Guerber, I. Jullian-Desayes, M. Joyeux-Faure, N. Arnol, N. Tuleux, R. Tamisier, J.L. Pepin, Grenoble, France</td>
<td>MOSCONE CENTER Area N, Hall D (North Building, Lower Level)</td>
<td>M. Macrea, MD, MPH, PhD, Salem, VA</td>
</tr>
<tr>
<td>Simple Strategy to Recognize Obesity Hypoventilation Syndrome in Hospitalized Patients</td>
<td>Z. Fast, S. Sharma, Philadelphia, PA</td>
<td>MOSCONE CENTER Area N, Hall D (North Building, Lower Level)</td>
<td>M. Macrea, MD, MPH, PhD, Salem, VA</td>
</tr>
<tr>
<td>Descriptive Characteristics of Obstructive Sleep Apnea Patients at Risk of Extended Stay in the Post-Operative Care Unit</td>
<td>E. Lee, J. Daugherty, San Diego, CA</td>
<td>MOSCONE CENTER Area N, Hall D (North Building, Lower Level)</td>
<td>M. Macrea, MD, MPH, PhD, Salem, VA</td>
</tr>
<tr>
<td>Peri-Operative Risk Following Bariatric Surgery Is Not Increased in Untreated Patients with Moderate Obstructive Sleep Apnea Selected by an Innovative Decisional Algorithm</td>
<td>M. Martin, C. Minic, J.T. Granton, C.M. Ryan, Toronto, Canada</td>
<td>MOSCONE CENTER Area N, Hall D (North Building, Lower Level)</td>
<td>M. Martin, C. Minic, J.T. Granton, C.M. Ryan, Toronto, Canada</td>
</tr>
<tr>
<td>Fluid Shifts in Pulmonary Hypertension in Those with and Without Sleep Apnea</td>
<td>C.G. Carvalho, M. Minic, J.T. Granton, C.M. Ryan, Toronto, Canada</td>
<td>MOSCONE CENTER Area N, Hall D (North Building, Lower Level)</td>
<td>M. Martin, C. Minic, J.T. Granton, C.M. Ryan, Toronto, Canada</td>
</tr>
<tr>
<td>Evaluation of Right Ventricular Remodeling and Expansion of Extracellular Volume (ECV) Using Cardiac Magnetic Resonance Imaging in Co-Existen CHronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea</td>
<td>R. Jen, J.R. Wilson, R.L. Owens, Y. Li, P.N. DeYoung, E.T. Smales, A. Malhotra, La Jolla, CA</td>
<td>MOSCONE CENTER Area N, Hall D (North Building, Lower Level)</td>
<td>R. Jen, J.R. Wilson, R.L. Owens, Y. Li, P.N. DeYoung, E.T. Smales, A. Malhotra, La Jolla, CA</td>
</tr>
</tbody>
</table>

Facilitator: J.E. Orr, MD, La Jolla, CA

P1571 The Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea/L. Oliveira, J.C. Mendes, J.J. Urbano, A.S. Silva, E.F. De Oliveira, N.T. Fonseca, E.A. Perez, Sao Paulo, Brazil, p.A5996

Facilitator: J.E. Orr, MD, La Jolla, CA

P1572 Increased Neural Respiratory Drive Due to Upper Airway Resistance; A Possible Protective Mechanism in COPD?/B. He, L. Zhou, S. Xiao, J. Steier, J. Moxham, M.I. Polkey, Y. Luo, Guangzhou, China, p.A5997

Facilitator: J.E. Orr, MD, La Jolla, CA


Facilitator: J.E. Orr, MD, La Jolla, CA


Facilitator: J.E. Orr, MD, La Jolla, CA

P1575 Cardiorespiratory Responses and Acute Mountain Sickness in Humans During Aerobic Exercise While Exposed to Hypobaric and Normobaric Hypoxia/L. Rausch, S. Pramsohler, S. Wimmer, M. Faulhaber, Innsbruck, Austria, p.A6000

Facilitator: J.E. Orr, MD, La Jolla, CA

P1576 Spiroergometry in Normobaric and Hypobaric Hypoxia/M. Frieb, S. Pramsohler, M. Koop, H. Gatterer, M. Faulhaber, M. Burtscher, N. Netzer, Innsbruck, Austria, p.A6000

Facilitator: J.E. Orr, MD, La Jolla, CA


Facilitator: A. Sankari, MD, PhD, Detroit, MI


P10 Large Cell Neuroendocrine Carcinoma of the Lung: A Rare Cancer by EBUS Guided Core Needle Biopsy/D. Mabe, S.C. Parrish, A. Lazarus, Gaithersburg, MD, p.A6015


P16 Single Port Video Assisted Lobectomy and Mediastinal Lymph Node Dissection for Pulmonary Cancer Surgical Treatment - Experience of a Surgical Center/R. Ferreira, A. Sena, J. Cruz, Lisboa, Portugal, p.A6021

P17 Robotic Video-Assisted Thoracoscopic Lung Resection: Comparison of Outcomes and Learning Curve from a Single Surgeon in a Tertiary Care Center/P. Kanagarajah, A. Torres, A. Bacigalupo, S. Shaukat, F.A. Myslicki, R. Williams, Miami Beach, FL, p.A6022


P20 Visceral Pleural Invasion Decreased Overall Survival in Resected Non-Small Lung Cancer Patients with Tumor Size Ranged 3 to 5cm Rather than 3cm or Less/P. Zhou, Chengdu Shi, China, p.A6025


P26 100 Months Surviving Rate Without Progression, the Best Answer in the Literature to Erlotinib in Wild Type EGFR Adenocarcinoma/Y. Rosati, G. Mattioli, A. Re, G. Riccioni, M. Serafini, T. Pieramici, T. Taccari, A. Tubaldi, Macerata, Italy, p.A6031

P27 Octreotide as Bridging Therapy to Erlotinib in Bronchorrhea-Induced Respiratory Failure/N. Bournival, J.D. Marshall, C.J. Britto, New Haven, CT, p.A6032


P29 Vasculitis Like Eruption Associated with Erlotinib Therapy/H.-Y. Fang, W.-C. Liao, C.-J. Hsu, P.-Y. Wu, T.-C. Hsia, C.-Y. Tu, Taichung City, Taiwan, p.A6034


P64 The Potential Malignancy of a Solitary Fibrous Tumour of the Pleura/D. Patrini, M. Hayward, N. Panagiotopoulos, United Kingdom, p.A6066


P68 Middle Mediastinal Schwannoma a Case Report and Literature Review/C.M.D.L. Lajom, Manila, Philippines, p.A6070

P69 An Anterior Mediastinal Adenocarcinoma in CREST Syndrome/E. Male, M. Fernandez, S. Ghamande, A. Arroliga, Temple, TX, p.A6071


P72 Ectopic Thyroid Masquerading as Lung Cancer/P.S. Pandya, London, United Kingdom, p.A6074

Facilitator: L.C. Moses, MD, Richmond, VA

P73 Granular Cell Tumor: A Case of a Rare Tumor with an Unusual Location and Presentation/A. Rudkowskaia, I.C. Forde, J.-P. Ayala, P.J. Cohen, Bridgeport, CT, p.A6075


P76 A Rare Case of Tracheal Hamartoma/O.D. Adejorin, R. Shrestha, M.P. Muthiah, M. Zaman, Memphis, TN, p.A6078

P77 Peribronchial Sclerosing Hemangioma with 68Ga Uptake of DOTATOC PET-CTI.J. Kelly-Garcia, B.B. Cano Vargas, J.L. Criales-Cortes, H. Santiago-Payan, C. Canales-Ibarra, Mexico, Mexico, p.A6079


P80 A Series of Unfortunate Events: A Case of True Spontaneous Lung Herniation Resulting in Multiple Rib Fractures/K. Downey, Y.B. Mehta, Z. Mehta, Danville, PA, p.A6082

P81 An Unusual Source of Endobronchial Metastases/L. Cruz, R. Mutneja, B. Lahiri, Farmington, CT, p.A6083

P82 An Embolic Quandary/A. Giri, P. Bansal, M. Kosters, P. Kohlitz, Syracuse, NY, p.A6084


P84 Appearances Are Deceptive: An Unusual Presentation of a Rare Primary Lung Tumor/J.D. Dhingani, I. Waheed, L. Srinivasan, U. Sagheer, S. Sivaraman, North Chicago, IL, p.A6086

THESIS POSTER SESSION

C81 UNUSUAL PRESENTATIONS OF LUNG CANCER: CASE REPORTS

9:00 a.m. - 4:15 p.m.
Area A, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: D.W. Hsia, MD, Torrance, CA

P88 DIPNECH a Rare Cause of Obstructive Airway Disease/P. Vishwasrao, J. Davis, L. Palmer, Stony Brook, NY, p.A6087

P89 A Narrow Escape from Bilateral Adrenalectomy: A Case of Unrecognized Ectopic Adrenocorticotropic Hormone Production/B.S. Grimes, I. Barjaktarevic, Los Angeles, CA, p.A6088


P91 Spontaneous Tumor Lysis Syndrome (TLS) in Small Cell Carcinoma of the Lung (SCLC)/W. Eegubunam, K. Ayinapudi, E. Kupferstein, Brooklyn, NY, p.A6090


P94 Spontaneous Regression Of Non-Small Cell Lung Cancer After Biopsy/F. Elmufdi, R. Andrade, A. Begnaud, Minneapolis, MN, p.A6093

P95 A Case of Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE) Syndrome Presenting as a Para-Neoplastic Syndrome/D. Dhingani, A.S. Copur, A. Fulambarker, North Chicago, IL, p.A6094


P99  Stroke and a Valvular Lesion in a Patient with Stage IV Non-Small Cell Lung Cancer/A.A. Mitma, S. Zarich, D. Witt, Bridgeport, CT, p.A6098

P100  Spindle Cell Carcinoma Masquerading as Metastatic Renal Cell Carcinoma/B. Lou, C. Peng, N. Rohs, R. Sulica, New York, NY, p.A6099


P102  Coexistent Pulmonary Granular Cell Tumor and Adenocarcinoma of the Lung with Pulmonary Tuberculosis/S. Uslu, C.E. Dagil, H. Erdem, M. Karakoglanoglu, Ordu, Turkey, p.A6101

P103  Lung Nodule- Thoracic Endometriosis/V. Angirekula, Z. Shaman, Cleveland, OH, p.A6102

P104  A Rare Cause of Hemoptysis: Mucoepidermoid Carcinoma of the Bronchus/K. Lam, A. Gohil, Palo Alto, CA, p.A6103

P105  Metastasis to the Colon from Lung Adenocarcinoma Manifesting as Tarry Stool/S. Yi-Cheng, C.-Y. Tu, W.-C. Liao, Taichung, Taiwan, p.A6104


P111  Lung Cancer Presenting with Acute Onset Severe Chest Pain/C. Sutton, C. McCartney, R. Nayak, St. Louis, MO, p.A6110

P112  Adenocarcinoma of the Anus: An Extremely Rare Presentation of a Primary Lung Malignancy/J.A. Riggs, K. Carson, St. Louis, MO, p.A6111


P114  A Case of Scant Hemoptysis that Lead to the Discovery of a Rare Mid-Tracheal Tumor/I. E. Alwine, T. Smith, M. Shamiyia, R. Duff, Myrtle Beach, SC, p.A6113

P115  Small Cell Lung Cancer Presenting as Painful Obstructive Jaundice: Case Report/J.M. Scoon, Y.C. Yeh, A.E. Sagar, Houston, TX, p.A6114


P118  Unusual Presentation of Metastatic Lung Cancer in a Young Patient/P.S. Vayalil, C. Brown, B. Bumgarner, M. Mirza, J. Murray, A. Theertham, J. Lambrecht, Omaha, NE, p.A6117


P120  Small Cell Lung Cancer Presenting as Cystic Brain Metastases: An uncommon Presentation/A. Mohammed, J.M. Chowdhury, E. Green, Darby, PA, p.A6119

P121  Shoulder Pain Masquerading a Tumor: Pancoast Tumor/J. Aleman-Ortiz, W. Rodriguez-Cintron, San Juan, PR, p.A6120


P123  Seizure and a Solitary Brain Metastasis in a Non-Smoker - A Rare and Unusual Initial Presentation of Occult Asymptomatic Non-Small Cell Lung Cancer/D. Terrington, A. Craig-McQuaide, R. Tabbara, A. Arya, King’s Lynn, United Kingdom, p.A6122


P126  A Rare Type of Synchronous Multiple Primary Lung Cancer: Staging and Treatment Dilemma/C. Ghattas, M. Hundal, M. Agustin, J. Unterborn, Boston, MA, p.A6125

P127  Lung Cancer Presenting as a PET Negative Cystic Lung Lesion: Colloid Adenocarcinoma of the Lung with Cystic Changes and Enteric Differentiation/P. Dammert, R. Sawhney, D. Brenner, Dover, DE, p.A6126

P128  A Case of FDG-PET Uptake Heterogeneity in a Pulmonary Neuroendocrine Tumor/D.G. Washburn, D. Chooljian, Loma Linda, CA, p.A6127

P129  A Case of Sarcomatoid Carcinoma of the Lung in a Young Female/D.G. Venkat, G. Lyles, R. Elliot, C. Teba, Cleveland, OH, p.A6128

Objectives
At the conclusion of this session, the participant will be able to:

- learn recent advances in our understanding of the host-microbe interactions on disease and maintenance of lung health;
- appreciate the vast emerging information on microbial communities in specific disease states and how the dynamic host-microbe interaction affects disease progression and treatment decisions, allowing attendees the ability to apply this knowledge to their own areas of interest;
- understand the functional significance of the lung microbiome and how these microbes can alter the lung environment in specific disease states. Attendees will be able to critically examine microbiome research and further investigate how these organisms can affect the lung milieu.

Understanding the composition of various aspects of what makes us who we are and how we develop disease is paramount to understanding disease pathogenesis, treatment responses, and personalizing medical care. The lung microbiome is not only an area of emerging research interest, but also one that has considerable clinical impact. Improved knowledge about microbial communities in the lung will ultimately contribute to development of innovative approaches and therapies to diagnose and treat chronic respiratory diseases. This workshop will highlight the latest findings on lung microbiome investigations in gut-lung interactions, disease states such as asthma and HIV, and the potential for novel therapeutic strategies.

Chairing:
M.R. Gingo, MD, MS, Pittsburgh, PA
H.L. Twigg, MD, Indianapolis, IN

11:45 Normal Lung Microbiome and Lung Pneumotypes
L. Segal, MD, New York, NY

12:07 Microbiome and Asthma
Y.J. Huang, MD, Ann Arbor, MI

12:29 Gut-Lung Microbial Interaction
S.V. Lynch, PhD, San Francisco, CA

12:51 Correlation of the Lung Microbiome with Metabolome in HIV
S.K. Cribbs, MD, MSc, Decatur, GA

Target Audience
Clinical and laboratory investigators and health care professionals interested in microbiome research and application of microbiome to patient care in the outpatient, hospital and/or critical care setting, including physicians, trainees, early career investigators.

The information contained in this program is up to date as of March 9, 2016.
For the most current session information, please visit the online program itinerary.
• become acquainted with and review different types of social media and web-based information sharing platforms;
• discover how patients and providers are using digital and social media to transform the way health care is delivered and taught worldwide;
• develop strategies to integrate social media into clinical practice, academic research, and education.

Social media and digital communication are dramatically changing the way patients and health care providers communicate and interact. Cell phones allow 63% of cell phone owners to use mobile internet where social media has empowered patients to expand their health care knowledge and participate in research. Social media provides practitioners with new ways to learn about real-time information about relevant topics, lead discussions, promote causes, and build relationships with patients. In this session, five social media experts will discuss how to navigate social media platforms and review how others are using digital tools and social media platforms to improve communication, increase knowledge acquisition, and improve patient care. With a combined following of over 13,000 Twitter followers, these four experts demonstrate how both junior and senior faculty, individuals with MDs and PhDs, can incorporate Twitter into their daily lives to discuss the results of studies, promote studies, ask questions, and network. This workshop includes a hands-on component as participants who sign up for a Twitter account prior to the workshop will have the opportunity to tweet questions to the speakers using a predesignated workshop hashtag. The speakers will answer questions at the end of the session and also tweet responses during the workshop. This interactive component will have two purposes. First, participants will get their questions answered. Secondly, participants will learn some of the basics of tweeting, retweeting, marking favorites, using hashtags and more. Finally, we will discuss how to leverage social media to improve the health education of students, patients, and providers.

Chairing: W.G. Carlos, MD, MSCR, Indianapolis, IN
A.C. Wu, MD, MPH, Boston, MA

11:45 To Thine Own Self Be True: What to Expect
W.G. Carlos, MD, MSCR, Indianapolis, IN

11:50 Much Ado About Something: Introduction to Social Media
B.E. Himes, PhD, Philadelphia, PA

12:05 The Taming of Social Media: #ATS2016
C.L. Carroll, MD, Hartford, CT

12:20 All of Health Care Research is a Stage: The Role of Social Media
A.C. Wu, MD, MPH, Boston, MA
N. Kaminski, MD, New Haven, CT

12:40 The Merchant of Medical Education
A.S. Clay, MD, Durham, NC

12:50 As You Tweet It: The Perils of a Social Media Presence
E. Skinner, PhD, PT, Melbourne, Australia

1:00 All’s Well That Ends Well
A.C. Wu, MD, MPH, Boston, MA
W.G. Carlos, MD, MSCR, Indianapolis, IN
ME3 PRACTICAL SKILLS FOR TEACHING IN SMALL GROUPS

Registration Fee: $70.00 (includes box lunch)

Attendance is limited. Pre-registration is required.

12:15 p.m. - 1:15 p.m. INTERCONTINENTAL HOTEL
InterContinental Ballroom A (Fifth Floor)

Target Audience
Providers, including physicians, nurses and advanced practice providers, within pulmonary, critical care and sleep medicine who seek to expand their teaching repertoire and, in particular, improve their skills in small group setting.

Objectives
At the conclusion of this session, the participant will be able to:

• describe strategies that can be employed before entering the classroom to ensure a productive small group learning environment;

• delineate an approach to manage challenging learners in the small group setting;

• describe the appropriate balance of speech between students and teacher and tools for managing the white board effectively during small group teaching.

The small group is one of the primary settings in which medical educators may be asked to interact with learners. While often a highly rewarding experience, it can be a challenging environment in which to teach due to the small number of learners, the emphasis on interaction and active participation and the less structured nature of the teaching encounter. This session will use an interactive format to impart strategies for managing these and other challenges and ensuring successful small group teaching encounters.

Speaker: A.M. Luks, MD, Seattle, WA

THEMEDIC EDUCATION SEMINAR

CME Credits Available: 1.0

TSS1 CONTEMPORARY CONTROVERSIES IN THE DIAGNOSIS AND MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS: A PRO/CON DEBATE

Registration Fee: $140.00 for full series (includes box lunch)

Attendance is limited. Pre-registration is required.

This is part 3 of a 3-part series. Those registering for this seminar series will be registered for all 3 parts. The program for the full series is included with the Sunday, May 15, 12:15 p.m. program.

Tuesday 12:15 p.m. - 1:15 p.m. INTERCONTINENTAL HOTEL
InterContinental Ballroom C (Fifth Floor)

PRO: Decline of 10% or Greater in FVC Should be Regarded as Treatment Failure in IPF

V. Cottin, MD, PhD, Lyon, France

CON: Decline of 10% or Greater in FVC Should be Regarded as Treatment Failure in IPF

P.W. Noble, MD, Los Angeles, CA

THEMEDIC SEMINAR SERIES

CME Credits Available: 1.0

TSS2 REDUCING HOSPITAL READMISSIONS

Registration Fee: $140.00 for full series (includes box lunch)

Attendance is limited. Pre-registration is required.

This is part 3 of a 3-part series. Those registering for this seminar series will be registered for all 3 parts. The program for the full series is included with the Sunday, May 15, 12:15 p.m. program.

Tuesday 12:15 p.m. - 1:15 p.m. INTERCONTINENTAL HOTEL
InterContinental Ballroom B (Fifth Floor)

PRO: Medications Are the Key to Reducing Readmissions in COPD

G.T. Ferguson, MD, Livonia, MI

CON: Medications Are the Key to Reducing Readmissions in COPD

R.A. Wise, MD, Baltimore, MD
CC4 SLEEP MEDICINE CLINICAL CORE CURRICULUM II

Adult Core Curriculum Working Group
2:15 p.m. - 4:15 p.m. MOSCONET CENTER
Gateway Ballroom 102-104 (South Building, Lower Level)

Target Audience
Internists and subspecialists in pulmonary, critical care, and sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification.

Objectives
At the conclusion of this session, the participant will be able to:
- remain current with medical knowledge relevant to their practice in pulmonary, critical care, and sleep medicine;
- evaluate their understanding of key skills and content areas in pulmonary, critical care and sleep medicine, as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of pulmonary, critical care, and sleep medicine.

The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice, as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

Chairing: J.S. Balachandran, MD, Chicago, IL
T.S. Wang, MD, Los Angeles, CA

2:15 Circadian Disorders: Overview of Biology
S.P. Shea, PhD, Portland, OR

2:45 Circadian Disorders: Shift Work, Advanced, Jet Lag
K.M. Sharkey, MD, PhD, Providence, RI

3:15 Parasomnias: REM
S. Pamidi, MD, Montreal, Canada

3:45 Parasomnias: NREM
A.V. Shelgikar, MD, Ann Arbor, MI

C82 INFECTION AND EXACERBATIONS: LEARNING ACROSS PULMONOLOGY

Assemblies on Clinical Problems; Microbiology, Tuberculosis and Pulmonary Infections
2:15 p.m. - 4:15 p.m. MOSCONET CENTER
Room 135 (North Building, Lower Level)

Target Audience
Clinicians and researchers interested in infection as applied to exacerbations and progression of chronic respiratory disease.

Objectives
At the conclusion of this session, the participant will be able to:
- describe new findings about infection as applied to disease progression and exacerbations across the major chronic respiratory diseases;
- understand novel strategies to manage infection in the context of chronic lung diseases;
- apply learning from different disease areas in relation to infection, exacerbations, and the healthy human airway microbiome.

We believe that clinicians and scientists in one discipline can learn much from the experience of those working in others, even within a specialty such as pulmonology. This symposium unites the areas of infection and clinical problems across disease areas, to discuss the role of infection and exacerbations in chronic respiratory disease. The Symposium will be of interest to a wide range of clinicians, scientists and industry professionals from across our Society.

Chairing: J.R. Hurst, MBChB, PhD, London, United Kingdom
K.L. Gates, MD, Chicago, IL
S. Sethi, MD, Buffalo, NY

2:15 The Healthy Human Airway Microbiome
R.P. Dickson, MD, Ann Arbor, MI
2:35  Infection and Exacerbations of Asthma  
Y.J. Huang, MD, Ann Arbor, MI

3:00  Respiratory Infection and COPD  
J.R. Hurst, MBChB, PhD, London, United Kingdom

3:25  Microbial Dysbiosis and Exacerbations of Bronchiectasis  
J.D. Chalmers, MBChB, PhD, Dundee, United Kingdom

3:50  The Role of Infection in the Progression of ILD  
H.R. Collard, MD, San Francisco, CA

There will be a 5-minute discussion after each talk.

---

C83  NEW CONCEPTS REGARDING LUNG TRANSPLANT ALLOGRAFT DYSFUNCTION

Assemblies on Clinical Problems; Allergy, Immunology and Inflammation
2:15 p.m. - 4:15 p.m.  
MOSCON Center  
Room 134 (North Building, Lower Level)

Target Audience
Physicians and surgeons, nurses, respiratory therapists, pharmacists, trainees, industry.

Objectives
At the conclusion of this session, the participant will be able to:

• gain an understanding of changes in the definitions of PDG, AMR, and CLAD;

• improve diagnostic approaches to lung allograft dysfunction that include HLA monitoring and pathology assessment;

• develop new strategies for diagnosing PGD, AMR, and CLAD.

Lung allograft dysfunction definitions and diagnoses have evolved over time. Speakers will address reassessment of primary graft dysfunction definition and grading, diagnosis of antibody mediated rejection of the lung allograft, the pros and cons of HLA antibody monitoring, and recognition of new subtypes of chronic lung allograft dysfunction.

Chairing:  D.J. Levine, MD, San Antonio, TX

2:15  Redefining Primary Graft Dysfunction  
J.D. Christie, MD, MSCE, Philadelphia, PA

2:39  Definition and Diagnosis of Lung Allograft Antibody Mediated Rejection  
R.D. Yusen, MD, MPH, St. Louis, MO

3:03  HLA Antibody Monitoring in Lung Transplantation  
D.B. Tyan, PhD, Palo Alto, CA

3:27  Chronic Lung Allograft Dysfunction (CLAD) Classification Update  
A.R. Glanville, MBBS, MD, Sydney, Australia

3:51  Pathology of Pulmonary Allograft Dysfunction  
G.J. Berry, MD, Palo Alto, CA

There will be a 5-minute discussion after each talk.

---

C84  THE NEW ICU RECOVERY TOOLKIT: 5 HAMMERS LOOKING FOR THE RIGHT NAIL

Assemblies on Critical Care; Behavioral Science and Health Services Research; Clinical Problems
2:15 p.m. - 4:15 p.m.  
MOSCON Center  
Room 3000/3002/3004 (West Building, Level 3)

Target Audience
Clinicians working in the ICU or dealing with patients in its aftermath.

Objectives
At the conclusion of this session, the participant will be able to:

• more appropriately evaluate proposals for what post-ICU interventions their program should find;

• recommend resources to their patients on ICU discharge more selectively and with increased effectiveness;

• understand the strengths and limitations of existing data on ICU recovery interventions.

While we all know that problems are common after the ICU, nobody really knows what to do to make those problems better. Some people are worried enough that they seem ready to jump on any potential solution. Five approaches seem to garner the most excitement. In this session, we step back from the individual solutions to ask emerging leaders in the field: Why should this approach work? What are the data so far? (And why might they have been negative despite the approach still being hopeful?) How do we pick the right patient and system for that intervention?

Chairing:  T.J. Iwashyna, MD, PhD, Ann Arbor, MI

C. Hodgson, PT, PhD, Melbourne, Australia

N. Pinto, MD, Chicago, IL

2:15  Fix the Brain  
J.C. Jackson, PsyD, Nashville, TN

2:35  Move the Body  
C. Hodgson, PT, PhD, Melbourne, Australia

2:55  Recruit the General Practitioners  
J. Gensichen, MD, MSc, MPH, Jena, Germany

3:15  Do it Ourselves (with a Post-ICU Clinic)  
E. Wilcox, MD, MPH, Toronto, Canada

3:35  Help Survivors Help Each Other  
M.E. Mikkelsen, MD, Philadelphia, PA

3:55  Not if, but Which: Selecting the Right Follow-Up for the Right Patient  
H.C. Prescott, MD, MA, Ann Arbor, MI
**BASIC • CLINICAL • TRANSLATIONAL**

**BASIC SCIENCE CORE**

C85  SCIENTIFIC BREAKTHROUGHS IN RNA BIOLOGY: WHAT’S NEW, EXCITING AND THERAPEUTIC!

2:15 p.m. - 4:15 p.m.  
MOSCONEN CENTER

Room 2009/2011 (West Building, Level 2)

Assemblies on Allergy, Immunology and Inflammation; Clinical Problems; Pulmonary Circulation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function; Thoracic Oncology

**Target Audience**

Providers and trainees interested in clinical, basic and translational lung physiology, development and disease and molecular biology.

**Objectives**

At the conclusion of this session, the participant will be able to:

- understand and improve knowledge of the role of Linc RNA in lung development;
- understand the potential use of MicroRNAs as therapeutic targets.

This session will focus on some of the recently identified and novel roles of RNA species in regulating lung development and in treating lung disease. Speakers will discuss the role of long non-coding RNA in lung development and the potential for micro RNA as therapies for lung cancer. Thus the session will span basic biology and development to cutting edge therapeutics. It will synergize with the 2016 Scientific Core theme. Presentations from experts in the field will be complemented by abstract related to the topic being discussed.

**Chairing:**  
N. Kaminski, MD, New Haven, CT
P.J. Sime, MD, Rochester, NY
D. Erle, MD, San Francisco, CA

2:15  Talk and Speaker to be Announced

2:45  FENDRR is an Epigenetic Regulator of Cellular Senescence in Pulmonary Fibroblasts  
K. Sakamoto, MD, New Haven, CT

3:00  Identification of Novel MicroRNA Targets in Neonatal Lungs of CTGF-Transgenic Mice  
C. Miranda, MD, Nashville, TN

3:15  Monocyte-Derived Alveolar Macrophages Contribute to the Development of Lung Fibrosis and Persist in the Lung Over the Lifespan  
A. Misharin, PhD, Evanston, IL

3:30  MicroRNA Regulation of Allergic Inflammation and Asthma  
K.M. Ansel, PhD, San Francisco, CA

*This session and the International Conference are supported by an educational grant from AstraZeneca LP.*

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

---

**BEHAVIORAL • CLINICAL**

**SCIENTIFIC SYMPOSIUM**

C86  SELF-MANAGEMENT AND RISK REDUCTION CHALLENGES IN VULNERABLE POPULATIONS

2:15 p.m. - 4:15 p.m.  
MOSCONEN CENTER

Room 307 (South Building, Esplanade Level)

Assemblies on Nursing; Behavioral Science and Health Services Research; Clinical Problems

**Target Audience**

Nurses, physicians, physician assistants, respiratory therapists, respiratory care practitioners, pharmacists, physical therapists involved in providing or directing care in underserved populations in developed countries.

**Objectives**

At the conclusion of this session, the participant will be able to:

- identify current disparities in health delivery in underserved, disenfranchised and vulnerable populations.
- foster health professional attitudes to promote and frame actions to reduce disparities through identification and management of key risk factors;
- look to the future of greater equity in the delivery and access to health care for all communities.

This session will identify vulnerable populations across the world and discuss the unique challenges of modifying risk in these groups.

**Chairing:**  
R.T. Disler, PhD, RN, Sydney, Australia
L.B. Gerald, MSPH, PhD, Tucson, AZ

2:15  A Patient’s Perspective  
D. Breslawsky, La Quinta, CA

2:20  Differences in Self-Management Preferences Increases Risk of Uncontrolled Asthma in Urban Black Adults  
M.R. George, AE-C, PhD, RN, New York, NY

2:40  Disparities in Respiratory Health in Indigenous Australians  
E. Tikoft, CNC, Alice Springs, Australia

3:00  Tuberculosis Among Homeless People in London, United Kingdom  
A. Story, PhD, RN, London, United Kingdom

3:20  Sexual Orientation, Respiratory Disease Risk Factors and Access to Health Care  
N. Sitkin, BS, New Haven, CT

3:40  Children with Asthma Living in Rural Settings  
L. Cicutto, PhD, RN, Denver, CO

4:00  Panel Discussion

*This session and the International Conference are supported by an educational grant from AstraZeneca LP.*

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
### BASIC
#### PUBLIC ADVISORY ROUNDTABLE

**C87 NEW INSIGHTS INTO THE GENETIC BASIS OF PEDIATRIC LUNG DISEASE**  
Public Advisory Roundtable; Assembly on Pediatrics  
2:15 p.m. - 4:15 p.m. MOSCONE CENTER  
Room 3007/3009 (West Building, Level 3)

**Target Audience**  
Physicians, basic and translational scientists, clinician-investigators, nurses, patients, and parents.

**Objectives**  
At the conclusion of this session, the participant will be able to:

- understand the genetics of interstitial lung diseases in neonates and children, and how this information is providing new insights into pathogenesis, improved diagnostic tests, and potential therapeutic targets;  
- appreciate the emerging genetics of primary ciliary dyskinesia and importance as a diagnostic approach, and understand genotype-phenotype relationships in this disease;  
- recognize the importance of genetics in the pathophysiology of cystic fibrosis lung disease, and how this knowledge has led to the development of precision medicine.

The emergence of powerful, more affordable genomic technologies have advanced our knowledge of lung diseases at a rapid pace, providing greater insights into the genetics and pathophysiology of pulmonary diseases in children and adults. The progress made in genomics will increasingly translate into improved patient health, with improved diagnostic tests and personalized therapies. This session will highlight the progress made in genomics of lung diseases, focusing on the genetic and cellular bases of four childhood diseases, which will serve as a roadmap for other conditions.

**Chairing:** G.R. Porta, BS, Mason, OH  
T.W. Ferkol, MD, St. Louis, MO

#### CLINICAL • TRANSLATIONAL
#### SCIENTIFIC SYMPOSIUM

**C88 VIRAL COMMUNITY-ACQUIRED PNEUMONIA**  
Assemblies on Microbiology, Tuberculosis and Pulmonary Infections; Clinical Problems; Critical Care; Pediatrics  
2:15 p.m. - 4:15 p.m. MOSCONE CENTER  
Room 3016/3018 (West Building, Level 3)

**Target Audience**  
Pulmonologists, critical care specialists, pediatricians, scientists, hospital administrators, medical providers, trainees, fellows, and advanced practice providers.

**Objectives**  
At the conclusion of this session, the participant will be able to:

- understand and learn about recent epidemiological data on respiratory viruses as etiology of community acquired pneumonia;  
- learn new diagnostics tools to detect viral infection, including understanding the utility of procalcitonin in clinical medicine;  
- understand how to integrate new information on respiratory viruses into clinical practice.

This session will provide the learner a comprehensive overview on how respiratory viruses contribute to current causes of community acquired pneumonia (CAP) and acute lung injuries in the ICU especially in the setting of the increasing use of genetic-based diagnostic approaches to detect viruses. Speakers in this symposium will highlight the current epidemiology of viral CAP and review the existing diagnostics of viral CAP including a pro/con debate on the role of procalcitonin in viral pneumonia. The role of viral pneumonia as cause of ARDS, and how RSV contributes to the disease in children and the elderly will be explored. And finally, given the increased use of molecular diagnostics to detect respiratory viruses, there will be a timely and careful discussion on what to do with a positive respiratory virus panel, including an analysis of whether rhinovirus ever causes pneumonia. These series of talks will update the audience on the recent information on viral pneumonia in clinical medicine with the goal of improving not only understanding of this topic but better implementation of current knowledge on viral pneumonia into practice.

**Chairing:** C.S. Dela Cruz, MD, PhD, New Haven, CT  
R.D. Shah, MD, Chicago, IL

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Chairing</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15</td>
<td>Annual PAR Awards</td>
<td>G.R. Porta, BS, Mason, OH T.W. Ferkol, MD, St. Louis, MO</td>
</tr>
<tr>
<td>2:30</td>
<td>Introduction</td>
<td>T.W. Ferkol, MD, St. Louis, MO</td>
</tr>
<tr>
<td>2:35</td>
<td>Neonatal Lung Diseases</td>
<td>F.S. Cole, MD, St. Louis, MO</td>
</tr>
<tr>
<td>3:00</td>
<td>Cystic Fibrosis</td>
<td>G.R. Cutting, MD, Baltimore, MD</td>
</tr>
<tr>
<td>3:25</td>
<td>Primary Ciliary Dyskinesia</td>
<td>M. Knowles, MD, Chapel Hill, NC</td>
</tr>
<tr>
<td>3:50</td>
<td>Childhood Interstitial Lung Diseases</td>
<td>L.M. Nogee, MD, Baltimore, MD</td>
</tr>
<tr>
<td>2:15</td>
<td>Epidemiology of Viral CAP</td>
<td>W. Self, MD, MPH, Nashville, TN</td>
</tr>
<tr>
<td>2:35</td>
<td>Pro/Con Debate: Procalcitonin for Viral Pneumonia (Con)</td>
<td>G.W. Waterer, MBBS, PhD, MBA, Perth, Australia</td>
</tr>
<tr>
<td>2:50</td>
<td>Pro/Con Debate: Procalcitonin for Viral Pneumonia (Pro)</td>
<td>T. File, MD, Akron, OH</td>
</tr>
<tr>
<td>3:05</td>
<td>RSV in the Young and Old Patients</td>
<td>J. Devincenzo, MD, Memphis, TN</td>
</tr>
<tr>
<td>3:25</td>
<td>Viral Pneumonia and ARDS: A Lethal Combination</td>
<td>J.E. Chastre, MD, Paris, France</td>
</tr>
<tr>
<td>3:45</td>
<td>What to Do with a Positive Respiratory Virus Panel (RVP)?</td>
<td>R.G. Wunderink, MD, Chicago, IL</td>
</tr>
<tr>
<td>4:05</td>
<td>Discussion</td>
<td>C.S. Dela Cruz, MD, PhD, New Haven, CT</td>
</tr>
</tbody>
</table>

*There will be a 5-minute discussion after each talk.*
C90  IT TAKES TWO TO TANGO: RIGHT AND LEFT VENTRICLE INTERACTIONS IN PULMONARY VASCULAR DISEASE

Assemblies on Pulmonary Circulation; Clinical Problems; Critical Care; Respiratory Cell and Molecular Biology
2:15 p.m. - 4:15 p.m.  MOSCONE CENTER
Room 3010/3012 (West Building, Level 3)

Target Audience
Basic, translational and clinical researchers interested in right and left ventricular function in health and disease.
Clinicians (especially internists, pulmonologists/intensivists, and cardiologists) interested in RV and LV function as well as in RV-directed therapies in pulmonary vascular diseases.

Objectives
At the conclusion of this session, the participant will be able to:
• understand differences and similarities between the RV and LV
• identify the interplay between RV and LV function in health and disease
• understand how research and therapeutic approaches to LV disease can be translated to RV disease

This session will focus on interactions between the right ventricle (RV) and left ventricle (LV) in pulmonary hypertension (PH). While it has long been known that the RV is at risk for failing in PH, little is known about how PH and RV dysfunction affect the LV. Similarly, the potential effect of PH-specific therapies on LV function has been poorly understood. Lastly, the exact mechanisms of RV dysfunction in LV disease are only incompletely understood. This session will address these knowledge gaps by providing novel evidence indicating that complex RV and LV interactions underlie the pathophysiology of decreased cardiac output in PH. Novel and emerging approaches in LV research and their implications for the study of the RV will be discussed.

Chairing:  T. Lahm, MD, Indianapolis, IN
C.E. Ventetuolo, MD, MS, Providence, RI
W.M. Kuebler, MD, PhD, Toronto, Canada

2:15  RV and LV: Twins or Strangers?
T. Lahm, MD, Indianapolis, IN

2:39  RV Involvement in LV Disease: What Makes the RV Fail in the Setting of LV Failure?
R. Tedford, MD, Baltimore, MD

3:03  Relax! RV and LV Diastology in Pulmonary Hypertension
F. De Man, PhD, Amsterdam, Netherlands

3:27  Left, Right, or Both? Is There a Role for Beta Blockers, ACE Inhibitors, or Neurohormonal Modulators in RV Failure?
C.E. Ventetuolo, MD, MS, Providence, RI

3:51  Lessons Learned from Left Heart Failure: Which Novel Approaches and Directions in LV Research Can Be Applied to the RV?
M. Bristow, MD, PhD, Denver, CO
C91  OPTIMIZING ICU ROUNDS: EVIDENCE-BASED APPROACHES FOR IMPROVING PATIENT CARE AND TEACHING

Assemblies on Behavioral Science and Health Services Research; Clinical Problems; Critical Care; Nursing; Sleep and Respiratory Neurobiology
2:15 p.m. - 4:15 p.m.  MOSCON CENTER
Room 3006/3008 (West Building, Level 3)

Target Audience
Families of critically ill patients, critical care providers, and those with clinical, teaching, research, or administrative responsibilities.

Objectives
At the conclusion of this session, the participant will be able to:

- become familiar with evidence-based interventions designed to improve patient care and teaching during ICU rounds;
- integrate effective strategies regarding communication with patients and their families while rounding in the ICU;
- understand the importance of incorporating multidisciplinary teams (nursing, respiratory therapists, pharmacists, and other providers) into ICU rounds.

The scientific symposium aims to provide the attendee with complementary tools leading to organized and efficient ICU rounds that also excel in delivering high value patient care and quality resident and fellow teaching. Attendees will gain a better understanding of the forces influencing change in the current rounding structure. Attendees will then learn about seminal work in the development and evaluation of interventions to improve the rounding structure. Gaps in our current understanding and areas for further exploration will be emphasized.

Chairing: A. Amaral, MD, Toronto, Canada
D.K. Costa, PhD, RN, Ann Arbor, MI

2:15  The Challenge of Competing Priorities in ICU Rounding in 2016
H.T. Stelfox, MD, PhD, Calgary, Canada

2:25  Pre-Rounding in the ICU: The Effects of Disrupted Patient and Provider Sleep on ICU Outcomes
B.K. Gehlbach, MD, Iowa City, IA

2:45  Beyond Pimping: Teaching Effectively While Rounding Efficiently
A.S. Clay, MD, Durham, NC

3:05  Choosing Wisely in the ICU: Integrating Principles of High Value Care into Rounds
J. Wagner, MD, MSHP, Philadelphia, PA

3:25  Speak Up: Incorporating Patients and Their Families into Daily Rounds
M. Happ, PhD, RN, Columbus, OH

3:45  Embracing Multidisciplinary Team Rounding in the ICU
D.K. Costa, PhD, RN, Ann Arbor, MI

4:05  Integrating the Evidence for Effective Rounding in the ICU
A. Amaral, MD, Toronto, Canada

*There will be a 5-minute discussion after each talk.*

C92  ATS CLINICAL PRACTICE GUIDELINES: CLINICAL PRACTICE ON THE CUTTING EDGE

Documents Development and Implementation Committee; International Conference Committee; Education Committee; Assemblies on Behavioral Science and Health Services Research; Critical Care; Microbiology, Tuberculosis and Pulmonary Infections; Nursing; Pediatrics; Pulmonary Circulation
2:15 p.m. - 4:15 p.m.  MOSCON CENTER
Room 2006/2008 (West Building, Level 2)

Target Audience
Physicians, nurses, respiratory therapists, and others who care for children who require flexible bronchoscopy or have pulmonary hypertension, or for adults or children with acute respiratory distress syndrome, hospital-acquired pneumonia, ventilator-associated pneumonia or tuberculosis.

Objectives
At the conclusion of this session, the participant will be able to:

- understand how evidence is used to inform diagnostic and treatment recommendations;
- apply clinical recommendations from recently published guidelines and technical standards in clinical practice, improving patient outcomes;
- obtain new strategies to manage exercise induced bronchoconstriction, pulmonary hypertension of sickle cell disease, Bronchiolitis Obliterans Syndrome.

This session is the second annual scientific symposium highlighting recently approved or published ATS evidence-based clinical practice guidelines and technical standards. This year’s symposium will highlight guidelines on hospital-acquired and ventilator-associated pneumonia, diagnosis of tuberculosis, treatment of tuberculosis, and pediatric pulmonary hypertension, as well as technical standards on pediatric flexible bronchoscopy. Speakers will describe the clinical recommendations formulated by the guideline panels, discuss the rationale for each, and critically review the evidence supporting each recommendation. Speakers will also describe how the guidelines provide the foundation for improving care. Speakers include the chairs of the panels that developed the guidelines and technical standards.

Chairing: K.C. Wilson, MD, New York, NY
C.C. Thomson, MD, MPH, Cambridge, MA

2:15  Implementation of ATS Clinical Practice Guidelines
C.C. Thomson, MD, MPH, Cambridge, MA

2:25  Strength of Recommendations and Quality of Evidence
K.C. Wilson, MD, New York, NY

2:35  Hospital Acquired Pneumonia/Ventilator-Associated Pneumonia Guidelines
M.L. Metersky, MD, Farmington, CT

2:50  Diagnosis of Tuberculosis Guidelines
D.M. Lewinsohn, MD, PhD, Portland, OR

3:05  Treatment of Drug Sensitive Tuberculosis Guidelines
P. Nahid, MD, MPH, San Francisco, CA
MINI SYMPOSIUM

C93 IMMUNE REGULATION OF INFECTION: BUILT IN PROTECTION
2:15 p.m. - 4:15 p.m. MOSCONE CENTER Room 3020/3022 (West Building, Level 3)

Chairing: M.A. Olman, MA MD, Cleveland, OH
J.K. Kolls, MD, Pittsburgh, PA
J.C. Deng, MD, Los Angeles, CA

Oral Presentations
3:30 Resistin-Like Molecules as Antiviral Mediators Against Influenza A Virus Infection/A.E. Samarasinghe, Y. Lin, K. LeMessurier, J.A. McCullers, Memphis, TN, p.A6135
4:00 IL-33 Protects Against Influenza-Associated Bacterial Super-Infection/K.M. Robinson, M.E. Clay, K. Ramanan, K.J. McHugh, J.F. Alcorn, Pittsburgh, PA, p.A6137
Chairing: H. Wunsch, MD, MSc, Toronto, Canada  
A.J. Walkey, MD, MSc, Boston, MA

Oral Presentations


3:45 Clinical and Sociocultural Factors Causing In-Hospital Medical Emergencies: A Qualitative Study/F. Elmufdi, S. Burton, N. Sahni, C. Weinert, Minneapolis, MN, p.A6152


MINI SYMPOSIUM

C96 GLOBAL PERSPECTIVES ON COPD BURDEN AND CARE DELIVERY

2:15 p.m. - 4:15 p.m.  
Room 130-132 (North Building, Lower Level)

Chairing: J. Bourbeau, MD, Montreal, Canada  
J.A. Ohar, MD, Winston-Salem, NC  
S.R. Russell, MD, Chicago, IL

Featured Speaker

2:15 COPD Care in the U.S.: A Special Report on Behalf of the Lancet Respiratory Medicine Commission/M.K. Han, MD, MS, Ann Arbor, MI,

Oral Presentations


MINI SYMPOSIUM

C97 COPD: EPIDEMIOLOGY, RISK FACTORS, AND BIOMARKERS

2:15 p.m. - 4:15 p.m.  
Room 2002/2004 (West Building, Level 2)

Chairing: R.G. Barr, MD, DrPH, New York, NY  
M.G. Foreman, MD, Atlanta, GA  
J.M. Brehm, MD, MPH, Pittsburgh, PA

Oral Presentations


2:30 Socioeconomic Status and Chronic Obstructive Pulmonary Disease Among Low- and Middle-Income Countries: The GRAND South Study/M. Grigsby, T. Siddharthan, W. Checkley, Baltimore, MD, p.A6162
2:30 Brain Derived Neurotrophic Factor Effects on Asthmatic Airways Smooth Muscle: A Profile of Epigenetic Regulation

2:45 Quantitative Assessment of Airway Remodeling with Birefringence Microscopy: Phenotyping Asthma

3:00 Heterogeneity of Airway Remodeling Contributes to Airway Hyperresponsiveness in Asthma
C.D. Pascoe, P.D. Pare, G.M. Donovan, Winnipeg, Canada, p.A6172

3:15 Novel Non-Linear Optical Imaging to Understand the Composition of Fibrilar Collagen and Elastin in Remodeled Asthmatic Airways

3:30 Mast Cell Trypsin Activates Matrix Metalloproteinase-1 Causing Matrix Remodelling, Airway Smooth Muscle Growth and Airway Obstruction During Asthma Exacerbations
S. Naveed, D.J. Jackson, D. Clements, C. Reynolds, D. Shaw, S.L. Johnston, S.R. Johnson, Nottingham, United Kingdom, p.A6174

3:45 Fibulin-1 Plays Critical Roles in the Pathogenesis of Pulmonary Diseases

4:00 MMP-13 is a Critical Driver of Lung Destruction in a Viral Exacerbation Model of COPD

MINI SYMPOSIUM

C99 BEYOND THE NATIONAL LUNG SCREENING TRIAL

2:15 p.m. - 4:15 p.m. MOSCONE CENTER

Room 306/308 (South Building, Esplanade Level)

Chairs: C.G. Slatore, MD, Portland, OR
M.K. Gould, MD, MS, Pasadena, CA

Featured Speaker

The Future of Lung Cancer Screening
R.S. Wiener, MD, MPH, Boston, MA

Oral Presentations

2:30 Using Electronic Health Records to Assess Eligibility for Lung Cancer Screening: An Examination of Capture and Reliability of Smoking History Data

2:45 Airflow Limitation and Lung Cancer Risk in a Large Prospective Screening Study (NLST-ACRIN Cohort Analysis, N=18, 714)
J.C. Hogg, T.-L. Hackett, Vancouver, Canada, p.A6178

MINI SYMPOSIUM

C98 AIRWAY REMODELING IN COPD AND ASTHMA

2:15 p.m. - 4:15 p.m. MOSCONE CENTER

Room 2016/2018 (West Building, Level 2)

Chairs: T. Hackett, PhD, Vancouver, Canada
H. Meurs, PhD, Groningen, Netherlands
A.L. James, MD, MBBS, PhD, Nedlands, Australia

Oral Presentations

2:15 Investigating the Features of Small Airway Obstruction in COPD: Obstructed Small Airways Are an Early Feature of Mild and Moderate Disease

2:30 Brain Derived Neurotrophic Factor Effects on Asthmatic Airways Smooth Muscle: A Profile of Epigenetic Regulation
3:00 Racial and Gender Disparities for Curative Lung Cancer Surgery in the National Lung Screening Trial/A.A. Balekian, Los Angeles, CA, p.A6179


C101 SARCOIDOSIS

2:15 p.m. - 4:15 p.m. MOSCONE CENTER

Room 3014 (West Building, Level 3)

Poster Viewing
2:15-3:00

Discussion
3:00-4:15

Chairing: M.A. Judson, MD, Albany, NY
A.S. Morgenthalau, MD, New York, NY
E.S. Chen, MD, Baltimore, MD


902 Comparison of Cardiac Magnetic Resonance Imaging and 18F-Fluoro-2-Deoxyglucose Positron Emission Tomography Used for Diagnostic Assessment of Cardiac Involvement in Suspected Cardiac Sarcoidosis Patients/V. Kouranos, R. Sharma, M. Kokosi, J. Baksi, S. Prasad, R. Khattar, K. Wechalekar, A.U. Wells, London, United Kingdom, p.A6185


904 The Impact of Age and Left Ventricular Function on Survival in Cardiac Sarcoidosis/Y. Zhou, H. Li, E. Lower, A. Costea, M. Attari, R.P. Baughman, Shanghai, China, p.A6187

905 Clinical Characteristics of Sarcoidosis Patients in America and China/Y. Zhou, H. Li, E. Lower, Shanghai, China, p.A6188


907 Stepwise Approach to Bronchoscopic Diagnosis of Sarcoidosis in Patients with Intrastrachial Adenopathy Employing EBUS, ROSE, and Histology Needles/C. Oberg, T.J. Harkin, New York, NY, p.A6190

908 The Complimentary Role of Transbronchial Cryobiopsy Versus Endobronchial Ultrasound (EBUS) for Diagnosing Pulmonary Sarcoidosis/S. Benzaquen, A. Aragaki, T.S. Sripasart, D. Tanase, G. Khana, M. Kirschner, R.P. Baughman, Cincinnati, UT, p.A6191


910 The Use of Registry for Sarcoidosis Associated Pulmonary Hypertension (ReSAP) in the Design of the Riociguat for Sarcoidosis Associated Pulmonary Hypertension (RasAP)/R.P. Baughman, S.D. Nathan, P. Engel, J.B. Barney, M.B. Scholand, D.A. Culver, Cincinnati, OH, p.A6193


913 Correlation Between Serum Biomarkers (ACE and Chitotriosidase) and 18F-FDG PET/CT -Follow Up Study/V. Mihailovic-Vucinic, S. Filipovic-Stepic, J.L. Videnovic Ivanov, M. Stjepanovic, B. Gvozdenovic, Z. Sumarac, Belgrade, Serbia, p.A6196


918 Sarcoïdosis Associated Pulmonary Hypertension Across the World: Results of a Registry of Sarcoïdosis Associated Pulmonary Hypertension (ReSAPH)/J.B. Barney, O.A. Shlobin, D.A. Culver, M.B. Scholand, E.M. Carmona, V. Kouroanos, E. Alhamad, F. Cordova, B. Van Den Blink, R.P. Baughman, Birmingham, AL, p.A6201


921 Proposal for a Neurosarcoïdosis Classification System/D. Perlman, A. Johnson, M. Bhargava, M. Fiol, Minneapolis, MN, p.A6204


923 Evolution of EBUS in the Diagnosis of Sarcoïdosis in Ireland/K. Sharma, A. O'Regan, Dublin, Ireland, p.A6206

924 Study on Staging of Sarcoïdosis Using the Combination of Chest Computed Tomography Scan and Radiography/Y. Zhang, D. Weng, Shanghai, China, p.A6207

925 The Importance of Diagnostic Metabolic Syndrome During the Course of Sarcoïdosis/J.L. Videnovic, Ivanov, V.V. Vucinic-Mihailovic, S. Filipovic-Stepic, D. Gostiljac, M. Stjepanovic, Belgrade, Serbia, p.A6208

C102 STRATEGIES TO UNDERSTAND ILD: REGISTRIES, PROGNOSTIC INDICATORS AND MORE

2:15 p.m. - 4:15 p.m. MOSCON E CENTER

Room 304 (South Building, Esplanade Level)

Poster Viewing 2:15-3:00
Discussion 3:00-4:15

Chairing: T. Corte, MD, PhD, Sydney, Australia
R. Bascom, MD, MPH, Hershey, PA
G.P. Cosgrove, MD, Denver, CO


204 Mortality and Comorbidity Among Danish ILD Patients 1998-2010/O. Hilberg, A. Lokke, C. Hyldgaard, E. Bendstrup, Aarhus, Denmark, p.A6212


208 Longitudinal Change in Lung Function in Patients with Non-Usual Interstitial Pneumonia Fibrotic Interstitial Lung Disease/S. Sheth, M. Xia, S. Murray, K.R. Flaherty, Ann Arbor, MI, p.A6216


217 Association Between Clinical Characteristics and In-Hospital Mortality in Patients with Idiopathic Pulmonary Fibrosis/J. Mooney, K. Raimundo, E. Chang, M.S. Broder, Stanford, CA, p.A6225

218 The Diagnosis of Idiopathic Non-Specific Interstitial Pneumonia (NSIP): Are International Multidisciplinary Team Discussions Feasible?/J. Moller, A. Altraja, T. Sjäheimer, L.B. Madsen, F. Rasmussen, E. Bendstrup, Aarhus, Denmark, p.A6226


222 Low Sensitivity of Trans Bronchial Biopsies in Diagnosing Interstitial Lung Diseases/W. Thijs, R. Snooks, S. Fletcher, Hoofddorp, Netherlands, p.A6230


225 Population Demographics of Patients Diagnosed with Interstitial Lung Disease with Major Complications: A Study Involving 14,015 Patients/R. Chandrashekar, M. Konda, Kalamazoo, MI, p.A6233

219 The Clinical Utility of a Genomic Diagnostic Test in Population Demographics of Patients Diagnosed with Optimal Low Dose Computed Tomography Parameters for Validation of a Method for Automatic Detection of Lung Low Sensitivity of Trans Bronchial Biopsies in Diagnosing Prevalence and Determinants of Frailty in Fibrotic Interstitial Lung Disease/ Association Between Clinical Characteristics and In-Hospital Mortality in Patients with Idiopathic Pulmonary Fibrosis/ The Diagnosis of Idiopathic Non-Specific Interstitial Pneumonia (NSIP): Are International Multidisciplinary Team Discussions Feasible?/ The Clinical Utility of a Genomic Diagnostic Test in Differentiating Usual Interstitial Pneumonia from Other Interstitial Lung Disease Pathologies/ Prevalence and Determinants of Frailty in Fibrotic Interstitial Lung Disease/ Quantitative CT Analysis of Honeycombing Area Predicts Survival in Idiopathic Pulmonary Fibrosis/ Low Sensitivity of Trans Bronchial Biopsies in Diagnosing Interstitial Lung Diseases/ Validation of a Method for Automatic Detection of Lung Sounds in Fibrotic Interstitial Lung Disease/ Optimal Low Dose Computed Tomography Parameters for Evaluating Interstitial Lung Disease: A Systematic Simulation Study/ Population Demographics of Patients Diagnosed with Interstitial Lung Disease with Major Complications: A Study Involving 14,015 Patients/
410 Effectiveness Using Higher ICS Dosage in Patients with COPD by Different Blood Eosinophilic Counts/S.-L. Cheng, Taipei, Taiwan, p.A6243


416 Blood Eosinophil Count to Predict Bronchial Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease (COPD)/F.N. Schleich, J.-L. Corhay, R. Louis, Liege, Belgium, p.A6249


418 Clinical Characteristics in COPD Patients with Eosinophilia/Peripherally Blood Eosinophil Levels at the Time of Blood Eosinophil Count to Predict Bronchial Eosinophilic Relationship Between Serum Eosinophil Levels and COPD Evaluating Serum Periostin as a Biomarker in Chronic Obstructive Pulmonary Disease During Stable State and Exacerbations/Is Inhaled Corticoid Steroid Therapy One of Keywords for Omalizumab in Patients with COPD and Atopic Phenotype: A Case Series/Evaluating Serum Periostin as a Biomarker in Chronic Obstructive Pulmonary Disease During Stable State and Exacerbations/Relationship Between Serum Eosinophil Levels and COPD Exacerbations/Blood Eosinophil Count to Predict Bronchial Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease (COPD)/Peripheral Blood Eosinophil Levels at the Time of Hospitalization in COPD Patients/Clinical Characteristics of Asthma—COPD Overlap Syndrome Patients with Fungal Sensitization/Effectiveness Using Higher ICS Dosage in Patients with COPD by Different Blood Eosinophilic Counts/Airway Hyperresponsiveness in COPD: A Marker of Asthma-COPD Overlap Syndrome?/Clinical Characteristics of Asthma—COPD Overlap Syndrome Patients with Fungal Sensitization/Serum Autoantibodies and Comorbid Collagen Vascular Diseases in Lymphangioleiomyomatosis/Evaluation of FEV1 Measurements in Patients with Lymphangioleiomyomatosis/Reproducibility of FEV1 Measurements in Patients with Lymphangioleiomyomatosis/Clinical Characteristics of Asthma—COPD Overlap Syndrome Patients with Fungal Sensitization/Clinical Characteristics of Asthma—COPD Overlap Syndrome Patients with Fungal Sensitization/Peripheral Blood Eosinophil Levels at the Time of Hospitalization in COPD Patients/Is Inhaled Corticoid Steroid Therapy One of Keywords for Omalizumab in Patients with COPD and Atopic Phenotype: A Case Series/effects of the new 9039 and 9040 Clinical Characteristics of Asthma—COPD Overlap Syndrome Patients with Fungal Sensitization/Peripheral Blood Eosinophil Levels at the Time of Hospitalization in COPD Patients/Is Inhaled Corticoid Steroid Therapy One of Keywords for Omalizumab in Patients with COPD and Atopic Phenotype: A Case Series/
110 Pulmonary Talcosis in a Community Based HIV Clinic/B.J. Saczek, Z. Belak, G. Kraushaar, M. Pandey, J. St Onge, Saskatoon, Canada, p.A6263


113 Organizing Pneumonia in Myelodysplastic Syndrome: A Case Series/S.S. Hoskote, V. Trivedi, B.S. Pannu, V.N. Iyer, Rochester, MN, p.A6266

114 Clinical Course of Patients with Bronchiolitis Obliterans After Hematologic Stem Cell Transplantation/M. Yomota, M. Nagamata, O. Tasuru, K. Ohashi, T. Hishima, Tokyo, Japan, p.A6267


117 Elements of Diagnosis in Hypersensitivity Pneumonitis/K. Ussavarungsi, A. Arcadu, T. Moua, Rochester, MN, p.A6270

118 Respiratory Manifestations of IgG4 Related Disease: A Retrospective Analysis of 97 Cases in a Single Chinese Hospital/H. Huang, X. Song, S. Li, K. Xu, Y. Bi, R. Feng, Z. Xu, Beijing, China, p.A6271


120 Inhalation Antigens Sensitisation in Czech Hypersensitivity Pneumonitis Patients/M. Sterclová, M. Paulík, J. Skibová, M. Vasakova, Prague, Czech Republic, p.A6273


710  Follistatin-like Protein-1 Limits Inflammation in Acute Lung Injury/B. Campfield, M. Majevski, T.J. Eddens, R. Hirsch, J.K. Kolls, Pittsburgh, PA, p.A6288


712  Human Neutrophil-derived Microvesicles Activate Pulmonary Endothelial Cells In an In Vitro Model of Pulmonary Microvascular Inflammation/N. Tilrapur, K.P. O’Dea, M. Takata, London, United Kingdom, p.A6290

713  Murine Bone Marrow-derived Mesenchymal Stem Cells Exert Anti-viral and Barrier-protective Properties in Influenza Virus Infection/L. Jankauskaite, C. Schmoldt, J. Wilhelm, J. Lohmeyer, S. Herold, Giessen, Germany, p.A6291

714  Human mesenchymal stem/stromal cells produce distinct M1- and M2-like macrophage phenotypes, enhance reactive oxygen species production and augment phagocytosis and bacterial killing in macrophage from healthy volunteers and from patients with severe sepsis/G.F. Curley, A. Volchuk, M. Jerkic, C. Masterson, K. Szaszi, J.G. Laffey, S. Grinstein, Toronto, Canada, p.A6292


721  R-107 Attenuates Severity of Acute Respiratory Distress Syndrome Induced by Chlorine Gas Inhalation in Ovine Model/S. Fukuda, K. Ihara, E. Lopez, R. Cox, G. Southan, A. Salzman, J.R. Salsbury, D.S. Prough, P. Enkhaataar, Galveston, TX, p.A6299


C106  WRECKING BALL: NEW PARADIGMS IN UNDERSTANDING AND TREATMENT OF PH

2:15 p.m. - 4:15 p.m.  MOSCONIE CENTER

Poster Viewing  2:15-3:00
Discussion  3:00-4:15

Chairing:  A.W. Trammell, MD, Atlanta, GA
P.J. Leary, MD, MS, Seattle, WA
P. Corris, MD, Newcastle, United Kingdom

1001  Benchmarking Quality Initiatives in the Care of Pulmonary Arterial Hypertension Patients at an Academic Medical Center/C. Khodani, H. Hedlin, A. Hsi, K. Kudelko, Y. Sung, V. De Jesus Perez, E.F. Spiekerkoetter, J. Liu, R.T. Zamanian, Stanford, CA, p.A6304


1010 Borderline Pulmonary Pressure Is Associated with Worse Survival in Patients at Risk for Pulmonary Hypertension - A Retrospective Single Center Analysis/P. Douschan, G. Kovacs, V. Foris, A. Avian, A. Olszewski, H. Olszewski, Graz, Austria, p.A6313


1012 The RESPITE Study: Riociguat in Patients with PAH and an Inadequate Response to Phosphodiesterase 5 Inhibitors/M.M. Hooper, P.A. Corris, J. Klinger, D. Langleben, R. Hartline, R.P. Frantz, M. Selez, D.R. Mink, H.W. Farber, St. Louis, MO, p.A6315


1015 Comparative Outcome of Incident Patients with Pulmonary Hypertension Due to Left Heart Disease According with the Haemodynamic Classification of the 2015 ESC-ERS Pulmonary Hypertension Guidelines/A. Rinaldi, M. Palazzini, C. Bachetti, E. Gotti, G. Mazzanti, F. Dardi, A. Albini, E. Monti, S. Fukui, D. Guarino, N. Galie, A. Manes, Bologna, Italy, p.A6318


<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
<th>Keywords</th>
</tr>
</thead>
<tbody>
<tr>
<td>605</td>
<td>Clinical Significance of Isolated Decrease in Single Breath Lung Volume-Total Lung Capacity Ratio (VA/TLC)/Y.-C. Huang, L.G. Que, Durham, NC</td>
<td>A.R. Eckert, Randwick, Australia, p.A6351</td>
<td></td>
<td></td>
</tr>
<tr>
<td>606</td>
<td>Automated Full-Range-Pressure-Volume Curves in Mice/A. Robichaud, L. Feredyoenndazd, N. Limjuyawong, R. Rabold, W. Mitzner, Montreal, Canada</td>
<td>P.A6352</td>
<td></td>
<td></td>
</tr>
<tr>
<td>609</td>
<td>No Effect of the Measurement Duration on the Within-Session Repeatability of Respiratory Impedance in Adults/E. Oosteen, K. Leemans, W. De Backer, K. De Soomer, Antwerp, Belgium</td>
<td>p.A6355</td>
<td></td>
<td></td>
</tr>
<tr>
<td>610</td>
<td>The Effect of Inspired Oxygen Fraction on Ventilation Heterogeneity in the Healthy Lung/S.R. Hopkins, A.R. Elliott, G.K. Prisk, C. Darquenne, La Jolla, CA</td>
<td>p.A6356</td>
<td></td>
<td></td>
</tr>
<tr>
<td>615</td>
<td>Lung Clearance Index (LCI) as a Potential Indicator of Pulmonary Impairment in Adolescent Idiopathic Sclerosis (AIS)/A.K.B. Blyme, B. Hanel, M. Gehrenchen, K.G. Nielsen, B. Dahl, Copenhagen, Denmark</td>
<td>p.A6361</td>
<td></td>
<td></td>
</tr>
<tr>
<td>616</td>
<td>Comparison of Two Methods for Automatic Multiple Breath Washout Phase-III Analysis/C. Buess, K. Nilsen, B.R. Thompson, Zurich, Switzerland</td>
<td>p.A6362</td>
<td></td>
<td></td>
</tr>
<tr>
<td>617</td>
<td>Normative Values for the Test of Incremental Respiratory Endurance (TIRESI)/L.P. Cahalin, C. Garcia, T.S. Denis, S. Colas-Salgado, B. Eisenhardt, M.F. Formiga, M. Cohen, Coral Gables, FL</td>
<td>p.A6363</td>
<td></td>
<td></td>
</tr>
<tr>
<td>618</td>
<td>Characterizing Respiratory Muscle Weakness in Amyotrophic Lateral Sclerosis with the Combined Use of Lung volumes, Spirometry and Muscle Strength/F.M. Pais, T. Tyner, V.V. Jain, J.J. Vempilly, Fresno, CA</td>
<td>p.A6364</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
806  Upper Airway Dynamics During Wakefulness and Natural Sleep in OSA Subjects: Preliminary Results/C. Darquenne, A.R. Elliott, R.J. Theilmann, E.T. Smales, P.N. DeYoung, A. Malhotra, La Jolla, CA, p.A6373

807  Negative Effort Dependence in a Starling Resistor Bench Model of the Upper Airway: Role of Surrounding Chamber Pressure/K. Kairaitis, C. Lambeth, B. Kolvevski, T. Amis, Westmead, Australia, p.A6374


810  Assessment Of Genioglossus Fatigue Using Different Contraction Tasks/W. Li, S. Gakwaya, F. Series, Quebec, Canada, p.A6377


815  Does Norepinephrine Participated in the Central Regulation of Genioglossus Movement During CIH in Rats?/L. Zhou, W. Wang, A. Wang, J. Kang, Shenyang, China, p.A6382

816  Desipramine Increases Genioglossus Activity and Reduces Upper Airway Collapsibility During Non-REM Sleep in Healthy Subjects/L. Taranto Montemurro, B.A. Edwards, S.A. Sands, M. Marques, D.J. Eckert, D.P. White, A. Wellman, Boston, MA, p.A6383

817  Effect of Sustained Hyperoxia on Breathing Stability in Older Adults During NREM Sleep/S. Pranathiageswaran, M.S. Badr, K. Ross, A. Ahmed, S. Chowdhuri, Detroit, MI, p.A6384


819  Mild Intermittent Hypoxia with Sustained Hypercapnia Reduces Therapeutic Continuous Positive Airway Pressure and Upper Airway Resistance in Participants with Obstructive Sleep Apnea/M. El-Chami, D. Shaheen, S. Sudan, H.-S. Lin, J. Mateika, Detroit, MI, p.A6386

820  Lowered Metabolic Rate as a Potential Avenue for Stabilizing Breathing in Obstructive Sleep Apnea: An Observational Study/C.M. De Melo, L. Taranto Montemurro, J. Butler, D.P. White, A. Wellman, S.A. Sands, Boston, MA, p.A6387


822  Neural Lineages That Control Inspiration In Intact Animals/N.A. Baertsch, J.-M. Ramirez, Seattle, WA, p.A6389


307 Prognostic Factors of Mortality After Palliative Procedures in Patients with Malignant Pleural Effusion/F.C. Abrao, M.C. De Oliveira, G.G. Viana, I.R. Abreu, Sao Paulo, Brazil, p.A6397


311 A Novel Combination of Calprotectin and CXCL12 for Predicting Malignancy in Patients with Exudative Pleural Effusion/D. Liu, J. Luo, C.-T. Li, Z.-A. Liang, Chengdu, China, p.A6402

312 Diagnosing Mesothelioma Via Its Effect on Chest Wall Mechanics/G. Elsehaie, A. Alverthe, P. Kumar, P. Rajesh, R. Steyn, M. Kalkat, E. Bishay, B. Naidu, Birmingham, United Kingdom, p.A6402


**PCC4  PEDIATRIC CLINICAL CORE CURRICULUM**

Pediatric Core Curriculum Working Group  
6:45 a.m. - 7:45 a.m.  
MOSCONETR CENTER  
Room 3007/3009 (West Building, Level 3)

**Target Audience**  
Pediatric pulmonary and critical care physicians who work in a clinical setting and are currently engaged in maintenance of certification.

**Objectives**  
At the conclusion of this session, the participant will be able to:
- remain current with medical knowledge relevant to their practice in pediatric pulmonology;
- evaluate their understanding of key skills and content areas in pediatric pulmonology as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The Pediatric Core Curriculum symposia promote lifelong learning and the enhancement of the clinical judgment and skills essential for practicing pediatricians. The symposia will address topics that have been identified by an ATS pediatric working group, which is comprised of members of the ATS Education Committee and the International Conference Committee, who have identified important areas within pediatric medicine (including vasculitic pulmonary diseases, lung defense mechanism, congenital abnormalities of the airways, and respiratory failure). Attendees will increase their medical knowledge as a result of attending this symposium, and this will be measured by a comparison of pre-test vs. post-test results on the corresponding maintenance of certification module. The ATS Pediatric Core Curriculum will focus on a 3-year content cycle of key medical content in the area of pediatric medicine.

**Chairing:**  
D.M. Boyer, MD, Boston, MA  
P.E. Moore, MD, Nashville, TN

### Clinical Symposium  
**6:45   Acute Respiratory Failure**  
J. Rettig, MD, Boston, MA

**7:15   Chronic Respiratory Failure**  
C.D. Baker, MD, Aurora, CO

---

**SUNRISE SEMINARS**  
CME Credits Available: 1.0

**Registration Fee:**  
$65.00 (includes continental breakfast.)  
Attendance is limited. Pre-registration is required.

**6:45 a.m. - 7:45 a.m.  
INTERCONTINENTAL HOTEL**

- **SS301**  
  **ROLE OF THE MICROENVIRONMENT IN CELL FATE: MACROPHAGES MEET MECHANOBIOLOGY**  
  R.G. Scheraga, MD, Cleveland, OH  
  Union Square (Third Floor)

- **SS302**  
  **HEME OXYGENASE ACTIVITY IN PULMONARY DISEASE MEASURED BY TRANSCUTANEOUS CARBOXYHEMOGLOBIN**  
  L.E. Kurlandsky, MD, Fayetteville, NY  
  SoMa (Third Floor)

- **SS303**  
  **CHRONIC LUNG DISEASE IN HIV**  
  J. Leung, MD, Vancouver, Canada  
  Mission (Third Floor)

- **SS304**  
  **DIFFUSE CYSTIC LUNG DISEASE**  
  N. Gupta, MD, Cincinnati, OH  
  Marina (Third Floor)

- **SS305**  
  **APPROACH TO PATIENTS WITHOUT DEFINITE UIP ON HRCT: LESSONS LEARNED FROM DIFFICULT CASES**  
  M. Porteous, MD, Philadelphia, PA  
  Grand Ballroom C (Third Floor)

- **SS306**  
  **ADVANCES IN NON-CF BRONCHIECTASIS THROUGH THE LENS OF PRIMARY CILIARY DYSKINESIA**  
  M. Prickett, MD, MPH, Chicago, IL  
  Grand Ballroom B (Third Floor)

- **SS307**  
  **COPD PHENOTYPES: DO THEY MAKE A DIFFERENCE?**  
  T. Beiko, Dr., Charleston, SC  
  Grand Ballroom A (Third Floor)

- **SS308**  
  **EVALUATION AND MANAGEMENT OF PATIENTS WITH CTD-ILD FOR LUNG TRANSPLANTATION**  
  R.J. Shah, MD, San Francisco, CA  
  Twin Peaks (Fourth Floor)

- **SS309**  
  **A SECOND LUNG TRANSPLANT: WHO AND UNDER WHAT CIRCUMSTANCES?**  
  A.L. Gray, MD, Durham, NC  
  Telegraph Hill (Fourth Floor)

- **SS310**  
  **RACIAL AND ETHNIC HEALTH DISPARITIES IN SEPSIS**  
  G.J. Soto, MD, Bronx, NY  
  Potrero Hill (Fourth Floor)

- **SS311**  
  **VITAMIN D AND ASTHMA**  
  J.M. Brehm, MD, MPH, Pittsburgh, PA  
  Nob Hill (Fourth Floor)
SS312 TREATMENT OF DRUG RESISTANT INFECTIONS IN INDIVIDUALS WITH BRONCHIECTASIS
E.C. Dasenbrook, MD, Cleveland, OH
Laurel Hill (Fourth Floor)

SS313 UNTANGLING PATIENT REPORTED OUTCOME AND EXPERIENCE MEASURES
M. Hodson, MSC, RN, London, United Kingdom
J. Yorke, PhD, RN, Manchester, United Kingdom
Cathedral Hill (Fourth Floor)

SS314 NON-INVASIVE POSITIVE PRESSURE VENTILATION FOR THE PEDIATRIC PULMONOLOGIST
R. Amin, MD, Toronto, Canada
Sutter (Fifth Floor)

SS315 ACUTE RIGHT HEART FAILURE: THE PRACTICAL NUTS AND BOLTS OF ASSESSMENT AND MANAGEMENT
W.H. Fares, MD, MSc, New Haven, CT
Stockton (Fifth Floor)

SS316 “MIND THE GAP”: USE OF NATIVE TISSUE SLICES AND DECELLULARIZED HUMAN MATRICES AS EX VIVO MODELS OF REGENERATION AND DISEASE
D.E. Wagner, PhD, Munich, Germany
Howard (Fifth Floor)

SS317 THE MODERN APPROACH TO THE MANAGEMENT OF PNEUMOTHORAX AND AIR LEAK
A. Chopra, MD, Albany, NY
Fremont (Fifth Floor)

SS318 EXERCISE TRAINING IN SLEEP DISORDERED BREATHING: TIME TO MAKE A NEW FRIEND
M. Macrea, MD, MPH, PhD, Salem, VA
InterContinental Ballroom C (Fifth Floor)

SS319 MANAGEMENT OF MALIGNANT PLEURAL EFFUSION BY THE PULMONOLOGIST: UPDATES
S. Shojaee, MD, Richmond, VA
A.C. Argento, MD, Chicago, IL
InterContinental Ballroom B (Fifth Floor)

FACULTY DEVELOPMENT SEMINAR

FD3 THE ROADMAP TO SUCCESS IN EARLY ACADEMIC CAREER DEVELOPMENT: YOUR FIRST FIVE YEARS

Pre-registration is required. There is no additional fee.
Attendance is limited.

6:45 a.m. - 7:45 a.m.
InterContinental Ballroom A (Fifth Floor)

Target Audience
Early career clinical and/or research faculty, clinical and post doctoral fellows, graduate students, residents, nurses, and allied health professionals already involved in or seeking a career in academic pulmonary, allergy, critical care, and/or sleep medicine.

Objectives
At the conclusion of this session, the participant will be able to:
• able to identify components necessary for success in their career path;
• understand how to balance various expectations and interests needed for career advancement;
• gain strategies to protect their time from competing obligations.

As a junior faculty member, are you confronted with numerous, potentially competing, obligations on your time and effort? The first five years of your faculty appointment is crucial for establishing the proper trajectory of your career. This seminar will provide valuable insights and strategies on balancing professional activities while developing a successful academic career.

Chairing: J.C. Horowitz, MD, Ann Arbor, MI
Speakers: L.E. Crotty Alexander, MD, San Diego, CA
M. Peters-Golden, MD, Ann Arbor, MI
J.B. Richards, MD, MA, Charleston, SC
M. Ballinger, PhD, Columbus, OH
C.M. Waters, PhD, Memphis, TN

The ATS Keynote Series provides state of the art lectures on selected topics in an unopposed format to showcase major discoveries in pulmonary, critical care and sleep medicine. The speakers have been chosen by input from the members and various ATS committees with consensus built via the ATS executive committee.

Two sessions are presented each morning during the conference. Below are the topics for the Wednesday, May 18th series.

K7 BIOMARKERS FOR PRECISION MEDICINE IN ASTHMA
8:00 a.m. - 8:45 a.m.
Room 134 (North Building, Lower Level)

Speaker: Serpil C. Erzurum, MD, Cleveland, OH
This session and the International Conference are supported by an educational grant from AstraZeneca LP.
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

K8 ARDS: MECHANISMS AND PROFESSIONAL SOCIETIES
8:00 a.m. - 8:45 a.m.
Room 135 (North Building, Lower Level)

Speaker: Brian P. Kavanagh, MD, Toronto, Canada
D1  CLINICAL YEAR IN REVIEW 4

9:00 a.m. - 11:00 a.m.  MOSCONE CENTER
Gateway Ballroom 102-104 (South Building, Lower Level)

Target Audience
Providers including physicians, nurses, respiratory therapists, nurse practitioners, physician assistants. Trainees including residents and fellows; clinical researchers.

Objectives
At the conclusion of this session, the participant will be able to:
• apply new clinical research knowledge to clinical practice;
• learn new findings about key conditions in pulmonary, critical care and sleep;
• have new strategies to manage the care of common conditions in pulmonary, critical care, and sleep.

The annual Clinical Year in Review symposia topic reviews of the key clinical research publications over the last year. Each speaker is asked to review the 5-7 most important and influential publications on their topic in the prior year.

Chairing: J.L. Taylor-Cousar, MD, Denver, CO
D.J. Lederer, MD, MS, New York, NY
D.W. Ford, MD, MSCR, Charleston, SC

9:00  Asthma
A. Sood, MD, MPH, Albuquerque, NM

9:30  Medical Education
J.W. McCallister, MD, Columbus, OH

10:00  Pulmonary Vascular Disease
H.J. Bogaard, MD, PhD, Amsterdam, Netherlands

10:30  ILD
D.J. Lederer, MD, MS, New York, NY

This session and the International Conference are supported by educational grants from AstraZeneca LP, Boehringer Ingelheim Pharmaceuticals, Inc. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

D2  WHAT, WHEN, WHERE: CLEARING THE AIR ON STEM CELL THERAPIES IN PULMONARY DISEASES

9:00 a.m. - 11:00 a.m.  MOSCONE CENTER
Room 135 (North Building, Lower Level)

Target Audience
Providers of lung health; patients victimized by biotourism; researchers; clinicians.

Objectives
At the conclusion of this session, the participant will be able to:
• understand the terminology surrounding stem cell therapies;
• recognize the lack of efficacy data surrounding cell based therapies at this time;
• discuss future areas of investigation and application of cell based therapies in lung disease.

This session will highlight seminal basic science information and recent advances in the application of cell based therapeutics to the treatment of lung disease (IPF, COPD, and ARDS). For patients and physicians who search for treatments for incurable lung diseases, stem cell therapies have drawn increasing attention. Unfortunately, patients become victims of biotourism. Several well designed and completed phase 1 clinical trials have now been completed with mesenchymal stem cells (MSCs) that demonstrate patient safety. The results of these trials will be reviewed as they are paving the way for productive phase 2 and 3 studies and ultimately new therapeutic modalities. Controversies and cautions will be addressed.

Chairing: M. Glassberg, MD, Miami, FL
V. Lama, MD, MS, Ann Arbor, MI
M. Rojas, MD, Pittsburgh, PA

9:00  Introduction and Overview
M. Glassberg, MD, Miami, FL

9:05  Vocabulary Check: Let’s All Talk the Same Language
V. Lama, MD, MS, Ann Arbor, MI

9:25  The Journey from Bench to Bedside: Deciphering How MSCs Work
D.J. Weiss, MD, PhD, Burlington, VT
B. Thebaud, MD, PhD, Ottawa, Canada

9:45  Moving Stem Cell Therapies to Patients with IPF
M. Glassberg, MD, Miami, FL

10:05  The Stem Cells for ARDS Treatment Trial: What Lies Ahead
M.A. Matthay, MD, San Francisco, CA

10:25  A Note of Caution in Stem Cell Therapies: Separating the Wheat from the Chaff
Speaker To Be Announced

10:45  Panel Discussion: Conclusions and Questions
V. Lama, MD, MS, Ann Arbor, MI

D3  TRANSLATIONAL ADVANCES IN PLEURAL DISEASES: WHAT CLINICIANS NEED TO KNOW

Assembly on Clinical Problems
9:00 a.m. - 11:00 a.m.  MOSCONE CENTER
Room 134 (North Building, Lower Level)

Target Audience
Clinicians and allied health professionals with clinical and research responsibilities in respiratory diseases; especially chest physicians, interventional pulmonologists, respiratory nurses, thoracic surgeons, internists, general physicians and junior.

Objectives
At the conclusion of this session, the participant will be able to:
• apply new clinical research knowledge to clinical practice;
• learn new findings about key conditions in pulmonary, critical care and sleep;
• have new strategies to manage the care of common conditions in pulmonary, critical care, and sleep.

This session will highlight seminal basic science information and recent advances in the application of cell based therapeutics to the treatment of lung disease (IPF, COPD, and ARDS). For patients and physicians who search for treatments for incurable lung diseases, stem cell therapies have drawn increasing attention. Unfortunately, patients become victims of biotourism. Several well designed and completed phase 1 clinical trials have now been completed with mesenchymal stem cells (MSCs) that demonstrate patient safety. The results of these trials will be reviewed as they are paving the way for productive phase 2 and 3 studies and ultimately new therapeutic modalities. Controversies and cautions will be addressed.

Chairing: M. Glassberg, MD, Miami, FL
V. Lama, MD, MS, Ann Arbor, MI
M. Rojas, MD, Pittsburgh, PA
Objectives
At the conclusion of this session, the participant will be able to:

• understand and learn the rationale of gene therapy, stem cell treatment and phenotyping of malignant effusion patients;
• describe the interactions between bacteria and the pleura, and its therapeutic potentials;
• learn new technologies being applied in pleural diagnosis and management.

This symposium will provide learners with up to date information and evidence on several exciting developments in translational research of pleural diseases which have impacted clinical care, or are likely to do so in the future. The session will provide leading translational research on pleural disease, including pleural malignancy and infection, and novel investigative technologies. The session will cover cutting edge approaches of using stem cell therapy in the pleura and the role of mesothelial cells in lung fibrosis.

Chairing:
N.M. Rahman, MSc, PhD, Oxford, United Kingdom
M.M. Wahidi, MD, Durham, NC

9:00 Gene Therapy for Pleural Cancers: Hurdles and Progresses
D.H. Sterman, MD, New York, NY

9:20 Phenotyping Malignant Pleural Effusions: Why and What for?
N.A. Maskell, MD, Bristol, United Kingdom

9:40 Stem Cell Therapy in Pleural Diseases: Fact or Fiction
S. Janes, MD, PhD, London, United Kingdom

10:00 The Pleura: A New Co-Conspirator in Pulmonary Fibrosis
V.B. Antony, MD, Birmingham, AL

10:20 Bacteria, Fibrinolytics and Pleural Space: Exciting New Lessons
Y.C.G. Lee, MBChB, PhD, Perth, Australia

10:40 Novel Interventional Technologies in Pleural Diseases
D.J. Feller-Kopman, MD, Baltimore, MD

Objectives
At the conclusion of this session, the participant will be able to:

• describe how real-time analytics can be leveraged to improve critical care delivery;
• understand how a re-engineered electronic health records system will improve the delivery of critical care.

Silicon Valley companies like Google, Apple, and Uber create simple tech solutions to enhance our everyday lives. These innovations also have pertinent applications in critical care, and this session will detail technological solutions that can enhance clinical research and care for patients with critical illness. Examples highlighted in the session will include developing apps to improve patient care tasks, crowd-sourcing research communities for solutions to complex problems in critical care, gathering data from wearable devices to monitor critical illness, utilizing real-time analytics to identify critical illness and improve hospital efficiency, and re-engineering EHR’s to improve bedside critical care.

Chairing:
M.W. Sjoding, MD, Ann Arbor, MI
M.M. Churpek, MD, MPH, PhD, Chicago, IL
C.E. Cox, MD, MPH, Durham, NC

9:00 Learning from Silicon Valley: Safer, Efficient, Patient-Centered Care with Technology
M.W. Sjoding, MD, Ann Arbor, MI

9:10 Mapping Real-Time Alerts to Identify Critical Illness
M.M. Churpek, MD, MPH, PhD, Chicago, IL

9:28 Crowdsourcing Research Communities to Solve Problems in Critical Care
T.J. Pollard, PhD, Cambridge, MA

9:46 Building EHR-Integrated Apps for More “Meaningful” Use in Critical Care
C.E. Cox, MD, MPH, Durham, NC

10:04 Next Generation Wearable Technologies for Monitoring Critical Illness
G.S. Martin, MD, MSc, Atlanta, GA

10:22 Bringing the “Sharing Economy” to Hospitals
V. Liu, MD, MS, Oakland, CA

10:40 Engineering Electronic Health Record Systems of the Future
M.N. Gong, MD, MS, Bronx, NY

Target Audience
Practicing clinicians who care for critically ill adults, researchers studying critical illness, health system administrators and trainees.

Objectives
At the conclusion of this session, the participant will be able to:

• understand how apps may be developed and used to improve clinical research and bedside critical care;
Objectives
At the conclusion of this session, the participant will be able to:

• explore issues related to respiratory symptom management and respiratory symptom clusters with a focus on cough;
• identify a theoretical understanding of the relationship of psychologic symptoms and chronic cough and to understand the role of speech pathology in the management of chronic cough;
• become aware of recent finding of systematic reviews and guidelines related to the diagnosis and management of chronic refractory cough.

This session will use interprofessional inquiry and recent findings from the literature to broaden the attendees understanding of the symptom of chronic cough and refractory chronic cough and its management in 2016.

Chairing:
P.M. Meek, RN, PhD, Denver, CO
A.M. Russell, MSc, London, United Kingdom

9:00 Reflections from Symptom Management
P.M. Meek, RN, PhD, Denver, CO

9:15 Respiratory Symptom Clusters
J. Yorke, PhD, RN, Manchester, United Kingdom

9:30 Examining Change in Symptoms of Depression, Anxiety, and Stress in Adults After Treatment of Chronic Cough
C.L. French, PhD, RN, Worcester, MA

9:45 Update Refractory Chronic Cough and Management
P.G. Gibson, MBBS, Newcastle, Australia

10:00 The Role of the Speech Pathologist and Speech Pathology in the Management of Chronic Cough
A.E. Vertigan, PhD, MBA, BAppSc(Sp.Path), Newcastle, Australia

10:15 Is the Refractory Cough of a Psychogenic Nature a Habit or an Undiagnosed Tic Cough?
R.S. Irwin, MD, Worcester, MA

10:30 Panel Discussion

There will be a 5-minute discussion after each talk.

D6 CANNABIS, CANNABIMIMETICS, AND OPIATES IN SLEEP AND BREATHING

Assemblies on Sleep and Respiratory Neurobiology; Behavioral Science and Health Services Research; Pediatrics

9:00 a.m. - 11:00 a.m. MOSCONE CENTER Room 2001/2003 (West Building, Level 2)

Target Audience
Pulmonologists, pediatricians, respiratory therapists, nurses practitioners, sleep medicine research scientists, epidemiologists, public health providers and health services researchers.

Objectives
At the conclusion of this session, the participant will be able to:

• discuss neurodevelopmental and respiratory effects of cannabis use in adolescents and young adults;
• learn emerging data on effects of cannabis on sleep and novel therapeutic applications of cannabimetic drugs in sleep related breathing;
• review effects of opioids on sleep related breathing and discuss ampakines; a novel therapy for opioid induced respiratory depression.

Legalization of cannabis in the U.S. and other countries has led to increasing medicinal and recreational use of cannabis. This symposium will describe the known effects of cannabis on neurodevelopment of adolescents and its effects on sleep. Current and potential therapeutic uses of cannabis and cannabimimetics in sleep and breathing disorders will be discussed. Acute and chronic use of opioids in hospitalized patients, perioperative settings and for opioid use disorders is increasingly prevalent. Effects of opioids on sleep related breathing and novel preclinical pharmacologic interventions to reverse opioid effects on breathing will be reviewed.

Chairing:
B. Prasad, MD, MS, Chicago, IL
L. Kheirandish-Gozal, MD, MSc, Chicago, IL

9:00 A Patient’s Perspective
J. Jorgensen, Vista, CA

9:05 Opioid-Induced Sleep Apnea: Precursor to Periodicity
S. Chowdhuri, MD, MS, Detroit, MI

9:25 Ampakine Therapy for Alleviating Opioid-Induced Respiratory Depression
J.J. Greer, PhD, Edmonton, Canada

9:50 Cannabis and Human Sleep: What Have We Learned So Far?
K. Babson, PhD, Menlo Park, CA

10:10 Neurodevelopmental and Respiratory Effects of Cannabis in Adolescents and Adults
R. Bhattacharjee, MD, San Diego, CA

10:25 Cannabinoids: Novel Translational Potential for Sleep Apnea Therapy?
D.W. Carley, PhD, Chicago, IL

D7 EXPLOITING GPCRS FOR NEW AND IMPROVED ASTHMA MEDICINE

Assemblies on Respiratory Structure and Function; Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology

9:00 a.m. - 11:00 a.m. MOSCONE CENTER Room 2002/2004 (West Building, Level 2)

Target Audience
Basic, translational and clinical scientists who wish to learn about the exciting discoveries of new targets for asthma therapy, and how these targets are being validated both in vitro and in vivo.

Objectives
At the conclusion of this session, the participant will be able to:
• learn new findings about the identification and validation of new asthma drug targets;
• screen drug candidates that improve lung function;
• gain knowledge on GPCR signaling in the lung.

There is still an urgent need to develop new and improved therapy for asthma. G-protein coupled receptors (GPCRs) are the targets of more than 50% of all known pharmaceuticals. Current mainstay asthma therapies including beta-agonists, anticholinergics, and leukotriene inhibitors, all directly target GPCRs. Recent studies have identified several GPCRs and many of them unexpectedly as new potential targets for asthma therapy. In this session, we will bring a high-caliber list of experts to discuss the latest developments in this exciting area that promises to change the face of asthma medicine in the coming decades.

Chairing: Q. Lu, PhD, Boston, MA
R. Penn, PhD, Philadelphia, PA

9:00 Targeting Calcium Sensing Receptor (CaSR) in Allergic Asthma
D. Riccardi, PhD, Cardiff, United Kingdom

9:20 Function and Targeting of Proton-Sensing GPCR OGR1 in ASM
R. Penn, PhD, Philadelphia, PA

9:40 Bitter Taste Receptors as Targets for Novel Bronchodilators
D.A. Deshpande, PhD, Philadelphia, PA

10:00 Screening GPCR Targets with Force
R. Krishnan, PhD, Boston, MA

10:20 Structural Insights into β2-Adrenergic Receptor Signaling
R. Sunahara, PhD, La Jolla, CA

10:40 Cholecystokinin (CCK) and Its Receptor CCKAR as Novel Therapeutic Targets for Asthma
Q. Lu, PhD, Boston, MA

This session and the International Conference are supported by an educational grant from AstraZeneca LP.

All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.
D9 CRACKING THE CELL CODE: UNDERSTANDING THE CONTRIBUTION OF CELLS TO PULMONARY VASCULAR DISEASES

Assemblies on Pulmonary Circulation; Respiratory Cell and Molecular Biology
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 3020/3022 (West Building, Level 3)

Target Audience
Pulmonary and critical care physicians, nurse practitioners, pulmonary vascular biologists and trainees who conduct research in diseases of the pulmonary circulation.

Objectives
At the conclusion of this session, the participant will be able to:
• review the state of the art knowledge regarding normal development of the pulmonary circulation and how these cellular mechanisms are recapitulated in adult disease;
• discuss how interactions between components of the vessel wall (endothelial cells, pericytes, fibroblasts and smooth muscle cells) serve to respond to vascular injury and how their dysregulation can result in disease;
• establish relevance of abnormal cell to cell interactions in the setting of specific pulmonary vascular diseases such as pulmonary arterial hypertension, lung fibrosis and ARDS.

As a vital part of the cardiovascular system, the pulmonary circulation is dependent on its cell components to coordinate adequate responses in both health and disease. While much focus has been devoted to understanding the work of individual cells, limited attention has been given to how these cells interact with each other to preserve the balance required for adequate gas exchange. This symposium will summarize seminal findings regarding how cell behavior is organized during development and how these actions are recapitulated as part of the pulmonary vasculature’s efforts to preserve homeostasis in response to injury and disease.

Chairing: V. De Jesus Perez, MD, Stanford, CA
K. Birukov, MD, PhD, Chicago, IL
C. Guignabert, PhD, Le Plessis Robinson, France

9:00 Development of the Pulmonary Circulation: A Blueprint for Understanding Pulmonary Vascular Diseases
D. Greif, MD, Guilford, CT

9:20 Pulmonary Angiogenesis in Health and Disease
V. De Jesus Perez, MD, Stanford, CA

9:40 Endothelial-Pericyte Interactions in Health and Disease
C. Guignabert, PhD, Le Plessis Robinson, France

10:00 Exosomes, Microparticles in Cell-Cell Communication Within the Pulmonary Circulation
J.R. Klinger, MD, Providence, RI

10:20 The Pulmonary Circulation Under Attack: Endothelial-Leukocyte Communication During Lung Injury
K. Birukov, MD, PhD, Chicago, IL

10:40 Epithelial-Mesenchymal Crosstalk During Lung Tissue Remodeling
O. Eickelberg, MD, Munchen, Germany

D10 NEW CONCEPTS IN TB IMMUNITY AND TARGETS FOR TREATMENT

Assemblies on Allergy, Immunology and Inflammation; Microbiology, Tuberculosis and Pulmonary Infections
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 3016/3018 (West Building, Level 3)

Target Audience
Providers of care for tuberculosis, those with clinical and research interests in TB drug development and immune responses, and those who research the immune response to other intracellular pathogens and treatment of those infections.

Objectives
At the conclusion of this session, the participant will be able to:
• learn new findings and developments about host response and susceptibility to TB and other intracellular infections;
• apply knowledge gained from the session to new diagnostic and biomarker strategies for patients with TB or other infections;
• utilize knowledge gained to help form new strategies for treatment or prevention of TB and other intracellular infections.

This session will provide an update on developments in innate and acquired immunity on tuberculosis, seeking lessons that may be gleaned from the host responses to other intracellular pathogens. This sessions will seek cross fertilization of knowledge of the host response between TB and non-TB infections. This session will discuss new developments in TB biomarkers and diagnostics, consider host susceptibilities, present TB strain differences in pathogenicity, TB lineage and co-evolution, and conclude with therapeutic targets for MTB treatment utilized in new treatment.

Chairing: J.J. Saukkonen, MD, Boston, MA
J.M. Keane, MD, Dublin, Ireland
A. Haczku, MD, PhD, Davis, CA

9:00 Developments in Innate Immunity of Tuberculosis
J.M. Keane, MD, Dublin, Ireland

9:20 Developments in Acquired Immunity of Tuberculosis and Other Intracellular Pathogens
S.A. Khader, PhD, St. Louis, MO

9:40 TB Lineage, Host Response and Biomarkers
P. Nahid, MD, MPH, San Francisco, CA

10:00 New Developments in TB Diagnostics
C. Boehme, MD, Geneva, Switzerland
D11 ARDS AND INFLAMMATORY INJURY

Assemblies on Allergy, Immunology and Inflammation; Critical Care; Respiratory Cell and Molecular Biology; Respiratory Structure and Function
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 3006/3008 (West Building, Level 3)

Target Audience
Clinical researchers, basic scientists and clinicians interested in understanding the inter-dependence between the innate immune response, excessive inflammation, and acute lung injury/ARDS.

Objectives
At the conclusion of this session, the participant will be able to:

• understand the mechanisms which lead to differing outcomes in ARDS;
• learn and understand the mechanisms contributing to inflammatory response following ALI.

Acute respiratory distress syndrome (ARDS), the most severe form of ALI, has a mortality rate of approximately 40%, despite modern ICU care. The importance of inflammation in initiation and progression of acute lung injury has been previously established. Inflammation signaling is critical in the host defense response to infectious and non-infectious agents known to contribute to lung pathology. Inflammatory responses are typically initiated by the innate immune system, leading to the production of IL-1β and IL-18, which recruit neutrophils and monocytes to the site of infection. However, these same cytokines and cells can damage the alveolus and impair respiratory function. An important goal of this session is to illustrate how data derived from patient samples and clinically relevant animal models points to a common pathway(s) and helps to define the basic mechanisms which impacts disease outcomes in patients.

Chairing:
C. Hardin, MD, PhD, Boston, MA
T. Cohen, PhD, Gaithersburg, MD

D12 ADVANCES IN TOBACCO DEPENDENCE TREATMENT FOR THE HOSPITALIZED PATIENT

Tobacco Action Committee
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 130-132 (North Building, Lower Level)

Target Audience
Health care workers treating tobacco dependence and tobacco related disease.

Objectives
At the conclusion of this session, the participant will be able to:

• gain new strategies to initiate a quit attempt for hospitalized smokers;
• become familiar with the tools available to implement a hospital-based smoking cessation program that includes post-discharge follow up;
• improve smoking cessation rates among hospitalized patients.

Hospitalization marks a unique opportunity to impact the tobacco epidemic. The effective health care system must consider a number of variables in devising interventions for promoting abstinence and facilitating transition to outpatient care. In this session various aspects of tobacco dependence treatment in hospitalized smokers will be explored. Common obstacles including initial counseling of resistant patients, personalizing treatment plans, use of technology, and effective discharge planning will be reviewed.

Chairing:
F.T. Leone, MD, MS, Philadelphia, PA

D13 VIRAL INFECTIONS AND ASTHMA: HOST DEFENSE AND SELF DEFEAT

9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 2005/2007 (West Building, Level 2)

Chairing:
J.E. Gern, MD, Madison, WI
M.M. Wurfel, MD, PhD, Seattle, WA
T.S. Hallstrand, MD, MPH, Seattle, WA

There will be a 5-minute discussion after each talk.
Oral Presentations


9:45  The Relevance of Humoral and Cellular Innate Responses in Virus-Induced Exacerbation of Experimental Asthma/L. Ravanetti, A. Dijkhuis, Y.S. Sabogal Pineros, S.M. Bal, R. Lutter, Amsterdam, Netherlands, p.A6419

10:00 Interferon-Gamma Reduces Type 2 Innate Lymphoid Cell Expansion and IL-13 Production, Mucous Metaplasia and Airways Hyperresponsiveness in Rhinovirus-Infected Immature Mice/M. Han, J. Young Hong, J.K. Bentley, C. Rajput, S. Jaipalli, J. Lei, M.B. Hershenson, Ann Arbor, MI, p.A6420


10:30 The Role of IL-17A in the Pathogenesis of Early Infection with RSV Breaking Immune Tolerance in Mice/Z. Jie, Y. He, W. Sun, T. Shi, J. Shi, X. Su, Shanghai, China, p.A6422

10:45 Among Asthmatic Children, Low Expression Patterns of TLR Expansion and IL-13 Production, Mucous Metaplasia and Airways Hyperresponsiveness in Rhinovirus-Infected Immature Mice/M. Han, J. Young Hong, J.K. Bentley, C. Rajput, S. Jaipalli, J. Lei, M.B. Hershenson, Ann Arbor, MI, p.A6420

D14 IMPROVING CARE AND REDUCING DISPARITIES IN ASTHMA AND SLEEP

9:00  Demographic and Socioeconomic Determinants of Asthma in the US/B.E. Himes, O. Mansour, R. Greenblatt, M. Ross, Philadelphia, PA, p.A6424

D15 NEW THERAPIES IN ILD


9:45 Practice Patterns and Utilization of Procalcitonin in Critically Ill Patients with Sepsis/D.C. Chu, A.B. Mehta, A.J. Walkey, Boston, MA, p.A6442

10:00 Sepsis Case Volume and Evidence-Based Processes of Care/A. Fawzy, A.J. Walkey, Boston, MA, p.A6443


MINI SYMPOSIUM

D17 “OMICS” OF ENVIRONMENTAL LUNG DISEASE

9:00 a.m. - 11:00 a.m. MOSCONE CENTER

Room 2006/2008 (West Building, Level 2)

Chairing: A.A. Litonjua, MD, MPH, Boston, MA
E. Forno, MD, MPH, Pittsburgh, PA
V.E. Ortega, MD, Winston Salem, NC

Oral Presentations


9:30 Genetic and Epigenetic Regulation of MUC5B Expression in Idiopathic Pulmonary Fibrosis/B.A. Helling, B. Pedersen, K.K. Brown, M.P. Steele, J. Loyd, G. Cosgrove, M.I. Schwarz, S. Groshong, C.M. Evans, T. Fingerlin, I.V. Yang, D.A. Schwartz, Aurora, CO, p.A6449


MINI SYMPOSIUM

D16 CRITICAL CARE: REDUCING VARIATION IN USUAL CARE

9:00 a.m. - 11:00 a.m. MOSCONE CENTER

Room 3003/3005 (West Building, Level 3)

Chairing: G.D. Rubenfeld, MD, MSc, Toronto, Canada
H.B. Gershengorn, MD, Bronx, NY
A.J. Walkey, MD, MSc, Boston, MA

Oral Presentations


9:45 Practice Patterns and Utilization of Procalcitonin in Critically Ill Patients with Sepsis/D.C. Chu, A.B. Mehta, A.J. Walkey, Boston, MA, p.A6442

10:00 Sepsis Case Volume and Evidence-Based Processes of Care/A. Fawzy, A.J. Walkey, Boston, MA, p.A6443


---

### D19 CLINICAL STUDIES IN PH

**9:00 a.m. - 11:00 a.m.**

**MOSCONE CENTER**

**Room 3007/3009 (West Building, Level 3)**

Chairing: R.T. Zamanian, MD, Stanford, CA

**R. Souza, MD, PhD, Sao Paulo, Brazil**

I. Lang, MD, Vienna, Austria

Oral Presentations


9:45 Extended Evaluation of emPHasis-10 Quality of Life Questionnaire in PH/I. Smith, C. Billings, D. Kiely, J. Yorke, I. Armstrong, Sheffield, United Kingdom, p.A6465


10:30 A Randomized Open Label Study Comparing First-Line Treatment with Bosentan or Sildenafil in Chronic Thromboembolic Pulmonary Hypertension/E. Gotti, M. Palazzini, A. Manes, C. Bachetti, G. Mazzanti, A. Rinaldi, F. Dardi, A. Albini, E. Monti, S. Fukui, D. Guarino, N. Galie, Bologna, Italy, p.A6468
POSTER DISCUSSION SESSION

D21  ASTHMA TREATMENT: GLUCOCORTICOIDS, BIOLOGICS AND BEYOND

9:00 a.m. - 11:00 a.m.  MOSCONET CENTER
Room 2010/2012 (West Building, Level 2)

Poster Viewing  9:00-9:45
Discussion  9:45-11:00

Chairing: S.E. Wenzel, MD, Pittsburgh, PA
L.E. Cohn, MD, New Haven, CT
N.J. Kenyon, MD, Sacramento, CA


404  Baseline IgE Levels as a Marker of Type 2 Asthma Among Patients Enrolled in the Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab (PROSPERO)/ E. Chipps, W.W. Busse, A.T. Luskin, R.S. Zeiger, B. Trzaskoma, N.M. Griffin, T.A. Omachi, T.B. Casale, Sacramento, CA, p.A6473

405  Omalizumab - Response in Patients with Severe Allergic Asthma in a Real Life Setting/ L. Ziera, E.S. Walsted, V. Backer, Copenhagen, Denmark, p.A6474

406  Regulating Goblet Cell Formation and Mucus Production with Inhaled Sam Pointed Domain Containing ETS Transcription Factor (SPDEF) Antisense Oligonucleotides/ D. Bai, M. McCaleb, S. Guo, B.P. Monia, Carlsbad, CA, p.A6475

407  A Randomized, Double-Blinded, Placebo-Controlled, Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAbr7195/A. Gershman, R. Goldwater, P. Foster, San Diego, CA, p.A6476

408  L-Arginine and Glucagon-Like Peptide 1, a Novel Pathway to Asthma Control/ D.-V. Nguyen, A.L. Linderholm, L. Franzl, N.J. Kenyon, Sacramento, CA, p.A6477


413  Selective Targeting of STAT6 at Antigen Priming Reduces OX40L and TH2-Biased Airway Inflammatory Responses/ Lee, J. Shan, B.T. Srinivasa, M. Jin, E.D. Fixman, Montreal, Canada, p.A6482


415  Developing FOXM1 Inhibitors to Suppress Goblet Cell Metaplasia and Airways Hyperresponsiveness/ V. Kalinichenko, L. Sun, X. Ren, I.-C. Wang, A. Pradhan, Y. Zhang, B. Han, J.A. Whitsett, T.V. Kalin, Cincinnati, OH, p.A6484

416  A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Oral Azithromycin (500 Mg OD) as a Supplement to Standard Care for Adult Patients with Acute Exacerbations of Asthma (the AZALEA Trial)/ L. Sun, X. Ren, I.-C. Wang, A. Pradhan, Y. Zhang, B. Han, J.A. Whitsett, T.V. Kalin, Cincinnati, OH, p.A6484


423 Exploring the Safety and Efficacy of CRD007, an Oral Mast Cell Inhibitor, on Responsiveness to Inhaled Manitol in Adults with Asthma: A Double-Blind, Placebo-Controlled, Cross-Over Phase II Trial/V. Backer, S.-E. Dahlen, G. Tornling, C.B. Barnes, E.S. Walsted, C. Porsbjerg, C.S. Ulrik, Copenhagen, Denmark, p.A6492


POSTER DISCUSSION SESSION

D22 REDUCING HARSMS OF TOBACCO USE

9:00 a.m. - 11:00 a.m.   MOSCONNE CENTER

Room 133 (North Building, Lower Level)

Poster Viewing  9:00-9:45

Discussion  9:45-11:00

Chairing:  H.J. Farber, MD, Houston, TX

H. Kathuria, MD, Boston, MA

A. Vachani, MD, MS, Philadelphia, PA

101 Internal Medicine Resident Perceptions and Knowledge Regarding Smoking Cessation/R. Sedhom, S. Parikh, A. Sarkar, M. Steinberg, New Brunswick, NJ, p.A6494

102 Do Physicians Address Smoking Status in Patients Admitted to the Hospital?/R. Sedhom, A. Sarkar, S. Parikh, M. Yacoub, New Brunswick, NJ, p.A6495


106 Effectiveness of Deep Breathing, a Self-Help Book and Addictive Effects of the Two Interventions in Cigarette Consumption, Anxiety and Depression and Motivation to Stop Smoking in Students of the Anhembi Morumbi University/B. Polonio, I. Ueda, J. Carvalho, R. Amaral, Sao Paulo, Brazil, p.A6499

107 Efficacy and Safety of β-Adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, in Smoking Cessation of Patients with Chronic Cough with or Without Airflow Obstruction/M. Castro, G. Sajol, D. Ksiazek, T. Koch, H. Yin-Declue, N. Oleka, C. Pitts, M. Glass, St. Louis, MO, p.A6500

108 Factors Associated with Effective Outpatient Smoking Cessation Counseling/T.B. Lumpkin, D. Ksiazek, K. Scholl, K. Schechtman, M. Castro, St. Louis, MO, p.A6501


110 Factors Affecting Smoking Cessation Interventions in Pulmonary Clinic/L. Shiekh Sroujineh, M.N. Iqbal, C. Castro, M. Elrifai, S. DixonWilliams, J.D. Thornton, Cleveland, OH, p.A6503

111 Identifying Clinician Barriers to Improve Smoking Cessation Integration Within a Lung Cancer Screening Program at an Urban Safety-Net Hospital/L. Swamy, K.A. Sloan, C. Fitzgerald, G. Millien, C. O’Donnell, C.C. Reardon, K. Steiling, R.S. Wiener, H. Kathuria, Boston, MA, p.A6504

112 Varenicline for Smoking Cessation: Be Alone or Together?/Y. Yu, Y. Ni, G. Shi, T. Chen, J. Hao, Shanghai, China, p.A6505


115 The Important of Partner Support in Smoking Cessation/O. Turan, P.A. Turan, A. Mirici, Canakkale, Turkey, p.A6508

116 Evaluation of Electronic-Cigarette and Nicotine Alone Effect in Comparison to Tobacco Cigarette Smoke/V. Reinikovalte, A. Rau, F. Deleyiannis, L. Tarasevicvicien-Stewart, Aurora, CO, p.A6509


119 A Qualitative Study of Discourse from Proponents and Opponents of Electronic Cigarettes on Twitter/S.A. Spence, M.B. Stanbrook, Toronto, Canada, p.A6512

120 The Adverse Effects of Waterpipe Smoking: A Systematic Review/M.H. Khan, R. Al-Lehebi, M.B. Stanbrook, Toronto, Canada, p.A6514

121 Respiratory Symptoms Predict Motivation to Quit Smoking Undergoing a Tobacco Treatment Program: A Pilot Prospective Study/S.R. Baldassarri, S.L. Bernstein, G.L. Chupp, B.A. Toll, New Haven, CT, p.A6511


126 A Phase 2 Dose-Escalation Study with AF-219, a P2X3 Antagonist for the Treatment of Chronic Cough/J.A. Smith, M. Kitt, M. Sher, P. Butera, A.P. Ford, Manchester, United Kingdom, p.A6524


128 A Predictive of Cough-Related Quality of Life in Patients with URTI Related Cough/A. Zanasi, L. Lanata, F. Saibene, F. De Blasio, Bologna, Italy, p.A6525


130 A Randomized Clinical Trial of Levodropropizine Effect on Respiratory Centre Output in Patients with Intractable Chronic Cough/C. Mannini, F. Lavorini, F. Saibene, L. Lanata, F. Fontana, Florence, Italy, p.A6527

131 M. Sher, P. Butera, A.P. Ford, Manchester, United Kingdom, p.A6524


133 A Phase 2 Dose-Escalation Study with AF-219, a P2X3 Antagonist for the Treatment of Chronic Cough/J.A. Smith, M. Kitt, M. Sher, P. Butera, A.P. Ford, Manchester, United Kingdom, p.A6524

134 A Predictive of Cough-Related Quality of Life in Patients with URTI Related Cough/A. Zanasi, L. Lanata, F. Saibene, F. De Blasio, Bologna, Italy, p.A6525


136 A Randomized Clinical Trial of Levodropropizine Effect on Respiratory Centre Output in Patients with Intractable Chronic Cough/C. Mannini, F. Lavorini, F. Saibene, L. Lanata, F. Fontana, Florence, Italy, p.A6527


138 A Phase 2 Dose-Escalation Study with AF-219, a P2X3 Antagonist for the Treatment of Chronic Cough/J.A. Smith, M. Kitt, M. Sher, P. Butera, A.P. Ford, Manchester, United Kingdom, p.A6524

139 A Predictive of Cough-Related Quality of Life in Patients with URTI Related Cough/A. Zanasi, L. Lanata, F. Saibene, F. De Blasio, Bologna, Italy, p.A6525


141 A Randomized Clinical Trial of Levodropropizine Effect on Respiratory Centre Output in Patients with Intractable Chronic Cough/C. Mannini, F. Lavorini, F. Saibene, L. Lanata, F. Fontana, Florence, Italy, p.A6527


143 A Phase 2 Dose-Escalation Study with AF-219, a P2X3 Antagonist for the Treatment of Chronic Cough/J.A. Smith, M. Kitt, M. Sher, P. Butera, A.P. Ford, Manchester, United Kingdom, p.A6524

144 A Predictive of Cough-Related Quality of Life in Patients with URTI Related Cough/A. Zanasi, L. Lanata, F. Saibene, F. De Blasio, Bologna, Italy, p.A6525


146 A Randomized Clinical Trial of Levodropropizine Effect on Respiratory Centre Output in Patients with Intractable Chronic Cough/C. Mannini, F. Lavorini, F. Saibene, L. Lanata, F. Fontana, Florence, Italy, p.A6527


148 A Phase 2 Dose-Escalation Study with AF-219, a P2X3 Antagonist for the Treatment of Chronic Cough/J.A. Smith, M. Kitt, M. Sher, P. Butera, A.P. Ford, Manchester, United Kingdom, p.A6524

149 A Predictive of Cough-Related Quality of Life in Patients with URTI Related Cough/A. Zanasi, L. Lanata, F. Saibene, F. De Blasio, Bologna, Italy, p.A6525


151 A Randomized Clinical Trial of Levodropropizine Effect on Respiratory Centre Output in Patients with Intractable Chronic Cough/C. Mannini, F. Lavorini, F. Saibene, L. Lanata, F. Fontana, Florence, Italy, p.A6527


153 A Phase 2 Dose-Escalation Study with AF-219, a P2X3 Antagonist for the Treatment of Chronic Cough/J.A. Smith, M. Kitt, M. Sher, P. Butera, A.P. Ford, Manchester, United Kingdom, p.A6524

154 A Predictive of Cough-Related Quality of Life in Patients with URTI Related Cough/A. Zanasi, L. Lanata, F. Saibene, F. De Blasio, Bologna, Italy, p.A6525


156 A Randomized Clinical Trial of Levodropropizine Effect on Respiratory Centre Output in Patients with Intractable Chronic Cough/C. Mannini, F. Lavorini, F. Saibene, L. Lanata, F. Fontana, Florence, Italy, p.A6527


158 A Phase 2 Dose-Escalation Study with AF-219, a P2X3 Antagonist for the Treatment of Chronic Cough/J.A. Smith, M. Kitt, M. Sher, P. Butera, A.P. Ford, Manchester, United Kingdom, p.A6524
Simplifying the Cardiopulmonary Exercise Test Enables Pattern Recognition and Differentiation Between Diseases Causing Exertional Dyspnea/K.H. Melamed, B. Dolezal, X. Wang, C.B. Cooper, Los Angeles, CA, p.A6531


Validation of the Objective Simplified Wells Score and Comparison with Clinical Judgement/J. Seashore, M. Farokhi, J.P. Wisnivesky, O. Epelbaum, Queens, NY, p.A6533


Interleukin (IL)-1α and IL-1β Contribute to Host Defense Against Pulmonary Klebsiella Infection Via Different Mechanisms/S. Cai, P. Baral, L. Jin, S. Jeyaseelan, Baton Rouge, LA, p.A6546

Diet-Induced Obesity Impairs Pulmonary Bacterial Clearance in Klebsiella Pneumoniae/P. Mancuso, J.B. Weinberg, K. Singer, Ann Arbor, MI, p.A6547


ST191 Belonging to CC92 Became Dominante Carbenpenem-Resistant Acinetobacter Baumannii that Cause Nosocomial Pneumonia in Intensive Care Units in a Teaching Hospital in Central China/P. Fan, H. Tan, M. Li, X. Su, C. Hu, ChangSh, China, p.A6550

Outcome and Prognostic Factors of Pneumonia Patients with Acinetobacter Baumannii Bacteremia/W.-C. Fan, A.F. Shorr, Goshen, MA, p.A6551


Effectiveness of High Dose Sulbactam for the Treatment of Ventilator Associated Pneumonia Caused by Carbapenem Resistant Acinetobacter Baumanii/J. Jeong, J.W. Son, M.J. Na, S.J. Kwon, Daejeon, Korea, Republic of, p.A6552
D25 NEONATAL AND CONGENITAL LUNG DISEASES

9:00 a.m. - 11:00 a.m. MOSCONE CENTER Room 3011 (West Building, Level 3)

Poster Viewing 9:00-9:45
Discussion 9:45-11:00

Chairing: L.M. Nogee, MD, Baltimore, MD
J. Wambach, MD, St. Louis, MO
C.V. Lal, MD, Birmingham, AL


920 Macrophage Galactose-Type Lectin-1 (MGL1) Deficiency Is Associated with Increased Lung Pathology and Hyperinflammation in Gram-Negative Pneumonia/J. Sharma, C.N. Jondle, A. Sharma, T.J. Simonson, B.B. Mishra, Grand Forks, ND, p.A6555


802 Pulmonary Vasculature in Infants with Down Syndrome Is Underdeveloped/D. Bush, C. Galambos, S.H. Abman, Aurora, CO, p.A6558

803 Identification of Vitamin D Sensitive Pathways During Lung Development/L. Chen, R. Wilson, E. Bennett, G. Zosky, Hobart, Australia, p.A6559


806 IL-1Ra Protects Against Impaired Alveolar Development and Airway Fibrosis but Not Airway Hyperresponsiveness in a Mouse Model of Bronchopulmonary Dysplasia/J.E. Bourke, S.G. Royce, E. Lamanna, M. Lam, C. Donovan, C. Bui, M. Nold, C. Nold, Clayton, Australia, p.A6562

807 Inflammation Downregulates Fibulin-5 Expression and Disrupts Elastic Fiber Assembly During Saccular Stage Lung Development/J.T. Benjamin, R. Van Der Meer, L.R. Young, T.S. Blackwell, Nashville, TN, p.A6563

808 A Role for the Accessory Type III Transforming Growth Factor-β Receptor in Post-Natal Lung Alveolarization/A.E. Pozarska, G. Niess, W. Seeger, R.E. Morty, Bad Neuheim, Germany, p.A6564


810 Echocardiographic and Catheterization Patterns in Pediatric Patients with Secondary Pulmonary Arterial Hypertension Due to Bronchopulmonary Dysplasia/A. Singh, B. Feingold, B. Rivera-Lebron, S. Drant, Pittsburgh, PA, p.A6566


813 A Novel Role for Transforming Growth Factor Beta-Induced Protein in Promoting Pulmonary Endothelial Migration in the Alveolar Lung/M. Liu, S.P. Rao, C. Husted, G. Umbach, C.M. Alvira, Stanford, CA, p.A6569

814 Muring Lung Lipofibroblast Lineage Tracing/A. Ntokou, R.E. Morty, W. Seeger, K. Ahlbrecht, Bad Neuheim, Germany, p.A6570

816 The Impact of Mesenchymal Stem Cell Therapy in Bronchopulmonary Dysplasia: The Interaction Between Inflammation and Oxidative Stress/C.R. Niktin, T.L. Bonfild, Cleveland, OH, p.A6572


822 Nutritional Follow-Up of Congenital Diaphragmatic Hernia Survivors - The Sydney Children’s Hospital Experience/J. Mui, A. Num, A. Jaffe, S. Chuang, Randwick, Australia, p.A6578


Chairing: F. Perros, PhD, Le Plessis Robinson, France
M.R. Nicolls, MD, Palo Alto, CA
L.C. Price, MBBS, London, United Kingdom


1005 Hemodynamic Unloading Rapidly Reverses Perivascular Inflammation in a Rat Model of PAH/K. Abe, I.F. McMurtry, M. Oka, Fukuoka, Japan, p.A6583

1006 Pulmonary Adventitial Remodeling in Pulmonary Hypertension: Fibroblast Responses to Changes in Matrix and Intersitial Fluid/M.E. Yeager, K.L. Colvin, Aurora, CO, p.A6584


1008 Adventitial Fibroblasts Shape the Local Microenvironmet to Induce and Sustain Alterations in Macrophage Metabolism as a Critical Adaptation to Promote a Pro-Inflammatory and Pro-Remodeling Phenotype/K. EL Kasmi, A. D‘Alessandro, S. Riddle, H. Zhang, M. Li, A. Anderson, K. Rawlinson, A. Flockton, B.A. McKeon, K.C. Hansen, M. Frid, K.R. Stenmark, Aurora, CO, p.A6586


1010 4-Methylthio-2-Oxobutyric Acid (MTOB), a Novel Small Molecule and Inhibitor of CTBP1, Inhibits the Proliferative and Pro-inflammatory Phenotype of Adventitial Fibroblast in Pulmonary Hypertension/M. Li, B.A. McKeon, S. Kumar, M. Frid, A. Flockton, S. Riddle, A. D‘Alessandro, H. Zhang, M.A. Fini, K. El Kasmi, Q. Zhang, K.R. Stenmark, Aurora, CO, p.A6588
1011 The Role of the Bone Morphogenetic Protein 9 in Endothelial Inflammation/C.G. Mitrofan, S. Appeby, N. Morrell, Cambridge, United Kingdom, p.A6589

1012 The NF-κB Pathway Is Important for Phenotype and Proliferation of Pulmonary Microvascular Endothelial Cells and Lung Endothelial Progenitor Cells/D. Farkas, V. Kraskauskiene, A.A. Fowler, K. Islam, R. Natarajan, L. Farkas, Richmond, VA, p.A6590

1013 Autocrine Regulation of Interleukin 33 Expression in Human Pulmonary Artery Endothelial Cells/T.C. Tsui, S. Boeder, E.C. Breen, T.D. Bigby, La Jolla, CA, p.A6591

1014 TNFα Stimulates an Inflammatory Response in Human Pulmonary Microvascular Endothelial Cells (HPMECs): The Role of NF-κB and BET Proteins/A. Natsuki, J. Wort, F. Chung, I.M. Adcock, S. Mumba, London, United Kingdom, p.A6592

---

**POSTER DISCUSSION SESSION**

**D27**  MACROPHAGES: RESolvers, RESPONDERS OR BOTH?

9:00 a.m. - 11:00 a.m.  MOSCONE CENTER

Room 2014 (West Building, Level 2)

**Poster Viewing**  9:00-9:45

**Discussion**  9:45-11:00


---

ATS 2016 • San Francisco
D28  NOVEL IMAGING METHODS TO STUDY LUNG DISEASE

9:00 a.m. - 11:00 a.m.  
MOSCONEx CENTER  
Room 2024 (West Building, Level 2)

Poster Viewing  
9:00-9:45

Discussion  
9:45-11:00

Chairing:  
E.A. Hoffman, PhD, Iowa City, IA  
M.F. Vidal Melo, MD, PhD, Boston, MA  
M. Kirby, PhD, Vancouver, Canada


609  Imaging Alveolar Dynamics with 4D Optical Coherence Tomography (OCT) and Time-Resolved Intravital Microscopy (IVM) During Uninterrupted Mechanical Ventilation of Rats/C. Schnabel, E. Koch, Dresden, Germany, p.A6619


612  Magnetic Resonance Imaging of Radiation-Induced Lung Injury with Correlation to Histology/B. Zanette, E. Stirrat, S. Shojaei, O. Doganay, G.E. Santyr, Toronto, Canada, p.A6622

613  Is the Lung in Obesity Also Obese?: Lung Tissue Volume Is Elevated in Obesity and Reduced by Bariatric Surgery/A. Santos, E. Rivas, R. Rodriguez-Roisin, M. Sanchez, J. Ruiz-Cabello, E. Arismendi, J.G. Venegas, Boston, MA, p.A6623


D29 BENCH TO BEDSIDE: TRANSLATIONAL SCIENCE IN SDB

9:00 a.m. - 11:00 a.m. MOSCONE CENTER Room 3001 (West Building, Level 3)

Poster Viewing 9:00-9:45
Discussion 9:45-11:00

Chairing: D. Gozal, MD, Chicago, IL
J.C. Jun, MD, Baltimore, MD
A. Goldbart, MD, Beer Sheva, Israel
S.P. Patil, MD, PhD, Baltimore, MD


704 Obstructive Sleep Apnea Features, Lower Airway Obstruction and Inflammation in Patients with Asthma/M. Teshome, T. Denman, M. Teodorescu, Madison, WI, p.A6639


706 Time Course of Cardiac Troponin in Patients with Acute Coronary Syndrome and Sleep Apnea/A. Sanchez-de-la-Torre, M. Sanchez-de-la-Torre, J. Valls, M. Flores, A. Maisel, A. Malhotra, F. Barbe, X. Soler, Lleida, Spain, p.A6641


709 Carotid Body Involvement in a Translational Ovine Model of Renovascular Hypertension: Sensitivity to Purinergic P2X3 Receptor Antagonism with AF-130/J.F. Paton, R. Ramchandra, F.D. McBryde, A.P. Ford, Bristol, United Kingdom, p.A7900

710 Effectiveness of Two Maintenance Diets Following a Very Low Energy Diet to Reduce Cardio-Metabolic Risk in Obese Sleep Apnea Patients: A Randomized Controlled Trial/C.M. Hoyos, E.A. Cayanan, N. Marhsall, B. Yee, K. Wong, Y. Djavadkhani, R. Grunstein, Glebe, Australia, p.A6644


715 The Role of Complement in Obstructive Sleep Apnea/A. Daggan, M. Emin, F. Castagna, S. Jelic, New York, NY, p.A6649

716 Effect of Sleep-Deprivation on Cytokines Level, Neutrophils Functions and Lymphocyte Populations/D. Daggan, A. Eklund, B. Yee, F. Monsef, N. Djavadkhani, R. Grunstein, Al-Khoudh, Oman, p.A6650

717 Low Integrated Area of Desaturation Index After Adaptive Servo Ventilation Therapy Is Strong Indicator to Predict Fatal Cardiovascular Events in Patients with Heart Failure/A. Umeyama, N. Takama, M. Kurabayashi, Iseesaki, Japan, p.A6651

718 Is Periodic Breathing During Exercise Controlled by Chemical Feedback Signals/?P. Haouzi, D. Kim, Hershey, PA, p.A6652

D30

NOVEL CLINICAL APPROACHES TO THORACIC MALIGNANCIES

9:00 a.m. - 11:00 a.m.  MOSCONOE CENTER

Room 309 (South Building, Esplanade Level)

Poster Viewing 9:00-9:45
Discussion 9:45-11:00

Chairing:  G.L. Narsavage, APRN, PhD, RN, Morgantown, WV
T.J. Harkin, MD, New York, NY


305  Comorbidities Are Associated with Stage I Lung Cancer Diagnosis/M.C. Aldrich, H.M. Munro, E.L. Grogan, P.P. Massion, W.J. Blot, Nashville, TN, p.A6660


308  Lepidic Growth Component and Nodal Metastasis of Invasive Pulmonary Adenocarcinoma/J. Kim, K.W. Lee, Seongnam-si, Korea, Republic of, p.A6663


310  Predictor of Mortality in Patients with Solid Malignancy Admitted to the ICU - A Prospective Observational Study/P.L. Kingah, Houston, TX, p.A6665


314  High Temperature Requirement A3 (HtrA3) Inhibits Cell Migration and Predicts Survival in Resected Non-Small-Cell Lung Cancer/J. Zhao, J. Zhang, M. Feng, J. Qu, Shanghai, China, p.A6669


317  Use of 4DCT in the Measurement of Respiration-Induced Catheter Motion in Endobronchial High Dose Rate Brachytherapy/C. Parks, S. Cavanaugh, A. Vidovic, T. Law, S. Crawford, J. Wei, Newnan, GA, p.A6672


320  Does EGFR Mutation or Younger Age (Age<50 Years) Affect EGFR TKI Treatment Outcome? - A Cohort Study Among Lung Adenocarcinoma Patients in Taiwan/S.-G. Wu, C.-J. Yu, J.C.-H. Yang, J.-Y. Shih, P.-C. Yang, Doulou City, Taiwan, p.A6675

321  Efficacy, Safety and Dosage of Afatinib in Patients with Non-Small Cell Lung Cancer After Failure of Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)/ C. Park, T. Kim, H. Shin, H. Ban, J. Lim, Y. Kwon, I. Oh, S. Lim, Y. Kim, Hawsun, Jeonnam, Korea, Republic of, p.A6676
D31 NOVEL MECHANISMS OF ALLERGY AND AIRWAY INFLAMMATION

9:00 a.m. - 3:30 p.m.  MOSCONIE CENTER

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Facilitator: N.J. Kenyon, MD, Sacramento, CA


P378 Association Between the CDHR3 rs6867330 Risk Allele and Chronic Rhinosinusitis/E. Chang, A. Willis, J. Calton, C. Thompson, A. Chiu, P.D. Martin, Tucson, AZ, p.A6687


Facilitator: P. Akuthota, MD, La Jolla, CA


P382 Production of Human Monoclonal IgE from Patients with Allergic Bronchopulmonary Mycosis/M.A. Wurth, D.J. Horvath, R.F. Brown, Y. Khan, S. Smith, Nashville, TN, p.A6691


P389 Extracellular Signal-Regulated Kinase1/2 Signaling Pathway Regulates the Phenotype Transition of Human Bronchial Smooth Muscle Cells Passively Sensitized by Asthmatic Serum/M. Xie, X. Liu, Y. Xu, Wuhan, China, p.A6698

Facilitator: S.F. Ma, PhD, Chicago, IL


P391 Is There a Mediation Effect of Systemic Inflammatory Mediators for Obesity Contributing to Poor Asthma Control?/X. Zhang, J. Zheng, L. Zhang, H.P. Zhang, L. Wang, G. Wang, Chengdu, China, p.A6700

P392 PIM2 Can Induce Asthma Pathogenesis Through IL-10/W. Du, G. Shi, 200032, China, p.A6701

P393 Galangin Attenuates Airway Remodeling by Inhibiting TGF-β1-Mediated ROS Generation and MAPK/Akt Phosphorylation in Asthma/Y.-N. Liu, W.-J. Zha, X.-N. Zeng, M. Huang, Nanjing, Jiangsu, China, p.A6702

P394 Oligomeric Proanthocyanidins Attenuates Airway Chronic Inflammation and Remodeling Via TGF-β1-ROS-MAPK Pathway/X. Zeng, Y. Ma, H. Gu, M. Huang, Nanjing, Jiangsu, China, p.A6703


P396 Airway Exposure to Staphylococcus Aureus Particles Promotes Characterization of Airway Immune and Physiological Changes in Patients with Metabolic Syndrome (MetS)/M. Xie, X. Liu, Y. Ni, Y. Yu, W. Du, G. Shi, Shanghai, China, p.A6706


Facilitator: A. Haczku, MD, PhD, Davis, CA

P399 A Change in Frequency and Function of Regulatory T Cells in Asthmatic Patients/T. Chen, J. Hao, Y. Ni, Y. Yu, W. Du, G. Shi, Shanghai, China, p.A6708

P400 Characterization of Human Innate Lymphoid Cell Type 2 (ILC2) Responses to TSLP, IL-33 and IL-25/C. Vissinga, M. Comeau, Rotterdam, Netherlands, p.A6709

P401 Development of A Novel Atmospheric Aerosol Simulate Permits Chronic Exposure to Atmospheric Secondary Organic Particulate Matter and Shows Dose Response Effect on Airway Responsiveness to Methacholine/J. Ye, A. Portelli, M. North, A. Chan, C.-W. Chow, Toronto, Canada, p.A6710


P403 Regulation of Immune Response by TSLP in Children with Atopic Diseases/A. Chauhan, M. Singh, A. Agarwal, Chandigarh, India, p.A6712

P404 Induction of Neutrophil Apoptosis by a Novel Monoclonal Antibody Against the Sialic Acid-Binding Immunoglobulin-Like Lectin 9 (Siglec-9)/Z. Chen, F.-F. Bai, L. Han, J. Zhu, T. Zheng, Z. Zhu, L.-F. Nanjng, China, p.A6713


P408 Interleukin-17 and Leptin Contribute to Airway Fibrosis and Altered Interleukin-13 Receptor Expression in Obese Asthma/J.L. Ingram, M. Ghio, R.W. Sigmon, J. Wong, B. Theriot, A. Hegde, J.K.L. Walker, M. Kraft, Durham, NC, p.A7902


P418 Scavenger Receptor B-I Protects the Lung from Influenza Induced Inflammation/K.M. Gowdy, M. McPeek, M.J. Yaeger, B. Luo, A. Malur, M.J. Thomassen, M.B. Fessler, Greenfield, NC, p.A6724


P420 The Effect of Corticosteroids on Neutrophil Recruitment and Interferon-Gamma Production in the Lungs After S. Pneumoniae Pneumonia/O.K. Giddings, J. Martin, J. Gomez, C.M. Doerschuk, Chapel Hill, NC, p.A6726


P423 Multiple Abnormal Gene Mutation Identified in Patients with H7N9 Influenza Pneumonia/C. Chen, M. Wang, Z. Zhu, X. Lao, X. Fan, Y. Song, Shanghai, China, p.A6731

P424 The Protective Effect of N-Acetylcysteine on Streptococcus Pneumoniae Murine Pseudomonas Pneumonia Model of Simulated Weightlessness Rats/P. Wang, M.H. Li, Beijing, China, p.A6732


P426 The Clinical Value of Serum Albumin and Prealbumin Levels in Children with Lobar Pneumonia Caused by Mycoplasma Pneumonia/S.L. Hua, X.J. Jiang, Putuo District, China, p.A6735

P427 The Effects of Fluticasone Propionate on Growth of Stenotrophomonas Maltophilia and Klebsiella Pneumoniae/S. Nariya, J. Durack, R. Singh, Y.J. Huang, Ann Arbor, MI, p.A6736


P439 Oxidative Stress Is Associated with Airway Hyperresponsiveness Induced by Increased Osmolality in Patients with Asthma/D. Naumov, E. Borodin, A. Prikhodko, J.M. Perelman, V. Kolosov, Blagoveshchensk, Russian Federation, p.A6742


P442 Role of High Mobility Group Box 1 Protein in Respiratory Syncytial Virus Pathogenesis/Y.M. Hosakote, A. Kurosky, Galveston, TX, p.A6745

Facilitator: M. Christofidou-Solomidou, PhD, Philadelphia, PA


P445 Caffeic Acid Phenethyl Ester Attenuates Allergic Airway Inflammation and Remodeling by Inhibiting ROS Generation and MAPK/Akt Phosphorylation in Asthma/Y. Ma, J.-X. Zhang, X.-N. Zeng, M. Huang, 210029, China, p.A6748


---

D34 SARCOIDOSIS

9:00 a.m. - 3:30 p.m. MOSCONE CENTER

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion

11:45-12:15: authors will be present for discussion with assigned facilitators

Facilitator: K.C. Patterson, MD, Philadelphia, PA


P452 The Role of CXCL9 and Monocytes in Sarcoidosis/B.S. Benn, S.A. Sun, M.E. Ho, J. Ramstein, R. Su, S. Garudadri, N.R. Bhakta, L. Koth, San Francisco, CA, p.A6752


---

D35 SARCIOIDOSIS

9:00 a.m. - 3:30 p.m. MOSCONE CENTER

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion

11:45-12:15: authors will be present for discussion with assigned facilitators

Facilitator: R.W. Harper, MD, Sacramento, CA

P457 Resolution of Propionibacterium Acnes-Induced Granulomatous Pulmonary Inflammation and Fibrosis in C57BL/6 Mice Despite Continued Antigen Exposure/ N. Pouladpour, M. Moyer, D. Nethery, J.R. Jarvela, J. Tomasehfski, R.F. Silver, Cleveland, OH, p.A6757

P458 BNP, 6MWD Test, DLCO% and the Severity of Sarcoidosis-Associated Pulmonary Hypertension/R. Omar, R.P. Baughman, R.F. Machado, N. Sweiss, M. Mirsaeidi, Miami, FL, p.A6758


P462 Increased PP2A Expression in Sarcoidosis CD4+ T-Cells May Reduce Proliferation and Induce Apoptosis/J. Rosinski, R. Wang, L. Celada, W. Drake, Nashville, TN, p.A6762

### D35 SEPSIS: INNATE IMMUNE MECHANISMS

**9:00 a.m. - 3:30 p.m.**  
**MOSCONE CENTER**  
**Area D, Hall D (North Building, Lower Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:00-11:45: authors will be present for individual discussion  
11:45-12:15: authors will be present for discussion with assigned facilitators

**Facilitator:** P.A. Verhoef, MD, PhD, Chicago, IL

**P466** Peritoneal CD49d+CD4++ T Cells Have a Role of Early Sepsis Development in an Intra-Abdominal Polymicrobial Sepsis Mice Model  


**P468** Mesenchymal Stem Cells Decrease CD14++CD16+ Monocytes of Sepsis Patients Via Prostaglandin E2/G. Qi, L. Huang, G. Zheng, M. Ge, D. Lai, Q. Shu, J. Xu, Hangzhou, China; p.A6765


**P472** Immunological Mechanism of Lung Inflammation by Lipopolysaccharide (LPS)/M. Takeuchi, A. Kawazoe, M. Takasaki, N. Miwa, Y. Tanaka, K.E. Pinkerton, Kyoto, Japan; p.A6769


### D36 COPD: LABA, LAMA, ICS, AND COMBINATIONS

**9:00 a.m. - 3:30 p.m.**  
**MOSCONE CENTER**  
**Area A, Hall D (North Building, Lower Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:00-11:45: authors will be present for individual discussion  
11:45-12:15: authors will be present for discussion with assigned facilitators

**Facilitator:** A. Anzueto, MD, San Antonio, TX

**P1** Reduction in Clinically Important Deterioration in Chronic Obstructive Pulmonary Disease in Patients Treated with Aclidinium/Formoterol Combination/D. Singh, A. Durzo, F. Chuecos, A. Munoz, E. Garcia Gil, Manchester, United Kingdom; p.A6771

**P2** Comparison of Extrapulmonary Beclometasone Dipropionate/Formoterol Fumarate (BDP/FF) Versus Other Double Combinations on Reduction of Moderate/Severe Exacerbations/D. Singh, A. Bizzi, M. Spinola, S. Petruzzelli, A. Papi, Manchester, United Kingdom; p.A6772

**P3** Efficacy of Aclidinium/Formoterol on Bronchodilation and Symptoms in Symptomatic and Asymptomatic Patients with COPD: Pooled Analysis of Two Phase III Studies/M. Miravitlles, K.R. Chapman, F. Chuecos, A. Ribera, E. Garcia Gil, Barcelona, Spain; p.A6773

**P4** Efficacy of Inhaled Glycopyrrolate for Moderate-to-Severe COPD: A Subgroup Analysis by Gender from the Pooled GEM1 and GEM2 Studies/D.A. Mahler, A. Satti, S. Spangenthal, A. Yadao, P. D’Andrea, A. Uddin, B. Franke-Bray, Hanover, NH; p.A6774

**P5** Effect of Glycopyrrolate on Lung Function, Health Status and Dyspnea in Age Subgroups: A Pooled Analysis from the GEM1 and GEM2 Studies/D.A. Mahler, E. Kerwin, A.H. Gifford, A. Yadao, P. D’Andrea, A. Uddin, B. Franke Bray, Hanover, NH; p.A6775

**P6** Indacaterol/Glycopyrrolate Improves Dyspnea in US Patients with Moderate-to-Severe COPD: A Subgroup Analysis of the Pooled FLIGHT1 and FLIGHT2 Studies/D.A. Mahler, S. Maitra, R. Fogel, D. Banerji, Hanover, NH; p.A6776

**P7** Indacaterol/Glycopyrrolate Improves Health Related Quality of Life in US Patients with COPD: A Subgroup Analysis from the Pooled FLIGHT1 and FLIGHT2 Studies/D.A. Mahler, T. Ayers, F. Patalano, S. Maitra, D. Banerji, Hanover, NH; p.A6777

**P8** 1-Year Follow-Up of COPD Patients After Withdrawal of Inhaled Corticosteroid Maintenance Therapy: A Subgroup Analysis of the DACCORD Study/R. Buhl, C.-P. Criece, P. Kardos, C. Vogelmeier, C. Mailaender, N. Lossi, H. Worth, Mainz, Germany; p.A6778

**P9** Benefits of Tiotropium + Olodaterol Over Tiotropium at Delaying Clinically Significant Events in Patients with COPD Classified as GOLD B/R. Buhl, L. McGarvey, S. Kom, G.T. Ferguson, L. Gronke, C. Hallmann, F. Vob, K.F. Rabe, F. Maltais, Mainz, Germany; p.A6779
P10 Treatment Persistence in a German Real-Life COPD Cohort (DACCORD)/C.-P. Crie, R. Buhl, P. Kardos, C. Vogelmeier, C. Mailaender, N. Lossi, H. Worth, Bovenden, Germany, p.A6780

P11 Gender Differences in Baseline Characteristics of Patients with COPD: A Pooled Analysis of Pivotal Trials of Indacaterol/Glycopyrronium from the IGNITE Program/S. Fucile, I. Tsiligianni, K. Mezzi, K. Kostikas, R. Fogel, East Hanover, NJ, p.A6781


Facilitator: S.C. Lazarus, MD, San Francisco, CA


P18 Long-Term Safety and Tolerability of Indacaterol/Glycopyrrolate in Moderate-to-Severe COPD Patients from the US: A Subgroup Analysis from the FLIGHT3 Study/G.T. Ferguson, A.A. Schubert-Tennigkeit, C. Thach, D. Banerji, Farmington Hills, MI, p.A6788

P19 Benefits of Tiotropium + Olodaterol on Symptoms and Health-Related Quality of Life in Patients with Moderate to Severe COPD with Chronic Bronchitis and/or Emphysema/G.T. Ferguson, R. Abrahams, L. Bjerner, L. Gronke, F. Vob, D. Singh, Farmington Hills, MI, p.A6789


P25 Improvement in Lung Function with Indacaterol/Glycopyrrolate (IND/GLY) in Patients with Moderate to Severe COPD from the US: A Subgroup Analysis from the FLIGHT1 and FLIGHT2 Studies/E. Kerwin, D.A. Mahler, A. FowlerTaylor, S. Maitra, D. Banerji, Medford, OR, p.A6795


P27 UMEC/VI as Step-Up Therapy from Tiotropium in Moderate Symptomatic COPD: a Randomized, 12-Week Study/E. Kerwin, C.J. Kalberg, D. Galkin, C.-Q. Zhu, A. Church, W. Fahy, Medford, OR, p.A6797

Facilitator: V. Kim, MD, Philadelphia, PA


P33 Using Different Sets of Patient-Relevant Outcomes in Chronic Obstructive Pulmonary Disease to Evaluate Efficacy of Tiotropium Respimat - a Post-Hoc Analysis/R. Dahl, A. Anzueto, N. Metzdorf, A. Mueller, P.M. Calverley, Odense C., Denmark, p.A6803

P34 Efficacy and Safety of Tiotropium + Olodaterol in Patients with COPD by ATS Category/F. Maltais, E. Pizzichini, L. Gronke, F. Vob, E. Derom, Quebec, Canada, p.A6804


P37 Analysis of Rescue Medication Use Over 1 Year in Patients Receiving LAMA, LABA, or Combination Maintenance Treatment for COPD in the TONADOR Studies/C.B. Cooper, R. Abrahams, G.T. Ferguson, E. Clerisme-Beaty, F. Vob, R. Buhl, Los Angeles, CA, p.A6807

P38 Lung-Function Response to Tiotropium + Olodaterol in Patients with COPD with β-Agonist Reversibility/D.P. Tashkin, G.T. Ferguson, E. Clerisme-Beaty, F. Vob, R. Buhl, Los Angeles, CA, p.A6808


P40 Treatment with Tiotropium Plus Olodaterol Respimat Improves Physical Functioning of COPD Patients in a Real Life Setting/M. Haensel, T. Glaab, R. Sauer, R. Rubin, R. Buhl, Ingelheim am Rhein, Germany, p.A6810

Facilitator: C.B. Cooper, MD, Los Angeles, CA

P41 Inhaler Errors After Reading the Patient Information Leaflet in Patients with COPD: A Comparison of Elliptair with Five Inhaler Devices/J. Van Der Palen, M. Thomas, H. Chrystyn, R. Sharma, V. Imber, C.-Q. Zhu, N. Barnes, Enschede, Netherlands, p.A6811


P44 Benefits of Tiotropium Versus Placebo for Delaying Clinically Significant Events in Patients with Moderate COPD (GOLD 2)/K. Rabe, N. Metzdorf, F. Vob, C. Hallmann, L. Gronke, D. Tashkin, Grosshansdorf, Germany, p.A6814

P45 Comparative Efficacy of Umeclidinium Versus Other Long-Acting Muscarinic Antagonist in Combination with ICS/LABA/V. Chounta, E. Huisman, A.S. Ismaila, A. Karabis, Y.S. Punekar, Brentford, United Kingdom, p.A6815

P46 Treatment Satisfaction and Preference with Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Comparison to Tiotropium Monotherapy - Results of the FAVOR Study/P. Kardos, I. Hagedorn, Frankfurt, Germany, p.A6816

P47 Improvement in Lung Function and Symptom Control with Aclidinium Bromide Versus Tiotropium and Placebo in Symptomatic Patients with COPD: Post-Hoc Analysis of a Phase IIib Study/J. Beier, R. Mroz, A.-M. Kirsten, F. Chuecos, E. Garcia Gil, Wiesbaden, Germany, p.A6817

P48 Improvement in Symptom Severity and Quality of Life in Patients with COPD Treated with Aclidinium Bromide: Results of a Non-Interventional Study/J. Beier, T. Plate, A. Prechtl, Wiesbaden, Germany, p.A6818


P50 The Effect of Aclidinium Bromide 400 µg on Lung Function, Sleep Quality and Physical Activity in Patients with Chronic Obstructive Pulmonary Disease: Results of a Phase IV Pilot Study/H. Magnusson, M. Arzt, S. Andreas, T. Plate, A. Ribera, B. Seoane, H. Watz, A.-M. Kirsten, Grosshansdorf, Germany, p.A6820

P51 Should Inhaled Corticosteroids Be Considered in Group A and B COPD Patients with Marked Post-Bronchodilator Reversibility of FEV1/J. Balachandran, 691009, India, p.A6821


Facilitator: N.R. Bhakta, MD, PhD, San Francisco, CA

P54 A Novel Biophysical Model to Investigate Regional and Total Lung Delivery of QVA149 (IND/GLY) Delivered Via the Neohaler Device/A. Kuttler, T. Dimke, Basel, Switzerland, p.A6824

P55 Comparative Efficacy of Umeclidinium with Other Once-Daily Long-Acting Muscarinic Antagonists in Moderate-to-Severe Chronic Obstructive Pulmonary Disease/I. Naya, P. Shah, M. Vahdati-Bolouri, W. Fahy, Uxbridge, United Kingdom, p.A6825

P56 The Effect of Indacaterol/Glycopyrronium on Lung Function and Physical Activity in More Severe COPD - A Posthoc Subgroup Analysis of the MOVE Study/H. Watz, C. Mallaender, A.-M. Kirsten, Grosshansdorf, Germany, p.A6826

P57 Pharmacokinetic and Safety Profile of a Novel Co-Suspension Technology Fixed-Dose Combination of Budesonide/Glycopyrrolate/Formoterol Delivered by Metered Dose Inhaler in Healthy Adult Subjects/C. Orevillo, J. Miller, P. DePetrillo, S. Siddiqui, S. Ballal, C. Reisner, Morristown, NJ, p.A6827


P60 Pharmacokinetics of a Novel Triple Fixed Dose Combination Metered Dose Inhaler: Comparison with the Free Combination and the Single Components/D. Cuomo, F. Mariotti, S. Collarini, A. Muraro, D. Acerbi, Parma, Italy, p.A6830

P61 Umeclidinium Dose-Response in Patients with Fixed Airflow Obstruction and Reversibility to Albuterol Irrespective of a Primary Diagnosis of Asthma or COPD/L. Lee, E. Kerwin, K. Collison, W. Wu, S. Yang, S. Pascoe, Stevenage, United Kingdom, p.A6831

P62 Comparative Assessment of Umeclidinium/Vilanterol (UMEC/VI) Combination Therapy Among Symptomatic Patients with COPD/E. Huisman, A. Ismaila, I. Naya, A. Karabis, Y.S. Punekar, Houten, Netherlands, p.A6832

P63 Health-Related Quality of Life Among Patients Who Experienced Prior COPD-Related Exacerbations: Post Hoc Analysis of a 52-Week Randomized Placebo-Controlled Trial of Nebulized Arformoterol Tartrate/J. Donohue, V. Ganapathy, L. Nelson, X. Zhou, Chapel Hill, NC, p.A6833


P66 SURF-COPD: The Recording of Cardiovascular Risk in Patients With Chronic Lung Disease/A. Dudina, S. Lane, M. Butler, M.-T. Cooney, I. Graham, Dublin, Ireland, p.A6836


THEMATIC POSTER SESSION

D37 COPD: DEVELOPMENTAL THERAPEUTICS

9:00 a.m. - 3:30 p.m.

Area A, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion 11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: R.C. Balkissoon, MD, Denver, CO


P71 A Phase I, Randomised, Double Blind, Placebo Controlled, Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Inhaled Doses of RPL554 Administered by Nebuliser to Healthy Male Subjects and Stable COPD Patients/D. Singh, K.H. Abbott-Banner, F. Reid, K. Newman, Manchester, United Kingdom, p.A6838

P81 Effects of Carbocysteine Lysine Salt in Patients with COPD/A. Lazaar, A. Baines, M. Ahmed, R. Boardley, A. Hussaini, King of Prussia, PA, p.A6840


P75 Safety and Efficacy of AQX-1125 in Chronic Obstructive Pulmonary Disease (COPD) - Results of the Phase 2 Flagship Study/D. Scholl, J. Vestbo, P. Tam, L. Mackenzie, C. Harwig, J. Toews, S. Shrewsbury, Vancouver, Canada, p.A6842


Facilitator: S.A. Christenson, MD, San Francisco, CA

P77 A Novel COPD Exacerbation Trial Design/M. Fageras, B.J. Make, N. Patel, P.M. Calverley, Molndal, Sweden, p.A6844

P78 Safety, Tolerability and Pharmokinetic Profile of CHF6001, a Novel COPD Exacerbation Trial Design/S.A. Christenson, MD, San Francisco, CA

P79 Genes or Dose, East or West What Makes N Acetyl Cysteine Safety, Tolerability and Pharmacokinetic Profile of CHF6001, a Novel COPD Exacerbation Trial Design/M.-A. Nandeuil, F. Mariotti, G. Lucci, D. Santoro, G. Poli, D. Acerbi, Courbevoie Cedex, France, p.A6845

P80 Too Much or Not Enough? Natural Products for Chronic Obstructive Pulmonary Disease (COPD)/A. Janssens, Leuven, Belgium, p.A6851


Facilitator: F.C. Sciurba, MD, Pittsburgh, PA


P87 The Inverse Relationship Between Volume and Expiratory Flow Identifies Chronic Obstructive Pulmonary Disease/A. Oh, T.A. Morris, I.T. Yoshii, T. Morris, San Diego, CA, p.A6853

P88 Oscillometry Small Airways Phenotypes Are Predictive of GOLD Classification, Lung Function and Emphysema but Not Chronic Bronchitis in Community Practice COPD/R.J. Dandurand, M. Dandurand, R.S.J. Estepar, J. Bourbeau, D.H. Eidelman, Montreal, Canada, p.A6854


P91 Influenza Vaccination in COPD Patients - No Detectable Changes in Lung Function, Systemic or Airway Inflammatory Markers/G. Donaldson, B. Kowlessar, R. Sapsford, A.R.C. Patel, A.J. Mackay, R. Singh, J.A. Wedzicha, United Kingdom, p.A6857


P97 Validation of Structured Light Plethysmography (SLP) Generated Respiratory Rate (RR) Against Clinician Over-Scored Capnography/S. Molamedi-Faktbr, R. Wilson, R. Iles, Ely, United Kingdom, p.A6863

P98 Validity Evaluation of Impulse Oscillometry (IOS) in Obstructive Lung Diseases Among Filipinos/A. Quing, R. Zotomayor, M. Ang, B.E. Macaraig, Quezon City, Philippines, p.A6864


P100 Application of Impulse Oscillometry and Bronchial Dilation Test for Analysis in Patients with Asthma and Chronic Obstructive Pulmonary Disease/P. Wang, Beijing, China, p.A6866

P101 Stops During the Six-Minute Walk Test and Its Correlation with New Measurements in Patients with Chronic Obstructive Pulmonary Disease (COPD)/M.J. Fernandez Sanchez, C.A. Celis Preciado, X. Correa Rios, O.M. Garcia, A. Canas-Arboleda, J.I. Lasso, C. Villaquiran-Torres, J.R. Lutz, Bogota, Colombia, p.A6867

P102 Correlation Between Percent Predicted of Forced Expiratory Volume in First Second (FEV1 % Predicted) and Six Minute Walk Distance (6MWD) in Patients of Chronic Obstructive Pulmonary Disease/N.K. Chauhan, S. Kumar, L.K. Saini, N. Dutt, P. Sanwaria, Jodhpur, India, p.A6868


Facilitator: C.H. Martinez, MD, MS, MPH, Ann Arbor, MI

P104 Correlation of Current Classification of Severity of Chronic Obstructive Pulmonary Disease in Global Initiative for Chronic Obstructive Lung Disease (GOLD 2015) with the 6 Minute Walk Test (6MWT) and 6 Minute Work (6MWT) Among Filipino Patients/M.M.J. Jampayas, C.A. Uy, R.F. Cabahug, Davao, Philippines, p.A6870


THEMATIC POSTER SESSION

D39 COPD: NON-PHARMACOLOGIC THERAPIES

9:00 a.m. - 3:30 p.m. MOSCONE CENTER

D39 COPD: NON-PHARMACOLOGIC THERAPIES

9:00 a.m. - 3:30 p.m.

Area A, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire duration.

Discussion: 11:00-11:45: authors will be present for discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: B.J. Make, MD, Denver, CO


P116 Impact of Non Invasive Open Ventilation (NIOV) on Dyspnea and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF)/A. Breiburg, K. Lam, G. Dhillon, C. Zone, M. Nicolls, W. Kuschner, Palo Alto, CA, p.A6881
D40  CRITICAL CARE: DIAGNOSING AND TREATING BACTERIAL AND VIRAL INFECTIONS IN THE ICU

9:00 a.m. - 3:30 p.m.  MOSCONEN CENTER

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators:  M.H. Kollef, MD, St. Louis, MO
K. Akrami, MD, Bethesda, MD


P696  CLABSI Data and Numeracy Among Clinicians: Results of a Twitter-Based International Survey/S. Govindan, V. Chopra, T.J. Iwashyna, Ann Arbor, MI, p.A6896

P238  Pre-Cannulation Lung Biopsy Shortens ECMO Course/P. Lohmann, T.C. Lee, D.L. Kearney, C.J. Fernandes, Houston, TX, p.A6919

P239  When Shortness of Breath is the Opposite of Orthopnea/A. Arjuna, New Jersey, NJ, p.A6920


P242  Dysphagia Aortica/R. Bansal, A. Surana, Upland, PA, p.A6923


P244  Aorto-Right Ventricular Fistula Following Percutaneous Trans-Catheter Aortic Valve Replacement/M.-K. Konda, J. Kalavakunta, V. Gupta, Kalamazoo, MI, p.A6925

P245  Left Main Coronary Artery Fistula to Right Pulmonary Artery Presenting as Sustained Monomorphic Ventricular Tachycardia/A. Al Akshar, S. Daniels, A. Abu Homoud, Neptune, NJ, p.A6926

P246  “Shot Through the Heart”: Atrial-Septal Fistula/C. Schuring, L. Mountjoy, Des Moines, IA, p.A6927


Facilitator: S.I. Kumar, MD, Los Angeles, CA

P248  Mild and Persistent Haemoptysis as a Rare Presentation of Aortic Pseudoaneurysm After Previous Coarctation Surgery/A.R. Garcia, H. Karlen, S. Quadrelli, M.A. Solis, M. Heres, Buenos Aires, Argentina, p.A6929


P250  Bilateral Central Retinal Artery Occlusion in Pregnant Women with Severe Preeclampsia Post Caesarian Delivery/G. Khifan, A. Arunachalam, S. Krishnan, Cleveland, OH, p.A6931


P252  Saved by the Bell: An Unusual Case of Aortic Dissection in a 40 Year Old Male/F. Khalid, S. Rehman, K. Alluri, S. Gupta, McKeesport, PA, p.A6934


P255  From Throat to the Heart, Until It Ripped Apart/H. Arshad, M. Young, R. Adury, Pittsburgh, PA, p.A6937


Facilitator: A. Bhardwaj, MD, Philadelphia, PA

P258  Intracardiac Leiomyomatosis: An Unusual Case of a Fatal Benign Tumor in a Post Total Abdominal Hysterectomy with Bilateral Oosalpino-Oophorectomy Woman/M.N. Jao, J. Orcasitas, Davao City, Philippines, p.A6940


P261  A Forgotten Cause of Cardiac Tamponade/J. Albo-Sanchez, J. Martinez-Gonzalez, W. Rodriguez-Cintron, San Juan, PR, p.A6943


P263  Simultaneous Pulmonary and Paradoxical Emboli with Impending Paradoxical Embolus; A Rare Presentation/M.Z. Rizwan, Z. Ahmad, S.N. Chalise, M. Al Janabi, N. Sultana, Z. Rehman, Greenville, NC, p.A6945

P264  TKO (The Knockout) of TPA, a Rare Case of Developing a STEMI Despite Being on a Tissue Plasminogen Activator Infusion/J.M. Chowdhury, V. Mehta, N. Pozzessere, A. Mohammed, A. Maheshwari, M. Kosa, S. Manns, Darby, PA, p.A6946


P266  A Case of an Incidental Finding of Persistent Left SVC/H. Hussein, H. Youness, Oklahoma City, OK, p.A6948


P269  Dabigatran Absorption and Congestive Heart Failure, a Potential Mechanism for Dabigatran Failure/A. Mack, Jacksonville, FL, p.A6951

P285 Left Ventricular Wall Rupture and Cardiac Tamponade During Transcatheter Aortic Valve Replacement/Y. Agrawal, J. Kalavakunta, F. Saltiel, V. Gupta, Kalamazoo, MI, p.A6964

P286 "Foreign Body in Heart", Complication from Central Venous Catheter Insertion/W. Humayun, A. Niroula, Abington, PA, p.A6965

P287 Large Pericardial Effusion Causing Recurrent Syncope - A Unique Presentation of Severe Untreated Hypothyroidism/S. Mawri, R. Dirani, S. Varghese, T. Raymond, C. Calle Muller, K. Alaswad, Detroit, MI, p.A6966


P293 A Case of Type 1 Cardiorenal Syndrome Treated with Using Velocity Time Integral to Non-Invasively Evaluate the Response to Dobutamine in Cardiogenic Shock/R. Pillai, B. Zakhary, V. Mukherjee, New York, NY, p.A6971


P295 A Case of Type 1 Cardiorenal Syndrome Treated with Combination Diuretic and Dobutamine Therapy/G.S. Thind, P. Patel, K. Kailasam, Kalamazoo, MI, p.A6972

P296 A Rare Cause of Cardiogenic Shock in a Young Male/Z.S. Shakir, Kansas City, KS, p.A6975


P304 Vasovagal Aystole from Bedside Pleurodesis with Doxycycline/ M. Islam, M. Harris, M. Bergman, New York, NY, p.A6982

P305 Synthetic Cannabinoid (K2) Related Cardiac Arrest and Death in Young Drug Abuser/E.E.-N. Wan, D. Frank, E. Bang, New York, NY, p.A6983

P310 HHV-6: An Unusual Cause of Psychosis in a Healthy Woman/ O. Chaudhary, M. Paul, Liverpool, NY, p.A6993


P312 Use of Extracorporeal Membrane Oxygenation and Aminocaproic Acid in a Severe Case of Leptospirosis Pulmonary Hemorrhage Syndrome/M.A. Pardinas Gutierrez, R. Mendrichaga, L. Rosario, R. Rico, H. Baier, S. Krick, Miami, FL, p.A6995

P313 An Unusual Case of Acute Respiratory Failure/T.A. Jabuonski, N. Alavian, D. Nandra, Houston, TX, p.A6996


D43 CRITICAL CARE CASE REPORTS: INFECTIONS LEADING TO CRITICAL ILLNESS

9:00 a.m. - 3:30 p.m. MOSCONTE CENTER Area G, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion 11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: G. Nair, MD, Mineola, NY/ S. Kanagalingam, MD, Burlington, VT

P721 Laryngeal Histoplasmosis Mimicking Laryngeal Cancer with Acute Life-Threatening Upper-Airway Obstruction/A. Rajagopal, M. Khosravi, Lexington, KY, p.A6984

P722 An Unusual Case of Pleuroparenchymal Abscess Formation from Esophageal-Pulmonary Fistula in Chronic Aspiration/A. Rajagopal, M. Khosravi, Lexington, KY, p.A6985


P729 An Unexpected Cause of Sudden Brain Death in an Immunocompetent Patient/A. Baig, J. Scott, Grand Rapids, MI, p.A6992


P732 Use of Extracorporeal Membrane Oxygenation and Aminocaproic Acid in a Severe Case of Leptospirosis Pulmonary Hemorrhage Syndrome/M.A. Pardinas Gutierrez, R. Mendrichaga, L. Rosario, R. Rico, H. Baier, S. Krick, Miami, FL, p.A6995

P733 An Unusual Case of Acute Respiratory Failure/T.A. Jabuonski, N. Alavian, D. Nandra, Houston, TX, p.A6996


P736 A Resident of the Bronx with Legionella Pneumonia and Cardiomyopathy/A. Gupta, M. Parekh, New York, NY, p.A6999


P739 A Case of Severe Legionnaires’ Disease with Hilar Lymph Node Necrosis in an Immunocompetent Host/S. Baroson, O. Anozie, S. Greuel, M. Patel, A. Ghimire, Syracuse, NY, p.A7002


P741 Management of Bilateral Infected Bullae in a Critically Ill Patient/J.K. Medepalli, R. Hebbeler-Clark, Cincinnati, OH, p.A7004

P742 Transbronchial Biopsy in a Severely Thrombocytopenic Patient with Cardiopulmonary Instability Required to Ultimately Diagnose Disseminated Histoplasmosis/T. Sjulin, D. Ferraro, C. Madar, Fort Sam Houston, TX, p.A7005


P746 An Unusual Case of Spontaneous Bacterial Peritonitis/A. Anozie, S. Grewal, M. Patel, A. Ghimire, Syracuse, NY, p.A7009

P747 Severe Generalized Tetanus: A Rare Complication of a Forgotten Disease/V.S. Sambhara, M. Abidali, A. Abidali, J.A. O’Hea, Phoenix, AZ, p.A7010


THEMATIC POSTER SESSION

D44  RESPIRATORY FAILURE: EXTRACORPOREAL LIFE SUPPORT
9:00 a.m. - 3:30 p.m.  MOSCONE CENTER
Area C, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: K. Gray, MD, MSci, Denver, CO
A. Combes, MD, PhD, Paris, France

P309  Early Prediction of ECMO-Eligibility for Severe ARDS in Adults/J.K. Bohman, Rochester, MN, p.A7014


P312  Predictors of Mortality in Adults with Acute Respiratory Failure Treated with Extracorporeal Membrane Oxygenation/S. Sangli, S.F. Noronha, R.A. Jean, N. Kotecha, R. Jean, New York, NY, p.A7017


Facilitator:  H.J. Dalton, MD, Anchorage, AK


P320  Extracorporeal Carbon Dioxide Removal to Facilitate Extubation in Severe Chronic Obstructive Pulmonary Disease Exacerbation - Preliminary Experience in Chile/J. Graf, R. Lopez, I. Caviedes, H. Cabello, F. Dascalzi, A. Umana, Santiago, Chile, p.A7025

P321  Extracorporeal Membrane Oxygenation Use in a Patient with Multiple Severe Co-Morbidities/A.J. Shah, R. Doobay, D. Landsberg, Syracuse, NY, p.A7026

P322  Use of Continuous Venovenous Hemofiltration to Curtail Myoglobin-Induced Pigment Nephropathy: A Case Report/M. Yaqoob, A. Alkhaitib, B.L. Jaber, Brighton, MA, p.A7027


THEMATIC POSTER SESSION

D45  CRITICAL CARE: CIRCULATORY HEMODYMANICS, SHOCK, CARDIOVASCULAR DISEASE, AND FLUID MANAGEMENT
9:00 a.m. - 3:30 p.m.  MOSCONE CENTER
Area C, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.
Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitators: B.T. Thompson, MD, Boston, MA
K.R. Famous, MD, PhD, San Francisco, CA
D. Kadaria, MD, Memphis, TN

P327  Adherence to Advanced Cardiac Life Support (ACLS) and Outcomes at an Inner Urban City Hospital/J.A. Kileci, A. Patrawalla, Newark, NJ, p.A7029


P336 Ultrasound Hemodynamics and Lung Ultrasound Identify Under- Resuscitated Patients in the Medical Intensive Care Unit/V. Sharma, R. Gueret, A. Vasireddy, B. Ninan, J. Bailitz, Chicago, IL, p.A7038

P337 Epoint to Septal Separation (EPSS) Is a Better Discriminant of Left Ventricular Function than Fractional Shortening in Critically Ill Patients/V. Sharma, R. Gueret, B. Ninan, A. Vasireddy, J. Bailitz, Chicago, IL, p.A7039


P341 Specific Components of the Inflammatory Reflex: Heart Rate Variability (HRV) and IL-6 Predict Septic Shock in Critical Ill Patients/M.J. Fernandez Sanchez, A. Riveros Rivera, O. Sanabria, Bogota, Colombia, p.A7043

P342 Variations in Pulse Oximetry Waveforms in Critically Ill Patients to Assess Hemodynamic Changes During Mechanical and Spontaneous Ventilation: A Pilot Study to Evaluate Reliability/K. Stern, S. Chowdhury, E. Kapttein, A. Baydur, Los Angeles, CA, p.A7044


P345 Effects of Fluids Administration in Patients with Septic Shock with or Without Heart Failure/... L. Sargsyan, G.M. Aisenberg, M. Rosenthal, B. Alhafez, K.-W. Chang, Houston, TX, p.A7049


P347 Pericardial Effusion in End-Stage Renal Disease/L. Sargsyan, G.M. Aisenberg, M. Rosenthal, B. Alhafez, K.-W. Chang, Houston, TX, p.A7049


Facilitators: P.L. Silva, PhD, Rio de Janeiro, Brazil
R.S. Stephens, MD, Baltimore, MD


P352 Levosimendan Use Increases Cardiac Performance After Coronary Artery By-Pass Grafting in End-Stage Renal Disease Patients/O.F. Dogan, S. Colak, H. Ozgen, A.H. Kurt, C.C. Okten, Adana, Turkey, p.A7054
P353  A New Surgical Approach to Internal Thoracic Artery Spasm Treatment Using the Radial and Gastroepiploic Arteries during Coronary Artery Bypass Graft/O.F. Dogan, H. Ozgen, C.C. Okten, Adana, Turkey, p.A7055


P357  Anticoagulation May Increase the Risk of Acute Respiratory Failure in Patients with Acute Cardiogenic Pulmonary Edema/M. Ghamlouch, J. Abulkhair, M. Habib, N.S. Hill, Boston, MA, p.A7059

P358  Serum Pregnancy-Associated Plasma Protein A (PAPP-A) Vs GRACE Scale for Risk Estimation in Patients with Acute Coronary Syndrome/M. Ojrzanowski, A. Lipinska-Ojrzanowska, J.D. Kasprzak, Lodz, Poland, p.A7060


P360  Predictors of Repeat Invasive Percardial Procedures/D. Herman, S. Lilly, Columbus, OH, p.A7062


THEMATIC POSTER SESSION

D46  CASE REPORTS IN ENVIRONMENTAL AND OCCUPATIONAL HEALTH

9:00 a.m. - 3:30 p.m. MOSCONE CENTER


D46.04  Pleuroparynchelal Fibroelastosis Due to Long-Term Silica Exposure/C.C. Shaffer, N. Rassaei, Hershey, PA, p.A7070

D46.05  Chronic Hypersensitivity Pneumonitis Associated with Inhaled Exposure to Nylon Powder for 3-D Printing: A Variant of Nylon Flock Worker’s Lung Disease/R. Almadi, G.R. Bourjeily, R. El-Bizri, Providence, RI, J.W.E. Fleischman, J. Shin, F. Li, Walnut Creek, CA, p.A7065


Metastatic Desmoplastic Mesothelioma Presenting with Bone Pain and Diplopia/ A. Moskowitz, P. VanderLaan, A. Anandaiah, K. Krecko, H. Koziel, Boston, MA, p.A7078

Organizing Pneumonia in a Military Deployer Returning from Iraq/ S. D. Krefft, S. P. DelVecchio, C. Rose, Aurora, CO, p.A7079

Anything to Get Out of House Work?/ Z. S. Dreyfuss, K. Proud, San Antonio, TX, p.A7080

Facilitator: K. A. Pacheco, MD, MSPH, Denver, CO


Endobronchial Silicosis and Tuberculosis Presenting as the Right Middle Lobe Syndrome/ J. Anderson, S. Leong, D. Godbolt, K. Fong, H. Marshall, Brisbane, Australia, p.A7083


Pneumoconiosis Presenting with Recurrent Pneumothorax/ J. Seashore, T. McGarry, Queens, NY, p.A7085


Facilitator: P. S. Lai, MD, MPH, Boston, MA

Hot Tub Lung. Unique Diffuse Environmental Pulmonary Lung Disease Due to Atypical Mycobacterium/ M. Rudrappa, L. Kokatnur, Shreveport, LA, p.A7087


9/11 Consequences; Reversible or Not?/ S. Shihadeh, Flushing, NY, p.A7089

Twenty Year Old Female with Rapidly Progressive Dyspnea/ N. R. Mohammed, Minia, Egypt, p.A7090


An Unexpected Bronchoscopic Finding Associated with Marijuana Use/ M. Shaftq, G. J. Berry, Y. Sung, Stanford, CA, p.A7092

Facilitator: R. A. Accinelli Tanaka, MD, Lima, Peru

Factors Associated with Tuberculosis Infectiousness and Excess Alcohol Use in Franklin County, Ohio/ Y. Negatu, M. Exline, S. Tapyrik, T. Mathew, S.-H. Wang, Columbus, OH, p.A7099

Chernobyl Disaster and Tuberculosis Among Children and Teenagers/ L. Gorbach, Minsk, Belarus, p.A7100

Exposure to a Mycobacterial Antigen Exacerbates Inflammation and Fibrosis in a Multi-Wall Carbon Nanotube MWCNT Model of Pulmonary Granulomatous Disease/ A. Malur, B. P. Barma, M. McPeek, L. Dobbs, C. J. Wingard, M. J. Thomassen, Greenville, NC, p.A7101

Environmental Exposure of Panamanian Health Care Workers to Mycobacterium Tuberculosis at Hospital and Clinics in Colon, Panama/ D. Sambrano, C. Ordonez, V. Batista, A. De Chavez, O. Luque, A. Goodridge, City of Knowledge, Panama, p.A7102
The Effect of Simulated Microgravity on Biological Characteristics of Klebsiella Pneumoniae/P. Wang, J. Wang, Beijing, China, p.A7103


Facilitator: E.M. Carmona, MD, PhD, Rochester, MN


Cancer Is Not Always the Answer/D.U. Otu, R.M. Ruggiero, Dallas, TX, p.A7118


Laryngeal Histoplasmosis as Cause of Chronic Dysphonia and Dysphagia: A Case Report and Review of Literature/C. Villaquiran-Torres, J. Buitrago, J. Torres, Bogota, Colombia, p.A7123

Healing and Hardening: Focal Fibrosing Mediastinitis Due to Histoplasmosis/R. Bishwakarma, R. Papani, V.G. Valentine, Galveston, TX, p.A7124

Facilitator: O. Hilberg, MD, Aarhus, Denmark


Hypercalcemia of Coccidioidomycosis, Less Prevalent and Unknown Complication of Primary Disease/E. Jaffer, S. Patel, A. Pothehalu, Tucson, AZ, p.A7126

Isolated Coccidioidomycosis Empyema Diagnosed from a Pleural Biopsy in a Serology-Negative Patient/J. Hall, A. Thomas, Phoenix, AZ, p.A7127


A Rare Case of Coccidioides Immitis Cultured from an Immunocompetent Patient in Non-Endemic UK/C.L. Tey, B. Prathibha, Ashford, United Kingdom, p.A7129
P795 Could There Be a Fungus Among Us?

P793 Unusual Presentation of an Unusual Fungus: Blastomycosis-Associated ARDS, Case Report and Review of Disseminated Blastomycosis in an Immunocompetent Patient

P791 Exophiala Pneumonia Presenting as an Eosinophilc A. Catanzaro, MD, La Jolla, CA

P790 Pulmonary Cryptococcosis in Immunocompetent Patient, a Case of Endobronchial Ultrasound Use in the Diagnosis of Pneumocystis Jirovecii Pneumonia in an Immunocompetent Patient

P789 A Unique Presentation of Asymptomatic Pulmonary Mucormycosis as a Pulmonary Mass/K. Bakhsh, G. Lenchner, Philadelphia, PA, p.A7132

P788 A Unique Presentation of Asymptomatic Pulmonary Mucormycosis as a Pulmonary Mass/K. Bakhsh, G. Lenchner, Philadelphia, PA, p.A7132

P787 Are We Missing a Fungus Among Us?/J. Loeb, D.R. Fraidenburg, Chicago, IL, p.A7133


P784 Pneumocystis Jirovecii Causing Necrotizing Granulomas Presenting as Multiple Pulmonary Nodules in an Immunocompetent Patient/B.M. Walsh, Y.B. Mehta, Danville, PA, p.A7135

P783 Are We Missing a Fungus Among Us?/J. Loeb, D.R. Fraidenburg, Chicago, IL, p.A7133


P780 AN UNUSUAL CAUSE OF CAVITARY LESION: WHEN DIAGNOSIS REQUIRES BIOPSY/P. Tsing, A. Chung, Los Angeles, CA, p.A7131


P778 Saccharomyces Cerevisiae Empyema/M. Al Janabi, M.S. Tale of Three Fungi/Dr. sale of Literature/T. Kazui, J. Malo, Tucson, AZ, p.A7140

P777 Rare Fungal Infection in Patient with Pulmonary Tuberculosis Sequelae/B.N. Endlich, F.M. Costa, E.P. Oliveira, C.M. Padovesi, M.C.N.T. Maiorano, A.W. Mariani, R.A. Athanazio, S.Z. Rached, R.K.B. Sales, A.N. Costa, Sao Paulo, Brazil, p.A7149


P774 Mediastinal Mass, Growth Hormone and Septic Arthritis/Not an Everyday Case of Dyspnea-Pseudomembranous Tracheobronchitis Caused by Pseudomonas Aeruginosa Infection/M.S. Khan, J.C. Claros-Sorto, A.C. Porter, Oklahoma City, OK, p.A7152

P773 A Case of Pseudomonas Aeruginosa Bacteremic Pneumonia in a Patient with Pulmonary Coccidioidomycosis-Related Acute Respiratory Distress Syndrome/Requires Biopsy/J. Callaway, K. Swanson, A. Budavari, K. Yaqub, Scottsdale, AZ, p.A7145

P772 Necrotizing Bacterial Tracheobronchitis in a Non-Mechanically Ventilated Adult/A. Shahmohammadi, A. Biswas, E.S. Papierniak, Gainesville, FL, p.A7156


P769 Necrotizing Granulomas Associated ARDS, Case Report and Review of the Literature/D. Frye, F. Almeida, Cleveland, OH, p.A7140

P768 A Case of Endobronchial Ultrasound Use in the Diagnosis of Thoracic Infection/L. Frye, F. Almeida, Cleveland, OH, p.A7140


P764 A Case of Pulmonary Cryptococcosis in an Immunocompetent Woman /M.K. Loya, Sayre, PA, p.A7139

P763 A Case of Pseudomonas Aeruginosa Bacteremic Pneumonia in a Patient with Pancreatic Cancer Who Received Pegfilgrastim Followed by Outpatient Chemotherapy/F. Morita, Y. Hirai, K. Suzuki, Y. Uehara, K. Mitsushi, M. Takahashi, S. Watanabe, T. Naito, Hong, Bunkyou-ku, Tokyo, Japan, p.A7153


P758 A Case of Pseudomonas Aeruginosa Bacteremic Pneumonia in a Patient with Pulmonary Coccidioidomycosis-Related Acute Respiratory Distress Syndrome/Requires Biopsy/J. Callaway, K. Swanson, A. Budavari, K. Yaqub, Scottsdale, AZ, p.A7145

P757 Blastomycosis-Associated ARDS, Case Report and Review of the Literature/D. Smith, N. Abi Hatem, S. Le, S. Aziz, Roanoke, VA, p.A7143

P756 Unusual Presentation of an Unusual Fungus: Blastoschizomyces Capitatus/H.H. Desai, M. Dalalih, A. Witten, Tucson, AZ, p.A7144

P755 Exophiala Pneumonia Presenting as an Eosinophilc Pneumonia in an Immunocompetent Patient/J. Callaway, K. Swanson, A. Budavari, K. Yaqub, Scottsdale, AZ, p.A7145

P754 Could There Be a Fungus Among Us?/M.J. Sanley, R. Gross, Washington, DC, p.A7146

Facilitator: O. Epelbaum, MD, Elmhurst, NY

Facilitator: A. Catanzaro, MD, La Jolla, CA

Facilitator: G.W. Waterer, MBBS, PhD, MBA, Perth, Australia
P809  Papular-Purpuric Gloves and Socks Syndrome in a 46-Year-Old Man with Mycoplasma Pneumoniae Infection/J. Jankovic, D. Pesut, Belgrade, Serbia, p.A7159

P810  Mycoplasma Pneumoniae Infection Alone Leading to Severe, Complicated Pneumonia and Respiratory Failure in a Previously Healthy Child/A.G.S. St-Laurent, T. Sotindjo, A. Roberts, Montreal, Canada, p.A7160


P813  Legionella Pneumonia in a Systemic Lupus Erythematosus Patient Requiring Extracorporeal Membrane Oxygenation/E. Espinoza Moscoco, J. Swiderek, Detroit, MI, p.A7163


P818  Pulmonary Nocardiosis Masquerading as Metastasis in a Patient with Pancreatic Neuroendocrine Cancer/A. Selvachandran, K. McDonald, P. Desilva, D. Datta, Farmington, CT, p.A7168

P819  Rising Incidence of Nocardiosis: A Conundrum of Monoclonal Antibody Therapy/A. Tirmizi, E. Galvez-Guerra, L. Beachamps, J. Parham, Jackson, MS, p.A7169

P820  Cavitary Pulmonary Disease Due to Achromobacter Denitrificans/A. Tirmizi, E. Galvez-Guerra, L. Beachamps, Jackson, MS, p.A7170

P821  The Great Pretender/N. Alvi, R. Almeida, Kankakee, IL, p.A7171


P823  A Rare Case of Empyema Caused by Community Acquired Pulmonary Actinomycosis and Group D Streptococcus/Y. Naidu, N. Alqsous, C. Rusu, M. Matos, Rochester, NY, p.A7173

P824  Human Necrobacillosis: Let's We Forget/E. Nadler, J. Goralkin, B. Considine, Z. Tushak, Farmington, CT, p.A7174

P825  Pseudomonal Pneumonia and Empyema Complicating Lemierre's Syndrome/M. Megally, S. Milan, R. Minkin, Brooklyn, NY, p.A7175


P829  Aspiration Meningitis: Mediastinitis and Brain Abscess Due to Streptococcus intermedius/A. Alam, A. Aragaki-Nakahodo, R.R. Balestra, Cincinnati, OH, p.A7179


P833  Curing the Contaminant/G. Thompson, J. O'Horo, R. Vassallo, Rochester, MN, p.A7183

P834  Rare Case of Empyema with Clostridium Septicum Lead Us to Diagnosis of GI Malignancy/M. Alzoby, M. Shorman, M. Al-Ourni, E. Alkhankan, N. Munn, Huntington, WV, p.A7184


P840 Is Lung Biopsy Needed for Positive Cytomegalovirus Poly
Chain Reaction (PCR) on Bronchoalveolar Lavage in
Immunocompromised Host?/F. Aldaas, D.J. Rudolph, Z. Saul,
Bridgeport, CT, p.A7190

P841 First Reported Case of Respiratory Syncytial Virus Infection
Causing Guillain-Barre Syndrome/S. Helgeson, D. Harris,
Jacksonville, FL, p.A7191

P842 Severe Pneumonia and Acute Respiratory Distress Syndrome
Caused by Human Metapneumovirus in an Immunocompetent

P843 Rhinovirus Infection Resulting in Respiratory Failure and
Acute Respiratory Distress Syndrome/J. Krings, R.D. Shah, R.G.
Wunderink, Chicago, IL, p.A7193

P844 Motor Nerve Involvement with Herpes Zoster Infection/S.
Hadigal, S. Daouk, V. Vanam, S. Chandrashekaran, Gainesville,
FL, p.A7194

P845 Pleuropulmonary Disease as the Initial Presentation of
Extra-Intestinal Amebiasis/C.A. Goulbourne, F. Christian, T.
James-Goulbourne, Brooklyn, NY, p.A7195

Facilitator: I. Martin-Loeches, MD, PhD, Barcelona, Spain

P846 Ameobic Pneumonia: A Unique Case/B. Lopez-Gonzalez, S.
Rodriguez-Llamazares, E. Pena-Mirabal, O. Sanchez-Cabral,
Mexico City, Mexico, p.A7196

P847 A Case of Primary Pulmonary Amebiasis/R.C. Daya, Davao
City, Philippines, p.A7197

P848 Massive Pulmonary Echinococcal Cyst Infiltration
Masquerading as a Non-Resolving Tuberculous Pleural
Effusion/A.K. Graham, Johannesburg, South Africa, p.A7198

P849 An Unlikely Cause of Shortness of Breath in an AIDS Patient/S.
Dixit, L. Santhosh, L. Huang, San Francisco, CA, p.A7199

P850 The Clot Thickens/J.Y. Fung, T.J. Harkin, New York, NY, p.A7200

P851 Microfilaria in Transbronchial Lung Biopsy (TBLB) in Patient
with Multiple Lung Infections and Low Serum IgM Levels/G.C.
Khinani, P. Tiwari, S. Arava, A.S. Bhalla, V. Hadda, K. Madan, A.
Mohan, R. Guleria, New Delhi, India, p.A7201

P852 Recurrent Pneumonia Secondary to Endobronchial
Hamartoma/J.-P. Soberano, K. Hussain, Morgantown, WV, p.A7202

Facilitator: L.R. Young, MD, Nashville, TN

P513 A Panel of Novel Blood Tests Based on GM-CSF Signaling
Facilitates the Differential Diagnosis of PAP-Causing
Diseases/B. Carey, C. Chalk, T. Suzuki, B.C. Trapnell, Cincinnati,
OH, p.A7224

P514 Pulmonary Abnormalities in Adults with Familial
Neuroendocrine Cell Hyperplasia of Infancy (NEHI)/L.R. Young,
p.A7232

P515 Bombseline Staining May Be a Useful Marker in Idiopathic
Interstitial Pneumonias Other Than NEHI/N. Emiralioglu, D.
Orhan, N. Kiper, G. Cinel, G. Tugcu, E. Yalcin, D. Dogru, U.
Ozcilk, M. Gries, Ankara, Turkey, p.A7214

P516 Respiratory Characteristics in Patients with Familial
Dysautonoma/M. Kazachkov, N. Tkachenko, J.A. Palma, L.
Norcliffe-Kaufmann, N. Fefferman, C. Spalink, S. Kothare, H.
Kaufman, New York, NY, p.A7206

P517 Long Non-Coding RNA Malat1 Participates in the
Pathogenesis of Pulmonary Fibrosis/N. Xie, J. Ge, H. Cui, S.
Banerjee, V.J. Thannickal, G. Liu, Birmingham, AL, p.A7238

P518 Soluble Ephrin-B2 Is a Novel Biomarker of Pulmonary
Fibrosis/S.B. Montesi, M. Namade, A. Pardo, M. Seiman, A.M.
Tager, D. Lagaes, Boston, MA, p.A7217

Facilitator: A.M. Casey, MD, Boston, MA

P519 The Morphology of Tricuspid Valve at TVR in Physiologic
Surgery for cCTGA Patients/K. Hirose, K. Yamanaka, T. Nishina,
A. Mizuno, Tenri City, Japan, p.A7209

P520 The Clinical Implications of Lower Airway Anomalies in
Children with Congenital Heart Disease/C.-C.E. Wang, S.-J.
Chen, E.-T. Wu, S.-C. Huang, M.-H. Wu, J.-K. Wang, Taipei,
Taiwan, p.A7210

P521 Impact of School Electrocardiography Mass Screening on the
Diagnosis of Atrial Septal Defect in Children/H. Sawada, H.
Shimp, K. Maruyama, Y. Komada, Y. Mitani, Tsu City, Mie, Japan,
p.A7211

P522 Aortic Wall Shear Stress and Left Ventricular Systolic
Performance are Reduced in Pediatric Patients with Pulmonary
Arterial Hypertension/M. Schafer, K.S. Hunter, D. Ivy, S. Abman,

P523 Right Ventricular Function Is a Predictor of Functional Class in
Pediatric Pulmonary Hypertension/B. Pandya, S. Moleidina, V.
Muthurangan, United Kingdom, p.A7228

Facilitator: D.R. Liptzin, MD, Aurora, CO

P524 HEATR2 Regulates Ciliogenesis and Distinguishes Subclasses
of Preassembly Factors Mutated in Primary Ciliary
Dyskinesia/A. Horani, T. Huang, J. Pan, S.L. Brody, St. Louis, MO,
p.A7236

P525 Cri-du-Chat Syndrome and Primary Ciliary Dyskinesia: A
Genetic and Clinical Connection/C. Donnellan, M. Leigh, M.
Zarivala, M. Knowles, W. Wolf, D. Campbell, A.J. Shapiro, Chapel
Hill, NC, p.A7235


P537  Antibody-Mediated Rejection Is Associated with Decreased Survival Following Pediatric Lung Transplantation/P.H. Michelson, J. Blatter, A. Faro, R.M. Grady, P. Egthesady, S. Sweet, St. Louis, MO, p.A7222


Facilitator:  S.D. Dell, MD, Toronto, Canada

P539  Natural Evolution and Impact of Respiratory Tract Infections in Nasal Nitric Oxide Level During First 2 Years of Life - A Longitudinal Study/J.K. Marthin, M.C. Philipsen, S. Rosthoj, K.G. Nielsen, Copenhagen, Denmark, p.A7203

P540  Nasal Nitric Oxide in Primary Immunodeficiency: Helping to Distinguish Between Clinically Similar Diseases/Z. Zysman-Colman, R. Alizadehfar, A.J. Shapiro, Montreal, Canada, p.A7204


P542  Ciliary Functional Biomarker Analysis in Pediatric Patients with Chronic Cough/P. Shukla, A. Bangoura, L. Leatherbury, D.K. Pillai, Washington, DC, p.A7208


Facilitator:  A. Hilgendorff, MD, Munich, Germany


P549  In Pulmonary Artery Smooth Muscle Cells, HIF-1α Downregulates Endothelin Expression Via microRNA-543/C.-C.E. Wang, L. Ying, D.N. Cornfield, E. Adam, Stanford, CA, p.A7915

P550  Diagnosing Foreign Body Aspiration in Children Using a New Clinical Algorithm and Scoring System/L.A. Janahi, S. Khan, P. Chandra, N. Al-Marri, A. Sadoon, L. Al-Naimi, W. Greer, M. Al-Thani, Doha, Qatar, p.A7916

P565 Pulmonary Hemorrhage in Food-Induced Anaphylaxis in a Pediatric Patient/A. Sheybani, H.S. Agarwal, Albuquerque, NM, p.A7266

Facilitator: C. Rosas-Salazar, MD, MPH, Nashville, TN


P569 A Rare Case of Eosinophilic Pneumonia/F. Afolabi, T. Martinez, Dallas, TX, p.A7263

Facilitator: M. Bansal, MD, Los Angeles, CA

P570 Infection of a Chronic Pleural Effusion Associated with Persistent Right Lung Collapse/E. Kramer, K.M. McDowell, Cincinnati, OH, p.A7246


P572 Pulmonary Hemorrhage in a Child with a Single Ventricle and Glenn Physiology Found to Have Hemophagocytic Lymphohistiocytosis/M. Mahabee, Y. Vaks, Ioma linda, CA, p.A7254

P573 Right Lung Agenesis with Dextrocardia Presenting with Stridor requiring Tissue Expander Placement/Y. Agrawal, C. Jacob, J. Kalavakunta, Kalamazu, MI, p.A7262

P574 Chronic Eosinophilic Pneumonia in a 15-Year-Old Girl with Persistent Cough/E. Hamberger, K. Tsirilakis, Great Neck, NY, p.A7264

P575 Misdiagnosis of Recurrent Pneumonia in an Obese Boy Found to Be Secondary to Protein Malnutrition/R. Wadia, E. Fong, Oakland, CA, p.A7247

Facilitator: M. Newaskar, MD, Oakland, CA

P576 Not Your Ordinary Pneumonia in a Teen/B.A. Stewart, D. Mark, Mark, D. N. Cornfield, Palo Alto, CA, p.A7245


P578 Unilateral Hyperlucent Lung in an Infant/J.C. Lee, St. Louis, MO, p.A7259

Facilitator: M. Neubauer, MD, Oakland, CA
Molecular Insight into Pulmonary Hypertension

Enlarged, Hyperlucent Lung in a Five Month Old Male with Multiple Congenital Anomalies/S.J. Khalfoun, B. Allen, Columbus, OH, p.A7260

Hemorrhagic Complication of Intrapleural tPA in a One Year Old Baby/S.Q. Ahmad, S. Agrawal, H. Lee, Brooklyn, NY, p.A7267

Hemolysis Reduces HUWE1 Through PPAR Deficiency of TIMP-1 Is Protective in a Model of Pulmonary Hypertension and Improved Pulmonary VascularSmooth Muscle Cells/D.E. Green, T.C. Murphy, C.M. Hart, Atlanta, GA, p.A7279

Facilitator: P. Dorfmuller, PhD, MD, Le Plessis Robinson, France


The Role of Macrophage Migration Inhibitory Factor on Antioxidant Responses During Cigarette Smoke/M. Aladdin, L. Varela, J. Fallica, P.M. Hassoun, R.L. Damico, Baltimore, MD, p.A7281


Aerobic Glycolysis Is Sufficient, but Not Necessary, for Rapid Proliferation of Pulmonary Endothelial Cells/J.Y. Lee, T. Stevens, Mobile, AL, p.A7283


RP5063 Prevents Monocrotaline Induced Pulmonary Arterial Hypertension in Rats/L. Bhat, D. Salvail, A. Bouchard, J. Hawkinson, M. Cantillon, Santa Clara, CA, p.A7286

Lactate Activates Akt Through Calpain in Pulmonary Artery Smooth Muscle Cells/L. Kovacs, Y. Su, Augusta, GA, p.A7287

A Scratch-Induced Interaction Between Extracellular Sodium and Orai1 Is Critical for Endothelial Wound Healing/N. Xu, T. Stevens, Mobile, AL, p.A7288


Characterization of TGF-β and BMP Signaling in Rat Models of PH/C.M. Happe, K. Kurakula, N. Rol, D. Bos, X. Sun, C. Van Der Bruggen, A. Vonk Noordegraaf, M.-J. Goumans, F.S. De Man, H.J. Bogaard, Amsterdam, Netherlands, p.A7278

MicroRNA-21 and PDCD4 Mediate Antiproliferative Effects of PPAγ in Hypoxia-Exposed Human Pulmonary Artery Smooth Muscle Cells/D.E. Green, T.C. Murphy, C.M. Hart, Atlanta, GA, p.A7279

Facilitator: P. Dorfmuller, PhD, MD, Le Plessis Robinson, France


The Role of Macrophage Migration Inhibitory Factor on Antioxidant Responses During Cigarette Smoke/M. Aladdin, L. Varela, J. Fallica, P.M. Hassoun, R.L. Damico, Baltimore, MD, p.A7281


Aerobic Glycolysis Is Sufficient, but Not Necessary, for Rapid Proliferation of Pulmonary Endothelial Cells/J.Y. Lee, T. Stevens, Mobile, AL, p.A7283


RP5063 Prevents Monocrotaline Induced Pulmonary Arterial Hypertension in Rats/L. Bhat, D. Salvail, A. Bouchard, J. Hawkinson, M. Cantillon, Santa Clara, CA, p.A7286

Lactate Activates Akt Through Calpain in Pulmonary Artery Smooth Muscle Cells/L. Kovacs, Y. Su, Augusta, GA, p.A7287

A Scratch-Induced Interaction Between Extracellular Sodium and Orai1 Is Critical for Endothelial Wound Healing/N. Xu, T. Stevens, Mobile, AL, p.A7288

P919  Alternative Splicing of the Cardiac Sodium Channel in Pulmonary Arterial Hypertension

P920  Increased Expression of NPY1R Mediated Increased Vascular Reactivity to NPY

P921  16α-Hydroxyestrone Increases Oxidative Stress Through NADPH Oxidase 4 and Nrf2 Dysfunction Specifically in Human Pulmonary Artery Smooth Muscle Cells

P922  Dynamic Mapping of Lung Vascular Development

P923  Intrauterine Caloric Restriction Affects the Expression of Genes Involved in Pulmonary Endothelial Function

P924  FTY720 S-Phosphonate Does Not Activate GRK2-Mediated S1PR1 Phosphorylation and Degradation

P925  Structure Dependent PK Profiles of Alkyl Ester Treprostinil Prodrugs (TPD) Administered Via Metered Dose Inhaler to Rats

P926  The Matrinike Acetylated Proline-Glycine-Proline (AcPGP) Couples Extracellular Matrix Fragmentation to Pulmonary Microvascular Remodeling and Pulmonary Hypertension

P927  Hyperspectral Imaging Approaches Allow Real Time 3D Measurement of cAMP Gradients in Pulmonary Microvascular Endothelial Cells

P928  Simultaneous, Real Time, Measurement of 3D cAMP and Ca2+ Signals Using Hyperspectral Imaging and Analysis Approaches

P929  Differential Response to Serial Microsphere Infusions During Creation of Canine and Porcine Models of Pulmonary Hypertension

P930  Heme Oxygenase-1 Is Cardioprotective Against Hyperoxia

P931  Sustained Activation of RhoGTPases Promote a Synthetic Pulmonary Artery Smooth Muscle Cell Phenotype in Nephrilysin Null Mice

P932  Lympathics in Pleura in Normal, Malignant Pleural Effusion, and Septic Mouse Models

P933  Bone Morphogenetic Protein 9 Enhances Toll-Like Receptor 4 Expression and Lipopolysaccharide-Induced Leukocyte Recruitment to the Vascular Endothelium Via Activin Receptor-Like Kinase-2

P934  SMAD3 Contributes to Lung Vascular Remodeling in Pulmonary Arterial Hypertension Via MRTF Disinhibition: A New Pathomechanism

P935  Bortezomib Alleviates Experimental Pulmonary Hypertension by Regulating Intracellular Calcium Homeostasis in PASMCs

P936  Quercetin Induce Autophagy Via FOXO1-Dependent Pathways and Autophagy Suppression Enhances Quercetin-Induced Apoptosis of PASMCs

P937  Therapeutic Role of Serum Response Factor (SRF) Specific shRNA in the Treatment of Hypoxic Pulmonary Hypertension

P938  Fucoidan, a Natural Polysaccharidic Ligand of P-Selectin, Obstructs Hypoxia-Induced Pulmonary Arterial Hypertension and Acute Lung Vasocstriction

P939  Adventitial Remodeling of Experimental Pulmonary Hypertension Induces Myofibroblast-Produced Collagen V in a Th17-Pathways-Related Manner

P940  The Regulation of Hypoxia-Inducible Factors by C-Jun N-Terminal Protein Kinases

P941  The Role of Smooth Muscle Cathepsins in Pulmonary Arterial Hypertension Associated with Systemic Lupus Erythematosus

P942  LIM-Only Protein FH2 Suppresses Pulmonary Artery Endothelial Cell Proliferation Through Activation of BMP Signalling

P943  ARDS Decreases Pulmonary Artery Compliance in a Porcine Model
### THEMATIC POSTER SESSION

- **D53**
  - **THE PROMISED LAND: CLINICAL STUDIES IN PULMONARY HYPERTENSION**
  - **9:00 a.m. - 3:30 p.m.**
  - **MOSCONCE CENTER**
  - **Area H, Hall D (North Building, Lower Level)**
  - **Viewing:** Posters will be on display for entire session.
  - **Discussion:**
    - 11:00-11:45: authors will be present for individual discussion
    - 11:45-12:45: authors will be present for discussion with assigned facilitators
  - **Facilitator:** Z. Jing, MD, Beijing, China

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>P946</td>
<td>Application of the Criteria for Satisfactory Clinical Response to Thermodilution and Indirect Fick Are Inaccurate Methodologies to Determine Cardiac Index in Patients with Pulmonary Arterial Hypertension/W. Dakkak, Y. Rao, X. Zhou, R. Dweik, A.R. Tonelli, Cleveland, OH, p.A7315</td>
</tr>
<tr>
<td>P947</td>
<td>Early Pulmonary Vascular Dysfunction in Exercise-induced Heart Failure with Preserved Ejection Fraction: Prognostic Implications/W. Huang, R.K. Oliveira, D. Systrom, H. Lei, A. Waxman, Chongqing, China, p.A7316</td>
</tr>
<tr>
<td>P949</td>
<td>The Long-Term Outcomes in Patients with Exercise-Induced Pulmonary Arterial Hypertension/W. Huang, D. Systrom, A. Waxman, Chongqing, China, p.A7317</td>
</tr>
<tr>
<td>P950</td>
<td>The Comparative Outcome of Incident Patients with Pulmonary Hypertension Due to Lung Disease According with the Haemodynamic Classification of the 2015 ESC-ERS Pulmonary Hypertension Guidelines/C. Bachetti, A. Rinaldi, M. Palazzini, F. Dardi, G. Mazzanti, E. Gotti, A. Albini, E. Monti, S. Fukui, D. Guarino, N. Galie, A. Manes, Bologna, Italy, p.A7318</td>
</tr>
<tr>
<td>P955</td>
<td>Calificed Lesions on Computed Tomography and Their Clinical Impact in Pulmonary Arterial Hypertension/V. F. Tanguay, G. Ruffenach, S. Chabot, D. Montani, S. Bonnet, O. Boucherat, S. Provence, Quebec, Canada, p.A7323</td>
</tr>
<tr>
<td>P956</td>
<td>Exercise Pulmonary Hypertension in Fibrotic Interstitial Lung Disease with Borderline Resting Mean Pulmonary Arterial Pressure/R.K. Oliveira, J.A. Tracy, A.L. Karin, A. Waxman, D. Systrom, Sao Paulo, Brazil, p.A7324</td>
</tr>
<tr>
<td>P957</td>
<td>Prevalence of Exercise Pulmonary Hypertension in Borderline Resting Mean Pulmonary Arterial Pressure/R.K. Oliveira, M.F. Urbina, J.A. Tracy, A.L. Karin, A. Waxman, D. Systrom, Sao Paulo, Brazil, p.A7325</td>
</tr>
<tr>
<td>P959</td>
<td>Thermomutation and Indirect Fick Are Inaccurate Methodologies to Determine Cardiac Index in Patients with Pulmonary Arterial Hypertension/M.K. Ahmed, R. Dweik, G. Agmy, A.R. Tonelli, Assiut, Egypt, p.A7327</td>
</tr>
<tr>
<td>P964</td>
<td>Do Patients with Pulmonary Arterial Hypertension Survive Inpatient Cardiac Arrest?/A.G. Kassar, N.H. Kim, R. Sell, San Diego, CA, p.A7331</td>
</tr>
</tbody>
</table>
P969 End Tidal CO2 as a Predictor of Outcomes in Patients with Pulmonary Arterial Hypertension

P971 The Ratio of Pulmonary Artery Over Wedge Nitrite Predicts the Time-Constant of the Pulmonary Arterial Windkessel in Patients with Pulmonary Hypertension

P968 Comparison of Different Types of Pulmonary Hypertension in Patients with Connective Tissue Disease

P973 The Geometry of the Right Ventricle from CT Scans as a Facilitator:

P975 Patient Characteristic Cluster Analysis Predicts Response to Therapy to Oral Treprostinil in Pulmonary Arterial Hypertension

P971 The Ratio of Pulmonary Artery Over Wedge Nitrite Predicts the Pulmonary Vascular Response to Inhaled Nitric Oxide in Idiopathic Pulmonary Arterial Hypertension

P970 Mechanisms of Gas Exchange Impairment in Chronic Obstructive Pulmonary Disease (COPD) with Severe Pulmonary Hypertension

P972 The Prevalence of Pulmonary Hypertension in Patients with Multiple Myeloma

P973 Patient Characteristic Cluster Analysis Predicts Response to Therapy to Oral Treprostinil in Pulmonary Arterial Hypertension

P974 Bisoprolol in Idiopathic Pulmonary Arterial Hypertension: A Sub-Group Analysis in Patients with Lower Versus High Right Ventricular Ejection Fraction

P975 The Geometry of the Right Ventricle from CT Scans as a Predictor of Pulmonary Vascular Disease in Smokers in the COPDGene Study

P976 Long Term Health Outcomes of Individuals with High Altitude Pulmonary Hypertension: A 55 Year Follow Up Study

P977 Galectin-3 and Aldosterone as Potential Tandem Biomarkers in Pulmonary Arterial Hypertension

P978 Fick Principle Determinants of the 6-Minute Walk Test (6-MWT) Distance

P979 Impact of Intrathoracic Pressure in the Assessment of Pulmonary Vascular Pressure

P980 Pulmonary Venous Hypertension in Patients with Systemic Sclerosis: Baseline Characteristics and Survival

P981 Pulmonary Arterial Hypertension (PAH) Specific Therapy Induce Changes in L-Arginine and Methylarginines Compared to Baseline Values in Healthy Subjects and Patients with Heart Failure

P982 The Potential Use of Left Atrial to Right Atrial Size Ratio in Discriminating Idiopathic Pulmonary Arterial Hypertension from Pulmonary Hypertension Due to Heart Failure with Preserved Ejection Fraction

P983 Impact of Pulmonary Arterial Hypertension on Dynamic Cerebral Autoregulation

P984 Role of Cardiac Magnetic Resonance in Stratifying the Prognosis of Patients with Pulmonary Arterial Hypertension

P985 Defining The Role of Balloon Pulmonary Angioplasty (BPA): U.S. High-Volume Pulmonary Thromboendarterectomy (PTE) Single-Center Experience

P986 Pulmonary Arterial Capacitance as an Indicator of Response to Therapy in Pulmonary Arterial Hypertension

P987 Breath Volatolome for the Detection of Pulmonary Arterial Hypertension

P988 Elevated Bilirubin Levels Are Associated with Intrapulmonary Vascular Dilation in Patients with Cirrhosis

P989 Toward Theranostic Biomarkers in Pulmonary Hypertension

P990 Riociguat Treatment for Porto-Pulmonary Hypertension: A Subgroup Analysis from the PATENT-1 Study


The Effects of Combination Therapy on Clinical Worsening: A Non-Invasive Evaluation of Right Ventricular Function, Non-Invasive Estimation of Pulmonary Artery Wedge Pressure/P.996

Discussion:
9:00 a.m. - 3:30 p.m. MOSCONE CENTER

THEMATIC POSTER SESSION

D54 CLINICAL PULMONARY HYPERTENSION
9:00 a.m. - 3:30 p.m. Area H, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion 11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: M.R. Lammi, MD, New Orleans, LA


New Approaches in Narrative Analysis Highlight Marked Issues of Adaptation and Change for Patients with Pulmonary Hypertension and Explore How Identity Is Modified in the Context of Clinical Care/J. Goddard, I. Armstrong, B. Stone, I. Sabroe, Sheffield, United Kingdom, p.A7365


In Depth Analysis of Six Minute Walk Test Parameters in Scleroderma Patients with and Without Pulmonary Hypertension/A. Gadre, C. Ghattas, O.A. Minai, K.B. Highland, Cleveland, OH, p.A7370

Pulmonary Function Phenotypes in Heart Failure with Preserved Ejection Fraction (HfPEF)/N. Shea, M. Cuttica, R. Kalhan, S. Shah, Chicago, IL, p.A7371


Use of Trevprostinil in Pregnant Women with Pulmonary Arterial Hypertension During Peripartum Period/B. Liu, X. Huang, W. Zhang, Z. Yu, Changsha, China, p.A7374

Comparison of Trans-Thoracic and Trans-Esophageal Echocardiography in Measurement of Tricuspid Annular Plane Systolic Excursion (TAPSE) to Diagnose Pulmonary Hypertension/B.M. Buddhdev, K.B. Buddhdev, V. Mallingarapu, Omega, NE, p.A7375

Use of Treprostinil in Pregnant Women with Pulmonary Arterial Hypertension/B.Liu, X. Huang, W. Zhang, Z. Yu, Changsha, China, p.A7374

Comparison of Trans-Thoracic and Trans-Esophageal Echocardiography in Measurement of Tricuspid Annular Plane Systolic Excursion (TAPSE) to Diagnose Pulmonary Hypertension/B.M. Buddhdev, K.B. Buddhdev, V. Mallingarapu, Omega, NE, p.A7375

Use of Treprostinil in Pregnant Women with Pulmonary Arterial Hypertension During Peripartum Period/B. Liu, X. Huang, W. Zhang, Z. Yu, Changsha, China, p.A7374

Facilitator: C.D. Burger, MD, Jacksonville, FL


P1015  Effects of Spironolactone in Pulmonary Arterial Hypertension: Results of SPIRO Study/Z. Safdar, E. Tamez, A. Thakur, M. Entman, A. Basant, A. Frost, Bellaire, TX, p.A7380

P1016  Reduced Venous Vessel Density in Pre-Capillary Pulmonary Hypertension/M. Pienn, C. Payer, M. Urschler, C. Olschewski, R. Neuwirth, R. Stollberger, G. Kovacs, V. Foris, H. Olschewski, M. Balint, Graz, Austria, p.A7381


P1020  Clinical Characteristics and Treatment Outcomes of Primary Pulmonary Artery Sarcoma in Korea/Y. Lee, D.S. Lee, S.-D. Lee, J.S. Lee, Seoul, Korea, Republic of, p.A7385


P1022  Usefulness of Echocardiography in Predicting Survival Benefit of Sildenafil in Patients with Intestinal Lung Disease/Y. Tomita, A. Miyamoto, K. Kishi, S. Ishiwata, M. Ohno, Tokyo, Japan, p.A7387

Facilitator:  J.M. Elwing, MD, Cincinnati, OH

P1023  Riociguat as a Bridge Therapy for Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension/J. Ueda, T. Ogo, S. Fukui, A. Tsuji, Y. Morita, T. Fukuda, S. Yasuda, H. Ogawa, N. Nakanishi, Suita, Japan, p.A7388


P1032  The Qutenza (8% Capsaicin) Patch for Disabling Treprostinil Infusion Site Pain/A. Light, K. Frutiger, K. Wessman, A. Heiniger, R.J. White, Rochester, NY, p.A7397


Facilitator:  A. Vaidya, MD, Philadelphia, PA

P1035  Relative Importance of Hemodynamics, Pulmonary Mechanics, Body Habitus, Demographics, and Time to Diagnosis and Treatment in Predicting 6 Minute Walk Test Results Before and After Treatment in Patients with Pulmonary Arterial Hypertension/C. PenA Orbea, N. Quesada, R. Lenhardt, Chicago, IL, p.A7400
P1036  The Effect of Lung Capacity on Response to Treatment in Patients with Pulmonary Arterial Hypertension (PAH)/S. Shenoy, M. Aveladovic, Sacramento, CA, p.A7401


P1038  Predictors of Survival in Patients with Scleroderma-Related Pulmonary Arterial Hypertension (SSc-PAH)? Cleveland Clinic Experience/M. Ghobrial, O.A. Minial, K.B. Highland, Cleveland, OH, p.A7403

P1039  Hemodynamic Dose-Response to Parenteral Treprostinil Occurs at Low Dose and Is Poorly Related to Biomarker and Functional Improvements in Patients with Advanced Treatment Naive Pulmonary Arterial Hypertension/L. Hansen, F. Rischard, Tucson, AZ, p.A7404


P1043  Methamphetamine-Induced Pulmonary Artery Hypertension—Efficacy of Oral Vasodilator Therapy in Advanced Disease/J. Scott, I. Subramanian, Oakland, CA, p.A7408


P1045  Design and Development of the Institutional Registry of Pulmonary Hypertension in Fundacion Valle del Lili, a University Hospital of Reference in Latin America/L. Fernandez, M. Ramos, J.E. Gomez, W. Martinez, F. Sanabria, D.C. Carrillo, Cali, Colombia, p.A7410


**THEMATIC POSTER SESSION**

D55  LAB METHODOLOGY AND BIOENGINEERING: JUST DO IT

9:00 a.m. - 3:30 p.m.  MOSCONE CENTER

Area D, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators

Facilitator: G.N. Maksym, PhD, Halifax, Canada


P479  A Novel Platform to Investigate the Mechanisms of Particle Deposition in the Lung/A. Sonnenberg, I. Puranam, M. Basile, E. Bartolak-Suki, S.D. Amin, B. Suki, Boston, MA, p.A7413


P481  Combinatory Simulation Study of Ventilation, Diffusion, and Perfusion by the Use of a 4D Model of the Human Pulmonary Subacinus/H. Kitaoka, Tokyo, Japan, p.A7415

P482  Evidence for Parallel Pathway Organization of the Pulmonary Circulation/R.L. Conhaim, G. Segal, K.E. Watson, Madison, WI, p.A7416


Facilitator: R. Krishnan, PhD, Boston, MA

P486  Computational Modeling of the Evolution of Tissue Stiffness Following Surgical and Bronchoscopic Lung Volume Reduction Techniques in Emphysema/J.R. Mondenodo, B. Suki, Boston, MA, p.A7420


**P488** Engineered Human Lung Generated from Human iPSCs was Functional in Bioreactor System In Vitro/M. Ghadai, L.E. Niklason, New Haven, CT, p.A7422

**P489** Fe2O3 Nanoparticles Cause Alteration of Microstructure and Rheological Properties of Simulated Mucus/L. Deng, M. Luo, J. Wang, Y. Wang, X. Yan, Z. Sun, J. Li, Changzhou, China, p.A7423

**P490** Novel Methodology to Isolate Endothelial Cells from the Pulmonary Vasculature of Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension/S. Lenna, M. Trojanowska, H.W. Farber, Boston, MA, p.A7424


**P492** CallistoTM Is an Automated In Vitro Cell Culture System to Study Small Cell Populations/A. Srivastava, Y. Sun, P. Mannam, J. Koff, New Haven, CT, p.A7426

**P493** Introduction of a New Cellular Collection Tube for Body Effusion Cytology/Q. Li, Y. Yang, Y. Zheng, Y. Wu, Y. Zhu, L. Ren, X. Yang, Tianjin, China, p.A7427


---

**D56** CUDDLE UP A LITTLE CLOSER: SDB NONPULMONARY OVERLAPS

**9:00 a.m. - 3:30 p.m.**

**MOSCONNE CENTER**

**Area J, Hall D (North Building, Lower Level)**

**Viewing:** Posters will be on display for entire session.

**Discussion:** 11:00-11:45: authors will be present for individual discussion 11:45-12:45: authors will be present for discussion with assigned facilitators

**Facilitator:** B. Prasad, MD, MS, Chicago, IL


**P1052** Clinical Correlates of Sleep Disordered Breathing in Sickle Cell Disease/C.M. Worsham, S.T. Martin, E.S. Klings, R.T. Cohen, Boston, MA, p.A7431

**P1053** The Association Between Hypertension and Neutrophil to Lymphocyte Ratio in Patients with Obstructive Sleep Apnea Syndrome/O. Ercen Diken, M. Arslan, H. Deniz, O. Haneden, Corum, Turkey, p.A7432

**P1054** Genome-Wide Gene Expression Microarray Identifies Novel Genes Related to Endothelial Tight Junctions and Apoptosis in Patients with Obstructive Sleep Apnea/Y. Chen, M.-C. Lin, K.-D. Chen, M.-C. Su, C.-H. Chin, Kaohsiung, Taiwan, p.A7433

**Facilitator:** G.R. Bourjeily, MD, Providence, RI


**P1057** The Impact of Renal Replacement Therapy on Sleep Disordered Breathing in Patients with End Stage Renal Disease/A. Kaur, B. Link, D. Shemin, P. Risica, S. Martin, J. Parker, R. Millman, L. Dworkin, G.R. Bourjeily, Providence, RI, p.A7436


**Facilitator:** S. Sinha, MD, New Delhi, India

**P1060** Incidence of Obstructive Sleep Apnea in Type 2 Diabetes Mellitus Patients in Tertiary Care Center of North India/A.K. Kashyap, P. Dhiman, H.S. Pannu, P. Singh, U.S. Sidhu, Ludhiana, India, p.A7439

**P1061** Serum Gamma-Glutamyltransferase in Obstructive Sleep Apnea and Its Role in Predicting Concomitant Diabetes Mellitus/C. Gu, M. Li, Q. Li, J. Zhou, J. Du, H. Yi, J. Feng, China, p.A7440
P1069 Erythrocyte Sedimentation Rate May Help Predict Severity of C. Lal, MD, Charleston, SC


P1066 Plasma Concentration of Gelatinases and Their Inhibitors in ATS 2016 • San Francisco

Discussion:
9:00 a.m. - 3:30 p.m. MOSCONE CENTER

D57 DON’T BE A DO-BADDER: NEW INTERVENTIONS FOR OSA

9:00 a.m. - 3:30 p.m. MOSCONE CENTER

Area J, Hall D (North Building, Lower Level)

Viewing: Posters will be on display for entire session.

Discussion: 11:00-11:45: authors will be present for individual discussion 11:45-12:45: authors will be present for discussion with assigned facilitators

P1086  Evaluating the Use of Quality Care Measures in the Assessment and Management of Obstructive Sleep Apnea Patients/N. Uppal, C. Ryan, Toronto, Canada, p.A7464

Facilitator:  J.E. Metz, DDS, Columbus, OH


Facilitator:  S. Redolfi, MD, PhD, Paris, France

P1090  Three Year Outcomes of Upper Airway Stimulation for Obstructive Sleep Apnea/P. J. Strollo, W. Randerath, K.P. Strohl, Pittsburgh, PA, p.A7468


P1093  Effects of Melatonin Supplementation in Obstructive Sleep Apnea Patients/N. L. Deacon, E. Smale, R. Jen, S. Jaiswal, Y. Li, A. Malhotra, La Jolla, CA, p.A7471

P1094  The Effect of Donepezil on Sleep Apnea in Patients with Obstructive Sleep Apnea- a Randomized, Double Blind Cross-Over Study/Y. Li, R.L. Owens, S.A. Sands, J.E. Orr, P.N. DeYoung, E.T. Smale, R. Jen, A. Malhotra, La Jolla, CA, p.A7472
11:45 Introduction
A.C. Argento, MD, Chicago, IL

11:55 EBUS Diagnostic Yield
M.M. Wahidi, MD, Durham, NC

12:15 Patient Factors That Affect EBUS
A.C. Argento, MD, Chicago, IL

12:35 Procedural Aspects of EBUS
C.T. Gillespie, MD, Chicago, IL

12:55 Training for EBUS
H. Lee, MD, Baltimore, MD

WS8 PRECISION MEDICINE IN ASTHMA: CURRENT PRACTICE, GAPS, FUTURE DIRECTIONS

Registration Fee: $75.00 (includes box lunch)

Attendance is limited. Pre-registration is required.

Assemblies on Allergy, Immunology and Inflammation; Environmental, Occupational and Population Health; Pediatrics

11:45 a.m. - 1:15 p.m. MOSCONE CENTER
Room 302 (South Building, Esplanade Level)

Target Audience
Clinicians will benefit by learning about the current state of the art in the treatment and prophylaxis of asthma, which they may consider applying to their practice; researchers will benefit by identifying gaps for future research; trainees will benefit by learning a cutting-edge concept in scientifically underpinned medical management.

Objectives
At the conclusion of this session, the participant will be able to:

• apply knowledge in day-to-day management of asthma patients;
• identify new areas for asthma related research;
• recognize the full scope of personal factors that affect asthma development and outcomes.

Before precision medicine became a household term and focus of research, physicians treating asthma had grappled with the different endotypes of this syndrome and had sought to understand why some patients develop hard to treat asthma, while others are protected. We are finally at the point where research insights are starting to inform treatment decisions in a tailored approach to asthma treatment. Much more needs to be done. This session will crystallize the current state of the art, that can be immediately implemented in clinical practice, as well as identify areas of interest for future research.

Chairing: S. Garantziotis, MD, Research Triangle Park, NC
D.A. Schwartz, MD, Aurora, CO

11:45 Identifying Biologic and Genetic Risk Factors for Asthma in Minority Patients
E.G. Burchard, MD, MPH, San Francisco, CA

12:00 Genes, Psychosocial Stress and Asthma
J.C. Celedon, MD, DrPH, Pittsburgh, PA

12:15 Microbiome Factors in the Development and Severity of Asthma
E. von Mutius, MD, MS, Munich, Germany

12:30 Asthma Endotypes: Are the Visions Becoming Reality?
S.E. Wenzel, MD, Pittsburgh, PA

12:45 Role of Environmental Exposures in the Precision Medicine Approach to Asthma
F. Gilliland, MD, MPH, PhD, Los Angeles, CA

1:00 Plenary Session: An Integrated Approach to Precision Asthma Treatment
S. Garantziotis, MD, Research Triangle Park, NC

CC5 CRITICAL CARE CLINICAL CORE CURRICULUM I

Adult Core Curriculum Working Group

11:45 a.m. - 1:15 p.m. MOSCONE CENTER
Room 2005/2007 (West Building, Level 2)

Target Audience
Internists and subspecialists in pulmonary, critical care, and sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification.

Objectives
At the conclusion of this session, the participant will be able to:

• remain current with medical knowledge relevant to their practice in pulmonary, critical care, and sleep medicine;
• evaluate their understanding of key skills and content areas in pulmonary, critical care and sleep medicine, as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
• support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of pulmonary, critical care, and Sleep medicine. The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice, as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

Chairing: J.I. McSparron, MD, Boston, MA
A.M. Luks, MD, Seattle, WA

11:45 Airway Emergencies
W.G. Carlos, MD, MSCR, Indianapolis, IN

12:05 Massive Resuscitation and Transfusion
R. Sell, MD, San Diego, CA

12:45 Emergent Renal Replacement and Therapy
K. Liu, MD, PhD, San Francisco, CA
L21  LATE BREAKING RESULTS FOR THE ALA-ACRC LASST STUDY

12:15 p.m. - 1:15 p.m.  MOSCONE CENTER
Room 3006/3008 (West Building, Level 3)

Target Audience
Physicians, clinical scientists, nurses, paraprofessionals, educators, health care providers.

Objectives
At the conclusion of this session, the participant will be able to:
• learn new findings about new, safe, and effective approaches to asthma treatment;
• gain new strategies to manage the care of asthma;
• learn new findings about adherence, safety, and tolerability of LASST.

The ALA Airways Clinical Research Centers’ (ACRC) purpose is to conduct clinical trials with practical importance to both adults and children with COPD and asthma. One of the trials was the LASST Study (Long-acting Beta Agonist Step Down Study). This trial verified these findings: to test the hypothesis that in patients with well-controlled asthma on combination ICS/LABA, discontinuing LABA while continuing with the same ICS dose will be inferior to continuing LABA and reducing the dose of ICS in preventing treatment failure during step-down therapy. This session will be the first presentation of the results of the LASST Study.

Chairing:
- W.C. Bailey, MD, Birmingham, AL
- R.A. Wise, MD, Baltimore, MD

12:15  LASST Background and Rationale
K. Blake, PharmD, Jacksonville, FL

12:30  LASST Study Design and Baseline Characteristics
C. Bime, MD, Tucson, AZ

12:45  LASST Main Results, Summary, and Conclusions
L. Rogers, MD, New York, NY

1:00  Discussion/Questions and Answers
R.A. Wise, MD, Baltimore, MD

L23  PULMONARY UPDATE FROM THE U.S. FOOD AND DRUG ADMINISTRATION

12:15 p.m. - 1:15 p.m.  MOSCONE CENTER
Room 3016/3018 (West Building, Level 3)

Target Audience
Clinicians in practice, researchers, pharmaceutical industry representatives, international regulators.

Objectives
At the conclusion of this session, the participant will be able to:
• understand how FDA-approved biomarkers can be used to enhance clinical trial drug development;
• learn new therapeutic targets for asthma (general asthma population as well as specific phenotypic subsets);
• integrate new treatment options regarding maintenance bronchodilator choices for management of stable asthma, and understand the role of clinical and biomarker criteria for patient selection for anti-IL-5 therapy.

The most recent regulatory FDA actions including discussion of current safety and efficacy issues of products for pulmonary indications will be presented. A summary of the Agency’s biomarker qualification process exemplified by the recent qualification of fibrinogen for use in COPD clinical trials will be discussed. Recent approvals for asthma highlighting targeted therapy to specific asthma phenotypes, as well as the use of a long-acting anticholinergic as a new bronchodilator in asthma will be presented.

Chairing:
- L.I. Gilbert-McClain, MD, Silver Spring, MD
12:15 Update on Current Pulmonary Issues at the FDA
L.I. Gilbert-McClain, MD, Silver Spring, MD

12:33 Old Drug New Use: Anticholinergics and Asthma
S.J. Chin, MD, Silver Spring, MD

12:51 Targeted Therapy for Asthma: Lessons from the IL-5 Pathway
K.M. Donohue, MD, Silver Spring, MD

1:09 Questions and Answers
L.I. Gilbert-McClain, MD, Silver Spring, MD

VARIOUS ORGANIZATIONS

L24 RESEARCH FUNDING OPPORTUNITIES
12:15 p.m. - 1:15 p.m. MOSCON CENTRE
Room 2001/2003 (West Building, Level 2)

Target Audience
Any ATS member who conducts research and is seeking funding.

Objectives
At the conclusion of this session, the participant will be able to:

• describe the research priorities of each funding agency represented on the panel;
• discuss practical steps that researchers take to improve quality of grant applications;
• identify a funding agency that is most closely aligned with the attendee’s research interests.

This session will introduce programs and research grant opportunities offered from major funding agencies. Speakers will present current research priorities and mechanisms of research funding available from each agency.

Chairing: J. Yorke, PhD, RN, Manchester, United Kingdom
J. Choi, PhD, RN, Pittsburgh, PA

12:15 National Institute of Nursing Research
N. Redeker, PhD, RN, West Haven, CT

12:25 National Heart, Lung, and Blood Institute
L. Reineck, MD, Bethesda, MD

12:35 Department of Veterans Affairs
E.G. Collins, PhD, RN, Chicago, IL

12:45 American Lung Association
S. Rappaport, MPH, New York, NY

12:55 ATS Program of Research
Speaker To Be Announced

1:05 Panel Discussion
J. Yorke, PhD, RN, Manchester, United Kingdom

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE,
DIVISION OF LUNG DISEASES, NIH

L25 NEW RESULTS FROM THE COPDGENE STUDY
12:15 p.m. - 1:15 p.m. MOSCON CENTER
Room 2002/2004 (West Building, Level 2)

Target Audience
Those with clinical or research responsibilities.

Objectives
At the conclusion of this session, the participant will be able to:

• learn about imaging in the COPDGene study;
• understand and learn about subtypes identified by the COPDGene study;
• learn about longitudinal follow-up in the COPDGene study.

Chronic obstructive pulmonary disease (COPD), the third leading cause of death in the United States, is a heterogenous syndrome. The COPDGene study has created the largest cohort of well-characterized current and former smokers for respiratory disease research. The primary goals of COPDgene are: 1) to identify new genetic loci that influence the development of COPD and COPD-related phenotypes and 2) to reclassify COPD into subtypes that can ultimately be used to develop effective therapies. This session will describe the progress and future plans of the COPDGene study.

Chairing: E.K. Silverman, MD, PhD, Boston, MA
J.D. Crapo, MD, Denver, CO
L. Postow, PhD, Bethesda, MD

12:15 Overview of COPDGene
J.D. Crapo, MD, Denver, CO

12:27 Longitudinal Follow-Up of COPDGene Subjects: Clinical Epidemiology
M.K. Han, MD, MS, Ann Arbor, MI

12:39 Advances in Quantitative Lung Imaging and Visual CT Assessment
D.A. Lynch, MD, Denver, CO

12:51 COPD Genetics: From GWAS to Sequencing
E.K. Silverman, MD, PhD, Boston, MA

1:03 Defining Subtypes of COPD
M.H. Cho, MD, MPH, Boston, MA

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE,
DIVISION OF LUNG DISEASES, NIH

L26 ENHANCED PHENOTYPING OF PULMONARY VASCULAR DISEASES
12:15 p.m. - 1:15 p.m. MOSCON CENTER
Room 2006/2008 (West Building, Level 2)

Target Audience
Health providers, trainees, and researchers.
Objectives
At the conclusion of this session, the participant will be able to:

• learn about current deep-phenotyping of PH;
• understand and learn pediatrics PH registry;
• learn about the national biorepository of PH patient samples for PH research.

Pulmonary hypertension (PH) currently has no cure, thus PH research remains a high priority for NHLBI. Recently, NHLBI launched several major multi-center clinical studies of PH including: Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics (PVDOMICS); and Pulmonary Hypertension Breakthrough Initiative (PHBI), which will help us understand the molecular mechanisms of PH in adult patients, and provide phenotypic data and biomarkers for future clinical trials and measures of disease severity. Data Fusion: A Sustainable, Scalable, Open Source Registry Advancing PVD Research using a novel biomedical informatics approach will develop computable phenotypes of pediatric pulmonary vascular diseases. This session will introduce these programs and present data from these studies.

Chairing:  
L. Xiao, MD, PhD, Bethesda, MD  
C.J. Blaisdell, MD, Bethesda, MD

12:15 NHLBI PVDOMICS Program Overview  
S.C. Erzurum, MD, Cleveland, OH

12:25 PVDOMICS Study Design and Update  
J.H. Newman, MD, Nashville, TN

12:35 Data Fusion: A Sustainable, Open Source Registry Advancing Pediatric Pulmonary Vascular Disease Research - Part I  
S.H. Abman, MD, Aurora, CO

12:45 Data Fusion: A Sustainable, Open Source Registry Advancing Pediatric Pulmonary Vascular Disease Research - Part II  
K. Mandl, MD, MPH, Boston, MA

12:55 Pulmonary Hypertension Breakthrough Initiative (PHBI) Update  
M. Geraci, MD, Indianapolis, IN

1:05 National Biological Sample and Data Repository for Pulmonary Arterial Hypertension  
W. Nichols, PhD, Cincinnati, OH

Objectives
At the conclusion of this session, the participant will be able to:

• improve target possibilities for treating lung inflammatory diseases such as pulmonary hypertension in HAART treated HIV patients;
• learn new findings about the role of oxidative stress in the onset of lung complications in HIV (+) patients undergoing ART.

HIV-infected patients on antiretroviral therapy (ART) have now a longer life expectancy, but as a consequence chronic diseases are increasingly becoming a major cause of morbidity and death. Many pulmonary conditions, including PAH, and COPD are more prevalent in HIV infected individuals under treatment but the mechanisms by which HIV and ART induce cellular dysfunction that may trigger these pathologies are largely unknown. One such pathway is oxidative stress (OS), which results from excessive free radical production, and exceeding endogenous antioxidant defense mechanisms, which can damage a wide variety of cellular components. The session will address current research and results in this area and will give an overview of current HIV research on the oxidative stress role in HIV infection. Presenters will delineate current knowledge of lung complications in relationship to OS, and describe latest results and techniques utilized in their projects.

Chairing:  
H.L. Twigg, MD, Indianapolis, IN  
E. Caler, PhD, Bethesda, MD

12:15 HIV Proteins and Pulmonary Hypertension  
S. Flores, PhD, Aurora, CO

12:30 Oxidative Stress in HIV Associated COPD  
B.D. Medoff, MD, Boston, MA

12:45 Redox Stress and Chronic Lung Disease in HIV  
J. Roman, MD, Louisville, KY

1:00 HIV+ Alveolar Macrophage Oxidant-Mediated Apoptosis of Pulmonary Endothelium  
M.R. Staudt, PhD, New York, NY

Target Audience
Practicing critical care and emergency medicine clinicians and clinical researchers would benefit from this session. This includes fellows, students, nurses, and other medical professionals. Persons interested in clinical trial design and conduct would also benefit from this session.

Objectives
At the conclusion of this session, the participant will be able to:

• understand the role of oxidative stress in the onset of lung diseases associated with HIV infection in the HAART era;
This session will provide information on the NHLBI Prevention and Early Treatment of Acute Lung injury (PETAL) clinical trials network. The session will describe the structure and goals of the PETAL network, provide an overview of the trials currently under way, and describe features of the PETAL network including utilization of a central IRB and outreach efforts.

**Chairing:** R.G. Brower, MD, Baltimore, MD  
L. Reineck, MD, Bethesda, MD

12:15  **Introduction**  
R.G. Brower, MD, Baltimore, MD

12:25  **ROSE Trial Update**  
M. Moss, MD, Aurora, CO

12:35  **New Trial Presentation**  
A. Ginde, MD, MPH, Aurora, CO

12:50  **Outreach Efforts**  
B.T. Thompson, MD, Boston, MA

1:00  **General Discussion**

---

**Target Audience**
Internists and subspecialists in pulmonary, critical care, and sleep medicine who work in a clinical setting and are currently engaged in maintenance of certification.

**Objectives**
At the conclusion of this session, the participant will be able to:

- remain current with medical knowledge relevant to their practice in pulmonary, critical care, and sleep medicine;
- evaluate their understanding of key skills and content areas in pulmonary, critical care and sleep medicine, as well as receive feedback on their comprehension of a result of a pre-test/post-test comparison;
- support clinicians who are engaged in maintenance of certification activities by providing updates on subjects included in recertification requirements.

The ATS Clinical Core Curriculum Symposia focus on a 3-year content cycle of key medical content in the areas of pulmonary, critical care, and sleep medicine. The topics are also aligned with corresponding MOC Medical Knowledge modules. This symposium is intended to assist clinicians with staying current with the growth of information relevant to their medical practice, as well as provide an opportunity to evaluate individual knowledge and skills while earning MOC Medical Knowledge points.

**Chairing:** J.I. McSparron, MD, Boston, MA  
A.M. Luks, MD, Seattle, WA

1:30  **Non-Invasive Ventilation**  
B.K. Patel, MD, Chicago, IL
2:00 Managing Exacerbations of Obstructive Lung Disease
N.G. Shah, MD, Baltimore, MD

2:30 Management of Severe Hypoxemic Respiratory Failure
A. Rogers, MD, MPH, Palo Alto, CA

3:00 Sedation, Delirium, and Mobilization in the ICU
W.D. Schweickert, MD, Philadelphia, PA

D82 THE ROAD TO PRECISION MEDICINE IN IPF: BIOMARKERS AND CLINICAL PREDICTORS

Assemblies on Clinical Problems; Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology
1:30 p.m. - 3:30 p.m. MOSCONE CENTER Room 135 (North Building, Lower Level)

Target Audience
Anyone interested in idiopathic pulmonary fibrosis, other interstitial lung diseases, outcome prediction, biomarkers and Precision Medicine. Trainees at all levels will find the information and style of open discussion uniquely informative as will clinicians, translational researchers, health care delivery experts, and patient advocacy group members.

Objectives
At the conclusion of this session, the participant will be able to:

• gain and in depth understanding of the role of molecular markers in implementation of precision medicine approaches in IPF;
• learn new findings on the potential value of lung and BAL molecular analyses in guiding diagnosis and management of IPF;
• understand findings on the clinical management of patients with IPF.

Despite significant progress in understanding disease mechanisms, genetics, and approval of two drugs, IPF remains a significant challenge to practicing physicians, in part because of its grave prognosis and unpredictable course. In this interactive session we summarize the huge amount of information collected on the use of molecular and clinical markers and try to answer the question whether they can be used in clinical practice. Each talk will include a dynamic interaction with the audience through social media and other tools and after the talks, the chairs will provide a brief summary of the talks and open them for discussion. The session will end with a general discussion followed by a vote by the audience on the feasibility and potential for clinical application of molecular markers in IPF.

Chairing: R.P. Marshall, MBBS, MD, PhD, Stevenage, United Kingdom
J. Herazo-Mayo, MD, New Haven, CT
J.S. Lee, MD, Aurora, CO

1:30 What Does the Clinician Need from Molecular Markers?
H.R. Collard, MD, San Francisco, CA

1:45 The Road to Precision Medicine in IPF Goes Through the Lung
R.G. Jenkins, MD, PhD, Nottingham, United Kingdom

2:01 No Need for Biopsy: BAL Predicts Outcome, New Mechanisms in IPF
A. Prasse, MD, Hannover, Germany

2:17 It’s Not Your Cells but Your Bugs: The Microbiome in IPF
T.M. Maher, MD, MSC, PhD, London, United Kingdom

2:33 Genetic Markers Can Lead the Way to Precision Medicine in IPF
T. Fingerlin, PhD, Denver, CO

2:49 All We Need Is One Drop of Blood: Peripheral Blood Markers Predict Outcome in IPF
N. Kaminski, MD, New Haven, CT

3:05 Will Precision Medicine Be Applicable to IPF? General Discussion
R.P. Marshall, MBBS, MD, PhD, Stevenage, United Kingdom
J. Herazo-Mayo, MD, New Haven, CT
J.S. Lee, MD, Aurora, CO

This session and the International Conference are supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests.

D83 COPD EXACERBATIONS: BIOLOGY AND TARGETS FOR NOVEL TREATMENTS

Assemblies on Clinical Problems; Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology; Respiratory Structure and Function
1:30 p.m. - 3:30 p.m. MOSCONE CENTER Room 134 (North Building, Lower Level)

Target Audience
Clinicians, clinical researchers and trainees who are involved in the research and care of patients with COPD.

Objectives
At the conclusion of this session, the participant will be able to:

• understand what cells and mechanisms are important during COPD exacerbation;
• understand the potential role of several novel treatments for COPD;
• understand the inflammation is not the only mechanism for targeted treatment in COPD exacerbations.

This session will be focused on COPD exacerbations and discussed the biology and targets for novel treatments in this disease.

Chairing: G.J. Criner, MD, Philadelphia, PA
B.R. Celli, MD, Boston, MA
S.I. Rennard, MD, Melbourne, United Kingdom
### D84  
**STAY AWAY FROM THE ICU: IS PREVENTING ICU ADMISSION GOOD FOR PATIENTS?**

**Assembly on Critical Care**  
**1:30 p.m. - 3:30 p.m.**  
**MOSCONEx CENTER**

**Room 3000/3002/3004 (West Building, Level 3)**

**Target Audience**  
Critical care and emergency medicine professionals; anesthesia clinicians, including physicians, nurses, and advanced practice providers.

**Objectives**  
At the conclusion of this session, the participant will be able to:

- learn new data on how to identify patients at risk for clinical deterioration;
- better discuss the risks and benefits of ICU admission with patients and their families;
- better identify patients that will not benefit from ICU admission.

ICU beds and the nurses and physicians that staff them remain a scarce and costly resource. In addition, admission to an ICU is associated with both increased intensity of therapy, but also potential increased risks of treatment. One way to deal with the limitations of bed space as well as the increased risk of ICU care is to attempt to identify and treat patients at risk for critical illness earlier in their illness. This session will review available data on identification of and treatment for patients on the wards and in the prehospital phase, and whether this will prevent need for ICU admission.
CONTROVERSIES AND ADVANCES IN THE MANAGEMENT OF VENTILATOR ASSOCIATED PNEUMONIA

Assemblies on Microbiology, Tuberculosis and Pulmonary Infections; Critical Care
1:30 p.m. - 3:30 p.m. MOSCONE CENTER Room 3016/3018 (West Building, Level 3)

Target Audience
Clinicians working in the ICU, including doctors (attending and fellow), respiratory therapists, nurses and trainees.

Objectives
At the conclusion of this session, the participant will be able to:

- understand new diagnostic tools for VAP;
- learn how to apply biomarkers to manage VAP;
- discuss the value and limitation of reporting VAC rates.

Ventilator associated pneumonia (VAP) remains an important illness in the ICU, in spite of reports of “zero VAP”. In the current era, we are being asked to report rates of ventilator associated complications (VAC), although the relation to VAP remains unclear. At the same time, we may be able to improve management with the application of anti-inflammatory therapies, rapid diagnostics, and biomarker-guided therapy, and new antibiotics are being developed. This session will examine these issues.

Chairing: M.S. Niederman, MD, New York, NY
C.J. Chastre, MD, Paris, France

1:30 Can Anti-Inflammatory Therapy Help Improve Outcomes in VAP?
C. Feldman, MBCh, DSc, PhD, Johannesburg, South Africa

1:50 Are New Antibiotics Going To Help Us Manage VAP in the ICU?
M.H. Kollef, MD, St. Louis, MO

2:10 Can Biomarkers Help with Antibiotic Stewardship in the ICU?
R.G. Wunderink, MD, Chicago, IL

2:30 Does Reporting Rates of VAC Improve Patient Care?
M.S. Niederman, MD, New York, NY

2:50 New Diagnostic Tests for VAP: Faster and Better?
I.S. Douglas, MD, Denver, CO

3:10 Discussion
J.E. Chastre, MD, Paris, France
D88  THE PATIENT-CENTERED JUGGERNAUT: THE RIGHT MOVE FOR CLINICAL CARE, POLICY, AND RESEARCH?

Assemblies on Behavioral Science and Health Services Research; Critical Care; Thoracic Oncology

1:30 p.m. - 3:30 p.m. MOSCONE CENTER
Room 303/305 (South Building, Esplanade Level)

Target Audience
Clinicians or researchers who incorporate patient centered outcomes in their practice or research.

Objectives
At the conclusion of this session, the participant will be able to:

• understand the benefits and limitations of patient and family satisfaction as a quality metric in critical care;

• learn about advantages and disadvantages of shared decision making as a policy requirement in lung cancer screening;

• determine if the methods to conduct high quality patient engaged research are available for implementation by researchers.

There is an emerging trend toward incorporating patients’ values, opinions and feedback in both patient care and research. Patient engagement is expected to address patients’ health care concerns and close the gaps in evidence needed to improve key outcomes. However, it remains unclear how this process will actually improve meaningful clinical outcomes and research products. Despite the difficulties in measuring the benefits and harms of this strategy, patient centered approaches are being adopted in clinical care, health policy and research. We will select case examples from key pillars of PCCM to highlight the current controversies for and against incorporating patient centered outcomes.

Chairing:
D.R. Sullivan, MD, MA, Portland, OR
L.C. Feemster, MD, MSc, Seattle, WA
R.S. Wiener, MD, MPH, Boston, MA

1:30  A Patient’s Perspective
J. Lefferts, San Francisco, CA

1:35  Incorporating Patient Centered Outcomes in Clinical Practice and Research
S.D. Halpern, MD, PhD, Philadelphia, PA

1:47  PRO: Patient and Family Satisfaction is a Key Quality Metric in Critical Care
E.K. Kross, MD, Seattle, WA

2:02  CON: Patient and Family Satisfaction is a Key Quality Metric in Critical Care
G.D. Rubenfeld, MD, MSc, Toronto, Canada

2:17  General Discussion

2:21  CON: Shared Decision Making Improves Outcomes in Lung Cancer Screening
C.G. Slatore, MD, Portland, OR

2:36  PRO: Shared Decision Making Improves Outcomes in Lung Cancer Screening
R.S. Wiener, MD, MPH, Boston, MA

2:51  General Discussion

2:55  PRO: We Possess the Methods to Conduct High Quality Patient Engaged Research
S. Parthasarathy, MD, Tucson, AZ

3:10  CON: We Possess the Methods to Conduct High Quality Patient Engaged Research
M. Helfand, MD, MS, MPH, Portland, OR

3:25  General Discussion

D89  NOVEL APPROACHES TO TREAT PULMONARY INFECTIONS

Assemblies on Allergy, Immunology and Inflammation; Microbiology, Tuberculosis and Pulmonary Infections; Pediatrics; Respiratory Cell and Molecular Biology; Respiratory Structure and Function

1:30 p.m. - 3:30 p.m. MOSCONE CENTER
Room 3007/3009 (West Building, Level 3)

Target Audience
Scientists, physician scientists and clinicians working on developing and utilizing novel therapeutics to treat and prevent pulmonary infections.

Objectives
At the conclusion of this session, the participant will be able to:

• identify novel strategies for treatment of respiratory infection.

• understand how these novel therapies target the pathogen or the host to promote innate immune clearance.

• recognize and understand the pitfalls and/or challenges present in the development of such therapies.

Opportunistic bacterial pathogens are a common cause of respiratory infection, especially in the immune compromised or in hospital settings. Widespread use of broad spectrum antibiotics has led to the emergence of antibiotic resistance in a group of respiratory pathogens labeled the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter species) and damaging effects of antibiotics on the gut microbiome. These factors, coupled with a reduction in the discovery rate of new antimicrobial therapies, necessitate efforts aimed at identifying novel and potentially pathogen specific antimicrobial therapeutics. This session will highlight recent discovery of novel treatment modalities for respiratory infection and exacerbation, including strategies targeting both the microbe and the host.

Chairing:
J.K. Kolls, MD, Pittsburgh, PA
T. Cohen, PhD, Gaithersburg, MD

1:30  Antibodies: A Pathogen Specific Approach to Combating Respiratory Infection
S. Projan, PhD, Gaithersburg, MD
D90 RESPIRATORY HEALTH IN MIGRANT POPULATIONS
1:30 p.m. - 3:30 p.m. MOSCONEN CENTER
Room 2009/2011 (West Building, Level 2)

Target Audience
Physicians (pulmonologists, critical care providers, and sleep medicine doctors), nurses, and other health care providers as well as trainees (residents and fellows) interested in learning about the clinical problems inherent in migrant populations, in educating others about how to care for these patients, and in how to engage in research.

Objectives
At the conclusion of this session, the participant will be able to:
• summarize the challenges inherent in the delivery of care to migrants;
• discuss the social, political, and economic circumstances that prevent optimal delivery of care to migrants;
• propose innovated approaches to this issue targeting specific needs of distinct populations.

The crisis in the Middle East has raised awareness about the challenges encountered by migrant populations; in particular, health care access and delivery. Similar challenges are encountered by migrant populations all around the world including those entering the U.S. as refugees and/or survivors of torture as well as Mexicans and other Latin Americans crossing the border. Migrants suffer from medical conditions typical of other populations (e.g., asthma, tobacco-related disease, sleep disorders) and conditions relevant to the nature of their situation including infection (e.g., tuberculosis) and malnutrition. This session will discuss emerging problems related to health care access and delivery in migrant populations.

Chairing: J. Roman, MD, Louisville, KY
J.C. Celedon, MD, DrPH, Pittsburgh, PA
I.S. Douglas, MD, Denver, CO
D.J. Upson, MA, MD, Albuquerque, NM

1:30 Introduction
J.C. Celedon, MD, DrPH, Pittsburgh, PA

1:35 Health Inequality in Latinos
Speaker To Be Announced

1:55 Rapid Deployment of International Tele-ICU During Conflict in Syria
A.M. Moughrabieh, MD, MPH, Detroit, MI

2:00 Asthma in Migrants: A Route to Health or More Triggers?
F. Holguin, MD, MPH, Pittsburgh, PA

2:15 Sleep and Migrant Health
S.R. Patel, MD, Pittsburgh, PA

2:30 Infectious Diseases in Migrant Populations
J.A. Ramirez, MD, Louisville, KY

3:00 Summary
J.C. Celedon, MD, DrPH, Pittsburgh, PA
I.S. Douglas, MD, Denver, CO
D.J. Upson, MA, MD, Albuquerque, NM

D91 GENETICS AND GENOMICS OF COPD
1:30 p.m. - 3:30 p.m. MOSCONEN CENTER
Room 130-132 (North Building, Lower Level)

Chairing: E.K. Silverman, MD, PhD, Boston, MA
B.E. Himes, PhD, Philadelphia, PA

Oral Presentations


2:30 Whole Genome Rare Variant Association Study Identifies a Non-Genic Region and Several Genes Associated with Severe Emphysema/J. Radder, Y. Zhang, F.C. Sciurba, S.D. Shapiro, Pittsburgh, PA, p.A7477


MINI SYMPOSIUM

D94  NON-TUBERCULOUS MYCOBACTERIA: ORGANISM AND HOST
1:30 p.m. - 3:30 p.m.  MOSCONE CENTER
Room 3020/3022 (West Building, Level 3)

Chairing:  K.P. Fennelly, MD, MPH, Rockville, MD
D.E. Griffith, MD, Tyler, TX
C. Andrejak, MD, PhD, Amiens, France
R. Thomson, MBBS, PhD, Brisbane, Australia

Oral Presentations
2:00  Nitric Oxide Is a Potential Antimicrobial Against Slow- and Fast-Growing Mycobacteria/C. Miller, B. McMullin, C. Deppisch, J. Riethmuller, Vancouver, Canada, p.A7498

MINI SYMPOSIUM

D95  DARKNESS ON THE EDGE OF TOWN: NEW MOLECULAR PATHWAYS IN PULMONARY HYPERTENSION
1:30 p.m. - 3:30 p.m.  MOSCONE CENTER
Room 3010/3012 (West Building, Level 3)

Chairing:  E.F. Spiekerkoetter, MD, Palo Alto, CA
B.B. Graham, MD, Aurora, CO

Oral Presentations
1:30  Bone Marrow Endothelial Progenitor Cells Are the Cellular Mediators of Pulmonary Hypertension in the Murine Monocrotaline Injury Model/J. Aliotta, M. Pereira, S. Wen, M.S. Dooner, M. Del Tato, E. Papa, Y. Cheng, L. Goldberg, P.J. Quesenberry, J. Klinger, Providence, RI, p.A7504
2:15  Estrogen Contributes to the Pathogenesis of Experimental Pulmonary Hypertension in Obese Male Mice/K.M. Mair, M. Nilsen, L. Loughlin, M. MacLean, Glasgow, United Kingdom, p.A7507
2:30  Platelet Bioenergetic Screen Reveals Increased Glycolytic Rate in Group 1 Pulmonary Hypertension and Increased Oxygen Consumption in Group 2 Pulmonary Hypertension/Q. Nguyen, C. Corey, M. Reynolds, P. White, R.R. Vanderpool, M.T. Gladwin, M.A. Simon, S. Shiva, Pittsburgh, PA, p.A7508
2:45  HIF2α Deletion in the Pulmonary Endothelial Prevents Hypoxia-Induced Pulmonary Hypertension/A.S. Cowburn, A. Crosby, D. Macias-Gutierrez, M. Southwood, L. Crotty-Alexander, N.W. Morrell, E.R. Chilvers, R.S. Johnson, Cambridge, United Kingdom, p.A7509
3:00  Thrombospondin-1 Deficient Bone Marrow and Pharmacological Inhibition of TGF-β1 Activation Protects Against Schistosomiasis Pulmonary Hypertension/R. Kumar, C. Mickael, B. Kassa, L. Gebreab, D. Koyanagi, L. Sanders, R. Tuder, B.B. Graham, Aurora, CO, p.A7510

ATS 2016 • San Francisco
MINI SYMPOSIUM

D96 DAMAGING EFFECTS OF INHALED PARTICULATES
1:30 p.m. - 3:30 p.m. MOSCON CENTER
Room 2006/2008 (West Building, Level 2)

Chairing:

Oral Presentations

MINI SYMPOSIUM

D97 IMAGING AND MODELING: INSIGHTS INTO LUNG STRUCTURE AND FUNCTION
1:30 p.m. - 3:30 p.m. MOSCON CENTER
Room 2002/2004 (West Building, Level 2)

Chairing: K.R. Lutchen, PhD, Boston, MA
C.C. Hsia, MD, Dallas, TX
M.H. Tawhai, PhD, Auckland, New Zealand

Oral Presentations
2:00 Imaging a Single Slice Provides a Representative Measure of Specific Ventilation in a Normal Lung: A Computational Modeling Study/K.S. Burrowes, W. Kang, G.K. Prisk, M. Tawhai, Oxford, United Kingdom, p.A7522
2:30 Regional Increase in Airway Wall Thickness Could Explain Increase in Ventilation Defects (VDefs) and Heterogeneity in Ventilation in Asthma/T. Winkler, C. Thamrin, C.S. Farah, G.G. King, Boston, MA, p.A7524

MINI SYMPOSIUM

D98 AFTER SERVE-HF: NOW WHAT?
1:30 p.m. - 3:30 p.m. MOSCON CENTER
Room 2001/2003 (West Building, Level 2)

Chairing: S. Javaheri, MD, Cincinnati, OH
M. Arzt, MD, Regensburg, Germany
M. D’Ortho, MD, PhD, Creteil, France

Oral Presentations
1:30 Morbidity and Mortality of Chronic Heart Failure (CHF) Patients Treated by Adaptive Servo-Ventilation (ASV): Interim Data of the FACE Multicentre National Cohort Study/R. Tamisier, T. Gaass, J. Behr, F. Reichenberger, J. Dinkel, E. Silbemagel, Munich, Germany, p.A7527


2:15 Dissociation of Objective and Subjective Daytime Sleepiness Measures in Patients with Heart Failure and Obstructive Sleep Apnea/S. Javaheri, R. Mehra, N. Foldvary-Schaefer, Cincinnati, OH, p.A7531


3:00 Long-Term Effect of CPAP on Subclinical Atherosclerosis in Obstructive Sleep Apnea/J.M. Marin, T. Martin, V. Gil, P. Cubero, M. Forner, A.L. Simon, Zaragoza, Spain, p.A7534

Featured Speaker

3:15 Carotid Body Targeting in Cardiovascular Disease: Taming the Roar/J. Paton, PhD, Bristol, United Kingdom,

D99 NOVEL TRANSLATIONAL BIOMARKERS IN LUNG CANCER

1:30 p.m. - 3:30 p.m. MOSCON E CENTER

Room 306/308 (South Building, Esplanade Level)

Chairing: P. Nana-Sinkam, MD, Columbus, OH
S.D. Spivack, MD, MPH, Bronx, NY

Featured Speaker

1:30 Why Do We Need Biomarkers for Lung Cancer?/A. Vachani, MD, MS, Philadelphia, PA,

Oral Presentations

604 CARMA3 Mediates the Pulmonary Immune Response to Alternaria Alternata/B. Causton, K. Jones, J.L. Cho, B.D. Medoff, Charlestown, MA, p.A7545


606 The Expression of the Interleukin-33 Receptor ST2L on CLEC-2 Regulates Type 2 and Type 17 Lung Inflammation/T.S. Hallstrand, Seattle, WA, p.A7556

607 IL-36 Induces Inflammation in the Lung/Y. Sun, H.A. Arnett, South San Francisco, CA, p.A7548


610 TLR2 Contributes to Allergic Airway Inflammation Through JNK Signaling Pathway with Activation of Autophagy/L. Fang, R. Liu, Hefei, China, p.A7551


614 CLEC-2 Regulates Type 2 and Type 17 Lung Inflammation/P. Burkett, A. Wallrapp, V.K. Kuchroo, Boston, MA, p.A7555


617 Inhibition of RORα Blocks Rhinovirus-Induced Expansion of Type 2 Innate Lymphoid Cells and Expression of IL-13 in Immature Mice/C. Rajput, J.K. Bentley, T. Cui, J. Lei, M. Han, M.B. Hershenson, Ann Arbor, MI, p.A7558

618 Elevated Levels of Circulating CRTh2+CD4+T Cells Characterize Severe Asthma/N. Shrestha Palikhe, C.R. Laratta, D. Nahirney, D. Vethanyagam, M. Bhutani, H. Vliagoftis, L. Cameron, Edmonton, Canada, p.A7559

619 Peripheral Pathological Type 2 Innate Lymphoid Cells Associate with Human Asthma Control Status/Y. Jia, X. Fang, Z. Chen, R. Tang, Shanghai, China, p.A7560


---

**POSTER DISCUSSION SESSION**

**D102 FIGURING OUT WHAT WE DON’T KNOW: ADVANCES IN MEDICAL EDUCATION**

1:30 p.m. - 3:30 p.m. MOSCONE CENTER

Room 304 (South Building, Esplanade Level)

**Poster Viewing**
1:30-2:15

**Discussion**
2:15-3:30

**Chairs:**
M.M. Hayes, MD, Boston, MA
J.B. Richards, MD, MA, Charleston, SC
R. Adamson, MBBS, Seattle, WA

**201 Building Research Capacity in Middle and Low-Income Countries Through Research Methodology and Career Development Education**
C.M. Patino, D.H. Au, C.J. Lane, A.S. Buist, W.M. Vollmer, Los Angeles, CA, p.A7567

**202 Increased Mortality Associated with Resident Handoff in a Multi-Center Cohort**
J.L. Denson, A. Jensen, H. Saag, B. Wang, Y. Fang, L. Horwitz, L. Evans, S. Sherman, Denver, CO, p.A7568
POSTER DISCUSSION SESSION

D103 CRITICAL CARE: IMPROVING PALLIATIVE AND END OF LIFE CARE IN THE ICU

1:30 p.m. - 3:30 p.m.

MOSCONET CENTER

Room 3001 (West Building, Level 3)

Poster Viewing
1:30-2:15

Discussion
2:15-3:30

Chairing:
J.R. Curtis, MD, MPH, Seattle, WA
W.J. Ehlenbach, MD, Madison, WI
P.R. Menon, MD, Burlington, VT

701 ICU Nurses Focus Group on Acceptability Testing of VidaTalk
T.T. Von Visger, J.A. Tate, B. Traughber, L. Patak, M.B. Happ, Columbus, OH, p.A7592


1007 Utility of Pre-Hospital Glasgow Coma Scale in Predicting In-Hospital Mortality in Patients with Sepsis/R. Dolan, C. Polito, A. Isakov, A. Yancey, I. Bloom, G.S. Martin, J.E. Sevransky, Atlanta, GA, p.A7619


1011 Sepsis Alerts in the Emergency Department to Expedite the Care of Severe Sepsis and Septic Shock/B. Keveson, B. Smith, M. Cate, P. Steves, R. Clouser, M. Holman, G.B. Allen, Burlington, VT, p.A7623

1012 Prediction of Acute Respiratory Failure in Severe Chronic Obstructive Respiratory Disease: What Do We Need to Learn in Emergency Department?A. Sadigov, K. Agayeva, S. Huseynova, G. Sadigova, Baku, Azerbaijan, p.A7624


1017 Impact of Delayed Admission to the Intensive Care Unit from the Emergency Department upon Sepsis Outcomes and Sepsis Protocol Compliance/M. Agustin, L.L. Price, P. LaCamera, A. Andoh-Duku, Boston, MA, p.A7629


1019 Evaluation of Adjudicated Sepsis Diagnosis and a Novel, Host Response Assay in the Diagnosis of Sepsis in Critically Ill Patients/R.R. Miller, B. Lopansri, L. McHugh, T. Seldon, J. Burke, Murray, UT, p.A7631


1023 Effect of Care Fragmentation on Outcomes of Rehospitalizations For Severe Sepsis Survivors/M. Hua, M.N. Gong, A. Miltiades, H. Wunsch, New York, NY, p.A7635


817 Diaphragm Pacing as Successful Salvage Therapy in Failure to Wean Patients: Should This Novel Technology Be Used Earlier? R. Onders, M. Elmo, C. Kaplan, H. Nearman, R. Schilz, Cleveland, OH, p.A7653


D106 BIOMASS SMOKE, VOG, AND POLLUTANTS

1:30 p.m. - 3:30 p.m. MOSCON CENTER

Room 133 (North Building, Lower Level)

Poster Viewing 1:30-2:15

Discussion 2:15-3:30

Chairing: A. Sood, MD, MPH, Albuquerque, NM

G. Diette, MD, MHS, Baltimore, MD

J.E. Sordillo, DSc, Boston, MA


Amyotrophic Lateral Sclerosis A. Larsson, G. Perchiazzi, Uppsala, Sweden, p.A7646

Formation A. Mireles-Cabodevila, E.P. Pioro, L.S. Aboussouan, Phoenix, AZ, p.A7648


Amyotrophic Lateral Sclerosis A. Larsson, G. Perchiazzi, Uppsala, Sweden, p.A7646

Formation A. Mireles-Cabodevila, E.P. Pioro, L.S. Aboussouan, Phoenix, AZ, p.A7648


111 Epithelial-Mesenchymal Transition-Induced by Trans,Trans-2,4-Decadienal, a Component of Cooking Oil Fumes, in Human Bronchial Epithelium Cells/J.R. Tsai, I.-W. Chong, Kaohsiung, Taiwan, p.A7667

112 Swine Housing Dust Extract Elicits Inflammation and Oxidative Stress in Macrophages/K. Locke, P. McIntosh, C. Murray, R. Minor, J. Waterman, Greensboro, NC, p.A7668


114 Endotoxin Levels Enhance the Allergenicity of Phthalates in Adults: Findings from the NHANES 2005-2006/J.A. Hoppin, P.D. Strassle, Raleigh, NC, p.A7670


120 Volcanic Sulfur Dioxide Air Pollution and Reduced FEV1/FVC Ratio in Hawai’i Island Schoolchildren/E.K. Tam, K. Sircar, R. Miike, F. Yip, Honolulu, HI, p.A7676


122 Effects of Particulate Matter Exposure on Glucocorticoid Responsiveness in Human Airway Epithelial Cells/C.F. Rider, J.A. Hirota, C. Carlsten, Vancouver, Canada, p.A7930


125 Atopy in Relation to Endotoxin and Fungal Exposures in Early Life: Results from the National Health and Nutrition Examination Survey 2005-2006/P.M. Salo, J. Wilkerson, R.D. Cohn, D.C. Zeldin, Research Triangle Park, NC, p.A7933

---

**D107 TUBERCULOSIS INFECTION AND DISEASE: EPIDEMIOLOGY AND DIAGNOSIS**

1:30 p.m. - 3:30 p.m. MOSCONE CENTER Room 3014 (West Building, Level 3)

**Poster Viewing**

1:30-2:15

**Discussion**

2:15-3:30


905 Diagnostic Accuracy of the Novel C-Tb Skin Test for Latent M.tuberculosis Infection: Results from Two Phase III Clinical Trials/M. Ruwald, J.A. Cayla, H. Aggerbaek, K. Dheda, P. Andersen, Copenhagen, Denmark, p.A7684

906 Protective Efficacy of Preventive Therapy/P. Kouw, S. Keizer, M. Mensen, W. Meijer, Amsterdam, Netherlands, p.A7685

907 The Cost-Effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Foreign-Born Persons in the United States/B. Linas, A. Teper, MD, Caba, Argentina


910 Challenges in Laboratory Diagnosis of Tuberculosis in the Bacilloscopy Laboratory at the Maputo Central Hospital/P.M. Zindoga, S. Peleve, S. Amade, A. Hassane, J. Pondo, A. Daniel, E. Nunes, Maputo, Mozambique, p.A7689


916 Cartidge Based Nucleic Acid Amplification Test (CBNAAT) for the Diagnosis of Pulmonary Tuberculosis in Children/M. Singh, G.R. Sethi, M. Mantan, A. Khamna, M. Hanif, Chandigarh, India, p.A7695


POSTER DISCUSSION SESSION

D108 PEDIATRIC CASES: A ROOM FULL OF ZEBRAS
1:30 p.m. - 3:30 p.m. MOSCONE CENTER
Room 2014 (West Building, Level 2)

Poster Viewing 1:30-2:15
Discussion 2:15-3:30

Chairing: M. Santiago, MD, Great Neck, NY
B.T. Kopp, MD, Columbus, OH
A. Teper, MD, Caba, Argentina

501 Eosinophilic Pneumonitis as Initial Presentation of Acute Lymphoblastic Leukemia/E.B. Burgener, C.E. Milla, Palo Alto, CA, p.A7697
517 Prolonged Tachypnea and Hypoxemia as Presentation of Bare Minocycline-Induced Eosinophilic Pneumonia in a Pediatric Case of Bronchiectasis in a 6 Year Old with STAT1 Gain of Carotid Body Dysfunction Limits Exercise Performance/Constrictive Bronchiolitis: A Rare Complication of Toxic Pulmonary Alveolar Proteinosis Associated with Secondary Respiratory Failure, Septicemia/Disseminated Intravascular Cystic Fibrosis: Yes or No- A Case Report/An Unusual Cause of Tachypnea and Hypoxemia in an A Rare Cause of Unilateral Lung Hyperinflation in an Infant Congenital Pulmonary Artery Atresia Masquerading as a Left Sided Anomaly/D/J. Heintz, E.D. Allen, R. Shell, Columbus, OH, p.A7701

518 Diaphragm Pacing Can Be Used to Successfully Wean from Tracheostomy Mechanical Ventilation in SMA Type 2/R. Onders, M. Elmo, C. Kaplan, D.I. Craven, K. Lidsky, Cleveland, OH, p.A7714


520 Pulmonary Hypertension and Right Heart Failure Due to Severe Hyponatremic Dehydration/S. Chiwane, J. Klein, M. Chauhan, Detroit, MI, p.A7716

521 An Infant with Tachypnea and Progressive Respiratory Failure/N. Joshi, S. Martinez, Akron, OH, p.A7717


523 A Rare Case of Asymptomatic Left Pulmonary Artery Sling/S. Raj, S. Chandra, Iowa City, IA, p.A7719

524 Presentation of Relapsing Polychondritis in an Adolescent/ M.B. Dennis, P. Sammut, H. Thomas, Omaha, NE, p.A7720


405 nmMLCK: A Key Player in Intermittent Hypoxia-Induced Inflammatory Vascular Remodeling?/C. Arnaud, S. Recoquillon, S. Bouyon, E. Lemarie, S. Cachot, M. Toral, C. Martinez, R. Andriantsitohaina, J.L. Pepin, Grenoble, France, p.A7726


407 Activation of Integrated Stress Response (ISR) and Intermittent Hypoxia (IH)-Induced Metabolic Dysfunction in a Mouse Model of Sleep Apnea/A. Khalyfa, Z. Qiao, A. Gileles-Hillel, A.A. Khalyfa, M. Akbapour, B. Popko, B. D. Gozal, Chicago, IL, p.A7728

408 Activation of Integrated Stress Response (ISR) By Sleep Fragmentation During Late Gestation (LG-SF) in Mouse Is Critical to Emergence of Metabolic Phenotype in Adult Offspring/A. Khalyfa, Z. Qiao, A.A. Khalyfa, A. Gileles-Hillel, M. Akbapour, B. Poroyko, D. Gozal, Chicago, IL, p.A7729


410 High-Intensity Training Reduces Intermittent Hypoxia-Induced ER Stress and Myocardial Infarct Size/G. Bourdier, P. Flore, H. Sanchez, J.L. Pepin, E. Belaidi, C. Arnaud, Grenoble, France, p.A7731

411 NF-κB Pathway Plays a Critical Role in Intermittent Hypoxia Induced Macrophage Foam Cell Formation/T. Imamura, G.G. Haddad, La Jolla, CA, p.A7732

412 Endothelial Dysfunction in Diabetic Mice Is Exacerbated by Chronic Intermittent Hypoxia (CIH)/M. Badran, N. Ayas, I. Laher, Vancouver, Canada, p.A7733

413 Low Frequency Intermittent Hypoxia Reduces Endothelium-Dependent Contraction in C57 Mice with Diet-Induced Obesity/M. Y. K. Lee, J. C. W. Mak, M. S. M. Ip, Hong Kong, Hong Kong Prc, p.A7734


415 Various Degrees of Intensities of Intermittent Hypoxia on Adipogenesis in Diet-Induced Obese Mouse Model/Y. Wang, M. Y. K. Lee, J. C. W. Mak, M. S. M. Ip, Hong Kong, Hong Kong Prc, p.A7736

416 Late Gestational Intermittent Hypoxia Leads to Metabolic and Epigenomic Alterations in Adult Offspring/R. Cortese, A. Khalyfa, R. Bao, J. Andrade, D. Gozal, Chicago, IL, p.A7737


418 Intermittent Hypoxia Increases Tumor Angiogenesis in a Mouse Model of Heterotopic Kidney Cancer/M. Torres, A. Vilaseca, N. Campillo, M. Musquera, J. M. Montserrat, A. Alcaraz, R. Farre, I. Almendros, Barcelona, Spain, p.A7739

419 Progression of Tumor Growth in Intermittent Hypoxia is Associated with Decreased Number of Granzyme B Expressing CD8+ T Cell Lymphocytes/M. Akbapour, A. Khalyfa, Q. Zhanhong, A. A. Khalyfa, A. Gileles-Hillel, I. Almendros, R. Farre, D. Gozal, Chicago, IL, p.A7740

420 Antioxidant Tempol Ameliorates Intermittent Hypoxia-Induced Melanoma Lung Metastasis in a Mouse Model of OSA/L. Li, M. Liang, Y. Fang, J. Cao, B. Shen, Tianjin, China, p.A7741

421 A Membrane Progesterone Receptor Agonist Reduces Apnea Frequency in Newborn Male and Female Rats/N. Uppari, H. Kouchi, V. Joseph, A. Bairam, Quebec, Canada, p.A7742


---

POSTER DISCUSSION SESSION

D110 UNUSUAL TUMORS OF THE CHEST

1:30 p.m. - 3:30 p.m. MOSCONE CENTER

Room 309 (South Building, Esplanade Level)

Poster Viewing 1:30-2:15

Discussion 2:15-3:30

Chairing: D.E. Ost, MD, MPH, Houston, TX
L.T. Tanoue, MD, New Haven, CT

301 Atypical Multifocal Pulmonary Carcinoid Tumor: A Case Report of a Very Rare Neoplasm/C.A. Celis Preciado, P. Gil, C. Zuluaga, L. Jaramillo, Bogota, Colombia, p.A7744

302 Bilateral Synchronous Pulmonary Carcinoid Tumors Treated with Staged Segmentectomy/A. Attili, J. Shaw, Brooklyn, NY, p.A7745


304 A Rare Case of Mucoepidermoid Carcinoma of the Lung/A. Rajagopal, A.P. Maskey, Lexington, KY, p.A7747


309 Congenital Pulmonary Airway Malformation (CPAM) with Malignant Transformation/N. Soriano, D. Chia, S.I. Aronin, Waterbury, CT, p.A7752


311 Cardiac Tamponade Due to Primary Pericardial Mesothelioma Thirty Years After Radiation-Treated Hodgkin’s Lymphoma/S.E. Richter, C.T. Sheth, Los Angeles, CA, p.A7754

312 Tracheal Mucosa Associated Lymphoid Tissue Lymphoma as a Cause of Chronic Cough and Prandial Dyspnea/ E.J. Swanson, K.M. Kunisaki, H. Mesa, J. Silva, Minneapolis, MN, p.A7755

313 Leukemic Infiltration in the Setting of Acute Respiratory Failure/M.A. Fayed, T. Evans, H. Abdulhaq, Fresno, CA, p.A7756

314 Extranodal NK/T-Cell Lymphoma Masquerading as Limited Granulomatosis with Polyangiitis/N.A. Braus, T. Peikert, Rochester, MN, p.A7757

315 Castleman’s Disease Presenting as a Mediastinal Mass: Mimicker of Malignancy/M.U. Khawar, H. Hussein, H. Youness, Oklahoma City, OK, p.A7758

316 Adult Type T Cell Leukemia/Lymphoma Presenting as a Tracheal Mass/G. Dutta, J. Qin, J. Gorga, S. Fahmy, Brooklyn, NY, p.A7759

317 Massive Thymolipoma: An Unusual Cause of Acute Respiratory Failure/C. Di Felice, H. Chhatrala, M. Konda, S. Ansari, Kalamazoo, MI, p.A7761


321 A Rare Case of Primary Pulmonary Melanoma/G. Gilroy, C. Zhang, E. Bendaly, K. Diab, Indianapolis, IN, p.A7765

323 An Asymptomatic Case of Tracheal Hamartoma/A. Cilli, F. Uzer, L. Dertsiz, Antalya, Turkey, p.A7766

Where today’s science meets tomorrow’s care™